<SEC-DOCUMENT>0000950170-25-034185.txt : 20250306
<SEC-HEADER>0000950170-25-034185.hdr.sgml : 20250306
<ACCEPTANCE-DATETIME>20250306080722
ACCESSION NUMBER:		0000950170-25-034185
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250306
DATE AS OF CHANGE:		20250306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38997
		FILM NUMBER:		25713668

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rapt-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-06T07:12:48.3691+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:rapt="http://www.rapt.com/20241231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_de655c8d-69da-4a1b-a3af-7cf99da5ff3d" name="dei:EntityCentralIndexKey" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035">0001673772</ix:nonNumeric><ix:nonNumeric id="F_7cfe9c1d-8752-4820-9e9b-980e63244ca3" name="dei:DocumentFiscalPeriodFocus" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035">FY</ix:nonNumeric><ix:nonNumeric id="F_e4a453de-31ed-4ee0-be8d-8dbbc0fd1745" name="dei:AmendmentFlag" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035">false</ix:nonNumeric><ix:nonFraction id="F_119d5c31-574a-41b1-bb0c-c45232e3a0fb" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_29c1e797-26fc-49db-8445-893357da5c44" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f4cafdc4-5da6-43ff-95bd-69630443c804" name="us-gaap:PreferredStockValue" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_60da1fb1-1699-4d6e-8077-8710d40b7a31" name="us-gaap:PreferredStockValue" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_5478996a-804a-4f18-89f0-88f2679981b1" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_5b2c0381-34b5-4225-b14c-08e039f44849" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_02b5724b-2262-4373-b315-c82a3fbab1fb" format="ixt-sec:duryear">3</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rapt-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80a183b9-14ce-4b94-97fa-8410f324fd16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8234c17c-ee4d-4a80-9c05-28fda21083ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_835d629a-8341-447d-9b31-2b46252b4801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:ExchangeWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a36a6b4-2ad5-4767-8ac9-f1a57de88015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a7cc3d9-d3e4-4c52-8a5d-bca0e011b505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b9b3e34-2570-4302-8da4-f3602f968f0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f0468c1-4f1c-4002-aff0-929369045db5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:SharesAvailableForFutureGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f6dc9ac-cad7-4b38-9d58-a1763e1d61e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9001335a-7425-4825-a5e8-855ff463d619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93fa0d2c-4808-4cba-b804-5817b70b6002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94651108-608c-4b19-95e3-37570aa77a57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9721513b-6988-4fc5-9022-6cb8d96513e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9aa83cf2-b703-419f-8280-e04589a8890b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9abc0e8c-51a8-434c-a1d1-15cb685a695f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bacd39c-e2ef-403d-878e-b81822f43a06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c01b00d-c8c0-44b6-a41b-56900a5fff28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9db51527-1de4-457c-b360-21ef8df86299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f58d34c-283d-4d45-8629-2ad0f013648f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a14673d3-4c5c-4205-aba2-4b02e4aef4ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1474cef-956f-46e7-9e3d-008021bbe380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1e1225b-2612-4af9-939a-2d52c9f5e2f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:ShanghaiJemincarePharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a395a028-b159-4fe1-a41e-dbb49da699ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7ae680f-040b-4295-a0e6-b8be8d744edf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad8a92e7-a170-450d-96fe-0db4664c91f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0562cd3-883d-4446-80de-a657e0fd2fe1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3f24917-b3a5-49bd-8fb0-e640d29eee1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4b55243-d136-47d3-a127-156fda882df4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4dd74b2-7b1d-41b5-80ac-555fdb0af990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5311bec-6438-4c93-a187-0201963f9310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba019106-668d-4085-9682-6ff1e01b2cec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba2021a0-4327-4bd0-aac5-d66d26d8d350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba3ba657-8b8c-4939-87cf-2c03c023d913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb74bca5-cd20-442e-a1a9-9ce66456c288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc3a237f-db8c-4eb6-ad25-be4c30946b6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc91c928-5abe-4ffe-a8c2-90f5cbb4d036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0d8be9a-a9d5-4da0-bb1b-b686503d1d6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1f11e91-1cbf-4c2e-aecc-69ab59127c69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3c8c90f-d90e-46ba-865e-536f40880787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5036115-0ce3-49f9-b87d-f4affdbd9129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c663eb36-dd20-48b2-8b42-6761ae70257c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc2ab253-a7db-4cd8-aca4-5879a7c0fe34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc2b05a5-eacc-40fa-9ee3-edb7df38df49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d07dd25e-838e-46eb-b796-57384523a826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d10cbbed-ca3e-473c-ae9c-39f3c1a71274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d431e111-293a-40bd-89cf-4ae204a20ac1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d733af1e-23fc-411c-a82f-13e6af25be62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9234fac-4296-4532-b5c8-44c5a7ab179e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc38ef0e-2c99-4a0f-bab8-195d55c11e72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcaa91d1-9b01-4910-b0d7-9d8ec5902432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de601727-b928-46a5-ac54-e85f0fa3c27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df1b1c57-47c3-4026-b445-8a31e755c7c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0707604-10e1-4c66-b961-1f5ccf14dc5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1066a6a-e09d-458e-acdd-6e64892bf012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e29bc580-c8e8-4a17-a9a1-642394e12639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2cf0836-a57d-4015-a9af-0546d1d46c80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e791417b-0181-463a-ab8a-f33a0e466058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e82bdaae-dee6-461f-b8f4-c790e6fb1c0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec7bc9d3-76ec-4a11-8d01-81dfe77946de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed365124-41c8-4f2d-90b2-8eb22147ede5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee90ccbb-6c06-48ca-9de4-a94e0bd95940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef44fb3b-2619-440a-8db8-260a42eaf37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0afabfb-107b-4ed2-bd84-3925d8b53326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f53811ad-a51a-40a4-8001-17b6fbbea400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f57a54f1-5233-4d73-9bd8-566ae74872e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f719cc4a-1b2f-4a9f-8aa9-a03779cd52bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f78b877b-0271-4d1a-947d-9c726f07a8bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7b273cd-4c72-409d-97ae-7c64008c43b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7d224a0-d8ce-405f-8a66-7a5c7ceec004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f88ae597-74c9-41cb-8da2-ca7e310ac907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa219022-bcdb-4c57-9659-88770a219b25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb99ca50-d416-41f6-891a-c4cf6cba220c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_006a226d-1684-4b7d-aef7-38226ec504b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02b5724b-2262-4373-b315-c82a3fbab1fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05fa6023-9251-45f1-b9a3-f304f3689065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06cd052d-df60-42b2-bbee-bb15f02e89e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08197314-2cfa-4bcf-ab84-5468f429d84d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08bbabe7-2cfc-4fb4-869c-d82c58a794fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_093ed038-7ba6-4156-b45c-e468a7894554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0986cdf2-4ce0-4de3-bb22-9ebbf6a743b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e2a4e95-63a9-4653-b397-04670a792eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_108ceae3-8677-4c2a-bece-c31f8942d06e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_110c283e-33db-423a-9912-c4662332850f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_117752af-ee4a-40bc-b530-1ca28e52766e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_119abe86-5d9b-4ff1-b9ae-9decf2c2298c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11ca0293-f87d-4136-bd9f-6c3103db98f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12ad4aaf-5e7d-4fa1-9234-52fe93bfd5bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17084da0-52d8-4270-8220-a08b6ecfaf36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18730f9a-a885-4097-a823-63b86ec6829b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18f57745-d287-4eac-8622-5474e59d7035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19638482-6283-456c-9cef-dc88ad0ab44d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b3ef3ae-d5cc-45c4-ae05-160ed7b1ac2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bcb0469-f3b0-4af9-b7bf-1fed7508ba3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f0242db-35be-4a94-996c-e3a0577776cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f4d112b-20a6-4e9d-97f9-f7a1a462f430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2152facb-460b-4ca8-8869-28dc2ee681ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2424ad23-6a69-42b1-a6e1-2f30f781a186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_255e918e-22cd-4e56-adc9-8e0aea00d489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:PreFundedWarrantsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26ef2d05-ad13-40b9-b1cd-8c679a6ad1df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28f891fe-292b-4351-a216-491a3a56cdf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29f339b8-0983-4068-aee7-ce961fb7cfc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f4f1a74-621e-4e7e-aeb7-2562d72aa3c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fe731eb-6df8-4233-8a24-a64517ed6900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3072375a-82e6-4b42-a83d-501afdf94d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:PreFundedWarrantsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_365cd7e2-07a9-4efd-af57-00bb25764e5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3706be79-6eca-451d-b612-a19d5eada7ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_388b46ad-84e8-4acc-b6cd-3a828d7b5577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39770d05-317d-4e4d-a9cd-aadde8fbebc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a7401ae-87da-4602-a270-a264467fbebd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:ShanghaiJemincarePharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ad90f5b-fa56-4503-84e3-c127661aabaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bb7c759-dbd3-4996-adf8-03437b940c96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46e9a44b-4010-48bc-aa78-5d77603ab178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_474bbfae-df71-4a9f-b05e-2f653dc760c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dc15569-4eb9-4821-a23f-93603c6bda00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4eb091eb-a136-4c83-90f1-55a88abbc9c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_508274a6-0773-4df0-8e48-b81976e6b710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:SharesAvailableForFutureGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52a5a19e-2682-4c27-890f-1cf4909b6bb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54a69405-ede9-4232-ba03-df78ed069f51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5850ebc9-a864-4a07-a4fc-8f60c63fa87e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60522021-60ee-4c57-928c-e5bf166e8dd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60748a66-c7ad-493a-bbe4-e095553212e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_628c0f63-7e74-4ded-878d-c94d2ab2ac7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63adb612-f691-4603-b16a-5c0d182d8352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67fdbf90-7e52-44e3-b080-ab409b95b669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d1d2bf1-3fd1-4020-ae5b-151e6c3dfe1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e61294d-f16c-4cf1-97b3-5a12f717970c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ebc3359-abcc-404b-a473-e2b68d08293c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6efad3db-74b5-461f-bbce-26e3290c27ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70e17388-d873-445b-a20e-38ec5ac336ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7737f7f8-c088-4597-a957-a9d86cf2d767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dfadab9-2f94-475c-bf05-4080b7f6c2de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e94663b-2499-455a-afcd-6856ab82b16c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ed4539c-e1c4-44f1-882d-04dd7e36cd8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Employees"><xbrli:measure>rapt:Employees</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>rapt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Institution"><xbrli:measure>rapt:Institution</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_768a7b42-ecbf-4a0f-8cfc-39dcf36d8695" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0ba8831a-5c71-43b9-920b-b98befea66cc" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43f99aa5-70bc-486c-84c9-29a6225bf706" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d54cb0c5-5eb2-49fc-bdd3-dc2a6431af5b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1dacc67f-cbaa-4484-9e98-bb22db3e7c88" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ed00cc7e-af5c-4b51-805d-c55850a08922" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from                      to</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission file number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7dbf976-1410-4184-bd26-c6917dcbd83d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-38997</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce943e60-e24e-4b8b-87ea-146b4d58affa" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its charter)</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4f8faeb4-8f17-4fd1-b5f5-ed650a73bbcd" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_de489393-eac0-45b8-813c-266adb1a2551" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-3313701</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abfd0d5b-6ba0-4690-bf4c-54785a9dea5a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">561 Eccles Avenue</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c3e896b-fb1a-4287-bbd4-6930845ac945" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de407228-7d82-4e28-9dca-bfaca76c1870" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e1a83ca-3aca-4dea-b603-cba95e2aded4" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices and zip code)</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abfc093b-ddf7-430c-a3e7-7344d21f2798" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bed0990c-7cfa-4c42-b351-18f4785aa6ae" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">489-9000</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.988%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.004%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:40.008%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of Each Class of Securities Registered</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Each Exchange on Which Registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ebe7c0e1-798a-4e95-8225-7842bf709d07" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_d2726bdc-d200-474f-b4f3-8032969cdc9d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RAPT</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_8133232d-eea3-4726-9b79-a1956e437633" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f6831a3-ef19-4d61-8ed0-8bacfa93536a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da3a15f5-554f-4112-8cec-ca2931c0f74d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e586ead7-cf5e-41b8-9338-04ae18c251d5" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a220f39b-f5a0-4a1c-9625-43b2d58b6fc5" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:25%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_196be88c-c5eb-437c-8809-3b67d6602247" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1a98a1e7-04ab-48b4-9d1c-9ac20efb30cb" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_68b734b2-5e41-47fb-9dd2-8b1bdec486f4" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7ffdf790-0657-4746-bc8f-ac9c4fe6104e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f094f5a5-d9a5-43ca-9eb9-ffc62755df9b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0d6f8e5b-1205-4f9f-b96c-c6d975093c91" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 28, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebd894b0-5b8e-4d30-b3c4-b36c93d30be4" contextRef="C_a1e1225b-2612-4af9-939a-2d52c9f5e2f3" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, based on the closing price of the registrant&#8217;s common stock, as reported by the Nasdaq Global Market on June 28, 2024 of $3.05 per share. Shares of the registrant&#8217;s common stock held by each executive officer, director and holder of 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 3, 2025, the number of outstanding shares of the Registrant&#8217;s common stock, par value $0.0001 per share, was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b2c105a-a921-4c8d-84f0-2b794f8fdebb" contextRef="C_93fa0d2c-4808-4cba-b804-5817b70b6002" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">132,006,828</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_599cef7b-c543-4958-be6e-612b9720c07a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="table_of_contents"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TAB</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LE OF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:79%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7__management_s_discussion_and_anal"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclo1"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">__________________________________</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the context suggests otherwise, references in this Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) to &#8220;us,&#8221; &#8220;our,&#8221; &#8220;RAPT,&#8221; &#8220;RAPT Therapeutics,&#8221; &#8220;we,&#8221; the &#8220;Company&#8221; and similar designations refer to RAPT Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Annual Report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements are often identified by the use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for additional financing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, cost, timing, progress and results of research and development activities, preclinical studies and clinical trials with respect to RPT904, tivumecirnon (FLX475) and other potential future drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify, develop and commercialize drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to advance RPT904, tivumecirnon or other potential future drug candidates into, and successfully complete, preclinical studies and clinical or field trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of RPT904, tivumecirnon or other potential future drug candidates, and any related restrictions, limitations and/or warnings in the label of an approved drug candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our technology and any of our drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize any of our current or potential future drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance of any of our drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments in the United States and international jurisdictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability lawsuits and penalties related to our technology, our drug candidates and our current and future relationships with third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain key scientific and management personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage the growth of our operations;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete effectively with existing competitors and new market entrants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding uses of proceeds from capital raising transactions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential effects of extensive government regulation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the volatility of the trading price of our common stock; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These statements are based on the beliefs and assumptions of our management, which are in turn based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; included under Part I, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations, prospects and stock price. Some of these risks are:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future product candidates may fail or suffer delays in clinical development that materially and adversely affect their commercial viability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage therapeutics company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to build a pipeline of drug candidates, and as an organization we have no history of successfully developing drugs.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market may not be receptive to our current or potential future drug candidates and we may not generate any revenue from the sale or licensing of our drug candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or others later identify undesirable side effects caused by our current or potential future drug candidates, our ability to market and derive revenue from the drug candidate could be compromised.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need substantial additional funds to discover and advance development of drug candidates and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future drug candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If third parties on which we rely to conduct certain preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse impacts on our business and financial condition.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we may rely on third parties, some of which are or may be sole source vendors, for manufacturing and supply of our drug candidates and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face intense competition from entities that have developed or may develop drug candidates for the treatment of the diseases that we are currently targeting or may target in the future. If these companies develop technologies or drug candidates more rapidly than we do, or if their technologies or drug </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates are more effective, our ability to develop and successfully commercialize drug candidates may be adversely affected.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our drug candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our present and potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business could be materially and adversely affected in the future by effects of disease outbreaks, epidemics and pandemics.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, enforce or defend intellectual property rights related to our technology and current or future drug candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure, or that of the third parties with whom we work, to comply with such obligations could lead to government investigations or enforcement actions, which could include civil or criminal penalties, litigation, including class claims, and mass arbitration demands; fines or penalties; or disruptions of our business operations, reputational harm, loss of revenue or profits, adverse publicity and other adverse business consequences, which could negatively affect our operating results and business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal stockholders own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report on Form 10-K are the property of their respective owners.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1. Business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Our lead drug candidate, RPT904, is a half-life extended monoclonal antibody (&#8220;mAb&#8221;) designed to bind free human immunoglobin E (&#8220;IgE&#8221;), a key driver of several allergic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into an exclusive license agreement (the &#8220;Jemincare License Agreement&#8221;) with Shanghai Jemincare Pharmaceutical Co., Ltd (&#8220;Jemincare&#8221;), a subsidiary of Jiangxi Jemincare Group</span><span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Co., Ltd., under which we have exclusive rights to develop and commercialize RPT904 worldwide, excluding mainland China, Hong Kong, Macau and Taiwan (together, the &#8220;Jemincare Territory&#8221;). We believe RPT904 could offer patients a potentially improved therapeutic option compared to omalizumab (Xolair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), an anti-IgE antibody approved for asthma, chronic spontaneous urticaria (&#8220;CSU&#8221;), chronic rhinosinusitis with nasal polyps and food allergy. In a Phase 1 clinical trial conducted by Jemincare comparing RPT904 and omalizumab, the median half-life of RPT904 was more than two times that of omalizumab at the same dose, and RPT904 demonstrated deeper and more sustained reduction of free IgE and higher total IgE accumulation compared to omalizumab at the same dose. We plan to pursue clinical development of RPT904 initially in food allergy and CSU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (&#8220;CCR4&#8221;) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (&#8220;T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) into tumors. Data from a Phase 2 trial of patients with advanced checkpoint-na&#239;ve non-small cell lung cancer (&#8220;NSCLC&#8221;) treated with tivumecirnon in combination with the checkpoint inhibitor</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pembrolizumab showed greater confirmed objective response rate and progression free survival than what has historically been demonstrated by pembrolizumab monotherapy. We hold worldwide rights to tivumecirnon, with the exception of the exclusive license (the &#8220;Hanmi License Agreement&#8221;) granted to Hanmi Pharmaceutical Ltd. (&#8220;Hanmi&#8221;) in Korea, mainland China, Hong Kong, Macau and Taiwan (together, the &#8220;Hanmi Territory&#8221;). We are seeking a partner to further develop tivumecirnon outside the Hanmi Territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zelnecirnon, our small molecule CCR4 antagonist for inflammatory disease, was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis (&#8220;AD&#8221;). Both trials were placed on clinical hold by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2024 due to a serious adverse event (&#8220;SAE&#8221;) of liver failure in one patient in the AD trial, and we subsequently closed both trials. In November 2024, based on feedback from the FDA, we ceased development of zelnecirnon. We are currently pursuing different novel CCR4 antagonists that we believe may have improved safety margins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.139%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.283692012392944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance RPT904 through clinical development to commercialization in food allergy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Food allergy is a significant and growing health problem in the United States, Europe and throughout the developed world, affecting as much as 10% of the population. Food allergy represents a large and significant unmet need and omalizumab is the only FDA-approved drug to reduce allergic reactions to multiple foods. We believe RPT904, if approved could offer an improved treatment option with a less burdensome dosing regimen than omalizumab and could also treat patients with high IgE or high weight who are not currently eligible to be treated with omalizumab. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.139%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.283692012392944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand development of RPT904 into CSU and potentially other inflammatory diseases. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSU affects 1% of the general population and patients are generally treated first with H1-antihistamines. However, approximately 40% of patients with CSU do not respond to H1-antihistamines, and omalizumab is the only approved biologic drug that can be prescribed as second-line treatment for CSU patients. As with food allergy, we believe RPT904, if approved, could offer an improved treatment option with a less burdensome dosing regimen than omalizumab for patients with CSU.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.139%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.283692012392944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilize collaborations and partnerships to support our long-term goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We plan to selectively enter into collaborations and partnerships as strategic tools aimed at maximizing the value of our drug candidates. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.139%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.283692012392944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance a next-generation CCR4 antagonist to clinical development for a range of inflammatory diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We believe there remains significant unmet medical need and market potential for a safe and efficacious oral agent for the treatment of Th2-driven inflammatory diseases, such as AD, asthma and potentially additional inflammatory diseases. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RPT904 &#8211; Our half-life extended anti-IgE monoclonal antibody</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RPT904 is a half-life extended anti-IgE monoclonal antibody. IgE plays a role in causing multiple diseases such as food allergy, CSU, asthma and chronic rhinosinusitis. While omalizumab was recently approved to treat food allergy, we believe RPT904, if approved, could provide an improved treatment option with a less burdensome dosing regimen than omalizumab and could be used to treat high-IgE and high-weight patients who are not currently eligible to be treated with omalizumab.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under the Jemincare License Agreement, we hold exclusive rights worldwide, excluding the Jemincare Territory, to RPT904 and to patent applications with respect to RPT904; any patents that might issue from our licensed patent applications are scheduled to expire in 2041 (not including any applicable patent term extensions, if approved). These patent applications cover the RPT904 composition of matter, pharmaceutical compositions thereof and uses thereof, as well other related compounds. As consideration for the license, we paid Jemincare a $35.0 million upfront license fee and could pay up to $672.5 million in milestone payments as well as tiered royalty payments (at percentages ranging from high single-digit to low double-digit) on future net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Food Allergy Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Food allergy is a significant and growing health problem in the United States, Europe and throughout the developed world. It is estimated that over 17 million people in the United States have been diagnosed with a food allergy, including approximately six million children. Approximately 40% of people with a food allergy are allergic to more than one food and approximately half of food-allergic people in the United States have had a severe reaction from their food allergy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Food allergy occurs when the immune system responds to a harmless food as if it were a threat. In a non-allergic patient, tolerance for food proteins develops early in life and the immune cells do not mount a response when food proteins are detected. In an allergic patient, the immune system is sensitized to one or more food proteins, or allergens (&#8220;sensitization&#8221; phase). As a result of this sensitization, the patient&#8217;s immune system produces IgE antibodies, which are directed against that particular allergen. The IgE antibodies bind to mast cells and basophils via its receptor called Fc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R1. When an IgE antibody bound to these immune cells encounters the allergen it is directed against the mast cells and basophils are activated and release histamine and other inflammatory mediators which then provoke the symptoms of an allergic reaction (&#8220;effector&#8221; phase). Symptoms may include hives, swelling, vomiting, abdominal pain, wheezing, breathlessness and lowered blood pressure. Allergic reactions can be triggered by exposure to minute quantities of the relevant food allergen and can be painful, frightening and potentially deadly. Severe and potentially life-threatening reactions are referred to as anaphylaxis, and such reactions require urgent medical attention and often result in treatment at hospital emergency departments.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img57771353_0.jpg" alt="img57771353_0.jpg" style="width:545px;height:248px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most common approach to manage food allergy is strict avoidance of food allergens and emergency treatment of allergy symptoms in the event of an accidental exposure. Strict avoidance can be difficult to achieve and the burdens of practicing avoidance can have a substantial negative impact on the quality of life of food-allergic patients and their families. Moreover, accidental exposures, especially in children, remain a common issue, and food-allergic patients typically must carry rescue medication to treat severe and possibly life-threatening allergic reactions. The most widely used rescue medication is epinephrine, which blunts certain symptoms of the allergic reaction but does not treat the allergic reaction itself. While epinephrine is useful as a rescue medication, it may not be sufficient to counteract the effects of the allergic reaction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Desensitization therapy, which consists of repeated administrations of increasing quantities of an allergen in order to decrease the immune response to that allergen, is the most common proactive approach to treating food allergy. Oral immunotherapy (&#8220;OIT&#8221;), which involves the oral consumption of increasing doses of a food-based product on a daily basis over a period of months, has the potential to produce a high degree of desensitization and a proprietary form of OIT, Palforzia</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is approved in the United States and the European Union for the treatment of peanut allergy in children aged 4&#8211;17 years. OIT, however, has a number of limitations, such as a relatively high rate of systemic side effects, limitations it places on many activities of daily living, including exercise, and unpredictability of tolerance in the setting of intercurrent illness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other desensitization approaches under clinical investigation include sublingual immunotherapy (&#8220;SLIT&#8221;), which involves the administration of increasing amounts of food extract under a patient&#8217;s tongue, and epicutaneous immunotherapy (&#8220;EPIT&#8221;), which involves the use of a patch that causes allergens to be absorbed by the skin to initiate desensitization. Both SLIT and EPIT approaches have shown some clinical success with less severe side effect profiles compared to OIT; like OIT, however, they generally are specific to a single food allergen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-IgE therapy aimed at blocking the binding of IgE to mast cells and basophils is another therapeutic approach. The anti-IgE antibody omalizumab was recently approved by the FDA for the reduction of allergic reactions, including anaphylaxis, that may occur upon accidental exposure to one or more foods in patients with IgE-mediated food allergy. As shown in the graphic above, anti-IgE mAbs such as omalizumab bind to IgE, eliminating most of the IgE in the systemic circulation and preventing IgE from binding to mast cells and basophils; omalizumab also removes allergen-IgE complexes already bound to mast cells, thereby preventing and reducing the release of inflammatory mediators. Omalizumab reduces the availability of all IgE, not just IgE that recognize a specific allergen, so omalizumab can block reactions to multiple food allergens.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chronic Spontaneous Urticaria Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSU is one of a group of skin conditions that are characterized by hives, redness, itching and swelling, lasting for greater than six weeks. The trigger for CSU is unknown. Symptoms result from the degranulation of dermal mast cells and IgE signaling likely contributes to inappropriate mast cell activation. CSU affects 1% of the general population, with women affected more often than men. Though both children and adults can be diagnosed with CSU, patients typically show initial symptoms in the third to fifth decades of life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current treatment guidelines for CSU recommend the use of oral H1-antihistamines as a first-line therapy, with dose escalation of up to four times the standard dose in lower responders. Approximately 40% of patients with CSU do not respond to H1-antihistamines and can be prescribed omalizumab, which maintains an approximately 65% response rate as a second-line treatment. Omalizumab is currently the only FDA-approved biologic for treatment of CSU patients whose disease is inadequately controlled by antihistamines.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RPT904</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RPT904 is a half-life extended anti-IgE antibody we are developing for the treatment of food allergy, CSU and potentially other inflammatory diseases. RPT904 was developed by making targeted changes to the omalizumab sequence designed to preserve the epitope of omalizumab while improving drug-like properties, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">affinity maturation which resulted in a 4-fold increase in affinity compared to omalizumab in preclinical studies conducted by our partner Jemincare;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increase in antibody humanization level to reduce the potential for immunogenicity;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">removal of post translational modification sites to improve manufacturability and stability; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addition of the YTE mutation in the IgG1 of the Fc region of the antibody to increase the half-life of the antibody.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical studies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our partner Jemincare conducted preclinical binding studies to determine the affinity of RPT904 (Jemincare designation JYB1904) to free human IgE and to the neonatal Fc receptor (&#8220;FcRn&#8221;), which is required for the recirculation of IgG molecules and protects the antibody from degradation. In these studies, as shown below, RPT904 demonstrated an increase in affinity to free human IgE and FcRn.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57771353_1.jpg" alt="img57771353_1.jpg" style="width:624px;height:59px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in functional cell-based assays, RPT904 demonstrated an enhanced ability to prevent the degranulation of RBL-2H3/Fc&#603;RI cells and release of hexosaminidase, which is known to contribute to the inflammatory response to allergen exposure.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img57771353_2.jpg" alt="img57771353_2.jpg" style="width:540px;height:266px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RPT904 was also assessed in a non-human primate model of asthma. In this model, the animals were characterized by (i) significant increases in airway resistance and decrease in lung compliance, and (ii) increased levels of free IgE, eosinophils and Th2-associated cytokines in the peripheral blood and the bronchoalveolar lavage fluid (&#8220;BALF&#8221;), all of which are consistent with the disease. Animals receiving RPT904 demonstrated significantly decreased levels of free IgE, eosinophil and white blood cell counts in the BALF following an intranasal allergen challenge. Importantly, animals receiving RPT904 demonstrated improved respiratory function as measured by airway resistance and dynamic lung compliance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RPT904 Phase 1 clinical data</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our partner Jemincare conducted a randomized, double-blind, placebo-controlled Phase 1 study in healthy volunteers evaluating single doses of RPT904 ranging from 75 mg to 600 mg (75, 150, 300, 450, 600 mg) administered subcutaneously with six months of follow-up to evaluate safety, pharmacokinetic (&#8220;PK&#8221;), and pharmacodynamic (&#8220;PD&#8221;) properties of RPT904. The study also included a cohort of healthy volunteers who received a single subcutaneous dose of 150 mg of omalizumab to allow direct comparison of PK and PD properties. At the head-to-head 150 mg dose, RPT904 demonstrated superior (deeper and more prolonged) free IgE reduction and more than twice the half-life (60 days vs 26 days) compared to omalizumab. Our PD modeling suggests that these properties could allow less frequent dosing regimens, such as every 8 weeks or every 12 weeks (Q8W or Q12W, respectively) for RPT904 to achieve similar effects to omalizumab, which currently requires every 2 weeks or every 4 weeks (Q2W or Q4W, respectively) dosing for efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RPT904: Phase 2b Clinical Trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in Food Allergy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are planning a double-blind, placebo-controlled Phase 2b trial in patients with at least one documented food allergy (using stringent criteria based on those used in the omalizumab pivotal trial), randomized 2:2:1 to receive RPT904 on a Q8W regimen, RPT904 on a Q12W regimen, or placebo. The primary objective of the study will be to compare the ability to achieve tolerance to a pre-specified threshold of food protein in a double-blind placebo-controlled oral food challenge.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tivumecirnon&#8212;Our Oncology Drug Candidate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into tumors, while sparing T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in healthy tissues and without negatively impacting effector immune cells. T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> represent a dominant pathway for downregulating the immune response. We are focused on developing tivumecirnon in NSCLC, a tumor type that has high levels of T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and CCR4 ligands, for which we believe there remains significant unmet need. We are seeking a partner to further develop tivumecirnon outside the Hanmi Territory.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own an issued U.S. composition of matter patent directed to tivumecirnon that is scheduled to expire in 2037 (not including any applicable extensions, if approved). We entered into the Hanmi License Agreement, whereby we granted Hanmi the exclusive rights to develop, manufacture and commercialize tivumecirnon in the Hanmi Territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Small Cell Lung Cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NSCLC is the most common type of lung cancer, representing 81% of all lung cancer cases in the United States. Squamous cell carcinoma, adenocarcinoma and large cell carcinoma are all subtypes of NSCLC. Lung cancer is one of the leading causes of cancer death for both men and women, with an estimated 127,070 deaths in the United States from lung cancer in 2023. There are approximately 238,000 diagnoses of lung cancer annually in the United States. Despite the availability of numerous therapies, the prognosis remains poor, with an overall five-year survival rate for all patients diagnosed with NSCLC as low as 28%.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard therapies include surgery, chemotherapy and radiation therapy. Up to a third of NSCLC patients have tumors with mutations in genes, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> epidermal growth factor receptor and anaplastic lymphoma kinase, for which molecularly targeted therapies have been approved, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> erlotinib, gefitinib or crizotinib.</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, these treatments usually do not result in long-term remissions, and the tumors generally return and become resistant to therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immunotherapies that target PD-1 or the PD-1 ligand (&#8220;PD-L1&#8221;), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, pembrolizumab, nivolumab and atezolizumab, have been approved for the treatment of patients with advanced or metastatic NSCLC either alone (for previously untreated or treated patients) or in combination with chemotherapy (for previously untreated patients). Treatment with these anti-PD1 agents in NSCLC has resulted in promising activity ranging from approximately 15-30% overall response rates (with the higher response rates in tumors expressing higher levels of PD-L1) in previously treated patients to approximately 40-60% response rates in combination with chemotherapy in previously untreated patients. However, approximately 50-80% of patients do not respond to these therapies, indicating significant unmet medical need remains. NSCLC is a tumor type that has high levels of T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and CCR4 ligands, which suggests that the presence of T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be interfering with an antitumor response.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tivumecirnon Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FLX475-01: A Phase 1 Clinical Trial of Tivumecirnon in Healthy Volunteers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a placebo-controlled, double-blind dose-escalation Phase 1 clinical trial of tivumecirnon in 104 healthy volunteers. In this Phase 1 trial, tivumecirnon was well tolerated and demonstrated dose-dependent inhibition of CCR4 with no observed immune-related adverse events or significant clinical adverse events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Oral dosing of tivumecirnon led to linear pharmacokinetics and a clear dose-related inhibition of CCR4 with low subject-to-subject variability. Based on analysis of the multiple dose data, at the 75 mg once-daily dose, 75% receptor occupancy was achieved in six out of six healthy volunteers, which, in our preclinical studies, corresponded with 90% inhibition of in vitro T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> migration and the highest level of inhibition of in vivo T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> migration and antitumor activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tivumecirnon was well tolerated, with no significant lab abnormalities, serious adverse events or dose-limiting clinical adverse events. There was no evidence of autoimmunity or changes in peripheral blood immune cell populations. Sporadic Grade 1 corrected Q-T interval (&#8220;QTc&#8221;) prolongation was observed in nearly every cohort, including placebo. No QTc prolongation greater than Grade 1 was observed in 14-day multiple ascending dose cohort doses through 300/100 mg (300 mg Day 1 loading dose followed by 100 mg once daily), including the projected efficacious dose of 75 mg once daily. At the highest dose (300/150 mg) correlating with exposures three to five times that needed to achieve efficacious exposure, two subjects out of six dosed with tivumecirnon met QTc stopping criteria (greater than 60 msec prolongation from baseline, one of whom also exhibited a transient Grade 2 QTc prolongation), which were asymptomatic and not associated with arrhythmia or any other adverse event.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FLX475-02: A Phase 1/2 Dose Escalation and Expansion Study of Tivumecirnon Alone and in Combination with Pembrolizumab in Advanced Cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also conducted a Phase 1/2 trial of tivumecirnon as monotherapy and in combination with pembrolizumab for various advanced cancers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 portion of the trial was a standard dose escalation study intended primarily to evaluate safety, pharmacokinetics and pharmacodynamics in patients with multiple tumor types. A total of 37 patients with cancers of different types were enrolled. Nineteen patients were treated with one of four doses (25 mg, 50 mg, 75 mg or 100 mg once daily) of tivumecirnon monotherapy and 18 were treated with one of three doses (50 mg, 75 mg or 100 mg once daily) of tivumecirnon in combination with the standard dose of pembrolizumab. The Phase 1 results showed tivumecirnon had a favorable safety profile, with no maximum tolerated dose reached. Two dose-limiting toxicities (&#8220;DLTs&#8221;) of asymptomatic QTc prolongation were observed in the monotherapy cohorts, one in the 75 mg cohort and one in the 100 mg cohort. No DLTs were observed in the Phase 1 combination cohorts. Based on the Phase 1 data, 100 mg was selected as the recommended Phase 2 dose for both the monotherapy and combination therapy cohorts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug exposures were roughly dose-proportional and consistent with the previous Phase 1 study in healthy volunteers. The majority of patients on the 75 mg daily dose reached the targeted exposure level. Receptor occupancy of CCR4 on T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was also proportional to tivumecirnon exposure levels and consistent with that previously observed in healthy volunteers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Phase 1 portion of the trial, of 17 evaluable monotherapy patients, there was one unconfirmed partial response in a patient with relapsed metastatic cervical cancer. Of 14 evaluable patients in the combination cohorts, there were two confirmed partial responses: a patient with NSCLC who had progressed on prior anti-PD1 checkpoint treatment (atezolizumab) and who at the time of disclosure was on study for 18 months of treatment, and a patient with checkpoint inhibitor-na&#239;ve urothelial cancer who at the time of disclosure was on study for over nine months of treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Data in Checkpoint Inhibitor-Naive Non-Small Cell Lung Cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 2 portion of the Phase 1/2 trial was designed to evaluate tivumecirnon as monotherapy and in combination with pembrolizumab in patients with several cancer types including NSCLC. Patients were dosed with tivumecirnon as monotherapy (100 mg once daily) or in combination with pembrolizumab (100 mg once daily and a standard regimen of pembrolizumab).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we completed the enrollment and follow-up of patients with CPI-na&#239;ve NSCLC treated with the combination of tivumecirnon and the anti-PD1 checkpoint-inhibitor pembrolizumab. In this cohort of NSCLC patients, 36 patients were evaluable for efficacy, of whom 20 were PD-L1 positive (TPS &#8805; 1%). In these PD-L1 positive patients, the combination of tivumecirnon and pembrolizumab showed a 45% (9/20) confirmed ORR and a median PFS of 6.5 months. For comparison, historical pembrolizumab monotherapy activity in checkpoint inhibitor-na&#239;ve and previously treated NSCLC patients showed a confirmed ORR of 18% and a median PFS of 4.0 months. The confirmed ORRs for the combination of tivumecirnon and pembrolizumab in the PD-L1 low and high subsets were 44% (7/16) and 50% (2/4), respectively. For comparison, the ORR for pembrolizumab monotherapy in the PD-L1 low and high subsets has been previously reported as 10% and 30%, respectively.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The combination of tivumecirnon and pembrolizumab was well tolerated in this Phase 2 NSCLC cohort. The most common treatment-emergent adverse event deemed related to study treatment was QT prolongation, which was asymptomatic and reversible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img57771353_3.jpg" alt="img57771353_3.jpg" style="width:619px;height:312px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Efficacy Data Reported from Phase 1/2 Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, we reported data from the Phase 1/2 trial from six patients with EBV+ NK/T cell lymphoma treated with tivumecirnon monotherapy. Of these six patients, there were four responses, with two durable complete metabolic responses (CMR), one unconfirmed CMR and one unconfirmed partial metabolic response.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safety Data from Phase 1/2 Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tivumecirnon has demonstrated a favorable safety profile with once-daily oral dosing both as monotherapy and in combination with pembrolizumab, with no new significant safety findings compared to those previously reported in healthy volunteers and in patients from the Phase 1 portion of the trial. The only adverse event deemed related to the trial treatment was QT prolongation, which was asymptomatic and reversible. As of December 2024, tivumecirnon has been dosed in more than 300 patients with various advanced cancers and has been generally well tolerated, and the combination with pembrolizumab has not increased immune-related toxicity beyond that expected with pembrolizumab alone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biomarker Data from Phase 1/2 Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biomarker data obtained from the patients in the Phase 1/2 trial may inform the generation of a companion diagnostic that could potentially be used to prospectively select for patients who may be more likely to respond to tivumecirnon therapy in a future study, thus increasing the chances of a positive trial result and regulatory approval. Key biomarkers include the CD8:T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ratio as detected by immunohistochemistry or transcriptomics, and exploratory analyses including immune phenotyping and T cell clonality. Preliminary data from our measure of CD8 and T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by IHC indicate an increase in the CD8:T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ratio in the majority of monotherapy patients with paired tumor biopsies from both the Phase 1 and Phase 2 portions of the ongoing Phase 1/2 trial. This suggests activity consistent with our intended mechanism of action and potentially beneficial changes in the TME. Analysis of transcriptomic data from biopsies obtained from CPI-na&#239;ve patients prior to treatment suggest that higher levels of T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at baseline correlate with improved response. Analysis of T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in peripheral blood of patients prior to treatment indicate that subjects with lower levels had better progression-free survival than those with higher levels. Both of these findings are consistent with our T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-focused mechanism of action and contrasted with reported data for pembrolizumab, suggesting specificity for tivumecirnon. These observations will require further validation in subsequent studies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img57771353_4.jpg" alt="img57771353_4.jpg" style="width:624px;height:458px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">owe</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Next-Generation CCR4 Antagonist for Inflammatory Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have identified the cell surface receptor CCR4 as a drug target that potentially has broad applicability in inflammatory diseases. Receptors such as CCR4 bind to chemokines that orchestrate migration and homing of immune cells to specific tissues throughout the body. Chemokines specific for CCR4 are secreted from inflamed tissues but are not highly expressed in healthy tissues. Th2 cells produce inflammatory cytokines such as IL-13, express high levels of CCR4 and are clinically validated drivers of many inflammatory diseases, including AD, asthma, CSU, CRSwNP, alopecia areata, prurigo nodularis and eosinophilic esophagitis. When a pathogen comes into contact with the skin or mucosal lining of the nose or lungs, innate immune cells and antibodies that recognize the pathogen initiate a release of inflammatory cytokines. While this Th2 response may be highly effective against foreign pathogens, particularly parasites, sometimes the body overreacts to benign substances in this way, resulting in a significant influx of Th2 cells, leading to highly inflammatory conditions. We believe there is an unmet need in the treatment landscape for a safe and efficacious oral therapy for the long-term treatment of these inflammatory diseases and that an oral, small molecule CCR4 antagonist designed to block the migration of inflammatory Th2 cells into inflamed tissues, can, if approved, fill this unmet need. We are currently pursuing different novel CCR4 antagonists.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining, enforcing and defending our intellectual property rights, including patent rights, whether developed internally or licensed from third parties. We rely, in part, on trade secrets and know-how relating to our proprietary technology and drug candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely, in part, on data exclusivity, market exclusivity and patent term extensions if and when available. Our commercial success will depend in part on our and our partners</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ability to obtain and maintain patent and other intellectual property protection for our and our partners</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> licensed technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we own or license or for which we may obtain ownership or a license to in the future; and to operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and other intellectual property rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RPT904</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have exclusively licensed one pending U.S. patent application directed to RPT904 and other related compounds, pharmaceutical compositions comprising the same and therapeutic methods of using the same for the treatment of diseases associated with abnormal IgE levels; and thirteen corresponding pending patent applications in Australia, Brazil, Canada, China, Europe (European Patent Convention), Hong Kong, Israel, India, Japan, South Korea, New Zealand, Singapore and Taiwan. Any patents that may issue from our licensed pending applications worldwide are scheduled to expire in 2041, excluding any additional term for patent term adjustment(s) or extension(s), and assuming payment of all applicable maintenance or annuity fees.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tivumecirnon</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we own two issued U.S. patents directed to tivumecirnon and other related compounds, pharmaceutical compositions comprising the same and therapeutic methods of using the same for the treatment of diseases including cancers; one corresponding pending patent application in the U.S. and three corresponding pending patent applications in Canada, Israel and Japan; and 37 corresponding issued patents in Australia, China, Hong Kong, 23 countries through the European Patent Convention, India, Japan, South Korea, Macao, Mexico, New Zealand, Singapore, South Africa and Taiwan. Our issued U.S. patents, and any patents that may issue from our pending applications worldwide, are scheduled to expire in 2037, excluding any additional term for patent term adjustment(s) or extension(s), and assuming payment of all applicable maintenance or annuity fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also own one granted U.S. patent, one U.S. patent application, corresponding issued patents in China and South Africa and 13 corresponding pending patent applications in Australia, Brazil, Canada, Hong Kong, the European Patent Convention, India, Israel, Japan, South Korea, Mexico, New Zealand, Singapore and Taiwan directed to polymorphic forms of tivumecirnon and formulations thereof. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2040, excluding any additional term for patent term adjustment(s) or extension(s).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the composition of matter patents and patent applications described above, as of December 31, 2024, we own one issued U.S. patent, six corresponding patents issued in Australia, Israel, Mexico, New Zealand, South Africa and Taiwan, and 9 corresponding pending patent applications in Brazil, Canada, China, Hong Kong, the European Patent Convention, Japan, South Korea, and Singapore, all directed to the use of CCR4 antagonists generally, including tivumecirnon specifically, in therapeutic methods of treating EBV positive cancers. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2038, excluding any additional term for patent term adjustment(s) or extension(s).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the above-mentioned patents and applications remain in force subject to us making timely payment of all applicable maintenance and annuity fees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of our provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent application, we may lose our priority date with respect to any such provisional patent application and any patent protection on the inventions disclosed in any such provisional patent application. With respect to our drug candidates, we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. We may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world. Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States expire 20 years after the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. For more information regarding patent term extensions, please see &#8220;Business&#8212;U.S. Patent Term Restoration and Marketing Exclusivity&#8221; below. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. The patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or drug candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining, maintaining, enforcing and defending patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we ensure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, any issued patents we obtain do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our drug candidates and practicing our proprietary technology, and our patent rights may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our drug candidates. In addition, the scope of the rights granted under any issued patent that we own or license, now or in the future, may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents we obtain. For these reasons, we may face competition with respect to our drug candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular drug candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential information are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with collaborators, scientific advisors, employees and consultants, and invention assignment agreement with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or drug candidates or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreement with Jemincare</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into the Jemincare License Agreement. Subject to certain retained rights, Jemincare granted us: (1) the exclusive and sublicensable rights to develop, manufacture, commercialize and otherwise exploit Jemincare&#8217;s anti-IgE monoclonal antibody RPT904 (together with certain related molecules, the &#8220;Licensed Molecules&#8221;) throughout the world (except the Jemincare Territory) for any and all uses; (2) the non-exclusive and sublicensable rights to develop the Licensed Molecules in the Jemincare Territory solely for the purposes of exploiting the Licensed Molecules in our territory; and (3) the non-exclusive and sublicensable rights to manufacture the Licensed Molecules in the Jemincare Territory solely for the purposes of exercising our rights in the foregoing (1) and (2).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the rights granted to us by Jemincare, we paid Jemincare $35.0 million, an upfront license fee, and could pay up to $672.5 million in additional milestone payments as well as tiered royalty payments (at percentages ranging from high single-digit to low double-digit) on future net sales. The additional milestone payments include $1.5 million upon the completion of manufacturing technology transfer, up to $226.0 million upon the achievement of specified development and regulatory milestones, and up to $445.0 million upon the achievement of specified commercial milestones. Royalty payments will be payable on a product-by-product and country-by-country basis during the period commencing on the first commercial sale and continuing until the later of: (a) the 10-year anniversary of the date of such first commercial sale; (b) the expiration of the relevant patent claims; and (c) the expiration of the relevant regulatory exclusivity (the &#8220;Jemincare Royalty Term&#8221;). Subject to a certain floor, royalty payments will be reduced by specified percentages for patent expiration, biosimilar entry, payments for third party intellectual property, compulsory sublicenses or drug pricing programs. The Jemincare License Agreement will expire on a product-by-product and country-by-country basis upon the expiration of the applicable Jemincare Royalty Term, unless the agreement is earlier terminated by Jemincare or us in accordance with the agreement. Subject to certain exceptions and requirements, the Jemincare License Agreement may be terminated: by us for any or no reason, by a party for the other party&#8217;s material breach that is not cured within certain days, by a party for the other party&#8217;s bankruptcy, insolvency, dissolution, liquidation or winding up; or by Jemincare if we or any of our affiliates or sublicensees challenges the validity, enforceability or patentability of any licensed patent. Upon termination of the Jemincare License Agreement, the rights granted to us by Jemincare and any sublicenses granted by us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement with Hanmi</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2019, we entered into the Hanmi License Agreement, with Hanmi, a corporation organized under the laws of the Republic of Korea, pursuant to which we granted Hanmi an exclusive license to develop, manufacture and commercialize tivumecirnon and related compounds and products with respect to human cancers in the Hanmi Territory, and certain sublicense rights. In consideration of such rights, under the agreement we received $10.0 million in an upfront payment and milestone payment, and will be eligible to receive (i) additional contingent payments of up to $108.0 million upon the achievement of specified milestones, consisting of up to $48.0 million based on the dosing of the first patient in a Phase 3 clinical trial in the Hanmi Territory and the filing and approval of a new drug application in the Hanmi Territory and up to $60.0 million based on annual net sales, and (ii) low double-digit royalties on future net sales of tivumecirnon in the Hanmi Territory. Royalties will be payable on a product-by-product and country-by-country basis for a period commencing with the first commercial sale until the latest of (a) the expiration of the relevant patent right, (b) the expiration of regulatory or data exclusivity granted by the applicable governmental authority, and (c) five years from such first commercial sale (such period being the &#8220;Royalty Term&#8221; for such product and country); provided that the royalties will be reduced (x) by 50% if the product in question is not covered by a valid claim during the Royalty Term in the applicable country, (y) in connection with a license obtained from such third party in order to develop, manufacture or commercialize tivumecirnon in the Hanmi Territory and (z) by a percentage dependent on any generic products&#8217; market share in the Hanmi Territory. If we sponsor Phase 3 clinical trials for tivumecirnon for human cancers, Hanmi will have the right to participate in such trials in the Hanmi Territory. We will supply tivumecirnon for use in Hanmi&#8217;s Phase 2 clinical trials and Hanmi will reimburse us for our manufacturing costs. If requested, we will facilitate technology transfer to Hanmi for their manufacture of tivumecirnon product for Phase 3 trials and commercialization. The term of the agreement will continue until Hanmi&#8217;s royalty payment obligations have expired, unless sooner terminated by Hanmi for convenience, safety reasons, if we abandon our development of tivumecirnon and related products, if we do not consent to Hanmi&#8217;s use of tivumecirnon in any study required by applicable governmental authorities, or breach by us of our representations and warranties under the agreement. The agreement may also be terminated by either party in connection with a material breach by, or insolvency of, the other party. If Hanmi terminates the agreement with cause or for our abandonment of development of tivumecirnon and related products, material breach or insolvency, Hanmi will retain a perpetual license to certain our intellectual property related to tivumecirnon.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Merck</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, we entered into a clinical trial collaboration and supply agreement with MSD International GmbH, an affiliate of Merck (known as MSD outside the United States and Canada), under which we conducted a clinical trial evaluating tivumecirnon as monotherapy and in combination with pembrolizumab (KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. In March 2022 and February 2024, we and Merck amended the agreement to provide for additional supply of pembrolizumab. We are the sponsor of the clinical trial and are responsible for the costs of conducting it, and Merck supplied pembrolizumab for use in the clinical trial at no charge to us. Neither party has any other obligations to reimburse any costs or expenses incurred by the other party. We retain ownership of the quantities of tivumecirnon used in the clinical trial and we own the quantities of pembrolizumab supplied to us by Merck for use in the clinical trial. The agreement provides for joint ownership of any inventions, clinical data and results generated in the clinical trial that relate to the combined use of the two drugs. Merck will solely own any inventions generated in the clinical trial that relate solely to pembrolizumab and all data resulting from testing performed by or on behalf of Merck upon samples collected during the clinical trial. We will solely own any inventions generated in the clinical trial that relate solely to tivumecirnon, clinical data resulting from the use of tivumecirnon as monotherapy, and from all data resulting from testing performed by or on behalf of us upon samples collected during the clinical trial. The term of the agreement continues until delivery of the final report for the clinical trial, provided that either party may terminate the agreement due to the other party&#8217;s uncured material breach, a violation of anti-corruption obligations, patient safety concerns, regulatory action that prevents supply of such party&#8217;s compound, or such party&#8217;s termination of its compound&#8217;s development or withdrawal of its compound&#8217;s regulatory approval. Merck may also terminate the agreement if we fail to make any changes to the clinical trial protocol regarding the use of pembrolizumab that are reasonably requested by Merck to address any concern raised by Merck that pembrolizumab is being used in the clinical trial in an unsafe manner.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries, including the inflammatory disease and oncology fields, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property protection. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. We believe that the key competitive factors affecting the success of any of our drug candidates will include patient selection strategies, efficacy (single and combination strategies), safety profile, method of administration, cost, level of promotional activity and intellectual property protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RPT904 is a novel long-acting anti-IgE monoclonal antibody intended to treat allergic diseases, including food allergy and CSU. If approved for food allergy, we could face branded competition from omalizumab (Xolair) and an FDA-approved peanut allergen powder used in OIT (Palforzia</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). In addition, it is likely that omalizumab biosimilars will become available before RPT904 is approved. There are several companies developing anti-IgE treatments that may be approved for food allergy and CSU, including LongBio Pharma, United Biopharma and Yuhan. Additionally, some food allergen specific immunotherapies are currently in development and may be approved. If approved for CSU, we could face branded competition from omalizumab, as well as biosimilars. There are several large and specialty pharmaceutical companies, as well as biotechnology companies, with products in late-stage clinical development for CSU, including Sanofi, Novartis, Otsuka, and Celldex.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved, tivumecirnon will compete with current therapies approved for the treatment of cancer, particularly immuno-oncology. Potential immuno-oncology therapeutics are being developed or marketed by many large and specialty pharmaceutical and biotechnology companies such as AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer and Roche/Genentech. Additionally, there is one approved CCR4-targeting T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-depleting antibody, mogamulizumab developed by Kyowa Hakko Kirin, as well as other T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-targeting agents currently in early development by companies such as Agenus/Gilead and Tusk/Roche.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trials sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business activities are subject to various laws, rules and regulations of the United States as well as of foreign governments. Compliance with existing or future governmental regulations, including, but not limited to, those pertaining to product development and approval, business acquisitions, healthcare, consumer and data protection, employee health and safety and taxes, could have a material impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drug products such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before drug candidates may be marketed in the United States generally involves the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;), regulation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an Investigational New Drug application (&#8220;IND&#8221;), which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent Institutional Review Board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the trial is commenced;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug candidate for its intended purpose;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;) or Biologics License Application (&#8220;BLA&#8221;) after completion of all pivotal clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with Good Clinical Practices (&#8220;GCP&#8221;); and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to beginning the first clinical trial with a drug candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Some trials may combine aspects of Phase 1 and Phase 2 into a single clinical trial that can examine both safety in healthy volunteers and safety and preliminary efficacy in patients with a specific disease. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A registrational trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a drug candidate&#8217;s efficacy and safety such that it can be used to justify the approval of the drug. Generally, registrational trials are Phase 3 trials but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the NDA or BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the product and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NDA and BLA Submission and Review</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA (for a small molecule) or BLA (for a biologic) requesting approval to market the product for one or more indications. The application must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. A determination by the FDA within 60 days of the receipt of an NDA or BLA to file the application for review for its completeness is initiated at the time of submission. If the FDA determines there is significance to the missing or incomplete information in the context of the proposed product, the proposed indication(s) and the amount of time needed to address any given deficiency, it can issue a refusal-to-file letter. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an NDA or BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective, and for a BLA, whether it is safe, pure and potent (effective). The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an application, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates an application and conducts inspections of manufacturing facilities where the product will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the application. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the application in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an application if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA requires a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA offers several expedited development and review programs for qualifying drug candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections, the FDA agrees to accept sections and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires, as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics and drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a non-provisional patent application. Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, one or more issued U.S. patents we obtain may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent, limited to the approved indication (or any additional indications approved during the period of extension), as compensation for patent term lost during the FDA regulatory review process. The patent term restoration period granted on a patent covering a product is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the ultimate approval date of that application. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for extension and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restoration of patent term for an issued patent we own and, if eligible for such restoration, to add patent term beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. There can be no assurance that any of our pending patent applications will be issued or that we will benefit from any patent term extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing exclusivity provisions under the United States Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) can also delay the submission or the approval of certain marketing applications for competing products. The Biologics Price Competition and Innovation Act provides twelve years of reference product exclusivity to the first applicant to obtain approval of a new biologic. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, which were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) applications for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described below, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Drug Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, our future drugs may also be subject to extensive regulatory requirements. As in the United States, medicinal products can only be marketed if a marketing authorization from the competent regulatory agencies has been obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the United States, the various phases of preclinical and clinical research in Europe are subject to significant regulatory controls. Clinical Trials Regulation 536/2014 seeks to simplify and streamline the approval of clinical trials in the European Union. For example, the sponsor shall submit a single application for approval of a clinical trial via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State who will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an application is rejected, it can be amended and resubmitted through the EU Portal. If an approval is issued, the sponsor can start the clinical trial in all concerned Member States. However, a concerned Member State can in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Drug Review and Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Economic Area (&#8220;EEA&#8221;), which is comprised of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of marketing authorizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of drugs, such as biotechnology medicinal drugs, orphan medicinal drugs and medicinal drugs containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The Centralized Procedure is optional for drugs containing a new active substance not yet authorized in the EEA or for drugs that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for drugs not falling within the mandatory scope of the Centralized Procedure. Where a drug has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in other Member States through the Mutual Recognition Procedure. If the drug has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). The competent authority of the RMS prepares a draft assessment report, a draft summary of the drug characteristics (&#8220;SPC&#8221;), and a draft of the labeling and package leaflet, which are sent to the other Member States (&#8220;Member States Concerned&#8221;) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the drug is subsequently granted a national MA in all the Member States (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., in the RMS and the Member States Concerned).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the drug on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Chemical Entity Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, new chemical entities, sometimes referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic application for eight years, after which generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced but not approved for two years. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Privacy and Security</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we and the third parties with whom we work collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) personal data, such as clinical trial data and other health data. Accordingly, we may be subject to numerous data privacy and security obligations, which may include federal, state, local and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations related to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These frameworks are evolving and may impose potentially conflicting obligations. Such obligations may include, without limitation, the Federal Trade Commission Act, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;) and the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;) (collectively, &#8220;GDPR&#8221;), Australia&#8217;s Privacy Act, data breach notification laws and other similar laws (e.g., wiretapping laws). Further, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information. In addition, several U.S. states, have enacted comprehensive data privacy laws, and similar laws are being considered at the federal, state and local levels.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally we are, and may in the future become, subject to privacy regimes in other jurisdictions in Asia, including the Personal Information Protection Law (&#8220;PIPL&#8221;) of the People&#8217;s Republic of China, the Personal Information Protection Act (&#8220;PIPA&#8221;) in the Republic of Korea, Taiwan's Personal Data Protection Act (&#8220;PDPA&#8221;), Thailand's Personal Data Protection Act (&#8220;TPDPA&#8221;) and Hong Kong's Personal Data Privacy Ordinance (&#8220;PDPO&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR is an example of the increasingly stringent and evolving regulatory frameworks related to personal data processing that may increase compliance obligations and exposure for any noncompliance, both for us and the third parties with whom we work. European data privacy and security laws (including the GDPR) impose significant and complex compliance obligations on companies that are subject to those laws, notably with respect to the processing of health-related data from EEA or UK-based individuals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally our information technology systems and those of third parties with whom we work face a variety of evolving threats, including but not limited to ransomware attacks, which could result in security incidents. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators and investors, of security incidents or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rest of the World Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country. In all cases the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our drugs will depend, in part, on the extent to which our drugs will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical drugs and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property protection, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower-cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Even if favorable coverage and reimbursement status is attained for our drug candidates, once approved, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal drugs for which their national health insurance systems provide reimbursement and to control the prices of medicinal drugs for human use. A member state may approve a specific price for the medicinal drug or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal drug on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical drugs will allow favorable reimbursement and pricing arrangements for any of our drugs. Historically, drugs launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#8220;ACA&#8221;) was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been executive, judicial and Congressional efforts to modify, repeal or otherwise invalidate all, or certain provisions of, the ACA. For example, in August 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was signed into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how any future challenges and healthcare reform measures will impact the ACA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. The Budget Control Act of 2011 among other things, created measures for spending reductions by Congress, including aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and will remain in effect until 2032 unless additional Congressional action is taken.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental scrutiny has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the IRA, among other things, (i) directs the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to negotiate the price of certain high-expenditure, single-source drugs that have been on the market for seven years, covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law (the &#8220;Medicare Price Negotiation Program&#8221;), and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively in fiscal year 2023. In August 2024 HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. In January 2024, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Price Negotiation Program. Further, in December 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights that, for the first time, includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While the government has not previously exercised march-in rights, it is uncertain if that will change under the proposed</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">framework. At the state level, legislatures are increasingly passing legislation and implementing regulations designed (i) to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and (ii) to encourage importation from other countries and bulk purchasing. For example, in January 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (&#8220;SIP&#8221;) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current presidential administration is pursuing policies to reduce regulations and expenditures across government, including at HHS, the FDA, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions may, for example, include directives to reduce agency workforces, rescinding a prior executive order tasking the Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) to consider new payment and healthcare models to limit drug spending and eliminating a prior executive order that directed HHS to establish an artificial intelligence (&#8220;AI&#8221;) task force and develop a strategic plan. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo (&#8220;Loper Bright&#8221;), the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass healthcare-related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we may market our drug candidates, if approved. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The majority of states also have anti-kickback laws, which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalties law, prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the United States, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> HIPAA also created additional federal civil and criminal penalties for, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by HITECH, imposes obligations on certain covered entity healthcare providers, health plans and healthcare clearinghouses as well as their business associates and subcontractors that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. It also requires notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has also been a recent trend of increased federal and state regulation of payments and other transfers of value made to physicians and other healthcare providers. The ACA, through the Physician Payments Sunshine Act, imposed new reporting requirements on drug manufacturers for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Drug manufacturers are required to submit annual reports to the government and these reports are posted on a website maintained by the CMS. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, imprisonment, disgorgement, exclusion from participation in government healthcare programs, additional reporting obligations and oversight obligations, and the curtailment or restructuring of our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to achieve our goals and expectations, it is crucial that we continue to attract and retain top talent. To facilitate talent attraction and retention, we strive to make our Company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits and health and wellness programs, and by programs that build connections among our employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 68 employees, including 46 in research and development and 22 in general and administrative functions. As of December 31, 2024, 23 of our full-time employees had completed a Ph.D. or other advanced science or medical degree. We believe our employee relations are good.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are committed to their health, safety and wellness. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs, including benefits that provide protection and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being; that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors; and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We provide robust compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs include competitive compensation packages, a 401(k) plan, healthcare and insurance benefits and family leave, among others.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the state of Delaware in March 2015 under the name FLX Bio, Inc. In May 2019, we changed our name to RAPT Therapeutics, Inc. Our principal executive offices are located at 561 Eccles Avenue, South San Francisco, CA 94080. Our website address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.rapt.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information contained on, or that can be accessed through, our website is not incorporated by reference into this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business and investing in our common stock involve a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Annual Report on Form 10-K, including our financial statements and related notes, our &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other public filings. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations, prospects and stock price. In such a case, the market price of our common stock could decline and you may lose all or part of your original investment. This Annual Report on Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current or future product candidates may fail or suffer delays in clinical development that materially and adversely affect their commercial viability.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no products that have gained regulatory approval. Other than RPT904 and tivumecirnon, none of our drug candidates has ever been tested in humans. None of our drug candidates has advanced into late-stage development or a pivotal clinical trial and it may be years before any such trial is initiated, if at all. Our ability to achieve and sustain profitability depends on us developing, obtaining regulatory approval for and successfully commercializing one or more drug candidates, either alone or with partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approval for any of our drug candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. While our partner Jemincare is conducting clinical trials of RPT904 in China, we have not yet submitted an IND to the FDA and there is no guarantee that FDA or other foreign regulatory authorities will permit us to conduct clinical trials of RPT904. We have successfully completed a Phase 1 clinical trial of tivumecirnon in healthy volunteers and a Phase 1/2 clinical trial investigating tivumecirnon as a single agent and in combination with pembrolizumab in a range of tumors, however, more clinical trials are needed. There is no guarantee that the FDA will permit us to conduct additional clinical trials of tivumecirnon or conduct trials in any other potential drug candidates. Further, we cannot be certain of the timely completion or outcome of any of our</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials and cannot predict if the FDA or other foreign regulatory authorities will accept our proposed clinical programs, or if the outcome of any preclinical studies or clinical trials will ultimately support the further development of tivumecirnon or any other potential drug candidates. For example, in 2024, clinical holds were placed on our Phase 2 clinical trials of zelnecirnon following an SAE of liver failure in one patient in one of the trials; we subsequently stopped the zelnecirnon program based on feedback from the FDA. There can be no guarantee that we will not be required to stop, either temporarily or permanently, any other clinical trials as a result of similar events relating to any other current or potential future drug candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical development efforts</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are subject to the risks of failure inherent in the development of drug candidates based on novel approaches, targets and mechanisms of action. While targeted minimal and conservative changes were made to the omalizumab sequence in developing RPT904 with the goal of preserving the epitope of omalizumab while improving certain drug-like properties, the full impact of those changes is unknown and RPT904 may not have the efficacy and safety profile that was intended or that is sufficient for regulatory approval. It may not ultimately be shown to benefit patients or the benefit may not be sufficient to be an attractive alternative to other therapies. While tivumecirnon has shown activity in a small number of patients in a Phase 1/2 trial in various advanced cancers, there is no guarantee that tivumecirnon will ultimately prove to benefit patients. It is possible that no further responses will be observed in other patients or that the observed responses in patients who received tivumecirnon and pembrolizumab were caused solely by the pembrolizumab administered to the patient and not by tivumecirnon, or that the responses were spontaneous and unrelated to either tivumecirnon or pembrolizumab. We have discontinued, and may elect in the future to discontinue, development of tivumecirnon in certain indications if, among other reasons, data does not warrant moving forward. For example, in 2022, we made the decision not to move forward with development of tivumecirnon in nasopharyngeal cancer and checkpoint-na&#239;ve head and neck squamous cell carcinoma. There can be no assurance that the intended effects of our drug candidates will be observed or avoided, as the case may be, in clinical trials or that the drug candidate will offer any significant clinical benefit to humans. Results in preclinical studies do not necessarily predict the results of clinical studies. Additionally, even though our drug candidates are designed to address the same indications as existing drugs and therapies, we have not conducted head-to-head clinical trials comparing our drug candidates with such existing drugs and therapies. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by clinical and preclinical stage therapeutics companies such as ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tivumecirnon is in clinical development as a single agent and in combination with pembrolizumab. If tivumecirnon is approved as a treatment in combination with pembrolizumab, then the future availability of pembrolizumab for administration with tivumecirnon would affect our ability to commercialize tivumecirnon. For example, if the supply of pembrolizumab were constrained for any reason it could have the effect of limiting the commercial uptake of tivumecirnon, if approved for commercial sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have the financial resources to continue development of, or to enter into new collaborations or partnerships for our existing or any potential future drug candidates. Our position may be exacerbated if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, a drug candidate, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product-related side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutics similar to ours;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in submitting INDs or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions imposed by the FDA, or other regulatory authorities, regarding the scope or design of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or termination of our clinical trials for various reasons, including a clinical hold based on a finding that our drug candidates have undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in enrolling research subjects in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">high drop-out rates of research subjects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inadequate supply or quality of drug candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater-than-anticipated clinical trial costs;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">poor effectiveness of our drug candidates during clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable FDA or other regulatory agency inspections and review of a clinical trial or manufacturing site;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays and changes in regulatory requirements, policies and guidelines; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA&#8217;s or other regulatory agencies&#8217; data interpretation. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we and our potential future partners may never receive approval to market and commercialize any drug candidate. Even if we or a potential future partner obtain regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a clinical stage therapeutics company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to research and development, including preclinical studies and clinical trials; raising capital; building our management team; and developing and maintaining our intellectual property portfolio. Our net loss was $129.9 million and $116.8 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $614.5 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Furthermore, we do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials and the regulatory approval process for our current and potential future drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue incurring net losses as we make efforts to advance the clinical development of our drug candidates. However, the amount of our future losses is uncertain. Our ability to generate revenue from product sales and achieve or sustain profitability, if ever, will depend on, among other things, successfully developing drug candidates, obtaining regulatory approvals to market and commercialize drug candidates, manufacturing any approved products on commercially reasonable terms, entering into any future collaborations or other partnerships, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient capital to finance our operations. If we, or any of our future partners, are unable to develop and commercialize one or more of our drug candidates, or if sales revenue from any drug candidate that receives regulatory approval is insufficient, we will not achieve or sustain profitability, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current or potential future drug candidates may not demonstrate the safety and efficacy necessary to support further clinical development or commercial viability. Further, success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our partner, Jemincare, has completed a Phase 1 clinical trial of RPT904 in healthy volunteers to evaluate the safety, PK and PD properties of RPT904. Jemincare is currently conducting Phase 2 clinical trials of RPT904 in asthma and CSU. We may ultimately discover that RPT904 does not meet criteria to be determined to be therapeutically effective or safe. As a result, we may never succeed in developing a marketable product based on RPT904.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed a Phase 1 clinical trial with healthy volunteers for tivumecirnon and a Phase 1/2 clinical trial investigating tivumecirnon as a single agent and in combination with pembrolizumab. We may ultimately discover that tivumecirnon does not meet criteria to be determined to be therapeutically effective or safe. As a result, we may never succeed in developing a marketable product based on tivumecirnon.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If RPT904, tivumecirnon or any of our potential future drug candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could require us to change our focus and approach to discovery and development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have in the past, and may in the future, cease development of a drug candidate due to an inability to demonstrate adequate safety to the satisfaction of regulators. For example, in 2024, clinical holds were placed on our Phase 2 zelnecirnon clinical trials following an SAE of liver failure in one patient in one of the trials; we subsequently stopped the zelnecirnon program based on feedback from the FDA. There can be no guarantee that we will not be forced to suspend or cease clinical development of a current or potential future product candidate as a result of similar or other events.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, results from research and preclinical studies or early clinical trials are not necessarily predictive of future clinical trial results, and preliminary, initial and interim results of a clinical trial are not necessarily indicative of final results. From time to time, we have and may in the future publish or report preliminary, initial or interim data. Preliminary, initial or interim data from our clinical trials and those of our collaborators may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit but, as patients continue to be followed and more patient data becomes available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time, or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such setbacks could adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to build a pipeline of drug candidates, and as an organization we have no history of successfully developing drugs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key element of our strategy is to build a pipeline of potential drug candidates and advance these drug candidates through preclinical studies and clinical development for the treatment of various diseases. As an organization, we have never developed a drug candidate through to commercialization nor have we ever conducted a pivotal clinical trial. Our current drug candidates may not be safe or effective therapeutics and we may not be able to develop any successful drug candidates. Even if we are successful in building our pipeline of drug candidates, the potential drug candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including unacceptable toxicity or other characteristics that indicate that the drug candidates are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. Even if the drug candidates we identify are suitable for clinical development, our lack of experience as an organization at developing drugs may cause us to fail in successfully developing the drug candidate through to commercialization. If we do not successfully develop and commercialize drug candidates, we will not be able to generate product revenue in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market may not be receptive to our current or potential future drug candidates, and we may not generate any revenue from the sale or licensing of our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if regulatory approval is obtained for a drug candidate, we may not generate or sustain revenue from sales of such products. Market acceptance of our current and potential future drug candidates will depend on, among other factors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of our receipt of any marketing and commercialization approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any approvals and the countries in which approvals are obtained; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety and efficacy of our drug candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with our drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration of our drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which physicians recommend our products to their patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate government and third-party payor reimbursement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing of our products, particularly as compared to alternative treatments; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of alternative effective treatments for the disease indications our drug candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any drug candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to expand indications for approved drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part of our drug development strategy is to clinically test and seek regulatory approval for our drug candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof of concept data. We then intend to expand clinical testing and seek regulatory approvals in other indications. Conducting clinical trials for additional indications for our drug candidates requires substantial technical, financial and human resources and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be successful in our effort to obtain regulatory approval for our drug candidates for additional indications even if we obtain approval for an initial indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or others later identify undesirable side effects caused by our current or potential future drug candidates, our ability to market and derive revenue from the drug candidate could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects caused by our current or potential future drug candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have not discovered any adverse side effects of RPT904 or tivumecirnon that have limited our ability to test either drug candidate in humans, it is possible that there will be undesirable side effects associated with their use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated, and the FDA or other regulatory authorities could order us to cease further development, or deny approval, of a drug candidate for any or all targeted indications. For example, in 2024, clinical holds were placed on our Phase 2 clinical trials of zelnecirnon following an SAE of liver failure in one patient in one of the trials; we subsequently stopped the zelnecirnon program based on feedback from the FDA. There can be no guarantee that we will not be forced to stop any other clinical trials, either temporarily or permanently, as a result of similar events relating to any other current or potential future drug candidates. Any side effects of our drug candidates could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business and financial condition and impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a drug candidate may only be uncovered when a significantly larger number of patients are exposed to the drug candidate or when patients are exposed for a longer period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our current or potential future drug candidates receives regulatory approval and we or others identify undesirable side effects caused by that product, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or seize the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall the product or change the way the product is administered to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need substantial additional funds to discover and advance development of drug candidates and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially in the foreseeable future. Discovering and developing our drug candidates and conducting clinical trials for the treatment of inflammatory diseases, cancer and any other indications that we may pursue in the future will require substantial amounts of capital. Accordingly, we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of and seek marketing approval for, our drug candidates. We will continue to expend significant resources for the foreseeable future in connection with these activities. In addition, if we obtain marketing approval for any of our drug candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $231.1 million in cash and cash equivalents and marketable securities. Based on current business plans, we believe that our current cash and cash equivalents and marketable securities will provide sufficient funds to enable us to meet our obligations for at least the next 12 months from the date of this Annual Report. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our current and potential future drug candidates and the extent to which we may enter into collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated preclinical studies, clinical trials and any approved marketing and commercialization activities. The timing and amount of our operating expenditures will depend largely on:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and progress of preclinical and clinical development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the price and pricing structure that we are able to obtain from our third-party contract manufacturers to manufacture our preclinical study and clinical trial materials and supplies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our current licenses, collaboration and research and development programs and supply agreements, including our agreement with Jemincare to supply RPT904 to us for use in our initial clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish new collaborations and licensing agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress of the development efforts of parties with whom we may in the future enter into collaboration and research and development agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of regulatory approvals; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational systems, secure sufficient laboratory space and hire additional personnel, including personnel to support development of our drug candidates and satisfy our obligations as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have primarily financed our operations through the sale of equity securities. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. We cannot assure you that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain adequate financing when needed, we may be required to implement cost reduction measures, such as reducing operating expenses, or otherwise be required to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs or commercialization efforts. For example, in July 2024, our board of directors approved a reduction of our workforce to conserve cash resources. The workforce reduction impacted 47 people, or approximately 40% of our headcount.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our current and potential future drug candidates, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted and the terms of these securities may include liquidation preferences or other rights that adversely affect our and our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not expect to realize revenue from product sales in the foreseeable future, if at all, and unless and until our current and potential future drug candidates are clinically tested, approved for commercialization and successfully marketed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular drug candidate and fail to capitalize on drug candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we intend to prioritize our efforts on specific research and development programs, including clinical development of current and other potential future drug candidates. As a result, we may forgo or delay pursuit of other opportunities, including with potential future drug candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable drug candidates. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through partnership, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to enter into collaborations or strategic transactions on acceptable terms, if at all, which could adversely affect our ability to develop and commercialize current and potential future drug candidates, impact our cash position and increase our expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases, joint ventures and out- or in-licensing of drug candidates or technologies. For example, we entered into the Jemincare License Agreement in December 2024 to obtain exclusive rights to develop, manufacture and commercialize RPT904 worldwide, excluding the Jemincare Territory. We also entered into the Hanmi License Agreement in December 2019, pursuant to which we granted Hanmi the exclusive rights to develop, manufacture and commercialize tivumecirnon in the Hanmi Territory. The competition for partners is intense, and the negotiation process may be time-consuming and complex. If we are not able to enter into collaborations or other strategic transactions, or continue our existing collaborations, we may not have access to necessary capital or expertise to further develop our potential future drug candidates. Any such collaboration or other strategic transaction may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business, but we may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that we do enter into may be on terms that are not optimal for us. These transactions entail numerous operational and financial risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure to unknown liabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, drug candidates or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges or increased amortization expenses; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to retain key employees of any acquired business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, although there can be no assurance that we will undertake or successfully complete any collaborations or other strategic transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and our business could be materially harmed by such transactions. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and have a negative impact on the competitiveness of any drug candidate that reaches market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to the extent that any of our current or future partners were to terminate a collaboration agreement, we may be forced to seek additional partnerships, which may be less favorable to us, or independently develop our current and future drug candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and obtaining, maintaining, enforcing and defending intellectual property rights or, in certain instances, abandoning drug candidates altogether, any of which could result in a change to our business plan and materially harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If third parties on which we rely to conduct certain preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse impacts on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party clinical investigators, contract research organizations (&#8220;CROs&#8221;), clinical data management organizations (&#8220;CDMOs&#8221;) and consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had if we conducted them on our own. These investigators, CROs, CDMOs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. In addition, we may contract with CROs, CDMOs and other third parties outside the United States, including without limitation, in China. For example, under the Jemincare License Agreement, we expect Jemincare, a company incorporated in China, will provide the initial supply of drug product for certain of our clinical trials and may act as a supplier for our future needs. Any disruption in the operations of Jemincare or other third parties or in their ability to meet our needs, whether as a result of a natural disaster, changes in the policies of the United States or non-U.S. governments, war, political unrest or unstable economic conditions in any of the countries where we conduct such activities or other causes, could impair our ability to operate our business on a day-to-day basis and to continue development of our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial. The FDA may require preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials, to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse impact on our commercial prospects and may impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our current or potential future drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities on anticipated timelines. We cannot predict how difficult it will be to enroll patients in future clinical trials or whether we will be able to meet our anticipated timelines. We have experienced in the past, and may experience in the future, difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the clinical trial protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our future clinical trials will compete with other clinical trials for drug candidates that are in the same therapeutic areas as our drug candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Additionally, because some of our clinical trials will be conducted in patients with advanced solid tumors, the patients are typically in the late stages of the disease and may experience disease progression or adverse events independent from our drug candidates, making them unevaluable for purposes of the trial and requiring additional enrollment. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain laws and regulations relating to drug development require us to test our drug candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we may rely on third parties, some of which are or may be sole source vendors, for manufacturing and supply of our drug candidates for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on third-party contract manufacturers for our current and future clinical trial product materials and supplies. We do not produce any meaningful quantity of our drug candidates for clinical development, and we do not currently own manufacturing facilities for producing such supplies. Furthermore, some of our manufacturers represent our sole source of supplies of current and future clinical development materials, including our source for the manufacture of RPT904. We cannot assure you that our preclinical or current or future clinical development product supplies and commercial supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply partners, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. For our current and future sole source third-party manufacturing and supply partners, we may be unable to negotiate binding agreements with them or find replacement manufacturers to support our preclinical and current and future clinical activities at commercially reasonable terms in the event that their services to us are interrupted for any reason. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or do not timely provide sufficient quantities to us. Establishing additional or replacement sole source vendors, if required, may not be accomplished quickly. Any delays resulting from manufacturing or supply interruptions associated with our reliance on third-party manufacturing and supply partners, including those that are sole source, could impede, delay, limit or prevent our drug development efforts, which could harm our business, result of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for a drug candidate is subject to FDA and other regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices (&#8220;cGMP&#8221;). If any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our current and future drug candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our drug candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop drug candidates in a timely manner or within budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect to rely on third-party manufacturers if we receive regulatory approval for any drug candidate. We have existing, and may enter into future, manufacturing arrangements with third parties. We will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for any drug candidate, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our drug candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to initiate or continue clinical trials of drug candidates under development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of the cooperation of a potential future partner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjecting third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to cease distribution or to recall batches of drug candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event of approval to market and commercialize a drug candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our third-party manufacturers may be unable to successfully scale manufacturing of current or potential future drug candidates in sufficient quality and quantity, which would delay or prevent us from developing drug candidates and commercializing approved products, if any.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to conduct clinical trials of our current and any potential future drug candidates, we will need to manufacture large quantities of these drug candidates. We may continue to use third parties for our manufacturing needs. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any current or potential future drug candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale the manufacture of any current or potential future drug candidate in sufficient quality and quantity, the development, testing and clinical trials of that drug candidate may be delayed or infeasible, and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenue may be adversely affected and our business may suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our understanding of the number of people who suffer from certain diseases that our current or potential future drug candidates may have the potential to treat is based on estimates. These estimates may prove to be incorrect, and new studies may demonstrate or suggest a lower estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our current or potential future drug candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition. In particular, the treatable population for our candidates may be further reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from such drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there are several factors that could contribute to making the actual number of patients who receive our current or potential future drug candidates less than the potentially addressable market, including limited reimbursement for new therapies in many markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face intense competition from entities that have developed or may develop drug candidates for the treatment of the diseases that we are currently targeting or may target in the future. If these companies develop technologies or drug candidates more rapidly than we do, or if their technologies or drug candidates are more effective, our ability to develop and successfully commercialize drug candidates may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of drugs and therapeutic biologics is highly competitive. We compete with a variety of large pharmaceutical companies, multinational biopharmaceutical companies, other biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors are often larger and better funded than we are. Our competitors have developed, are developing or will develop drug candidates and processes competitive with ours. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that are currently in development or that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing or may try to develop drug candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical, inflammation, immunology and oncology fields.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of numerous companies that are developing biologics and small molecule drugs for the treatment of inflammatory and immunological diseases and cancer. Many of these companies are well capitalized and, in contrast to us, have significant clinical experience, and may include our future partners. In addition, these companies compete with us in recruiting scientific and managerial talent. Our success will partially depend on our ability to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to small molecule drugs or biologics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective or less expensive than the drugs we develop are or become available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to compete with small molecule, biologics and other therapeutic platforms and development companies, including, but not limited to, companies such as LongBio Pharma, United Biopharma and Yuhan which are developing anti-IgE treatments for food allergy and CSU and Sanofi, Novartis, Otsuka and Celldex, which have products in late-stage clinical development for CSU. In addition, we expect to compete with large, multinational pharmaceutical companies that discover, develop and commercialize small molecule drugs and other therapeutics for use in treating inflammatory diseases and cancer such as AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Roche/Genentech and Sanofi/Regeneron. If any current or future drug candidate is eventually approved, it will compete with a range of treatments that are either in development or currently marketed.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any drug candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any product we develop obsolete or noncompetitive before we recover the expense of developing and commercializing such product. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Brian Wong, M.D., Ph.D., our President and Chief Executive Officer, Rodney Young, our Chief Financial Officer, William Ho, M.D., Ph.D., our Chief Medical Officer, and Dirk Brockstedt, Ph.D., our Chief Scientific Officer, as well as our ability to attract and retain other highly qualified personnel. The loss of one or more members of our executive team, management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our drug candidates and technologies and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success will also depend in large part on our ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face significant competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 we had 68 full-time employees. Our focus on the development of current and potential future drug candidates will require adequate staffing. We will need to hire and retain new employees to execute our future clinical development and manufacturing plans. We cannot provide assurance that we will be able to hire or retain adequate staffing levels to develop our current and potential future drug candidates or to run our operations or to accomplish all of our objectives.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays or other difficulties effectuating the transition of certain responsibilities that were previously performed by employees impacted by the workforce reduction, which could result in significant disruptions to our business and delays in our development efforts and timelines. In addition, our workforce reduction could yield unanticipated consequences, such as reputational risk, litigation risk and expense, attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and loss of institutional knowledge and expertise. The workforce reduction could also harm our ability to attract and retain qualified personnel who are critical to our operations. In addition, we may need to undertake additional workforce reductions or restructuring activities in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may experience difficulties in managing our growth and expanding our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in product development. As our current and potential future drug candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures and to secure adequate facilities for our operational needs. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our drug candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities or experience. We will need to develop internal sales, marketing and distribution capabilities to commercialize each current and potential future drug candidate that gains FDA approval, which would be expensive and time-consuming, or enter into partnerships with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market any approved products or decide to co-promote products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business and results of operations could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our present and potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and clinical trial centers are located outside of the United States. We are party to the Jemincare License Agreement with Jemincare, which is located in China and owns the intellectual property that we need to develop, manufacture and commercialize RPT904 and upon whom we are currently dependent for clinical drug supply for our development program. Additionally, we are party to the Hanmi License Agreement. Furthermore, if we or any future collaborator succeeds in developing any products, we anticipate marketing them in the European Union and other jurisdictions in addition to the United States. If approved, we or our collaborator may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rejection or qualification of foreign clinical trial data by the competent authorities of other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional potentially relevant third-party patent and other intellectual property rights that may be necessary to develop and commercialize our products and drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities and difficulties in obtaining, maintaining, enforcing and defending our patent and other intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in staffing and managing foreign operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limits in our ability to penetrate international markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters; political and economic instability, including tariffs, embargoes, sanctions or other limitations on trade, wars, terrorism and political unrest, including as a result of ongoing overseas conflicts; outbreak of disease; boycotts, curtailment of trade and other business restrictions and implementation of tariffs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain expenses, including among others, expenses for travel, translation and insurance; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Global trade issues and changes in and uncertainties with respect to trade policies and regulations, including import and export license requirements, trade sanctions, tariffs and international trade disputes, could adversely impact our business and operations and reduce the competitiveness of our products relative to local and global competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is inherent risk, based on the complex relationships among the United States and the countries in which we conduct our business, that political, diplomatic and national security factors could lead to global trade restrictions and changes in trade policies and regulations that may adversely affect our business and operations. The United States and other countries have imposed, and may continue to impose, new trade restrictions and regulations, have levied tariffs and taxes on certain goods, and could significantly increase tariffs on a broad array of goods. While pharmaceutical products have customarily been granted exemptions from tariffs, recent proposals do not contemplate such exemptions. Trade restrictions and regulations, or increases in tariffs and additional taxes, including any retaliatory measures, can negatively impact demand, increase our supply chain complexity and our manufacturing costs, decrease margins, reduce the competitiveness of our products, or restrict our ability to sell products, provide services or purchase necessary equipment and supplies, any or all of which could have a material and adverse effect on our business, results of operations, or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future growth may depend, in part, on our ability to develop and commercialize drug candidates in foreign markets for which we may rely on partnering with third parties. We will not be permitted to market or promote any drug candidate before we receive regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval for any drug candidate. To obtain separate regulatory approval in foreign countries, we generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy, and governing, among other things, clinical trials and commercial sales, pricing and distribution of a drug candidate, and we cannot predict success in these jurisdictions. If we obtain approval of any of our current or potential future drug candidates and ultimately commercialize any such drug candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Price controls imposed in foreign markets may adversely affect our future profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure exerted by governments and other stakeholders on prices and reimbursement levels, including as part of cost-containment measures. Political, economic and regulatory developments, in the United States or internationally, including tariffs, embargoes, sanctions or other limitations on trade, wars and terrorism, may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or future partners may be required to conduct clinical trials or other studies that compare the cost-effectiveness of a drug candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any current or potential future drug candidate that is approved for marketing in the future is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business and results of operations or prospects could be materially and adversely affected and our ability to commercialize such drug candidate could be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disease outbreaks, epidemics and pandemics in regions where we have concentrations of clinical trial sites and other business operations, could adversely affect our business, including by causing significant disruptions in our operations and/or in the operations of manufacturers and CROs we rely on. Disease outbreaks, epidemics and pandemics have had, and may have, negative impacts on our ability to initiate new clinical trial sites, enroll new patients and to maintain existing patients who are participating in clinical trials, which may result in increased clinical trial costs, longer timelines and delay in our ability to obtain regulatory approvals of our product candidates, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General supply chain issues may be exacerbated during disease outbreaks, epidemics or pandemics and may also impact the ability of our clinical trial sites to obtain basic medical supplies used in our trials in a timely fashion, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the extent to which disease outbreaks, epidemics and pandemics may impact our business, results of operations and financial position will depend on future developments, which are highly uncertain and cannot be predicted with confidence. New health epidemics or pandemics may emerge that result in similar or more severe disruptions to our business. To the extent any future disease outbreak, epidemic or pandemic adversely affects our business, financial condition, results of operations and growth prospects, it could also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by natural or other disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current operations are concentrated in the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather, medical epidemic, pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities or the manufacturing facilities of our third-party contract manufacturers, or lose our repository of preclinical and clinical human samples and other valuable laboratory samples, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis. Such an event would have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our drug candidates or interruption of our business operations. Natural disasters such as earthquakes or wildfires, both of which are prevalent in Northern California, floods or tsunamis could further disrupt our operations, and have a material negative impact on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, enforce or defend intellectual property rights related to our technology and current or future drug candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain protection in the United States and other countries for our intellectual property rights and proprietary technology. We rely on patents and other forms of intellectual property rights to protect our current or future drug candidates, methods used to manufacture our current or future drug candidates and methods for treating patients using our current or future drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we or our collaborators will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. The patent applications that we own or license may fail to result in issued patents, and, even if they do issue as patents, such patents may not cover our current or future technologies or drug candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, although we and our licensors make reasonable efforts to ensure patentability of inventions, we cannot guarantee that all of the potentially relevant prior art relating to the patent applications and any issued patents we obtain has been found. For example, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing and, in some cases, not at all. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug candidates or the use of our technologies. We thus cannot know with certainty whether we or any of our current or future licensors or strategic partners were the first to make the inventions claimed in our pending patent applications or any issued patents we obtain, or that we or any of our future licensors or strategic partners were the first to file for patent protection of such inventions. For this reason, and because there is no guarantee that any prior art search is correct and comprehensive, we may be unaware of prior art that could be used to invalidate an issued patent or to prevent our pending patent applications from issuing as patents. Invalidation of any of our patent rights, including in-licensed patent rights, could materially harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the patent positions of biopharmaceutical companies are generally uncertain because they may involve complex legal and factual considerations that have, in recent years, been the subject of legal development and change. As a result, the issuance, scope, validity, enforceability and commercial value of our pending patent rights is uncertain. The standards applied by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) and foreign patent offices in granting patents are not always certain and, moreover, are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patent rights or narrow the scope of our patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if patents do successfully issue and even if such patents cover our current or any future technologies or drug candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful challenge to any patents we own or license could deprive us of rights necessary for the successful commercialization of any current or future technologies or drug candidates that we may develop. Likewise, if patent applications we own or license with respect to our development programs and current or future technologies or drug candidates fail to issue, if their breadth or strength is threatened or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with us to develop current or future technologies or drug candidates. Lack of valid and enforceable patent protection could threaten our ability to commercialize current or future products and could prevent us from maintaining exclusivity with respect to the invention or feature claimed in the patent applications. Any failure to obtain, or any loss of, patent protection could have a material adverse impact on our business and ability to achieve profitability. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as current or potential future drug candidates that emerge from our discovery program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications or patent applications filed by any of our current or future licensors or strategic partners may be challenged through third-party submissions, opposition or derivation proceedings. By further example, issued patents may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO or patent offices in other jurisdictions or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our patent rights; limit our ability to stop others from using or commercializing similar or identical products; allow third parties to compete directly with us without payment to us; or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patent rights is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, some of our intellectual property, including patents and patent applications, are or may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such intellectual property, including patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may need the cooperation of any such co-owners of our patent rights to enforce such patent rights against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business prospects and financial conditions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or drug candidates or we could lose certain rights to grant sublicenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any license, collaboration or other intellectual property-related agreements impose, and any future license, collaboration or other intellectual property-related agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license. Despite our best efforts, any of our future licensors or strategic partners might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technologies covered by these license agreements. Any license agreements we enter into may be complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek to obtain licenses from licensors in the future. However, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at all. In addition, if any of our future licensors or strategic partners terminates any such license agreement, such license termination could result in our inability to develop, manufacture and sell products that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce and defend patents we may in-license, or they lose rights to licensed patents or patent applications, our license rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or drug candidates that is the subject of such licensed rights could be materially adversely affected. In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s intellectual property rights and the amount of any damages or future royalty obligations that would result if any such claims were successful would depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, the standard patent term is typically 20 years after filing. Various extensions may be available. Even so, the life of a patent and the protection it affords are limited. As a result, our patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing products similar or identical to ours. For example, given the large amount of time required for the research, development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extensions of patent term may be available, but there is no guarantee that we would succeed in obtaining any particular extension or that any such extension would lengthen the patent term for a sufficient period of time to exclude others from commercializing products similar or identical to ours. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication or any additional indications approved during the period of extension. A patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it or a method for manufacturing it. The applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to any patents we obtain, or may grant more limited extensions than we request. An extension may not be granted or may be limited where there is, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply before expiration of relevant patents or some other failure to satisfy applicable requirements. If this occurs, our competitors may be able to launch their products earlier by taking advantage of our investment in development and clinical trials along with our clinical and preclinical data. This could have a material adverse effect on our business and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other therapeutics companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs of, and may diminish our ability to protect, our inventions, obtaining, maintaining, and enforcing our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. In September 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law, which increased uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These provisions affected the way patent applications are prosecuted, redefined prior art and provided more efficient and cost-effective avenues for competitors to challenge the validity of patents. This included allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures that attacked the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. In March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application would be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. This required us to be cognizant of the time from invention to filing of a patent application. The Leahy-Smith Act and its implementation resulted in uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse impact on our business prospects, financial condition and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Courts in the U.S. continue to refine the heavily fact-and-circumstance-dependent jurisprudence defining the scope of patent protection available for therapeutics, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This creates uncertainty about our ability to obtain patents in the future and the value of such patents. We cannot provide assurance that future developments in Congress, the federal courts and the USPTO will not adversely impact our patent rights. The laws and regulations governing patents could change in unpredictable ways that could weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing patent rights or patent rights that we might obtain or in-license in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may have a material adverse effect on our and our licensors&#8217; ability to obtain new patents or to protect and enforce our owned or in-licensed patent rights or patent rights that we may obtain or in-license in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, a new unitary patent system took effect in June 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent, which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our current or future products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may attempt to invalidate our intellectual property rights. Even if such rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse impact on our profitability, financial condition, prospects or ability to successfully compete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we cannot guarantee that we are aware of all patents and patent applications potentially relevant to our technology or products. There may be issued and pending patents that claim aspects of our current or potential future drug candidates and modifications that we may need for our current or potential future drug candidates. We may not be aware of potentially relevant third-party patents or applications for several reasons. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our drug candidates or technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug candidates or the use of our technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to priority disputes, inventorship disputes and similar proceedings that could, if resolved unfavorably, narrow the scope of our intellectual property protection. We cannot provide any assurances that third-party patents do not exist that might be enforced against our drug candidates or technologies or future methods or products, resulting in either an injunction prohibiting our manufacture or sales or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thus, it is possible that one or more third parties will hold patent rights to which we will need a license, which may not be available on reasonable terms or at all. If such third parties refuse to grant us a license to such patent rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, drug candidates or the methods for manufacturing our drug candidates, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such case, we may not be able to market such technology or drug candidates and may not be able to perform research and development or other activities covered by these patents. This could have a material adverse effect on our ability to commercialize our drug candidates and our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on current or future technologies or drug candidates in all countries throughout the world would be prohibitively expensive. Competitors or other third parties may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export infringing products to territories where we have patent protection or licenses, but where enforcement is not as strong as that in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Many companies have encountered significant difficulties in protecting and defending intellectual property rights in such foreign jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patent rights or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. Such proceedings could also put our patent rights at risk of being invalidated or interpreted narrowly, could put our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or any of our future licensors or strategic partners. We may not prevail in any lawsuits or other adversarial proceedings that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects, financial condition and results of operations may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends, in part, upon our ability or the ability of any of our current or future collaborators to develop, manufacture, market and sell our current or any future drug candidates and to use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary and intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or any of our current or future licensors or strategic partners may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current or any potential future drug candidates and technologies, including derivation, reexamination, inter partes review, post-grant review or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United States, such as opposition proceedings. If we or our licensors or strategic partners are unsuccessful in any interference proceedings or other priority or validity disputes (including through any patent oppositions) to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents or our patent claims may be narrowed, invalidated or held unenforceable. In some instances, we may be required to indemnify our licensors or strategic partners for the costs associated with any such adversarial proceedings or litigation. Third parties may also assert infringement, misappropriation or other claims against us, our licensors or our strategic partners based on existing patents or patents that may be granted in the future, as well as other intellectual property rights, regardless of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with us, our licensors or our strategic partners to enforce or otherwise assert their patent rights or other intellectual property rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents and other intellectual property rights are valid, enforceable and infringed, which could have a material adverse impact on our ability to commercialize our current or any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity by presenting clear and convincing evidence of invalidity. There is no assurance that a court of competent jurisdiction, even if presented with evidence we believe to be clear and convincing, would invalidate the claims of any such U.S. patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we cannot guarantee that we or our licensors or strategic partners will be able to successfully settle or otherwise resolve such adversarial proceedings or litigation on terms acceptable to us. If such proceedings or litigation is not settled on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our drug candidates. If we or any of our licensors or strategic partners are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, we could be required to pay damages, including treble damages and attorney&#8217;s fees, if we are found to have willfully infringed. In addition, we or any of our licensors or strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us, and we could be required to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease utilizing, developing, manufacturing and commercializing our drug candidates deemed to be infringing. We may be forced to redesign current or future technologies or products. Any of the foregoing could have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we or our licensors or strategic partners may find it necessary to pursue claims or to initiate lawsuits to protect or enforce our patent or other intellectual property rights. If we or our licensors or strategic partners were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates or our technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, claiming patent-ineligible subject matter, lack of novelty, indefiniteness, lack of written description, non-enablement, anticipation or obviousness. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome of such invalidity and unenforceability claims is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensors or strategic partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection for one or more of our drug candidates. The narrowing or loss of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. All of these events could have a material adverse effect on our business, financial condition, results of operations and prospects. Patent and other intellectual property rights also will not protect our drug candidates and technologies if competitors or third parties design around such drug candidates and technologies without legally infringing, misappropriating or violating our patent or other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost to us in defending or initiating any litigation or other proceeding relating to our patent or other intellectual property rights, even if resolved in our favor, could be substantial, and any litigation or other proceeding would divert our management&#8217;s attention and distract our personnel from their normal responsibilities. Such litigation or proceedings could materially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We or our licensors or strategic partners may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of complex patent litigation because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and materially limit our ability to continue our operations. Furthermore, because of the substantial amount of discovery required in connection with certain such proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such announcements could have a material adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or drug candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or drug candidates, which may not be available on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the immunology, inflammatory and oncology disease landscapes are still evolving, it is difficult to conclusively assess our freedom to operate. Thus, we may unknowingly pursue development of a product or technology that infringes, misappropriates or otherwise violates third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering immune-therapies generally or covering molecules directed against the same targets as, or targets similar to, those we are pursuing. Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies, drug candidates or elements thereof or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies, drug candidates or elements thereof unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties, that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or drug candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or drug candidates. Should such an infringement claim be successfully brought, we may be required to pay substantial damages or be forced to abandon our current or future technologies or drug candidates or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party intellectual property right holders may also actively bring infringement, misappropriation or other claims alleging violations of intellectual property rights against us or our licensors. We cannot guarantee that these claims will be successfully settled or otherwise resolved on terms acceptable to us. If such claims cannot be successfully settled on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our drug candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or future technologies or drug candidates that are held to be infringing, misappropriating or otherwise violating third-party intellectual property rights. We might, if possible, also be forced to redesign current or future technologies or drug candidates so that we no longer infringe, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on our financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining necessary or exclusive rights to any drug candidates or products we may develop through acquisitions and in-licensing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to acquire or otherwise in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for drug candidates that we may wish to develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent rights we may in-license in the future may be subject to a reservation of rights by one or more third parties. For example, the research resulting in any in-licensed patent rights and technology may be funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As referenced above, in addition to seeking patent protection for certain aspects of our current or future technologies and drug candidates, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. However, trade secrets and know-how can be difficult to protect. We protect and plan to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to us. Despite these efforts, we may not obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, individuals with whom we have such agreements may not comply with their terms. Any of these parties may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for any such breaches. We may be forced to bring claims against third parties, including current or former employees or consultants, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property, including our patent rights. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or securing title to an employee- or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. If we are unsuccessful in any inventorship disputes to which we are subject, we may lose valuable intellectual property rights, such as ownership of our patent rights. In addition, some courts in the United States and certain foreign jurisdictions disfavor or are unwilling to protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent that competitor from using the technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be materially and adversely harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#8217; or consultants&#8217; former employers or their clients.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees or consultants and our licensors&#8217; employees or consultants were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that one or more of these employees or consultants or we have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of any such individual&#8217;s current or former employers. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or may be enjoined from using such intellectual property. Any such proceedings and possible aftermath would likely divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future technologies or drug candidates, which could materially harm our business. Even if we are successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patent rights and any patent rights we may own or in-license now or in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirements, and we may also be dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products, which could have a material adverse effect on our business prospects and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We own a U.S. registered trademark for RAPT and a U.S. registered trademark for a design used in our corporate logo. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we use for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make small molecule drugs, biologics, inhibitors or formulations that are similar to our drug candidates, but that are not covered by the claims of any patents that we own, license or control; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or any our licensors might not have been the first to make the inventions covered by the patent rights that we own, license or control; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors might not have been the first to file patent applications covering certain of our owned and in-licensed inventions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop the same, similar or alternative technologies without infringing, misappropriating or violating our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our or our licensors&#8217; pending patent applications will not lead to issued patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we may own, in-license or control may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our strategic partners may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse impact on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal and Regulatory Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug candidates RPT904 and tivumecirnon are in clinical development and the risk of failure is high. It is impossible to predict when or if our candidates or any potential future drug candidates will prove effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of a drug candidate in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process. The results of preclinical studies and clinical trials of any of our current or potential future drug candidates may not be predictive of the results of later-stage clinical trials. For example, while Jemincare conducted certain preclinical studies and a head-to-head clinical study of RPT904 and omalizumab in healthy patients, future clinical trials may not be consistent with the results of those studies. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety issues, notwithstanding promising results in earlier trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed a Phase 1/2 clinical trial investigating tivumecirnon as a single agent and in combination with pembrolizumab in a range of tumors and our partner Jemincare is conducting clinical trials of RPT904 in China. In connection with these clinical trials or any other clinical trials we conduct in the future, if any, each of the following, among other factors, could prolong and/or cause the clinical development process to be even more expensive:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate or continue a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining regulatory approval to commence a clinical trial, such as an IND prior to commencing a clinical trial in the United States for RPT904; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining IRB approval at each clinical trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting suitable patients to participate in a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">having patients complete a clinical trial or return for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adding new clinical trial sites; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing sufficient quantities of our drug candidates for use in clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our current or potential future drug candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our partners, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, in 2024, clinical holds were placed on our Phase 2 clinical trials of zelnecirnon following an SAE of liver failure in one patient in one of the trials; we subsequently stopped the zelnecirnon program based on feedback from the FDA. There can be no guarantee that we will not be forced to stop any other clinical trials, either temporarily or permanently, as a result of similar events relating to any other current or potential future drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our current or potential future drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and potential future drug candidates are and will be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug, therapeutic or biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the drug candidates we may develop will obtain the regulatory approvals necessary for us or our potential future partners to begin selling them.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the drug candidate. The standards that the FDA and its foreign counterparts use when regulating us and other companies developing drugs require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenue from the particular drug candidate for which we are seeking approval. Further, we and our potential future partners may never receive approval to market and commercialize any drug candidate. Even if we or a potential future partner obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval. If any of our drug candidates prove to be ineffective, unsafe or commercially unviable, we may have to re-engineer them, and our entire pipeline could have little, if any, value, which could require us to change our focus and approach to drug discovery and development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval for any of our current or potential future drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or potential future drug candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we or potential future partners obtain for our current or potential future drug candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#8220;Phase 4&#8221; clinical trials, and surveillance to monitor the safety and efficacy of such drug candidate. In addition, if the FDA or other regulatory authority approves current or potential future drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for such product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration and continued compliance with cGMP and good clinical practices for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or revocation of product license approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been executive, judicial and Congressional challenges and amendments to certain aspects of the ACA. For example, in August 2022, the IRA was signed into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and healthcare reform measures will impact the ACA and our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there has been heightened government scrutiny over the manner in which manufacturers set prices for their marketed products. For example, there have been several Congressional inquiries, Presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the IRA, among other things, (1) directs the HHS to negotiate the price of certain single-source drugs that have been on the market for 7 years covered under Medicare (the &#8220;Medicare Price Negotiation Program&#8221;) and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. In August 2024, HHS announced the agreed-upon reimbursement price of the first ten drugs that were subject to price negotiations, although the Medicare Price Negotiation Program is currently subject to legal challenges. In January 2024, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Price Negotiation Program. Further, in December 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights that, for the first time, includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While the government has not previously exercised march-in rights, it is uncertain if that practice will change under the new framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current presidential administration is pursuing policies to reduce regulations and expenditures across government, including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions may, for example, include directives to reduce agency workforces, rescinding a prior executive order tasking CMMI to consider new payment and healthcare models to limit drug spending and eliminating a prior executive order that directed HHS to establish an AI task force and develop a strategic plan. Additionally, in its June 2024 decision in Loper Bright, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA. We cannot predict which additional measures may be adopted or the impact of current and additional measures on the marketing, pricing and demand for our products, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to (i) control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and (ii) encourage importation from other countries and bulk purchasing. For example, in January 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (&#8220;SIP&#8221;) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our future customers and accordingly, our financial operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or potential future partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and third-party payors, among others, will play a primary role in the prescription and recommendation of any drug candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors, providers and customers, among others, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our drug candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order, arranging for or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act (discussed below); </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False Claims Act, which provides for civil whistleblower or qui tam actions, that impose penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a referral made in violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. As amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), HIPAA also imposes obligations on certain covered entity healthcare providers, health plans and healthcare clearinghouses as well as their business associates and subcontractors that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, created as part of ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value made by that entity to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services reimbursed by third-party payors, including private insurers; local, state and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other healthcare providers and healthcare entities, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the location and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive marketing and commercialization approval of a drug candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. We intend to rely on third-party manufacturers and we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future partners, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we are able to commercialize any drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers and health maintenance organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future products, if any, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. We plan to develop, either by ourselves or with collaborators, in vitro companion diagnostic tests for our drug candidates for certain indications. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. The failure to obtain coverage reimbursement for the companion diagnostic tests may hinder our ability to commercialize our product candidates, once approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost-containment is a priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its product. Commercial third-party payors often rely upon Medicare coverage policy and payment limitations in setting their reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the U.S. can differ significantly from payor to payor. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Further, coverage policies and third&#8209;party reimbursement rates may change at any time. Thus, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Coverage and reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any drug candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;FCPA&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, which can result in added costs and administrative burdens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we conduct clinical trials, we will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of inflammatory disease and cancer treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities, our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to clinical trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, our partners or we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business and financial condition, including the imposition of significant criminal, civil and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure (or that of the third parties with whom we work) to comply with such obligations could lead to government investigations or enforcement actions (which could include civil or criminal penalties), litigation (including class claims) and mass arbitration demands; fines or penalties; or disruptions of our business operations, reputational harm, loss of revenue or profits, adverse publicity and other adverse business consequences, which could negatively affect our operating results and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we and the third parties with whom we work collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, &#8220;process&#8221;) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial information and clinical trial and other health data (collectively, &#8220;sensitive data&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our data processing activities subject us to numerous data privacy and security obligations, such as various federal, state, local and foreign data protection laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security. In the United States, federal, state and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Section 5 of the Federal Trade Commission Act) and other similar laws (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security and transmission of protected health information. In the past few years, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct or delete certain personal data and to opt-out of certain data processing activities, such as targeted advertising, profiling and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While these laws also exempt some data processed in the context of clinical trials, these developments further complicate our compliance efforts and increase compliance costs for us, the third parties with whom we work and our future customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;) (collectively, &#8220;GDPR&#8221;) and Australia&#8217;s Privacy Act impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to &#8364;20 million under the EU GDPR, &#163;17.5 million under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In addition, we are, and may in the future become subject to new and emerging data privacy regimes in Asia, including China's Personal Information Protection Law, South Korea's Personal Information Protection Act, Taiwan&#8217;s Personal Data Protection Act, Thailand&#8217;s Personal Data Protection Act and Hong Kong&#8217;s Personal Data (Privacy) Ordinance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (&#8220;EEA&#8221;) and the United Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws they generally believe are inadequate. Other jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA's standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Regulators in the United States such as the Department of Justice are also increasingly scrutinizing certain personal data transfers and have proposed and may enact certain data localization requirements, for example, the executive order entitled Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups, and we are, and may in the future become, subject to such obligations. We are also bound by other contractual obligations related to data privacy and security and our efforts to comply with such obligations may not be successful. For example, clinical trial subjects about whom we or the third parties with whom we work obtain information, as well as the providers who share this information with us, contractually limit our ability to use and disclose the information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also publish privacy policies, marketing materials and other statements concerning data privacy and security. Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deceptive, unfair, misleading, deficient, lacking in transparency or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems and practices and to those of any third parties that process personal data or sensitive data on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may at times fail, or be perceived to have failed, in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. In the event of failure (or perceived failure) of us or the third parties with whom we work to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, investigations, fines, civil or criminal penalties, audits, inspections, and similar); litigation (including class claims) and mass arbitration demands, additional reporting requirements and/or oversight, bans on processing personal data, orders to destroy or not use personal data, adverse publicity or imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class action claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business or financial condition, including but not limited to: loss of customers, inability to process personal data or to operate in certain jurisdictions, limited ability to develop or commercialize our products, expenditure of time and resources to defend any claim or inquiry, adverse publicity or substantial changes to our business model or operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems (or those of the third parties with whom we work) or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we and the third parties with whom we work process sensitive data. As a result, we and the third parties with whom we work face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity and availability of our sensitive data and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain and ability to produce, sell and distribute our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI and other similar threats.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. It may be difficult and/or costly to detect, investigate, mitigate, contain and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain and remediate a security incident could result in outages, data losses and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions, such as acquisitions or integrations, could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we rely on third parties and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, clinical trials, CROs, encryption and authentication technology, employee email and other functions. We also rely on third parties to provide other products, services, parts or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If the third parties we rely on experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages or we may be unable to recover such award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or the supply chain of third parties with whom we work have not been compromised.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with whom we work</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). We have not and may not in the future, however, detect, mitigate and remediate all such vulnerabilities including on a timely basis. Further, we have (and may in the future) experienced delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and result in a security incident.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the previously identified or similar threats have in the past and may in the future cause a security incident or other interruption that could result in unauthorized, unlawful or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to, our sensitive data or our information technology systems or those of the third parties with whom we work. For example, our CROs have been subject to cyber attacks in the past that impacted certain of our non-clinical trial data. A security incident or other interruption could disrupt our ability (and that of the third parties with whom we work) to provide our services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations have required us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or a third party with whom we work experiences a security incident or is perceived to have experienced a security incident, we may experience adverse consequences such as: government enforcement actions (for example, investigations, fines, penalties, audits and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; disputes with physicians, patients and our partners; monetary fund diversions; interruptions in our operations (including availability of data and interruptions and delays in our research and development work; financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect or infer sensitive data about us from public sources, data brokers or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, disclosed or revealed as a result of or in connection with the use of generative AI technologies by our personnel or our vendors.</span><span style="color:#0000ff;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing of these materials in our facilities comply with the relevant guidelines of the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Although we have some environmental liability insurance covering certain of our facilities, we may not maintain adequate insurance for all environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Environmental, social and governance matters and any related reporting obligations may impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies across many industries are facing increasing scrutiny related to their environmental, social and governance (&#8220;ESG&#8221;) practices and reporting, both in the United States and internationally. For example, new domestic and international laws and regulations relating to ESG matters, including environmental sustainability, climate change and human capital management, are under consideration or being adopted, which may include specific, target-driven disclosure requirements or obligations. If increased ESG disclosure requirements apply to us, we may require additional investments and implementation of new practices and reporting processes, all entailing additional compliance risk regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in the level of expense related to the ongoing development of our drug candidates or future development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials, or the addition, delay or termination of clinical trials or funding support by us or potential future partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions and departures of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if any of our drug candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments affecting our drug candidates or those of our competitors; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in general market and economic conditions, including declines in economic growth, rising inflation, tariffs, higher borrowing rates and adverse changes in liquidity and credit availability. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price has been and is likely to continue to be highly volatile. The market price for our common stock may be influenced by many factors, including the other risks described in this &#8220;Risk Factors&#8221; section and the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to advance our current or potential future drug candidates through clinical development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of our preclinical studies, non-clinical studies and clinical trials for our current and future drug candidates or those of our competitors or potential future partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introductions and announcements of new products by us, our future commercialization partners or our competitors, and the timing of these introductions or announcements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions taken by regulatory agencies with respect to our products, clinical trials, manufacturing process or sales and marketing terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our efforts to acquire or in-license additional technologies, products or drug candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments concerning any future collaborations, including, but not limited to, those with our sources of manufacturing supply and our commercialization partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments, disputes or litigation matters concerning patents or other intellectual property rights, and our ability to obtain and maintain patent protection for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to raise additional capital and the terms on which we raise it; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in earnings estimates or changes in securities analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure or the failure of our competitors to meet securities analysts&#8217; projections or guidance that we or our competitors may give to the market; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">speculation in the press or investment community; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us or our stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the concentrated ownership of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting principles; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terrorist acts, acts of war or periods of widespread civil unrest, including as a result of ongoing overseas conflicts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters, medical epidemics, pandemics and other calamities</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with listing requirements of the Nasdaq Stock Market; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">corporate actions, such as reverse stock splits; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, therapeutics, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer, including in connection with ongoing overseas conflicts and past United States bank failures, each of which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Substantial purchases of common stock by existing stockholders could reduce the liquidity of the trading market for our common stock and increase volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our company, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property rights or our common stock performance, or if our clinical studies and operating results fail to meet the expectations of the analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of 5% or more of our capital stock and their respective affiliates, beneficially own a significant percentage of our common stock. As a result, these stockholders, if acting together, will have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The interests of these stockholders may not be the same as, and may even conflict with, your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; and our election of reduced reporting requirements applicable to such companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by nonaffiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. We cannot predict if investors will find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result of any choice we make to reduce disclosure, there may be a less active trading market for our common stock and the market price for our common stock may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) and certain other tax attributes is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#8220;&#8212;Risks Related to Our Business,&#8221; we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; thus, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs and certain other tax attributes. Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Federal NOLs generated in tax years beginning before January 1, 2018, are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), as modified by the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) signed into law in March 2020, federal NOLs arising in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and certain other pre-change tax attributes (such as research and development tax credits) to offset post-change taxable income. Our existing NOLs and certain other tax attributes may be subject to substantial limitations arising from previous ownership changes, if any, and if we undergo an ownership change, our ability to utilize NOLs and certain other tax attributes could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change. Our NOLs and certain other tax attributes may also be impaired under state law. For example, California Senate Bill 113 imposed limits on the usability of California state NOLs and certain California state tax credits in tax years beginning after 2023 and before 2027. Accordingly, we may not be able to utilize a material portion of our NOLs and certain other tax attributes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted differently, changed, repealed or modified at any time. Any such enactment, interpretation, change, repeal or modification could adversely affect us, possibly with retroactive effect. For instance, the IRA imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. In addition, for certain research and experimental expenses incurred in tax years beginning after December 31, 2021, the Tax Act requires the capitalization and amortization of such expenses over five years if incurred in the United States and fifteen years if incurred outside the United States, rather than deducting such expenses currently. There have been legislative proposals to repeal or defer the capitalization requirement, including H.R. 7024 (The Tax Relief for American Families and Workers Act of 2024) passed by the U.S. House of Representatives that would restore the deductibility of research and experimental expenses incurred in the United States (but not research and experimental expenses incurred outside the United States); however, there can be no assurance that such requirement will be repealed, deferred or otherwise modified. Changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges and increase our future tax expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may incur significant costs from class action litigation due to the volatility of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price has fluctuated and may continue to fluctuate for many reasons, including as a result of public announcements regarding the progress of our drug candidates, the development efforts of future partners or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies. This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on actions by our stockholders by written consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that special meetings of stockholders, which our company is not obligated to call more than once per calendar year, be called only by the chair of our board of directors, our chief executive officer or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">division of our board of directors into three classes, serving staggered terms of three years each; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a breach of fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees arising under any provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act or the rules and regulations thereunder. However, these provisions apply to Securities Act claims and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce a duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such provisions, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. For the avoidance of doubt, this provision is intended to benefit, and may be enforced by, us, our officers and directors, the underwriters to any offering giving rise to such complaint and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and the provisions may not be enforced by a court in those other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div><ix:nonNumeric id="F_6e355224-ab73-41aa-a26b-02ddb3887d9f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_6e355224-ab73-41aa-a26b-02ddb3887d9f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, hardware, software and critical data, including intellectual property, clinical trial data, and other confidential information that is proprietary, strategic or competitive in nature (&#8220;Information Systems and Data&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function, led by our Director of Information Technology, helps identify, assess and manage the Company&#8217;s cybersecurity threats and risks. Our Director of Information Technology helps to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example, monitoring provided by a third-party security operations center, deploying manual and third-party service provider automated tools in certain environments, subscribing to reports and services that identify cybersecurity threats (and analyzing such reports), conducting scans of certain environments, evaluating our industry&#8217;s risk profile and threats reported to us, conducting internal audits and threat assessments for certain threats, conducting vulnerability assessments using third-party tools to identify vulnerabilities,</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d292a549-b0e0-409a-b1fe-49ff251e3619" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> engaging third parties to conduct threat assessments, using external intelligence feeds and monitoring the dark web.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment and system, we implement and maintain various technical, physical and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data including, for example: incident response plans and policies; vulnerability management policy; disaster recovery and business continuity plans; risk assessments; encryption of certain data; network security controls and data segregation for certain systems; access controls; physical security controls; asset management, tracking, and disposal; systems monitoring for certain systems; employee training; penetration testing of certain environments and cybersecurity insurance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are taken into account as part of the Company&#8217;s risk management processes. For example, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_795c187e-2868-4d08-8c4a-365b0d42a496" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Director of Information Technology works with management to help mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess and manage material risks from cybersecurity threats, including for example professional services firms (including legal counsel), threat intelligence service providers, cybersecurity consultants and software providers, managed cybersecurity service providers, penetration testing firms, dark web monitoring services, forensic investigators and endpoint detection and response vendors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations, contract manufacturing organizations, distributors and supply chain resources. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5eaad186-f4c9-412a-9951-dac23de1df54" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, we may utilize various vendor management processes that may include reviews of security assessments or certifications and contractual measures.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or those of the third parties whom we work with, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse consequences.&#8221;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_6e355224-ab73-41aa-a26b-02ddb3887d9f_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c075e99e-44ea-4441-bd3c-4346fca8808e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><ix:nonNumeric id="F_dff422ea-cf50-4686-b7b0-2a853fbec5b7" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16307ed2-8967-48ef-af5b-2506469d2888" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><div><ix:nonNumeric id="F_9390dcbe-d67a-4bac-a1a8-03e5759257bd" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfa5780d-8650-43f8-afc7-8e4fd7ab9d3b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a Corporate Information Security Steering Committee (&#8220;CISSC&#8221;), which includes several members of senior management, including the Chief Financial Officer (&#8220;CFO&#8221;) and General Counsel.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CISSC oversees corporate information security initiatives and the Company&#8217;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#8217;s corporate security programs and investments.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8365e303-036e-4844-86b9-17eff60ee1f2" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#8217;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.</span></p><div><ix:nonNumeric id="F_07e4c2b6-f76a-4ac1-8a5c-dddf7b3e4d92" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9485de9e-cc87-4890-94b6-4b528e49f639" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company&#8217;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:nonNumeric id="F_a8b94fe3-a2a7-45f1-898c-998b3bdcd59f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in South San Francisco, California, and comprise approximately 36,754 square feet of space, pursuant to an operating lease that expires in November 2026. This lease includes an option to extend for a further eight years, at market rates that prevail at the time of our election to extend.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we entered into an operating lease for an additional 13,232 square feet of office facilities in South San Francisco, California, which expires in July 2025. The lease agreement contains an option to extend the lease for an additional six-month term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that these facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;RAPT&#8221; on October 31, 2019.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the close of business on March 3, 2025, there were 44 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, we may enter into agreements in the future that could contain restrictions on payments of cash dividends.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Price Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a &#8220;smaller reporting company,&#8221; as defined by Item 10 of Regulation S-K, we are not required to provide this information.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 6. [Reserved]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7__management_s_discussion_and_anal"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled &#8220;Risk Factors&#8221; included under Part I, Item 1A and elsewhere in this Annual Report. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Our lead drug candidate, RPT904, is a half-life extended monoclonal antibody (&#8220;mAb&#8221;) designed to bind free human immunoglobin E (&#8220;IgE&#8221;), a key driver of several allergic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into an exclusive license agreement (the &#8220;Jemincare License Agreement&#8221;) with Shanghai Jemincare Pharmaceutical Co., Ltd (&#8220;Jemincare&#8221;), a subsidiary of Jiangxi Jemincare Group</span><span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Co., Ltd., under which we have exclusive rights to develop and commercialize RPT904 worldwide, excluding mainland China, Hong Kong, Macau and Taiwan (together, the &#8220;Jemincare Territory&#8221;). We believe RPT904 could offer patients a potentially improved therapeutic option compared to omalizumab (Xolair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), an anti-IgE antibody approved for asthma, chronic spontaneous urticaria (&#8220;CSU&#8221;), chronic rhinosinusitis with nasal polyps and food allergy. In a Phase 1 clinical trial conducted by Jemincare comparing RPT904 and omalizumab, the median half-life of RPT904 was more than two times that of omalizumab at the same dose, and RPT904 demonstrated deeper and more sustained reduction of free IgE and higher total IgE accumulation compared to omalizumab at the same dose. We plan to pursue clinical development of RPT904 initially in food allergy and CSU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (&#8220;CCR4&#8221;) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (&#8220;T</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) into tumors. Data from a Phase 2 trial of patients with advanced checkpoint-na&#239;ve non-small cell lung cancer (&#8220;NSCLC&#8221;) treated with tivumecirnon in combination with the checkpoint inhibitor</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pembrolizumab showed greater confirmed objective response rate and progression free survival than what has historically been demonstrated by pembrolizumab monotherapy. We hold worldwide rights to tivumecirnon, with the exception of the exclusive license (the &#8220;Hanmi License Agreement&#8221;) granted to Hanmi Pharmaceutical Ltd. (&#8220;Hanmi&#8221;) in Korea, mainland China, Hong Kong, Macau and Taiwan (together, the &#8220;Hanmi Territory&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zelnecirnon, our small molecule CCR4 antagonist for inflammatory disease, was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis (&#8220;AD&#8221;). Both trials were placed on clinical hold by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2024 due to a serious adverse event (&#8220;SAE&#8221;) of liver failure in one patient in the AD trial, and we subsequently closed both trials. In November 2024, based on feedback from the FDA, we ceased development of zelnecirnon. We are currently pursuing different novel CCR4 antagonists that we believe may have improved safety margins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to building our research and development capabilities and establishing our corporate infrastructure. As a result, we have incurred net losses since inception. As of December 31, 2024, we had an accumulated deficit of $614.5 million. We have incurred net losses of $129.9 million and $116.8 million for the years ended December 31, 2024 and 2023, respectively. We do not expect to generate product revenue unless and until we obtain approval for the commercialization of a drug candidate, and we cannot assure you that we will ever generate significant product revenue or profits.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have financed our operations primarily through the sale of equity securities. In December 2024, we entered sold through a private placement to a select group of accredited investors 100,000,000 shares of common stock at a price of $0.85 per share and pre-funded warrants to purchase up to 76,452,000 shares of common stock at a purchase price of $0.8499 per pre-funded warrant, resulting in net proceeds of $143.0 million, after deducting offering expenses (the &#8220;Private Placement&#8221;). Additionally on August 2023, we filed with the SEC and the SEC declared effective, a shelf registration statement on Form S-3 related to the sale and issuance of up to $450 million of the our securities, including up to $150 million of shares of common stock that may be offered and sold from time to time in one or more &#8220;at-the-market&#8221; offerings pursuant to a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) and Leerink Partners LLC. The ATM Sales Agreement replaced the Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement, dated November 4, 2020, by and among us, Cantor and Stifel, Nicolaus &amp; Company, Incorporated. During the year ended December 31, 2024, we sold 365,316 shares of common stock under the ATM Sales Agreement, for net proceeds of $9.0 million, after deducting sales agent commissions and other offering related costs. As of December 31, 2024, there were up to $140.6 million of shares of common stock available for future issuance under the ATM Sales Agreement. As of December 31, 2024, we had cash and cash equivalents and marketable securities of $231.1 million and working capital of $186.9 million. We believe our current cash and cash equivalents and marketable securities will be sufficient to fund our planned operations for a period of at least 12 months following the filing date of this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, our board of directors approved a reduction of our workforce to conserve cash resources. The workforce reduction impacted 47 people, or approximately 40% of our headcount. All employees affected by the workforce reduction were eligible to receive, among other things, severance payments and paid COBRA premiums for a specified time period post-termination. We incurred $0.9 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. We completed the workforce reduction and the cash payments related to the restructuring during the quarter ended September 30, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur substantial expenditures in the foreseeable future as we expand our pipeline and advance our drug candidates through clinical development, undergo the regulatory approval process and, if our drug candidates are approved, launch commercial activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until we can generate significant revenue from sales of our drug candidates, if ever, we expect to finance our operations through equity or debt financings or other capital sources, including potential collaborations with other companies, or other strategic transactions. Adequate funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our drug candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties rights to develop or commercialize our drug candidates that we would prefer to retain.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense both internal and external research and development costs as such expenses are incurred. We track the external research and development costs incurred for each of our drug candidates. However, we do not track our internal research and development costs by drug candidate, as the related efforts and their costs are typically spread across multiple drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. We expense costs for our clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with the associated agreements. We use information received from our personnel and outside service providers to estimate the clinical trial costs incurred.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">External research and development expenses consist primarily of costs incurred for the development of our drug candidates and include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred under agreements with CROs, investigative sites and consultants to conduct our clinical trials and preclinical and non-clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to acquire, develop and manufacture supplies for clinical trials and other studies, including fees paid to contract manufacturing organizations (&#8220;CMOs&#8221;);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to compliance with drug development regulatory requirements; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost related to strategic licensing agreements such as upfront license and milestone fees.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal research and development costs include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries and related costs, including stock-based compensation and travel expenses, for personnel in our research and development functions; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">depreciation and other allocated facility-related and overhead expenses.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluding the $35.0 million expense in the fourth quarter of 2024 related to the upfront license fee for RPT904, our research and development expenses decreased in 2024 compared to 2023 due to the early closure of the zelnecirnon clinical trials and termination of the zelnecirnon program. However, we expect to devote substantial resources towards research and development during the next few years as we seek to conduct clinical trials for RPT904 and advance other programs into clinical development, which we expect to result in increased research and development expenditures as compared to our 2024 research and development expenses excluding the $35.0 million upfront license fee for RPT904. Predicting the timing or the final cost to complete our clinical program or validation of our manufacturing and supply processes is difficult and delays may occur because of many factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist principally of personnel-related costs including payroll and stock&#8209;based compensation for personnel in executive, finance, human resources, business and corporate development and other administrative functions; professional fees for legal, consulting and accounting services; rent and other facilities costs, depreciation and other general operating expenses not otherwise classified as research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur expenses to support our continued operations as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq Global Market, insurance expenses, investor relations expenses, audit fees, professional services and general overhead and administrative costs. If we are no longer deemed to be a smaller reporting company, we expect that we will incur increased expenses to support our continued operations as a public company.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cash and cash equivalents and marketable securities are invested in money market funds, corporate debt securities, commercial paper and U.S. government agency securities. Other income, net, consists primarily of interest earned on our cash and cash equivalents and marketable securities and remeasurement gains and losses on foreign currency transactions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related costs. We account for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the related goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. We expense costs for our clinical trial activities performed by third parties, including CROs and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. We use information we receive from internal personnel and outside service providers to estimate the progress of services performed and the associated clinical trial costs incurred, which have inherent uncertainties and involve significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for stock-based compensation arrangements with employees and non-employees in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock-based awards issued by us have been primarily stock options with time-based vesting or performance-based vesting. ASC 718 requires the recognition of compensation expense, using a fair value-based method, for costs related to all stock-based awards. To determine the grant-date fair value of stock-based awards with time-based vesting, we utilize the Black-Scholes option pricing model, which is impacted by the fair value of our common stock as well as other variables including, but not limited to, expected term that stock-based awards will remain outstanding, expected common stock price volatility over the term of the stock-based awards, risk-free interest rates and expected dividends. The fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Market as reported on the date of grant.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards with time-based vesting, stock-based compensation is recognized over the period during which an awardee is required to provide services in exchange for the stock-based award, known as the requisite service period (usually the vesting period), on a straight-line basis. For stock-based awards with performance-based vesting, the fair value of the award is recognized as expense when the achievement of the associated performance criteria becomes probable, using an accelerated attribution method. For both time-based and performance-based stock-based awards, stock-based compensation expense is recognized based on the fair value determined on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimates of the fair value of stock-based awards as of the grant date using the Black-Scholes option pricing model are affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. These inputs are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; The expected term represents the period that our stock-based awards granted is expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). We have very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock-based awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Since we have only recently become a public company and have only a limited trading history for our common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies as well as our historical volatility over a period, where available, equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock-based awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each purchase under our employee stock purchase plan is estimated at the beginning of the offering period using the Black-Scholes option pricing model.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assumptions we used in applying the Black-Scholes option-pricing model to determine the estimated fair value of our stock options granted involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation could be materially different.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the accounting standards for uncertain tax positions, we evaluate the recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our total net deferred tax assets were $134.6 million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating loss carryforwards (&#8220;NOLs&#8221;). Utilization of NOLs may be limited by the &#8220;ownership change&#8221; rules, as defined in Section 382 of the Internal Revenue Code. Similar rules may apply under state tax laws. Our ability to use our remaining NOLs may be further limited if we experience an ownership change as a result of future changes in our stock ownership.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to our financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.09%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.322000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.322000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.062000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.802%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,217</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,002</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,215</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,884</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,060</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,824</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,101</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127,062</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,039</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(136,101</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(127,062</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,039</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,236</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,264</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,028</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(129,865</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(116,798</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,067</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased $6.2 million, or 6%, to $107.2 million for the year ended December 31, 2024 from $101.0 million for the year ended December 31, 2023. The increase in research and development expenses was primarily due to the $35.0 million expense relating to the upfront license fee for RPT 904 and an increase of $1.3 million in stock-based compensation expense, partially offset by decreases of $20.9 million in development costs related to zelnecirnon, $3.5 million in development costs related to tivumecirnon, $1.8 million in development costs related to early-stage programs, $3.0 million in lab supply costs and $0.9 million in personnel costs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a comparison of research and development expenses for the years ended December 31, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.09%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.322000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.322000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.062000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.802%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External development expenses:</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RPT904</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zelnecirnon</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,499</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,410</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,911</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tivumecirnon</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,588</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,123</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,535</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">852</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,575</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,723</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,278</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,894</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,616</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,217</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,002</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,215</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*: percentage not meaningful</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously noted, we do not track our own internal research and development costs by drug candidate, as the related efforts and their costs are typically spread across multiple drug candidates and programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased $2.8 million, or 11%, to $28.9 million for the year ended December 31, 2024 from $26.1 million for the year ended December 31, 2023. The increase was primarily due to increases of $1.6 million in non-cash stock-based compensation expense, $0.4 million in personnel costs, $0.7 million in professional fees and $0.1 million in facilities costs and other expenses.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net decreased $4.0 million, or 39%, to $6.2 million for the year ended December 31, 2024 from $10.3 million for the year ended December 31, 2023. The decrease was driven primarily by lower interest income due to lower interest rates from lower invested cash balances for the year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources; Plan of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have financed our operations primarily through the sale of equity securities. In December 2024, we closed the Private Placement, resulting in net proceeds of $143.0 million, after deducting offering expenses. During the year ended December 31, 2024, we sold 365,316 shares of common stock under the ATM Sales Agreement, for net proceeds of $9.0 million, after deducting sales agent commissions and other offering related costs. As of December 31, 2024, there were up to $140.6 million in shares of common stock available for future issuance under the ATM Sales Agreement. We had cash and cash equivalents and marketable securities of $231.1 million and working capital of $186.9 million as of December 31, 2024. Our cash equivalents and marketable securities consist of commercial paper, corporate bonds and U.S. government agency securities. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view towards liquidity and capital preservation. Since inception, we have incurred net losses and negative cash flows from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had an accumulated deficit of $614.5 million. In addition, we expect to incur substantial additional costs in order to conduct research and development activities necessary to develop and commercialize our drug candidates. Additional capital will be needed to undertake these activities and we intend to raise such capital through the issuance of additional equity or debt, strategic alliances with other companies or other sources of financing. However, if such capital is not available at adequate levels or on acceptable terms, we could be required to significantly reduce operating expenses and delay or reduce the scope of, or eliminate, some of our development programs. We believe our current cash and cash equivalents and marketable securities will be sufficient to fund our anticipated level of operations through at least the next 12 months following the filing date of this Annual Report.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to require additional capital to develop our drug candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with other companies, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our drug candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of clinical programs we decide to pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and costs of manufacturing development and commercial manufacturing activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other drug candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost, timing and outcome of regulatory review of our drug candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of establishing sales and marketing capabilities, if any of our drug candidates receive marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company, which we expect will increase if we are no longer a smaller reporting company, as defined in the Exchange Act; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost associated with commercializing our drug candidates if they receive marketing approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the global financial markets have previously experienced significant disruptions due to various macroeconomic factors, including among other things, the impact of ongoing overseas conflicts, resulting in a general global economic slowdown,</span><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and significant disruptions may occur in the future as a result of these activities or other economic factors, such as tariffs. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other parties rights to develop or commercialize our drug candidates that we would prefer to retain.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary Statements of Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.08%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(83,297</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(97,048</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,702</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,133</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,852</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,447</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,257</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,532</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $83.3 million for the year ended December 31, 2024, reflecting a net loss of $129.9 million, partially offset by net cash used by changes in operating assets and liabilities of $25.9 million and non-cash charges for primarily depreciation, amortization, stock-based compensation expense and non-cash lease expense totaling $20.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $97.0 million for the year ended December 31, 2023, reflecting a net loss of $116.8 million, partially offset by net cash used by changes in operating assets and liabilities of $5.5 million and non-cash charges for primarily depreciation, amortization, stock-based compensation expense and non-cash lease expense totaling $14.3 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by investing activities was $52.7 million for the year ended December 31, 2024, primarily from the proceeds from maturities of marketable securities of $135.0 million, partially offset by the purchase of marketable securities for $82.2 million and purchase of property and equipment of $0.1 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by investing activities was $104.1 million for the year ended December 31, 2023, primarily from the proceeds from maturities of marketable securities of $266.7 million, partially offset by the purchase of marketable securities for $161.5 million and purchase of property and equipment of $1.1 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $152.9 million for the year ended December 31, 2024, from $143.0 million in net proceeds from the Private Placement, $9.0 million in net proceeds from the sale of shares under the ATM Sales Agreement and $0.8 million in net proceeds from our employee stock plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $1.4 million for the year ended December 31, 2023, from $1.4 million in net proceeds from our employee stock plans.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our material cash requirements in the short- and long-term consist of the following operational expenditures, a portion of which contain contractual or other obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary uses of cash and operating expenses relate to paying employees and consultants, administering clinical trials and providing technology and facility infrastructure to support our operations. Our research and development expenses in 2024 were $107.2 million, which includes the $35.0 million expense related to the upfront license fee for RPT904. Excluding the $35.0 million expense related to RPT904, our research and development expenses in 2024 were $72.2 million, and we expect to increase our investment in research and development expenses in 2025 compared to this level as we commence clinical development of RPT904. Our general and administrative expenses were $28.9 million in 2024 and we expect to increase our general and administrative expenses to support our business growth in 2025. We manage future cash requirements relative to our long-term business plans.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating costs also relate to our building leases for our office and laboratory facilities expiring in 2025 through 2026 that contain rate escalations and options for us to extend the leases. Our future minimum lease payments as of December 31, 2024 were $4.8 million. Refer to Note 6 in the Notes to Financial Statements in Item 8 of this Annual Report for further detail of our lease obligations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller Reporting Company Status</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies, including, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002,and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclo1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">smaller reporting company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as defined by Item 10 of Regulation S-K, we are not required to provide this information.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ts and Supplementary Data.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.12%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:85.9%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:6.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_ac"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(PCAOB ID:</span><span><ix:nonNumeric id="F_8cc12c61-2d04-447b-a298-d2fad83e61c4" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_stockholders_eqi"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:center;" id="report_independent_registered_public_ac"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Indepe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ndent Registered Public Accounting Firm</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of RAPT Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f86c96e-0643-4e38-8b55-bbda2bf8f589" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of RAPT Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stockholders' equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial accounting for the December 2024 common stock and pre-funded warrants</span></p>
  <table style="margin-left:3.87%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14%;box-sizing:content-box;"/>
    <td style="width:86%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.03in;padding-left:0.03in;vertical-align:top;padding-bottom:0.03in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-top:0.03in;padding-left:0.03in;vertical-align:top;padding-bottom:0.03in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As described in Note 8 to the financial statements, in December 2024, the Company issued 100,000,000 shares of common stock and pre-funded warrants to purchase 76,452,000 shares of common stock in connection with a securities purchase agreement. The common stock and pre-funded warrants were classified as stockholders&#8217; equity on the Company's balance sheet.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the Company&#8217;s initial accounting for the December 2024 common stock and pre-funded warrants was especially challenging with respect to the evaluation of the terms and conditions of the securities purchase agreement in relation to the applicable accounting guidance.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.03in;padding-left:0.03in;vertical-align:top;padding-bottom:0.03in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0.03in;padding-left:0.03in;vertical-align:top;padding-bottom:0.03in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Our audit procedures included, among others, reviewing the related securities purchase agreement and assessing management's application of the appropriate accounting guidance, including the determination that both the common stock and pre-funded warrants were appropriately presented as stockholders&#8217; equity on the Company&#8217;s balance sheet.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8897d51a-b699-4190-819e-8486a12b5b32" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2017.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d5e4488-64c4-4024-8c2c-319491e1d0a3" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALANCE SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.08%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #ffffff;padding-top:0.01in;border-left:0.5pt solid #ffffff;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-left:0.5pt solid #ffffff;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b71b29-a35c-4987-9b4b-026d51d02a2e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,735</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e18cc0a2-fa79-4094-b137-e2e46a18dc24" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,478</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de82d0ef-ab56-45f9-9e05-ef07f048df82" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,320</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5cc1794-4c28-44ec-8215-f9940374c607" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,384</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f8ca948-f539-40de-9d18-d6830e0dec7f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,181</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d54b38-ed2b-4b85-b7dd-c040e50fff85" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,920</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6937699-250d-4c8a-bbeb-87c96b4f0489" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,236</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a38bdf1-b9a8-4099-9e28-3d0bdd6c27da" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,782</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6746c8e5-d82c-459a-8353-0124872fa5eb" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,367</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7afa0b3-0293-49d8-b11b-2e7a5e8c8fb6" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_402e25d6-59b0-4dee-b6ee-28df42378ce8" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4077603e-dc50-4613-8fa7-7cc4005c0515" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb24991c-40e5-4a9f-8ed8-7add6121b96d" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22f43ebb-9bee-41e1-b759-4693f978e9e4" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,871</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d75e059-d66b-4878-aa70-34fa63a705b8" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,325</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64725e62-dfa0-47a7-8354-14e1936f23ad" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,329</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_147b4cda-0d87-437a-9a01-750f2a72e91f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,275</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05ad8d36-a943-40da-a1c3-05aca1658056" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,176</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cacf1c2-6fa4-4ea6-90e1-3bb990d5f40d" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,597</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62708ea6-5bff-4247-8452-9aa2452bf8f2" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fees payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_060b9bca-22e3-4890-b9fc-64b69a99554a" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:LicenseFeesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1443eac-637b-4705-8dc5-0c823c1c4074" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,422</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bab648c-2f91-4c3d-ac8e-2d311d2eff19" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1225de06-c312-4ca3-b85d-43eea89755d5" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">57</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05a0fa9e-439f-41a8-830b-02b53cbca9ab" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8649582b-1bc5-4783-9972-68a353bd345e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,351</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a468320a-627c-4e9b-bce2-30dc66c53929" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,836</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee449fd0-b708-4612-89e1-8983b2cbf416" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f27f2fb1-e132-447f-a879-4ccd5ef2df43" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff2519c1-1181-4fd6-a21c-a635baaa81d4" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,421</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d3caf73-88d3-403d-9a71-033fbc5bd434" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,294</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_119d5c31-574a-41b1-bb0c-c45232e3a0fb;"><span style="-sec-ix-hidden:F_29c1e797-26fc-49db-8445-893357da5c44;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(see note 6)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31ca3b57-3729-47bd-9908-83534a8679f0" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eae186fa-4e50-4396-8680-dfb51982bf89" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaab2ad8-fa13-4116-9fd5-6483108563c4" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bf72d60b-455f-4164-a490-eef7a33da449" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4447f30-b6a1-4f3a-b7c5-cd7173704253" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_804ef9d1-5686-4b53-82e9-ceeb226ca855" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c62ff526-dfe5-47db-9163-c9479b60e54c" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a860e120-ad56-475f-939e-2cdc14178560" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_f4cafdc4-5da6-43ff-95bd-69630443c804;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_60da1fb1-1699-4d6e-8077-8710d40b7a31;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1cedc61-0713-4a44-a60f-2ce55f0c7021" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c70174b-1344-46a9-817c-1e3a316e0f4c" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd0ac2e9-8da7-4ac3-991d-54a0f86ef8c7" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b74f800d-1ab0-4303-887f-94b920db6af4" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized;<br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1792d97a-6418-4de7-b76f-1f4a306f8111" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d819af5a-eb7a-46e9-a9c6-45d7a79ed003" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">132,006,828</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78883bb3-5c25-46a2-bf75-f3584a57d1dc" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bfe1bba4-3dfe-4c89-a9c3-176d61e2b98b" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,398,312</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at<br/>&#160;&#160;&#160;December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9e94d3e-a0be-45ba-ab15-137fc7330cd2" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e224045-4d17-42aa-99b3-9d92a1faba95" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_070cc20a-6c85-4997-9416-2b742a09a777" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">804,388</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7bde45f-01d7-40a8-9c71-58e8bb7246a5" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_749af9fc-a9da-455b-8889-36455e07913e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f707fb1f-46e4-43be-ab9a-b3bb0dd90b1e" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #ffffff;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_159d86f2-261e-49b4-98d1-9f46007d3c2d" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">614,547</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37a4772c-3a85-4463-8ae5-5c3264b707b4" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">484,682</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dab20569-cb30-4f44-b16d-1e0117ba46a2" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6b5d057-8462-45ea-96a3-27cb4d826404" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,035</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bcc8644-3b27-47b1-9f19-1ec7131066e1" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,325</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa52a0f-0f19-4b5a-be49-7152a09967ac" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,329</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENTS OF OPE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RATIONS AND COMPREHENSIVE LOSS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.08%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a1a9b3-7aca-4fc5-8961-af85a6595055" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,217</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60558d9e-05c8-4956-8a8a-85beece514fb" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe6cd925-cf58-45a8-a95c-906b40a26d18" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,884</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb1cd388-a650-405b-9e4f-3f43c5c44197" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,060</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e4a36c0-f498-4b86-a19a-488192161b6b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,101</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c195cd14-46cf-41f4-a59d-b8526868daa8" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cc3df17-e61a-4306-a60a-4233ebaec14d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136,101</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_286dc46e-2f28-4f9b-bc3b-41664fd1fdbb" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">127,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fad2bde6-3767-4ffa-aede-c5b390c652c6" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,236</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f8b954-8094-48b2-9bf3-506558c5168e" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,264</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e37f4237-1463-4e0e-993c-b43de3e86330" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77a67614-a47f-4dc4-8e42-bf3c6aa56828" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9bfac4c-f2cb-4bab-a017-f80818505ae3" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b5c9dbe-ff08-46e5-a1a8-50386123ef41" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">655</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized (loss) gain on marketable securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecefb05b-5036-4396-9c0c-e7ea8f723952" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833651ba-b1d4-4c5d-92dd-2cb8b61e0eb7" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3">784</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d3bb79-a3c2-40ae-b54e-6befcf4bc051" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,918</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5faebb1-a7ea-4bd1-b333-c7b3a23808ca" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,669</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c37bd809-f96c-4db9-929c-1c2c6bd1e5a6" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_415f983d-0134-4d72-9054-17cfabe5f23a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.19</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_485d61b7-f463-4787-8850-a02f33aa3833" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_698beb3e-9a11-4bfe-a4f4-ffc3034991a3" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.05</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in computing net loss<br/>&#160;&#160;&#160;per share, basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_355fd057-e71c-4c84-be30-03ec79f7fbe6" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6120a431-d426-478b-8708-2fa6beac533a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,761,143</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f5738e-9258-43eb-a2f6-ba29c7867f34" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_34105604-43f9-4eea-8794-7fcc9eda71f8" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">38,338,161</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_stockholders_eqi"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PT THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28b4cf0a-1ae0-4ff8-9c9c-956ddefa5034" contextRef="C_df1b1c57-47c3-4026-b445-8a31e755c7c5" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,254,314</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c444e659-2896-4280-9f1c-1e81ca2cc9da" contextRef="C_df1b1c57-47c3-4026-b445-8a31e755c7c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffeb7171-f05b-4f2b-9ce3-54e13e42e7ed" contextRef="C_5850ebc9-a864-4a07-a4fc-8f60c63fa87e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">613,073</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc74ad00-9ee1-4d0c-b0e4-723172d5c298" contextRef="C_3706be79-6eca-451d-b612-a19d5eada7ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">367,884</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82c245d2-651e-48aa-99bc-7ccf9976e604" contextRef="C_ba2021a0-4327-4bd0-aac5-d66d26d8d350" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad88a1c0-6a35-4de9-ad25-47105cedb6f6" contextRef="C_80a183b9-14ce-4b94-97fa-8410f324fd16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuances of common stock under employee stock plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006e76ed-45fa-475e-9876-17f1e44a2d48" contextRef="C_e1066a6a-e09d-458e-acdd-6e64892bf012" name="rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,998</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beb3f4d9-7d8e-4428-b167-877d8c78cde3" contextRef="C_06cd052d-df60-42b2-bbee-bb15f02e89e9" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a99fec52-e3b5-4a3d-bab6-ea1937a2835e" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b8eb995-92aa-4755-adcc-3bbd68efecb8" contextRef="C_06cd052d-df60-42b2-bbee-bb15f02e89e9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b67228b0-225d-47b3-a1ba-6743d064aed5" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03bc2916-1804-4095-a83c-3ec526007913" contextRef="C_70e17388-d873-445b-a20e-38ec5ac336ff" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72d11c2c-0d85-4e71-9532-e912a824d5a1" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c616f6-13b9-45a5-a516-98aeaf1a305f" contextRef="C_70e17388-d873-445b-a20e-38ec5ac336ff" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">784</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f898de3f-ab36-45da-88b4-3f85df04fffb" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">784</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f289475-78b6-4ca0-9505-bf16abcc83a8" contextRef="C_b4b55243-d136-47d3-a127-156fda882df4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e9d299-cbda-4c13-b6ed-6aa2939600e6" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d0fed4-f5f1-4acb-8303-e9901f18744a" contextRef="C_f0afabfb-107b-4ed2-bd84-3925d8b53326" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,398,312</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d44352b2-9202-40d8-b852-9ddb0d1e1a6a" contextRef="C_f0afabfb-107b-4ed2-bd84-3925d8b53326" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6114e7a3-08a7-4aad-8f94-a553d010e6e4" contextRef="C_12ad4aaf-5e7d-4fa1-9234-52fe93bfd5bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_674125de-e6e3-41df-b92b-b1641f362357" contextRef="C_d07dd25e-838e-46eb-b796-57384523a826" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">484,682</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72894586-758b-4f23-81d8-72bf78040733" contextRef="C_006a226d-1684-4b7d-aef7-38226ec504b9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7883894-ba25-4701-889e-d2d76e52e847" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,035</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and pre-funded warrants in a private placement, net of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08042118-b41f-42b7-bca8-2d6284afe924" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">&#160;million of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_485b4328-f44b-4f36-8fed-d6b9a83a67b1" contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352" name="rapt:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4817baf3-410e-44ca-994d-78f6d231ee6b" contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352" name="rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b96aed-5b4b-479f-bd69-488996dc6e0a" contextRef="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71" name="rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,040</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d469980-9f6c-46d6-99dd-021dc5ac829e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,050</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exchange of common stock for pre-funded warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09efd63e-c6e6-499a-b10f-465c938d1a56" contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352" name="rapt:ExchangeOfCommonStockForPre-FundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,951,425</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuances of common stock under employee stock plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b30cb09-abac-4835-bd23-8a01c106dd4b" contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352" name="rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">194,625</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5835f398-908e-4564-a096-cc1e94282f22" contextRef="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa755884-fe52-4d7a-a898-05409b8cab74" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuances of common stock in &#8220;at-the-market&#8221; offerings, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c410012-f8a3-436e-bda4-56730ee36aa8" contextRef="C_093ed038-7ba6-4156-b45c-e468a7894554" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">365,316</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b7246a6-3258-4787-94ec-053ce12258e7" contextRef="C_117752af-ee4a-40bc-b530-1ca28e52766e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,957</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc3eacf-c55c-4bbf-8577-e84c36004ef3" contextRef="C_29f339b8-0983-4068-aee7-ce961fb7cfc0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,957</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71896824-efbc-4ec8-b3d1-156dafd140f0" contextRef="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,935</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22be34d5-70d8-49e6-a4ec-99077e6eb35d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,935</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02613f40-3c2c-4824-a0fa-ee59cfb41b7f" contextRef="C_f7b273cd-4c72-409d-97ae-7c64008c43b9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3922c22d-b9d6-4719-acf4-2f1d687a9ed7" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">53</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ce5db00-c47d-43dc-a591-7b8f7ecc5fd6" contextRef="C_f88ae597-74c9-41cb-8da2-ca7e310ac907" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7de7b15f-9092-4500-b094-689a0b68e689" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a1e3693-c63d-403b-a652-46285dc8c5ee" contextRef="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">132,006,828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66cded7b-56db-4869-8890-2709242d297a" contextRef="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7234d1a1-e263-4716-b1ff-7c2f16d6fbfb" contextRef="C_d733af1e-23fc-411c-a82f-13e6af25be62" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">804,388</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c500e2f0-2810-4209-9ee7-c4043df3ea35" contextRef="C_9001335a-7425-4825-a5e8-855ff463d619" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">614,547</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae4278d7-3b1a-4b96-b8e9-0fc5491bd630" contextRef="C_05fa6023-9251-45f1-b9a3-f304f3689065" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2d3669f-3072-4a70-83f6-ecc78752394a" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENTS OF CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.08%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9a76ad3-a496-4d2a-b3d3-ea3424cf6dca" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61dcb757-9f24-41c9-adb7-223fec2be4e2" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discounts on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b321a11-d8fb-4528-ac77-8d4d9838cd85" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41e7e437-a5c9-48de-9be0-9c3612b081a9" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28acb738-a18e-4f35-82bf-2a13916f5cc3" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,203</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c319e1a-02dd-48c2-aab2-209b2d8e5b64" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8fcd71c-477c-40b9-b793-0ea169c1826b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,935</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e46838-f313-446f-923c-2a4a7584465c" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on foreign currency translation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86d436e5-f459-427a-a61b-607c1cd2163e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18b7597a-2bec-4b2d-96ff-f28eb73dd9a6" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e53a57f1-d048-4889-a0f6-97851f58f659" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:NonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,336</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_387f56a7-6fe3-4c32-ad67-530249b0896b" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="rapt:NonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,335</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a5519e-622f-4c1c-a609-abb6b349a6a9" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,221</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97b2c55c-9f4f-4a5c-ae34-84951ffa2da1" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">871</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable, accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d01bb6f8-b8d8-4340-bd98-ab7bf7fb4c24" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,459</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf29b508-6208-4e85-93e9-3288122a7041" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,335</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fees payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9950c9-4ead-4fd6-81ac-5a631c486860" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:IncreaseDecreaseInLicenseFeesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a7c0a0c-02c7-4a8e-9ce8-4ddd001e5331" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="rapt:IncreaseDecreaseInLicenseFeesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60f5a073-944d-46d4-99b1-571e550350dd" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,855</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fa0cb77-6542-4eca-b1ea-7aa6e0f4a0ca" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,707</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59e31d7a-1fdb-43c4-a264-402d8234de74" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">83,297</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfadf49b-a3ce-4aab-922d-44e007fa9203" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,048</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_082a6c16-c863-470b-833e-841c244e6453" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,218</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_443b021d-1f8e-42cf-beb0-e9afea61b4c2" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9c1972f-7e37-400e-9543-cf2dd92c4535" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,042</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8726a782-08ac-46e2-9757-67bf2fcd5763" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,755</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11c6a184-ff3a-4efc-93a6-f2533f9e21c4" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">122</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96b956fd-5c5c-4a2c-8a05-c7fd619cdbe9" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,125</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e99f7663-66df-45fc-ae89-fa9b42edf960" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,702</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9021a2ec-1a04-4843-9447-5ea730145d47" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,133</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of common stock and pre-funded warrants in a private placement, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bb3116d-56b5-4cee-af2c-2393fb0a0425" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,050</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52849f8e-e9cf-4448-8f15-777ad2c4ea16" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuances of common stock in &#8220;at-the-market&#8221; offerings, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68d0026b-615a-4428-82c4-93015f1fdf34" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,957</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eadd13a9-facf-4420-bf08-a0c634d73612" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under employee stock plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e8beeb4-75be-455a-a52b-7b85b5cdbcc9" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76bc8449-f6c0-41f2-81e0-fae18fdc78da" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2c82184-6b31-445c-bd0a-41160b08e517" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,852</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5318642c-c047-4eaa-95c5-05ea875727f8" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29933eed-8426-45da-9232-bed3252a7f2d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,257</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64bd43af-063d-4258-a855-133059d3e93f" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,532</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0228210-23f4-4878-85c3-1a0fd35bd224" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,478</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a01456e6-c38e-4f6d-b7e8-d8253801a18b" contextRef="C_80a183b9-14ce-4b94-97fa-8410f324fd16" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,946</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be3307c9-94e6-4f58-97f8-8c651f1fcb56" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,735</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87a82958-137e-4373-80f2-1ff72c22cd30" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,478</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09e2281f-e314-491b-a490-013db93b783f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT Therapeutics, Inc. (&#8220;RAPT&#8221; or the &#8220;Company&#8221;) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. The Company's lead drug candidate, RPT904, is a half-life extended monoclonal antibody designed to bind free human immunoglobulin E (&#8220;IgE&#8221;), a key driver of several allergic diseases. The Company&#8217;s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (&#8220;CCR4&#8221;) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company ceased development of zelnecirnon, its small molecule CCR4 antagonist for inflammatory disease. The Company is currently pursuing different novel CCR4 antagonists, which it believes may have improved safety margins. The Company is located in South San Francisco, California.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Management Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2024, the Company incurred a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31c65794-2187-49a1-9a31-b1a9591469a4" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">129.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d73df01c-57aa-499b-82c8-486e053477c6" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">83.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash in operations. At December 31, 2024, the Company had cash and cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9145fd-fe86-4347-8953-745bd04f1bdc" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">231.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c533be0-11f3-492b-a922-a7c53de2ad18" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:WorkingCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">186.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July, 2024, the Company's board of directors approved a reduction of the Company's workforce to conserve cash resources. The workforce reduction impacted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91e7c505-5958-4bcb-ba9b-17c275fd1694" contextRef="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Employees" decimals="INF" format="ixt:num-dot-decimal">47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> people, or approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99472a91-32de-406f-ba40-1719c2dd8f90" contextRef="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's headcount. All employees affected by the workforce reduction were eligible to receive, among other things, severance payments and paid COBRA premiums for a specified time period post-termination. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d270fcbb-6512-4d68-b7db-a7a0931d9623" contextRef="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. The Company completed the workforce reduction and all cash payments related to the restructuring during the year ended December 31, 2024. As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b73817d1-e7b9-46c5-8a6d-fa02e42b735f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:AccruedExpensesRelatedToWorkforceReductionPlan" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued expenses associated with this workforce reduction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#8217;s current cash and cash equivalents and marketable securities will provide sufficient funds to enable the Company to meet its obligations for at least 12 months from the filing date of this Annual Report on Form 10-K. The Company&#8217;s evaluation was based on the facts known as of the date of filing of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdc5a2cc-31f5-47d7-a600-fffdb37d344f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company. The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) until December 31, 2024.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_1" continuedAt="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de2b2f26-2805-4b71-abc6-fb7fc096ed14" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee524c2f-de63-46d5-aa9f-7c45fe9dd2a2" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b34932f-aca3-4e62-904c-7b91558c69dc" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:NumberOfFinancialInstitution" unitRef="U_Institution" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a789f07-6fa2-40f4-91c7-24c8a9dc8a6a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5478996a-804a-4f18-89f0-88f2679981b1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Brian Wong, M.D., Ph.D. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_490be401-b098-4c84-a148-82c7ca35e25c" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company&#8217;s operating segment and decides how to allocate resources based on the Company&#8217;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024 and 2023, all of the Company&#8217;s property and equipment was maintained in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93efbb92-380d-40f6-bc8b-090445669e41" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c12093bb-d12c-428a-b310-b520a9cf6ad8" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_2" continuedAt="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_701effce-51f6-46e0-bdbf-9f8fc6ab5a8c" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities primarily consist of commercial paper, corporate debt securities and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the Company's available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, the Company determines if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#8217;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. If the impairment is a result of a credit-related loss, the Company recognizes an allowance for credit losses. If the impairment is not a result of a credit loss, the Company recognizes the loss in other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35becc42-3808-4ecd-9e2e-f25fc644876e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b2c0381-34b5-4225-b14c-08e039f44849;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a833d09d-1dc8-4e94-a251-57a7a71028fa" contextRef="C_fb99ca50-d416-41f6-891a-c4cf6cba220c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_888efa48-92e2-4275-82a3-82859019fc93" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b8a00c2-ec08-4d98-85f0-cc3585c9753e" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_77026660-110a-4450-a49e-934c82e7a26e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record any impairment losses on long-lived assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31616198-072d-41e9-b35c-5b00bb509b44" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_3" continuedAt="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7794f3f-669b-44e1-82e0-58ed60cadf50" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. Amounts incurred in connection with license agreements, such as upfront license and milestone fees are also included in research and development expense. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_546a9b82-28c0-443d-b2d8-a3cf1587d8fd" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines employee, non-employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f38db42c-eb13-445d-80f0-0153549b3b37" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_071a3128-3345-46d0-a33a-3fe3977b5fd5" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7963dc3-1437-4dbc-8a6a-0b164ce49256" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99ebdbc2-9c08-4058-8066-cdb1a8ef82eb" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7ebf2f4-085c-4498-a887-4d0a2e5598e5" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company retrospectively </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c596937a-5a74-49b4-b59e-b92653a4c29d" contextRef="C_a7ae680f-040b-4295-a0e6-b8be8d744edf" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2023-07 on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c751aa81-0a17-4348-b7a6-ea1174a02438" contextRef="C_a7ae680f-040b-4295-a0e6-b8be8d744edf" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and will adopt it for its interim reporting starting with the quarter ending March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The adoption of ASU 2023-07 did </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0aa67c15-f673-492f-87e0-06f9e4e968cc" contextRef="C_a7ae680f-040b-4295-a0e6-b8be8d744edf" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company&#8217;s financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (&#8220;ASU 2024-03&#8221;). ASU 2024-03 requires disaggregated disclosures of certain categories of expenses in the notes to the financial statements that are included in expense line items on the face of the income statement in annual and interim periods. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on its financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this standard on the income tax disclosures within the financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_996046ea-d753-40e4-924b-c079544b0530" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_996046ea-d753-40e4-924b-c079544b0530_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts payable and accrued expenses that approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_996046ea-d753-40e4-924b-c079544b0530_1" continuedAt="F_996046ea-d753-40e4-924b-c079544b0530_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair values of investments in corporate debt securities, commercial paper and U.S. government agency securities using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b8b4898-b476-4544-beae-05abe128cbe1" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.187%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:10.582%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8549bd0-8117-4451-81b2-33655e0cf43a" contextRef="C_7e94663b-2499-455a-afcd-6856ab82b16c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,776</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d3efc8e-c341-491e-b809-6ddb5c58b968" contextRef="C_7e94663b-2499-455a-afcd-6856ab82b16c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,776</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d688794-7dce-4ec6-bed3-f6033a1fddb2" contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,772</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2075ea1a-899f-4c52-b35a-6eca2d500dac" contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70c5cedf-d2f6-469a-996d-e231337da090" contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ad5871e-e655-468c-b660-92e37c3a6a18" contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffe4630b-495b-4377-8c1e-b9b2e3b34fe5" contextRef="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,820</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dd32f14-aaf0-46b7-9515-2282eec73c81" contextRef="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e224a728-22f4-45ca-a2e2-5f486ef15b70" contextRef="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,825</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8037295-e1c4-4ce0-a079-4fdd68643f4d" contextRef="C_8a36a6b4-2ad5-4767-8ac9-f1a57de88015" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,795</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2286c437-1676-4899-9ee7-6678e84d8b6e" contextRef="C_8a36a6b4-2ad5-4767-8ac9-f1a57de88015" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,795</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5afed3f-3d52-485a-98fc-542342dacf7f" contextRef="C_0e2a4e95-63a9-4653-b397-04670a792eda" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec63ba92-5687-46fb-a866-0b6c6353df48" contextRef="C_0e2a4e95-63a9-4653-b397-04670a792eda" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c208db33-01b7-49dc-a196-b726f805e78b" contextRef="C_0e2a4e95-63a9-4653-b397-04670a792eda" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04c63f6a-cab3-444f-a4ca-1583726c8b29" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,906</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d60a9168-9126-4ec2-a3ae-aefa6e7c7f80" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ee843c-10c9-4758-9662-0a366ff1faca" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef351a5d-9355-4787-8ea6-f68d5208c5f7" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,956</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f42e460f-1b25-4581-9f36-08e45ff189fe" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93e6ab76-e7f4-436d-8194-365454057df6" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de04dd02-4d9f-4a79-b492-c0bcfe44de80" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:MarketableSecuritiesAtAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,270</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_898acb52-0c10-4978-870c-2fb89d66615e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:MarketableSecuritiesAtUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2404e6af-d0de-4044-a054-f975567212c9" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:MarketableSecuritiesAtUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62e2bb26-2896-42a2-9341-7859bdf6d22d" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.187%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:10.582%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.382%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c009c1ca-2ffa-4647-99ac-0da1c4c20a82" contextRef="C_9abc0e8c-51a8-434c-a1d1-15cb685a695f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cc589bb-f78a-46ad-bb69-da2aaf7b234e" contextRef="C_9abc0e8c-51a8-434c-a1d1-15cb685a695f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a9b2b16-a282-4dc9-a935-9aa29d2eac84" contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,531</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b14750b7-a44d-47b5-935f-99f78fd22aae" contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47b0da59-9bea-4303-b723-83227ce49afa" contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">9</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47a4fdcd-3250-4cc6-85c7-e9de05585a08" contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,559</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1226c244-9be9-4aa9-a7a6-e9e1bca664a2" contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,242</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd80bdbe-512c-4e27-8573-484e6716ebe7" contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6de324c-d924-4783-b917-45bd2de4d005" contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bda3aea-287e-4a95-b418-19faecae21da" contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ca3dab3-4d80-49c8-a2ca-aeff696a0fe6" contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,828</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4a02ba9-f259-4ecd-8153-bc62cee215cc" contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b188f35-6471-4955-873f-d6c2d3b8bed4" contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a237852-186f-4f2c-82c6-67a94ee183c5" contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,827</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c40d687-e875-448a-af61-e0e1374b1ed6" contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,206</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f5ba670-2377-456f-b685-dfaca11a97dc" contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_064c13e8-9c9e-4b23-be3f-76c7f2a1ea79" contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">18</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5588ed2d-54a4-4b7b-8fae-5b4bf7403c00" contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,279</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd138a2d-7304-47ac-8113-638e023a65b6" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,676</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_297ac28e-753b-428b-bcb9-f19e5df05dd4" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdf5e0a4-8be5-4968-92bd-9320c3fd8289" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8636980c-ae72-45c6-a408-86f52f378edf" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,779</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c304476-3e9c-478c-ad7f-0ab4a638fc3a" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,395</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8a1c196-2cd7-4ca5-a7fb-40f7562f3325" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,395</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c6de256-69d8-4aa9-8f24-826da86a2e23" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:MarketableSecuritiesAtAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd9bbfe-e20b-4ee0-a065-7b67196478fa" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:MarketableSecuritiesAtUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc7e935e-1f00-426c-9e59-cd9e75aabf15" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:MarketableSecuritiesAtUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b182c3b-caac-4994-85ce-9bbb0277a6e5" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,384</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_996046ea-d753-40e4-924b-c079544b0530_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrealized losses on the Company&#8217;s securities that were in an unrealized loss position were caused by interest rate changes and were not attributable to credit losses. The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a546329d-319b-43be-8ebb-eb94d6807c1b" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fffa39ee-fc57-493d-b51f-e48bf0bcd22e" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an allowance for credit losses or other impairment charges related to its marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e22b6a90-d740-422f-936c-e5364f6751cf" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.548%;box-sizing:content-box;"/>
        <td style="width:4.159%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:33.293%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturing in one year or less</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eda2e2b3-b1cb-4383-afe1-7d80efd49127" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturing after one year through five years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72eeb297-ae12-4bb9-bfc5-20bca22afd10" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b6caa55-ae99-4cfd-8c17-f3e075f8234d" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11a08204-139c-4f48-9663-1d7284897fc7" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae54f747-5313-456c-9a55-0a5c8304803b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0792c15-0c88-41be-bb80-47129a7db6c1" contextRef="C_6efad3db-74b5-461f-bbce-26e3290c27ef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,035</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d883e4e6-010e-4ab8-af2b-e97f5ec792f3" contextRef="C_08197314-2cfa-4bcf-ab84-5468f429d84d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,399</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcdf2d54-68db-4fa0-a71e-b3a666b2cbf5" contextRef="C_cc2ab253-a7db-4cd8-aca4-5879a7c0fe34" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73d1032f-6efa-4053-8e0b-db72ab1d2473" contextRef="C_f53811ad-a51a-40a4-8001-17b6fbbea400" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02c4981c-ae9d-4d3e-b975-766d0ee0664d" contextRef="C_bc3a237f-db8c-4eb6-ad25-be4c30946b6b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">706</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3b4eebe-ba86-47ed-9afb-8fdc4729969e" contextRef="C_ee90ccbb-6c06-48ca-9de4-a94e0bd95940" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">727</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_945d82ef-78b4-4985-8f49-701fa7fee611" contextRef="C_8234c17c-ee4d-4a80-9c05-28fda21083ac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">411</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b3f035-81f1-4eee-8a25-bb0302b9efd2" contextRef="C_7737f7f8-c088-4597-a957-a9d86cf2d767" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">394</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bec815c-45f2-42db-a696-e536c8a94b67" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,448</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fa7f0c-3eb5-4f63-8737-e55b29f5847e" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,815</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fac805f0-c2d9-4aef-91a1-9cc7a11d7848" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10219bc6-8859-408b-bef9-01721631a7c8" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,367</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26de2ba1-18e2-4ddb-aee0-828e9fe139d4" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,367</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f39bd3-9616-48e5-bdb6-3ff3186cc8d5" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,448</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expenses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15efb393-fe3a-4645-bc3b-3027f420ba21" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c03aa555-0604-485d-92ed-0a76ea1c69ec" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_82ecb3ad-dbd2-4593-82c6-b0dfed83b25e" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37ee3105-3836-4d66-b4e3-e72b2f5bfbca" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_37ee3105-3836-4d66-b4e3-e72b2f5bfbca_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aef7cda8-15e2-4945-bc99-30038d482c1f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006e3a21-6043-44c8-9dc6-10b354a7b850" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ee99e10-4903-4150-b199-af922da1622f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,723</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_994e7b6f-53d9-42af-949b-60e376ac8177" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional and consulting services</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b782b47a-eae0-4f62-af32-e7381f8cc1b2" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,493</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00a90cc3-cc42-49dd-8e7e-68b42d418e6a" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3">341</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd92aa28-5db8-4271-9f7c-4750f3d06841" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">142</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee59a169-2af9-4b31-873d-034fb0a477c1" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">178</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd15e937-1677-4eb1-abb6-b63e1f5ffbb1" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,597</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8be849e-f4fa-4b29-99b1-1e29f7b0fa9b" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,103</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_37ee3105-3836-4d66-b4e3-e72b2f5bfbca_1"></ix:continuation></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_61359cf1-b463-4cb6-9b58-01928262cfe0" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_61359cf1-b463-4cb6-9b58-01928262cfe0_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_61359cf1-b463-4cb6-9b58-01928262cfe0_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a1ab948-caef-4af9-aeeb-603b101bdc8d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:LossContingencyAccrualPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f59c0346-3a22-4b0b-a3db-09d88bb387d6" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:LossContingencyAccrualPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contingency losses were accrued at either </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2015, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b401be7-fa56-4a2c-b506-a4c1337c1a14" contextRef="C_0986cdf2-4ce0-4de3-bb22-9ebbf6a743b8" name="rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">30,376</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of laboratory and office facilities in South San Francisco, California. In April 2018, the Company amended the lease agreement to include an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dc0ead5-9e07-452d-98c0-abcd9022beeb" contextRef="C_1b3ef3ae-d5cc-45c4-ae05-160ed7b1ac2f" name="rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">6,378</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of laboratory and office space increasing the total leased premises to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_858bed4c-4f0e-457c-81c7-9fc6358922b1" contextRef="C_1b3ef3ae-d5cc-45c4-ae05-160ed7b1ac2f" name="rapt:IncreasedAreaOfLeasedPremises" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">36,754</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet. The lease amendment extended the lease term to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24dbbd3b-099b-4056-b7fd-4a890155b045" contextRef="C_19638482-6283-456c-9cef-dc88ad0ab44d" name="rapt:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and contained scheduled rent increases over the lease term and an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03531d36-65e6-4309-9899-0c0ab3e5e0e2" contextRef="C_c1f11e91-1cbf-4c2e-aecc-69ab59127c69" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option for the Company to extend the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7105e57-ab53-44ed-a080-5d58af56fd3e" contextRef="C_a395a028-b159-4fe1-a41e-dbb49da699ec" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f9de8b9-d26d-4483-8d26-8252d1a19497" contextRef="C_628c0f63-7e74-4ded-878d-c94d2ab2ac7a" name="rapt:SquareFeetAreaOfOfficeFacilityUnderLease" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">13,232</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office facilities in South San Francisco, California, which expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b14b198e-6bc9-4da0-a871-3ad04981261b" contextRef="C_1bcb0469-f3b0-4af9-b7bf-1fed7508ba3b" name="rapt:OperatingLeaseExpirationYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease agreement contained an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1a538a9-4506-4724-b403-e5f21e5f03d1" contextRef="C_1bcb0469-f3b0-4af9-b7bf-1fed7508ba3b" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c459b030-0fd7-4443-a200-9719cfcbba22" contextRef="C_3ad90f5b-fa56-4503-84e3-c127661aabaa" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a3e5ae-e51c-494a-b231-99c9deabf882" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and was included in net cash used in operating activities in the Company&#8217;s statements of cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the weighted-average remaining lease term and discount rate for the Company&#8217;s operating leases was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33d555a8-1524-407a-b933-4f7ba01a4b2f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.72</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb31610e-8c76-4e90-a17b-1cc8b287a1de" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f647d86-3cd3-4b9c-92dc-ea6cca5e896f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturities of operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.856%;box-sizing:content-box;"/>
        <td style="width:2.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.703000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b0e33c2-fa75-481f-b942-1add3d8810a0" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,662</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a270d4df-7e50-403a-8c94-524b6466632c" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,137</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_540a7712-d8cb-4bbb-8597-1ee3cdc9ff8d" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,799</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7529d34e-a3c7-463f-aea2-cf9642b0a439" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Lease Liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb4bc442-b429-4c2b-bd6b-d271f6f65b04" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43f92133-b8ee-42f5-8fd9-c9054d48f59f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the supplemental balance sheet information related to operating leases at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.447%;box-sizing:content-box;"/>
        <td style="width:2.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.737%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.737%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ac5d8c6-add5-46a9-b230-c75833eec521" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_176b8757-5e9f-437c-8c7c-d52498f6eaba" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef2e6e66-69be-43ef-a444-29d5960bcc75" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,422</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62bad25a-1997-4ffd-906a-e7274de82abb" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,448</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c380d335-a878-424c-b768-2070f79af570" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,070</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76f04fcf-49cd-4aea-a337-740da92f91a9" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,458</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c70c6b7e-c880-4a84-ac74-dd381b5e303f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef99071a-f19d-4834-abc2-957d1b6533db" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,906</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b8edd9-77f7-40c0-9a67-29b3f64b9eb4" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_92c8d4e1-3d2f-46c5-bfd3-47575868498e" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of lease expense included in operating expenses in the statement of operations in relation to operating leases. Variable lease expense was insignificant for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91ebbc2-3b83-4fe6-b1d8-9e5ccd159b18" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6967ca0c-ecbd-4bda-984b-975efbd3ccfb" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The Company does not have any financing lease agreements as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31a21338-6b11-4893-b4e2-43cbf8f1d06f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Shanghai Jemincare Pharmaceutical Co., Ltd.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a license agreement (the &#8220;Jemincare License Agreement&#8221;) with Shanghai Jemincare Pharmaceutical Co., Ltd., a company incorporated in the People&#8217;s Republic of China (&#8220;Jemincare&#8221;), and a subsidiary of Jiangxi Jemincare Group</span><span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Co., Ltd. Under the Jemincare License Agreement and subject to certain rights, Jemincare granted the Company: (1) the exclusive and sublicensable rights to develop, manufacture, commercialize and otherwise exploit Jemincare&#8217;s anti-IgE monoclonal antibody JYB1904/RPT904 (together with certain related molecules, the &#8220;Licensed Molecules&#8221;) throughout the world, except mainland China, Hong Kong, Macau and Taiwan (together, the &#8220;Jemincare Territory&#8221;) for any and all uses; (2) the non-exclusive and sublicensable rights to develop the Licensed Molecules in the Jemincare Territory solely for the purposes of exploiting the Licensed Molecules outside of the Jemincare Territory; and (3) the non-exclusive and sublicensable rights to manufacture the Licensed Molecules in the Jemincare Territory solely for the purposes of exercising the Company&#8217;s rights in the foregoing (1) and (2).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As consideration for the rights granted, the Company paid Jemincare a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30e111bf-50d9-45d7-86c2-253013c6d905" contextRef="C_3a7401ae-87da-4602-a270-a264467fbebd" name="rapt:UpfrontLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront license fee, and could pay up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96dced10-6d7d-4952-bac3-6469c8713d66" contextRef="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53" name="rapt:AdditionalMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">672.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments, as well as tiered royalty payments (at percentages ranging from high single-digit to low double-digit) on future net sales. Those additional milestone payments include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7518ca16-a885-44dc-bb38-eed83bb38e8c" contextRef="C_3a7401ae-87da-4602-a270-a264467fbebd" name="rapt:ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million contingent upon the completion of manufacturing technology transfer, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c529cb-fb33-4251-a602-04e5e3dcbd11" contextRef="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53" name="rapt:ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">226.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million contingent upon the achievement of specified development and regulatory milestone events, and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bcd6d5e-0b20-49b4-9a5d-79ccd4398e79" contextRef="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53" name="rapt:ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">445.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million contingent upon the achievement of specified commercial milestone events. As of December 31, 2024, the Company accrued the upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68b7258-1b6f-44be-b704-a317c07c4b88" contextRef="C_3a7401ae-87da-4602-a270-a264467fbebd" name="rapt:AccruedUpfrontLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as research and development expense. The Company paid the upfront license fee in January 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Jemincare License Agreement, royalty payments will be payable on a product-by-product and country-by-country basis during the period commencing on the first commercial sale and continuing until the later of: (a) the 10-year anniversary of the date of such first commercial sale; (b) the expiration of the relevant patent claims; and (c) the expiration of the relevant regulatory exclusivity (the &#8220;Jemincare Royalty Term&#8221;). Subject to a certain floor, the Company&#8217;s royalty payments will be reduced by specified percentages for patent expiration, biosimilar entry, payments for third party intellectual property, compulsory sublicenses or drug pricing programs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Merck</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company conducted a clinical trial evaluating tivumecirnon in combination with pembrolizumab (KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck supplied pembrolizumab for use in the clinical trial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022 and February 2024, the Company and Merck amended the agreement to provide for additional supply of pembrolizumab.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_2bc93469-a0d6-4a05-a1d2-215116cf42f1" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_2bc93469-a0d6-4a05-a1d2-215116cf42f1_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Company&#8217;s common stock have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11ce9230-59c8-4d05-947c-fe55afb9838f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:CommonStockNumberOfVotesPerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share of common stock held by them. Holders of shares of the Company&#8217;s common stock are entitled to dividends when, as and if declared by the board of directors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_150af929-cae4-4bdf-9c75-9282cc2ffed4" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_13f19f19-8f86-4e94-a68b-1b2dbf0b852a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends had been declared as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 or December 31, 2023.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2bc93469-a0d6-4a05-a1d2-215116cf42f1_1"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93f2fedc-4317-45ff-8dc2-e548f788ead8" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options issued and outstanding under the 2019 Equity Incentive Plan and<br/>&#160;&#160;&#160;2015 Stock Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1713829-1f9c-4385-af22-0549afb68a85" contextRef="C_11ca0293-f87d-4136-bd9f-6c3103db98f2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,005,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af3a5879-32bb-4197-8877-fe0a140dbcc3" contextRef="C_60522021-60ee-4c57-928c-e5bf166e8dd2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,099,947</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units issued and outstanding under the 2019 Equity<br/>&#160;&#160;&#160;Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddb1a0f7-de39-482b-9025-65dd9278fa2a" contextRef="C_f719cc4a-1b2f-4a9f-8aa9-a03779cd52bb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grants under the 2019 Equity Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ee5c12-8ab6-4055-9622-872bad015c62" contextRef="C_508274a6-0773-4df0-8e48-b81976e6b710" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,489,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83badb0e-269e-4dac-88f9-683f9f8af6f6" contextRef="C_8f0468c1-4f1c-4002-aff0-929369045db5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,032,820</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db81947d-0871-4e0b-8e49-bd3e06b5387b" contextRef="C_3072375a-82e6-4b42-a83d-501afdf94d3e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,403,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a39fca40-301b-4cd0-bd69-4235b985be76" contextRef="C_255e918e-22cd-4e56-adc9-8e0aea00d489" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d42e8d53-201e-41ec-8e07-f724af184c49" contextRef="C_dcaa91d1-9b01-4910-b0d7-9d8ec5902432" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">492,307</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66d16259-c643-4ebf-a889-0098489b6858" contextRef="C_b4dd74b2-7b1d-41b5-80ac-555fdb0af990" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">410,522</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_100f8c7c-e072-41d5-ac8c-9ce6dd07db61" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">92,390,057</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6e1e37d-f347-4bc4-9d98-c0f73eb315ed" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,556,789</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company sold through a private placement to a select group of accredited investors </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b20844f-3f4f-44f4-85d3-3831e6a7cd63" contextRef="C_474bbfae-df71-4a9f-b05e-2f653dc760c7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af6048c2-9f19-458b-83a9-b92435356f36" contextRef="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bc975f3-44ca-42c4-b400-ade7306d869d" contextRef="C_f7d224a0-d8ce-405f-8a66-7a5c7ceec004" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,452,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2971a7c-09b3-49f5-96ef-1f420606a7ae" contextRef="C_f7d224a0-d8ce-405f-8a66-7a5c7ceec004" name="rapt:ClassOfWarrantOrRightPurchasePricePerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.8499</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479dea34-722c-4cba-a3f7-e7f30e58f350" contextRef="C_9db51527-1de4-457c-b360-21ef8df86299" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting offering expenses (the &#8220;Private Placement&#8221;). Also in December 2024, the Company entered into an exchange agreement  with The Column Group II, LP and certain of its affiliated funds (collectively, the &#8220;TCG Funds&#8221;), pursuant to which the TCG Funds agreed to exchange an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31b86910-736f-4a16-be08-1152f66f2576" contextRef="C_9aa83cf2-b703-419f-8280-e04589a8890b" name="rapt:ConversionOfCommonStockForPre-FundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,951,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62582d27-ce6e-4a80-b8c8-af4bdd719fda" contextRef="C_835d629a-8341-447d-9b31-2b46252b4801" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,951,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock (the &#8220;Exchange&#8221;). The material terms of the Exchange Warrants are identical to the pre-funded warrants issued in the Private Placement and the accounting impact of the exchange was deemed immaterial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company filed with the SEC, and the SEC declared effective, a shelf registration statement on Form S-3 related to the sale and issuance of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1b5c52c-aba0-4f15-b038-433d06171416" contextRef="C_1f4d112b-20a6-4e9d-97f9-f7a1a462f430" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s securities, including up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b16c209-ab81-4c49-a36e-d7881daac948" contextRef="C_bb74bca5-cd20-442e-a1a9-9ce66456c288" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of common stock that may be offered and sold from time to time in one or more &#8220;at-the-market&#8221; offerings pursuant to a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) and Leerink Partners LLC. The ATM Sales Agreement replaced the Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement, dated November 4, 2020, by and among the Company, Cantor and Stifel, Nicolaus &amp; Company, Incorporated. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_005d8ffc-3e47-4303-84a5-2376275a1bea" contextRef="C_54a69405-ede9-4232-ba03-df78ed069f51" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">365,316</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock in &#8220;at-the-market offerings&#8221; under the ATM Sales Agreement, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_068c8ffb-c727-42ca-9f70-8ea9d7b487d4" contextRef="C_54a69405-ede9-4232-ba03-df78ed069f51" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting sales agent commissions and other offering related costs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No shares were sold under the ATM Sales Agreement or the Prior ATM Sales Agreement during the year ended December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of filing of this Annual Report there were up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b60c1ef4-2a44-4583-957b-f191ab903c34" contextRef="C_9721513b-6988-4fc5-9022-6cb8d96513e9" name="rapt:CommonStockCapitalSharesAvailableForFutureIssuanceValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">140.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock available for future issuance under the ATM Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2022, through a private placement financing, the Company issued pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_734d0932-91c2-4ac3-bcbe-5b3cd80b5c9c" contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e238d99-1ca2-454a-96a7-a6cd644e43e9" contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The purchase price per pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a3474f0-3825-41f8-964d-be78ebced1aa" contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96" name="rapt:ClassOfWarrantOrRightPurchasePricePerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">12.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (representing the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3025dc5f-08cd-429f-b084-0dbfc1db25fd" contextRef="C_9bacd39c-e2ef-403d-878e-b81822f43a06" name="rapt:ClosingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share closing price of the common stock on May 24, 2022, less the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e28533a-45d3-43c1-b63c-ed27764db3d1" contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant). The private placement financing of the pre-funded warrants resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd49bd9-f8c1-48af-80a9-40398e5ff688" contextRef="C_fa219022-bcdb-4c57-9659-88770a219b25" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All pre-funded warrants, including Exchange Warrants were classified as a component of permanent equity in the Company&#8217;s balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#8220;2015 Plan&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2019, the Company&#8217;s board of directors adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221; and collectively with the 2015 Plan, the &#8220;Option Plans&#8221;). Upon the effectiveness of the 2019 Plan, the 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. In addition, the number of shares reserved for issuance under the 2019 Plan automatically increases on January 1 of each year beginning January 1, 2020 by a number equal to (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1138984-7c96-49dd-ab8b-4ab148ddcf70" contextRef="C_e29bc580-c8e8-4a17-a9a1-642394e12639" name="rapt:PercentageOfIncreaseInSharesReservedForIssuance" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#8217;s board of directors. As of January 1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6378aec3-cfe9-4912-b983-0a5a905eaffb" contextRef="C_7ed4539c-e1c4-44f1-882d-04dd7e36cd8f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,375,932</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for issuance pursuant to the automatic increase to the authorized shares under the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Option Plans provide for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e35aa4ca-95b2-4ba5-b03a-d09ef738c335" contextRef="C_7dfadab9-2f94-475c-bf05-4080b7f6c2de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f5ab9c3-e46d-4fcf-95b2-5d6adcb42fd0" contextRef="C_6ebc3359-abcc-404b-a473-e2b68d08293c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. As a private company, the estimated fair value of the Company&#8217;s underlying common stock was determined by the board of directors. Following its initial public offering, the fair value of the Company&#8217;s common stock is based on the closing price of its common stock on the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2bd4705-63e3-4b20-97a6-53cc30c356b3" contextRef="C_f78b877b-0271-4d1a-947d-9c726f07a8bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">240,336</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock pursuant to purchase rights to be granted to the Company&#8217;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance automatically increases on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86df040c-2a9d-470b-b588-3d9c2aa1648a" contextRef="C_f78b877b-0271-4d1a-947d-9c726f07a8bf" name="rapt:PercentageOfIncreaseInSharesReservedForIssuance" unitRef="U_pure" scale="-2" decimals="3">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d527f338-159b-4784-8f80-33f192cef22b" contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">240,336</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13307204-524d-4bdc-b373-000d1d7f909f" contextRef="C_9c01b00d-c8c0-44b6-a41b-56900a5fff28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">240,336</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41779f09-d49e-4dd2-af64-661a5fb3d538" contextRef="C_f78b877b-0271-4d1a-947d-9c726f07a8bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each employee&#8217;s compensation. The 2019 ESPP generally provides for a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37ff4efc-7027-4b50-a189-dc181710f4d3" contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-month offering period, which includes four </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8eb1e0f-fb0b-47b9-a0f5-6e2b6b9508f2" contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c37af897-5cbc-42b2-a9fe-369eb9e3ea31" contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, employees purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_557e83fe-864b-49a9-9fe3-ab4b1360bb88" contextRef="C_ed365124-41c8-4f2d-90b2-8eb22147ede5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">158,551</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares at weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9533aab8-262d-4231-af59-0e0e57fdfd11" contextRef="C_4dc15569-4eb9-4821-a23f-93603c6bda00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdba6541-f81b-444a-a884-a25c03b865e6" contextRef="C_2fe731eb-6df8-4233-8a24-a64517ed6900" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">87,671</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares at a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51a29f27-f190-4af0-a5b9-7dcfd1fb9ff3" contextRef="C_1f0242db-35be-4a94-996c-e3a0577776cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bac3914-6f46-4895-ab03-0983b0952272" contextRef="C_ed365124-41c8-4f2d-90b2-8eb22147ede5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57536f78-ca2e-479e-85d4-ff1676de696c" contextRef="C_2fe731eb-6df8-4233-8a24-a64517ed6900" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52_1" continuedAt="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11d2c0dd-ee24-4f60-acc8-0578d6e54944" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the 2019 Plan is set forth below for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.777%;box-sizing:content-box;"/>
        <td style="width:1.18%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.385%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.641%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.904%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.18%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.385%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.641%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.904%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price Per</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c927a638-ea61-4c0b-a188-ca029d413c82" contextRef="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,099,947</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9d7d57b-8237-493e-91be-1d5ebe4226a4" contextRef="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7be78658-8cc5-461f-b7d6-a02736c77ade" contextRef="C_cc2b05a5-eacc-40fa-9ee3-edb7df38df49" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99c9908a-c686-410c-9b7e-f89136378912" contextRef="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,206</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd120809-ae00-432d-9e42-53f41198d753" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,648,459</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_609d411f-7da7-45ef-972c-d262cc38332f" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.74</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d3c2d4e-f8ed-4003-b164-0bc6b1dfedf6" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63c904c6-1341-4a17-85b2-ed251b064cd3" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.67</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_469cc0f1-52ad-4908-b1bc-9c0edd572bf5" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">728,712</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_104f9f1c-71a5-4d06-9bab-ab1703718db4" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">23.36</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65967378-1985-48bb-8547-0563f53ba1d3" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,005,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_063e3559-18e3-4036-b9e1-e51c5a5f8977" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4bc80b8f-4f19-423d-94d3-48684c364c0a" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73a27210-ed79-41e8-a6c2-4899f71f9f87" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0fbe57f-39ea-493f-bc9a-b5340ac61646" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,005,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_758db90d-e64c-4571-b9b5-5dd7cc2f083c" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5505efe7-3252-484e-b181-2b9ca8ae286f" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45d07062-b262-4e41-ac12-53e2607647ca" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9119525-374c-4c04-9998-233afc79ac7e" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,224,884</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_002e99a4-9e6f-43a3-a30f-f38f90f35768" contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.65</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2288ad8f-f4e9-4b66-a14e-49b54995d8de" contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock for options that were in-the-money as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options granted in the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> had a weighted average per share grant-date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bef16608-2e3b-4034-a27d-6317c119231d" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b07e5ec-e88e-43d2-8bb2-9b355d116450" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and a total grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f50e0ebc-f4b7-4cfd-ab61-9473e3f798a3" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae5db281-862f-462d-9020-ce38d409d2e2" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45bdf85-bb0a-43eb-b495-570b98874f4b" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ccd4eb9-782a-48e3-8476-7f834de68baa" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash received from stock option exercises were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ae9348-03d4-4aba-8ef9-40f673ef7379" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">67,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed3d3a3c-73c6-4f8e-b5b8-6aec84631325" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The Company issues new shares of common stock upon exercise of options. In connection with these exercises, there was no tax benefit realized by the Company due to its current loss position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fair value of options that vested in the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a8ad40d-2a1e-498a-a4f8-ae5a22c64788" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8081abd-f891-45e3-9eb1-728fc9d8c5e9" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_c6de9e56-d9b4-4fca-a663-69cb846e825f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.92%;box-sizing:content-box;"/>
        <td style="width:1.86%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.32%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_846c310d-3838-4abc-8fbe-de2322474b1d" contextRef="C_e0707604-10e1-4c66-b961-1f5ccf14dc5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba6be89-e15e-403d-bc56-7b8fcb77625e" contextRef="C_e0707604-10e1-4c66-b961-1f5ccf14dc5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">44.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs vested and settled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f578bc1-a657-421d-b74e-8fe4574a682a" contextRef="C_a14673d3-4c5c-4205-aba2-4b02e4aef4ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b77fd3-927a-4631-90c8-44a1c06355fb" contextRef="C_a14673d3-4c5c-4205-aba2-4b02e4aef4ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">44.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e22b404-3fc6-4499-870d-184917f4a873" contextRef="C_d9234fac-4296-4532-b5c8-44c5a7ab179e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02624d99-da65-4c45-857a-a142e1aefde7" contextRef="C_d9234fac-4296-4532-b5c8-44c5a7ab179e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee stock option valuation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52_2" continuedAt="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52_3"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f17c8b21-45be-4d70-b54f-28d254eced01" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f9172f7-0ff7-439e-b65d-6855862fe585" contextRef="C_108ceae3-8677-4c2a-bece-c31f8942d06e" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.432%;box-sizing:content-box;"/>
        <td style="width:1.235%;box-sizing:content-box;"/>
        <td style="width:16.049%;box-sizing:content-box;"/>
        <td style="width:1.235%;box-sizing:content-box;"/>
        <td style="width:16.049%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8da5117-47ad-4b86-9099-c644ec3cd6b2" contextRef="C_08bbabe7-2cfc-4fb4-869c-d82c58a794fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9ae292c-f867-4cbc-a437-e7e4f7d1373d" contextRef="C_ba3ba657-8b8c-4939-87cf-2c03c023d913" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.75</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3423bcb5-4729-4572-8b6f-e87f9adf3253" contextRef="C_e791417b-0181-463a-ab8a-f33a0e466058" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3c6322f-a5a0-427a-b9be-8467f0ed0d0d" contextRef="C_f57a54f1-5233-4d73-9bd8-566ae74872e1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.70</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0c83dd77-3812-4502-b779-46fba7d6c5d9" contextRef="C_b0562cd3-883d-4446-80de-a657e0fd2fe1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.88</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_ee734c35-42e4-49bb-8400-e03240b101de" contextRef="C_8a7cc3d9-d3e4-4c52-8a5d-bca0e011b505" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.06</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2cb9d16c-197f-45d1-8b87-dfcfe53dc6ae" contextRef="C_4eb091eb-a136-4c83-90f1-55a88abbc9c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.87</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_f1df6b6a-79ec-4bbc-b314-ab4a65f64d65" contextRef="C_bc91c928-5abe-4ffe-a8c2-90f5cbb4d036" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.06</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bff32ad8-e299-47eb-a31c-bdc9e12ccfc2" contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">99.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57844a15-5dc8-4513-ad13-d7cf91be23c6" contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">110.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7c262c-f60a-451d-83ac-b004e2f2dca1" contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">94.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee48802f-25ed-475c-98dd-13dc17f41986" contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">97.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7127f1e7-b42c-443d-9be4-e3374e0dcf08" contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3a01cd7-ee8e-4c79-af67-193a3f06d59f" contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09e55b3c-f0d1-400e-923a-cc91b583b28d" contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.46</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae604d38-863c-47c2-8793-badd14644c3f" contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e04bc99-d3b6-4c47-a06a-7b345bc2c271" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.432%;box-sizing:content-box;"/>
        <td style="width:1.235%;box-sizing:content-box;"/>
        <td style="width:16.049%;box-sizing:content-box;"/>
        <td style="width:1.235%;box-sizing:content-box;"/>
        <td style="width:16.049%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29dd6c76-3e59-4d8c-8e18-b311e562da63" contextRef="C_d10cbbed-ca3e-473c-ae9c-39f3c1a71274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c55d6b-4526-4e39-b206-6546c3bcf72c" contextRef="C_ba019106-668d-4085-9682-6ff1e01b2cec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.90</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d364ea0-f3cf-4214-9634-e79b911a4343" contextRef="C_28f891fe-292b-4351-a216-491a3a56cdf0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77e9f89-958d-459a-95ec-68994afc4637" contextRef="C_ef44fb3b-2619-440a-8db8-260a42eaf37c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.12</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_df744a95-a5a5-4772-b4f1-39d1b7acdc16" contextRef="C_dc38ef0e-2c99-4a0f-bab8-195d55c11e72" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_1a8739f4-93de-45eb-b8e7-3651e8541114" contextRef="C_9f58d34c-283d-4d45-8629-2ad0f013648f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f206ecee-c54e-477b-870c-179461ba6e1a" contextRef="C_119abe86-5d9b-4ff1-b9ae-9decf2c2298c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_ec444a36-c514-4f4c-8097-f4572e360118" contextRef="C_26ef2d05-ad13-40b9-b1cd-8c679a6ad1df" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7491996-5834-46ab-bf2b-7e06bb14a23f" contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">95.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88b50de2-0929-4aac-a571-884fdd550c6a" contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">165.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff282e7e-827c-4292-985e-52fc523d5dd1" contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">64.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8efe7dc-6ac3-43fe-815c-ad9c3b0c945f" contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">93.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e44987d4-9640-49f1-84c9-29931139e0fe" contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a744d97-6e06-4768-b585-1ae7168f4d8b" contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_904315e3-352d-4d8e-890d-eab375490192" contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bf21f16-418e-434a-bed0-e511292a14ec" contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.51</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52_3"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_935d2f8c-6537-4e57-b2d9-f29370041247" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90651cf6-4e75-4d69-b140-45e2251fdf08" contextRef="C_c663eb36-dd20-48b2-8b42-6761ae70257c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,203</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dbbd1db-016a-4053-93df-a819b02e55f2" contextRef="C_e82bdaae-dee6-461f-b8f4-c790e6fb1c0d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,941</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2e2fb44-6fe7-4c36-99d2-b7c836dd1583" contextRef="C_b3f24917-b3a5-49bd-8fb0-e640d29eee1f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,732</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc91b15f-61c6-41f5-8204-6f760e893661" contextRef="C_c3c8c90f-d90e-46ba-865e-536f40880787" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,150</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74a93fdc-f153-4e68-b148-e7f09e7bfdb8" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,935</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_342232f4-619e-48c3-b7b2-69641a5bb5fa" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,091</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d885d744-cec3-4f33-ae79-78ddb9793134" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. This unrecognized stock-based compensation cost is expected to be recognized over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04fb040c-f497-4859-bf83-0e3f649359c2" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repricing of stock options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 12, 2024, the Compensation Committee (the &#8220;Committee&#8221;) of the Board of Directors of the Company approved an option repricing, which was effective on November 13, 2024 (the &#8220;Effective Date&#8221;). The repricing generally applies to options to purchase shares of the Company&#8217;s common stock that: (i) were granted under the Company&#8217;s 2019 Plan; (ii) as of the Effective Date, are held by the Company&#8217;s then-current employees and consultants (subject to the caveat below) (each, an &#8220;Eligible Participant&#8221;); and (iii) have an exercise price per share greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34cbb760-2a9b-49ac-ba4b-fc0f6e7d84fd" contextRef="C_46e9a44b-4010-48bc-aa78-5d77603ab178" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Eligible Options&#8221;). The Eligible Options include options held by certain of the Company's executive officers. Options held by non-employee members of the Board were not eligible for the repricing program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date, the Eligible Options were immediately repriced such that the exercise price per share for such options was reduced to the closing price of the Company&#8217;s common stock per share on the Effective Date, subject to certain retention requirements outlined below. The closing price of the Company&#8217;s common stock per share on the Effective Date was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9eb7d84-12b4-4139-8e45-d4d603b48c74" contextRef="C_46e9a44b-4010-48bc-aa78-5d77603ab178" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which became the reduced exercise price per share for the Eligible Options. If an employee exercises Eligible Options in advance of the end of the retention period as described below, the employee will be required to pay a premium exercise price equal to the original exercise price per share of the Eligible Options. There were no changes to the number of shares underlying the Eligible Options or to the vesting schedules or expiration dates of the Eligible Options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to exercise the Eligible Options at the reduced exercise price, holders of the Eligible Options are required to remain in service with the Company through the end of the relevant retention period. The retention period begins on the Effective Date and ends on the earliest of the following: (i) the date 12 months following the Effective Date; (ii) a Change in Control (as defined in the 2019 Plan) if the Eligible Options are not assumed or continued by the successor or acquiror entity (or its parent company) in such Change in Control or substituted for a similar award of the successor or acquiror entity (or its parent company); or (iii) the option holder&#8217;s termination of Continuous Service (as defined in the 2019 Plan) (a) due to such individual&#8217;s death or disability, (b) by the Company (or successor entity in a Change in Control) other than for Cause (as defined in the applicable 2019 Plan) or (c) due to such option holder&#8217;s resignation on or following a Change in Control under certain circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date, the total number of shares underlying all Eligible Options was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4bc638-ba58-446e-828f-784d2670f2ff" contextRef="C_46e9a44b-4010-48bc-aa78-5d77603ab178" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares. The effect of the repricing resulted in total incremental stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb0c2f01-e673-4148-a79d-48f7464f5f2a" contextRef="C_39770d05-317d-4e4d-a9cd-aadde8fbebc7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5c8b955-c4e4-4918-902f-0b084fc11aa2" contextRef="C_c0d8be9a-a9d5-4da0-bb1b-b686503d1d6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which will be recognized on a straight-line basis through the end of the retention period, while the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d51f061-a7bd-42cc-bc3d-5cbc2aab55a0" contextRef="C_67fdbf90-7e52-44e3-b080-ab409b95b669" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized on a straight-line basis over the original vesting period for those options that vest after the end of the retention period. The incremental stock-based compensation expense was calculated using the Monte Carlo option-pricing model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company recognized incremental stock-based compensation expense totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b62a7142-b3d5-43b5-bc67-a561b1b705a0" contextRef="C_52a5a19e-2682-4c27-890f-1cf4909b6bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the option repricing, which is included in general and administrative and research and development expense on the statement of operations.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_16230db6-61d4-4f9d-835e-76c5cd3070e9" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_16230db6-61d4-4f9d-835e-76c5cd3070e9_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc6693b9-a020-460c-9fce-0f50ce8b4972" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e25241d4-f0fc-46d4-a1d9-0176ee68c5c6" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d7afae-6655-4111-a0f4-1b29d842a900" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ecf6cca-0af7-4d6e-8fa4-31eaca96f4bf" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3454eeed-a0a8-46ae-b990-184e9bce123a" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c359e5e5-d30f-4f0d-852f-442b64f2fdd8" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d21be9bc-e702-47dc-b342-8a785ecaf196" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e6864e-ce4d-4aa7-99c3-2205766e1800" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03a60a35-fae4-4c7a-896c-de9ba01a45e8" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-">1.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8db00f7-8f89-46ae-8ead-f194b313020c" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-">0.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c23811f-1b71-4f14-99b6-587d9acaf3cf" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_960e0f43-8823-4cfd-be30-813898284a8e" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3">2.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign losses not benefited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Global intangible low-taxed income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6a49d80-5c6b-4cf3-b667-c5da09853ec8" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">21.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88b12aa8-b1ed-42d1-afd0-bcaf2cc1eb34" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">22.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36eb4154-5315-4919-b9a8-eba032d19386" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f187fb3e-f246-4154-99a4-2a9d4b32d88a" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db3f7279-349c-42fa-836e-758467d4d7ae" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,565</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08552d8f-dd8a-48a5-b0ea-9c70ab55c623" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,248</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30ba3916-48d1-4c2a-886a-a95cbb3b026e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,086</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4655853d-4a4a-4b01-9047-81729cbf0bce" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,601</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5934732-6c6d-4700-b39c-6abdf4ffc26e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,355</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9bb0517-47b8-4f8c-b951-029c2bc16fab" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,234</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11571c16-f39c-431c-9e59-0426c645e98e" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,588</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25297a0a-f468-414f-93ce-7ae6438dfbcb" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,238</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a356c0-1765-4f4a-8730-89662db1d48f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,036</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1635a6bc-f24f-4e1d-984c-9a9cc869e281" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c348a573-90d8-451c-9722-24015e878189" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed410974-b493-491d-af7a-081c5fd2e027" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development capitalized expenditures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa7afcb2-cb80-4b6b-8554-ae3199369b7f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,708</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdcd669e-3fab-449a-ba07-201e377c87c9" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,290</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cabe3397-2cc5-4d31-a59f-62b8f5c941bf" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,282</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5212f9a-f0fb-4fe1-864a-ef006d0238cb" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,750</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be6c9739-323c-4de9-a370-3f3ff565abdf" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,582</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b50c8a55-689c-46c3-9250-ca8b4dfad0c3" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,652</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b59ad03b-aa52-418e-8b85-dba7b65f2dd4" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="rapt:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db638fb-d84d-464b-b08e-792c0c3474c7" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="rapt:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1657c25-fb34-4151-9895-3e4c52cd7027" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9fb4e34-b311-42ea-88c2-62c3be134cf5" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90bdf402-aea1-447d-974f-c2236521643f" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8970b9de-cd3f-4abe-ae0f-52a648e6211c" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_16230db6-61d4-4f9d-835e-76c5cd3070e9_1" continuedAt="F_16230db6-61d4-4f9d-835e-76c5cd3070e9_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimentation (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e857ef3-0473-4ff5-a8b4-c12b30dd6af1" contextRef="C_94651108-608c-4b19-95e3-37570aa77a57" name="rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for domestic expenses and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_724a646a-5738-4fb6-9c79-af1ce7630fef" contextRef="C_2f4f1a74-621e-4e7e-aeb7-2562d72aa3c0" name="rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for foreign expenses. As a result of this provision of the 2017 Tax Act, deferred tax assets related to capitalized research expenses increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78859145-acee-4cd1-a18c-28d989d78532" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53ad444-57ad-454c-8e2b-8aa8bf7b748d" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="rapt:IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8fdc3c0-5775-4836-8959-f47ab63b7555" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5">27.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400aff0b-f28f-4a3f-a75e-f751fd5ddffa" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5">26.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The increase in the valuation allowance is mainly related to the capitalization of research and development expenses under Internal Revenue Code ("IRC") Section 174, capitalization of the Jemincare upfront fee as an intangible under IRC Section 197 and an increase in net operating loss carryforwards incurred during the respective taxable years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e89c9c60-5743-4e78-8dce-fe04f9943749" contextRef="C_ad8a92e7-a170-450d-96fe-0db4664c91f0" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">317.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28b29194-bc97-4ee9-a010-4c5f448655bc" contextRef="C_2424ad23-6a69-42b1-a6e1-2f30f781a186" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">273.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99271060-f504-49a3-93cd-9d1fb8deaf48" contextRef="C_94651108-608c-4b19-95e3-37570aa77a57" name="rapt:OperatingLossCarryforwardsExpirationBeginningYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9c0dce9-3c8d-48c1-ab98-14e0babef325" contextRef="C_17084da0-52d8-4270-8220-a08b6ecfaf36" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_837d4e5a-5e7b-47df-8ddc-31a027878bda" contextRef="C_e2cf0836-a57d-4015-a9af-0546d1d46c80" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d3aebf6-4614-41fc-bc68-0b5ebf0c094b" contextRef="C_365cd7e2-07a9-4efd-af57-00bb25764e5c" name="rapt:OperatingLossCarryforwardsExpirationBeginningYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and are available to offset future taxable income. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44f275b3-c09d-4d44-ae2b-ff3fea48a762" contextRef="C_b5311bec-6438-4c93-a187-0201963f9310" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e8c61da-ad76-492f-a4a9-a82b02b75517" contextRef="C_c5036115-0ce3-49f9-b87d-f4affdbd9129" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">10.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92c9ee59-3284-4848-b22a-2ef2833d8d5c" contextRef="C_2152facb-460b-4ca8-8869-28dc2ee681ef" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c07ee483-adf4-41ea-926e-385c1e9d080c" contextRef="C_8b9b3e34-2570-4302-8da4-f3602f968f0f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded federal and state reserves of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7fdcd80-6bd6-4698-af4d-9988e1832901" contextRef="C_ad8a92e7-a170-450d-96fe-0db4664c91f0" name="rapt:UncertainTaxPositionsReserves" unitRef="U_USD" scale="6" decimals="-5">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9fe84be-9d9f-4ed6-b3bc-74343f025384" contextRef="C_17084da0-52d8-4270-8220-a08b6ecfaf36" name="rapt:UncertainTaxPositionsReserves" unitRef="U_USD" scale="6" decimals="-5">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#8217;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the 2017 Tax Act as modified by the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) the carryforward period of net operating losses generated from 2018 forward is indefinite but the ability to deduct such federal net operating losses is limited to 80% of taxable income; however, the carryforward period for net operating losses generated prior to 2018 remains 20 years. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. In February 2022, California Senate Bill 113 &#8220;SB 113&#8221; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. In June 2024, California Senate Bill 167 (&#8220;SB 167&#8221;) was signed into law, which suspends the NOL utilization for companies whose California taxable income exceeds $1 million and limits R&amp;D credit utilization to $5 million. Given the Company&#8217;s loss position, SB113 and SB167  did not impact the Company's tax provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_16230db6-61d4-4f9d-835e-76c5cd3070e9_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c428045a-9aea-480a-b3cc-d64c7efb4277" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04cd5454-7ee0-4cd8-a86d-e2ddd77f62e4" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f98c294-3707-4721-a7dc-d265ab09c9d1" contextRef="C_80a183b9-14ce-4b94-97fa-8410f324fd16" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions on tax positions related to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddfc0f40-e854-49ab-9b03-798f4fd33aca" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions on tax positions related to current year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_113bf786-e1b1-4d1f-99d5-7b4aa5e67de6" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a0daebc-652c-4e69-ac6f-ee6df252949a" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d4df33-8cba-43a6-bcb6-4f81eb190c44" contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb3e3ed8-3cd3-4a7c-b1a9-f962a8560988" contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b38f3e23-d2f3-4bd3-aed7-c3b9ba4ba7a3" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest expense or penalties related to unrecognized tax benefits through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns with varying statutes of limitations in the United States and various states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was signed into law in August 2022 and contained several tax provisions to curb inflation by reducing the deficit, lowering prescription drug prices, investing into domestic energy production while promoting clean energy, and introduced the topic of corporate alternative minimum tax on applicable corporations. There is no impact to the Company&#8217;s current tax provision from this legislation.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_77bab098-b7ad-4398-8064-2c591272ad16" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_77bab098-b7ad-4398-8064-2c591272ad16_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bacb6eb-5c46-4720-a842-97e190b65e7f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c0e3cbe-eaa2-4538-9f72-0f5507510503" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,865</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_711c09ab-42d5-4189-bc61-af3fbe86b332" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,798</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net loss per share, basic and diluted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d50aa0ea-e332-405a-8d12-9bd25957f5d0" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_63d0162d-a772-4c44-95d0-b7b6dd0e261f" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,761,143</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf7ed9a7-c51e-4d73-bc89-1053750517f2" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_879b42ab-d7ce-4ecf-8fe4-ffc8162225bd" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">38,338,161</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6702c7d7-6c03-4cd9-ace5-56f3a0ed0043" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_e98c9e23-4c8c-41e7-a5f4-91cd7d8ad067" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.19</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b37dd211-7074-4062-b5e7-a4c787ba6332" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_e755885f-fcc9-49e1-8aaf-67a435f54a79" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.05</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe489c66-5345-446b-8230-edf21d00727c" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="rapt:PreFundedWarrantsToPurchaseCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,403,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f0f521b-5c6b-499f-b331-263fd1cfe1f7" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="rapt:PreFundedWarrantsToPurchaseCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants to purchase the Company's shares of common stock, respectively, issued in private placement financings (see Note 8), were included in the basic and diluted net loss per share calculation.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_77bab098-b7ad-4398-8064-2c591272ad16_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_665109a1-048d-495a-98ab-448b0f8c2421" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"/>
        <td style="width:1.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.243%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.243%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding under the 2019 Plan and 2015 Stock Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f974d932-2e0c-40f1-b517-6fae64d0ada1" contextRef="C_110c283e-33db-423a-9912-c4662332850f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,005,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c22ceb-59e7-426c-9dd4-da41b557dd18" contextRef="C_6e61294d-f16c-4cf1-97b3-5a12f717970c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,099,947</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated shares issuable under the 2019 ESPP</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24fbe2c0-a2e3-4a42-8d3f-d9dfa55cd978" contextRef="C_6d1d2bf1-3fd1-4020-ae5b-151e6c3dfe1c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">62,896</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18fa2c2b-36d5-4e33-8509-36ea905c4103" contextRef="C_ec7bc9d3-76ec-4a11-8d01-81dfe77946de" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,904</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs subject to future vesting</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc26a23a-4b27-4ed1-9b60-01ae78a1592e" contextRef="C_388b46ad-84e8-4acc-b6cd-3a828d7b5577" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0163091-d835-46f4-b6b9-f1c456f7aa04" contextRef="C_8f6dc9ac-cad7-4b38-9d58-a1763e1d61e9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_917fbc1a-655a-40e9-817b-e390729002bb" contextRef="C_18f57745-d287-4eac-8622-5474e59d7035" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,068,216</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e57e2f8-3fa9-4226-9318-ba3503632f57" contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,135,351</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024, the end of the period covered by this Annual Report on Form 10-K. Management&#8217;s assessment of internal control over financial reporting was conducted using the criteria defined in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management determined that, as of December 31, 2024, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control &#8211; Integrated Framework, management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting because we are a smaller reporting company under the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our Chief Executive Officer and our Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1514ce2-ec52-4619-adc0-013bfb5a2da6" contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_15465f8c-0a02-4a54-9d0a-a1801e7aba64" contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_4e585dac-0234-4db3-a460-ddecff306cb5" contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_5e67b40c-ca3c-4cc8-973f-1e069b9456ef" contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the section entitled &#8220;Election of Directors,&#8221; &#8220;Executive Officers,&#8221; &#8220;Corporate Governance and Board Matters&#8221; and, if applicable, &#8220;Delinquent Section 16(a) Reports&#8221; set forth in the Company's proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Conduct and Ethics (the &#8220;Code of Conduct&#8221;) that applies to all directors, officers and employees of the Company, is available on our website at www.rapt.com. We intend to promptly disclose on our website or in a Current Report on Form 8-K in the future (i) the date and nature of any amendment (other than technical, administrative or other non-substantive amendments) to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K and (ii) the nature of any waiver, including an implicit waiver, from a provision of the Code of Conduct that is granted to one of these specified individuals that relates to one or more of the elements of the code of ethics definition enumerated in Item 406(b) of Regulation S-K, the name of such person who is granted the waiver and the date of the waiver.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item will be included in the sections entitled &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Ow</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item will be included in the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive Compensation&#8212;Equity Compensation Plan Information&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item will be included in the sections entitled &#8220;Transactions with Related Persons and Indemnification&#8221; and &#8220;Corporate Governance and Board Matters&#8212;Independence of the Board of Directors&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 14. Principal Accountant Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item will be included in the section entitled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ratification of Selection of Independent Registered Public Accounting Firm&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules.</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following documents are filed as part of this Annual Report:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None. All financial statement schedules are omitted because they are not applicable, not required under the instructions or the requested information is included in the financial statements or notes thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The following is a list of exhibits filed with this Annual Report or incorporated herein by reference:</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INDEX</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.48%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:35.56%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:7.1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:12.98%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:6.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.2%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:10.26%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="9" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.014in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/04/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/04/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex42_1343.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description of Registrant&#8217;s Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/30/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312522163962/d310238dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/31/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024139667/rapt-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant and Exchange Warrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/23/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2015 Stock Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the 2015 Stock Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forms of Restricted Stock Unit Agreement and Notice of Grant of Restricted Stock Unit under the Amended and Restated 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement, by and between RAPT Therapeutics, Inc. and each of its directors and executive officers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Employee Offer Letter, by and between Brian Wong and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Employee Offer Letter, by and between William Ho and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Employee Offer Letter, by and between Dirk Brockstedt and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/22/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.48%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:35.56%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:7.1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:12.98%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:6.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.2%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:10.26%;box-sizing:content-box;"/>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519306278/d832916dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Offer Letter, by and between Rodney Young and RAPT Therapeutics, Inc., dated November 11, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/04/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017023041615/rapt-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/11/23</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024056302/rapt-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">05/09/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease, by and between HCP, Inc. and Flexus Biosciences, Inc., dated October 10, 2014</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">First Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated April 29, 2015</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Second Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated April 16, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1024.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated December 13, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18#</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1025.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-232572</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/05/19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19&#x5E;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017023007710/rapt-ex10_19.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated April 20, 2022, to the Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/14/23</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20&#x5E;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-ex10_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated February 1, 2024, to the Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/07/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21#</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/d131169dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement, dated as of December 1, 2019, by and between Hanmi Pharmaceutical Co., Ltd and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236256</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/04/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312522163962/d310238dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated May 27, 2022, by and between RAPT Therapeutics, Inc. and the investor party thereto</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">05/31/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23&#x5E;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024139667/rapt-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated December 22, 2024, by and between RAPT Therapeutics, Inc. and Shanghai Jemincare Pharmaceutical Co., Ltd</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/23/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.48%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:35.56%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:7.1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:12.98%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:6.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.2%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:10.26%;box-sizing:content-box;"/>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024139667/rapt-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/23/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rapt-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/07/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rapt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:bottom;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rapt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rapt-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1&#134;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rapt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2&#134;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rapt-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97+</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Incentive Compensation Recoupment Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38997</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/07/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#fefefe;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.028in;vertical-align:top;padding-bottom:0in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:70.37%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Portions of this exhibit (indicated by asterisks) have been omitted as we have determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to us if publicly disclosed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">#*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; The certifications attached as Exhibit 32.1 and Exhibit 32.2 accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of RAPT Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10&#8209;K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x5E; Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the Securities and Exchange Commission, certain portions of this exhibit have been redacted. The Registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission, upon its request, an unredacted copy of this exhibit.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreements and other documents filed as exhibits to this Annual Report on Form 10-K are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K Summary.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:36%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">RAPT Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Brian Wong, M.D. Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brian Wong, M.D. Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Wong and Rodney Young, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.14%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:44.84%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:23.02%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:26.65pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Brian Wong, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brian Wong, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(principal executive officer)</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rodney Young</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Secretary</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:25.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:top;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rodney Young</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(principal financial officer and principal accounting officer)</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lori Lyons-Williams</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chair of the Board of Directors</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lori Lyons-Williams</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael F. Giordano, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael F. Giordano, M.D.</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mary Ann Gray, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mary Ann Gray, Ph.D.</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Linda Kozick</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Linda Kozick</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Wendye Robbins, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wendye Robbins, M.D.</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.042in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>rapt-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:1.293%;text-indent:6.84%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p>
  <p style="margin-left:20.84%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.843%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:20.843%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading and Trading Window Policy June 27, 2019</font></p>
  <p style="margin-left:1.293%;text-indent:6.84%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because our stock is publicly traded, you must comply with the provisions of federal and state securities laws and with our policies. During the course of your relationship with RAPT Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you will learn information about us that is not publicly known. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is illegal for you to buy or sell our stock or the stock of companies working with the Company, on the basis of material, nonpublic information. It is also illegal for you to pass such information on to others who use it to buy or sell our stock.</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:12.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered Persons</font></p>
  <p style="font-size:10pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.839%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy applies to all directors, officers, employees, consultants and contractors of the Company. This policy also applies to all family members and other household members of those covered by this policy and all companies controlled by those covered by this policy.</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:12.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Policy</font></p>
  <p style="font-size:10pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.841%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy prohibits not only illegal activities, but also other trading activities that may not be illegal. These additional restrictions are designed to protect both you and us from even the appearance of improper activity. Our policy is as follows:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not trade our stock while you possess information about the Company that is both material and nonpublic. Material information is information that a reasonable person would consider important in deciding whether (or at what price) to buy or sell our stock. For example, material information may include (but is not limited to) financial results, merger or acquisition news, regulatory approval, clinical data, joint venture developments, litigation filings or results, governmental actions or key personnel hires or departures. Nonpublic information is information that has not been announced publicly, such as by press release, conference call, public filing or similar means of public dissemination. You must wait until the third trading day after the information is publicly announced before you can trade. For example, if the information is publicly announced late on a Tuesday, you cannot trade until Friday. In addition, you are not allowed to buy or sell stock during any &#x201c;blackout&#x201d; period announced by the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not discuss material, nonpublic information about the Company with anyone outside the Company. This prohibition covers spouses, family members, friends, business associates, or persons with whom we are doing business (except to the extent that such persons are covered by a non-disclosure agreement and the discussion is necessary to accomplish a business purpose of the Company).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may buy or sell our stock only when the trading window period is open and when you do not possess material, nonpublic information about the Company. If you are a director, officer or employee of the Company, you must also receive approval prior to engaging in transactions in the Company&#x2019;s stock, as described in paragraph 4 below. Trading window periods are those periods of time during which employees, contractors and consultants can, potentially, trade our stock, so long </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as they are not in possession of material, nonpublic information. At these times, the &#x201c;window&#x201d; is said to be &#x201c;open.&#x201d; This window period may be closed and may not reopen if, in the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">judgment of the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, there exists undisclosed information that would make trades by members of the Company&#x2019;s management and directors inappropriate. This closing of the window/prohibition on trading is commonly called, and referred to in this policy, as a &#x201c;trading blackout.&#x201d; A trading blackout may be implemented, for example, if there is some information or development with or relating to the Company&#x2019;s business that merits a suspension of trading. It is important to note that the fact that a trading blackout has been imposed and/or that the window period has not reopened should be considered inside information. If a trading blackout has been imposed due to the existence of material nonpublic information, generally the window period will not re-open until the third trading day (e.g., two full trading days have elapsed) after the Company&#x2019;s public dissemination of the material nonpublic information, or until such time a determination is made that it is no longer material nonpublic information. An officer or director or other member of management who believes that special circumstances require him or her to trade outside the window period (e.g., during any trading blackout period) should consult with the Company&#x2019;s Chief Financial Officer who will consult with the Company&#x2019;s counsel. Permission to trade outside the window period (during any trading blackout period) will be granted only where the circumstances are extenuating and there appears to be no significant risk that the trade may subsequently be questioned.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the requirements of paragraph 3 above, if you are a director, officer or employee of the Company, you may not may not engage in any transaction in the Company&#x2019;s securities, including any purchase or sale in the open market, loan, pledge, hedge or other transfer of beneficial ownership without first obtaining pre-clearance of the transaction from the Company&#x2019;s Chief Financial Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clearing Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at least two business days in advance of the proposed transaction. The Clearing Officer will then determine whether the transaction may proceed and, if required, will coordinate the Company&#x2019;s assistance in complying with the reporting requirements under Section 16(a) of the Exchange Act, if any, in compliance with any Section 16 policy that the Company has in place at that time. Pre-cleared transactions not completed within five business days shall require new pre-clearance under the provisions of this paragraph. The Company may, at its discretion, shorten such period of time.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not trade derivative securities of the Company at any time. Derivative securities are securities other than common stock that are speculative in nature because they permit a person to leverage his or her investment using a relatively small amount of money. Examples of derivative securities include (but are not limited to) &#x201c;put options&#x201d; and &#x201c;call options.&#x201d; These are different from employee stock options, which are not derivative securities.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not engage in short selling of our securities, pledge our securities, purchase our securities on margin or hold them in a margin account at any time. Selling short includes transactions in which you borrow stock from a broker, sell it, and eventually buy it back on the market to return the borrowed shares to the broker. Profit is made through the expectation that the stock price will decrease during the period of borrowing. Purchasing our securities on margin is the use of borrowed money from a brokerage firm to purchase our securities. Holding our securities in a margin account includes holding the securities in an account in which the shares can be sold to pay a loan to the brokerage firm.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not participate in &#x201c;chat rooms&#x201d; or other electronic discussion groups or contribute to blogs, bulletin boards or social media forums on the Internet concerning the activities of the Company or other companies with which the Company does business, even if you do so anonymously, unless doing so is part of your job responsibilities and you have explicit authorization from the Finance department.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:3.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may never recommend to another person that he or she buy, hold or sell our stock.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The restrictions above also apply to transactions in the stock of other companies, to the extent you have learned material nonpublic information about these companies as a result of your role with the Company.</font></div></div>
  <p style="margin-left:1.293%;text-indent:6.84%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The only exceptions to this policy are specifically noted below. Trading activities that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) or that are small transactions are </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exempted from this policy. The insider trading laws do not recognize any mitigating circumstances and, in any event, even the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans</font></p>
  <p style="font-size:10pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.839%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the prohibitions above, directors, officers and employees may establish written programs pursuant to Rule 10b5-1(c) of the Securities Exchange Act of 1934 which permit (a) automatic trading of our stock according to set criteria or (b) trading of our stock by an independent person (such as an investment bank) who is not aware of material nonpublic information. So long as the program is properly established, trading pursuant to a program may occur even at a time outside of our &#x201c;window period&#x201d; or when the plan participant is aware of material nonpublic information. Each form of program must be reviewed and approved by the Finance department on behalf of the Company, solely to confirm compliance with the guidelines set forth herein. The Company will not review or pre-approve the trading specifics of any program, only the form of program itself. These programs may only be established and subsequently amended at a time when the plan participant is not aware of material nonpublic information.</font></p>
  <p style="margin-left:1.293%;text-indent:6.841%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once the program is prepared and becomes effective, it cannot be changed or deviated from except (a) with notice to our Finance department, (b) in full compliance with the requirements of the program guidelines and (c) at a time when the plan participant is permitted to trade in our stock under the guidelines set forth herein. Furthermore, at the discretion of the Company, the terms of such a program may be disclosed to the public through a press release, by placement on our website or through other means to be determined by the Company.</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Violations</font></p>
  <p style="font-size:10pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.827%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violations of either the insider trading laws or this policy are extremely serious matters. The U.S. Securities and Exchange Commission and the stock exchanges monitor stock trading and routinely investigate suspicious activity. The penalties for violating the insider trading laws are severe (including fines and imprisonment), and even having to respond to an investigation can result in significant legal expenses and unwanted negative publicity for both you and us.</font></p>
  <p style="margin-left:1.293%;text-indent:6.841%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, violation of this policy may result in severe personnel action, up to and including termination of your employment or other relationship with us.</font></p>
  <p style="margin-left:1.333%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Information and Questions</font></p>
  <p style="font-size:10pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.844%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.296%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you have any questions about any aspect of this policy, you are encouraged to contact our Clearing Officer. You may also refer to the &#x201c;Frequently Asked Questions&#x201d; attached to this policy.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:20.84%;font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.843%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:5.583%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading and Trading Window Policy &#x2013; Frequently Asked Questions June 27, 2019</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is insider trading?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider trading is the buying or selling of stocks, bonds, futures, or other securities by someone in possession of material, nonpublic information. Insider trading also includes trading in options (puts and calls) the price of which is linked to the underlying price of a company&#x2019;s stock. It does not matter how many shares you buy or sell, or whether it has an effect on the stock price&#x2013; if you have material, nonpublic information and you trade, you have broken the law.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Why is insider trading illegal?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If company insiders are able to use their confidential knowledge to their financial advantage, other investors would not have confidence in the fairness and integrity of the marketplace. Requiring those who have such information to disclose (the information to the public) or abstain (from trading) ensures an even playing field.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is material, nonpublic information?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is material if it would influence a reasonable investor to buy or sell a stock, bond or other security or if it would influence the price that a reasonable investor would pay for a stock, bond or other security. This could mean many things &#x2013; financial results, potential mergers, major contracts, etc. Information is nonpublic if it has not yet been released and disseminated to the public.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Who can be guilty of insider trading?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anyone who buys or sells a security while in possession of material, nonpublic information. It does not matter if you are not an executive officer or director, or even if you do not work at RAPT Therapeutics &#x2013; if you know something material about the value of a security that not everyone else does, regardless of who you are, you can be found guilty of insider trading.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Does RAPT Therapeutics have an insider trading policy?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes. The policy is attached to this FAQ.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I work in a foreign office?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no difference. The policy and law applies to you. Because our common stock trades on a United States securities exchange, the insider trading laws of the U.S. apply. The U.S. Securities and Exchange Commission (the SEC) (a U.S. government agency in charge of investor protection) and the Financial Industry Regulatory Authority (FINRA) (a private regulator that oversees U.S. exchanges) routinely investigate trading in a company&#x2019;s securities conducted by internationally-based individuals and firms. In addition, as a RAPT Therapeutics employee, our policies apply to you no matter where in the world you work.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:4.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I don&#x2019;t buy or sell anything, but I tell someone else the information and they buy or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:4.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">sell?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That is called &#x201c;tipping.&#x201d; You are the &#x201c;tipper&#x201d; and the other person is called the &#x201c;tippee&#x201d;. If the tippee buys or sells based on that material, nonpublic information, you might still be guilty of insider trading. In fact, if you tell family members who tell others and those people then trade on the information, those family members might be guilty of insider trading too. As a result, you may not discuss material, nonpublic information about RAPT Therapeutics with anyone outside RAPT Therapeutics, including spouses, family members, friends, or business associates. This includes anonymous discussion on the Internet about RAPT Therapeutics or companies with which RAPT Therapeutics does business.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I don&#x2019;t tell them the information itself, I just tell them whether they should buy or sell?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That is still tipping, and you can still be found guilty of insider trading. According to our policies, you may never recommend to another person that they buy, hold or sell our common stock or any derivative security related to our common stock.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What are the penalties if I trade on inside information, or tip off someone else?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anyone found liable in a civil case for trading on inside information may need to pay the U.S. government an amount equal to any profit made or any loss avoided and may also face a penalty of up to three times this amount. Persons found liable for tipping inside information, even if they did not trade themselves, may face a penalty of up to three times the amount of any profit gained or loss avoided by everyone in the chain of tippees. In addition, anyone convicted of criminal insider trading can face prison terms and additional fines.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is &#x201c;loss avoided&#x201d;?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you sell a common stock or a related derivative security before the negative news is publicly announced, and as a result of the announcement the stock price declines, you have avoided the loss caused by the negative news.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Am I restricted from trading securities of any companies except RAPT Therapeutics (for example a customer or competitor of RAPT Therapeutics)?</font></div></div>
  <p style="margin-left:7.947%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes. U.S. insider trading laws restrict everyone from trading in a company&#x2019;s securities based on material nonpublic information about that company, regardless of whether the person is directly connected with that company. Therefore, if you obtain material nonpublic information about another company, you should not trade in that company&#x2019;s securities. You should be particularly conscious of this restriction if, through your position at RAPT Therapeutics, you sometimes obtain sensitive, material information about other companies and their business dealings with RAPT Therapeutics.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">So if I do not trade RAPT Therapeutics securities when I have material nonpublic information, and I don&#x2019;t &#x201c;tip&#x201d; other people, I am in the clear, right?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not necessarily. Even if you do not violate U.S. law, you may still violate our policies. Our policies are stricter than the law requires, so that we and our employees can avoid even the appearance of wrongdoing. Therefore, please review the entire policy carefully.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:4.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If I am aware of new product developments that have not been announced to the public, do I possess material nonpublic information?</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In most circumstances, RAPT Therapeutics does not consider product developments to be material information that would require the closing of the trading window with respect to those individuals that are aware of these developments. However, there are circumstances where a new product or service in development or issues with respect to current or past products or services could be so significant that it constitutes material nonpublic information. In these circumstances, you will be notified by email if the trading window is closed for you.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">So when can I buy or sell my RAPT Therapeutics securities?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to our policies, if you have material, nonpublic information, you may not buy or sell our common stock until the third trading day after that information is released or announced to the public. At that point, the information is considered public. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if you do not have</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material, nonpublic information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, you may not trade in our common stock during any trading &#x201c;blackout&#x201d; period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. (trading blackout periods may be announced by email.)</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What steps do I need to follow before engaging in any transaction in RAPT Therapeutics securities if I am an officer, director or employee of RAPT Therapeutics?</font></div></div>
  <p style="margin-left:7.96%;text-indent:-0.015%;padding-left:0.013%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to our policies, all officers, directors and employees must obtain pre-clearance of any transaction from the Company&#x2019;s Chief Financial Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clearing Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at least two business days in advance of the proposed transaction. The Clearing Officer will then determine whether the transaction may proceed and, if required, will coordinate RAPT Therapeutics&#x2019; assistance in complying with the reporting requirements under Section 16(a) of the Exchange Act, if any. Pre-cleared transactions not completed within five business days shall require new pre-clearance under the provisions of this paragraph. RAPT Therapeutics may, at its discretion, shorten such period of time.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If I have an open order to buy or sell RAPT Therapeutics securities on the date the trading window closes, my broker will cancel the open order and won&#x2019;t execute the trade, right?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. If you have any open orders at the time the trading window closes, it is your responsibility to cancel these orders with your broker. If you have an open order and it executes after the trading window closes, it is a violation of our insider trading policy and may also be a violation of the insider trading laws.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Am I allowed to trade derivative securities of RAPT Therapeutics? Or short RAPT Therapeutics common stock?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. Under our policies, you may not trade in derivative securities related to our common stock, which includes, but is not limited to publicly-traded call and put options. In addition, under our policies, you may not engage in short selling of our common stock at any time.</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Derivative securities&#x201d; are securities other than common stock that are speculative in nature because they permit a person to leverage his or her investment using a relatively small amount of money. Examples of derivative securities include (but are not limited to) &#x201c;put options&#x201d; and &#x201c;call options&#x201d;. These are different from employee stock options, which are not derivative securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.204%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Short selling&#x201d; is profiting when you expect the price of the stock to decline, and includes transactions in which you borrow stock from a broker, sell it, and eventually buy it back on the market to return the borrowed shares to the broker. Profit is made through the expectation that the stock price will decrease during the period of borrowing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Why does RAPT Therapeutics prohibit trading in derivative securities and short selling?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies with volatile stock prices have adopted such policies because of the temptation it represents to try to benefit from a relatively low cost method of trading on short- term swings in stock prices (without actually holding the underlying common stock) and encourages speculative trading. For this reason, we have decided to prohibit employees from such trading. As we are dedicated to building stockholder value, short selling our common stock is adverse to our stated values and would not be received well by our stockholders.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I purchase RAPT Therapeutics securities on margin or hold them in a margin account?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our policies, you may not purchase our common stock on margin or hold it in a margin account at any time.</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Purchasing on margin&#x201d; is the use of borrowed money from a brokerage firm to purchase our securities. Holding our securities in a margin account includes holding the securities in an account in which the shares can be sold to pay a loan to the brokerage firm.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Why does RAPT Therapeutics prohibit me from purchasing RAPT Therapeutics securities on margin or holding them in a margin account?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin loans are subject to a margin call whether or not you possess insider information at the time of the call. If your margin call were called at a time when you had insider information and you could not or did not supply other collateral, you and RAPT Therapeutics could be subject to litigation based on your insider trading activities: the sale of the stock (through the margin call) when you possessed material nonpublic information. The sale would be attributed to you even though the lender made the ultimate determination to sell. The U.S. Securities and Exchange Commission takes the view that you made the determination to not supply the additional collateral and you are therefore responsible for the sale.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I exercise stock options during a trading blackout period or when I possess material nonpublic information?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes. You may exercise the option and receive shares, but you may not sell the shares (even to pay the exercise price or any taxes due) or otherwise settle the option during a trading blackout period or any time that you have material, nonpublic information. Also note that if you choose to exercise and hold the shares, you will be responsible at that time for any taxes due.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Am I subject to the trading blackout period if I am no longer an employee of RAPT Therapeutics?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It depends. If your employment with RAPT Therapeutics ends on a day that the trading window is closed, you will be subject to the trading blackout period then in effect. If your employment with RAPT Therapeutics ends on a day that the trading window is open, you will not be subject to the next trading blackout period. However, even if you are not subject to our trading blackout period after you leave RAPT Therapeutics, you should not trade in RAPT Therapeutics</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.278%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities if you possess material nonpublic information. That restriction stays with you as long as the information you possess is material and not released by RAPT Therapeutics.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">23.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I gift stock while I possess material nonpublic information or during a trading blackout period?</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the potential for the appearance of impropriety, you may not make gifts, whether to charities, to a trust or otherwise, of our common stock when you possess material nonpublic information or during a trading blackout period.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">24.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I purchased publicly-traded options or other derivative securities before I became a RAPT Therapeutics employee (or contractor or consultant)?</font></div></div>
  <p style="margin-left:7.96%;text-indent:-0.015%;padding-left:0.013%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same rules apply as for employee stock options. You may exercise the publicly-traded options at any time, but you may not sell such securities during a trading blackout period or at any time that you have material, nonpublic information. When you become a RAPT Therapeutics employee, you must report to our Finance department that you hold such publicly traded options or other derivative securities.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">25.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May I own shares of a mutual fund that invests in RAPT Therapeutics?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">26.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Are mutual fund shares holding RAPT Therapeutics subject to the trading blackout periods?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. You may trade in mutual funds holding our common stock at any time.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">27.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May I use a &#x201c;routine trading program&#x201d; or &#x201c;10b5-1 plan&#x201d;?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes, subject to the requirements discussed in our Insider Trading and Trading Window Policy. A routine trading program, also known as a 10b5-1 plan, allows you to set up a highly structured program with your stock broker through which you specify ahead of time the date, price, and amount of securities to be traded. If you wish to create a 10b5-1 plan, you must contact the Finance department for approval.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">28.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What happens if I violate our insider trading policy?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of our policies may result in severe personnel action, including a memo to your personnel file and up to and including termination of your employment or other relationship with RAPT Therapeutics. In addition, you may be subject to criminal and civil enforcement actions by the government.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.757071766649437%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">29.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Who should I contact if I have questions about our insider trading policy?</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should contact our Clearing Officer.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>rapt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1.13in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-234448) pertaining to the 2015 Stock Plan, the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc.,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-237487 and 333-270523) pertaining to the 2019 Equity Incentive Plan of RAPT Therapeutics, Inc.,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-254127, 333-263426 and 333-277736) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc.; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-265812, 333-273910 and 333-284388) of RAPT Therapeutics, Inc.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our report dated March 6, 2025, with respect to the financial statements of RAPT Therapeutics, Inc. included in this Annual Report (Form 10-K) of RAPT Therapeutics, Inc. for the year ended December 31, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">                                                                                                                                                </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Mateo, California</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.65in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>rapt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Brian Wong, M.D. Ph.D., certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10&#x2011;K of RAPT Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:4.02%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:45.98%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Brian Wong, M.D. Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brian Wong, M.D. Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>rapt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Rodney Young, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10&#x2011;K of RAPT Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:4.02%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:45.98%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rodney Young</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rodney Young</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Secretary</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>rapt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Brian Wong, M.D. Ph.D., Chief Executive Officer of RAPT Therapeutics. Inc. (the &#x201c;Company&#x201d;) hereby certify pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Chapter 36 of Title 18 United State Code Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that, to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Annual Report of Company on Form 10&#x2011;K (the &#x201c;Annual Report&#x201d;) for the year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:4.04%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:45.96%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Brian Wong, M.D. Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brian Wong, M.D. Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>rapt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Rodney Young, Chief Financial Officer of RAPT Therapeutics. Inc. (the &#x201c;Company&#x201d;) hereby certify pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Chapter 36 of Title 18 United State Code Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that, to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Annual Report of the Company on Form 10&#x2011;K (the &#x201c;Annual Report&#x201d;) for the year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of RAPT Therapeutics, Inc.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:4.04%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:45.96%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rodney Young</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rodney Young</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Secretary</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img57771353_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57771353_0.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &$ U,# 2(  A$! Q$!_\0
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M!\9_^%+J_P#\ET?\+6^)W_10?&?_ (4NK_\ R77 44?ZS<2?]%!GG_AVQ_\
M\T>2^X/[ R+_ *$F4?\ AMP?_P I\E]QW_\ PM;XG?\ 10?&?_A2ZO\ _)='
M_"UOB=_T4'QG_P"%+J__ ,EUP%%'^LW$G_109Y_X=L?_ /-'DON#^P,B_P"A
M)E'_ (;<'_\ *?)?<=__ ,+6^)W_ $4'QG_X4NK_ /R71_PM;XG?]%!\9_\
MA2ZO_P#)=<!11_K-Q)_T4&>?^';'_P#S1Y+[@_L#(O\ H291_P"&W!__ "GR
M7W'?_P#"UOB=_P!%!\9_^%+J_P#\ET?\+6^)W_10?&?_ (4NK_\ R77 44?Z
MS<2?]%!GG_AVQ_\ \T>2^X/[ R+_ *$F4?\ AMP?_P I\E]QW_\ PM;XG?\
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MC/\ \*75_P#Y+K@**Y_]9N)/^B@SS_P[8_\ ^:/)?<;?V!D7_0DRC_PVX/\
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M\.!XJ_\ EI1_PT?^T%_T6_XL?^' \5?_ "TKQ>BC^W<[_P"ASFO_ (<<7_\
M+@_U<X>_Z$.2_P#AKP/_ ,H\E]Q[1_PT?^T%_P!%O^+'_AP/%7_RTH_X:/\
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M5_\ S\]?Z>GXW45^R/\ PQO\!_\ H6M9_P#"LUO_ .2*/^&-_@/_ -"UK/\
MX5FM_P#R11_Q(SXQ_P#0V\/O_#WGW_T+>?Y]F'_$TWAQ_P!"_B[_ ,-F5_\
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M_P#0V\/O_#WGW_T+>?Y]F'_$TWAQ_P!"_B[_ ,-F5_\ S\]?Z>GXW45^R/\
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M4FK@JK1E;G&HRO<XNA+R=GW %K]:O^&-_@/_ -"UK/\ X5FM_P#R11_PQO\
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M_0V\/O\ P]Y]_P#0MY_GV8?\33>''_0OXN_\-F5__/SU_IZ?C=17[(_\,;_
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M?^&S*_+_ *GG]:=]/QRHK]B?^&0OV?\ _H7]7_\ "LUS_P"/T?\ #(7[/_\
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M=XB_\+WQ-_\ 'J/^'<_[)G_0G>(O_"]\3?\ QZC_ (EKX_\ ^@[AC_POS/\
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M]F'_ !-CX9?]"_C+I_S*LIZV_P"I_P"?]:V_F_HK^D#_ (=S_LF?]"=XB_\
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M+_J?^?X>MOYNJ*_I%_X=P_LH_P#0E^(__"]\2_\ Q^C_ (=P_LH_]"7XC_\
M"]\2_P#Q^C_B6WCW_H/X7_\ "_,__G-Y_GV8?\39>&7_ $+^,?\ PU93Y?\
M4_\ /\/6W\W5%?TB_P##N']E'_H2_$?_ (7OB7_X_1_P[A_91_Z$OQ'_ .%[
MXE_^/T?\2V\>_P#0?PO_ .%^9_\ SF\_S[,/^)LO#+_H7\8_^&K*?+_J?^?X
M>MOYNJ*_I%_X=P_LH_\ 0E^(_P#PO?$O_P ?H_X=P_LH_P#0E^(__"]\2_\
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M[_T'\+_^%^9__.;S_/LP_P")LO#+_H7\8_\ AJRGR_ZG_G^'K;^;JBOZ1?\
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M#'PAI\KZ+)_:A7XB:-JVH?$*WU6\UR/PG';Z7XNL=3L7U;5A;6UQ:)YGXO\
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MSI**^5OC_P#M6_#O]G'PA_PGOCZ6['AM?$&D^'[FZL4B<V5UK+7$=E-<&5U
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MY9?&?XFZ;J:W$IT?PYK'Q#T/Q;=_#]!:(SS:G8> M T3P:XG=;7[<E[]HG,
M^;W"\_:*^%EEXOTWP@NH:Y>RZCKOAOPK_P )3I?AS5[[P)IGBWQA9P7_ (7\
M+:OXO@A.EV&O:U:W=C);63,_D-J.GQ7\EI-=PQMSVB_M9_ _73KD]MKVM6FD
M:#H?Q"\17/B?5?"^N:?X7O\ 3?A5JTFC?$%M#UN:V-MKEQX9OHPM[#IPG\U)
MHC:O/(7CCE_7))3]C._/&JIJGVE.I%6M91<Y.IRVM[J<4HIWI+!Q;7MGR\LH
M<CG&WPPA*[TVBHQOYM-W22S_ (>_#WQ5\,?''Q@^)GC#6?#NC^ _$<<_B ^!
MO Z^*_$EC'XA&HW=]XA^(WV;5M.;5='\0^(M(73M.U7PGX534M,OKRS;4A+/
M>R1J/&/ ?P4^(?CGP=H/Q!EGM?"'B'Q#KG[3WQ2AT;Q3;:M9:KIWBWXSVNI>
M%/A9?ZA8Q6[W&EQ^&/ DEE)JEI<C^V+*2Y^Q16RS1R+%[_X@_:C^%GA+PWI/
MB?Q%!X]T8:KI6M^)8] O/ FOP^+M.\(^&S9_VYXVUK0#$+C2/"&GKJ&GN=>N
MY4MKIKVWM[$7-XS6R=/X\^+OA[P==>!+FY\0:%I^@^(]%\7>.M8O]7L];N)#
M\._!GA0^)-:UK2Y+!0EC=6BWFD3N=8B:*>UFGM+:!M1:%*E+$Q;_ '3C.H[*
M7)I*-&E.$H+1\UU)N3;DVXJS23*MA=%[6].'O).4>:,JTX2C)2NN5:)**2LF
M[J[N_%F_9N\1Z+J7[/%GX!G\#^$-#^"6@>'/#L_BC3I-?L_&%]X?MSIS^//!
MB^'(;.;PEXA\,_$"?1]-O+F;7KFUU#2=2C.JP)<WL<;5I>'?@?\ $G2?V<?B
MA\'+OQ%X/3QAXRO/BX-)\8Z>^O-97$/Q0\2Z[K,NM^(;>XL8[RTUN&TU^>VN
M+#2Q>V,<EI;K;7KPN3%ZEJWQCT4?!W7/BQ86^J^&K*UL VEK\0_"WB'19?M]
M_/:66@SW^@1JFMW.E:G>:CI[0/II::[M;D-;LLH94RM&_:/^%^I^.W^&0U'5
MY?%6G^)=<\":OJ5OX9UF+P7#X]\+>&4\6>(?"MOXIN(CIK:G;Z$MUJ=O9_:)
M9?LUI<17$D=S"4=6Q4XO]W*7LI^TD^1N494I2J2<W:UDZK<DW:\F[)MMM+!Q
MEI.2=6"C%<T4G&K&,$DMW)J"M*UTKINVB\OA_9;GM]4U*]AN_"Z1:S\;_A+X
MSU1A;7XOI/A1\%?#>CZ3X(\"QS^1DZA9ZKHT6J+#YD6CV_VV\>.62=V,D/@7
M]F[QA8ZA\-1\1=4\#>(])^'?QO\ C1\:)&L8=9NKSQ3KOCVZ\17/@G6;^QU2
MRBL-.UWPM_PE-^+B*&6[L[66PT^XTRYDE)-NND_M<6$NKV^D:AX?O;W2C\#?
M$/QUU/XE:+H&OQ>!]$\.G6M4M?!,5_;Z@3J_E:OI.BZM/J-TK)(=3TUK'3K6
M1;ZWEA[Q?VG/ &B7OA3PMXLGUJ]\6ZO>_#OPKK.H>#?!'BK4?!.F?$+XD66G
MW?AWPI<:O+#,VC:AJD&H0:E!IVK2FYT[2I89M7FMI9(TDT=/').#A.5UI:*<
ME%4Y4;II7C:$N7WK-7@[)\K(4L WS\[235[M1CS.49VMI=N2NW&Z=Y)O5GAL
M?[)?Q.U/0E\%:[XX\%:9X?\ "NK?&[Q9X*\4^&[3Q!)X[\1>.?BSIWBW2-*\
M1^.GO8K6STW_ (173O%]]'=PZ)?ZM/KT]K82K=Z;!:K:M0O?V4/B]K?ASQ2F
MK:O\&=.UI_ _P!^'G@;PQH-AXH7P5IOA#X.>-[3QIXA\.:]JT^G0ZW+8^.KF
MPMH?M-AI+MI,8$/V.Z\II[CVKPM^UCX0UC0/$?B#7?"/CSP]#8_$KQ7\//!N
MF#PS?ZGK?Q&;PK-J,5]J?A73+4>;=K9QZ-J]UK@8Q66AVUH)+R__ 'J@9/Q$
M_;-^%WAWX;7'C;P0=:\<W=_X T?QKX>&F^%O$=YH%B/&=P^E?#Z'QYJ=G:D^
M$HO%.O;-/MH[WR[@JLDY\JV,-S):6/=11]D^;VD/^7<7%34U5^)724YZRUW<
MH1MK$5L ES>UE90G=.6KBX\FJ:N^1)6NM^6<KNTGR]C^SQ\:-,\1^'/B1)XB
M^%7B;X@6_P 7_BI\2_$6FZU;^*K#P9Y7CSPQI7@_PN=!DM+.^UAM8^'WA[1X
M=.T_^T($COX;_4=M]ITLJRBQ'^RMK-S\7_B+XT\07'A37O#_ (S\2P>-="U&
MXUWQS#K?@SQ'I'@BV\->$#IW@&'9X!O'\%:O!)JWAW7KN\>\L8;N98=-CU%(
MK]?MZTBN_LEJ;^*&._-M;F^CMV8V\=Z84-W';EV+F!+CS%A+DN8PN\ELFK'E
M?[/Z_P#UZY7B*^MO=;@Z3<8J+Y'-5%%.-M(R7NK:WNM-));K#4-'^]:YHU+2
MDFN90Y&];ZRC\36MTG%H^(O@;^SAX_\ !?B;0=6^)&K?#NZT7P5^S_;_  ,\
M'Z/\/K;Q':WL;W_B!=6\;>,-4UO5H[*]74O&$.G:+++#IYB;3;]+UH[FYE*Z
MA/[1X-_9X^%_@+Q!8^)_#EIXOBU;3UN([9]6^)?Q'\2602[@>VN!+I/B+Q5J
M>E7+-!*ZQO<V<KP.1-"T<JJX]U\K_9_7_P"O1Y7^S^O_ ->LZE2M4E*3E./.
ME&487A"25])16DKMMOFO=MMW;9K3HT*:247)Q=U*:4IIZ6M+2UK*UK6MH?$=
MO^S+XO7Q0?&5WK_A&\URT\3?M&?$31FN;?4[N"P^(GQ5TW3/"WPYU8+<6>([
M?P5X.TYM/U&X5)+Q;FXD72D>$F0\Q-^QE=Q>!(_AWI.J>#]/\/0_ CX7? Q(
M(K"_MTFTO3/'%IXK^,NJW<-K;1QR2^/K>"XM[*)2))[NY:75I84+EOT#\K_9
M_7_Z]'E?[/Z__7K18C$+EM)^ZXN/NK1QFYQW71RDDNBE)+1F;PN'=[J;NFG[
MW>*BWVNTDV]VTK]CXY_X9FN6\8:MXI,_@^W/B']HGP5\4]:^Q:7/;WC_  V^
M%GA"R\/?#;P%;O%:QH;G1=1TZ#4WCDD&DVXN+LVKO(P4^5Z5^R?\:1I-YHVN
M>._AN;?1OA]^T!X6\%7&D67B5+N]\7_'CQ6^J:M\0O%TMS:+]EOX?#MS>Z1)
MI>C&Y2*XN9WBO[B"X_T?]&O*_P!G]?\ Z]'E?[/Z_P#UZ%B*Z[.RBE>$790B
MX12NG9*#</\ #9= ^JT/^GJ^*]I64N9J3<ELWS14K_S:N^Q^??CS]CS7=;DU
MG_A%M8\*Z=I-B_[.FD^"/"QO/$GAC3SX)^!EGKMU<>&M:UGPU:R:CH<FI^+?
M$-QXBTJ^T6UU/[+-IFGF[A=Y9EC^L_A7X"M?A[X.L]#CTK1=)U.ZO-1UWQ*-
M"U#7=9M-2\3:S=/=:MJ\VN>)Y'\0ZW?7S^4UWJFKE;NZE3(AMX%A@C]1\K_9
M_7_Z]'E?[/Z__7K.I4JU81IS<G&+3T35W&$8)R2TD[15Y-.3>MS2G2HTIN<%
M*[3CKRNR<N;1VYEKT3M;=7U*?E^_Z?\ UZ/+]_T_^O5SRO\ 9_7_ .O1Y7^S
M^O\ ]>L/9>4ON_X!OSKL_P /\RGY?O\ I_\ 7H\OW_3_ .O5SRO]G]?_ *]'
ME?[/Z_\ UZ/9>4ON_P" '.NS_#_,I^7[_I_]>CR_?]/_ *]7/*_V?U_^O1Y7
M^S^O_P!>CV7E+[O^ '.NS_#_ #*?E^_Z?_7H\OW_ $_^O5SRO]G]?_KT>5_L
M_K_]>CV7E+[O^ '.NS_#_,I^7[_I_P#7H\OW_3_Z]7/*_P!G]?\ Z]'E?[/Z
M_P#UZ/9>4ON_X <Z[/\ #_,^6_VID/\ PJWQ-R,#1M48_A8SC)'?&<@>M=7^
MQ!(J?L<?LQLW_1#OAN3_ .$OIWZ9XKG?VJ4V_"SQ.2O31-3(Y'!^QS\X.0?Q
M]N>*\Z^ 7Q&M? /[#G[.&HRLH^S? #P#=;#(L>X6_A6V8(6=E5 PBY9B O5B
M,&OH,FIOV.(C%.\ZV'23[J%==;=[_P!6/&S2I%5*,I:*-*O)NVT5*A?:[;\D
MM;?=\[_\%._V^/B1^S9JG@GX<?"G3=6\/Z_XDM?^$D/Q&NO#$OB/PY?16GV^
M-_!NF0I9W=O)K&ZW6]U);@Q21V7E^7LC:29/PR\5_MF_'_\ :/\ #U]I_C[X
MFP_%W18]:C\467AF^\+^&O!VH>%=:2*YL=1\/>'+^WTRUU:W-GIK7=Q]FU"X
M>#5E%I-',RQNR?9WQR^+GB/]JIO#VM'5[R7P'H?B^^L_$?A3P[H>HS^(8=)%
MNT\6K68FO!<F2[G2TL+F\M;$3-I4MZEFR)*TM?AI^U3X!US3/BIXR\2^(9O%
MEQXF\-77A*^%AH=A8>&M'?X?7^FI:>'O$^J6&AW5S&L5E="6PNXHC<-,XNEU
M*:!IV)^BS/PTS3'Y3FV*H9IBJV=4J4<1@LBA46'PLZ5*=.G7P57W:D:^+JPG
M*KAZC]G2514:-2-15WB,/_&7'WB9B_[:^L87$XW$<*8JO#"^V56IAJ*A4P;K
M+$*C2KRISPU&=*K&7UG!5:U?DK59>Q>$C3Q/T'XB\=:)XEN-.T+P_-%XN@\'
MQV/B/28[[6]7FT?1+B\U66._TK2)X[J>S\/WHN-3GURZL;:WAM;B],KWJ8=W
M7N-,_;$\;_ 8>*=+^&?Q,^*'A72->L18_$G0H[[5M5\&PPS0S2Z?YFKZO>ZA
M=>$_&6HI'>6\%]H0CTZYL)/)O9-CVPB^2G^(%EXACU7PYX$U_7?!OC;4?[&T
MK6="_P"$5\.Z1I^I6NG7FF1:EKVAVID2XBU^TL[Y[K1[R5Y)-2MX4MX[6X6/
M>N+X(_9U^-.L> OC_P#'_P 0^-?%/PZ^&'@3QQH?@-O%'CN:_N=6^+7CG54N
MX=$\$:5I=K:_8&NK^T-M=ZEXBNS!IOA+3[E)%>:YD2W/\Y_6L5&HI82-251Q
MJ.56@E#V5.C3G*:YU4C*'+3@HU54E"'(W!KWE?G689C&MS9="M.OR59SQ.$Y
M:<,/0P]&M*I>M"O&5.,*$%"LJ]2G"5*3II2YX\W](G[ '_!2KX*?!?X+_"KX
M<_%?Q?\ %/Q+XM\;^(/%&N^+M7\1:8'TSX566H1P:CH=A:M=W/\ ;6O>$TTU
MK6>[UJSAN/L5U=7<DL$2>5:)_11:WMI?6MK?6=Q%=6=];PW=G<P.)(;FUN(E
MF@N(9%RLD4T3I)&ZDJR,&!(-?YT?Q(MIM+MO"&AV6OV>A_$#Q^+[P9JWB;4K
M_6M>DUFRBMKFUM=&%PL1M8K6TD=;!+O$$D3BWO)UP 5_HX_9+_X*FZ'I?['W
MA_P/<WFL>.OVG?A%I=EX)U/P-XDNH3K/BQQK,NDZ/XCT*_LR_P#PD7A#1=,,
M":I>VADO["&P^SZB\<LL<[?I'!F9XS,L5')*D(RJ1I8>G@I+W>::C3@Z-2<Y
M:U)1FJ[E.T8VJVDX1C;];X)X^CAJ.,R[B"K0PV#RO+(XC"8E1GSRA@\-"IB,
M*X.=2OB<9.@UBHT80E4G/V].A[2"I0C_ $6@AN00?I5.[OH+.,R2N$4 G<V,
M?S'?_P#4:_+;]A'_ (*+R?M3:WXC\!^/O!5C\._'7AZ[U/3=-GL=0NI_#7CN
M[T.YD768O"KZDD-R]]INFO8ZKJ&GK+=-:P7,@$LJ0LX]6_;S_:M^'_[)OPFN
M/B/\1]>&A:3<ZE!X>T-$MKF]O-:\17\%Q-I^DV-I:)+<2B06\DMW.D;0V-JL
MES<%4 S]_F."KY3B*F'S%0PLJ,5.I.I4I^R5.2NJGME)TO9M?;YK1:<96E%I
M?IN4<4Y'GN2QX@RS'0JY6U4YL15A5P[HRHRY:M/$4J\*=6C4INUXS@G)2A.'
M/"I"4O?_ !C^TA\)O!$UY9^(O&VA6%_92VL%SIGVP76J1S7JM):Q?V99BXOF
M>6)3.%2 M' #/*$BP[?"WQ1_X*1?!RZTG4['P#XKM=1U\>)8?!.G0:I;W>D6
ML_B#4)I;.TNU:]2![O1K:ZBD-S+!Y<\BP21Q1*664_C;:_%+7=;\5?#;XC0:
M-JWB>Q\8Z5JGB;0KADM[#4-0D^(L4^I+#/<3[H;B/1M-T6ZL+*^N-2CO[JZN
MM'TLPD2-CQ/5-)T?7_%7B3XZ76JHMQ.]YIFC^!M.^RKX@'BV[AAM-/?6_#^I
M7":9I]OX<_?)=:J)5N[\O(\[QP((I/OL#P;@DH3Q5>O5?LZ<XNE*G[.=5SLJ
M+A&,Y\E11E:KSI03>[@Y'X%GGC;G<G4IY-E^7T:;KUZ3>)AB7B:>#^KPJ1S"
ME6J5:5!U<.ZU-_5?J]7VLHQ=TJT*;ZGXWZ?\=/B!XKE/C?QY!\1+SXJ>)[G1
M;/34U_4+/X<>&(=-\/ZCY%ZUC]G>WTF#3S;7UV;2PM3?WD\%H;/4;R\:>1;V
MG>!_C?X8^'WA&3P[\3]9\"^'M"\&WFD:[IWAOQ%JHF\;->:1?/IMGH^DZ2\]
MG;:#?ZNT/VFRD:QFEL8D*+;2QNU?('B3X@_$CX1_'O3-&7X;?:-4\'_#/5O$
M&A_\)?XXEM=!^RW^C2V%QJVDQZ;+?:3K,:3SW%OIK"VBO9;^YND!M[=#)6-K
MG[3MUXD\$:QI/A'XPCP/)+ID'@;6?A]?V6D#3[?3AX?M8[:33/%WDRZQ?ZCJ
MNJQ:G;2WFF_9[/0XW=9'^SRQRO\ ?QR_$*AAH4HX*.#C3I5'/V--X>,9.I34
MO9T/;0IJ-!0Y*DZ<8<Z=YJ2@W_.]7B3+WCLTQ6,K9W+.95\3AU2>/Q-/'3J4
M_JN(FOK6-^I5\2YXYUY5J%'$3J1H37+2E2E6@ONOP_XMTBS\'_!H:9XI\4Z-
MX7U'P*UU-<67B/7;.>V\3Z)X>9[V73]#O4O?[5UVWU1[RWLM+CM+DRW5T+BW
MMS.3=5^P?_!/K]L;QA\1O'/B#X:_%?4_$5MJCZ+I<GA#0_$&EP@Z:NGSOI<=
ME)K=E9PF]U#5-/M3JT\E_*RS7$KPPR&>*5!_-_X'^+_PPL_%^E^*1::Y)X;^
M'MC!_P *\U/2?$VF>,O"_P &]4U^--&O-3\1Z8D/]JWC0Q&]DTY7FU&UMKR<
MS00-"RF/]1_V;?VJ/AQ\%/B^/%?QX\3ZA;^ ;"P2#X;:WJ?@R\7QG=7NO:3I
M^KP#5-/T6S"7]XMM<WL%H%M[.WM;)DU&Y>2[G@%?,<683"X;*<=B,;3C3IT<
M/4Q'UK$3ITY4)RKQE&U22G34I>UP].NG4ISE?EI)QM*M^B^&/%=2CQ#E,J&;
MT,)A98[#83&T(3J1RZMA*>"="I6Q:G5PTZ>'C4H9A5RZ;I5Z%.<J3Q,_:R=+
M"?U)(VY0?;_Z_P#+]:=6)X;UK3/$GA_1/$>BW/VW1]?TG3M:TF\\N2'[5INJ
M6<-]8W'E3*DT7G6T\4GERHLB;MKJ&!%;=?CJ::33332::=TT]4TUHTULS^X(
MR4HQE%IQDE)-----7336C33NFM&@HHHIC"BBB@ HHHH *_/'_@I<-WP.^'X]
M?VB/@WG/OK5V/0^O_P!<=:_0ZOSV_P""E S\$OAZ/7]HGX-#_P K=W2DKPJ+
MO2JK[Z<BJ;M5HOM6HO[JL#TWX;VH_P"$5T[*_P#+"+/+'G8 >GT]AZ5WGV4?
MW/U>L'X;P?\ %)Z7E>?L\1QQQE!W(YSU'\S7>>0/[O\ Z#7Y^\*KOKKYZ[=O
MZU7S_38XR222EVZOR\_^!YV;/P,_X*K_  Y_:4^(EOJFOW'P^ENO@3\&H+CQ
M+X9U+PS?:-J%]+=2Z?;)K?B_Q3!/=1ZW90VJF73UTNQL)H8+&!KZ6:7SG-O^
M/'PT\0Q:=Y&N66KR11&">>[M&BMBDLLB ^?)?;5NA' %+"$N8P !@;<5_:]X
MG\+:9XN\-^(/"FLI<-I'B;1M2T#55M;@VMR^G:M:2V5ZD%R@+P2O;S2(DJ@E
M"VX D5_(/^U9^S'HO[/'[1'Q'^&WPFU'Q%XM\#Z+#IU]'X<%H^L>*M%AUK1;
M?6-4TB 6$,CZE'X>L[H7<U]-:6RK92VZS 2#S)/XR\<> ?\ 5O.,/QM/,,;F
ME#/<WAAYO,\52GB,OSBK1KU,#A<MIX7#8:4<KAE^">'C3FZSHQP]-595959U
M'_I+]%?Q5R_B_AG&>%V-R_ 9-CN&\M^OY9_9F"Q*P&9Y*JV%PV;5\TKXO%8V
M%/.ZV:YA#&5*Z^K4<5/%UYTEA7AXTY>;V?BJ;1$U/6/AO%!?7&N7$$NIZ/<3
M_P!H:+JM@]V\NI1Z;:W$GV.WO+EI&=F<F*0!XRJYKZ!M-!U+QYX<\*OXDU33
M_"$.C3+J4_A7POIMH+#S[?44O;"=+GY%LM3CB18;J2V22$,[E"6)-?#GA[7_
M  EI-Y)-IVORZC']FM[2V66,64-O;VS;A!)8%AY%TI9O.E)>25B5RJX VIOB
ME)I-S'//XBENK.UU"XU.U87ABE1)K4P+I,L,++%-:1/B2(E2. "N\DG\(YJ$
M:-*.*PLJE+$.%#$8#"XNG#!89RQ$:T\1*6'E&3@YQ<YQHSE1J+W:B?-SK^JL
MRX:QN)KI9;>CB\/+ZQ0S'&9?5J9E7MA7AZ>&MB82I\U*$G3A4JT88FDWST:D
M5#V:][^,GQ*OCK=PD#7\&FV;S6-W9SV2+8WR31"1=5M-2#%BUJXV&)]H9=^
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M[6.W#S<8-+^=_E'_ "_)E?9_L_\ CO\ ]:C9_L_^._\ UJL45R>R\H_=_P
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M0J5ZC17I1A*#O%I-IQNM[2336W5-H\64E-6DKJZ=KNUXM-?BOR['Q/\ #_\
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M?EVUK[/]G_QW_P"M1L_V?_'?_K58HH]EY1^[_@![1_TWY?Y?EVUK[/\ 9_\
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M HHHHLNR_K_AE]P!11119=E_7_#+[@"BBBBR[+^O^&7W %%%%%EV7]?\,ON
M****++LOZ_X9?< 4444679?U_P ,ON ****++LOZ_P"&7W %%%%%EV7]?\,O
MN ****++LOZ_X9?< 4444679?U_PR^X#YG_:F /PL\4 C(_L#6CS[:;<D?D1
M5/\ 8@ '['?[,0'0? SX: ?0>%-,J[^U-_R2SQ1_V -:_P#39<U2_8A_Y,\_
M9B_[(;\-/_44TRM5_!E_U\A_Z3,S?\6'_7NK_P"E4O\ -GU)11169H%9NI7
MMK:67:#L4GH#SC.>O)Z8]\UI5AZZA>QG4<DHV/\ OG%-;J_<3OT/PA_X*H_M
M4_%WP-X=7X<_":6TTJZ\?:!K>CW>OW%K=M?64FH'^SY'T&^MI5%CJ>F:?)<Z
MF;A(9IK<I%*%50S+_,Q\-OC[\1OAAX_\/1_$CXJZCX@^!/ASQ/KBQZ]?:3J'
MB'7M1_M2%DU""*6"Z^W:U837D$%MK$\[""VMK:-8W5%*G][?^"LNAW#6_A/4
M;&:\?54UB]TA-/M[:^OFM-$UDVT&O^*K2UM"-^H:%8J3;##2SR7$<*H\7FJ?
MYX_C[X5\8>%?"]AX9TBUNF\*^(XY;"RN]?OM*AU"UOGN!=12SQ6EI;7EE+JR
M2M%<Z6#<1^>T)>> JR']GX3PN'>0X>=&%&G7K3Q"K2E"*G5Y)34I*I4@W*4:
M5HTU'1)U8IN2T_BCQ>S3,*?B%F&%QM;&XK+L)A\NJ8"C2KSG1P;Q&'P\Z4/J
MV'K05)5,9&I5KRK+VC<,-4:]C-\_ZHZGXP\9R^!/$L/AGQ9X'\(Z3XNU"^\5
M:?JFG:K%XG\2:I_;^E+JJ^'7DL+6XDN#/'.BSZN87@T>P:#2WF)MRU6/"'C+
MXY#1[7Q1XI\'3R6_@SP=I5C'_P )3:MI]C9W,VH6VEKXAT2TD:1?$.LW^@73
M+?R7DEO:V\$0_>1B4HWS_P#LMW7[,WA_P)!\-K3XBZ)KGB9C9GR);W[%J-C=
M:E(UE<Z0^KV\EW<K9Z7?W#2ZQIMDBVQWQP.BA"[??&B:S\(+I-/\'WWCBQ\:
M>(K#3)+;5;6YFEO)GT72;*3^T[;[ 1#96&AVUF[23>=^]%M&7:22=<CT*[5%
M.G]4]I[ZG.:PTTW#DBJDHS3C)P:7+*=2;6SBK.:?R>!I5,94AB/[8^K6I.C1
MH?VE0]VJJTWAX5J#YZ,*T*C]K3HX>ES*TXRG&I&A47R%\?OA'XA^)WQ$\(^"
M[31(]<_M*:Q\,R2>'] ,$^N3Q2SZUY&F;#=6UEMNI6M+Z&"=85ECCGR%#1+_
M &&_L[^%M1\#_!7X7^#=5:S;4O"W@CPWH-[_ &? MM9BXTW3+>VD2"!"441%
M#'*ZD+-,LDZA1+@?RJ>(M9U;PS8:!#\.M*U*<:[)::IX5\"^#+K5C=^$-&TN
M>'4+;QQ?>);99+V>]N)[0736OVV"SA^T)E+F19MW].7[(/QC7XT_!7PCXIO+
M:[L/$L.FV&E^+]-OXT2ZL_$5O90-=R%X@MO-!J,3Q:G;3VX$;172AECD5XQ\
M=QI];G@,M5H/"4*M522M[6-::C%5)Q4GR1FH2A[J=/G@E&I.+IV_:_ ]930X
MAXFNZL<ZQ^%PE2+;<L++ T9.I+#T:DH1=6M2E6IXA>U<<1['$-U<-0J0K\_N
M_P 0[_QMI?@3QAJ7PVT#2?%/Q L?#>L7?@OPWKNJG0]&UWQ-!8SR:-I6J:PL
M<ITVQOK]8+>XO-F(8W9R\8!D3G_#>L_$*Z^#VGZ]\1="TKP;\39/ C:EXK\/
M^'M3_M[2/#WBH:/)/?6.E:J5QJ5K8WJE8)_WBRA %DG7$K^HU6O;JTL;.[OK
M^>"UL;.VGNKVYN72*VM[2WB>:YGN))"(XX(84>25W(1(U9F(4$U^=)Z)<J;Y
MKWUYGTY=[6Z_#>_6VA_3%O>O=VM;ETY=[WVO?IO:W2^I^2GPD^./Q.?3/ E[
MX@U[Q1XD=)?AOXUFT^S\8V'C@ZXE_P#!OXGZMX@TB^U_1--T\:3?:]K^AV%X
M/AQJ5G=2Z T-K>P3S+<);Q>[Z1^U7XUU'4M*\/2S?"J%-<NO"=Q'\4D?6F^&
M7AZ'Q'X+\1>+KGP=KOFZ[#<-XTL9/#Z:7"Z:Y96UPNLV%Y<:797:?V/<_3?@
M[XI? K7/#_@[Q#X.\:_#<Z#\0KL2^";BQU;0--7Q1JKHD3P:-:/+:W%]KD2W
M"6UU8PP-JML\OV:Y@BD8QU6\0_$SX,^$-5'@KQA>>&?"AU#Q9X?\/:7;>(+?
M2=.TCQ%XN\3Z;=Z[I=KI2RDPW>HO;Z=.\UQ/! 4NTBB69YI8=^\I*4G^X:=O
MAU35FDW:VMG?1Z:N^BL<\8N,8_OTU=.^FM[.U[[26JM:VG+Y_(_AK]I'XBZ-
MIOQPM8++1[Z\\%?$SQ-_8DOC'5G-[XA\,:C\1-2MK_Q'X/BU+6_#>F:WX9\)
M:9')H>B>%5\0Z5K>J:O:"S$^F(^F6^J]S\6?VCM8\%+\._'VBWJW_AOQ'\)+
MS7YK-M$UK^RYM0UGQG\,-&L/$#>'&6U\3W4ND67B'4Y[7PXMY8ZC=I+)9-<Q
MSD3K]8-K_P ,]7TW7;QM:\"ZIH_AZ[O--\373:EH%[INAW\,\<M_8:[.9I;7
M3+N*Z$4EY:Z@T$R3B-YHQ)M-<WXFG^#/Q(L$\*:QXG\)ZHJ:58>-K.WT?QI;
M:9K>GZ+I-W!J&G>+])O] U>RUK3=+L;RUM[F#7;"Y@L4>%<W)0%3*G!R3=+W
M4WS):Z-)-ZI:WU6J2OVM:N2:32JIMI*-ULU*Z>CVLN5]_+6_R!\,?C!\1/B%
M\8?A])XRUO3+"SU;X>^'O$,^A^%_B/:>#O#EIJ5WXS\=:;%&?!FI?V[K'C'5
MM0T_2=%AUK0?[?BG\/7AETZ[B^TAEJEXC^/7COPGJ7QN\/0ZYI>MP/XZ^,-E
MI6FZ?J&K?\+$\%6_AKP-I?B;3=:>:66ZT_3_  D+E'TRV@CTA8X[C4K2XM]3
MGGDN-/C^O/ \?P!T#3O"6D>#M9^'EY'JSZ_KO@^Y/BC2/$NM>);EM0O=7\4^
M(-+UO4=3U/6O$EZVJ/J.I:]K$5]?3B\-U<7UPKJY6QJWQ@^ NB+;:UJ7C_X:
MQ)KOBBP^'*ZO%K?A^[2Y\4ZQ"U[8^%K_ %"TGG6"\NX8_M0LK^:)=C132*HE
MB9JYTYOEHMKE24;6U4M[6=M59V>ZM?=L46H:U4G>[DW=6<8W6K5UU3?=.RV/
MGG7_ -IOXC>&)/&]]/X7\*ZKH6C_ /"VM.\-6UL==AUE+[X82^$XAJ_B>^DF
MELIM)OH?$=Q>ZC!IEA;3V%IIDEQ%>7/G216OG.D?'CXC>'I/%VM#Q!H/CN_C
M\9_&&'3FTO4=9/PZNAI;_!73-%2TMVFU74$TNP?Q-J,\<%GJUS';W$FH+:SW
M*W!D3[XD\:_#,2^)+:7Q;X%$_A,[?%]O)KWA\2^&3JC+#M\21-=[]&.HMLBQ
MJBVQNVVQXD.!70:9;>';K3;*XT:WT6YTBXMH[C39],BL9M-GL[A(989[*2U5
MK66VGCC@DCD@9HI42%U9E5")52*6M)=$WT::3716=M='K>X<DF_XNW1*[35K
M];[KY;6U9\$>*?VL_B5X?\4Z/\.QI?@"/Q:?%VM>'=0UB[TWQ&/"NJVVD>-O
M#.@S72._B&S'@B*/P]KE[JQO]>U?6K*[U33%TFU7?>1,/T0'0=#P.1T_#V]*
M\J\:_!/X;?$+58-8\5Z#<7UW'8II=W'::[X@T?3];TF/4XM932?$NE:/JEAI
MOB72UU2&.]^P:[:7]LTH8-&T<DB-ZL  , 8 X '0#TJ)RA)0Y8\K5^;16;;T
MLUT\FE;II9+2$9IRYI<RTY>Z2WOY^?7KW97P9_P4,_Y)+\,O^SC_ (+?^I!/
M7WG7P9_P4,_Y)+\,O^SC_@M_ZD$]%+^)'Y_^DL*GP/UC_P"E(^MOAM_R*FF?
M]>T/_H%=[7!?#;_D5-,_Z]H?_0*[VLRPHHHH *_.S_@EE_R9_P"'?^RH_'__
M -7C\0*_1.OSL_X)9?\ )G_AW_LJ/Q__ /5X_$"MH_P*O_7RC_Z36,9?[Q2_
MZ\U__2\.?HG1116)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G+^U;
M_P GK?\ !-3_ +'[]HG_ -4C?5^C5?G+^U;_ ,GK?\$U/^Q^_:)_]4C?5M0_
MB?\ <.M_Z9J&5;X(_P#7VA_Z?IGZ-4445B:A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?-'[4W_)+/%'_8 UK_ --ES5+]B'_DSS]F+_LAOPT_]133*N_M3?\
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M6W\3WT<^@)H^FS0VNGVT;7=UK-S;3W<KPG[C1$C18XT5$10J(BA415&%554
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M#B:Z\/PS>(_!DMY>6$^O>%XY-4T:2>?3(()#<:QHH:8N;*.V2827]GB$11S
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M )/6_P"":G_8_?M$_P#JD;ZOT:K\Y?VK?^3UO^":G_8_?M$_^J1OJVH?Q/\
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M<31JX?$4J=>A7ISI5J-:$:M*K2J1<:E.K3FI0G3G%N,X23C*+:::9T83%XK
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M=4GDW&.4Y3AU*MA/$BA@*,OJ..P>%A&.%XJC3C"HE3PN)3K?5<+C?V[^-O\
MP59TSP=^VK\,?V1/@E\-;GX[:C?:\_A[XO7GAJ]QJ/AO4[U56'3O##AQI=U=
M^$8DN=9\;3ZK-%IUI9P3:8MW97UK?W-I^P5?D1_P2K_X)SVO[('@.?XF_%2W
MAUO]ICXFV2W7BW5;N2/4I_ VD7SI?'P9IFH,\YEU">?R[OQ?J\,\AU35(H[6
M*>:PTZWEG_2KXK?%+0?A-X8D\1ZVLDX:1K>SLH&C6>YF$3R%OG90MO#M4W,@
MR8T<%5=RB-]IP[G.=93PUG'&/B/F&'R?"XB<\X665(4X8?A3)XTH0P^"KXB%
M-8C$XR<%"KB_:<S6*J.C2I0FYP?XAXJY;X>UN*\CX$\',OQ&<T^'L%'A_,.+
MGB*]2OXA\1O$5*V/SK#8*=>>"P&5TJTZF$RI89157 485Z]>O35"HOQ-_P""
MBGAE_#'Q,USQ=XUT:^TWPIXPDL=(T+6_L<L_AJ;4([4QYOKA5DL['6(Y9T:T
MO+U(U6 R1H[ -LZK]B3Q[\*OAYXQMX/B7XVT'2;?0] 2W\%:WJE]H5MI$L<D
ML5H(M3N;FZ%WI-]'-<%-!M71VN;=YI6N5,)C/R)\;/BYKG[1>K_&?0_$FL:Q
M&]SK<5OX?\,Z?KNO7$>GV=LEI-;6ZVK"#15@FE6WNHI#;O= /,#N;$B?/_A"
MV\$_#+PS<77Q+L_#'AOQ'I>K*=(DUZSO/[3O-&ULPD^(+N.]%[-JMUJ5DI\C
M5+2$V=G;#]^MLT<IE_D#B#B')\[\3*_B#DN6TLXP.68W Y[@*F8T\?&E[;"P
M>!HXG$.G0IO#4JE6.&Q&$PN->&Q-.M6P>&Y*B]NW_5O#'"^,7A5DGAQQ/CW@
M*V:99C*.&J97]6ABJ%.I/"XO%8:FJ]>I#%XF%+&8BC6Q.#5;#5L-0S&O5ITY
MT*$Y_P!?EAK>BZJ%.EZOIFI!HXY5-A?VMWNBEC\V*0?9Y9,I)'^\C;[KI\ZD
MKS6I7\A^N_M/1>'OB5X=T/X=>)[GP2+.ZCU#0?$^G75SIMEJFH0V,FEQ06DR
MVT=E>!FC/V3>L]D\;Q!%(=T;]I?V9OVN?%LVIZ;H_P ;/&'A]O#FL)!;Z1XH
MU<:=I][#>7%G UHNKZK936NF;KZ_%Q;J)-.LHK57M@]Q))(2?Z1X1\><BXBS
M:638[+<3E.(=:E2HXV&)P^,RJ?MM*<JN)D\+6PR=3]US3PTJ2J-1E5C)V/YT
MXV^C;Q'PMDL<_P NS;"9UA50KUJ^73PF*P&=4_J]G5C0PD5C,/BW&F_:\M/%
MPK.G[T:,X^\?J7156ROK+4;:*\T^\M;^SG7=#=V5Q%=6TR_WHIX'DBD7W1R/
M>H-/U*/46U!$M=0M3IVH3:<YO[*:S6Z>".&0W5@TH N["03!8;R+,4KI*JG,
M9K]YBG.+G'WH149.2::2DTHN_5-M6:[G\VSE&$XTYOEJ3<HQA)-2<H)N2M;1
MQ2;:=GHS1HJ.1RJD)L,I5_)C=]@D=5+!<X) X^8A6*KEL'%5=-DU"6PM)-5M
M[:TU)X(VO;:TN'NK:"X*CS(X+AXH'FC5LA9&BC+#DJ.E/E?*Y7C924;<RYFV
MI.ZC?F<5RM.27*FTFTY)-<ZYU3M*[C*5U&3@N5P3C*:7+&;YTXP;4I14I134
M9-7J***DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *_.7]JW_D];_@FI_P!C]^T3_P"J1OJ_
M1JOSE_:M_P"3UO\ @FI_V/W[1/\ ZI&^K:A_$_[AUO\ TS4,JWP1_P"OM#_T
M_3/T:HHHK$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJE_?6>F6=UJ
M%_<16EE9027-U<SNL<4,,2EY)'=B  J@GKDG@9) KY,\;?M4?#NZTC4='\,Z
MYXAL==GLYGLM7@T"=["SN[619%M+VZD.+5KU(VA$RHX@CE\YF4KM/QW%_'O"
MG ^%=?B+.LNP&(JX;$U\OR_$X["87&YI+#J*^KX&GBJU&%2I4JSI48RG.%&$
MZD75J4X*4H_1</\ "N>\35U2RC+<9BZ4*U*EBL70PM>OA\%&JVW5Q,J-.HXP
MA3C.K*,8RJ.$'R0E)I/Z^HK\X[']K#QGX=\)^7>VNCZ[J<5RUQ9:SJUTT,5Y
MIBLQ:UNELT5V<DK)'J2X-O8LWVJ.XGMS+/Z7H/[86E.&?Q3X6DT^TDMMUEJ6
MBZFFI6CWK*C6]I?B[M[ Z>E\&?['="2ZA8QE9-A="?SC*OI(^%.8RP]'$9UB
M\GQ-;#4,15I9IE684Z6$G657FH8G&X:AB<#3G1E2E&=5XA8:7/2=.M/VB/L<
M=X-<>X.-6I2RRCF%&G6JTH3P6.PDZE=4W3M4HX:K5HXF:J*HG&FJ7MERS4Z<
M7'7[1HKS+X4_$=/B=X8'B1='NM%C?4;ZPMH[IF:*_6P=8IKO3Y9(X)+BWCN#
M+:2RB$1K<VTZ(\BINKTVOV3)<YRWB'*L!G>48GZWEF9X6EC,#B?95J'M\-7@
MJE*JJ6(ITJ\%4A*,XJI3A)QE&27+)-_G.8Y=C,IQV*RW,*/U?&X*M/#XF@YT
MZCI5J4G&I!SI3J4Y.,DXRY)R2DG%NZ:1112,RKRQ ^IQ7J'$+36=4&6( P22
M2  !]2/_ *]4KC4[.V1GDF3" EL$94 98\^@YQ_]>OA3]I7]L7PY\(K:WL[&
MUN?$?B*_N+:'3M!TTJ))!-<);M=7=VZ/#:PQ;G=8L2W=V(I$M+6<HY7S\VS;
M+,BR[%9OG.-H9=EF"A[3$XS$R<:5-.2C&*45*I5JU)RC3HT*,*E>O5E"E1IS
MJ2C%^IDF29OQ)FN$R/(<OQ&:YMCZGL\)@<+&+JU9*+G.4I3E&G1HTJ<95:^(
MKSI8?#T83K5ZM.E"4U][K(K8P>HW#/&0<<CU'(Y'K3Z_GW^#_P"WI\0O!OC'
MXL7NO./%WA"2T;Q;8Z-=ZK+]M\,PWVO:E.EK#>F&YCGE6SN!:);2+:F6RL;.
M1$0Q8?Z5T#_@HQKOB&WU[7[/X9I9^&]*BT(6L>M>(1I^NR7>MZ4VJ0B]B6QF
MTR*S>&2S>&X@O)-L$YE<22#R8_RW*/'7P[S3#4ZM7-:N Q-2OCJ7U&K@,QQ%
M94L%6QD'BU/"8.M2EA:U+!RKPFY1J4XU*=.O3I5N:G']CSSZ./BED^*JT:.3
M4,SPE/#Y=6_M##YEE6&H.KF-# 5%@G3QN.H5HXRA6Q\,-4IJ,J<YTJE7#U:U
M#DJR_7.BODOX*_M3Z!\3;_3?"VKZ/J7A[QK>F_+:;'&M]I$4=E&TT<[ZJD[/
M$-1@BN+C3XYX%:>*W>5"$=%/UF#D CH:_3LGSK*\_P %#,,IQ=/&864E!S@I
M1E2J^SIU94*]*I&%6A7IPJTW5HU80JTW)1G&,KH_(<]X?SCAK'SRS.\!6P&,
MC%U(TZKA.%:C[6K1CB,/6I2J4<3AJDZ-14L10J5*-51<J<Y1U/YM/^"KW_*3
MS_@FI_V-GPQ_]7I8U_297\V?_!5[_E)Y_P $U/\ L;/AC_ZO2QK^DROSS@+_
M )+3Q<_[*?)__6<P!^_^-?\ R:;Z,/\ V;WBG_UN<V"BBBOU<_F<**** "BB
MB@ HHI,@=2!^- 'D'Q_USXL^&_@Q\1]<^!7A73?&OQ<TWPQJ%QX$\-:M>QV%
MCJ.MA56+S))BL5Q-:0M->VFFR36T>K7EO!I;WEDEVUU#^,W_  2P_P""=OCC
M1O%VL?MP_MD6NIZW^T1XXU;5=:\)>'_&"23ZOX,;499HKWQ=K]M=H!;>+-2C
MW6N@V"QHGA?0!$+=;>YO4M-)_?8R <#D]NW_ -<U&93Q_09Z].OKVKY/-N#\
MMSOB+).(,SK8K%+A^G7EEV45)TWE5/,:LX.GF\L/[-3J8_#TU*E0G5J3I4KP
MJTJ=.M#GE^G<,^*N?\'\"<8<#\/87+<M?'%?!T\_XHH4J\>)J^0X:E4C5X6I
M8[V[I8?),;7E#$XRGA\/2Q&):JX?$UZV%K*C3F) ZFOR/_X*2>)/'^E:YX,T
MOPOIT$MAJWAS5=FJZT7FT>WU 22Q7.EVEK;^6_\ :E_:-"T"W,CP7LRPP+L,
M>V3]8GG5<Y=1S]3R2.>>OT!]CZ^>>-_"W@GQS91Z=XQT+3-?L[>=9H(=1@2Y
M6.9,D/&K9 /?J.<9''.'B!P1A/$+A3,N%\;B*V$I8WV%6G7I7:CB,+6CB,.J
MU-.+KX=U81]M24H2<?>A.$XQ:\/@'B>?!O%.5\1?V=1S6E@:LEB,#6G.DL1A
MJT)4J\*=:'O4:WLYR=*I:45-*,XRA*47_/-^R?\ LV:IXR^(^B>';G6?$5Q-
MK,[:SXQ\0G3('T[2+?2GDOKBPBU6XM3:W4]Q%):V=G9VTSQP^:P1LVLZM]+_
M /!2#PG^SGX+N/ &@(^N:W\:F\'V^@^"/AMX5M-(U+5;[PO8W 2+5_%FH:K'
M-!HN@?;;=XEN94EO=4D2YM]/M;D07)A_7K3Y/#WAJTBL-$TS3])L[6-8(;>Q
MM8+:..->B*L*H O7)R>>>PK^;3]J;]EW]O?6OV^_BW\6OA=X.TWQMX.^)=QH
M'_"$>.]1\6:)IND>"O#FG^'M,T>+0=7AU"Z34]+_ +'N+:\F>"PTV^6Y$SWE
ML)Y[J2,9^%G@-P=DF29QPYF[P&;X?'82.)QCSAQP-+,98:I@I8;+E6GB)U*.
M'H8J-3,U[.NL3*I!JDXN%)T?9\8_'_Q$S;.>&N)N&L+FV25,LQD,NRZEPW0J
M9I6R:AB*&-IU\S^JTL+"E6Q%; NCDR]MAI8.E2E&5=3C.LJ_P)9:SH'BT>(_
M!'B[X:ZO_P +(M-5G35?#.G(]_-80J\EY9ZIH=QIOV0QZ?%'';B+9%:^3?(\
M44"@$5H^"_B!<7>LPZ_?:M>7WA;2;;3O MWI%WY^EZSX9U#3[E1Y^O:"\LH$
MU]-,(Y+F6*);^'9)*KO$IK];/%7_  3 \2Z-\)?"WB_X4_$#2;S]L30;[5->
M\6^)]4,VF>$/B8-:6W>;P.MP8Y9]&L?#K6T47A76;JWF\YYM1.J1*-1$MKX!
M_P $FO@C\4O%?[7'QQ^,'QJ^&_A71_#WAGPYJ'P_UVQU271M<FUOQ]:^)S;0
MW6GVMJ]W;E-&DT36HWU9]@D2YCBMWD29C'\IG_T1^!L9EF;XWA'BC&9*J.*^
MM5,%C7A\?@XPGBI/^SL'@ZM+"YK7HR;I8G+\9B<SQDJDL+3IYA2DY5:M+[+A
MSZ:GBCE6=\/95QYP-AL]J8S"?5*&88".*R_&3E1P5-K-,QS"A6QN287$THPJ
M87-\!A<IR^%)8V=?*JRC&C2K?IO_ ,$_/%-R?$^H^'/#\^NZKX1NM(U/4K^6
MYM]5MM%TF^FDTRZTY=/2XWZ0 5%Y:1V^D2*+>-W6YB5E3/ZLZHVIK! =*DTV
M.;[;9FY;4Q<&'^S1.AU 0?9W1A>FU\P6;2$P+/L,RM'D5P'_  D6D>'[!Y+#
M2M,T#3M/\0:=H5U<:RUMX4TF2WO)(E>[T>ZD06^J$O+%;V-O'Y1OKSS+9&5X
MLGXB_:W\":[?^*/@)H%U;V'QIM_&'QR\=:[!X*^).NMX4\*V.DK\*]?FM_#[
MZEHVFWTW]G:');MJFFF[L;MI+P*DH^<,WZ7P;PE_JGD.$RF>93QL<(YO#SQ-
M!1=:\H3J8>C2A.K"C1H1FJD*>)Q,I*$U"%27N0C^/\?<:/C3B;&9Q3RA9>\9
M&$<8L'B$UAN2-2G2Q6(K5*>&GB*^)G2E1E5PF#C'VE+GJ4H>_4E^B]S9Z+?W
M^DWES'9W&HZ<;NZT:5I$:X@\^#[)>S6@#Y97@E$,SJKJ%< D$@UKU\":+K7Q
M#G^*NG_!WP(GPH^"EK\%?A/X \3:S8:AX=G\<_VI'X]U?5[:^\+>#M;FU?PK
M-I?A/2H?"XM;G7(K"6ZNM7O;%9+2.*!89.-\#_M&_'_XF>++_4+/P7*GPLNO
MB%\7/AMK5H?#^D6$/@[0_ P\4:+8>*V\9S^.#K.J^)+S6M!MWU/PNO@NT$-C
MJZO8.19"[N_H)TVXPM4<HTZ?PSDO<4ISFHTTI2CRR4O:632]I*HGKK+Y>G-1
ME5;I0C*K53<J4=:KC2I4I5*S<8RYX."I7?,U2ITM;+DA^E@96SM8-@X."#@C
MJ#CO[4M?B'^PGX:N)O%_P[T8Z/JOP';QC^QS%J5U+X?\:-JU[\>+K6=7T6T?
MXI6DR-<:7X=\6_#IO,.+BSG\2QGQQ#+<^9I-O:D?>/[#VEVN@?"[QWX=LKW4
MK^Q\/?'_ ..>BV%QK.LWWB#56L]/^(.KP0"_UC4I[F_U"Z*J6GN;F9Y)96=S
M@$*)J453YO>ORN/V4KJ7-K=2DOL]&^SY6FC2G6<W'W+*2D[\S;3BHNUG%/52
MW=MDTFFF?9=%%%8&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7\XG_!2/XH_MH>!_V_/V8=#^'.G^
M#?$$2ZQJNJ_LTRW?A2>:/^V_B#H$/PY\:Z+XPGAU5?[2707N'U)[E([!=-T?
M4].U*=I/+GV_T=UQ^O?#_P &>)_$G@SQ?X@\.:9JWB7X>7FKW_@K6;VW$M[X
M;O==TR31M7N=-D)Q#+?:9(]I,Q5OD(9=KJKC?#UHT*CG*G&HG"<>66UY1:3O
MNM=)6WBY+J8UZ4JL%&,W!J<)73:TC--K3K97CVDHO:YN:)#JUOHVDV^O7MMJ
M6N0:98Q:SJ%G;&RL[[58[6)-0O+2S+R&TMKF[$TUO;&21H(G2)I'*ECJ445@
M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH.&%C#V<H-QO"<I-*2=YK4]#T7]J;3#-$]_HWB/3T1T8LRZ?=\!N2J6]Z99
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M&ZUW4-,@NM5(M[V-=!CN;RY2629[?PY#H:))"8K5@@,5O$WF+7WJ
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M"JJCG@*!@=<#CBN@TO288(3<3M%;VMM%)+-/,WE00Q1)N>21V94CC1 2S9
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M.NCZQ$+G4)94662 75OJ)$<<<JI7](EG;BUMXH1C$:*@ &  HP,# P/08X&
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MUI=K9WNI^$M9O]/AN9[,W 5S8ZC':W/E2RVK(9(R2K&,FO&?''B=8$F5) N
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M@J567+&2C.-JDY37(H0C"G&,(IQC%/FE;25226GRSXE\.:+_ &HVN?V1IO\
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M2K.ABL)BZ-3#XG#5Z4G"I1KT*T85:-6G).,Z=2$9PDFI)-6"BBBM3G"BBB@
MHHHH **0D*"Q.  23Z #)/Y5^:W[9/[:&I_"F\A^&_PO^QS^.[VW6XU;5[B*
M*\M_"MC<+FW"6K[XI]<NXSY]M'<(]O86QBN[B&5YK6&6Z=.522C%7;UUT22W
M;?8B<XPBY2V[+=^2.:_X*":TMW-X"\+07,9GN]?N-4NK82+YC6%AIL]H)3$"
M69#>:C"%9@%8Q288E"I\C^&.I^'+5;73AJFGM>@*IMUGBW^8N,1YSL\S.<IO
MW X&#BOD6UOM=\2-K?C+QKJVL>*-<NK*[N+Z_O[VXN=2N ('+1V\TK-]G!W-
MY,5NL<$!9C#$@^4S^"KV_P##>E->I:VFM::=.&HW%C;B:YN])M[F3R([>_F*
M)*;V$R1S3$1HR!E<YY8>BHJG&-)RO)WM9/5QU>^UM%K9/N<7,Y2G42?*G%N]
MKI-J*Z:W;O97ZZ'ZV:=?Q>2L2@# YQC)R.AP?UYSCC%>:>-?'_PQECU#PKXD
M\1VY:]A:TO\ 3]->XO+VW3<K[9#81S?9I5902LK DC:R8)6O&-5\2>*;+X&7
MFJ6#7</B$^$HG#KO-Y9B94CFNE!!E^TVUC(\RDCS%=0_WEKQOX6>%K:XMH)4
M_?++&D[W)8RR2-*0[32S#<TKR-EG>0[B<ECGFE##^ZZC;TE9)6^)6;N]>^BW
MZW[YSQ5JGLDES**E)R3>DOAM%6OIN[I+MO;[S^$^B?#?R)8_"&H"XN+H(LKZ
M@9TU.>-#\L2B[B@Q"I.1% NUFRS[B!CI?B;\+H?%&BQZ?)-]GDLKZUU6U,L;
M2V[W-F6>..YB!#O"^?FV'<I .T\@\9X'73-'MD\^)%,:AAN&'4J<Y&2&7/52
MI!'8]Z]7T_Q_8^(#J.CRS1OJ.G0K.C$C?<V#DQ)(P!&9() (I#_$K1L?FR3A
M-2YFU=I;N5GNK7[-6LMK>>AT0DFHWT>C5M+-6:ZW\T^KT/D/5_ 4FB:-J5G<
MW2W]_J-Y<:A>S0P-;VQN)HDB\NUMV=VCA2.-."Q);)PH  ^D?V+?BO%/I^H_
M!?7IQ%K?AJ2^U;PN9656U+P_=7;7-_:1@A2T^CW]T\HC4,?[/O(,$_99B/%O
MBUXTM/#-QI%L+&75-2\0:A+IVEV$$L-N)98X#/,\MQ.PBB6./&%P7D9MH& S
M#\T?C/\ M:?\,]_%[X:^)M%M]/AU8Q/XIA&IWDUOY\5CJC:7J6B.EJP$]O=P
M_;;&[E1G'D7+-$N2#6D*3K0]E%7:BG'R<5:/7^71WU:N]Q3J*C+VLW9/XF_M
M<S2ET[M.RV=MEH?U'45^;7[!/[=U_P#MFZE\1K>YT3P)X<A\"V.@W"Z?HGB6
M]U'Q)=/K=SJ40NIM)O;:%DT:!=.:%]1C;:+Z:&V*?.&'Z2UQ5*<Z4W3FK2C:
MZNG:Z36JTV:.JG4C5BIP=XN]G:U[:===PHK\W/VT?&WB[PQXUT*V\/>)M>T6
MVF\*6,TEOI6L:EIL+3/JVNI),T=A=6ZO+(D,*,[AFV0HH( (/YD_$#XX_&&T
MMY3:?$[Q];$*V#!XQ\2Q$8 Z%-4&.O:M(4'-)\R5_7;_ #WT_'LIU%&^E[?J
M?N#X*_:D^'OBKXX_$7]GK4+A?#OQ'\$:A&NEZ=J%Q$(?&FC2Z38:J^H:!(2A
MDO-/COA'J.E./M*11_;K7[3:BY:T^F*_A+^*?Q'\>6GCN/XD0^+O$(\>:?JM
MMK5GXM?5[Z;7X-4T]4-I>KJL\\MX9X!!$B,TS?ND$1!BRA_IM_X)D?M^77[9
MO@/6= \::#>:;\6?AG:Z=#XNUBQTR=/"?BFRNRUMI^O6=Y%&;'2]:O7@E.J>
M'FDC(F2:^TJ,Z<SP6&^(P<J4%5A[T+14UUC*R3>NKC*3]4W;8YZ6*C.K*C/2
M=WR/I)6YFO)I?)I=]'^H]-=@BL[<!023Z =3VZ52U2_&EZ;?ZDUM=7BV%G<W
MAM;*+S[RY%M"\Q@M801YL\H39$F1N<@9'6OY[_VA/^"R_P 5O@W\5?&?PQM_
M@[\(O$]GHUV([+5+/XCZE]M6RO(H[JVL=2M(+=XE\1Z?;S)#K>GP3HEG.C3J
M7AD6(8Y5AJF=9N\AR^5.KFW]G5<V6#G-492R^AB\+@JV(C5J\E!JGB<9AJ;I
M^U59^U4H4Y0C.4>;/<YP/#F6PS?-IU*&75,;'+HXB%&IB/\ ;)X>OBX472H1
MG67-0P]::J>S]FN3EE-3E",OTL_:#\;W?B'7;7X?Z9/BV;R;K60I)+PO)(MG
M:, 1F*1X9;BXW$JPBMH9$:*>7$OAO0[70M-B(1581J20.IQR3GGJ3SW/KW_/
M_P#9*_:3O_VG=7/C#7="\(>'M6U>PN-8N='T/QM%K^HZ>+2[BTU89]%DLX;Z
MRM=D:R-<S7,JQR.D1#&16'W/\4?$K^$/ ?BGQ#" 7T+PYJ^JQJ<8,EAI\UQ"
M#G''FHF[MC-3BL+7RZOBJ>+IJG7P\Y4G!3C-)4VX:2IRE!\TDW=2>^O0\[+\
MQPN:8>>;X>I[7#U4_83=.=-JC%1<4H58QG%RB^:2:3YI-7TL?$W[2W[6?B#1
M?$%]\-/A2\-MJNG8@\4>,)(4NSI5U*@;^R=#MB)(6U""-E>]OKA)$MI'6W@A
M>5)'3X/O/#FO^*KI]2\4Z[KFOZA=,[SWVL:E?74\LG\:0F639 P)R8XXXT5"
MNQ2.*Z+X9:')JWF:YJ<LMUJ6LW$E_>W18RM->W\C7ES/)NW@,[EB)"<(C;0=
MI%?1=EX=B1';R1+#(#*XW1K(6^0(P/R!DD^18L9(X+.5(%>$UB<7-RYW"-]$
MNVEM'NM+WTOJNU_D,PS:O7K2O4E&,96C!/W8I-))1=];6NWN[K:QS7P=TS6O
M M[;WV@>(=8T*:-DGD^Q:A>-!( _*7-G))):2Q2 $-%+!A]K'@9(_5KX?_%3
MP]\2M-N])>6W3Q3HUM"VKV2 )'=0/^[35+)"2?(DE&RXB&?LL[;!\C)7YS_8
MI]*=EA1!NBWOR%?8C%3\W(**SA1EB%+'ITKR_2_'^M_#[XR^ O$]A(T-HOB>
MST'Q!;X(CO\ 1?$%Q#INH6[%,K)L%S'<QG:=MU!'(-I05UX=5L.XQDW.,FD[
M[V=E?R:[;ZV['HY/G7LYTZ$^:49SC&5^9V4N5<ZULK7^:T[6_2;Q;I^H^$-;
ML/&'AV4V6I:3>)>0RH,JRQL=\4Z#_76\T3213Q$?O8))45E9U9?T&\$>*[+Q
MOX5T3Q18 1PZK9)-+;[U=K.\C+0WUC(RD@O9W<<UN6'#^6''RL*^2?%EE'=Z
M9<QNH;"2KG&3A<\D=^.3_*OR)\2_\%8?''[,%Q_PK_PM\,/ACXWTN:\U76&U
M!_BD]TMB[WD=G):S2:;IR1V >2"2[F$T<KQ2S2_(RQ,S>YEN38_-L<\/EU&-
M6<X.<HRJTJ24HQE).]6<$[PISO:^R3MHG[&:9]EG#$GB<SKRP^#Q*2O"A7KM
M5HRIP3Y*%.I))JHHS;27P=(M+^E:BOSA_P""=_[:7CC]M+PSX\\7^*O#'PU\
M%V7A;6K;0+#P]X4\77OB+Q2]P;:.]N-6UBSN8H4L] NH;F"#1+]44ZG<6VHE
M51+?:/T>K/'X'$Y;BZV"Q<8PQ%!Q56$9QJ*+E",TN>#<6^62ORMI.ZO='N97
MF>$SG 8?,L!.=3"8J,IT)SIU*,IQC.4&W3JQC.-Y1=E**;6MM0KC?B)XK;P)
MX"\9>-EL3J?_  B/AG6_$ATY9?(:^31=.N-1>T6?9((6G2W:-93&ZQLP9E*@
MBOQ>^)/Q8^)5AXE\1067COQA;0P:QJ4<4<'B?7H8T1+J555(XM12- H "JBJ
MJCA HP*^&?C#\</C!<:7JNES?$[Q]+IU_:W-E>V,GC#Q'+:7=I<0/#/;7-O+
MJ;PSP31.\<L,J-'(C,KJ0QS%/#N3C>2L[-K7:ZNOQ.J57EBW9Z)[6T?S_J_2
MVI_2M\#/CI\/OVA/ .G>/_A[JL=[8W&+75]*DEA_M?PSK4<:->:'K=K$[_9K
MVU9@4<%K:]MFBO;*6>TGBE;V.OX;?@'^V'\2_P!CKXMP>/O!=Q)J>AW\\-EX
MW\$W=S*FC^+M#$Q>2VN$4.+74[7?+/HVKQ1/<:;=NQ"3VEQ>V=W_ &=? SXP
M>'/C[\)O _Q@\)6.N:9X?\=Z)!K.GV'B/3)]*U>T5WDAG@N+>=0DR17$,R6^
MH6<EQIVI6ZQ7VG75S9W$,SUBL+*ARS6M*;]UMJZ>_+)=[:IVLUYIHSPV)C73
MB]*D/B7\RVYUY-Z-='W5F>L5YQ\3O%<?A/POJ>IL^PVUK/-S_%Y<1<*#VW$*
MN>""?3D=GK>I/HVCZEJL=A>:H^GV5Q=KIVGQB6^O6@C9Q;VL9(#328VJ,]\X
M.,'^=7]J#_@JY?V7BWQY\+;OPKX"CB\-Z[=Z.T\>K:M/<HEK-%-]DU0^?%!'
MJ5LK?8=6BBA6.WOHKJ! ?+)/!AL3AJ^:QRE5&\:L&LRG1]E6Y?J,<3#"SJ^W
M]G]7YE6G&'L?;>W:;J*DZ<9273BH5:. ECN6*HNL\)";G3=\4Z,JT:;I\WM5
M%PBW[3D]DOA<U-J+_0?P!I=UK5_>>(M7<SZAJ%U-=7$KG<!++("RJVT92)0D
M$1Y(MXH5)(3-6_CG\5K+X0^ =2\0E(I]3)33/#NFR' U#7+P,EI$ZJ=YMH5#
MW=XR\BV@89!9:X;]CGXJ)\;O@5X1^)RZ=::6_B+^V8VM+&:6>SSI&LWFDFXM
M99U6:2"Y%GYR%MV"[!68*&/SS^VK+=WWC7X9Z3,LS:5%9^(-151GRWU#[39V
MGS*" TL=L1LX)59'(QNP?L,KPD,QS:G0JJU&#E.=-:<U.A!S]E'JE)0Y':S2
M;:O9'Q6=8ZID^15*]!VQ%10@JNCY:E><(NK?K*#DYJ^DI))WO8^2[N+Q9\0]
M7F\5^,]1NM?U*[D$@O+R=Y(;99I-J6VFV(W1VEE$" D-LB)L!W%G!8]AHW@A
M;>Z1[BW*^5\SL%63S"2P!BY)\MMI,4;$,N1NPU>N>%/#L<D$4/V5-RJI7Y/^
M6*!,R-N"["TI<1E<C*;@00!7HT?A:2./9)&1&R;869#O1@7($LF^13M0(H=\
M>9(1@L6VU^@34K<L5[.$8J,*<%RQA%62C&*]V*6ETK+338_*%B%"7,_WE27O
MSG.3E4J-V;E*3NY2;U?,[OK:P[P%XSN?A4$U[1X0MVL,8N(=Q$%_%P6M;Y
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MY/+WH'8(1N.;'_!/O_@H[XL_9;^(.G_"GQO%K7C+X(^--<@M/[&L(+G5M?\
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MML&U"?4KDP&5;AKPIJ.C&]>:&-H5MWCA25KF/^@RWE6:)'1UE1E5DD0@I(C
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M%=W5K_3+^SY^SW\,?V9?AKH_PO\ A7H46DZ)IJB?4+Z18Y-9\2:S+&BWNO\
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MPD\?5IU*7UC%5J%>G4KU*[^N^PPVU1117]'G\I!7Q_\ &G]E9OB[XON_%/\
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M^K5DKNRTO=+L8U,/3J./,M$[M7?O66B>NBO:_72W6YQWPF^$WP_^!_@'P_\
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MN%>K3P4\M^N5*$9RA2KUZF*K4N>K!-1JNG"A#DYU)4W*;BE*3/H70H2D*Y
M"# X/H/7KGN1G@CJ<UU40Z>P)_/I^AK&TU-L.!_=5<>ISDC.?4Y_#KUK=08'
MU_D./\:_.*CO)O\ KO\ J?RG7ES5'Y?Y+_)?.Y^>'B']@Z37KJZNC\1K:W-S
M*7VGPO<2E5P%4$KXBB!?:H+,%5=V0J@8Q\??M&_\$WW\*_"SXB_$9_BO;7*^
M#/">M^)CIO\ PA]Q!]N&DV4MX;4W9\33BV\X1[//-M,L9.YHV&<?NG69K.BZ
M3XBTN^T/7=.M-6T?4[=[74=,OX4N;*^M9,>9;75O(&CG@D VR12*T<BY1U92
M0;C7J1:?-HFF[1C>UU>UUUL<LJ<9)JW1V=WH[:/<_F__ .">O_!,.#XD:SI/
M[0G[0FC%O MK=1ZG\/\ X?:C"5_X3&>&1)+3Q%XBMY!E?"T;(LNGZ:XW>()-
MMQ<;-'B2/6/Z3X88K>**""*.&"&-(H88D6.***-0D<<<: (D:( J(H"JH
M %+%%%!%'##&D,,,:1111(J1Q11J$CCC10%1$4!410%50    *?16KSKRYIO
M1:1BOABNR\WU>[?DDDJ-&%&/+!:O64K:R?=_HNB^85Y)\??'NJ_"OX'?%_XE
MZ%;65YK7@#X:^-?&&D6FI)+)I]QJ7AWP]J&JV,-]'!+;SR6<ES:QK<I#/#*\
M)=8YHW(=?6Z\2_:5\'^(?B#^SS\;_ GA*T2_\4>,?A3X\\,^'K&2XAM([O6=
M;\-:EIVFV[W5PRP6R37=Q$C3S,L<08NY 4UYF9.NLNQ[PO/]96"Q3P_LDY5/
M;JA4='V<4FW/VG+R))MRLDFSW.'XX*>?Y'#,O8K+I9OEL<>\3-4\.L%+&T%B
MO;SDXJ%'V#J>UFY)1AS-M)7/B/X ?M8?'K4OC)\!_AA\6=6^!/Q,TW]H3X1Z
MY\3M-U;X*V'B'0=?^%<^@:1H6KOIWCS1=5\5^-;2[T;5AK1TG3-=BOM&DDUR
MTGM5L9$1ME_]E?XZ_M1_M!:C;^-=4^)?[,^@^ %^*OQ-\*W7POM?!7BB?XIR
M^&O 'CKQ%X2C$&NO\46L(M6U"VT5-0:[E\(FWACDWBRDB=6K,^#O[(&O?LV?
M%W]FOXE?!7X>>'?#&D>*?@]:?"3]K;PIH$NDZ59MJFD^'M.UCPK\2+: !;?4
MM=TCQ;;:OH>LRZ7Y=QJVG:T+N1;EX3*/,/V1?@GXW^!'B<Q>*OV"=*U/Q\/B
MO\7==_X:3L/$WPJ.K+X=\;^-_%&L:5?HTTH\8$0^&M5M-(DL=QN1")+=%$;M
M"/S+ RXEH8O*,/FBSF6'AC<;]95*>?8BC3A+#\,U,#?'X#!5<5C82=3-:DXY
MI'#X2CBIX_ 5:SH8'#5:G]%9Q#P\QF6\48WAM\)0QM;)\H6 >)I<$X'%UJM/
M,/$##YS;),ZS?#99D]:$,-PU0I5>&ZF-S3%Y;2R?/,-AEC,YS##T/?\ XC_M
MG>,/!W[7'AWX96'A_P .7'[/FD>)/ WPB^*WCR[%^->T3XU?%G1M<U_P'I.F
MW272:3'HME9V'A^TU\7-K-<K?^*[&-9[<P[).X^*OQU^-?B;X_W/[,G[-%A\
M.]/\3^$O >E?$3XK?$[XJ67B#7?#7@[3O$M[=6?@_P ,Z)X1\-:GH%_XB\2^
M(!IU_?W$USXATS3](TJ%9F2\N9HXD^,;G_@GA\;OB)^SW\4]6\:?&OXH>$/C
M5\5_%_BSXYW_ ,*=#USP;<_#?3/BO'K<>M?#ZSEO3X6O-<FBTB+0?"MA<W-I
MXDAC0V0%N]O;H4KVJV\)?M4_"KXR6/[3^A_!JQ^)6I_&WX'?##PC\?/A)IOC
M7P_H/B?P7\2O =C<K:ZQX6\1:F?^$:UW0S_:FHZ9J5K)<V4FV.UOK.27#P-O
M3QO%,G56887/,-E^8YCA,SJU<-1E7Q^"RC$/&TZF686E@85L7AIX=T\C6)IQ
MIK,E#%YOB*,:<J,IT>#$91X;4_J[R+,N#L?GN0Y%F7#V&H9AC(8/),XXHP"R
M6OA^(<QKYU5PF69A1QT:_&4\#B*E=\/3JY;PQ@<7.O3Q<:.+J?M*?&']OSX'
M?"./XJW6H_LQ:7-I.N^$O!>K>%U\&_$+Q1'K^H^)O&5GX7M?&&E:XOCSP\^A
MZ;=6NJ6>I/X5OM+U2]TZ6VN;(Z]>B:*ZC]A'QA_: ^%WQ6_9O^$_QBUWX3^+
MKKXOZK\8+OQ1XD\#^#O$W@^PTCPWX$^'<WBK1K;3-.UKQCXIG_M'^TK6<ZG?
MW%W+!<6#I!;V-M.AN),O]ICP#^T!^T1^RD_AN^^'>@>&OB?K7Q)^'FOP^!;#
MQ?;:K!HGACP]\1=$UQUUCQ1<VUAIESK=MH.GSW>HI81"Q^V?Z%92SD++)W7Q
MR^#GC/X@_M'?LN>,=)TR*X\%_#RR^-=KX]U.2_M[673+?QS\-K_PKHXM+65A
M<:A+=:E=+"Z6BLUM&3<RXC4FN^IALUI8ZOB,#7X@JT.3@N>%6+KX^49?6^(J
MM//O:82JHTX3AE-&A+&TWAX2P5"<JLJ="56I*7@T<QX=Q&3X++\XP7 V&QBK
M^+=/,)Y7@\CA5IO+>!<'7X,5#,\*ZE>M1J<2XK'PRFO#&UJ>;8RG3P\:V,AA
M:$*?@_A[]H']MCXX?#W7/VB/@;X<^ OASX0PWGB2?X;> /B19>-=6^(7Q4\+
M^%M0OK!M?U+Q7H&NZ9H/P]?Q5-IMR?#UB- \5-96LEI=:K,3*T2>8_$#_@I]
MXCTZP_9,^*7@?X>V-W\'?BK\/_$/Q.^.6FZJM[=^// GA/PUKNB>%?&$WAQK
M"ZM["]N?AWJFI7VJZVEQ93_VOHFD7,EFEF[AH^K^%.A?MH?L]?!6Y_98\)?
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M:IIE[IFF:;I][&)+Z%[5[R\O1'"+:**7$K0Q //*[)L#+$H8D\?86MZ9X?\
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MP/TJ:D  '\SZTM<1XH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+L/D>!>08O+\#DV25\?ET<!F69U\BJY96Q*R_,*]:C'"X_%4\4\?5I8.E0_
M[P;_ ,$\/BWI^A6$_B7XBZ-H&J20+)/H-IIM]KO]GNV"+>;4H;ZQMI9XP0)4
MMTG@CD!6*YG4!SU:?L>?$O13F+XB:1>E-QP=%U*T1L9*C#75WC=C!.3CG@XP
M?W1O/"D<F1Y2DYS]T>H/1@.,X('./?%<I?>!X7'$"\ _[.03R>>_3&#C@GTK
MPZ680M&+G55K+2M5CVV2G;\$M#^I)>+6?8RK4J8FIE[523DZ4<KRY4X<S3Y8
MREAYUK1O9.=:<W9.<Y2]Y_@WXFTKQE\.+J*P\?:+%<:7-*JV6LPK]OT:XE4X
M6/S'B1H;M0"WV>XB@F*D^6LJJ[+V6C^-M*NH(W5X&!4;0C(N , * O QV
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M(55>*DIX>O/16FES.!DVEY)I.G&WNKJ&:YGN)KN9;=V%I;M<%3]FM ^',,0
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M;6SU3;%!<7$-Q$@#PN!P.L?'C13XR\6^$_ _PE^*7Q5T_P"&VNVWAGXG^,_
M>G>')O#O@KQ#-;6=_=:'%;ZSKVDZYXQU;0].U"RO?$5CX.TS5Y=(CN(H9F>\
M)M5Z']F[PKXB\!?$7]H_PWKOPPU/P[9:_P#&#Q'\2O"_Q#AA\,GPMXM\.>+[
M;2&L])L+C3]3D\01:MH]S:WPU33]5TBTM('836ES.UPV?.OAN/C1^SEXL^,?
M@&W^!/BWXK:)\1?C5XO^*OPX^(/A'7O!UCX=%E\1KBSU+5-#^),OB'7=-UCP
MO?>$]5%Y;#4;+1_$%OJ^C+92V$(NH7M62J/FFHR3:4'!2J15T^5R?->.J3TB
MWS*[;ORLV>-Q5H7G*/O-2E"$G\+LH\K4FHRM9RZ[)V:M[K<ZE\-YO%H^'X\;
M>#3X[EM/MJ^"SX@TM/%C6QMQ="3^P)+E=5P;8B?:;<.(,S[1%^\/SC\/?BWH
MGQ*OO@U96O@N]TB3XQ>$OBCXMM'EUFWOAX?C^&7B.T\/7-A<B/3+9M3DUF2Z
M%U!<0M9K8(A@E@N2WF#RKP+^S3XLM_C'JEI\4O#O[0>KWD7[3.L_'#P_XO\
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M* "BBB@ KGO%_B6Q\&>$_$_C#4TFDTWPIX=UKQ+J$=NH:X>QT+3;G5+M(%)
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MAT?5KGQC;1V#:58QZYJ<;S_9I(Y(DUE9].F+S2S>7.%8?)S7Q2^#M]\7-/\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img57771353_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57771353_1.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* PP# 2(  A$! Q$!_\0
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MAAD>*2,J001U!!!YI3_P5<_:Q'63X6#J>?!%_P!!U/\ R-/;O7KOBO\ 9/\
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MFCK@#/O1_P /6_VL?[_PM_\ "'O_ /YJ*_-IOOR?]=9?_1CTE>TO#K@1I?\
M&)Y'LO\ F H__(GC?\1 XV_Z*G.O_"ZM_P#)'Z3?\/6_VL?[_P +?_"'O_\
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M5G^7U%%%?:'QI]X?L"?\C=^T/_V:3\:?_1?A^O@FW_X]X/\ KC%_Z M?>W[
MG_(W?M#_ /9I/QI_]%^'Z^";?_CW@_ZXQ?\ H"U\KE7_ "5/%W_7GAO_ -1,
M>?3YI_R3'"O_ %_XB_\ 4G+R:BBBOJCY@*D$4Q+*()RR;0ZB&4LA?)174)N5
MG )16 9@#M!P:=;$"ZM2Q 475L6)Q@*)XR22>  ,DD\ =:_?/7?%/A&]_:-\
M ZE\._%O@W3?"6C_ !R\2'XX64NN^'K>_P!;^(NH?!^YB^&_CA=7>^CM]5\"
MV^CEO#N@V]J5M/#?BA+\WK2WU\MQ%\EQ/Q/4X=GA8PRV>.6(P&<XV57V\J%&
MA+*:>$J0H59QPV)<99A+$K"867+9XZ6&P[C;$.I1^JX:X;I\01Q<JF90P'U;
M&93A8PE1C6J5UF<L;&=6E&>)PZ<<!'"?6L7'FO' 1Q6(3<\-"CB/P'961VCD
M1XY%QNCD1HY%W#*[D<*Z[ARN0,CD9%6KBPU"S6!KS3[^T2ZM8;^U>ZLKJV2Z
ML+DLMM?VSS1(L]C<LCBVO(B]M<%'$,KE6Q]D?M*:CKK_  3^$>C?&'Q!IOB/
M]H/3_%?Q"NM3NUU[0?%GB_2?A-=6NECPMI7C?Q'X?N]2@NKU]=35+[0+'4=3
MO=2LM(8JQMX9%C;[T?Q=X/\ #'C7]H'P=XMO=%A^'WC&+]CSX,V5E?W5E&+?
MX4>,_A-JV@V^LZ-#<2>:MAX=U/6;'Q'<WUB/)LI89+B>6+S&DKS\;QG7PN!P
MV+HY2L;5KRS!1HX7&RJ4<33P&>Y1DJJY?BOJ<?K4<5_:\,7AFZ%*%2-"I24W
M!K$KOPG!^'KX_$82OFTL%2H4\'.I7Q."5.MA98K)\TS>4<=A5BY?5_J\,JJ4
M*J5>I-/$8>HX*<G0/Q#L]/U#49EM].T[4-0N'6=TM["QNKV>1+6%[BZ>.&UA
MEDD2UMXY+BY9%9;>".2:8I%&[K4!!&0<@\@CH1ZU^V&F:SX?\/7O[*/PA^'F
MO:)K,7P5_:[\)_"\W^C7=A+=^*H+KX9PW'Q2\3R1VTAO+OP_X@\0>)/%-DUW
M*LEC)9VXM#,_EE!^.7C&WTNT\8^,+31&5]%M/%GB6UT=EQL.E6^MW\.GE,<;
M/LB0[,<;<8XKTN'N)I9]B,33> G@Z4*$<5A9U*DY5:V&J8K$TJ%6M2G0HO#2
MQ&%AAL1&BW4G3J5,1AY2;PW/4X<_X9CD>%PM;Z_#%UIU7A\73A3C&GA\5&E:
MOAZ-:%:M'%+#8JCBJ%2M'DA."PM:G'EQ"4><HHHKZL^4"OZZ_P!BW_DT[]GS
M_LEGA3_TW1U_(I7]=?[%O_)IW[/G_9+/"G_INCK^>OI%?\DYD/\ V.Y?^H&)
M/WKP _Y*+._^Q*O_ %.PI\7_ +:'_!/GXH?M*_&IOB9X2\<> O#^D'P;X>\-
MC3_$2>(6U+[7H]UK,]Q<$Z9IMU:_9Y5U*)8?WOF[HY-Z*-I/R=_PY[^.W_14
M_A+_ -^_&/\ \I*_7GXO>(=?TSQ@;73M;U6PMO[)L)/L]G?W-O#YCR78>3RX
MI%3>P50S8R0JY/ KR_\ X3'Q;_T,^O\ _@VO?_CU?FN1>(/'V79/EN!R_-,L
MI8'"8.A0PM*KE>'JU(4*<$H1G4E!RG)+>3;;>I^GYSX=<$9EFN88_'9;CZN,
MQ>*JU\34IYGB:4)UJDN:<HTX3481;O:*LE?TM^:W_#GOX[?]%3^$O_?OQC_\
MI*/^'/?QV_Z*G\)?^_?C'_Y25^E/_"8^+?\ H9]?_P#!M>__ !ZC_A,?%O\
MT,^O_P#@VO?_ (]7J_\ $3?$K_H<93_X9\-_\K/,_P"(6^'O_0JS+_P[8K_Y
M/^KORM^<VE_\$DOVC-#O$U'0_C3\.M$U&)72+4=%OO'VDZA$DB[9$CO=/TNV
MNHTD7Y9$24+(O#@BK=M_P2A_:=LH[Z&R^//@JSAU2X:[U2&TUSXDVL6J7;JZ
M/=ZG%!8QIJ%U(DDB27%XLTTB.Z.[*[ _<MG\:['4?%FK> -.^,6CZCX_T"SC
MU'7_  %I_P 1=(OO'.A:?,$,5_K?@^UUF;Q'I-E*)8S'=ZAIEM;N)(RLA#KG
MJ?\ A,?%O_0SZ_\ ^#:]_P#CU9/Q)\1*MYO-<DJ<R47)Y+@Y\RIS;47)TG=0
MJ*32NU&:;5I7-(^&7 5/W8Y=FL.5N7+'.<;'EE.$;NRJ*SG3:N[)RA)?9:/S
MK;_@DS^TH^_?\<? 3^;_ &=YN[5/B&WFC1@!HPEW:<?,&C!5&CA]PTH*/[/^
MS8&.VUK_ ()L?M::_P"!O#'PZU#XX?"X>&?"LOBR:".UE^(5O?:Z_C75K?7-
M<_X2^[%FR^)U?4K9)[0:G!)]F,D^3*\K/7V+XA^*=]X1T/5/$_BOXAW?AOPW
MH=J;[6=?UOQ%-IVD:59B2.$W6H7US<)!:VXEFBC,LKJF^1%SEA5VR^(.N:DM
MT^F^.+_4DL=0O=(OGT[Q(U^ECJVF3&WU/2;Q[2[F6UU33;@&WU'3K@QWMC.#
M#=00R@K6=3Q"X_K3HRJ9AD52>&J_6*#ED>#E*C5]E/#*M"]*\9JC5G14UJH3
M<4[6-:?AQP11C6C2P6<4XXFE]6KJ.=XV*K4O:4\0Z,[5/>C[6G"JX?S)2L?G
M_!_P2D_:?MI;V>V^/G@RVGU*TBT_4I[?7?B5!/J6GP1""WT_49HK%)+^PM[<
M"W@LKMIK:&W @BB2(!!1L_\ @DA^T7IR/%IWQH^'.G123VEW)%I][X]L8Y+N
MPD,MA=R1VNEQ))=6$K-+87+AIK*5FEM7B=BQ_1K_ (3'Q;_T,^O_ /@VO?\
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M4)*?/S1C&GB\2I05E)SBWK"-ORH_X<]_';_HJ?PE_P"_?C'_ .4E'_#GOX[
M@CXI_"4$$$'R_&.01R"/^))U!Y%?I3_PF/BW_H9]?_\ !M>__'J/^$Q\6_\
M0SZ__P"#:]_^/5V?\1-\2O\ H<93_P"&?#?_ "LX_P#B%OA[_P!"K,O_  [8
MK_Y/^KORM^?\G_!+7]K":XTZ[F_:,\-S7>D>=_9%W-XJ^*<MUI'VB-8KC^RK
MF2W:?31<1*L5P+*2 3Q(D<N]%512M/\ @E'^T]8+?+8?'OP78+JDYN]46QUS
MXDV:ZI=G=F[U-;:QB&HW1#N#<W@GF(=@7(8Y_0W_ (3'Q;_T,^O_ /@VO?\
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M2Y;O0XE4*(M%N9+)I])C" )LT^2V78 N-H K]"_^$Q\6_P#0SZ__ .#:]_\
MCU'_  F/BW_H9]?_ /!M>_\ QZN3!\<\<Y?AXX7 XKA_"X>$JDH4:.0X.$(R
MJQ4*C25+1S@E3?\ T[C&G\$8Q75C. .#LPKO$XW#YWBJ\HPA*K6SS'3FX4YN
MI"+;J;*K*=7SK3G5=ZDY2?YY2_\ !*+]IV>4SS_'KP5/.;JTOC//KGQ(FG^W
M:?YG]G7WG2V+2?;=.\V7^S[O=]HL1+*+26$2/NZSP3_P35_:Q\ 3>(I_#_QM
M^%AE\3>#_%7@F]?4W^(%^UCI7C22SFU^^T-C91-I'B"ZN+"VNEUNU870ND^T
MS">;:Z_</_"8^+?^AGU__P &U[_\>JEJ'Q#UO2+1[_6/'5]I%A'+:P27^K>)
M6TRQCGOKJ&QL8)+R^O+>V2>^OKFVL;*%I1)=WMS;VENLEQ/%&^U7Q"X_K4IT
M*V89%4HU%R3I3R/!N$HM*/*XNE9IJT;=O=VT,:7AQP10JPKT<'G%.M3E&<*D
M<[QJG&<9<\9*7M+IJ=Y)])-M:[?GQ+_P29_:5GDFEG^.7@.>6YU&+6+F:?5?
MB)-+<ZS I6WUBXEETYY)]7MT)2WU25GOX$)2*X120777_!)S]I>^U2/7;[XY
M^ [W78FADAUV\U;XB7>MPR6W_'M)#J]QITFHQ26V!]GDCN5># \IDQ7Z ZS\
M2=5\-Z5J6N^)/']SX;T+1;2>_P!:UWQ#XI70M$T:PM5+7-_K&KZK>VFG:78V
MR@M<7E_<V]M O,LJ#FL?P=\:K/XBZ(GB;X=?&#2OB'X:DNKBP3Q)X!^(6E^-
M?#SW]GY?VRQ37/#&KZKI37MIYL7VJT6[-Q;>;%YT:>8F[1>)/B)S6CFN2<ZI
MO19+@^94I<L'HJ5U3ERP@_LOEC'HDLWX9<!VUR[-N64T]<YQMI5(N4T_XEG-
M.4Y_S)SG)6YFSX;;_@E'^T\VE3:$WQ[\%MH-P\DEQH1UWXDG1+B265KB62?1
MS8_V;,\UP[W$SR6S-+<.\\A:5V<X?_#GOX[?]%3^$O\ W[\8_P#RDK]*?^$Q
M\6_]#/K_ /X-KW_X]1_PF/BW_H9]?_\ !M>__'JJ'B5XCT^;DS7)H<\G.7)D
MN$CS3=DY2M25Y-))R=V[+70F7AAP#/EY\MS2?)%1CSYQC)<L5M&-ZCM'?166
MK/S6_P"'/?QV_P"BI_"7_OWXQ_\ E)7MG[./_!,CXO\ P9^.'P\^*&O?$+X;
MZMH_@_4]3OK_ $[2$\3C4[J.]\.:UHT:6AO=)@M0Z7&I0ROYTJ+Y,<FTE]JG
MZ]_X3'Q;_P!#/K__ (-KW_X]78_#_P 3^)+WQGH-K>:_K-W;37-PLUO<:C=3
M0RJMA=NHDC>4HX5U5P&! 958<@5RYGXC>(>+RW,,+BLVRN>%Q6!Q>'Q,(95A
MX3GAZ^'J4JT(35-.$I4IRC&::<6U).Z.G+_#;@3!X_ XO#99F$,3A<;A<3AY
MSS3$SC"O0KTZM&4H.?+.,:D(N46FI*Z:LS\I3_P1[^.Q+$_%/X2_,[M_JO&/
M1G9@/^0)V!Y]Z/\ ASW\=O\ HJ?PE_[]^,?_ )25^E)\8^+<G_BI]?\ O,/^
M0K>]B1_SVH_X3'Q;_P!#/K__ (-KW_X]7:O$WQ*LK9QE-NG_  CX;_Y6<?\
MQ"WP]_Z%69?^';%?_)_U=^5OS6_X<]_';_HJ?PE_[]^,?_E)1_PY[^.W_14_
MA+_W[\8__*2OTI_X3'Q;_P!#/K__ (-KW_X]7GOCG]H[P=\+YM+M_BA^T'X)
M^&-QKJ7$FAV_Q)^+WA;P#/K<=I)%%=R:-#XM\1:/)JL=I+/!%=26"W"6TL\,
M<S(\L:LI>)_B1%7EG63Q3=DY93A4FWLKNFM7V&O"SP^>V4YD[*[MFV+>BM=Z
M3V[^OI;XJM?^"2G[1]BMFEC\;/A[8IIUZ^I:<EEJ'Q LUT[4I(UBEU+3UMM,
MB%CJ,L*)#)?6HBNY(46)YFC4*+5[_P $H_VGM2TZ+1]2^/?@O4M&MY$EM]'U
M'7/B3?:1;RQ_ZN2#2[NQFL8)(\GRWBMT:/)V%<U]R^(OC39^#]!A\5^,/C!I
M/A#PI<OIT=MXJ\6?$/2O#/ABYDU@H-'CMO$.N:Q8:/<2:N98AI20WKMJ7F1_
M8A/O7.?J?[0'AW1/%NB?#_6OCMX5T;X@>)XK:?PQX!U?XJ>'M,\=>)H+UI4L
MI_#?@Z^UZ#Q)KT%Z\$ZV4VDZ9>1W;03K;M*89 N4O$KQ#YXN6:Y'[2-2,8N6
M2X/G55WE%1;I<RJ.[E%+WG=M;MEQ\,N U!J.7YLH.F^9+.L:H.E[J=TJEG3T
M2=_=V7:WR7H__!,;]J/0? VM_#S3/C!\(;?P]KGBKP[XW:1(/'$.LZ/XI\,6
MU_8Z?K'AW5[73K>XTBZGL-2N;'47B$C7=LL"JT+PJYY9/^"2_P"TG$MNL/QP
M\ P"S^W_ &(0:I\0H18_VL&&K&R$>G*+,ZJ&8:H;81?VB&87OGAFS]=:7^UC
M\*]=E\0P:'^U-\*=;G\(Z??:OXN@T?X]> M4F\):1I<R6^J:MXJBL/%MQ)X;
MTO3+B2.WU+4=:6QLK"XDC@NYX99$0]IX-^-%K\1]&C\2?#GXO:7\1?#<UW<:
M?#XC\ ?$'3/&WA^;4+0QB[L(M;\+ZOJNER7UJ98A=6:7;7%N98Q-&AD3,4_$
M;C]3K3I9ID3GB9+$UI0R7!MUI*E#">WG:F^;]U2A0Y]FH\C=[IZ3\->!W&C3
MJ8#-^7"Q>'H0EG.-2HQ]M/&.C!>T7)^^K5,1R*S4ZDJEDVFOC3QO_P $O/VF
M/B#)X5;7_BI\%([?P5X*\/\ P_\ #6GZ3IOC#3M/TWPWX;CG6RA2V&DS;[V[
MN+J[U'5;TN'O]1N[BY9(PZQIQ'_#GOX[?]%3^$O_ '[\8_\ RDK[OA_:#\,W
M&@>*/%EO\>O"-QX3\#WU[I?C?Q7;_%CPU/X7\%:IIKI'J6F>,?$47B!]&\*Z
MCI\DD<=]8:]>Z?=VCR(EQ#&SJ#V%AX_U[5;&RU32O&^HZKI6IVEOJ&F:KI?B
M)]2TS4]/O(DN+._T[4;*[GLK^QNX)$GM;RTGFMKB%TEAE=&#&\/XD>(="E&E
MALUR6G2BE.,*638102K2G54[1IV_?2<ZG._XDG.=Y-MD5O#/@.O4=7$9=FM2
MJU&FYU,XQ;E;#PIT8T]9Z*C3A3I*"LJ<%&"44HI?G!_PY[^.W_14_A+_ -^_
M&/\ \I*/^'/?QV_Z*G\)?^_?C'_Y25^E/_"8^+?^AGU__P &U[_\>H_X3'Q;
M_P!#/K__ (-KW_X]6W_$3?$K_H<93_X9\-_\K,O^(6^'O_0JS+_P[8K_ .3_
M *N_*WS7^R)_P3F^*W[//QY\,?%;Q1X\^'NNZ)H>D^*-/N=-T!/$BZK-+KNB
M7&F6SP'4=+MK3RX9IEDG\R96\H'RPSX%?L37R=\*O$?B'4?&VG6FH:[J]]:O
M::DSVUWJ%S/ [1VCLC-%)(R,48!E)&58 CFOK&ORGC;/,[X@S>EC<^Q.'Q6-
MA@*.&A4PV&AA::P\*V)J0@Z=.,8N:G5JMSLVU**;]U)?I/"&19/P]EE7 Y)A
MZV&PD\;5Q,Z=?$5,3-UZE'#TYS52HW)1<*5)*"=DXMI>\PHHHKX\^I"BBB@
MHHHH ^>/VL/ACXG^,W[//Q/^&/@PZ8/$_BW1[&QT@ZS>2Z?IGGV^O:3J,GVN
M\AM;V6!/LUE-M9+68F38A4!BR_A3_P .H?VKO[_PJ_\ "UU3_P"9.OZ*OB%?
MWNE^#->O].N9+.]MK6)[>YAV^9$QN[="R[U=<E&93E3PQ[\U\F_\+%\=?]#1
MJ?\ Y*__ "-7ZQP'QKQ7PWE6*P60U,IAA*V85,556/PM:O5^L2P^%HR<)4ZD
M$J?LJ5.T6F^92=]5;\TXTX(X9XFS+#8W.H9G+$T<##"TW@L32HTO81Q%>JE*
M,Z<VZG/6J-R32<>56NC\A_\ AU#^U=_?^%7_ (6NJ?\ S)T?\.H?VKO[_P *
MO_"UU3_YDZ_7C_A8OCK_ *&C4_\ R5_^1J/^%B^.O^AHU/\ \E?_ )&K[?\
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MKK+;QQXO?P-J^HMX@OS?0>*-(LX;H_9_-CM9]/NY9H%_<;?+DD1';*EMRC#
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MCX3Y#.X/_"9ZED/(,.P/_")?><<.W5AP2:_7P?$3QV2 /$^J$D@  6Q))X
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MHP>2(_&6I("1T)V^$AG'O7Z^?\+%\=?]#1J?_DK_ /(U'_"Q?'7_ $-&I_\
MDK_\C5?_ !%;Q'_Y_P##?3_F7XKR_P"G_2[^[S(_XA)P#>_LL_OW^OX>^MK_
M /,/_P /;T/R'_X=0_M7?W_A5_X6NJ?_ #)T?\.H?VKO[_PJ_P#"UU3_ .9.
MOUX_X6+XZ_Z&C4__ "5_^1J/^%B^.O\ H:-3_P#)7_Y&H_XBMXC?\_\ AO\
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M5BTI(_W;_P"%5^(, ?VUX3P.@_MU\#Z?Z'Q0/A9X@ (&M>% #P0-=< CT/\
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M^3:/^%4:9_T/5A_X)[G_ .3:ZO[5P/\ S]J?^$V*_P#E/FOO,OJ.)_Y]Q_\
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M"]CX<\7RZ88:],_9"\)_%OPE\8?VRO#'A?2E\ _%7Q'\:OVH/%?PPUOXQ?\
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MJ\VEZKI,E[XF'=_\$J_ACKOP]\5>/WNO@C\0_ .E?\*#^"G@JZ\3?$/X!O\
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MZV*I0H8>E3]O]74444P.G\'_ /(=M_\ KE<_^B'KV&O'O!__ "';?_KE<_\
MHAZ]AKQ<P_CK_KW'_P!*D=^%_AR_QO\ ])B%%%%<)TA1110 4444 87B;_D!
M:C_UR3_T?%7BE>U^)O\ D!:C_P!<D_\ 1\5>*5[.7?P)_P#7V7_I$#AQ7QQ_
MP_JPHHHKO.4*X'Q=\5?AA\/]1TK1_'?Q"\'^#=5URV6]T?3_ !+KMEI%UJ5D
M_B7PYX-6]M([N2/S+,^+O&/A+PR;HE8%UOQ+HFGM(L^HVZOWU?GY\8?@]KOQ
M]_:MO]"\8?"'Q4GP)T']C'X[?"3Q#\1=6OO"]MX7\>>)?CCXH^$NM>'=$^'0
ML-?O?%R^)/"'_"O]9U#6]1UGP[X?M_#.L6OAN_TG4-4:]MY8,YU'!Q?)*:Y,
M54E&*]Z7U? XK%0IQE9QC.O6H4\/3<D[SK148SDXQ=1BFG>2C[^&@F]5%5\9
MA\/4J.*UE&C2JU*\DG%*-)N4HQ4I+WWXK?M<_LK? B9[?XU_M&?!KX3SQ^+?
M^$"EB\?>.]%\-M#XW'A_2O%DGA.8W\\:PZ]!X6UW1?$=U82E);/1=6T[4;OR
M+:[AD?U"3XF?#:'QAX.^'C_$'P5_PGWQ#T#5/%G@'P5'XFTB;Q3XU\*:';VE
MWJ_BCPQHD%U)?ZSX=TZUOK*XN=;LH9=,6*ZA=+EPXK\$_BS^S!^U+8_ /_@G
MSJ"^%/VN;CXOCPW^U!JO[9OBS]FWPW^S5X[_ &@%^*W[2?PTT/1?%.H>+=*^
M/-Y'\*Y]'\4:I!/X=U?4= $M_P"&=$T?1K'PU=Z5:VD-S'[SX/\  OQD\!?&
MC_@EQI7B#]B?XBC4_A!^SQXA^%W[1/Q9^"&B?#>Y^$7@>;QW\(/#/PH\%^%I
M_'&J?%#3_B%J>E_#%=!O)_%ITS1]?L/"T%]+>^#[KQ+]I-)SDI8BG[LZE*K1
MH4M7"GB*\\+C)5/9U+32PZQ6'H>SQ$[.5#%0C.A3J*G.O+:M2DKQA4A4JSNE
M*5*E'%8.%-SC>'[V6'Q%=SH*_+5P[<*M2#JJA^F&B?M4_LP>);;XM7WAW]HO
MX(ZY8_ -YT^-]]I?Q,\)W=E\)?LS7*3R>/KN+4S;^';>.:SO+7[5>R):O?VE
MSIT<S7]O+;)8A_:<_9ON/@Q%^T=;_'KX23_L_P SV\<?QIB\=:%)\-3/=:Y%
MX8M[1_%2W9TV*^D\23PZ#_9\TL=]'JTJ6,UO'.2H_!+1?V&/VIH[.WUO1O!7
MQF\0_"_]E#1?@SX ^$OP2^+_ ,/_ -FOX6_$_P",_P ,OA/^UQ\,?CEK?PTT
M6?X=?$#Q9X<^*EI9>#?AS>W?A;XC?%O6/ 1^('C37H(H?#.AWU_XF\0:AM_M
M-?LB?M]_&WX)_M8^,/A7\%OAEHOAGX__ !%^/_QL\,?LE_'KQ'JOA[XT^&O&
M7C;X?_"_X7>#/&=MIWPF3QC\)Y/B3<Z/X/\ '?BFT\)>*?&Z67AKQ+\1)]=U
M77;GQ!;))ILQJR=*%1J5Y4:U5P]FU.*I8G#0H<T(N:4LPPM:M5I4HSJ+"5<)
M4IU:^)HU(XJ'0J4'7C2=6*A+%4:#J*47&,*N'J3JU$Y<G-#!XB%.E4J/E]M3
MKJ<:=&M2>&J?NE<_M._LWV7QM@_9JO?CS\)K+]H>ZL[2_M?@E>>-]$M?B9=6
MFH:4=>T^2U\*SW,>H7#W^A@ZQ8VT*/=WFF*U[;02VZLX]QK^?GQ_^SY^V1K?
M[>5_XN_X5I\6M1T+5OCW^PK\<Q%HFE_!*]_8.U'5_@Y\)/"'@SXL>+O%WQ#\
M67FD_M5:;XO^'+'QD?A1HOA6QM].U[Q'I'@]_$7AG5+:\U01?T$R;/,?RRQ3
M>VPN '*;CM+ <!B,%@.,YQQ6M-\U)RD[3CB:U%Q5DG"G2PTU424I>ZZE:M0C
M)2DJCP\JEZ<Y3P]#DC-R</=<8RPU&L[WO"I4G7C*D[J.L:=*E6:<8RA[=4VI
MQC"O791115%A6W#_ ,B[>_\ 87L__22XK$K;A_Y%V]_["]G_ .DEQ6=3:/\
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M3+C6;JV2[N1YL33F/,-G'+'+>2V\4B.;?Q9^-7P=^ O@R7XC?&[XI^ /A)X
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M]6]?\SBO^$%TO_GZO_\ ONW_ /D:C_A!=+_Y^K__ +[M_P#Y&KM:*?UO$?\
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M_P#(U=K11];Q'_/V7X?Y!["E_(OQ_P SBO\ A!=+_P"?J_\ ^^[?_P"1J/\
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M4?6\1_S]E^'^0>PI?R+\?\SBO^$%TO\ Y^K_ /[[M_\ Y&H_X072_P#GZO\
M_ONW_P#D:NUHH^MXC_G[+\/\@]A2_D7X_P"9S.F>%K'2[M+R">[DDC5U"RM"
M4(D0H<A(4;(!.,,.>N>E=-1164ZDZDN:<G*5K7?9=/Q+C",%:*LKWMY_T@HH
MHJ"@HHHH **** ,C7K>:ZTB]M[>,RS2QH(XU*@L1+&Q +%5X4$\D=/6O*_\
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MUW_H'2_]]P?_ !VC_A&==_Z!TO\ WW!_\=KVNBC^T:O\E/[I?_)!]5A_-/\
M#_+U_I:^*?\ ",Z[_P! Z7_ON#_X[1_PC.N_] Z7_ON#_P".U[711_:-7^2G
M]TO_ )(/JL/YI_A_EZ_TM?%/^$9UW_H'2_\ ?<'_ ,=H_P"$9UW_ *!TO_?<
M'_QVO:Z*/[1J_P E/[I?_)!]5A_-/\/\O7^EKXI_PC.N_P#0.E_[[@_^.T?\
M(SKO_0.E_P"^X/\ X[7M=%']HU?Y*?W2_P#D@^JP_FG^'^7K_2U\4_X1G7?^
M@=+_ -]P?_':/^$9UW_H'2_]]P?_ !VO:Z*/[1J_R4_NE_\ )!]5A_-/\/\
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&O+LD?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img57771353_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57771353_2.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #N >(# 2(  A$! Q$!_\0
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M$^I:W?P>%_"7C6RT[Q!:>"HFN$_X1K5[JRM8_%UDQ\8V]O;0^(%MXOZB\6?
MGP<X+^ACX/>*64YO4K^-'$_'69Y#Q=A,-'-L?E,L!A,/G&(E2P>94,VQ_"KA
M@:%/(:\,SRV>)I9]_:DU@%AO[-S*E2^AP.9YAB.(LPP52FEEU'"PJX>4O9PJ
M<\G35Y0=.->\FZJ<)\KI>S]_FYX,_66BBBOX*/J HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFA@*6.?U_P#L;#_6IU,54GB/[-P?UOVOL,+*/05_/;_P7B_X)E_ S]MGP/X
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M-1ET:PO4LD.^Y:)>:_&?_@X@^!'A;XJ?\$Y_B/\ $'75\=:OKWP0UKX9>)_
M7A30/%7BVQ\(7OBK7OCE\(=!_P"$D\6^!/#E[;:7\0-2\,:+)JH\*1>*[+6=
M,\,SZMJNL66G1ZD8+ZT_,O\ X*0^&-(N/^"BO[2OA#Q/\-M<UW]KOXY?$_\
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ML-:N-"\-WGAY>=<MM9O[*;21S?I;BOXH/#WPX\;>*OB+X[^%?P ^&/C/3O\
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M ."VW_!&;5O^"J,_PAUKP)K?PZ^&WQ"^&.EZSHR_$WQ5JWBXZA<>']5U2UU
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M9ZXEYA4=7G]L[J2NU5FE_-K_ ,%']./AW]H#X_Z'X%USX!^*_CU^TO\ ![X
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M*VA#N=J*99G1 SL0JJ6RQ. ":R_^$H\,_P#0Q:%_X-]/_P#DBO@'_@JDBO\
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M$J?V4"5)^+GQ%)4[E)\8> "5;!&5)\)<'!(R.<$CO2_\.JOV4O\ HKWQ&_\
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MGSXA2QA4MA\/?VF+;3_#.CW&HS[#Y<&G_'7PU\$VBDF9((8KR_!DC,Y+?L_
M'^W8KB'AA[\6\+YIEF%2LZD\WRN>&XJR'#8:#C)2Q>:YSP]@LBI6Y9N&;5H1
MG'VDK_58KW8T:W_/BO"<NRISYJ%64GTC"G6E5?\ U[3Z'VW1117P)U!1110
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M_!4G]IVY\*_LE_$3X<^-/"/C#PQXE_8J^%W[1OQMU/P1^SA<?%7X2ZSXMO\
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M/"0]K[*FX3^MRH*C*"5/GY7&I[1J<(5.2E52INIR4Y_J]_PB7@3_ * 6J?\
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MDHSC**;YDN91:'[U.K2>L*U/V=3I)PYXSM&2M*#;@KN+3<;Q;<9-/\-OB_\
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MSK,7[7?@.PBU?5=+\(:3I%CJ&IQV,4=FE_=P2W:VL<=N)O)1$7]_*_%_6_\
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M5JUJEN5P<;1:Y73@J=-JTM'3@N2#5N6"48V6B_*[Q#_P3S_8I\5?\*QCUSX
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M^:RYKV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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JX]#^G^-&\>A_3_&@!]%,WCT/Z?XT;QZ']/\ &@!]%,WCT/Z?XT4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img57771353_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57771353_3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '* XT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH R-=\0:#X7TR?6O$NMZ1X=T>U,2W.K:[J5EI.F6[3R+#"L]_?S6]K
M"9IG2*(22J9)'6-,LP!X%?CM\$&957XR?"IF9@JJOQ#\(EF9B JJ!JY)9B0
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MKW@$6>G3ZK=-XCMH;B]M/L2V%K=W5OJNF7NH:7>1VEVEO=O<V=Y;V_P#K/\
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MSNH?%9IM7CUC\2[!'$T)+F52+2E&+W5G+X;II-*725K/N?H#17P[^V9^W?\
M#?\ 8N'PTM/%_A;Q=XZ\1_%75M4TOPQX6\$#1I-8=-)&FQW-]-'J^I:='Y#W
MNL:986R1/)-<W-PXB1A!+C[8L;B6ZLK.ZN+26PGN;6WN)K&=HWGLI9H4DDM)
MGB9XFEMW9H9&B=HV=&*,RD$Y.$XPA-QM"?,H/3WN5VE97OHW:]K7-5.,I2@G
M>4.7G6ON\RO&[VU6MK['G$_QQ^"MK/-;7/Q?^%UO<VTTMO<6\_Q \)Q3P3P.
MT4T$T4FK+)%-#(K1RQNJO&ZLCJ&! [+P]XK\+^+K)M2\)^)- \3Z<DAA>_\
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M/1[AY8X-5T'4[+5]-G>"1HITAOM/GN+61X95:.54E8QR*R. P(KX=_X*C?\
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MWU;>B2NV:JM2:IM35JJ<H/7WHQ7,WMHDM6W9(_0>BOQ(;_@N/\#3JESJUO\
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MX+R&8>8G[J2%9#N&%-?@S^R7XD^)_A/_ ((A_%;Q'\(9=1@\=Z=?_$B2TO\
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M6;73O$&F7.E7L^E:@(YC9:A';7<K6ET(I#;SA)0C%0*_)0?\$+/V(@S,)?C
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MMVW_  4 _P""ARZ>\<=^UY\1%LI)E+0QW9^,%Z+9Y5&"T:S%&D4<E00*H_\
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MFC);:AK$-X\<UYHD^DP7VGPR/YULTEMJ%LF)&DC/67_[;?[#/PW_ &)?B_\
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MY_P4,_8\M#J<.F_%?3;*+X0W42E(;+2_$^H06L>IB[!D>&XN/A1XHO[*[O\
M<JMK7ARW@)CEAC6OO'XF?LU^)_V>O^"'^M^%M'L+BW\:^*XO!'Q8^+"I%LOO
M)\4>,?#.I7EE>K!\ZIX<\-Q>'M)OD8ND:Z5>SRA/,F8?JO\ M%?\$^?V</VH
MOBEX'^+_ ,5=$UR[\6^!;/3-,MAI&J6^GZ9K^E:/K4^NV&F>)K233KN74K.*
MZO-0@*0W-G(]E?W%NTI @:'[&\0>'M"\5Z#K'A;Q+I.GZYX<\0:7>Z)K>B:G
M:Q7>FZII.HVTEG?:=>VDRM#/:75K+)!-"ZE7C<J12J8Z+5"48MS52G6Q-UI4
MG2C",;/LTFWII)WUL.&#FG7C*2Y'3J4L/9M\D*KE*7,K))IM1TO=+IH?R^_!
M7PS^TKXK_P"":UK:K^U'^R;X(_95O_!6O^%_%6F^)O#5]/XC\*R:GKVH)JFF
MZ]<Z7X0U*_'C4ZW<&_T]K4W6JS3SZ=J.F>=OLYS^PW_!+3X;I\*_V0O"?A*Q
M^*_@KXR^'HO%'C+4/#'C+P!-JMQX<.DZAJQENM*AEUG3]+OOM=AXA&N?;HGL
MH1;W$SVY!EBDKQ.\_P""(7[$UUXEGU>.+XJV/AZYU#^T9?A_9>.PGA3S/G_<
M)--H\_B=( 'V*P\1?;(XQMCNT/S#]6/!/@GPG\./"7A_P)X%T'3O"_A#PKIE
MOH_A_0-*A\BPTS3K5=L4$*$O([,Q:6>XGDEN;JXDENKJ::XFEE><5B:52G*%
M)MJ=9U6O8TZ2CHTN9Q<I3GJ[RNDUT*PV'J4YJ51)<E+V47[6=1O6-[)VC&%H
MZ1LVGL['X+_\%$R1_P %6?\ @G@1U%[\.O<?\E<U?@@\$'H0<@C(((.*^*_^
M"DGP=\;?\$_?CC\4/B%\(; +\!/VQ_AW\1/ 7B/00)DT31M6\8Z;,OB;PX8X
M4\BSFTS59;3QKX*?:K16C7^AV:QV.FZB\O\ 1E\7?V,O@]\:_CG\)?VA?&3^
M*U\??!>31Y?!ZZ1K4%CH;/H7B&?Q-8'5=/?3KF:[ U*YE$XAO+47%L5@D!"A
MJ]"_:(_9X^&/[47PNUGX1?%G2KC4_"NKW.GZ@DNGW"V.L:1JNE7*W-CJNBZ@
MT-Q]AOHOWUK))Y,L=QI]W>V%Q'+:W<\;NEC(4GAE9RA&FZ=>-MTZCFG'NX.T
MD]-4U=7N14P<ZCQ$DU&<JL:E&:;NK0C&49::*5G%K5;/6UC\6/V!?VAY?V6O
M^"2#?&L_#N_^)VG^&?B7XLM]:\-:=J4>ER)I>N>)+'1Y=3N+F73-7!L+.YO;
M5;Y!8RA+6>2XE:.W@F<6_#7[,_\ P2O_ &]_A!;?'BSA\+?L[>+M:L-4G\;Z
M7X+^)6C^&+CP)XD264ZBNL^&=>AA\,B.)PFHV>I6_A71[75;"ZBND.)WV_KQ
M\"?V4?A#^S[\$[K]GWPCIFH:[\,]0E\1OJ>C^-KFU\0-JEOXK4QZUI]^18V5
MM<:?<PEH/LS6H'E,P=G=F<_!?B[_ ((=?L1^)=>N]:TN+XI^";>\O9[U] \+
M^-;:31;=[B4RR060\1Z#X@U.VM@&:**/^TY#%"1%&RHD:JUB:#J5IJ=>A4G6
M<X5J>O-3?_+NI3YTM'=IV>KUT6K="NJ=&'LZ-:$:,82I3:CRU$DG*$^1NS6C
MVV5E=W7YZ_\ !(B[\8Z]XI_;:_9.\'_$"\\?? EOA]\1++P;KTYG308=:U75
M[GP9X?\ %&E13B5](C\:Z-?7FJ7MG;L$OO[/BNVCEFL)97ZC_@B7\</!GP&\
M0_M"?LO?&K6]-^&7Q F\=0:WI-CXPO[/0[6]UK0K:\\-^+?#T=_J,MK;_P!L
M:>=,T^>VM'E#:A;I?260D^R2;OWC_9P_96^!_P"RAX/NO!7P2\'0^&=/U.[3
M4-=U*YN[K5O$'B*_B61(+G6M9OY);JY%K'++'8V<1M].L$EF%E9VYN+@R^#?
MM/\ _!,[]E3]J_Q"WC;Q]X5UCPY\0)HHX+[QQX U@>'M:U>&%((8AK=M<6FI
MZ%JUQ%;V\=K'J-YI$FJI:JML+[[/'%$A/%T*L\1"<9PHUU2_>**=13I)>_**
M=GS:\R3;VZMVF.%KTH4)PE"56C[2\)2ER.%3[$9<M_=VBVEW>VODW[0W_!5#
MX>_"7]HGX4?L]_"WPI;?M#>(?'%];Z3XK7X?^+K![GPIK&O:C8:;X5TFSF@L
MM3T;5=6NI)[B[UG3[K4]+71]/:PN;R\MQ<D+\ ?\%--1T_2/^"K/[$>J:O?V
M6E:9I]O\&KS4-1U*[@L;"PM+?XQ^));BZO;RYDCM[:VMXE>6>>:1(HHU9W95
M4D?J[^R]_P $T_V5_P!DWQ&?&_P[\+:SKOC];9[2T\;>.]:/B#6=*@FBGM[D
M:-;P6NFZ)I4]W;W$EO<WUII*:B]LS6@O%M9)('7]JG_@F_\ L[_MA>.]%^(?
MQ<?QVOB#0?#-KX4L1X7\26ND6(TNSU+5-5@:2VN-(U%C="ZU>\WSI+'OC,2,
MG[I34TZV$I58\BJ<BHU*<ZK5YU)5$US<G-RQ4;V5FFUO>UW56CBJM*7,Z?.Z
MU.I"FG:$(P:;BY\O,Y-IWT:[>7TU_P -"_ +./\ A>/P?STQ_P ++\%YSZ?\
MAJOYZ_\ @J-<W?P#_P""B7[)_P"V/>02ZM\)[VV^'ES+K>D+_:%M.O@GQ)<W
M7B6VLKJ 2VDT]SX1UO3=2T:-)#_:)FEDMW>**5XON-?^"&?[%"LK+=_&0,I#
M*?\ A/+ X8'(.#X9(." <$$>H(K]&?&?[-/P:^(_P5T?]G_X@^#[3QG\-="\
M.^'_  YI>FZY)))J-E#X7TF'1M%U2RUBT-I?Z?KUG9PA5U;3I;.Y)EN$S]GN
M9X'BE5PV'J1G3E5JQE&=.K&4(P:IS23<'SRO+K9\JTM?5M74IXC$4Y1J1ITI
M1E"I2E&;FN>+O:2<%9-:72;UO;2S\J^,W[>'[-WPI^ ^O?'*S^*OP_\ &&G1
M^&I]4\%:+H?BW2+S5/&VN7-B\V@:!IVGV]S+J<<^H79ACU!I+)9-%M!=WNHQ
M01V4X6W^P]^U3?\ [8OP.LOC+>?#'5?A?!>:YJ6A6=AJ&L6^MV>NC1X[6._U
MS0;V.STZYDT<:G+>:0OV_3[6X74-+OX@)HH4N)?CG1/^"'/[$.D>)8]=NX/B
MGX@TV"]CO(?".L^-X/\ A'E$4RS1V<CZ7H>FZ]+9@+Y3(VM"=XBRM<$DL?UI
M\*^%?#?@;PWH?@[P?HFF^&_"WAK3+31M!T'1[6*RTS2M,L8E@M;.SMH55(HH
MHU Z%G8M)(SR.S-G5^J1I\M'VE2HY<SJ37(H0M\"BI-2;>\FK*WN[FE+ZU*?
M-6]G3@HV]G!\_-)V]YR<4TEK9)]=6S?HHHKE.D**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "LZ]T?2-1FM;G4-+TZ_N+
M%_-LKB]L;:ZFLY.OF6LL\4DEN^?XXF1O>M&B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **^7_ (V>)OBS)\4/A!\+/A9XR\-^
M 9/&^@_$_P 2ZWXBU_P2WCJ0Q>!1X*AL=+L=+/B/PW#;"\D\53SW-[)<SNHL
MX8HX )7<4_\ A6_[6_\ T<]\/_\ Q'.#_P">I6B@K1;J0CS)M)JHW9-QUY82
M6Z?4CGUDE"4N5I-KD2NXJ5O>DGM)=#ZLHKY3_P"%;_M;_P#1SWP__P#$<X/_
M )ZE'_"M_P!K?_HY[X?_ /B.<'_SU*.2/_/ZG]U7_P"5!S2_Y]S^^G_\L/JR
MBOE/_A6_[6__ $<]\/\ _P 1S@_^>I1_PK?]K?\ Z.>^'_\ XCG!_P#/4HY(
M_P#/ZG]U7_Y4'-+_ )]S^^G_ /+#ZLHKY3_X5O\ M;_]'/?#_P#\1S@_^>I1
M_P *W_:W_P"CGOA__P"(YP?_ #U*.2/_ #^I_=5_^5!S2_Y]S^^G_P#+#ZLH
MKY3_ .%;_M;_ /1SWP__ /$<X/\ YZE'_"M_VM_^CGOA_P#^(YP?_/4HY(_\
M_J?W5?\ Y4'-+_GW/[Z?_P L/JRBOE/_ (5O^UO_ -'/?#__ ,1S@_\ GJ4?
M\*W_ &M_^CGOA_\ ^(YP?_/4HY(_\_J?W5?_ )4'-+_GW/[Z?_RP^K**^4_^
M%;_M;_\ 1SWP_P#_ !'.#_YZE'_"M_VM_P#HY[X?_P#B.<'_ ,]2CDC_ ,_J
M?W5?_E0<TO\ GW/[Z?\ \L/JRBOE/_A6_P"UO_T<]\/_ /Q'.#_YZE'_  K?
M]K?_ *.>^'__ (CG!_\ /4HY(_\ /ZG]U7_Y4'-+_GW/[Z?_ ,L/JRBOE/\
MX5O^UO\ ]'/?#_\ \1S@_P#GJ4?\*W_:W_Z.>^'_ /XCG!_\]2CDC_S^I_=5
M_P#E0<TO^?<_OI__ "P^K**^4_\ A6_[6_\ T<]\/_\ Q'.#_P">I1_PK?\
M:W_Z.>^'_P#XCG!_\]2CDC_S^I_=5_\ E0<TO^?<_OI__+#ZLHKY3_X5O^UO
M_P!'/?#_ /\ $<X/_GJ4?\*W_:W_ .CGOA__ .(YP?\ SU*.2/\ S^I_=5_^
M5!S2_P"?<_OI_P#RP^K**^4_^%;_ +6__1SWP_\ _$<X/_GJ4?\ "M_VM_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=)0DU)+G:J1E:-DT#J8C67L[? N7EFWISJ=DGRWYXWBVXQ=.4;RU3/MKQ_\
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MO^%#_KY5_P#2:)K'^+4_PT__ &\****S- HHHH **** "BBB@ HHHH ****
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M_P#M%_\ 1H?B#_P]/PC_ /EQ1_PM_P#:+_Z-#\0?^'I^$?\ \N*^I**.>/\
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M>0<C@X/(]#P?>OACP;^UM\1;7XW?#[X(?M ?L\:C\%=7^+^F^)[WX6^(M/\
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M5/VM2-.[7-?5+F>B;TC=7;M9*ZN^IG5G[.$IV3M;1OE6LE'5V=DKW;L]#]=
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M*5K7NFM[23<9*^E[235^MKA1114%A1110 4444 %%%% !1110 4444 %%%%
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MPKP(?L3Z2 0/VE/VQ &&& _: UH CT(_LKD>QI!^Q-I(.1^TG^V&".01\?\
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MY/F!A_8FTD@ _M)_MB$#@ _M :T0!UP/^)5QSZ4G_#$ND?\ 1R7[8?\ X?\
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M2?,KSDYNS[)R:7DD+12<^@_,_P"%'/H/S/\ A6)J+12<^@_,_P"%'/H/S/\
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MO@Y9:Q>WMK!=?%'Q->?$CPM?KI0V:?X>T;5M)U'Q%J.GIJUDC_?5?F]\1O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#XA7?BKQIXA\6:?I7A34O$EV'\+:E\-['Q7X>\'Z9X)GO/AY=:I?0:=?^/\
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M_=P-*V ?K;2_C'\-]:_X17^S?$J7/_":ZAK.E>&?^)5K</\ :=_X?+#5X/\
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M'(R#XR?#9E5QXE3:_C7_ (5VI_LO6QGQB"!_8^#IN1U'_$P(&E\C_3J].HH
M\SD^,7PWC$Q?Q(BB#QLGPZE_XE>MG9XRD)":.<::<Y*D?V@N=+&.;X4V7XR_
M#:".\EE\2JB:?XSA^'MVW]E:XWD^+YR1%I&%TPE]Y!_XF$8?2UQ\UZ*].HH
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M-87M[JIT3PK86FG6=S%I]QK.HWNHYUR^UR[T])8M)T>ZTW0[:WTR/R3XM?\
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MH?YK0 M(>J_7^AI:0]5^O]#0 M-*(3N*J6VE<E03M.<KDC.TY.1TY-.HH 0
M* J@!0      !@  <  < #@"OS>U;XD^)_@_^SU^W!\3/!;Z?'XI\'?'7XIZ
MMHKZK9G4-/6\5_!=N#=V8FMS<1>7/)^[$T?S;3NXP?TBK\H/C/\ \F=?\%"?
M^RQ_%7_TI\"UX7%%>MA>&>(L5AJLZ&(PV19O7H5J<G"I1K4<OQ%2E5IR6L9T
MYQC.$EJI)-;'F9W5J4,FS>M1G*G5HY9CZM*I!N,Z=2GA*LX3A):QE"24HM:I
MI-'YP'_@J[^U\ 3_ &A\,^!_T(TG_P NZ_;+X'_M6>#+S]G_ ."OQ ^/OQ/^
M&O@;QG\2/![:_+%K>O:-X.M=4EM[Z:UO)]'T[5M221K6WS;1S>3).L4DJAW!
MD45_)4W0_0_RKW;]OV**7X!?\$Y_,BCDQ\#O'V-Z*^/^*JT;IN!K\B^BE7S[
MQ)\2<3PUQ#Q)F^(P57A[,,7!UZ\L7[&OA*N&JQJ4Z5>?(IRBITG*Z:A4E8_D
M?/?&'B7P^X3XIXQE*?$E7)\%E:H99FN-Q$,).IF/$63Y5*JYTE.<)TJ6-J3B
MXQ?,URNT9,_JXT3]IW]G+Q+K&F>'O#WQV^$FN:]K5[!INCZ-I7Q!\+W^IZIJ
M%TXCMK*PLK74Y;B[NIW(2&""-Y)&(55)XKW.OX./V(+6W7]LS]E@QV\*M_PO
M3P" 5BC4Y_M52,$*#]X CT(![5_77XE_X*/_ +$?@[Q'K_A'Q-^T)X0TCQ'X
M6UG4O#VOZ5<67B9I]-UG2+N6QU*PF:#0I86EM+N&6"1HI9(RZ-L=EP3_ &;Q
MSX;8CAO,L%E^1QS7/GB,!+&UW1R^=:IAU]8G0BI0PD:O+"3@[2FHW>B/I_ _
MZ2&7^(_#>=9]QO4X5X#67Y[3R; K%Y_0PF'Q[EE]#&U'3K9O5PO/6IJLE*G1
M<^6%I223N?;E%> ?!#]J;X ?M(2>(XO@A\3-$^(4GA$::WB-='M]6@.E+K'V
MO^S3/_:>G6 87?V&[$?D^;@P/OV_+GW^OS3%83%8&O/"XW#8C!XFGR^TP^*H
MU,/7I\\(SAST:L85(<\)1G'FBN:$HR5TTW_2F5YME>>8&CF>2YE@,WRW$^T^
MKYAEF,P^/P-?V52=&K['%X6I5H5?9UJ=2E4Y*DN2I"=.5I1DD4445SGH!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM[;,2(?L\#33-##GRXFED**I=LW** $/3\5_F*6D/3\5_F*6@ HHHH ****
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M)SO3]I3I\SY?Z=:*_BXA_P""M_[?LD,4A^,VC9>.-S_Q;3P-U9 3R-* ZGL
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M-*()CEC="5)!*Y4D$$_C-^SC_P E]^#?_8_:'_Z')7D_B7_D,^)_^P]XB_\
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M!.J:^-'\4BWM?%&MZ;>ZQI>DM ="%X\UWING7ETLL=N]LB0,LDR2%4*^$?\
M@HI^QIX[C\72^$_CAH6L1^!/!NK_ !!\5M#H_BF+^R/!^A3V5OJVM3"YT*$S
M06<VHV4;PVPFNG-POE0. Q7^3;P__P H_?BW_P!G>?![_P!5AXRJS^Q_SIG[
M8^?^C(OC#_Z?O!%=]7P;X<IX3.*ZS#.G/+\SIX*BG6P7+.E-9:W*HOJ%W/\
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MB#7\IWB+_D9O%7_8U^*/_3_J-?Z([_<;_=;^1K_.X\1?\C-XJ_[&OQ1_Z?\
M4:_:?HK\)9'P?AN,<OR'#5<+A<17RC&585<3B,5*6(E3QM"4U4Q-2K.*=.A2
M7(I**<6TDVV_X?\ IR9!EG#N6^%V#RJC.AAZV.XWQ-2-2O6KMUI8?@^E*7/6
MG.:3A1IKE3Y4TVDFW?[L\)?\HLOC5_V>C\,?_4#2OSROO^/.Z_Z]YO\ T6U?
MH;X2_P"467QJ_P"ST?AC_P"H&E?GE??\>=U_U[S?^BVK^E>'?X_$?_938O\
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MX"_\FER;_LI^+?\ TUP\?<WCC_E'9^SS_P!G%_%;_P!-VH5\=^&O^1H\)_\
M8V^%O_4@TVOL3QQ_RCL_9Y_[.+^*W_INU"OCOPU_R-'A/_L;?"W_ *D&FU_&
MW$O_ ",<A_[)GA'_ -4F /WG.?\ >LI_[$?#W_JLPAN_\%0O^3]OVA_^PUX3
M_P#4"\,UM_\ !.__ %W[;'_9BGQG_P#1ND5B?\%0O^3]OVA_^PUX3_\ 4"\,
MUM_\$[_]=^VQ_P!F*?&?_P!&Z17^^TO^39Y7_P!D_P ,_EE9_!\?^4EN*/\
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MAWTHO^2:X#_[''%__JNX3/KW_@H;_P G9^-/^Q!^!W_JG_!]4_CU_P FH_\
M!/[_ +$?]HC_ -7;<5<_X*&_\G9^-/\ L0?@=_ZI_P 'U3^/7_)J/_!/[_L1
M_P!HC_U=MQ7]SY;_ ,BSPY],+_ZQV<GY1Q-_R4GTB/3,_P#U\O!)]-_L-_\
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MI,$_P'U+0OB[X(U74?B;J&K>// GPR\':KXUT+3;:^_X4U\-?B+XT\?6FF>
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M/_)??BE_V:E\>_\ TS:57B]E_P >=I_U[0?^BDKVC_@ES_R7WXI?]FI?'O\
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M959_8_\ ^09^V/\ ]F1?&'_T_P#@BJWA_P#Y1^_%O_L[SX/?^JP\959_8_\
M^09^V/\ ]F1?&'_T_P#@BO9Q/_(NXG_[']#_ -(R(\/*_P#DIO#;_L@<;_Z<
MXV.<_86_Y/,_96_[+=X&_P#2N2OTS\5?\ASQ9_V'_$W_ *=M0K\S/V%O^3S/
MV5O^RW>!O_2N2OTS\5?\ASQ9_P!A_P 3?^G;4*_Q(_;5_P"]^ O_ & ^(/\
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MB!_V-OC7_P!2'5J_2?\ 9(_Y.A_9T_[*UX-_]+*_-CQ]_P C/\0/^QM\:_\
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M_P#8KK_^I<C_ #(^@%_R1/'O_958#_U38<****_ S^^@HHHH **** "BBB@
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M&>X^RVYDB$TVSRXVDCW$;@:_EGN_V4?VHWM+@+^S5\<_FMY=I_X5?XKQAT8
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M_&JSM(FR6GN8TTN[DA0J&0,MM&\Q+LB[5P&+$*<;_@J&2W[>W[0Q8Y(UGPD
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M>JM?:K8P6UCIFIW=G( >"_&3_@IOJ_PI_:\U[]FZV^'_ ,/?$=MX>^(7P7\
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MI_\ PD'B/4_#TBZAH&E0MX?CTW.SQ%XB$7B"<67AS4\#^S+VU-]=3[@9K&V
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M:YXPL-.OO#L]C)XPU'X@37$ND_#U-7FE;PU9)=7WB&SUO6= T'4>/T[_ (+
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M;Q?1=K:VUC;6MC9016MG9VT5K:6T"+%!;VUO''#!!#&@"QQ0Q(D<:* J(H4
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M/#VK>(X'>XT33UBMM9O[&PL))O>OV?+OX@7O[1'[34_Q+T+PGX>\2_\ "-_
M-%T_P;XBU3Q/I#:<-+^()M[B34M7T#PW=)>/,;A);5=.,4<,<$BW$K2N$^T0
M         ,  <  #@ #H*^8/AQ_R=-^TW_V)_P"SY_Z;OB-0!]04444 %%%1
MF:)20TL8(X(+J"#Z$$Y% $E%-5T?.QU?'7:P;'UP3BG4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'S7XQ_9*^!_P 0?BHWQ=\<
M>&;GQ7XB-EIEH-'UW5K[4/!23Z3;R6EIJH\(3R-HS:O]D:&WEO)8)#+'96>Z
M/?$7?X*^-G_!-33O$.M:'X&^$'PS^#/A[X9RC1M3O?B!XQMKKQ3XX\':G]L%
MMXTM?#NB:A%+;7J^+--L-!U">1[^TBDU&SU3S6@?43*/V)HK?#8K%8.M'$8/
M$XC"5XJ2C7PU:IAZT5.+C-1JTI0G%2BW&24DI1;3NFT<.8Y9EF<82I@,WR[
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MZ#5O#OB?PUJEGK6A:UIER"8+W3-4L)I[2[MWPR^9#*X617C?;(CJO@_[,_\
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MR'_L5U__ %+D?YD?0"_Y(GCW_LJL!_ZIL.%%%%?@9_?04444 %%%% !1110
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MWQ&H ^H**** "OX4/V_8;1_VV_VI#)%:,W_"X/$&3)' 6S]GL">7!/WB2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKW&A1117Y8?U,%%%% !1110 4444 %%%% "'I^*_S%+2'I^*_P Q2T %%%%
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MXO):.*G3R_$+&9)BUB?:T%I/VW)#VB?QJ*3T/X[?V+?^3N?V6_\ LN7PY_\
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M:WH\XM]4T77?#OB33M'\1^'M9L7:)Y]*UW2=.OUM[BUNQ;FUN[::7S;X<?\
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M=&\5^&-6T:;4]+.IVGB#0KO^TM'U*VM+VU623X]_9S_X*??$Z;1/B;J/Q_\
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M9:C>7]]\/OAU\-OA[XW.HWEE/<3&_P#%%Y=>*]1L(K>P-I9W#)IL*1P.TTS
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M^"/PR;QKK>HP>$-0\0^,=7FT_1[BT\):-PWA/]DGXA?'G5/V?/'/PWT'Q?\
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M*%*I'#?5G76,DW"O2E[2.'=*TM9W4K>YT445]J?-B$@ DD  $DDX  Y))/
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MKNR83K.+J.,.:%+^(^:TE[JFU"/*U)J#4GS2ANDK]/UMHK\$?BIXW_94UO\
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M*<L+_0/#GA.PU3Q$SM=W=Q/HNE7E_*T\?I_DKXH_X)]O\0?@[\6_&WQ(\4?
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M6$QKQ,Z.8XB6,P>&OB,KQBC[U3))$BC>65UCCC1I)'<A51$4L[L3P%5022>
M 37X_P#Q^^)O[3VL?M%_M8^ /AO\>Y_A9X)^"O[-^D?&/2-/LO 7@_Q+J=SX
MATW0GU8:9!J6NV$TECI.NW*7*Z])+]NNO*CLH=,6R3[4TW$?"#]HK]IV?XE?
ML4ZE\2?BQ8^-?"_[9OPY^*6H^(/AY9^!?#WAK0? 9\'>#O[8T*^\-:C9BYU^
MZU'4O,MI];.I:E-9M<27\5G:06DEE%9>I#@C'3P4<:LQROWL!',/JJEC_K*I
MSR:IG\*-W@%AO;RRW#XFHO\ :/8JI15*593K4E/Y:OX\9#1SRKD<N&N+$J?$
M%7AW^UW2R#^RWB:/'&$\/*N,45Q!_:CP-/B?,LKPS?\ 9JQD\-C'BZ6$J4<)
MBY4?TUT']K3]E_Q/X@MO"N@?M _!_5?$M[<BRL]"M/B!X9?5+N]9S&EG;6;:
MBLT]U+)\D5M$C32N52-'9E!D\8?M7_LS_#[Q#J7A+QS\>?A3X2\3Z1,EOJF@
M>(?&^@Z5JUA/)#%<)%=6-Y>Q7$,C03PS*CH&,<L;8PPS_.U^SY^S?\9_VF/V
M1=&^''@3]F3X+V6G:U\1?$DUI^UOX@\4:/;>/M%BTSXBW$^JO!H6GZ=!XN,F
MGV]O=>&H%_M6^MKO28WBBL8?.CGM?HCPQ\-OBUXG_;A_;>T_X9_!S]FKXW/X
M?UCX1:=K^H?M*6EW?7VGM%X&AMK>\\-BTT[4AYVLO:7=SK;2^3F:&R*R.2P;
MZC%<!<.X;%YI0>=5)2RFECI8G#RQ^3QG!8;-,IRW#U\1BX3JX? QQ;S#$-8+
M&4Z6-HU,(H3B_;09^495](/Q)S/*.%,?'@7#0AQ?BL@I97F-+A_C.M0JO-.$
M^+>)LSP&7Y/6P^$S+/JF30X>RZ,L[R:OB<CQF%SGZQ0JIX&O!_MGXH_:0^ /
M@GPKX9\<>+OC+\-_#OA'QI;PW?A'Q#JWB_1;/3/$UI<1B6*\T.XENU74[0Q,
MLCW5F);>)'1I9$#J3Z=X:\3^&_&>AZ;XG\(Z_H_B?PYK%NMWI6NZ!J5GJ^D:
MC;,2HFLM0L)I[6XC#*R,T4K;75D;#JRC\</VAO@O=:]^TQ\-KCX,:Q^S;??'
MOX??L]:1HVO_ +*GQ@\)7M[\+$\%-J?FS:O\,9)M)BT:RGM[R]O]*2*SDL[^
MUTQ(+JY>*UEO;23Z)_X)F^+O!&M?"OXH>$O"GPLC^#VM?#GXT>+_  U\0/!F
MD>+;WQIX*M?&82RDU&X\":K=7^HQV?AR14CBM]%L;F6QT]X&DM+B[M;N"[F^
M8S'AK 8?AZ&<8+$XNO7C]6JXJA5CAZ:PN'QE?$4L.ZM&I*ABY4IQIT'A\QPM
M/&8'&RK2BI85QA&I^I\,^*/$&8^(]?@S/,LR; 8"HLTPN4X_"U,RKRS7,,CP
M.68K,8X7&X>GC\HABJ53$X^&8\-9MB<ES_)*>#IU'2S:G5K5,/\ I'17XO\
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M*4G5@TG>4E4A9.?(HN^JWA'EOHVFK/8^/-(_8F\0?$SX??M%>$O%OP>_9_\
MV7O#WQ:^',?P^\'>$?@]H.@ZYXFTS4K:^BUQ/&?CCX@:3X=\*R:O;2ZY8:/Y
M/@[3H6TU+#3Q++<)J+-/+N7'PT_;3^*OC+]E=_BGX,^#OA#PU^SU\3]'\7^,
M=7\.>/\ 5?$&I?$:\TSPEXC\+1^)/#>DR^%]/3PWI:0ZG)=2>'M5O[G4IKK6
M(U6ZC@T9FO\ [$^#/[3?P)_:"EURU^$?Q%T;Q9JGAD6S^(M 6'4='\2:+%>
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MOO22=TW[K2>_+%MH****P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img57771353_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57771353_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '* G # 2(  A$! Q$!_\0
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M$#D1N>NP'HN<"@#Y \=_'#XW^%_%7A'P5'XNOM5U/6/"LOC.?5=*TFPC;S&
M$=HBW#I&+:(KN=LF0K)VQ3/C)^U9\31X!TRZT[7[K0O&FD>!O^$EUO2- T^S
MN+1)]S!)I[N:0KY#A#B*$,Y+=<X%?:_CKX$?#WXF:3I6E^*O"&E:[8Z4GEV,
M-Y;A_LZ;0NU#U"E0 1G! YK-\2?LR?"GQ?<Z;<:S\/\ 0;^33;1;&T\RR0"&
MW7[L0 P-@[*1@=J /D/XQ?M(_%S3?[$\1CQ%<>'O!Z^$-,UJ>\\,:9:ZFUI=
MS(CS2:C:R2"9;;DA3'CC')-5O'W[6GQ>U;XF^.O^$)F:33/"$FDQV5F+>RAT
M_4DN8TDDDNY;F5)8Q(&/E>6#MXSDU]?:M^RO\(]>DTE]1^'^AWTFDVT=G9O/
M:AFC@3&R(G^-%P,*V0,5I>*OV>?AIXX\36/B'Q!X'T/5]:LEC6"\NK-'=0GW
M >,,%[ @X[4 ?)OQZ_:#^)WP]^,VMW=_XGN/"_P]TVYTV*TN]%TVUU>SMEFV
M><FJIY@N(G9F*H4P.5.#7L/[;GC*X\)^#?AO=V=IIE_]N\;:/9L-1LTN45)9
M<%XPWW7'4,.17IOB#]G/X8^*_&*>*]8\#Z+J/B-61CJ-Q:*TCLGW"_9RO&"P
M.,#%=-XQ^'_AWX@VUA;^(])MM9@L+R+4+6.Z3<(KB,YCE7T93T- 'P?\0/VF
M?B_INE_%#QG9>+[2VT[P-\2CX9M="&EQ&.]LVG2/;/(?FRJOP5P<YSGC'K'_
M  4<G\26OP_^'3:#XHG\-I<>,].L[D01@B;S&)1F)(RJ%22AX;//2O>;[X!?
M#S4M+US3;KPCIEQ8:YJ?]M:E;O""EW>[@WVAQW?< <^U;GC[X<>&/BGX=?0?
M%NAV?B#1WD64V=]&'3>IRK#T([$4 ?G=XN\2>/?AIX\_:[\>>$?&O]DW7A6X
MT&\N+4Z=%-'JL@@VD2%N8T(+\)C[W7BMW6/VN?C-XD^)'BR]\-V\EO8>&=9T
MW38]!:.RCT^XAFCC>8W,\\JS+*^XF(QC:!@'-?;4WP%^'US8^)K*7PEILEIX
MFC@BUJ%H?EOTA7;")?[VQ0 *KZS^SG\,?$7BC3_$FJ>!=#O]<L%B2WOKBS5G
M41C$><\,4'"ELD=J /(?^"A6O7^E_!/085OKK2?#6J>*--T_Q+?6DC1/#IDD
MA$N77E%8[%)'9C7!>+_AQ\!?A3=?$#3_ (;:N-$\57OPYU::3PQH=])+875L
ML#A;F9!N7S!T5BP)'.#7VCKV@Z;XHT>[TG5[&WU/3+N,Q7%G=Q+)%*AZJRD8
M(KA_!?[-_P +_ASI>M:=X9\"Z)HEGK4#VVHQVEHJ_:8F4JT;GJ5()&W..: /
M@#1_ 7@KX<_L^_LR^.?A];V.D_%W4-7T2V9M,NB+C4EG!%S%/&&.]"H);(X]
MLUC^&;RR'[8]C\01)_Q)KWXJW>C1:@MZ3XA:;[.8_LTL'W1IX920,;\$5^A/
M@+]E7X0_"_Q!%KOA3X>:#H>LQ*5BOK6T'FQ@\':QSMR/2MF'X"_#NV^(\GC^
M'P9HT7C23.[7%M%%R25VEMV/O$<;NOO0!P?B#X4V/Q4^'GBVS^)][H'Q,BL=
M2OKO2_L]H(DTV,1XBMW"N=TL?S98X)W#@5X?^PRGPR^ _P"R;\-/B%?Z.NG^
M(O%"+I,NH:=8S75WJ%P]S,(HMD89F)V>G85]A^%_AKX7\$V&LV6@Z)9Z5::Q
M>3:AJ$-M'M6YN)@!+*_JS #)]JPIO@/X.7PYX/T#3]._L71/"FJ0ZOI=AII$
M444T1=E!&#E"9&)'?/6@#EX_VR/A//=WEG!XCDN;^WG2V2S@L)Y)[J5I#%M@
MC";I2'!5M@.TJ<XQ5OQW\0M#^*7[+?C3Q3X;O&O=%OO#NIFWN&B>)FV131M\
MK@,,,C#D=J\^\5?L,^'K6*\O_ =Y)H/B!M475K.XN9"5L)O,:1S Z .NYG;.
MXN,'  KU3X,_!>W^&WP-TKX<ZQ<KXCMX;6>WOIID(2Z\^21Y0023M)E8<G)'
M6@#\RO@5\.9T\3?LQVFH^$?#WPT&K-;ZQIWC[29[B6[UIH5):PEZ)'+*"&(;
M(X&#VKWM?VIO'FL?'GPG)X<\7WVJ^#/$?C.[\,*+C1[6WTU(DC< 09<W,DD;
MKEI&"HV,8YK[.OO@?X$U+PEH/ABZ\+Z?-H&@S0W&E6#1?N[&2+/E/%W5ER<$
M'O6-'^RY\)H?$TGB*+P#HD.N/>KJ1OX[8+*+E6WB52/NMNY)&,]\T ?!GPY\
M:>+/#_P8TF_U?7K3QA-J'QTCTDIK>GQW#0#SY$DGC+$E7;"[3_RSQA>M=]<_
MM/\ Q.CT.Z^*@\86*VT/Q!_X1$?#;[%%S:BY^SX,G^N^TD?O<YV[>U?7P_9O
M^&*W%U.O@G1TENM7CUZ8K;@!M0C+,ES@<"0%V.1W8U9;X ?#B3Q\/&[>"]%;
MQ:)/._M8VB^=YF,>9GIOQQOQNQWH \+_ ."@&H1M9_"70==U.YTCX=Z[XM@L
MO%-Q#*T*/;;&:.&61>5C=P%;D#'>O-?$WA/P-\'?VK?!^@?!UK;3+#7O"FN/
MXLT31K@R6?V6.U=K6YD4,55_-PH;@D?7G[G\5>$=%\<:#=Z)XATJSUK2+M-E
MQ8W\"S12KZ,K @UR?P__ &>OAM\*;34K;PAX+T?P[%J49BO/L-JJ-/&1C8S=
M2N.V<4 ?!W[+_P 5?'7PO^%O[.2Z5XYT[Q)HWB^&]T=_#%Q;11Q:8T4<LB3&
M9#YGR.H\PMQANU:G@O\ :W^*7@>Q\1WGC?7;Z_\ %"^$M1URTT"[TBV?2K^:
M$EEETZ]M7.Z!%(W*X)//S<5]-Z+X<_9A^$OBF>6PD^''ACQ!80-IDRO?6D,]
MO&1M>%D9\KD<," 3WKIOA/\ "GX(Z/J>JW_P\T/PDUY-"(KV313#/MAF'F!"
M%)")(#NVC 8'/(H ^3O!O[3GQJTWX>^.-<U.]DO[5?AW)XLLM0U:WT^.2UU
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MW&W;A#U48&,#@BJWB3]GWX;>,--T'3]9\$:)J%CH'&E6\EF@2R& -L8 &U2
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ME&V2%O6,@ ;3QQP*CO?V4_A#J7A72_#5U\/=#N-"TN226RL9+4%+=I#F39W
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M=M?2QQ_=5Y(E8@>V366OP%^'R6^N0#PGIODZYI\.E:FGE<7EI$A2*&3U55)
MKL=%T:R\.Z19Z7IMM'9:=9PK;V]M$,)%&H 55'H  * +M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
M3_M4?"CP/-^UE^SMYW@[P_,VNZQJC:J9-,@8Z@1;!@9\K^](//S9YKF];\:>
M-_"NM?M'2^![R'2+'X;^(- O+?2--T^WB232DM4>[M3MC&5\O<P)Y4)A2!Q7
MW/J?A71]:U33=3O]-M;O4--9GLKJ:)6DMF888QL1E21P<5%;^"]!M;K6;F'2
M+.*?6L?VE(L*AKW";!YIQ\^%^7GMQ0!\)>*OVD/'EUX#/Q4TSQA<Z=X+\0?$
MZPTC1EDAB6&'1$+12R,Q3A9I%8[B> %P16/\0?VFO'VI_%CQQHGAKX@26^B#
MXD^'O#=A=6*03+;VEU;RBX2-BI#'>N<G."H^E??LWP[\+W'@]?"<OA[39/#"
MQB$:.]JAM0@.0OEXVXSSTK/L_@UX#T]8UM?!VAVJQS07"+#81(%EA7;"X 7A
MD!(4]1F@#\^M:^*GQ1\%V7CG48_BMXBOU\#_ !0L_"UE!?>0Z7=G-(OF+=$1
M@RG#8!XP![UIZ=^T3\7M:^/&K7!UZ+2DT_XA?\(V/#VI:Y96MF^GAMOD"S=?
M/>=TS(LP;GH!BOONZ^%O@^^AOHKCPSI<\5_>KJ-VDEHA$]TOW9GX^9Q@88\T
M^;X9^$KGQ=%XIF\-:3+XEB38FKO91FZ5?028W?K0!\B_!CXK:EXX^*6HZOXP
M^,UYX4UJ+QYJ'ART^'S+ ;>XM85 B@,)7S%=@=_FYYKRWPG\7/B-XI\/_"[P
MYI?C>X\*2>+/B/XBT._U#2K*V246L1)0(/+VAU&</C.2"=U?H:OPU\)KXN?Q
M4OAK25\3.FQM8%E']J*XQCS<;NG'6F6?PO\ "&GO8/:^&=+MVL+N6_M#':(/
M(N)/]9*G'RNW=AR: /@'XJ?%+XI:+X?_ &CM6L/BEKML?A5JFG0Z/;K';E;D
M/'&)!='R\R*W)QQRQ_#H?C9\;O%MQXR^-4US\4[KX:R?#_P]8:EX:T:V\E(]
M9EEMA,TLJR*3.KS?N B]-WK7V_??#/PGJ=OK<%WX<TRX@UQUDU2.2U0K?,O"
MF88^<CMG-&O?#'PCXHU#3;[6?#.DZM>:;C[%<7ME'*]MCIL9E)7\* /@GQE\
M9OBMXWC^+U^WC;6/ S^%/AYH_BNWTG2XH4$5_+:-+(CET+>664Y0GOVQ7L/[
M3WBF^\:?\$TO$/B'5'274=3\)V=W<NBA5:1S"S$#MDD\5]-7GP^\-:C=:Q<W
M6A:?<W&LVZVFI2RVZLUY"H(6.4D?.H!( /'-6;[P?H6I>&&\.7>D65SH#0K;
MG3)8%:W,:XVIL(QM&!QCM0!^2WQOT6[F^&^L_"FY29=+^##7&I@R-\C)>7ML
MNF G&&Q#//TZ%:]T^.7QP\96GB;X^:I_PL^Z\!ZA\-_L2^%_"T/DK#JRL@<2
M31NI:X$[DQ@(1M^M?=6H?#CPMJW]J&]\/:;=G5$BCOS-;(QNEB.8EDR/F"$#
M&>F*36OAKX3\2:YI^LZMX:TG4]7T_P#X]+^\LHY9X/\ <=E)% 'P)\3/C1\5
M=>7]H35H?'6K^#&\ Z-H6M:?HNGQP;8KB>RBEFBE9D+-&6+90GOUXQ4WQ _:
M \:^)+WXF:GJ?Q0NOAK<^#/".EZUX?TNR\B.+6IYK99WFD2129T>7]R(TZ9]
M2*^]KSX<>%M2;7'N_#^G7+:XB1ZHTMLC&^5!M03<?.%' ST%0:M\*_!NO7&D
MSZGX6T?49M)54T^2ZL8Y6M%4841EE.T# P!0!^>_]J:[XI^/GQ"U_P 2>(K_
M $K4-2^"HU.7P_.T:1;YK=]]JJL-VQ6S)Q\P/4X%9'@7XI?$;]GWX=_!:3PY
MXHU/Q-;^(OACJ.I+X=U"*.2VM9K6V26W,"(H;Y<X().X+[U^D^L_#OPOXBUJ
M+6-4\/Z;J&K16\EHE]<6J/,L+@J\8<C.U@2".A!-):_#GPO8RZ-+;^'].@DT
M:!K736CMD!LX6 5HXN/D4@ $#CB@#\\?AG^T)\5XO ?C/5I_&J:G#+\-;CQ(
MINM>L+^]M-0"@I<P0P(## <LIBD!VL!FNKUSXC>*] ^%_P (K+5/BGXLU3Q?
M\1(GU^1K>ZL-)@2)+1&DA6[E39;PH7#[0&=SD5]KZ7\'_ VB6^LP:=X0T2P@
MUD,NI1VUA%&MX&^\) %^8'T/%2ZW\*_!OB71].TG5_"^D:II>FE396=Y91RQ
M6VT87RU8$+@ =/2@#\^/ ?[2'CWQSX)_9DL]>^*%UX8MO&4FMV&NZ]!Y"RS"
MW=Q ?,=-J2':J[P!][..:Z3P5^TE\0/#'PV\,?$+7O%EUKO@3POXYU+PSK6I
MO#&W]M:4=T=M>L54 O'(H7<A 8MSG%?3_C7]DOP5XR\>>"->>QL[+2_#+ZA(
M?#\5C$;*^-W$8Y3*A&.^[@<D5?\ C-^SCI7Q:^'%A\/[?46\)^"TFC^W:1H]
MG J7ENC!Q "5_=+N49*#)YH B_9)U+QCXC^!^B>)/'.HS7^N^(&EU=8Y8UC^
MR6TSEK> * ,;8MF<Y.2>:]DJ"QLX=-L;>TMXEAM[>-8HHT& BJ, #V  J>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)T63:=SYP2P(8# QR*Z:>%J3C.:M:*N]?R[D.:32?4])\2S7-_96T#J(FFW
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M&<-C&<?2H8M%CM9O-@+;R<E7/4^IJW,/M4;1AMK8QNC."/I1.,9>@XN2//\
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M .CGJ^&OLC*0X^IK/\&;O^$?BW<-YT^<?]=GH W**** "BBB@ HHHH ****
M"BBB@ KY_P#$$)N/VT]/CVJRM\/YMVYL8_XF,7/O]*^@*^?/$;6D?[:FFRWA
M_=Q^ )V7G'/]HQ54=P/:$TNQC;?M4YXR6X__ %U!_8[W%O<6DS)<V<I^49Y
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M9(]1\=[F _XJ.;_TGMZ[C[9#_P ]%_.N+^&/_(0\=Y_Z&.;_ -)[>NYVCTH
MB^V0_P#/1?SJK87$:),&<#]ZW?WJ_M'I533?]7-Q_P M6_G0!-]LA_YZ+^='
MVR'_ )Z+^=2[1Z4;1Z4 1?;(?^>B_G6-XFNH9DTZ#S!^^O8@?H"6_I6]M'I6
M-JH$OB#18NRM+,?P3 _5J +=C<QJLVYP"96/ZU9^V0_\]%_.H=.4>7-Q_P M
M6_G5O:/2@"+[7"?^6B_G65X-.[0(B.GG3_\ HYZVL#TK&\'_ /(!B_Z[3_\
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MF" #G ;\ZC$UG&SMHOZL:8>FI:'K7PU\*OX/UW4;2?S-0OY@7FU.48+J,;4
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M"_#?XB_#2SU33K/7[+Q9#=7[WW]JZ](\=Y(71%*R") G&S P!QBND\OXG_\
M//PW_P"!-Q_\35728?%/C+7/%3P^,+G1[73]6:Q@M;>QMW546&)LEG0DDESW
MK5_X0;Q7_P!%$U'_ ,%UI_\ &Z *GE_$_P#YY^&__ FX_P#B:;';_$V,';%X
M;&22<7%Q_P#$U=_X0;Q9_P!%$U'_ ,%UI_\ &ZR]$\-^+]4DU)7^(5^OV6Z:
MW7;IMIR  <G]WUYH L^7\3_^>?AO_P ";C_XFCR_B?\ \\_#?_@3<?\ Q-6_
M^$&\5_\ 11-1_P#!=:?_ !NC_A!O%?\ T434?_!=:?\ QN@"IY?Q/_YY^&__
M  )N/_B:JOIOQ.?5(KPCPW^[A:(1_:+CN0=V=OMBM7_A!O%?_11-1_\ !=:?
M_&Z/^$&\5_\ 11-1_P#!=:?_ !N@"DMO\38\[8O#2Y.3BYN/_B:=Y?Q/_P">
M?AO_ ,";C_XFI;;P;XLN%<GXAZ@-KE?^0;:=O^V=3?\ "#>*_P#HHFH_^"ZT
M_P#C= %01_$\$'R_#9_[>;C_ .)KK/!^GWVE^';6VU(PM?J7:8VY)CW,[-\I
M/..>]<]_P@WBO_HHFH_^"ZT_^-UT'@V:[F\.6IOKMKZ[5I(Y+ED5#)MD90Q5
M1@< =* -NBBB@ HHHH **** "BBB@ HHHH *^?/%6EIKG[7[:;)*\$=Y\-KF
M!I(Q\RAM1B!(]Z^@Z^?/$FH-IW[:6GNBAV?X?SKANG_(1BHY>?W>XT[.YZ?X
M3^'>D>"[>'[(!'+Y8B::4C+J.@]*Y_XU?#_7/B'X;AL=%\02Z-Y<XEDVC<MP
MFT@1L!_#DAOPYXKNX;5-4L8GFC##!Q&_2I+:WBMMT4?[LGDA6R?P':H=.*CR
M[&OM9\W-NSRFZ\&V/PO\%F&RM9[F6988'2SC^=Y,8W\=\G->7^'?"_C>/7HK
MNU;5;.U%YL6XO"6=48[27CSRH(X]N]?5^Q5^0+R/ND]:HP:7;6MU/.[8+D$[
MCD"L9T/:O65K;&]/$>S3=M69>FV/V76L,^7P"3GCISP.E:CSF[,[0C$T1. X
M^4DC _6N,USXEZ5H/CHZ6UK,UPJQ^;<LX6%=YPN/>NKOKSRHA<1+&EJ,R2/Z
MX["NOGC46YS.,HM-H^5/%FJKK'B?68+G3+VPEA5HICIEWY8\LN V8F4JVXYQ
MT/'6OIKX9Z+I_AOP=IMAI;2#3TCW1"63<W)R<_B37-V>E^$?BO+-J9M6N#93
M&/=) 89$. <<_>'>NEL[*QTQ9);==W\*1#(5?<5PX7#\K<[W['77K<\5&UF:
MNH3JS&!C@,<!EZH?0BJ]C!(U\T$L7FPKR6D7(]JJZK:S:M;QW4<[V$L.U_E.
M ^.S&M%M22WL[=CM;S#G<I^4^N#7I\ON\J5S@OKN,N)H-8MI[=9,2VTFR38>
M8VQW'N*2ZT=+ZU19BPDB7B3.,^F:I6&FPPZCJM[;R SW7+*3W P,UCZ9XBU'
M5IKBZ9XGL(@T4MHN&RPX^7\>M-)W]U@1ZMXZLO"\USIR6T]_J'DNR11*,.P7
M(3/JQP*RO@A\6IOB]X5O+F?1;CP]J=C.UM=:;<$Y7'1E) S7G][XAO[?XK:W
MK=K9&\$-JBPZ>4_?3%6 ;RAGDD;LCK\H->QZ7FWU@W\EBEC+>JID"+\[\<;O
M0U.'K4ZD:E.</?333OLNWG?[T=%:DX*,D]/U-ZRMY<R!L)&#\DF021COBJ[3
M1Z3-F50N6VG:,#ZUI6MBMJ[/&@"'GRU.1GVJ'4-/.K92:)H]OS*RMC\*%)-Z
M[&!5,ENL(GC19$=MJ^6./Q]ZH^&FCL;B?3;:TFC6 [A--D[E;GY6/7G(K;AA
M-G8;=@0@D!0/UK/UCQ=HGA^WAAU#5(+*XN!B(7#89C["LIM15VRHIRT2N31Z
MS&EP\$3'Y3E@5X_"K&J70-K,(PS3!> O'-<+\1_$UUX#T&34K&!=1NRP1+=X
MW:-R> 6=02JCJ3@\5I_#/Q@GQ(\*VNNM MB[*R2PQN70,.#AL<].*'4IQGRH
MKV<N3GZ%L:IJ.FJ$<$#&1O&X'\:M/K]W<V$\EM;(;E(RT<><[V';%.M[F2-3
MY3QWUMNV\'('M[&K4B&Z4R6:K&5X(  (K>5I+3[S->Z]49?@GQ+>ZOX;2[O[
M=+>\+LK0JI 0AB.AYSQ6_:0EYA+*2Y'*^U<)HMOKN@_$%[>ZFAN-!U7?<0Q,
MI$MK*H&0#T*,>?4&O1@ZS,1'(<KU KCIR;CRRW6YK524KQV9E>)M4&FZ=+<2
M.EO:QJ6EFD;"J!W)[5#INK1_V?:RQ,MW]H7S(W0Y4J>ASWK7U.QMM4T^:TNX
M5N+>92LD3+D,".016=X;\.VWA[2H["VC\JVC)*1DD[ >@&>@'I6G/)24;:$6
MCRWOJ*VG+J*M-,Q@SQ\IP#]14]GI-O8H9 P=L??Z5@^*+[4-)U"S%MI<FHVT
MS'S[A90/(4#^[W)K7TF:/5--CD6.=$R0!.FQC^'I3]K&_)<.67+S=">:^>2-
MX[8[)F'R&084UX/^T?:7JWWPBGN)PR?\+ TL>66W'.V;^5>T_8=1M9 8PLB9
MSM?!KRC]IR'_ ))#*Z>7(?B%I0V^GRSUJVHJRZF9[[1116(PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBO(/B-\;;OPSXOGT'1H=%EN;.WBG
MG76=1%HUS)(3LM[<$?-(54G)X&5'>@#U^BO'M7^-FKV-]JNHP:';-X2T74;?
M2]1GEN"+L2R>6)&1 -NV-I44Y.3AL=.5M?C7JSWEGJDVBVW_  ANH:K/H]G<
MPSLUXTD?F*LK1[=NQWB=0 <C*GOP >P45X[X+^.UWXNMYHUTRQ_M&8VILHK.
M]^T)B?<?+F(4>7+&J,TB\X&*]3UC7M-\.:<]_J^H6NEV,9 >ZO9EAB7)P,LQ
M &: .4^%_P#R$?'G_8QS?^D]O7=5YO\ !W7--UIO&M]I^H6M_93>(IC%<VLR
MR1N!!;@[64D'D$<>E>A_:H?^>L?_ 'T* ):Y[PC_ *[7O^PE+_Z"M;GVJ'_G
MK'_WT*Y_PG/&LVN[I$&=2D(RP_NK0!TM%1?:H?\ GK'_ -]"C[5#_P ]8_\
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MM3AC>.:=XU"))'N 9!&1Z<\'C%9U*CIPORZ)!"FJCUDKGO>K2"2(QB#[1"X
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MER#(K @J:VA&,$DV^5&4Y.H[]3F/#?Q.\-?%CP^VK^%M6&HV,<QMI&1"I5@
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M@H4U9&U?$5<3-U:TN:3ZD MC_P ]I/S'^%9?@WC0(AG/[Z?_ -'/6W6+X/\
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M/_(]?0U%5S-JS)/E?QE\3/C7KFH6+Z3\(/%.E6463/ NJ:83-R, MYQ(&,C
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MOZM6W6+8_P"E>)M1GZK;Q1VR_4_.W\UH S/AO_R#-5_["UY_Z--=;7)?#?\
MY!FJ_P#86O/_ $::ZV@ K%\'_P#(!C_Z[3_^CGK:K%\'_P#(!C_Z[3_^CGH
MVJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(MLI6,;9G08!)/11WKO:B47&3B^ATT:L:].-6&TDFOF%%%%2;!1110 4444
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MWMFTK6KCR%BECD,<R/(FX94J<%<@UTVI>#]'UB'4X+ZPANX-3"B[CF&Y9=H
M7.>F,<8^M6]$T.P\-Z7;Z;I=I%8V-NNV*"%=JJ,Y/'UYH \R^ MYXFO-+\6S
M>(M-L-.UQ_$,_P!JM;*Y,T,9\F#&UR 3E<'IU->G>9??\\8O^^ZY+X7_ /(1
M\>?]C'-_Z3V]=U0!3\R^_P">,7_?=<_X1>Z']M>7%&?^)G,3EN_R\5UE<YX+
M^[KG_84G_P#9: -;S+[_ )XQ?]]T&2^_YXQ_]]U=I#TH ^/?V@/VAOB!X$^+
M&IZ'HNJVEAIMM;VSI$]BDQW/'N8EFYZUY;H_[5GQ3CMY)EU^S!N)6F.=*BYR
M>._H!4_[84IA^-WB9AU^Q68'U,6!7D$S-86"+&%W*%C7=T!) R?:OS#,LQQE
M/%U*=.HTKZ'[?DN39=7R^C5K44VXW;/6M+_:<^)NBPS1VNO6:I--)</NTR(_
M.[;F/TS5W_AK+XK8_P"1ALO_  51?XUXK$TUM>10R3FX216(+* 59<9Z=N?P
MJ[ZUY<LVQ\;?OF>XL@RI_P#,.OZ^9^F/PO\ $.K^*/AUX8U>^6&6]OM.@N9Y
M%^0%V0%B%'3D]*UO!F[_ (1^+<,-YT^<?]=GK"^!G_)&O!/_ &![7_T6M;_@
M_P#Y ,?_ %VG_P#1SU^P0=XIG\\5%:;2[FU1115F84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'D6/ 9@N?4XI]<%\8OA
M'IOQ?\*R:7>3SV5W'F2SOK9RKP28QG@\J>X/4544F[2=D8UI5(4Y2I1YI+97
MM?YZGR;_ ,%!'5OB%X6P0?\ B5/T/_38U\LYKK/B9X$\1?#?Q1/H7B593>0\
MQ3,[/'-&>CQL>JG]#UKD^:^YPL53HQBG='\OYWB)XO,:M:I#D;>J?2RMY'Z2
M?L:RHO[/OA\%U'[RXZG_ *:M7MZ2"094Y%?G%^S7^S[K/Q=U!+^]N;S3/!]J
M^)98Y70W3#K%%S^;=OK7Z):/I-KH6EVMA90BWM+:-8XHE)(50, 9/)_&OD\;
M3C"K*TKMO[C]XX9Q=?%8"G[2ER1BDDV_BLK7M;1%VO$_VN&"_"ZR)(7_ (GE
MAU_ZZU[95>^T^VU*$17=O%<QA@X29 Z[AT.#W%<E.7LYJ78^BQF'>*P\Z"=N
M96N>-?M8,%\"^'LD#_BI=-ZG_IN*K?'R^B^%_C;PA\3W5A8V;2Z1JQ3O;2J2
MA(]I%'YFO;;S3;74(ECN[>*ZC5@ZK,@<!@<A@#W'K2WVGVVIVS6]W;Q74#?>
MBG0.IQZ@\5I"KRI*VU_Q./$8"5:52<96<N6WDXMM/^NAX_\ "OPC?_\ "C=6
MN;B/?K_BF*[U2<=_,N%)C3/H%***YGX0?&+PEX:_9UTVQU;6K;3M4T736L+W
M3;B0)<QSH&79Y9Y))QCUR*^BXXUA0(BA548"J, 5B7?@/PY?ZLNJ7.@Z;<:D
MIRMW):(TH/KN(SFJ]K&5^=;NYF\!4I>S>'DKQBXNZO>]G??>Z^=SB_V8]%O/
M#_P+\*6=_;R6MSY$DQAE&&59)7=01V.UA7J5(!CI2UA.7/)R?4]3#T5AZ,**
M=U%)?<@HHHJ#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#A?A?_ ,A'QY_V,<W_ *3V]=U7"_"__D(^//\
ML8YO_2>WKNJ "N;\%?=UO_L*3_\ LM=)7-^"?]7K?_84G_I0!TE(W2EI&Z4
M?G=^V#^\_: U2'^_#9,?HL)/\\5Y/J3(MC.74."N-OJ3T_6O6?VLE,O[2/B
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M8?\ Q5(OQY^*KXQ^S_J_T_X2.P_^*H ]]HKY]A_:"^*-QYGE_ '5F\MMK?\
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M %VG_P#1SU^[4_@1_+%3XY>IM4445H9A1110 4444 %%%% !1110 5@^/O\
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M[&NN\&ZY#\1/#^C>(K" V=LNZ*-8\A4*MM/![8%8Q]RM[*3Z7.B:<J?M/,]
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M;9)CYP"!T_4CZ5:TVT>WTB.[C>2[N?LZA'GP)'/!.<<9.,U-;0/'J[X#722
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M@E)=#094N;$1SQK+#(-CK,H(16'(<'JM10W5O87&GV'EPV@E!"10 *B!5X
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M8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1HHD2SN!(KE)$?S2 C(0<@^G% "?##_D(>//^QCF_P#2>WKNJ_,CXB?MP?M
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MC*AN5!V=/6OJNWG?^UI82V9&.-N.JD\&L_\ X1RT77K^^:P6"_NHA;3S;?\
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M2JQL.#&><]ZO_;OB3_T"/#/_ (,;C_XS7=4E '#?;OB3_P! CPS_ .#&X_\
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M6$<R1-NA*]%;/WO;@FLV\T\WFCW++<W%D59)-]NPR=ISL(/!!Z$>E:&G0K-
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MN)%4[6*J6/7@J:K_  +^)&NWOQUO]"L?B#)\2O \.E?;+O6+F.-5M)\\*KJ
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MEP&U2UAQ(8GD)5-Q&<!=HQ[5ZS7;3YN5<^YS3Y>9\NP4445H0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "44M% "8I:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>rapt-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-06T07:12:49.6326+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.rapt.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:rapt="http://www.rapt.com/20241231" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100010 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails2" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails2">
        <link:definition>100030 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100060 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical">
        <link:definition>100070 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100080 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100090 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>995455 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995475 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>995485 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1" id="DisclosureAccruedExpenses1">
        <link:definition>995495 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments" id="Role_DisclosureCommitments">
        <link:definition>995505 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1" id="DisclosureLicenseAndCollaborationAgreements1">
        <link:definition>995515 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995525 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995535 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995545 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995555 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995565 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995575 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>995585 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>995595 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables" id="Role_DisclosureCommitmentsTables">
        <link:definition>995605 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995615 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995625 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995635 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>995645 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>995655 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995665 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995675 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995685 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
        <link:definition>995695 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995705 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>995715 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>995725 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" id="Role_DisclosureCommitmentsAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>995745 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" id="DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails">
        <link:definition>995755 - Disclosure - Commitments - Summary of Balance Sheet Classification of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" id="DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" id="Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
        <link:definition>995785 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails" id="DisclosureStockbasedCompensationSummaryOfOptionPlansDetails">
        <link:definition>995805 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
        <link:definition>995815 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
        <link:definition>995825 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>995835 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>995845 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>995855 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>995865 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>995885 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995895 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Net Loss Per Share Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" id="Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
        <link:definition>995915 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="rapt-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets" xlink:href="rapt-20241231.xsd#StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="rapt-20241231.xsd#StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="rapt-20241231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="rapt-20241231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:href="rapt-20241231.xsd#StatementStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="rapt-20241231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="rapt-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:href="rapt-20241231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="rapt-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="rapt-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="rapt-20241231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1" xlink:href="rapt-20241231.xsd#DisclosureAccruedExpenses1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments" xlink:href="rapt-20241231.xsd#Role_DisclosureCommitments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1" xlink:href="rapt-20241231.xsd#DisclosureLicenseAndCollaborationAgreements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="rapt-20241231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="rapt-20241231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="rapt-20241231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rapt-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="rapt-20241231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="rapt-20241231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="rapt-20241231.xsd#DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables" xlink:href="rapt-20241231.xsd#Role_DisclosureCommitmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="rapt-20241231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="rapt-20241231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="rapt-20241231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20241231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="rapt-20241231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="rapt-20241231.xsd#DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:href="rapt-20241231.xsd#DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:href="rapt-20241231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails" xlink:href="rapt-20241231.xsd#DisclosureStockbasedCompensationSummaryOfOptionPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="rapt-20241231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="rapt-20241231.xsd#Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="rapt-20241231.xsd#DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" xlink:label="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AdditionalMilestonePayment" xlink:label="rapt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LicenseAgreementMember" xlink:label="rapt_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseDecreaseInLicenseFeesPayable" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:label="rapt_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" xlink:label="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" xlink:label="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsMember" xlink:label="rapt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:label="rapt_OptionsAvailableForFutureGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:label="rapt_OptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" xlink:label="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UpfrontLicenseFee" xlink:label="rapt_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RepricedStockOptionsMember" xlink:label="rapt_RepricedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CollaborationAgreementsAbstract" xlink:label="rapt_CollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ExchangeOfCommonStockForPre-FundedWarrants" xlink:label="rapt_ExchangeOfCommonStockForPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxAssetsLeaseLiability" xlink:label="rapt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ConversionOfCommonStockForPre-FundedWarrants" xlink:label="rapt_ConversionOfCommonStockForPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OperatingLeaseExpirationYear" xlink:label="rapt_OperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedExpensesRelatedToWorkforceReductionPlan" xlink:label="rapt_AccruedExpensesRelatedToWorkforceReductionPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LicenseFeesPayableCurrent" xlink:label="rapt_LicenseFeesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" xlink:label="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SharesAvailableForFutureGrantsMember" xlink:label="rapt_SharesAvailableForFutureGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MaximumAggregateOfferingPriceOfCommonStock" xlink:label="rapt_MaximumAggregateOfferingPriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncomeTaxDisclosureTable" xlink:label="rapt_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsToPurchaseCommonStock" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ExchangeWarrantsMember" xlink:label="rapt_ExchangeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:label="rapt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UncertainTaxPositionsReserves" xlink:label="rapt_UncertainTaxPositionsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IssuanceOfWarrantsOfferingExpenses" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NumberOfFinancialInstitution" xlink:label="rapt_NumberOfFinancialInstitution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedUpfrontLicenseFee" xlink:label="rapt_AccruedUpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:label="rapt_CommonStockNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ClosingPricePerShare" xlink:label="rapt_ClosingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:label="rapt_IncreasedAreaOfLeasedPremises"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SalesAgreementMember" xlink:label="rapt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:label="rapt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:label="rapt_LeaseTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_WorkingCapital" xlink:label="rapt_WorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:label="rapt_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShanghaiJemincarePharmaceuticalCoMember" xlink:label="rapt_ShanghaiJemincarePharmaceuticalCoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized incremental stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized Through The End Of The Retention Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum employee subscription rate on salary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for future issuance of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Available for Future Issuance Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares available for future issuance value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square feet area of laboratory and office facilities under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Feet Area Of Laboratory And Office Facilities Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and office facilities under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award, Plan Modification, Exercise Price, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, plan modification, exercise price, minimum.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option repricing program, minimum exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments upon achievement of specified commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent payments upon achievement of specified commercial milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments upon achievement of specified commercial milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserved shares of common stock for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserved Shares Of Common Stock For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended lease term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease extended lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen stock plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, Stock options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In License Fees Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in license fees payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fees payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases (Decreases) Resulting From Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign losses not benefited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign losses not benefited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense or penalties related to unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Remaining Contractual Maturities of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in deferred tax assets related to capitalized research expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax Assets In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax assets in process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Common Stock To Pre Funded Warrants In Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of common stock to pre funded warrants in private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of common stock to pre-funded warrants in private placement, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Balance Sheets Adjustments Related To Lease Accounting Standard Update Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of balance sheets adjustments related to lease accounting standard update.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares underlying all Eligible Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash used in operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Officers, Directors, Advisors, and Consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee and Non-employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Recognition During And After The Retention Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting recognition during and after the retention period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized Through The Retention Period And After</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities at unrealized losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities at Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Payment Arrangement, Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options available for future grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Available For Future Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Future Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Taxable Income Exceeds R&amp;D Credit Utilization Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable Income Exceeds R&amp;D Credit Utilization Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Income Exceeds R And D Credit Utilization Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable income exceeds r and d credit utilization amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments upon completion of manufacturing technology transfer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent payments upon completion of manufacturing technology transfer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments upon completion of manufacturing technology transfer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Securities not Included in Diluted per Share Calculations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares not vested and subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants Issued and Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RepricedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repriced Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RepricedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repriced stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RepricedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repriced Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated shares issuable under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Shares Issuable Under the 2019 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from stock option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of pre-funded warrants in private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development capitalized expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, purchase price per warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Purchase Price Per Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs vested and settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, shares at weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Non-Cancelable Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Maturities of Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ExchangeOfCommonStockForPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Of Common Stock For Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ExchangeOfCommonStockForPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange of common stock for pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ExchangeOfCommonStockForPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exchange of common stock for pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost, expected period to be recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock and pre-funded warrants in a private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and experimental expenses required to amortized term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Experimental Expenses Required To Amortized Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimental expenses required to amortized term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, RSUs vested and settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units Issued And Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and pre-funded warrants, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, RSUs forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ConversionOfCommonStockForPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Common Stock for pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ConversionOfCommonStockForPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Common Stock for pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ConversionOfCommonStockForPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock for pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingency losses, accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right-of-use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average discount rate, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beneficial ownership limitation percentage of shares outstanding maximum.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Limitation Percentage of Shares Outstanding Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership limitation, maximum percentage of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during period value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from of net issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional square feet area of laboratory and office facilities under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Square Feet Area Of Laboratory And Office Facilities Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional laboratory and office facilities under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workers' Compensation Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares employee stock plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock under employee stock plans, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square Feet Area Of Office Facility Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Feet Area Of Office Facility Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional office facilities under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock options, exercises intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Value Under Stock Option Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per warrant share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedExpensesRelatedToWorkforceReductionPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Related to Workforce Reduction Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedExpensesRelatedToWorkforceReductionPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses related to workforce reduction plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedExpensesRelatedToWorkforceReductionPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses related to workforce reduction plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2023-07</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Issued And Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued and Outstanding Under the 2019 Plan and 2015 Stock Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing after one year through five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value employee stock plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock under employee stock plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit ("RSU")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award purchase period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LicenseFeesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Fees Payable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LicenseFeesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License fees payable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LicenseFeesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fees payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N O L Utilization Suspended When Taxable Income Exceeds Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">N O L Utilization Suspended When Taxable Income Exceeds Amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">N O L Utilization Suspended When Taxable Income Exceeds Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in shares reserved for issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Shares Reserved For Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in shares reserved for issuance on common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SharesAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SharesAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SharesAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MaximumAggregateOfferingPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate offering price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MaximumAggregateOfferingPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Offering Price Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MaximumAggregateOfferingPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate offering price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reduction existing headcount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities gross depreciation and amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Gross Depreciation And Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes for each share of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Balance Sheet Classification Related To Operating Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of balance sheet classification related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Balance Sheet Information Related Operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vested aggregate fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units (RSUs) subject to future vesting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S Us Subject To Future Vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Subject to Future Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South san francisco and california.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco And California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco and California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issuance of Common Stock and Warrants in Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value issuance of common stock and warrants in private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of workforce reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ExchangeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ExchangeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ExchangeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock in "at-the-market" offerings, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan and two thousand fifteen stock plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan And Two Thousand Fifteen Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan and 2015 Stock Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncertain tax positions reserves.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Tax Positions Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average Remaining Contractual Term (Years), Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hanmi Pharmaceutical Company Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hanmi Pharmaceutical Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hanmi Pharmaceutical Co., LTD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Hanmi Pharmaceutical Co., LTD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Warrants Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beneficial ownership limitation percentage of shares outstanding minimum.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Limitation Percentage of Shares Outstanding Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership limitation, minimum percentage of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions on tax positions related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of financial institution.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued upfront license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average Remaining Contractual Term (Years), Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities at amortized cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities at Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase in shares amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares at the beginning of each calendar year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-Backed Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-backed Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock number of votes per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Number Of Votes Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and consulting services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average Remaining Contractual Term (Years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized After The End Of The Retention Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increased area of leased premises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increased Area Of Leased Premises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased of leased premises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock as percentage of fair market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under employee stock plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies line items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Common Stock And Warrants In Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issuance of common stock and warrants in private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global Intangible Low-taxed Income (GILTI)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Global Intangible Low-taxed Income (GILTI)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses or other impairment charges related to marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized; 132,006,828 and 34,398,312 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments (see note 6)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Modification stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total future undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, employee purchased shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent payments upon achievement of specified development and regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments upon achievement of specified development and regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments upon achievement of specified development and regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium (accretion of discounts) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities at unrealized gains.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities at Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShanghaiJemincarePharmaceuticalCoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Jemincare Pharmaceutical Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShanghaiJemincarePharmaceuticalCoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Jemincare Pharmaceutical Co[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShanghaiJemincarePharmaceuticalCoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Jemincare Pharmaceutical Co.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration beginning year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Beginning Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration beginning year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" xlink:to="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:to="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AdditionalMilestonePayment" xlink:to="rapt_AdditionalMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LicenseAgreementMember" xlink:to="rapt_LicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreaseDecreaseInLicenseFeesPayable" xlink:to="rapt_IncreaseDecreaseInLicenseFeesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_NonCashOperatingLeaseExpense" xlink:to="rapt_NonCashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PublicOfferingMember" xlink:to="rapt_PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" xlink:to="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" xlink:to="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" xlink:to="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PreFundedWarrantsMember" xlink:to="rapt_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OptionsAvailableForFutureGrantMember" xlink:to="rapt_OptionsAvailableForFutureGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OptionsIssuedAndOutstandingMember" xlink:to="rapt_OptionsIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" xlink:to="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" xlink:to="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UpfrontLicenseFee" xlink:to="rapt_UpfrontLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:to="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RepricedStockOptionsMember" xlink:to="rapt_RepricedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:to="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="rapt_CollaborationAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandFifteenStockPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ExchangeOfCommonStockForPre-FundedWarrants" xlink:to="rapt_ExchangeOfCommonStockForPre-FundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:to="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxAssetsLeaseLiability" xlink:to="rapt_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ConversionOfCommonStockForPre-FundedWarrants" xlink:to="rapt_ConversionOfCommonStockForPre-FundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualPayments" xlink:to="us-gaap_LossContingencyAccrualPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OperatingLeaseExpirationYear" xlink:to="rapt_OperatingLeaseExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:to="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AccruedExpensesRelatedToWorkforceReductionPlan" xlink:to="rapt_AccruedExpensesRelatedToWorkforceReductionPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LicenseFeesPayableCurrent" xlink:to="rapt_LicenseFeesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" xlink:to="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SharesAvailableForFutureGrantsMember" xlink:to="rapt_SharesAvailableForFutureGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MaximumAggregateOfferingPriceOfCommonStock" xlink:to="rapt_MaximumAggregateOfferingPriceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" xlink:to="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="rapt_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PreFundedWarrantsToPurchaseCommonStock" xlink:to="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SouthSanFranciscoAndCaliforniaMember" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:to="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ExchangeWarrantsMember" xlink:to="rapt_ExchangeWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="rapt_SignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UncertainTaxPositionsReserves" xlink:to="rapt_UncertainTaxPositionsReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IssuanceOfWarrantsOfferingExpenses" xlink:to="rapt_IssuanceOfWarrantsOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_NumberOfFinancialInstitution" xlink:to="rapt_NumberOfFinancialInstitution_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AccruedUpfrontLicenseFee" xlink:to="rapt_AccruedUpfrontLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="rapt_MarketableSecuritiesAtAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockNumberOfVotesPerShare" xlink:to="rapt_CommonStockNumberOfVotesPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ClosingPricePerShare" xlink:to="rapt_ClosingPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreasedAreaOfLeasedPremises" xlink:to="rapt_IncreasedAreaOfLeasedPremises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SalesAgreementMember" xlink:to="rapt_SalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenStockPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AccruedResearchAndDevelopmentExpenses" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_SignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:to="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LeaseTerminationMonthAndYear" xlink:to="rapt_LeaseTerminationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:to="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_WorkingCapital" xlink:to="rapt_WorkingCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AtTheMarketMember" xlink:to="rapt_AtTheMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CollaborationAndLicenseAgreementMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MarketableSecuritiesAtUnrealizedGains" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShanghaiJemincarePharmaceuticalCoMember" xlink:to="rapt_ShanghaiJemincarePharmaceuticalCoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LicenseFeesPayableCurrent" xlink:label="rapt_LicenseFeesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="rapt_LicenseFeesPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" xlink:label="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ExchangeOfCommonStockForPre-FundedWarrants" xlink:label="rapt_ExchangeOfCommonStockForPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_16"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_ExchangeOfCommonStockForPre-FundedWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseDecreaseInLicenseFeesPayable" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rapt_IncreaseDecreaseInLicenseFeesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rapt_NonCashOperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CollaborationAgreementsAbstract" xlink:label="rapt_CollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_WorkingCapital" xlink:label="rapt_WorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedExpensesRelatedToWorkforceReductionPlan" xlink:label="rapt_AccruedExpensesRelatedToWorkforceReductionPlan"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="rapt_WorkingCapital" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SeveranceCosts1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="rapt_AccruedExpensesRelatedToWorkforceReductionPlan" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:label="rapt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:label="rapt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NumberOfFinancialInstitution" xlink:label="rapt_NumberOfFinancialInstitution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rapt_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_NumberOfFinancialInstitution" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="rapt_SignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtAmortizedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OperatingLeaseExpirationYear" xlink:label="rapt_OperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:label="rapt_IncreasedAreaOfLeasedPremises"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:label="rapt_LeaseTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_OperatingLeaseExpirationYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_IncreasedAreaOfLeasedPremises" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LeaseTerminationMonthAndYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:label="rapt_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CollaborationAgreementsAbstract" xlink:label="rapt_CollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UpfrontLicenseFee" xlink:label="rapt_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LicenseAgreementMember" xlink:label="rapt_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShanghaiJemincarePharmaceuticalCoMember" xlink:label="rapt_ShanghaiJemincarePharmaceuticalCoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AdditionalMilestonePayment" xlink:label="rapt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" xlink:label="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedUpfrontLicenseFee" xlink:label="rapt_AccruedUpfrontLicenseFee"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontLicenseFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_LicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rapt_ShanghaiJemincarePharmaceuticalCoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_AdditionalMilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_AccruedUpfrontLicenseFee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SalesAgreementMember" xlink:label="rapt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsMember" xlink:label="rapt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:label="rapt_CommonStockNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ExchangeWarrantsMember" xlink:label="rapt_ExchangeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MaximumAggregateOfferingPriceOfCommonStock" xlink:label="rapt_MaximumAggregateOfferingPriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" xlink:label="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ClosingPricePerShare" xlink:label="rapt_ClosingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ConversionOfCommonStockForPre-FundedWarrants" xlink:label="rapt_ConversionOfCommonStockForPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IssuanceOfWarrantsOfferingExpenses" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rapt_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyTwoPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockNumberOfVotesPerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rapt_ExchangeWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_MaximumAggregateOfferingPriceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClosingPricePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ConversionOfCommonStockForPre-FundedWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_IssuanceOfWarrantsOfferingExpenses" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:label="rapt_OptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SharesAvailableForFutureGrantsMember" xlink:label="rapt_SharesAvailableForFutureGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:label="rapt_OptionsAvailableForFutureGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsIssuedAndOutstandingMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_SharesAvailableForFutureGrantsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsAvailableForFutureGrantMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_PreFundedWarrantsIssuedAndOutstandingMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" xlink:label="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RepricedStockOptionsMember" xlink:label="rapt_RepricedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenStockPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandFifteenStockPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RepricedStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxAssetsLeaseLiability" xlink:label="rapt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="rapt_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rapt_DeferredTaxAssetsLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:label="rapt_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncomeTaxDisclosureTable" xlink:label="rapt_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UncertainTaxPositionsReserves" xlink:label="rapt_UncertainTaxPositionsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" xlink:label="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rapt_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="rapt_IncomeTaxDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositionsReserves" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsToPurchaseCommonStock" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="rapt_PreFundedWarrantsToPurchaseCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" xlink:label="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ExchangeOfCommonStockForPre-FundedWarrants" xlink:label="rapt_ExchangeOfCommonStockForPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_ExchangeOfCommonStockForPre-FundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseDecreaseInLicenseFeesPayable" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rapt_IncreaseDecreaseInLicenseFeesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rapt_NonCashOperatingLeaseExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:label="rapt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:label="rapt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NumberOfFinancialInstitution" xlink:label="rapt_NumberOfFinancialInstitution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_NumberOfFinancialInstitution" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OperatingLeaseExpirationYear" xlink:label="rapt_OperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:label="rapt_IncreasedAreaOfLeasedPremises"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:label="rapt_LeaseTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_OperatingLeaseExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_IncreasedAreaOfLeasedPremises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LeaseTerminationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:label="rapt_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UpfrontLicenseFee" xlink:label="rapt_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LicenseAgreementMember" xlink:label="rapt_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShanghaiJemincarePharmaceuticalCoMember" xlink:label="rapt_ShanghaiJemincarePharmaceuticalCoMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AdditionalMilestonePayment" xlink:label="rapt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" xlink:label="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedUpfrontLicenseFee" xlink:label="rapt_AccruedUpfrontLicenseFee"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rapt_ShanghaiJemincarePharmaceuticalCoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_AdditionalMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_AccruedUpfrontLicenseFee" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SalesAgreementMember" xlink:label="rapt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsMember" xlink:label="rapt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:label="rapt_CommonStockNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ExchangeWarrantsMember" xlink:label="rapt_ExchangeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MaximumAggregateOfferingPriceOfCommonStock" xlink:label="rapt_MaximumAggregateOfferingPriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" xlink:label="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ClosingPricePerShare" xlink:label="rapt_ClosingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ConversionOfCommonStockForPre-FundedWarrants" xlink:label="rapt_ConversionOfCommonStockForPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IssuanceOfWarrantsOfferingExpenses" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rapt_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyTwoPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockNumberOfVotesPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rapt_ExchangeWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_MaximumAggregateOfferingPriceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClosingPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ConversionOfCommonStockForPre-FundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_IssuanceOfWarrantsOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:label="rapt_OptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_SharesAvailableForFutureGrantsMember" xlink:label="rapt_SharesAvailableForFutureGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:label="rapt_OptionsAvailableForFutureGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_SharesAvailableForFutureGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsAvailableForFutureGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_PreFundedWarrantsIssuedAndOutstandingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RepricedStockOptionsMember" xlink:label="rapt_RepricedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" xlink:label="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RepricedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenStockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:label="rapt_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncomeTaxDisclosureTable" xlink:label="rapt_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_UncertainTaxPositionsReserves" xlink:label="rapt_UncertainTaxPositionsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" xlink:label="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" xlink:label="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositionsReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="rapt_LicenseFeesPayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_LicenseFeesPayableCurrent" xlink:label="rapt_LicenseFeesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rapt_IncreaseDecreaseInLicenseFeesPayable" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="8" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rapt_NonCashOperatingLeaseExpense" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="12" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="15" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_IncreaseDecreaseInLicenseFeesPayable" xlink:label="rapt_IncreaseDecreaseInLicenseFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rapt_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rapt_DeferredTaxAssetsLeaseLiability" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rapt-20241231.xsd#rapt_DeferredTaxAssetsLeaseLiability" xlink:label="rapt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount" name="TaxableIncomeExceedsRAndDCreditUtilizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" name="SquareFeetAreaOfOfficeFacilityUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_UpfrontLicenseFee" name="UpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" name="NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" name="SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_OptionsAvailableForFutureGrantMember" name="OptionsAvailableForFutureGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_PreFundedWarrantsIssuedAndOutstandingMember" name="PreFundedWarrantsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" name="ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_CommonStockNumberOfVotesPerShare" name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" name="ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" name="RestrictedStockUnitsRSUsSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_CommonStockOptionsIssuedAndOutstandingMember" name="CommonStockOptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandTwentyOnePublicOfferingMember" name="TwoThousandTwentyOnePublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue" name="CommonStockCapitalSharesAvailableForFutureIssuanceValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_LeaseTerminationMonthAndYear" name="LeaseTerminationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ShanghaiJemincarePharmaceuticalCoMember" name="ShanghaiJemincarePharmaceuticalCoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember" name="VestingRecognitionDuringAndAfterTheRetentionPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" name="ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_IncreasedAreaOfLeasedPremises" name="IncreasedAreaOfLeasedPremises" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_PercentageOfIncreaseInSharesReservedForIssuance" name="PercentageOfIncreaseInSharesReservedForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" name="RestrictedStockUnitsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ClosingPricePerShare" name="ClosingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" name="BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" name="StockIssuedDuringPeriodValueEmployeeStockPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_UncertainTaxPositionsReserves" name="UncertainTaxPositionsReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_TwoThousandNineteenStockPlanMember" name="TwoThousandNineteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" name="ResearchAndExperimentalExpensesRequiredToAmortizedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_ExchangeWarrantsMember" name="ExchangeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" name="ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_NonCashOperatingLeaseExpense" name="NonCashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" name="SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" name="DeferredTaxLiabilitiesGrossDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_MarketableSecuritiesAtAmortizedCost" name="MarketableSecuritiesAtAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" name="SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" name="ClassOfWarrantOrRightPurchasePricePerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_TwoThousandTwentyTwoPublicOfferingMember" name="TwoThousandTwentyTwoPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_PreFundedWarrantsToPurchaseCommonStock" name="PreFundedWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" name="ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_LicenseFeesPayableCurrent" name="LicenseFeesPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" name="AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_ConversionOfCommonStockForPre-FundedWarrants" name="ConversionOfCommonStockForPre-FundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_TwoThousandFifteenStockPlanMember" name="TwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_OperatingLossCarryforwardsExpirationBeginningYear" name="OperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_SharesAvailableForFutureGrantsMember" name="SharesAvailableForFutureGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_MarketableSecuritiesAtUnrealizedGains" name="MarketableSecuritiesAtUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" name="BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_MarketableSecuritiesAtUnrealizedLosses" name="MarketableSecuritiesAtUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" name="IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_MaximumAggregateOfferingPriceOfCommonStock" name="MaximumAggregateOfferingPriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_IssuanceOfWarrantsOfferingExpenses" name="IssuanceOfWarrantsOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_OperatingLeaseExpirationYear" name="OperatingLeaseExpirationYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" name="StockIssuedDuringPeriodSharesEmployeeStockPlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" name="EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_AdditionalMilestonePayment" name="AdditionalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_RepricedStockOptionsMember" name="RepricedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_IncreaseDecreaseInLicenseFeesPayable" name="IncreaseDecreaseInLicenseFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_NumberOfFinancialInstitution" name="NumberOfFinancialInstitution" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" name="TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_HanmiPharmaceuticalCompanyLimitedMember" name="HanmiPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_OptionsIssuedAndOutstandingMember" name="OptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_AccruedUpfrontLicenseFee" name="AccruedUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_SouthSanFranciscoAndCaliforniaMember" name="SouthSanFranciscoAndCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_ExchangeOfCommonStockForPre-FundedWarrants" name="ExchangeOfCommonStockForPre-FundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_AccruedExpensesRelatedToWorkforceReductionPlan" name="AccruedExpensesRelatedToWorkforceReductionPlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087860164272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RAPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RAPT THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001673772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3313701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">561 Eccles Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,006,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of RAPT Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stockholders' equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859670256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 169,735<span></span>
</td>
<td class="nump">$ 47,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">61,320<span></span>
</td>
<td class="nump">111,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,181<span></span>
</td>
<td class="nump">2,920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">235,236<span></span>
</td>
<td class="nump">161,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">5,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">3,871<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">240,325<span></span>
</td>
<td class="nump">173,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">5,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,597<span></span>
</td>
<td class="nump">14,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_LicenseFeesPayableCurrent', window );">License fees payable</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,351<span></span>
</td>
<td class="nump">21,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,421<span></span>
</td>
<td class="nump">26,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (see note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized; 132,006,828 and 34,398,312 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">804,388<span></span>
</td>
<td class="nump">631,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(614,547)<span></span>
</td>
<td class="num">(484,682)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">189,904<span></span>
</td>
<td class="nump">147,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 240,325<span></span>
</td>
<td class="nump">$ 173,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_LicenseFeesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fees payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_LicenseFeesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857783168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">132,006,828<span></span>
</td>
<td class="nump">34,398,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">132,006,828<span></span>
</td>
<td class="nump">34,398,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859212000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 107,217<span></span>
</td>
<td class="nump">$ 101,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,884<span></span>
</td>
<td class="nump">26,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">136,101<span></span>
</td>
<td class="nump">127,062<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(136,101)<span></span>
</td>
<td class="num">(127,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">6,236<span></span>
</td>
<td class="nump">10,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,865)<span></span>
</td>
<td class="num">(116,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (129,918)<span></span>
</td>
<td class="num">$ (116,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share, basic</a></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share, diluted</a></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in computing net loss per share, basic</a></td>
<td class="nump">40,761,143<span></span>
</td>
<td class="nump">38,338,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in computing net loss per share, diluted</a></td>
<td class="nump">40,761,143<span></span>
</td>
<td class="nump">38,338,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857371520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>At The Market</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At The Market</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 245,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 613,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (367,884)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,254,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans', window );">Issuances of common stock under employee stock plans</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans', window );">Issuances of common stock under employee stock plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">17,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="num">(655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(116,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 147,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484,682)<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="nump">34,398,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,398,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement', window );">Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs</a></td>
<td class="nump">$ 143,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement', window );">Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ExchangeOfCommonStockForPre-FundedWarrants', window );">Exchange of common stock for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,951,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from of net issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans', window );">Issuances of common stock under employee stock plans</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans', window );">Issuances of common stock under employee stock plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(129,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 189,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (614,547)<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="nump">132,006,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,006,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ExchangeOfCommonStockForPre-FundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of common stock for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ExchangeOfCommonStockForPre-FundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares employee stock plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock and warrants in private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value employee stock plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodValueEmployeeStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock and warrants in private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857410192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock and pre-funded warrants, issuance costs</a></td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858822528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (129,865)<span></span>
</td>
<td class="num">$ (116,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts on marketable securities</a></td>
<td class="num">(2,813)<span></span>
</td>
<td class="num">(5,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">19,935<span></span>
</td>
<td class="nump">17,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss on foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_NonCashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other current liabilities</a></td>
<td class="num">(8,459)<span></span>
</td>
<td class="nump">7,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncreaseDecreaseInLicenseFeesPayable', window );">License fees payable</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,855)<span></span>
</td>
<td class="num">(2,707)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(83,297)<span></span>
</td>
<td class="num">(97,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(82,218)<span></span>
</td>
<td class="num">(161,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">135,042<span></span>
</td>
<td class="nump">266,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(1,125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">52,702<span></span>
</td>
<td class="nump">104,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of common stock and pre-funded warrants in a private placement, net of issuance costs</a></td>
<td class="nump">143,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock in "at-the-market" offerings, net of issuance costs</a></td>
<td class="nump">8,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under employee stock plans</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">152,852<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">122,257<span></span>
</td>
<td class="nump">8,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">47,478<span></span>
</td>
<td class="nump">38,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 169,735<span></span>
</td>
<td class="nump">$ 47,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreaseDecreaseInLicenseFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in license fees payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreaseDecreaseInLicenseFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859905264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, hardware, software and critical data, including intellectual property, clinical trial data, and other confidential information that is proprietary, strategic or competitive in nature (&#8220;Information Systems and Data&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function, led by our Director of Information Technology, helps identify, assess and manage the Company&#8217;s cybersecurity threats and risks. Our Director of Information Technology helps to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example, monitoring provided by a third-party security operations center, deploying manual and third-party service provider automated tools in certain environments, subscribing to reports and services that identify cybersecurity threats (and analyzing such reports), conducting scans of certain environments, evaluating our industry&#8217;s risk profile and threats reported to us, conducting internal audits and threat assessments for certain threats, conducting vulnerability assessments using third-party tools to identify vulnerabilities,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> engaging third parties to conduct threat assessments, using external intelligence feeds and monitoring the dark web.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment and system, we implement and maintain various technical, physical and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data including, for example: incident response plans and policies; vulnerability management policy; disaster recovery and business continuity plans; risk assessments; encryption of certain data; network security controls and data segregation for certain systems; access controls; physical security controls; asset management, tracking, and disposal; systems monitoring for certain systems; employee training; penetration testing of certain environments and cybersecurity insurance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are taken into account as part of the Company&#8217;s risk management processes. For example, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Director of Information Technology works with management to help mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess and manage material risks from cybersecurity threats, including for example professional services firms (including legal counsel), threat intelligence service providers, cybersecurity consultants and software providers, managed cybersecurity service providers, penetration testing firms, dark web monitoring services, forensic investigators and endpoint detection and response vendors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations, contract manufacturing organizations, distributors and supply chain resources. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, we may utilize various vendor management processes that may include reviews of security assessments or certifications and contractual measures.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or those of the third parties whom we work with, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse consequences.&#8221;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a Corporate Information Security Steering Committee (&#8220;CISSC&#8221;), which includes several members of senior management, including the Chief Financial Officer (&#8220;CFO&#8221;) and General Counsel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CISSC oversees corporate information security initiatives and the Company&#8217;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#8217;s corporate security programs and investments.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#8217;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company&#8217;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></p></div></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a Corporate Information Security Steering Committee (&#8220;CISSC&#8221;), which includes several members of senior management, including the Chief Financial Officer (&#8220;CFO&#8221;) and General Counsel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CISSC oversees corporate information security initiatives and the Company&#8217;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#8217;s corporate security programs and investments.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#8217;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company&#8217;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></p></div></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a Corporate Information Security Steering Committee (&#8220;CISSC&#8221;), which includes several members of senior management, including the Chief Financial Officer (&#8220;CFO&#8221;) and General Counsel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CISSC oversees corporate information security initiatives and the Company&#8217;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#8217;s corporate security programs and investments.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#8217;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company&#8217;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a Corporate Information Security Steering Committee (&#8220;CISSC&#8221;), which includes several members of senior management, including the Chief Financial Officer (&#8220;CFO&#8221;) and General Counsel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CISSC oversees corporate information security initiatives and the Company&#8217;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#8217;s corporate security programs and investments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company&#8217;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863820304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (129,865)<span></span>
</td>
<td class="num">$ (116,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087856728784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863829328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAPT Therapeutics, Inc. (&#8220;RAPT&#8221; or the &#8220;Company&#8221;) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. The Company's lead drug candidate, RPT904, is a half-life extended monoclonal antibody designed to bind free human immunoglobulin E (&#8220;IgE&#8221;), a key driver of several allergic diseases. The Company&#8217;s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (&#8220;CCR4&#8221;) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company ceased development of zelnecirnon, its small molecule CCR4 antagonist for inflammatory disease. The Company is currently pursuing different novel CCR4 antagonists, which it believes may have improved safety margins. The Company is located in South San Francisco, California.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Management Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2024, the Company incurred a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash in operations. At December 31, 2024, the Company had cash and cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July, 2024, the Company's board of directors approved a reduction of the Company's workforce to conserve cash resources. The workforce reduction impacted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> people, or approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's headcount. All employees affected by the workforce reduction were eligible to receive, among other things, severance payments and paid COBRA premiums for a specified time period post-termination. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. The Company completed the workforce reduction and all cash payments related to the restructuring during the year ended December 31, 2024. As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued expenses associated with this workforce reduction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#8217;s current cash and cash equivalents and marketable securities will provide sufficient funds to enable the Company to meet its obligations for at least 12 months from the filing date of this Annual Report on Form 10-K. The Company&#8217;s evaluation was based on the facts known as of the date of filing of this Annual Report on Form 10-K.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863775472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company. The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) until December 31, 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5478996a-804a-4f18-89f0-88f2679981b1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Brian Wong, M.D., Ph.D. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company&#8217;s operating segment and decides how to allocate resources based on the Company&#8217;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024 and 2023, all of the Company&#8217;s property and equipment was maintained in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities primarily consist of commercial paper, corporate debt securities and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the Company's available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, the Company determines if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#8217;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. If the impairment is a result of a credit-related loss, the Company recognizes an allowance for credit losses. If the impairment is not a result of a credit loss, the Company recognizes the loss in other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b2c0381-34b5-4225-b14c-08e039f44849;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record any impairment losses on long-lived assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. Amounts incurred in connection with license agreements, such as upfront license and milestone fees are also included in research and development expense. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines employee, non-employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company retrospectively </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2023-07 on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and will adopt it for its interim reporting starting with the quarter ending March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The adoption of ASU 2023-07 did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company&#8217;s financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (&#8220;ASU 2024-03&#8221;). ASU 2024-03 requires disaggregated disclosures of certain categories of expenses in the notes to the financial statements that are included in expense line items on the face of the income statement in annual and interim periods. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on its financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this standard on the income tax disclosures within the financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087864693712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts payable and accrued expenses that approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair values of investments in corporate debt securities, commercial paper and U.S. government agency securities using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.187%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:10.582%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,776</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,776</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,772</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,790</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,820</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,825</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,795</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,795</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,743</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230,906</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230,956</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,636</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,636</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,270</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.187%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:10.582%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,869</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,869</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,531</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,559</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,242</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,245</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,828</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,827</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,206</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,279</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,676</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,779</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,395</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,395</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,384</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrealized losses on the Company&#8217;s securities that were in an unrealized loss position were caused by interest rate changes and were not attributable to credit losses. The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an allowance for credit losses or other impairment charges related to its marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.548%;box-sizing:content-box;"></td>
        <td style="width:4.159%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:33.293%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturing in one year or less</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturing after one year through five years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859565776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,035</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,399</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">706</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">394</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,448</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,815</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,081</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,448</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expenses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859410032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,239</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,723</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional and consulting services</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,493</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">341</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,597</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859415136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contingency losses were accrued at either </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2015, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,376</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of laboratory and office facilities in South San Francisco, California. In April 2018, the Company amended the lease agreement to include an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,378</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of laboratory and office space increasing the total leased premises to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,754</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet. The lease amendment extended the lease term to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and contained scheduled rent increases over the lease term and an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option for the Company to extend the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,232</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office facilities in South San Francisco, California, which expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease agreement contained an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and was included in net cash used in operating activities in the Company&#8217;s statements of cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the weighted-average remaining lease term and discount rate for the Company&#8217;s operating leases was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.72</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturities of operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.856%;box-sizing:content-box;"></td>
        <td style="width:2.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.703000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,137</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,799</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Lease Liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the supplemental balance sheet information related to operating leases at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.447%;box-sizing:content-box;"></td>
        <td style="width:2.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,422</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,458</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,906</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of lease expense included in operating expenses in the statement of operations in relation to operating leases. Variable lease expense was insignificant for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The Company does not have any financing lease agreements as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087860460944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Shanghai Jemincare Pharmaceutical Co., Ltd.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a license agreement (the &#8220;Jemincare License Agreement&#8221;) with Shanghai Jemincare Pharmaceutical Co., Ltd., a company incorporated in the People&#8217;s Republic of China (&#8220;Jemincare&#8221;), and a subsidiary of Jiangxi Jemincare Group</span><span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Co., Ltd. Under the Jemincare License Agreement and subject to certain rights, Jemincare granted the Company: (1) the exclusive and sublicensable rights to develop, manufacture, commercialize and otherwise exploit Jemincare&#8217;s anti-IgE monoclonal antibody JYB1904/RPT904 (together with certain related molecules, the &#8220;Licensed Molecules&#8221;) throughout the world, except mainland China, Hong Kong, Macau and Taiwan (together, the &#8220;Jemincare Territory&#8221;) for any and all uses; (2) the non-exclusive and sublicensable rights to develop the Licensed Molecules in the Jemincare Territory solely for the purposes of exploiting the Licensed Molecules outside of the Jemincare Territory; and (3) the non-exclusive and sublicensable rights to manufacture the Licensed Molecules in the Jemincare Territory solely for the purposes of exercising the Company&#8217;s rights in the foregoing (1) and (2).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As consideration for the rights granted, the Company paid Jemincare a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront license fee, and could pay up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">672.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments, as well as tiered royalty payments (at percentages ranging from high single-digit to low double-digit) on future net sales. Those additional milestone payments include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million contingent upon the completion of manufacturing technology transfer, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million contingent upon the achievement of specified development and regulatory milestone events, and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">445.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million contingent upon the achievement of specified commercial milestone events. As of December 31, 2024, the Company accrued the upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as research and development expense. The Company paid the upfront license fee in January 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Jemincare License Agreement, royalty payments will be payable on a product-by-product and country-by-country basis during the period commencing on the first commercial sale and continuing until the later of: (a) the 10-year anniversary of the date of such first commercial sale; (b) the expiration of the relevant patent claims; and (c) the expiration of the relevant regulatory exclusivity (the &#8220;Jemincare Royalty Term&#8221;). Subject to a certain floor, the Company&#8217;s royalty payments will be reduced by specified percentages for patent expiration, biosimilar entry, payments for third party intellectual property, compulsory sublicenses or drug pricing programs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Merck</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company conducted a clinical trial evaluating tivumecirnon in combination with pembrolizumab (KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck supplied pembrolizumab for use in the clinical trial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022 and February 2024, the Company and Merck amended the agreement to provide for additional supply of pembrolizumab.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087860301824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Company&#8217;s common stock have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share of common stock held by them. Holders of shares of the Company&#8217;s common stock are entitled to dividends when, as and if declared by the board of directors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends had been declared as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 or December 31, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options issued and outstanding under the 2019 Equity Incentive Plan and<br/>&#160;&#160;&#160;2015 Stock Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units issued and outstanding under the 2019 Equity<br/>&#160;&#160;&#160;Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grants under the 2019 Equity Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,489,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,032,820</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,403,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">492,307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410,522</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,390,057</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,556,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company sold through a private placement to a select group of accredited investors </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,452,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8499</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting offering expenses (the &#8220;Private Placement&#8221;). Also in December 2024, the Company entered into an exchange agreement  with The Column Group II, LP and certain of its affiliated funds (collectively, the &#8220;TCG Funds&#8221;), pursuant to which the TCG Funds agreed to exchange an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,951,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,951,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock (the &#8220;Exchange&#8221;). The material terms of the Exchange Warrants are identical to the pre-funded warrants issued in the Private Placement and the accounting impact of the exchange was deemed immaterial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company filed with the SEC, and the SEC declared effective, a shelf registration statement on Form S-3 related to the sale and issuance of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s securities, including up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of common stock that may be offered and sold from time to time in one or more &#8220;at-the-market&#8221; offerings pursuant to a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) and Leerink Partners LLC. The ATM Sales Agreement replaced the Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement, dated November 4, 2020, by and among the Company, Cantor and Stifel, Nicolaus &amp; Company, Incorporated. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365,316</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock in &#8220;at-the-market offerings&#8221; under the ATM Sales Agreement, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting sales agent commissions and other offering related costs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No shares were sold under the ATM Sales Agreement or the Prior ATM Sales Agreement during the year ended December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of filing of this Annual Report there were up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock available for future issuance under the ATM Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2022, through a private placement financing, the Company issued pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The purchase price per pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (representing the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share closing price of the common stock on May 24, 2022, less the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant). The private placement financing of the pre-funded warrants resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All pre-funded warrants, including Exchange Warrants were classified as a component of permanent equity in the Company&#8217;s balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087955153424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#8220;2015 Plan&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2019, the Company&#8217;s board of directors adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221; and collectively with the 2015 Plan, the &#8220;Option Plans&#8221;). Upon the effectiveness of the 2019 Plan, the 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. In addition, the number of shares reserved for issuance under the 2019 Plan automatically increases on January 1 of each year beginning January 1, 2020 by a number equal to (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#8217;s board of directors. As of January 1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,375,932</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for issuance pursuant to the automatic increase to the authorized shares under the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Option Plans provide for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. As a private company, the estimated fair value of the Company&#8217;s underlying common stock was determined by the board of directors. Following its initial public offering, the fair value of the Company&#8217;s common stock is based on the closing price of its common stock on the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240,336</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock pursuant to purchase rights to be granted to the Company&#8217;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance automatically increases on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240,336</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240,336</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each employee&#8217;s compensation. The 2019 ESPP generally provides for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-month offering period, which includes four </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, employees purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,551</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares at weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,671</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares at a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the 2019 Plan is set forth below for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.777%;box-sizing:content-box;"></td>
        <td style="width:1.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.385%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.385%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price Per</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099,947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,206</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,648,459</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,374</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">728,712</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.36</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,224,884</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.65</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock for options that were in-the-money as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options granted in the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> had a weighted average per share grant-date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and a total grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash received from stock option exercises were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The Company issues new shares of common stock upon exercise of options. In connection with these exercises, there was no tax benefit realized by the Company due to its current loss position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fair value of options that vested in the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.92%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs vested and settled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee stock option valuation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.432%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.16</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.75</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.70</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.88</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.06</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.87</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.06</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.93</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.64</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.432%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.91</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.90</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.79</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.12</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,203</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,941</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,732</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,150</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,091</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. This unrecognized stock-based compensation cost is expected to be recognized over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repricing of stock options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 12, 2024, the Compensation Committee (the &#8220;Committee&#8221;) of the Board of Directors of the Company approved an option repricing, which was effective on November 13, 2024 (the &#8220;Effective Date&#8221;). The repricing generally applies to options to purchase shares of the Company&#8217;s common stock that: (i) were granted under the Company&#8217;s 2019 Plan; (ii) as of the Effective Date, are held by the Company&#8217;s then-current employees and consultants (subject to the caveat below) (each, an &#8220;Eligible Participant&#8221;); and (iii) have an exercise price per share greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Eligible Options&#8221;). The Eligible Options include options held by certain of the Company's executive officers. Options held by non-employee members of the Board were not eligible for the repricing program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date, the Eligible Options were immediately repriced such that the exercise price per share for such options was reduced to the closing price of the Company&#8217;s common stock per share on the Effective Date, subject to certain retention requirements outlined below. The closing price of the Company&#8217;s common stock per share on the Effective Date was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.57</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which became the reduced exercise price per share for the Eligible Options. If an employee exercises Eligible Options in advance of the end of the retention period as described below, the employee will be required to pay a premium exercise price equal to the original exercise price per share of the Eligible Options. There were no changes to the number of shares underlying the Eligible Options or to the vesting schedules or expiration dates of the Eligible Options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to exercise the Eligible Options at the reduced exercise price, holders of the Eligible Options are required to remain in service with the Company through the end of the relevant retention period. The retention period begins on the Effective Date and ends on the earliest of the following: (i) the date 12 months following the Effective Date; (ii) a Change in Control (as defined in the 2019 Plan) if the Eligible Options are not assumed or continued by the successor or acquiror entity (or its parent company) in such Change in Control or substituted for a similar award of the successor or acquiror entity (or its parent company); or (iii) the option holder&#8217;s termination of Continuous Service (as defined in the 2019 Plan) (a) due to such individual&#8217;s death or disability, (b) by the Company (or successor entity in a Change in Control) other than for Cause (as defined in the applicable 2019 Plan) or (c) due to such option holder&#8217;s resignation on or following a Change in Control under certain circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date, the total number of shares underlying all Eligible Options was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares. The effect of the repricing resulted in total incremental stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which will be recognized on a straight-line basis through the end of the retention period, while the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized on a straight-line basis over the original vesting period for those options that vest after the end of the retention period. The incremental stock-based compensation expense was calculated using the Monte Carlo option-pricing model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company recognized incremental stock-based compensation expense totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the option repricing, which is included in general and administrative and research and development expense on the statement of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087954395168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,798</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,798</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign losses not benefited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Global intangible low-taxed income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,565</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,086</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,355</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,588</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development capitalized expenditures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,282</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,652</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimentation (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for domestic expenses and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for foreign expenses. As a result of this provision of the 2017 Tax Act, deferred tax assets related to capitalized research expenses increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The increase in the valuation allowance is mainly related to the capitalization of research and development expenses under Internal Revenue Code ("IRC") Section 174, capitalization of the Jemincare upfront fee as an intangible under IRC Section 197 and an increase in net operating loss carryforwards incurred during the respective taxable years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">317.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and are available to offset future taxable income. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded federal and state reserves of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#8217;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the 2017 Tax Act as modified by the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) the carryforward period of net operating losses generated from 2018 forward is indefinite but the ability to deduct such federal net operating losses is limited to 80% of taxable income; however, the carryforward period for net operating losses generated prior to 2018 remains 20 years. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. In February 2022, California Senate Bill 113 &#8220;SB 113&#8221; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. In June 2024, California Senate Bill 167 (&#8220;SB 167&#8221;) was signed into law, which suspends the NOL utilization for companies whose California taxable income exceeds $1 million and limits R&amp;D credit utilization to $5 million. Given the Company&#8217;s loss position, SB113 and SB167  did not impact the Company's tax provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,663</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions on tax positions related to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions on tax positions related to current year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">905</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,014</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,579</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest expense or penalties related to unrecognized tax benefits through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns with varying statutes of limitations in the United States and various states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was signed into law in August 2022 and contained several tax provisions to curb inflation by reducing the deficit, lowering prescription drug prices, investing into domestic energy production while promoting clean energy, and introduced the topic of corporate alternative minimum tax on applicable corporations. There is no impact to the Company&#8217;s current tax provision from this legislation.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087865023184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,798</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net loss per share, basic and diluted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,761,143</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,338,161</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.19</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.05</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,403,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants to purchase the Company's shares of common stock, respectively, issued in private placement financings (see Note 8), were included in the basic and diluted net loss per share calculation.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.243%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.243%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding under the 2019 Plan and 2015 Stock Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099,947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated shares issuable under the 2019 ESPP</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,896</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,904</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs subject to future vesting</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,068,216</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,135,351</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858264496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company. The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) until December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5478996a-804a-4f18-89f0-88f2679981b1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Brian Wong, M.D., Ph.D. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company&#8217;s operating segment and decides how to allocate resources based on the Company&#8217;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024 and 2023, all of the Company&#8217;s property and equipment was maintained in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities primarily consist of commercial paper, corporate debt securities and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the Company's available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, the Company determines if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#8217;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. If the impairment is a result of a credit-related loss, the Company recognizes an allowance for credit losses. If the impairment is not a result of a credit loss, the Company recognizes the loss in other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b2c0381-34b5-4225-b14c-08e039f44849;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record any impairment losses on long-lived assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. Amounts incurred in connection with license agreements, such as upfront license and milestone fees are also included in research and development expense. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines employee, non-employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company retrospectively </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2023-07 on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and will adopt it for its interim reporting starting with the quarter ending March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The adoption of ASU 2023-07 did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company&#8217;s financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (&#8220;ASU 2024-03&#8221;). ASU 2024-03 requires disaggregated disclosures of certain categories of expenses in the notes to the financial statements that are included in expense line items on the face of the income statement in annual and interim periods. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on its financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this standard on the income tax disclosures within the financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087865028496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.187%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:10.582%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,776</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,776</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,772</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,790</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,820</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,825</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,795</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,795</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,743</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230,906</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230,956</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,636</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,636</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,270</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.187%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:10.582%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.382%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,869</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,869</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,531</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,559</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,242</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,245</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,828</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,827</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,206</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,279</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,676</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,779</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,395</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,395</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,384</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Remaining Contractual Maturities of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.548%;box-sizing:content-box;"></td>
        <td style="width:4.159%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:33.293%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturing in one year or less</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturing after one year through five years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859430144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,035</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,399</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">706</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">394</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,448</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,815</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,081</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,448</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087865029248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,239</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,723</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional and consulting services</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,493</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">341</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,597</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087860287216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturities of operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.856%;box-sizing:content-box;"></td>
        <td style="width:2.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.703000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,137</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,799</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Lease Liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Supplemental Balance Sheet Information Related Operating leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the supplemental balance sheet information related to operating leases at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.447%;box-sizing:content-box;"></td>
        <td style="width:2.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,422</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,458</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,906</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of balance sheet classification related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863652912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock', window );">Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options issued and outstanding under the 2019 Equity Incentive Plan and<br/>&#160;&#160;&#160;2015 Stock Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units issued and outstanding under the 2019 Equity<br/>&#160;&#160;&#160;Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grants under the 2019 Equity Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,489,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,032,820</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,403,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">492,307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410,522</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,390,057</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,556,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserved shares of common stock for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858480592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the 2019 Plan is set forth below for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.777%;box-sizing:content-box;"></td>
        <td style="width:1.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.385%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.385%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price Per</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099,947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,206</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,648,459</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,374</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">728,712</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.36</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,224,884</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.65</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.92%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs vested and settled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Under Stock Option Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.432%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.91</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.90</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.79</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.12</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,203</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,941</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,732</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,150</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,091</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee and Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Under Stock Option Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.432%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
        <td style="width:1.235%;box-sizing:content-box;"></td>
        <td style="width:16.049%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year<br/>Ended December 31,</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.16</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.75</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.70</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.88</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.06</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.87</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.06</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.93</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.64</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858851232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,798</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,798</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign losses not benefited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Global intangible low-taxed income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,565</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,086</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,355</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,588</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development capitalized expenditures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,282</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,652</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.46%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,663</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions on tax positions related to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions on tax positions related to current year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">905</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,014</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,579</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858865072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.08%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,798</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net loss per share, basic and diluted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,761,143</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,338,161</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.19</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.05</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities not Included in Diluted per Share Calculations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.243%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.243%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding under the 2019 Plan and 2015 Stock Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,005,320</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099,947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated shares issuable under the 2019 ESPP</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,896</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,904</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs subject to future vesting</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,068,216</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,135,351</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857398912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>Employees</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,865,000<span></span>
</td>
<td class="nump">$ 116,798,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,297,000<span></span>
</td>
<td class="nump">$ 97,048,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of workforce reduction | Employees</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of reduction existing headcount</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Restructuring charges</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AccruedExpensesRelatedToWorkforceReductionPlan', window );">Accrued expenses related to workforce reduction plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AccruedExpensesRelatedToWorkforceReductionPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses related to workforce reduction plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AccruedExpensesRelatedToWorkforceReductionPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087856431088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Institution</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_NumberOfFinancialInstitution', window );">Number of financial institutions | Institution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses on long-lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The CODM assesses performance for the Company&#8217;s operating segment and decides how to allocate resources based on the Company&#8217;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU No. 2023-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_NumberOfFinancialInstitution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_NumberOfFinancialInstitution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857562176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 230,906<span></span>
</td>
<td class="nump">$ 158,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">230,956<span></span>
</td>
<td class="nump">158,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Less: Cash equivalents</a></td>
<td class="num">(169,636)<span></span>
</td>
<td class="num">(47,395)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_MarketableSecuritiesAtAmortizedCost', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">61,270<span></span>
</td>
<td class="nump">111,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_MarketableSecuritiesAtUnrealizedGains', window );">Marketable securities, Unrealized Gains</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_MarketableSecuritiesAtUnrealizedLosses', window );">Marketable securities, Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, Fair Value</a></td>
<td class="nump">61,320<span></span>
</td>
<td class="nump">111,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">152,776<span></span>
</td>
<td class="nump">10,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">152,776<span></span>
</td>
<td class="nump">10,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,772<span></span>
</td>
<td class="nump">19,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">17,790<span></span>
</td>
<td class="nump">19,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">5,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,825<span></span>
</td>
<td class="nump">5,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,795<span></span>
</td>
<td class="nump">59,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">16,795<span></span>
</td>
<td class="nump">59,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,743<span></span>
</td>
<td class="nump">63,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 39,770<span></span>
</td>
<td class="nump">$ 63,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_MarketableSecuritiesAtAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities at amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_MarketableSecuritiesAtAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_MarketableSecuritiesAtUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities at unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_MarketableSecuritiesAtUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_MarketableSecuritiesAtUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities at unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_MarketableSecuritiesAtUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087864994336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses or other impairment charges related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859339312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 61,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Total</a></td>
<td class="nump">$ 61,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859934912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 11,448<span></span>
</td>
<td class="nump">$ 11,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(10,081)<span></span>
</td>
<td class="num">(9,367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,035<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">3,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859317488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087865005152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 1,239<span></span>
</td>
<td class="nump">$ 7,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,723<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting services</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 9,597<span></span>
</td>
<td class="nump">$ 14,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857819792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Contingency losses, accrued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_OperatingLeaseExpirationYear', window );">Lease expiration period</a></td>
<td class="text">2025-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease', window );">Additional laboratory and office facilities under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncreasedAreaOfLeasedPremises', window );">Increased of leased premises | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_LesseeOperatingLeaseExtendedLeaseTerm', window );">Lessee operating lease extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee operating lease option to extend</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember', window );">South San Francisco and California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease', window );">Laboratory and office facilities under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SquareFeetAreaOfOfficeFacilityUnderLease', window );">Additional office facilities under lease | ft&#178;</a></td>
<td class="nump">13,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional square feet area of laboratory and office facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreasedAreaOfLeasedPremises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased area of leased premises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreasedAreaOfLeasedPremises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OperatingLeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OperatingLeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square feet area of laboratory and office facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SquareFeetAreaOfOfficeFacilityUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square Feet Area Of Office Facility Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SquareFeetAreaOfOfficeFacilityUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858682192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Summary of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future undiscounted lease payments</a></td>
<td class="nump">4,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 4,492<span></span>
</td>
<td class="nump">$ 6,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863937168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Summary of Balance Sheet Classification of Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,333<span></span>
</td>
<td class="nump">$ 5,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 4,492<span></span>
</td>
<td class="nump">$ 6,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859902256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - License Agreement - Shanghai Jemincare Pharmaceutical Co., Ltd.<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer', window );">Contingent payments upon completion of manufacturing technology transfer</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AccruedUpfrontLicenseFee', window );">Accrued upfront license fee</a></td>
<td class="nump">35.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rapt_LicenseAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">672.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone', window );">Contingent payments upon achievement of specified development and regulatory milestones</a></td>
<td class="nump">226.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone', window );">Contingent payments upon achievement of specified commercial milestones</a></td>
<td class="nump">$ 445.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AccruedUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AccruedUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of specified commercial milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of specified development and regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon completion of manufacturing technology transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rapt_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rapt_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rapt_ShanghaiJemincarePharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rapt_ShanghaiJemincarePharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858670384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,957,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance | shares</a></td>
<td class="nump">92,390,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,390,057<span></span>
</td>
<td class="nump">11,556,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">ATM Sales Agreement | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ATM Sales Agreement | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue', window );">Common stock available for future issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rapt_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="nump">76,452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">76,452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ClassOfWarrantOrRightPurchasePricePerWarrant', window );">Purchase price per warrant | $ / shares</a></td>
<td class="nump">$ 0.8499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4999<span></span>
</td>
<td class="nump">$ 0.8499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from issuance of pre-funded warrants</a></td>
<td class="nump">$ 143,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period | shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ClosingPricePerShare', window );">Closing Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Maximum | ATM Sales Agreement | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rapt_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ConversionOfCommonStockForPre-FundedWarrants', window );">Exchange of common stock for pre-funded warrants | shares</a></td>
<td class="nump">2,951,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,951,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rapt_ExchangeWarrantsMember', window );">Exchange Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="nump">2,951,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,951,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ClassOfWarrantOrRightPurchasePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, purchase price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ClassOfWarrantOrRightPurchasePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares available for future issuance value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ConversionOfCommonStockForPre-FundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Common Stock for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ConversionOfCommonStockForPre-FundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rapt_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rapt_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rapt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rapt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rapt_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rapt_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859307024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">92,390,057<span></span>
</td>
<td class="nump">11,556,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_PreFundedWarrantsIssuedAndOutstandingMember', window );">Pre-funded warrants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">83,403,425<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember', window );">2019 Equity Incentive Plan and 2015 Stock Plan | Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">5,005,320<span></span>
</td>
<td class="nump">4,099,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Shares Available for Future Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">3,489,005<span></span>
</td>
<td class="nump">3,032,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">492,307<span></span>
</td>
<td class="nump">410,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_PreFundedWarrantsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_PreFundedWarrantsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_OptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_OptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_RestrictedStockUnitsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_RestrictedStockUnitsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_SharesAvailableForFutureGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_SharesAvailableForFutureGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859652400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,390,057<span></span>
</td>
<td class="nump">11,556,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,935,000<span></span>
</td>
<td class="nump">$ 17,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.48<span></span>
</td>
<td class="nump">$ 20.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue', window );">Stock options grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Number of stock options, exercises intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock option vested aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,800,000<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, expected period to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,732,000<span></span>
</td>
<td class="nump">9,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance', window );">Percentage of increase in shares reserved for issuance on common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount', window );">Increase in shares at the beginning of each calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate on salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share-based compensation, employee purchased shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,551<span></span>
</td>
<td class="nump">87,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Share-based compensation, shares at weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 12.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_RepricedStockOptionsMember', window );">Repriced Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum', window );">Stock option repricing program, minimum exercise price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares underlying all Eligible Options</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental cost</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_RepricedStockOptionsMember', window );">Repriced Stock Options | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_RepricedStockOptionsMember', window );">Repriced Stock Options | Recognized Through The End Of The Retention Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental cost</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_RepricedStockOptionsMember', window );">Repriced Stock Options | Recognized After The End Of The Retention Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental cost</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans | Employees, Officers, Directors, Advisors, and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans | Maximum | Employees, Officers, Directors, Advisors, and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember', window );">2019 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance', window );">Percentage of increase in shares reserved for issuance on common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_PercentageOfIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase in shares amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, plan modification, exercise price, minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_RepricedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_RepricedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863783872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Plans (Details) - Option Plans - Share-based Payment Arrangement, Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">4,099,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Outstanding, Stock options granted</a></td>
<td class="nump">1,648,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Outstanding, Stock options exercised</a></td>
<td class="num">(14,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Outstanding, Stock options forfeited</a></td>
<td class="num">(728,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">5,005,320<span></span>
</td>
<td class="nump">4,099,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares Outstanding, Vested and expected to vest</a></td>
<td class="nump">5,005,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Outstanding, Exercisable</a></td>
<td class="nump">3,224,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Beginning Balance</a></td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options granted</a></td>
<td class="nump">21.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options exercised</a></td>
<td class="nump">4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options forfeited</a></td>
<td class="nump">23.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance</a></td>
<td class="nump">20.94<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">20.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 19.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Average Remaining Contractual Term (Years), Balance</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Average Remaining Contractual Term (Years), Vested and expected to vest</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 23,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087857773968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - 2019 Plan - Restricted Stock Unit ("RSU")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Beginning Balance | shares</a></td>
<td class="nump">13,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares Outstanding, RSUs vested and settled | shares</a></td>
<td class="num">(13,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Ending Balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 44.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, RSUs vested and settled | $ / shares</a></td>
<td class="nump">44.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087860149504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details) - Employee and Non-employees - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">95.60%<span></span>
</td>
<td class="nump">64.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">165.30%<span></span>
</td>
<td class="nump">93.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">4.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.53%<span></span>
</td>
<td class="nump">5.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">99.60%<span></span>
</td>
<td class="nump">94.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">110.70%<span></span>
</td>
<td class="nump">97.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.64%<span></span>
</td>
<td class="nump">4.71%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 12.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 24.75<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087859899504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,935<span></span>
</td>
<td class="nump">$ 17,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,203<span></span>
</td>
<td class="nump">7,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,732<span></span>
</td>
<td class="nump">$ 9,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087864993456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (129,865)<span></span>
</td>
<td class="num">$ (116,798)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">$ (129,865)<span></span>
</td>
<td class="num">$ (116,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087856574176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(21.50%)<span></span>
</td>
<td class="num">(22.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087864739776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 67,565<span></span>
</td>
<td class="nump">$ 58,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">15,086<span></span>
</td>
<td class="nump">12,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves', window );">Accrued liabilities and reserves</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,588<span></span>
</td>
<td class="nump">6,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">8,036<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxAssetsLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalized expenditures</a></td>
<td class="nump">33,708<span></span>
</td>
<td class="nump">27,290<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">135,282<span></span>
</td>
<td class="nump">107,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(134,582)<span></span>
</td>
<td class="num">(106,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087863923616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="nump">$ 26,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest expense or penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment', window );">Increase in deferred tax assets related to capitalized research expenses</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">15,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 317,600,000<span></span>
</td>
<td class="nump">273,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UncertainTaxPositionsReserves', window );">Uncertain tax positions reserves</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm', window );">Research and experimental expenses required to amortized term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UncertainTaxPositionsReserves', window );">Uncertain tax positions reserves</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm', window );">Research and experimental expenses required to amortized term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in deferred tax assets in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and experimental expenses required to amortized term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UncertainTaxPositionsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UncertainTaxPositionsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087858751728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 4,674<span></span>
</td>
<td class="nump">$ 3,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Additions on tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions on tax positions related to current year</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 5,579<span></span>
</td>
<td class="nump">$ 4,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087864806160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (129,865)<span></span>
</td>
<td class="num">$ (116,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per share, basic</a></td>
<td class="nump">40,761,143<span></span>
</td>
<td class="nump">38,338,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per share, diluted</a></td>
<td class="nump">40,761,143<span></span>
</td>
<td class="nump">38,338,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087865027248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_PreFundedWarrantsToPurchaseCommonStock', window );">Pre-funded warrants to purchase common stock</a></td>
<td class="nump">83,403,425<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_PreFundedWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_PreFundedWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45087954095824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,068,216<span></span>
</td>
<td class="nump">4,135,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember', window );">Stock Options Issued and Outstanding Under the 2019 Plan and 2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,005,320<span></span>
</td>
<td class="nump">4,099,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember', window );">Estimated Shares Issuable Under the 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">62,896<span></span>
</td>
<td class="nump">21,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember', window );">RSUs Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MT@<L45[.RH;BF^)^\\H5W):*QP0NM%1H _B^XEP=&KJ#^HH\_0]02P,$%
M  @ Z$!F6K!&-N!\!P  Z4   !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6RUG&MSFT88A?_*CIIIDYDH8KD)4ELSB<1MFL1N9+?3CVNTDIAP46%E)_WU
M71"6Q(+6T'F;#[$NO,]9EN,%]BR^>LKR;\664H:^)W%:7(^VC.W>3R9%N*4)
M*=YE.YKR;]99GA#&W^:;2;'+*5E514D\417%G"0D2D>SJ^JSVWQVE>U9'*7T
M-D?%/DE(_N,CC;.GZQ$>/7_P-=IL6?G!9':U(QNZI.Q^=YOS=Y,C914E-"VB
M+$4Y75^//N#W@:J7!=46?T3TJ3A[C<I=><BR;^6;8'4]4LH6T9B&K$00_N.1
MSFD<ER3>CK]KZ.BH61:>OWZFN]7.\YUY( 6=9_&?T8IMKT?6"*WHFNQC]C5[
M\FF]0T;)"[.XJ/Y'3_6VR@B%^X)E25W,6Y!$Z>$G^5YWQ%D!UBX4J'6!*A;H
M%PJTND#KJZ#7!;I0H$XO%!AU@=&WP*P+3*% QQ<*IG7!5%2XU*U676")"N:%
M KLNL"L['(Y?=? 7A)'959X]H;S<FM/*%Y6#JFI^S*.T-/N2Y?S;B->QV?+N
MPYWSV?ERMT0W+EK>W<Q_\V\^+9RORU^0\_M]</<7&J/[Y0*]?O4&O4)1BNZV
MV;X@Z:JXFC#>@!(S"6NQCP<Q]8+87<9(W%$VEY=]8%R4HL\D_T991_E"7C[/
MDH3_6BU9%G[KJ';Z5Z.76N*^L".K553^BI,8W9)H-0Y2-">[J+M3O/_*>K&5
M_@OD,-PG^Y@PND(+NH["J L2](?<L"W-$>](/AQORW'RD:(@#;.$HM>?LJ)X
MT\1/N(6//E://E8K/?V"WD>ZB=(T2C=\Z(M)&E)$&&]]^ YI^"U2%57MLNN!
M:5;,\K3P.%-U YOFU>3QW)Y2Z?)T]+[8D9!>C_@.%C1_I*/9SS]A4_FURZQM
M3:TIYT#*N6TY$VO*5-#T(#7]MN98,Z>6I3=%@X[MU%/?-WR@'7V@#?/!6U1L
M"6]S+S](V0-[80X)6QQ@QKEK=-70-2STJ0.IZD+"/$B8#PD+@& -P^I'P^I2
MPP9%L2]]6J!LC<+#R::H3C;[=,6'39KLXNP'I?6'.V[JSC.OWC((UO6I,)!)
MFS+4DI P!Q+F]ND+#U+1AX0%0+"&'8VC'0UP.SX/L5VVE*H-'5$A80NCPR2:
M;5O"> JIZ4+"/$B8#PD+@& - YM' YM2 U<7ZN/R_G=5^G?'KS=)>9W<94ZS
M;8&I8F-AT)3J#74=),R!A+F].L.#E/0A80$0K&&ZZ=%T4ZGIW"RGT2;E-^QY
M3M/P!V(Y'Q?CRG@HYK<X7>Z;MCI\;!J&8#ZI[E#S0<(<2)@+"?,@83XD+'CA
MD#>\9QV]9TF]=Y_FE,31/WR\VY H1:]+O[U!W'A)-0% 'F)^MJ;<FA&+ND_2
M5JM94_%>;2YMQ% C0L(<2)@+"?,@83XD+) ?\88/[:,/;:D/OU FF]4Y.,UN
M_P)@;$[%JZZY5&JHVR!A#B3,A81YD#"_YX$*@$0;CL/*:?):D7K.25>2*3^M
M<X9::4TZ87VJ:.*)5ZX\U((=JN*L'ZB@6]/.#Z"I81.+UW.@JGZ'ZEBW=--2
M!=MT;(@5K7L PF=9!AY@ATLS?]VVP!T3;)IM:5@5C2%MPV!C]-5U0'5=4)H'
M2O-!:0$4K>G)4RZ!Y<'$\X1*:SZ%I"O$%<?K<F)EA9Y(SN\96%%&;(1_$3T2
M1LOYE9 F-&5O4<K/KYP1/?/"K&#=&5Q[6AWKFF(HHI%!8XTN546T,&BR4=.$
M&1Q%5\0A#C3; *4%4+2F.4]A"9:G)?^O.67S@O*&#9T8!*4M<#MLP4K]3W0T
M:-P"2O- :3XH+8"B-7U_RERP/'1QOH=;DF[:OE]G>9?O.QT,.><_!Z4M<#L!
M&:NV@775$ T,&KR TCQ0F@]*"Z!H30.?4AK<+Z9I&SC/DO+#<D#N<:D &L_4
MM/-+ ,LVA-QM :KI@-)<4)K7JS]\4,T BM;TY2E\P?+T1>[+X5<)D G!')2V
M *4YN!V_:*;![]B;;G%!53U0F@]*"Z!H32>?$ATLCW2@UF7@]IR_I;<FFT!C
M'E": TIS^W2'!RKI@]("*%K3EJ>P!\O3'NCU&7*YP2,L:$J$VRD%MG6S?0T+
MF@"!TCQ0F@]*"Z!H32N?\B(L#XR&K-3 [3P"VW9[TAXT-P*E.: TMU^'>*"B
M/B@M@*(UUXN?LB-5GAW]IS4;:CNW$*=5Y;*#5XM#TAQ0F@M*\T!I/B@M@*(U
MK7K*M51YK@6PQ$-MYTQC0Q.M"QIM@=(<4)H+2O- :3XH+7CAP#<=>4JU5'FJ
MU6NQA]H.:,98M2U3/&W+Q0;[#I+F@-)<4)H'2O/['JX 2K;IO5-HI<I#*_FB
M#[W3B5H[G+1L6Q$7N<F5!QNQ0[7UK!=H@-2A:"FZ9@FK=CQ05;]#=6QBW1 ?
MN0@Z-CQ+I9MV.&4YZ@M93J]%']VV:,<D6"L?$[=4<4&:O!&#G=%;V $5=D%I
M'BC-!Z4%4+2#*R=G3UB7?P3@,\DW45J@F*XY7GDWY8<R/SQ7?WC#LEWUT/5#
MQEB65"^WE*QH7F[ OU]G&7M^4S['??SK!K-_ 5!+ P04    " #H0&9:C%2L
M.6L"  #I!   &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;'U4;6_3,!#^
M*Z<P 9-&TZ9=8:.-U+=I$Y25I0,AQ <WN336'#NS+^WV[[&3-A1IZY?89]\]
MSW.7.P^V2C^8#)'@*1?2#+V,J+CT?1-GF#/34@5*>Y,JG3.RIE[[IM#(DBHH
M%W[0;O?]G''IA8/J;*'#@2I)<(D+#:;,<Z:?QRC4=NAUO/W!'5]GY [\<%"P
M-49(]\5"6\MO4!*>HS1<2="8#KU1YW+<<_Z5PP^.6W.P!Y?)2JD'9]PD0Z_M
M!*' F!P"L\L&)RB$ [(R'G>87D/I @_W>_2K*G>;RXH9G"CQDR>4#;U/'B28
MLE+0G=I>XRZ?<X<7*V&J+VQKW_ZY!W%I2.6[8*L@Y[)>V=.N#@<!0?!*0+ +
M""K=-5&E<LJ(A0.MMJ"=MT5SFRK5*MJ*X]+]E(BTO>4VCL)H.5K.YK-ORPAN
MKR!:WDZ^7-]^G<[NHG<P^WY_L_P%[Q=,HZ0,B<=,G,()< ES+H2MJAGX9%4X
M+#_>,8YKQN 5QDX <V7A#,QD@LG_ +Z5W^00[',8!T<1IQBWH-LY@Z =]. ^
MFL+[D],CN-VF-MT*M_M:;8@1V@8D4"E$I.*'3(D$M;&E>2PY/</OT<J0MIWU
MYZ4ZU.B]E]'=M%V:@L4X].PX&=0;],*W;SK]]N<CVGN-]MXQ]'"B\MPVO7&J
M@<D$+,>'M'05ARW3FDDR9\"-*9F,$6)EZ,5_6;-<5"QNP#=AOW4Q\#>'TOR#
M]LM1KZLA,Q:SE%1W8G/:S/&H;M]_[O4C,&=ZS:4!@:D-;;<^VK'1]6#5!JFB
M:N:5(CL:U3:S;Q%JYV#O4Z5H;SB"YG4+_P)02P,$%     @ Z$!F6AJ,IP<M
M!@  3!D  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM66UOHS@0_BM6
M;G6ZDS8;;"! KXW4IEOM2OM2;;JWGUUP&E\!YVPGW=ZOOS%02,!X6ZE?6C#C
M\3,SGGG&SNF#D/=JPYA&/XN\5&>3C=;;D]E,I1M64/5.;%D)7]9"%E3#J[R;
MJ:UD-*LF%?F,>-Y\5E!>3A:GU=BU7)R*G<YYR:XE4KNBH/+Q@N7BX6R")T\#
MW_C=1IN!V>)T2^_8BNGOVVL);[-62\8+5BHN2B39^FQRCD^6)#$3*HF_.7M0
M!\_(F'(KQ+UY^9B=33R#B.4LU48%A7][MF1Y;C0!CG\;I9-V33/Q\/E)^U5E
M/!AS2Q5;BOP'S_3F;!)/4,;6=)?K;^+A VL,"HV^5.2J^HL>&EEO@M*=TJ)H
M)@."@I?U?_JS<<3!!#P?F4":":0_(1B9X#<3_,K0&EEEUB75='$JQ0.21AJT
MF8?*-]5LL(:7)HPK+>$KAWEZL;HYOWG_^?V7FQ7Z>H66YZL/Z.K3UQ\K-$7?
M5Y?HCS=_HC>(E^AF(W:*EIDZG6E8UDR>I<T2%_429&0)3-!G4>J-0N_+C&7'
M"F: MP5-GD!?$*?&2Y:^0SY^BXA' @N@Y?.G^PXX?NM#O]+GC^C[NF62:E[>
MU9N2:\ZL;JJU!'8M)E]/U):F[&P"":F8W+/)XO??\-S[RV;B*RD[,CAH#0Y<
MVA=?H+SD0EF-K&?.JYFFANP74TR2>!Z>SO:'^&UR>!XE<2MW!"ULH87.6)QG
M_T#20)W1"FD!A2859<ISALH&LQDUSRE5&[13+#.[6U@B>&*S+GS-$+Z2LB,_
MS5L_S9TA/$]3R:I"*M8HXRH5.^,R>(=J?L\TO06?*9;NY.AVKA<(#R-(8NSW
MXFR1"B-_;H]RU**/G.@O&;@DY;1F@C)#M!!2\_^J 1O6:( "$Z\/U2:$1Y#&
M+=+8B72E17H_-423H504P+ZJ1LU^FF=F QL/<22)WT\@BU3D)=@.-VGA)DZX
MGTR& #KH#X  2V @*5F9/B(M::GR4?\F S!>#^Y08CH/0SM:['7LY;DKD2BG
M529W&9PS<+;+O8W*0RC$/]B1-5Z[U!C@ [K%SOJTW-#RCJE>T5&*0?*9C9QS
M>LOS\0+4J'^E"O1:VHZ=03IG$&?TKB7;4IX]!:OV@- ;)AN76#U AH$A!/?#
M-Y2*HY'DP!W18R>MFJI9U\DM?305\BWP12IWS&I"G3OZ,*16>_QA9L1!F/0-
M&HI%X_NQ8W+LIO)//#6XT9JQUBHKRF"PO!]Z7C_++6+>",2.T;&3" _:JSJU
M?^7/T,9+8;]\6L4B+QI!V_$J=A/KE^?T%E;<%J:,?9)$?> 6N23R@I'&"7><
MBB-G:?I8[IEZ#E G-[^X!+V2MF.C.WK&;GZ^WLET8W85M$'/[GSPD'NG,=2@
MN!\JBQR>XR 9VV4=36,W3U]+D3*6*;26H@#@ND'[,C.&G(PAJ0/2-V,H1^;S
M:(R]2<?>Q,W>A\[?2I,H^K$JH.S?'=^:)MX&FPR9&8X8?=!6*4S&,'<$3IR<
MV.4W -YS.,^BVT=(\^>E3J/[$%0(16> ?2B&O0#[_@CXCG )<:;X%2\I'(=^
MC=/)VR]-\=?2=FQT1]K$3=K'N:)H7NTW:,8+:'25Z<^K/0=K3]<[<T.!'JB$
M=E=771J%#WQ/-4/;'#":3?FV.D""#J[4#OS)0)FR-RMDR-HX\+VPSYL6N1'>
M)!VU$S>U']O]A%4-C <C)U1/H6>9UJ5C B)K)F&;J)>8.J3^. G[[&61&C.T
M:Q"(NT&P&SJPT\16(E9L<_'(6#,(02WMY@S[ ^C*^M8,A7 0C%1WTO40Y)D]
MQ&&-63\W=X?] 0ZA 1H4&8O<./:NBR#NH[G!SLM45JT:;*W*#I-?U8,I['O(
MP')D#]F.X(0,=]%0+@Y],H*]:P:(NQE8CF%%5*-;=L?+TOC?L!6DA\BL)@PY
M/XB"J-\:6,3\. E&;AM(UQ@0=V/@-(&9LXD3?#*XE</S)!K</5CDCHVLT<\.
M[J4+)N^JZWJ%JC-4?=O;CK8_"9Q7%^&]\0M\LJPO]CLU]>\,GZF$L"@X&JQ!
MI?<N H_*^NJ^?M%B6]U^WPJM15$];AB%2F $X/M:"/WT8A9H?T!9_ ]02P,$
M%     @ Z$!F6G -#,G'#   "$,  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6SM7&MO&S<6_2N$"Q0MH,B6\VR<&$B<I VV00([N\6BV _4#"41GAFJ
M)$>V\NOWW$O.#"6/QG;2?6!7'Q+K05[>Y[GG4K9>7!E[Z19*>7%=%I5[>;#P
M?OG\\-!E"U5*-S9+5>&=F;&E]'AJYX=N:97,>5-9'!X?'3TY+*6N#DY?\&N?
M[.D+4_M"5^J3%:XN2VG7KU5AKEX>3 Z:%\[U?.'IA</3%TLY5Q?*_W7YR>+9
M82LEUZ6JG#:5L&KV\N#5Y/GKR1/:P"O^IM652QX+,F5JS"4]>9^_/#@BC52A
M,D\B)'ZLU)DJ"I($/?Z(0@_:,VEC^KB1_HZ-AS%3Z=29*7[3N5^\/'AV('(U
MDW7AS\W5+RH:])CD9:9P_+^XBFN/#D16.V_*N!D:E+H*/^5U=,1=-AS'#<>L
M=SB(M7PCO3Q]8<V5L+0:TN@!F\J[H9RN*"H7WN)=C7W^]&P]5=:IK+;:K\6Y
M=I?B@ZP0#WC>CP262J_F:R&K7/QL5LI6LLK4BT./LTG"81;/>1W..=YQSN18
M?#"57SCQMLI5OBG@$$JWFA\WFK\^'I3X1F5C\7 R$L='QX\&Y#UL/?&0Y3W\
M-D^,MEPA?O\5@L1[KTKWCSZ_A%,?]9]*1??<+66F7AZ@JIRR*W5P^OUWDR='
M)P,V/6IM>C0D?=@F\<F:3#FGG$!UBU?TR.EJ/A+O<[RM9VM^0N;R)CP3GQ<H
M?>_$[Y_5M1>O"Y-=]AH]K!8Y2TS.QB+H)S84+#L%Z6C79.!O2BSD2@E=+@M^
M6^6\@*#'XY]82:M-[82N EA1T;>V+UM;<^7TO,)F;X2.AL)*MCX*) 7PPRNK
M92$LM(*+K"E%MN%/'YT!0::V(L.+.L.&S)3+&IM%I3S#ZPA+M<T?+*7%MH5Q
MI#O%6D.G$:TOZPI;264GW-I1,HU@KLVOI%4CX<S,TR/6KSTG1\&/8&Y6U#D%
M!WX N@'N:KP)@Y<*QT$\W,_K/9L3=I$@XQ=0,C/5+/@!;Z:^\POIA78LR6KE
M =JC)APZ$\:RH<IKPE7L%)7T-73\X?OOGAT?'YV\3V1=!)OX6,(I7C(Y^7$L
M/L)SO1&;U14#]T@4\-9TS3Y^HRWLP]%F)E+YGU6VJ$QAJ#X7JEBZP=#";G$&
MW66U)D4F3T_<CM#2)HY_4/3VX^/I26ZQC*C#K:D$,TM3:1Q! :6=:B6+&J?@
M*3D@+!2J6FEK*JZ2FHJVS?Y2^87)79<6(ZYN=2VI;D:I> 1V!2W9N7(C15N]
M*(=B6F94<G:$^ED6AJ"!O$F91EIN;N;$;L1;(6MT,>FYY-"N*%4RI";5;&('
M$M[54X?LGI)P>-"JI;$Q"$VUQ*QL?-OOQ1_8Y94LUE](E*NS12/L1RJW*J\S
M]JC+)"Q#,/OUV?*]QC[D?Y<S%$XR<Z8+%=T0% B'!8RIW<:15*3H'' ;HA.-
MBT$-2<)G<\P:I:+4#3&KNJ@0FJDNR/!T9TB'-"#!ZVE*IKLU09"JY@'@>9^@
M?5KQGGAFCXZC>!0Z0; HX(^>*VJ+,Z7R6'1=QE'AY=)>BBLU'8LW"MR2D8O1
M1FUD-0>=46.$U1WJ]V.^IP(DD!N)Y6+M&.X8XNQ<5OH+IS!>*I5T@"BHWO8#
M@C2L!-0&;9>FT)G>ZA,1-_AH>&R.9+Y_?QC"PQWE^IQ>YZ@AI=P298BR*BAG
M4U5/MK(AZ:"\9'TB<NVDHY8$_"+J$E!I2@$D7$*0D54U-TH2?Q)2.PGV"8*3
MV?62M4\*AKK)2=/H.MP@@9:RCHZA-7AK;M4\6)\F=^QV)^#G6:,*[3SI GE#
MZ@EKYA-#T6&MS"Y;P@)[E\;)XJ21GV9A[_&J)%A3B@2A7U9S**!@EXW-4+F
M _U8$1KS1O1UA50CAAA:1^?+I!/Q4XB\>RX1"?#R4E54;8:<9FH2Z;AF259?
M<[-;Q*K-_K%XES:'N[58'K0<!A6_2(5"'6I^787LJ 8"<#*C-/BOT)>J((A"
MEY=<:[+S!HI>9KZIGR9;QT0%:Z<&FPY7'7RN'37(X%&/<9)>;G[^*>PO)6!)
MY7);(#[-N--VKYFVR,4?NBT%:H(88XW2+GX<-3"[ :4W;!MMJ8*Z<)A"99.(
M+5U,=@2[MI.T1W1?UK/:HQ:ZTV+J:"RLIVD]@_(KVH<<,#8H!)A?&M@$4/7-
M.$[,JL&T%19@[=TC"UI"F8EDH0Z@B*G,6L9(.69-/5^8VF]DSBA0 12+7"Z+
M2+A3VXF:DU$9UX\.Y+PB:&$ 5M)B>]I3T@5$AV9X4+-?ME8!D$"_IW7K$E=#
M!81N05 "V= SHWJ\T10CJXZ5W6920]Y&\65X'CQ<!T_02X/MAIF]J]4H\@\5
MBZ';WGB%NV\IUZ+VZ"Y?5-MR0\QZ4274.&T*B:Y@X(KN4TAXFWLI:8F(K&?M
M%,2 &EU;)ZT[():D]@RJV/8C4OGV1MRHU50W B!G,\7TID5-/GJ!01NOK7EY
M;E!22!YT!THG1E.*-,6RKHCB?B+PG8Q%F&Q?C<,H^RZN80Z'2>I5Q83YG-DA
MQ9<NEL3DZ,%?4A2)XY-X/XNL,QG).@QN^IJAF<"X-D$V"=S5 LY  +D[$V"/
M: .)C6,@99;%"ORDI(?OM*.DNJ+G=8'2O4:M:<8AF:_(J0PWZH^:7B.J2]##
M($&.YP+K)*5V(?E%93P@'QTB\"HP@KH@F%@GH,'AIQAGL78*W;P.D*%"#NQ'
M 5D#>T5QV7H9-\XV2CZ98$9$RVO?<$%,UZ"6A7&\!PFJJIJ=P80^(FD8D?L,
M'\<1-KT*HCX_-:"2)#&/?12"\MPV=7';X+G=J9/&3CJA(<"<0M"9CBX<6] ;
MB\\0?O/T>$X8-_BJ07N/1-:N@5\]1;NBUL5"E6J(^OT430AU%_).S80ZQXJ]
MK5JY&<C"F7#M(Z&/1=T0L=B MF;;!:QBY#UK;6QN(L[>7UR<-5<.R.V%1I)&
M:'(HZQ7[M%0EWT8Q1E5Z ]M2H]@W"ZUFXIVFN!-+^#@#<B%3VA/??6S."_>%
M,6YGH=&'8+%:C=>)^3;V]=Z'@)1Z+>FNQ;6@?8/GQ88:)K<M.AH&"3>*K3?,
MUD2'>O.&X*EANCM89:=P>LTVMS)VFE#2#/"! _=DT&Y:W'43 JE=MW[A]J)1
MM$'P_L#=]0+I9VW$+US3N?I"Z4(IZ#A08O)8K$$#.$L2:-15;]#&XH,==[)2
MKY,RR)*1.#=YA3[S=V3&O#L,!,6::TV-"DWJ^*CW5' (H@.NR<H=K:*#B$UM
M>B  S8,OGI;ATH]BBR.<J2I5A)NU>#>3HV@*L_P*H'#I1PK)U2?D7BK*(%2>
M;FX?K"K42E(V-%KT&,$@<<.2J.L2/J<$XJ%O9T4LF>X0\]M8DN0@UPR1F$!Z
M>SA,UR^:MQ] ?;[WBG$/NG.D^YR_0XM6RK3.YZJ_EFY>$Y VP]<".I96>M$!
M4B4+GMUB1>UP&5^*#. EW1)NTMA,VZPNZ:XEV^H1H1!8X0"K;Z]Q'E\J1U@=
M ^6W#X@4/R0@ VDRE?9EY4T7>27+=FI-"6 [P8:HERK7-^?9SA=P0&@I3!C)
MI: YH+(J!R&LJ/WK0%[NIM;=(M<Q:TJM6)5TP':CC^#=@_#I/<@.VT*CVA8)
M 8K[$"&1R3'R-<#&[3Q1%XP))U2[* 4E'G-^6CIX =^VO'3(Z")&D)FV"!K^
M ^NB966_&9%<N.;J"9N:X2;:,XJ?5I/#F1EB!JQ\I*A-6=YHM>W-0*MXQWS&
M Y_J/6X_U7O\#9_J?>8!X!//SF_I6A<J_OZND//>#^J&3_*V5@,*/VD5?G)?
MA5,M/VZPQ/CA8S.==Q]2[C9B^/1;C'C:&O'T_EYOQ\A7/$8JNG'&?"?1J^04
M+__:7F_=6(ME<[H4H-S?;=JP3C.D\)!MSUK;GMW7MM<-7KQI\:*+TVT?_PZ?
MMI^8]A/3?F+:3TS[B6D_,>TGIOW$M)^8]A/3UTU,/[7\]J>OX[<=\X&R%_6T
M,_5\"VKN3GZ'5=DSWC^3\0[DQN2H^Q7HH_MF1YPZV>1 >DC5?UW.W*+A'E+^
M;9 R27YS?G+?M#DW!;>/Y#KFUL@/'[*?Z/83W7ZBVT]T^XEN/]'M)[K_S$0W
MQ!:..[9P_"U_BF6<;G_QJ6W>;H-1[OZ0X):C;_D 9-+]A=QD\(_5_@P;;F-#
MPPKLV=#_#AL:RLCN[QLGW_('CF^))GCMMCGYO3)R6('_:RXU%,+NP^S)O3_-
M[I^^DP!^ \ ,*[-G%7M6\5_ *KI?K)C<^S<K[MF1XR^CP\1PNS7 ,K[NURP.
MDR\G*)6=\U<P./Z3%Q^^IZ!]M?V:AU?ARPVZY>$[(CY(.]>PIE S;#T:/T4Q
MV_"U"^&)-TO^JH.I\=Z4_'"A9*XL+<#[,V-\\X0.:+_\XO2?4$L#!!0    (
M .A 9EK/!GV-30(  *8%   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MK51M;]HP$/XK5E9-K;0V;Y!2ED0JL&F5U@F5=?MLDH-83>S,=DC[[^>7D-$J
MH&G:%^([W_/</8?OXI;Q)U$ 2/1<E50D3B%E/75=D15087'%:J#J9L-XA:4R
M^=85-0><&U!5NH'G16Z%"772V/B6/(U9(TM"8<F1:*H*\Y<9E*Q-'-_9.Q[(
MMI#:X:9QC;>P OE8+[FRW)XE)Q5001A%'#:)<^M/YR,=;P)^$&C%P1EI)6O&
MGK1QER>.IPN"$C*I&;#Z[& .9:F)5!F_.DZG3ZF!A^<]^V>C76E98P%S5OXD
MN2P29^*@'#:X*>4#:[] IV>L^3)6"O.+6AL['CLH:X1D50=6%52$VB]^[OIP
M /"C(X"@ P1O :,C@+ #A$:HK<S(6F")TYBS%G$=K=CTP?3&H)4:0O6_N))<
MW1*%D^D2OZ"=0$O@YD70#-""B*QDHN& +M'C:H'.SR[0&2(4?2]8(S#-1>Q*
ME5LSN%F79V;S!$?R^ &Z9U06 GVB.>2O"5Q5=%]YL*]\%IQD7$!VA4+_ PJ\
M8#10T/SOX>&)<L*^D:'A"_^ED4/]LG2C83H]O%-1XPP21TVG +X#)WW_SH^\
MCT-:_Q/9*^6C7OGH%'OZ3>V:.YJQ"M#Y5R;$Q9!:2Q$9"KU9=NFE']Q,HG'L
M[@Z%#,7YT?7-I(^S-;H'3[X"OC6;0*",-53:-]1[^V5S:V;LC7^FEI#=&7]H
M[ :[QWQ+J$ E;!2E=W6M9I[;K6 -R6HS6&LFU9B:8Z$6*7 =H.XWC,F]H1/T
MJSG]#5!+ P04    " #H0&9:+'5HOD,"  "*!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6R=E5MOFS 4@/^*Q:0]M>&6RY8!4M)N6AXZ16FW/3MP
M *O&9K8)[;^O;0C+IH1*>0';G//Y.T8<HI:+9UD"*/12429CIU2J7KJN3$NH
ML)SP&IA^DG-18:6GHG!E+0!G-JFB;N!Y<[?"A#E)9->V(HEXHRAAL!5(-E6%
MQ>L:*&]CQW>."SM2E,HLN$E4XP(>0?VLMT+/W(&2D0J8))PA 7GLK/SE>F'B
M;< O JT\&2-3R9[S9S/99+'C&2&@D"I#P/IV@#N@U("TQI^>Z0Q;FL33\9'^
MS=:N:]EC"7><_B:9*F/GDX,RR'%#U8ZWWZ&O9V9X*:?27E';Q8:?'90V4O&J
M3]8&%6'=';_TYW"2H#GG$X(^(;#>W4;6\AXKG$2"MTB8:$TS UNJS=9RA)F7
M\JB$?DITGDHV^G@S$.A)X(RP JV$P*P ?>Q*1J[2.Y@X-^UIZXX67*"%Z($S
M54KTE660_9OO:K-!+SCJK8-1X#VD$Q3Z-RCP@ND(+QS*#2TOO, [5^8-VK^B
M#<O(@60-IN>J[J#3\U#SW2QEC5.('?UA2! '<)*/'_RY]V5$>3HH3\?HR:ZA
M@'QO/[OU3[71*N.U^O^0.]UQ8(ZIA!&QV2 V&^7\X.SV"KEQZ'MR\T%N?M6I
M/8'07Q&^X#;.?,]M,;@MKCZX<;]Q[D4_]Z0_5" *VP4E2GG#5-<JAM6AT:ZZ
M_O(WO.O2#U@4A$E$(=>IWF2A7Z?H.E\W4;RVW6;/E>Y==ECJGP4($Z"?YYRK
MX\1L,/Q^DC=02P,$%     @ Z$!F6D:PL=/<!P  \Q$  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&ULG5C;<MRX$?T5U*RSV51)<Y/65TE5DFS7.KO.
MJB0G>4CE 4,V291 @ N &HV_/J<;'&IDC[6NO$@S(/I^^G1S3M8^W,:&**G[
MUKIX.FE2ZE[/9K%HJ-5QZCMR>%+YT.J$KZ&>Q2Z0+D6HM;/E?/Y\UFKC)F<G
M<G85SDY\GZQQ=!54[-M6A\T%6;\^G2PFVX-K4S>)#V9G)YVNZ8;2/[NK@&^S
M44MI6G+1>*<"5:>3\\7KBV.^+Q?^96@==SXKCF3E_2U_^5">3N;L$%DJ$FO0
M^'='EV0M*X(;?PPZ)Z-)%MS]O-7^7F)'+"L=Z=+;?YLR-:>3EQ-54J5[FZ[]
M^A<:XOF9]17>1OFKUL/=^405?4R^'83A06M<_J_OASQ\C\!R$%B*W]F0>/E6
M)WUV$OQ:!;X-;?Q!0A5I.&<<%^4F!3PUD$MGOX=:._-9<XI.9@D:^7Q6#-(7
M67KY#>G%4GWT+C51O7,EE8\5S.#*Z,]RZ\_%\DF-;ZF8JJ/%@5K.E\=/Z#L:
MXSL2?4??$=^!NO0N>FM*G1'A2G45*))+^<!7ZKUQVA5&6W6#0P+\4E3_.5_%
M% "@_^Y+47;@>+\#W%2O8Z<+.IUT;"O<T>3LQQ\6S^=OG@CO> SO^"GM?UJ^
MIZ474[6K0+VE6 33;7.1&E(7?810C.KZ_.J3^M10T!WUR13Q0'UPJ-5//_[P
M<KF<O^'G\G'Q1OD@LL.32]]VVFV&AW]3)BJM"OAB"FT/8T+O*].VO?/6UYM#
M[K%2K8SO&HVV*\0:ZE%D-:KR: O<@(^EB86_HV!<?8!6O /%=/@LA<7UE@)7
MTGSF,X>+EMU" (8BU 35(6PIL#5W?&=M4J.,JZP&0R4?-J)I]$W<@$V"AW'*
MR5!#;'^%"C"B*D-?JP)"##$Z4-=7GU[-CP]RR(VVU:$U%2FZ3\3]HEKO?&&]
M@U[MDEGY<H,XHJD='B:/+,!^%8A4T[?:#:[4UJ]ZY$^]&[/_H7ZWS>\!3-T2
M] 307> Z1F0FL EK*2"*_3&P_.+%FXC$%E*)KZ(!?_8M%28X[B6."3!AQ;&%
MZL/6@VI["X6'EX@LF4KQ"/&W !#XNZ .*57'H\^7E]?'(R@0OJZ],S$]2L!
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M=)@HH'T$*%_T]Q:)S]1\!WF&-VGL,G \X[O D*V)>X73[89=60;A-Z(]D+J
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M&E96V\U6=3L:OS2=ZFJCVLICB(8M!U^MU8VN%EIW%42T54XWE>EXGFLP6L,
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MHDU9^.!?1^I;HQ:FQ?0H&CCJ^O,QQ8>&]01ABX]EK%CT7&@?:,/1K0VF.R9
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ML*BHALC1O9.()5'A/GFY1P0.%_K^4U(AI]/H<2+$*D@B)A7D?F,KCG,($GN
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M>#@>!: [O>P65C5>HU;*DN+Y:46_&-3.@?;72MG#PAW0_[06OP%02P,$%
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M@EYZ7-2OE4R)"V?Z7$S%4T^M0Q#?XGRWPRF&5;7-!"?-5)I2K"JC69H)A.%
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M<I"6Z^:=5$)PH/!MB'H,H@;CCJL-O,=L(G]GX)+\;!\D:+G2H2@D.E$H<.U
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M1D:C8#$98WTT&YW\(*.@+,M@.6'C1Z$*A7H]W(E X5]E+;8>A1SGI O*-E[
MV7;"6&6N7NB-ABD?[>>:MI'#A=QDW-3CY+:U^1E<M.GGL*VMG$N,PZFU#2H"
MO<4>-!D^M2[$1&/+E2;TU&?B"W?J56<>6#^MBT7G>][X@=&[>F#4;2D)N:>)
MA UJSOD7'DL_@V"/Y"^Y4+AL,)TX^;6Q>5\OI=JQ.Z*L8;=*$J"04B9$XFS&
M^0-CB$=;823J9WSU@R/68=CL[ZX+Z.?V)H>LS^D288?Z6W(J1RYSX%EVX=L1
M7<-N73$09[V1?XPL5Y:VFCL79S2UX<L>GI5^7G,M"Z2Q&D>6GJ'V'A/0!MXH
M Y1-2SK-QG873C7C_R?BBKQS1V;^(->U[TJM_]9/I6IY><[$JB@E?%)76/_#
M/;2XLNKCKF0TMQG\YDX:M&,%,UU%9JGR0,XCY)UFHU=09\A]YT>?0[(LATBR
M7=/=3B4:B[A29B;" 53QMJEJC[*80P$M]4PALREHH-@,T \N&3RJT@U\EYOW
MB6DIE.=^@9(Y<Z;<7$P1[EYNW3OX\M] R'?'PME">/_A*DHK)\N/![DX))]0
M?%RSAGL%:5JA ]I)=WQX5NTH:A7Y#7-<OX+OHIBXT"O/FJ ;A_F&'3MV9F;B
M*PBZ(*-VNMKUJ>F4B*@P-YHN;1TEV6OI <5?;&?4*CUJ1+JM:CS<@\L)K9'"
MH((38_-.'X2N>2=5:J\>\$4A&V2H/V*.H_41]EVP1\T;H@:/="8S+/1 ()=-
M6C9^N+WH,KW@:1Z)EZZ.$!/KE->',S_0/Q!ZJFZI,NU+WT>EGD[PR-H<T7 >
M"KG"D<^1!<6OTA]6I]\V%/%LB/9%8[&SMZ2;!/T0O(]$XBW+FZCE\62>BC-6
MU37;L&M9UP'L7.@'N$@^DRL Q=-V?UVTCF;P6[$R)N<[C3(FEI-*8!72]3/7
MT=E+#FZN'W3.<B!_=X@H>\(5E*RL2I<DR[J;P35MW2OY%PY^[BY>.MZZK,4J
M4Q./6VTRG/764HQ,6=PXW7F8FV?RW \:F$B=<:4/PZZ/2!!2MX1+0E-#+FT"
M<;8Z[\\KSFQ@<'0ZVLA''7(.B1N-0VR8)K:]E9491)63IIA[22VLB3%Q%_%A
M]L!AZ(UG3\8W,&J='%(]FT+Y !/K(JYVE'C'RCP6:8_<I6I/0.%?#^,Q:$:Q
M7H]8[#9KKZ[W5!NWC_U8@$3+,8F/Y:M(%/Y^I%QQ%R-:<\/N3 WO74)<1X0F
MU2=Y4K%$U?X%Q5EJJ6ESW"-U70['RM0'27]KH7M/XV>.Y=*C$W^\UW<NS@;:
MW*C#B9B0Z]+M?@!C*XJ?8C#)M#4X;YI0].L1& P<:3[8VZ"+H(]/L[JMNA:7
M?@I)5AS+_,[L%M8;:\:[CCK'"B9=9\BLBIOC5;6[Y3Q<G==ZF;F^,D[G%SS&
M5#9:FW#H1R:7K9\%[52QX1\_42979:7]A5#]M/Y]U6O[LZ)FN?UQUI]EP<$P
M56ML'86+V:GM:?DO9;[G'QFM\K+,=_QQJR2LFQ;@_3K/2_^%#JA_=?;JGU!+
M P04    " #H0&9:%*X]'W(-  #')@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6RM6EMSVS86?O>OP*AI:\^P,D5='2>9<9RDFTYO8S?=AYU]H$A(
MPH87%0"M>'_]?N< I$B9LCW9OM@B!1R<ZW<NT*M=J3^;C916?,FSPKP>;*S=
MOCP_-\E&YK$9EEM9X)M5J?/8XE&OS\U6RSCE37EV'H7A[#R/53%X\XK?_:[?
MO"HKFZE"_JZ%J?(\UO=O95;N7@]&@_K%C5IO++TX?_-J&Z_EK;2?MK]K/)TW
M5%*5R\*HLA!:KEX/KD8OWTYH/2_X4\F=:7T6),FR+#_3P\?T]2 DAF0F$TL4
M8OR[D]<RRX@0V/C+TQPT1]+&]N>:^@>6';(L8R.OR^R?*K6;UX/%0*1R%5>9
MO2EW_Y!>GBG12\K,\%^Q<VO'XX%(*F/+W&\&![DJW/_XB]=#:\,B/+(A\ALB
MYML=Q%R^BVW\YI4N=T+3:E"C#RPJ[P9SJB"CW%J-;Q7VV3<?BZ3,I?@C_B+-
MJW,+BO3^//&[W[K=T9'=HTC\4A9V8\3[(I5IE\ Y6&GXB6I^WD:/4GPGDZ$8
MCP(1A='D$7KC1KXQTQL_*9]XITR2E:;24OSK:FFLAD?\NT]F1W'23Y&BY*79
MQHE\/4 8&*GOY.#-=]^,9N'E(_Q.&GXGCU%_TAZ/[QZ%0]&F(/[82+$J,X2>
M*M;"QLM,"N:ZL$:D6&>L2D1<I%BEX<&%P.9M6?#WY4HH1^P4>C-G8BEI5?W2
M\@EX(RQ.V4JMRM34U&4J3E6!;\K*@+PY>WD"T\I\*369]X3,2S8>GWPJ%*V^
MM;$%N1?B5(RBBV QFXHS]S2:!?.+A3@[^>!9_.Z;132*+NO_)X_L$5= CJ0L
M$I6IF&$ 0A&[!L=5MM3WXM/P=BA6,I4ZSH0&$ZP.N5I)!@SW2AD1&Z])<U24
M#YX*-".BT3 4W_I_)RP=OS]D_M:6R><?"%A2UCWPSC$**8832' JPN$%I+^!
M7F.=;)B]5-X!3[= 1\M4$RU39;'C0D3#2:,I,AN46I06MBODBC5]R,&/6;D$
MTZJP<;%6Y"$0\@>R;EJ;^G#+]09+R1'$79Q5CM^8=!,7";R%I)XRZU%$,IS\
M!I7KA@I)-,+;CXT?"?F%!-\?]&WK$_GP-303%_=B RN ITI#7E$@9R$[P4#D
MW%Y6\D>PTOBC4<02_=D2F\,'Y$@YR 24)D"3WGI5D:N8"@I_>(Y(8JWO<=0N
MUBEQQ#X5)XFC2\M6JH R%!1+KB;)4N;AX8@_Q*0"?N-HL:K >)]&XS72J[%"
M4=3*E63Q26\Q9*9W%=18,A,5UFN+Y?8>W&M=5D7*L8_OD+4S]=\F#E@X1\%Q
MUHU]N^>5C3&_[#^<_!'1M42(604+Q("(?; \%P;>/:3\\N37IS3_0LSFP11Q
M_T),%T$T630Q2%RQYH5^.G",&$V#<#$#C 2S<'1RE22ZD@=B8;?'>RP/QM,I
M_D;CR?$(7@33Q4+,L&@!\0",B<<@(A7GI;:U,19!.)Z)V>+BY&<).LVY]^)B
M,L$QDVEX//Z3>*LL&1;G<QQ!("0Y(\;C8!XN1#0/HHOPY$=-ZNLSX&@\#:)%
M)$;A/)CCI#][8WHTGD">B,-Z%,Z"V12?NV9KJ>OE"==WY$>5D>XD;)R'H2,0
MA SI76!H$.DAJVU+/"1#?M)>SHFDIKK_]+'@&-4IB[13=L-.'H6C.5<(5XD-
MNNY"^M14A%H/RC??Q?GV\OU9C5@& 0>' VDK=0&_NX%EBHHB)Y7BUM>>H_F$
MPT++ORK%/)9 F8[EEG*MBH+<'/&"B(B&PI^U/ZJ'A'<C/)=W8"/VN$=ZGXI[
M".(0L4GU>UJ0;M1>4A< ]8JAN,(J4@<*7(<'BM)[>:=,*Y%VE=?G7EIFL74,
MMP5N]-RP!)#6DL-H>4^1C=21JRRK(^8%^$5:J5^EE:YQS0DAJ005;7CA(I+W
M$L2P:;<NJV?W4&\7#?M85^2%%%$49Q6P$1!-L45KN)9R^3$0:D69XRE\[X-V
M:*5<K<R! S?8RDA\7"81',-^;'-PS\FHX;I.;K"Y+G-.*$^F-SJLY$#M8=')
MW"=9QYSQ%I[S1:&-@NYARFB.4J5KW6@VC/X^ZQ)7-0=U@N[ET@CJ7<%4RT]I
M<>.KC8<<323/PH+3P<>;Z\%9&Q."GD/HZ)\D.KV$HKW:PDPX824YI\9%NTSS
MI]U<[VE>S%UR*3JR/Z. \2552^U[=3;>SI9@7'C**6TG#M*FOGZ2$Q ^=)7Q
M:#Z<'?K*?#P<U^_Z3/_L ]>(!\UV][*S_E:P($HXDX $$&[!T$L;E>16B?9"
M:X@'1>U+=A^(W49!151Z<JR8 )]+T&O2S*K5'?AZO<-*0'ZDN+_R/G^0$\93
M\57*=V70UZA^%*%0;[0,">'\S!0%R9Y;9HWU1J7?7:PR=I<]M/6BYO_E2,\H
MZIXEWH,4$^Y!Z-"OOEKU?PNS%P\ <['G_I#57Y#,J2 (CF:0+J_4)&L"V%5O
M^<PU;U]H[MVC#LQ]AN[RQ)PT"8HEWY9&$6P!4CZNN ^KK.+B(.@$3*^&=CC$
M^R([8BM*' (X[NOZGC?W1NY0/&P9LAB-BT(S!/PTU1(O"ZN<UUFM&&NA#Y=4
M',\-?O>$&=$]:FF?FBA3<)4%Z"YW@"2S45N1N#Z;9RRDL$H32X9UR1)PB][
M_QCEN4\AO3GH04G''>#A<2;H;?WJC@11[0H+Z>8^I95..3[(6]TS%^ZN+>_J
MP&!K3'E3&6ZZ+9.R*+1K_A_H((^I,4<[OR[42B4P"*?LM$IDVJF['NE5?0_G
MTGQ?,; KJXQ*\9HPYUROK_[)P3VHPMHT'><2KVT*8ZN4]95*& ,IW6D,)7OE
M;,VG6 Z5=@$9%T4%?68J5[[M(.&]U6I_(9]_Q.F\RFMU^\E=RU>'XA.7#X<U
M/(F<ERET[ HWYPHH0N([I2LCKA2B\T9F2JX"/N)]4A9ECM8"HB.#PD.(RBGM
M(U-$X>7UU<W[6WK+SZ/+,U]?[<.@U;7TBK)/TERU<D9N8MFTPEDL*^=++6]-
M6<O.UX^7!9*K?=:YJP$7X;?>AULYZU)LRIUD8#TF P7K$T)LL5#3&2R(EE2
M&CS4!1:<0+/!W"G]_H!V+LL>]8H::X]ZQU%0\NX"DDIWG08M] >YU%4,-*4N
M-1#7P *L+A0Y?T'H^988&XW&M?UOW]*3-[[8Q8:CF*$+.@#6#H5; A%7K/V-
M;$M+&FV=\NMO/S/WUX[S-OZFRG P.]=M[;F"S/D2B,&\+:8LR$]5(3D9'A=B
M-A>G+2EF\\:%>\2H*R13&>H9#<M!W+99)&'<F)!&&;L-I9C6Z5UW@T$3*6G.
MU<VSK!SC!P3O:ANVCP%'+YI,/!0_(@<7O;#.&:K.Q $,07:@,_ )TJ<J99Q#
M,HP3VZ;PO7$YJ1X(=/&1TS.0 2[G^M.\1'Q"=AQEN'MI"7TD9WJQ6IZ@F@;<
MCW>'#%O=GO9(D>&G)TF)!$+SA]T&&@%Y:@#)V3/UF8H:)*:")>8,Y3*<HU"7
M'&1?(@\:/!*07V)@>^QQO$BRB@>NB,PRJWRIP.C>I!Z44<B@>*T%C;363CAH
M,I&&T[L;)OH"P\ID4RCJ1'((77?</HNT!")!T/%5VN4M#J)8(Y_;5LIIC0"<
MA-BU1CZWG H@^C0DW294C7B-8-=2.HG\Z,:)W=R0(+/:C"?<PZ/W+?M6AL=J
M;B;MV&+U5$5+DNZ<PE\P/6\,X &1J -E\U@K2,!N\:PQ<)+%*G<MGEBBCW.W
M0^W[,>^GK0+P0:'DX)K(:@EGQ<J=_*J9^-LX<^-_V](?E$6J0*T]"6;S"57A
MP6PV/KE*4[7GJ^/YK<F&2SU.E_O[F+$X>^9^GA,4UK%P$=(,/!Q-VIS*(FWQ
M. VF\XN&US9"I*6_F:+I25)[HSW:)+CPH]9#H]J$59/F$HJL4,@O%@T=X8S=
M^!C1E*F1$9R#M:DVWN4JOGZ$:RRZ=W4V*M\1FD[_5".=8:BC"1R=]/4W.L.^
M6?75[;683\)NY^8$@-\"5E?WE(NDYI OJ")!!\ C\Y8%CZE7%:V+W7JDY0K3
M[38#_@"T?6G"R:\H]X?5UW>$[_UG'HMNN]%EM=X\C.AN.EFIS V(:_Z:R"+%
MW*$:H=!PE[JN5=UGC:;'ZMXTDX*P42$*7==W<#VGG'=ZAX>_N7%;"^VIQFBQ
M%%<(:>VN*"A1N5(S\"TE5.-FJ/]!D6Q2WT0",+,N5+AJD&#&U0H'YSWLSUO'
M.@&(FA_K\XBWOOIT[?%HVE3.[:-XGK,_J354YLJ0+Q<XBBIS[.;UH,5SS'PL
M5IDC>5,W.]P?@!:5CWUE%/%Y5:V19-T2+@7*PJ=<0S'MX;6I/8R'IB7VUN<M
M?7M8SS.I14B4#>AV6VJ7(*1)M'+*277%*2.A_*N*.[HNX9$"=1#-[0DJ^/4]
MG5O+XJ9^>)&7O#[)))*H6^?Z(U#@Y;ZNM>46A*@Z+]',.RS)N%=G@($%5%[E
M+!X!1A-ZS7KG-BX.E0M#CUQE+WC5B-U1F',-OM')D%F,T]FP[P<LYZT?%Z$
M6?-/J$"64K?[G5'SMOF5UI7[<=)^N?N)UR\H1ZC3R>0*6\/A?#H0VOULRCU
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M?<&@L@+T?B6I:-J--7#X)IK]"U!+ P04    " #H0&9:1RMLSAP8  "43
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MD>-@+9)3'[8DR+19'V^1#XNPMA!^@)71\P(.0S@ TLC>W*X-SM8+QM,#"9"
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MX&+Z@V$7'WNSV+23XLHT?2-I- V*2]/AI;"$/N\4RIV4FBE8*SD'E=X/&V%
M"5LU5Y?#WKM>L/=2J0_Q="\YGK8C!&/[SKU.O\2"?MU<'#8 D=3#PA*:E;?B
M^+0<ZU9%$P+#OD7V\N,'/^B.E3Q.Y!:%SEP-F@4TO8L@B>5T%KQD1Y%LUJ,F
MP)D:Z9DWM8[*((8VC\ZS"CST;#?6_ N78BG$)=N1A'_$^0^Z#=HH!CYFWF'9
MJ525;(%LMVLISKB_888Q84<!;(Z<?S)D4U:[[\@]G6[)O>;F3.D(N,R:,T?M
M]5\C->!:!J<U3LGN-&71H=CQ2F08P0^E?0_VCB:/NPS0/7^QN"U<-6P 0("U
M<D7T\EG U>>C+NH"%*[+M>4>*H9[Q[%@LK&5KB50&)F)128>9TH:4TQ5[V8/
M[V$/-429Y>9C;]I,4B0//)U#XU4N-:?\8A$F$8\:Q:A>Y'D8?6(,A(V#:%YW
MW")S3U=274K='@/ *N]S"2G>BL57'BW3C96N./N<DG"A\^<>F_KDW) =0:UY
MH9-*T3>GGDYWBX*!VJP:=<GUNG*G?L?Z?<&><1S)? .]B>;291A7QG'<9\?2
M%C*@]-; =L?0F(ZIL1('B6\7&EPN[WU/ZM&H; V$,U=7*11K#M/:6U<L4#+
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M-M/LK!SB=O!R%,:[7+%<8M@QJMI7(=Z9*,?+<J/XVHQT"ZYP0#3+!"=R*C0
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MQ\-! +J=7ZUA5>UGQD)9FD!^6]+(1^T<Z/U2*?MJN 3=3V3V#U!+ P04
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M:FRO1:)"&YE5QNA!QD3Y3Q\K(G[%(*P,PE<&8?B&0;\RZ+M 2\]<6)?4T.%
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M=S]PT'/N^0JM;/C";HB-&!2==;H>P)1!+9O^+QX''PX X[-7 /$ B-\+2 9
M<([WF059"^%$GAJ] ^.CB<T/@C<!36IDXV_QUAG:E81S^:60!NZ%ZA"N4=C.
M(%V1L_ %9F4IO=-"P573EXOW_62!3DAE3RGD[G8!)Q]/4^XH$\_'B^'4B_[4
M^)53%UB,(!E_ACB*SX[ Y^^')R_AG/3O38CW)L2!+_FW"0MI"Z6]#Q9^S5;6
M&2JTW\<4]I1GQRE]\TUM*PK,&'671;-%EG_Z,)Y$WX_I_4]D+]0G>_7)6^SY
M3%$KBZ9 H%N&PB#=.Y 'EBR@!>TJ-"#KEDSRM0%%)<R&]@PJX; $IZD@S0.5
MQ4HA6"PZ0X6#]IAI?2:3D(E_8+9YE/+MH1-O1?3R^$&U^Y?FFM*1C06%:\)$
MHZ_G#$S?O?W$Z38TP$H[:J<PK.C!0^,#:'^MM7N>^)[:/Z'Y7U!+ P04
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M970S-BYX;6RU6%UOFS 4_2L6FZ9-V@H&$I(N0=K25:NT2=&ZCX=I#R[<--8
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MKV,W3/$#")0-P.>)E&8SL7=R\TD5_0)02P,$%     @ Z$!F6MPSN3CE"
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MQ/?++"L/&U4%Q]>TS_\$4$L#!!0    ( .A 9EH_%J01ZP,  !P3   9
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MQ@J!UT<Q]42RK3G->&92LL(,-T!3X#I W5\Q)M\F^H"D/1";_0=02P,$%
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M*MFS]P['4 L*2@N@M!!*BU TM6%(/\LV&UJWC,="Y,8.+I<D+6+.A/ABH_.
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MN[=G=!_J<M.^[>&AK.LR;S?7C":,-PG$[\NRK%\^- 7LWF%R]1]02P,$%
M  @ Z$!F6LU@BZ'A!   5A<  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULM9CO;^(V&,?_%2L[3:U$2>R$ !T@%7K3*NUVJ%Q[FJ:],(F!J$G,; /M
M?S_;"0F$X!;:OH'$\?/C\]B.OW%O0]D37Q BP',2I[QO+8187MLV#Q8DP;Q)
MER253V:4)5C(6S:W^9(1'&JC)+:1X_AV@J/4&O1TVY@->G0EXB@E8P;X*DDP
M>QF2F&[Z%K2V#??1?"%4@SWH+?&<3(AX6(Z9O+,++V&4D)1'- 6,S/K6#;P>
M(:0,=(_'B&SXSC50*%-*G]3-7=BW')41B4D@E LL_]9D1.)8>9)Y_)<[M8J8
MRG#W>NO]=PTO8::8DQ&-?T:A6/2MC@5",L.K6-S3S1\D!VHI?P&-N?X%F[RO
M8X%@Q05-<F.901*EV3]^S@NQ8X!:1PQ0;H"J!MX1 S<W<#5HEIG&NL4"#WJ,
M;@!3O:4W=:%KHZTE392J89P()I]&TDX,)H(&3U=#68@0C&@B9P?'NKY78)*-
M+* S\'VIV\8Q3CFXN"4"1S&_E'WV'DB3!6;D:JJ]C?&+'&X!;AC#Z9RHZ\:V
M_Q5XF-R"BR^7X NP 5=6'$0I>$@CP1NR45[_6- 5QVG(>[:0H"I=.\BAAAD4
M.@(%$?A&4['@X&L:DG#?@2TK5)0);<LT1$:/MR1H A<V '*05Y/0Z.WFKB$=
MMQ@U5_MSCXV:JABH&;6=8H/A"]CM5XS'!K,0_/.G= GN!$GXOW4%SN)[]?'5
MN^6:+W% ^I9\>7#"UL0:_/H+])W?ZHKS0<[V2N45I?),W@=_K9(I86H23[)I
M]GTEN)#S*DKG#3 D\RA-Y:4LDIS# :FK11:@I0.HU^)ZX#G=;M=K]^SU+J8Q
MD3,Q6P5FZQV8>I4#JA<?!W,Y1T1U662HK0-4Z'L=K]6MH!J3.1/5+U#]#T,E
MSX0%$:^']0]@KZ#GMKT*JS&;,UG;!6O[PUCEGCXCT9&!;1^RME&G#5$%UIC.
MF;"= K;S#MBO^M^T3CL'C"W':;G(J3 >]JNNY[WTNT7ZW7>D_TBX'!H@;^6D
M7$H1(V\$!6O97,?2?2.+,:4SQPLZI7APWC-BV>+#T[AVN'+?NXPN0EZG4UV
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MY=;*LD/<[$;0I3X'G5(A:*(O%P2'A*D.\OF,4K&]40&*H_3!_U!+ P04
M" #H0&9:WWL5.PX#  "P"   &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6RMEEE/VT 0@/_*R*TJ*@%VG(.CB:6$HT4J;40$/%1]6.Q)LL+>37<G"4C]
M\9U=!Y.*Q$*"%^_A.;Z9'>^XN]3FWDX1"1Z*7-E>,"6:'8>A3:=8"+NO9ZCX
MS5B;0A OS22T,X,B\TI%'L91U D+(560=/W>T"1=/:=<*AP:L/.B$.9Q@+E>
M]H)&\+1Q)2=3<AMATIV)"8Z0KF=#PZNPLI+) I656H'!<2_H-XX'1T[>"]Q(
M7-JU.;A([K2^=XN+K!=$#@AS3,E9$#PL\ 3SW!EBC#\KFT'ETBFNSY^LG_O8
M.98[8?%$Y[<RHVDO. P@P[&8YW2EE]]P%4_;V4MU;OT3EBO9*(!T;DD7*V4F
M**0J1_&PRL.:0C/>HA"O%&+/73KRE*>"1-(U>@G&2;,U-_&A>FV&D\H=RH@,
MOY6L1\F(='J_-^"X,CC1!9^U%3Y=>S JSPGT&*Y&U]!W^9/T"#NG2$+F]C/+
MQ%'C"(:Y</)7:,G(E-B2MPK72A+L!*P<?.Z&Q+3.9YBNR 8E6;R%K!'#I58T
MM7"F,LS^-Q!RF%6L\5.L@[C6XBFF^]!L[#)UW(*/$(*="H-V-=1X:%;9;'H/
MS6W9=(9@0S;[Q@@U0:YF@L$CK,L-Q:/?[B^%R>#7=S8)%X2%_;TI9Z7_UF;_
M[@L^MC.18B_@3]2B66"0?/K0Z$1?:J)K5=&UZJPG/^;%'1I7#Z,R;S_G9$FH
M3*K)+@QP(I7B*<?%!9$B_-V8V#*.TE/;>W(7QR)I--M1U T7&P#;%6#[#8!<
MAQ867*2<=-X#BT0YS^LPVR\P]VHX.Q5GYPV<9WY\518[+_"VD!U49 >U9+?^
M%N.D]!=H^%*&KURW!'RU()P+:>!&Y'.$(=-[],W'_OQI;8(N"0[7H%NM_4YG
M,_AA!7[XSN#;RZ$>O^1H-%_'?U3Q'[TS_XLRJ<<NW7=J2B5<ZR(%FHGOE192
M/5=4-I1JMVK'_;(+/8N7O?Q2&*X*"SF.637:/^ 2-65_+!>D9[XGW6GB#N>G
M4_ZE0.,$^/U8:WI:. ?53TKR#U!+ P04    " #H0&9:IU-(UR4%  "E'
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M,_IWH+(!M+^4TFPG]@/MWRC^ U!+ P04    " #H0&9:J@&_U_L"  #9"
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M^0@[/UW+ETBNW9-LRM@^!B>%-C+?@5%!SD3YIMM='@X 8>\$(-H!HI> S@E
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MZ@,  )T-   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*V7;6_;-A"
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M9@W@^Q.@/P"XA.R*!/0WXGM^:%&__7GUX*6ZBZ%JX^6W\?)K>\&@O28,&L/
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MV(X^-3J.=XK1$@_-V%\SH8.0NRTO>8-JB6%=*,-^5LAUO43$!8PRS5GP2,6
MC*C@8\6!E=&<BZ4+=R P*42A FT*U:1J0Z1Z<G#;]:"&:YV<RT+9W"Z#^SVN
MA^\ JQX8Y$(T!CO$!8;]DFK-E+PQ'3O8!E] 0=V^7Y;&X5319;MS1=8$>S-)
MQH5*F6K2M,DJ-.P+EH$=Q:<SN.NB# '4NLA-(^5T6DAJ/:P8=</(3I@0=_"
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( .A 9EKC^8-GM00  .PE   /
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M1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U [XAZ1P*](^H="?2.J'<DT#NBWI%
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M@O1Q!M+'.4@??(;2"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!(JM
MD56@R"I09!4HL@H4606*K )%5H$BJT215:+(*E%DE2BR2A19)8JL$D56B2*K
M1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLFH4636*K!I%5HTB
MJT:15:/(JE%DU?\IZY.UZ[_^I:"_YZVIN_=\-ORW<?4*4$L! A0#%     @
MZ$!F6@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " #H0&9:&?J+<.\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " #H0&9:L$8VX'P'  #I0   &
M    @('*'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MZ$!F6HQ4K#EK @  Z00  !@              ("!?"<  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .A 9EH:C*<'+08  $P9   8
M          " @1TJ  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " #H0&9:< T,R<<,   (0P  &               @(& ,   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ Z$!F6L\&?8U- @  I@4
M !@              ("!?3T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( .A 9EHL=6B^0P(  (H&   9              " @0!   !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ Z$!F6D:PL=/<
M!P  \Q$  !D              ("!>D(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " #H0&9:$P_P;O@6  "60P  &0
M@(&-2@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .A
M9EJU$YX1>P@  # 6   9              " @;QA  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ Z$!F6I/;-+T$ P  P 8  !D
M         ("!;FH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " #H0&9:'0?5J*0"  #@!0  &0              @(&I;0  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .A 9EI<\2CSR@8  #D1
M   9              " @81P  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ Z$!F6L:'+6H[!P  :Q(  !D              ("!A7<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #H0&9:R3ZE
M:P8(  #O%   &0              @('W?@  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( .A 9EID+XVUKA$  ($V   9
M  " @32'  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MZ$!F6A2N/1]R#0  QR8  !D              ("!&9D  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " #H0&9:&^VYX",$   ?"0  &0
M            @('"I@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( .A 9EI'*VS.'!@  )1,   9              " @1RK  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ Z$!F6M-YQ(J=!
M[PL  !D              ("!;\,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " #H0&9:"L6 @M\"  !0!@  &0              @(%#
MR   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( .A 9EIT
M3,R_KP(  .$%   9              " @5G+  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ Z$!F6@J6/SQ: P  /P@  !D
M     ("!/\X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .A 9EI$I=A7YP,  "T/   9              "
M@7KE  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ Z$!F
M6ASN/\L]!0  OA4  !D              ("!F.D  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " #H0&9:4\95TMT%   J(0  &0
M        @($,[P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( .A 9EKNRZ5D3@(  $X%   9              " @2#U  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ Z$!F6D4SQ*AR @  @04
M !D              ("!I?<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " #H0&9:7S4>39P#  !!$0  &0              @(%.^@
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( .A 9EK$EFM+
M< (  -P%   9              " @2'^  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ Z$!F6H(%X12_ @  OP<  !D
M ("!R  ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #H
M0&9:)!:7[Y(%  !])   &0              @(&^ P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .A 9EKQ>R7QPP(  %8(   9
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M970T-"YX;6Q02P$"% ,4    " #H0&9:?0=77]P*  #/9   &0
M    @($4( $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M .A 9EK-8(NAX00  %87   9              " @2<K 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ Z$!F6M][%3L. P  L @  !D
M             ("!/S ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " #H0&9:IU-(UR4%  "E'   &0              @(&$,P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( .A 9EH;BD8:,0,
M /,+   9              " @> X 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ Z$!F6@FK::R? @  F08  !D              ("!
M2#P! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #H0&9:
MJ@&_U_L"  #9"   &0              @($>/P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .A 9EIJ/LC[Z@,  )T-   9
M      " @5!" 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ Z$!F6EIS+:/A!   \QD  !D              ("!<48! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #H0&9:T<[V2^P"   F"
M&0              @(&)2P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( .A 9EIG\$]_#0,  +T)   9              " @:Q. 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ Z$!F6E0=&K5L
M @  R 4  !D              ("!\%$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " #H0&9:C$E=%JH#   '#P  &0
M@(&35 $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( .A
M9EH$0YR=1P,  ,P4   -              "  718 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ Z$!F6I>*NQS     $P(   L              ( !YEL!
M %]R96QS+RYR96QS4$L! A0#%     @ Z$!F6N/Y@V>U!   ["4   \
M         ( !SUP! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .A 9EKS
M((MYZ0$  !(B   :              "  ;%A 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( .A 9EJR:$G8U0$  +\A   3
M      "  =)C 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !! $$ OA$
' -AE 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>328</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments - Summary of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Commitments - Summary of Balance Sheet Classification of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails</Role>
      <ShortName>Commitments - Summary of Balance Sheet Classification of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995765 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail</Role>
      <ShortName>Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Net Loss Per Share Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rapt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="rapt-20241231.htm">rapt-20241231.htm</File>
    <File>rapt-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img57771353_0.jpg</File>
    <File>img57771353_1.jpg</File>
    <File>img57771353_2.jpg</File>
    <File>img57771353_3.jpg</File>
    <File>img57771353_4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="511">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rapt-20241231.htm": {
   "nsprefix": "rapt",
   "nsuri": "http://www.rapt.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "rapt-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "rapt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 279,
   "keyCustom": 49,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 20,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 149,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 623,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 511,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 13,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets",
     "longName": "100010 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "longName": "100040 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100050 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "longName": "100060 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_80a183b9-14ce-4b94-97fa-8410f324fd16",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80a183b9-14ce-4b94-97fa-8410f324fd16",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical",
     "longName": "100070 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
     "longName": "100080 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100090 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganization",
     "longName": "995455 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995475 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "longName": "995485 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1",
     "longName": "995495 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments",
     "longName": "995505 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1",
     "longName": "995515 - Disclosure - License and Collaboration Agreements",
     "shortName": "License and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995525 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995535 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995545 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995555 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995565 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995575 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "longName": "995585 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables",
     "longName": "995595 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables",
     "longName": "995605 - Disclosure - Commitments (Tables)",
     "shortName": "Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "995615 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995625 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995635 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "995645 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "longName": "995655 - Disclosure - Organization - Additional Information (Details)",
     "shortName": "Organization - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995665 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:NumberOfFinancialInstitution",
      "unitRef": "U_Institution",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:NumberOfFinancialInstitution",
      "unitRef": "U_Institution",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995675 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995685 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails",
     "longName": "995695 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "longName": "995705 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "longName": "995715 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "longName": "995725 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "rapt:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "rapt:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails",
     "longName": "995735 - Disclosure - Commitments - Additional Information (Details)",
     "shortName": "Commitments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:LossContingencyAccrualPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:LossContingencyAccrualPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "995745 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments - Summary of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
     "longName": "995755 - Disclosure - Commitments - Summary of Balance Sheet Classification of Leases (Details)",
     "shortName": "Commitments - Summary of Balance Sheet Classification of Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
     "longName": "995765 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_3a7401ae-87da-4602-a270-a264467fbebd",
      "name": "rapt:UpfrontLicenseFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3a7401ae-87da-4602-a270-a264467fbebd",
      "name": "rapt:UpfrontLicenseFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:CommonStockNumberOfVotesPerShare",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:CommonStockNumberOfVotesPerShare",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
     "longName": "995785 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)",
     "shortName": "Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3072375a-82e6-4b42-a83d-501afdf94d3e",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
     "longName": "995805 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)",
     "shortName": "Stock-Based Compensation - Summary of Option Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6693188f-4e4f-4506-9db1-d13478fdd1b5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails",
     "longName": "995815 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_e0707604-10e1-4c66-b961-1f5ccf14dc5d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e0707604-10e1-4c66-b961-1f5ccf14dc5d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
     "longName": "995825 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_3bb7c759-dbd3-4996-adf8-03437b940c96",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3bb7c759-dbd3-4996-adf8-03437b940c96",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "longName": "995835 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c663eb36-dd20-48b2-8b42-6761ae70257c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails",
     "longName": "995845 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "995855 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "995865 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "995885 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80a183b9-14ce-4b94-97fa-8410f324fd16",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "995895 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:EarningsPerShareBasic",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Net Loss Per Share Additional Information (Details)",
     "shortName": "Net Loss Per Share Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:PreFundedWarrantsToPurchaseCommonStock",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "rapt:PreFundedWarrantsToPurchaseCommonStock",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
     "longName": "995915 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)",
     "shortName": "Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18f57745-d287-4eac-8622-5474e59d7035",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rapt-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU No. 2023-07",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r155",
      "r156",
      "r157",
      "r205",
      "r206",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r237",
      "r238",
      "r241",
      "r364",
      "r365",
      "r366",
      "r367",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r399",
      "r400",
      "r401",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r444",
      "r445",
      "r460",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r858"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpenses1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43",
      "r46",
      "r920"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r700"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "terseLabel": "Amortization of premium (accretion of discounts) on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "rapt_AccruedExpensesRelatedToWorkforceReductionPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "AccruedExpensesRelatedToWorkforceReductionPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses Related to Workforce Reduction Plan",
        "documentation": "Accrued expenses related to workforce reduction plan",
        "terseLabel": "Accrued expenses related to workforce reduction plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and consulting services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "rapt_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_AccruedUpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "AccruedUpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Upfront License Fee",
        "documentation": "Accrued upfront license fee.",
        "terseLabel": "Accrued upfront license fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r122",
      "r540"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r58",
      "r128",
      "r536",
      "r560",
      "r564"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r17",
      "r404",
      "r407",
      "r481",
      "r555",
      "r556",
      "r847",
      "r848",
      "r849",
      "r855",
      "r856",
      "r857",
      "r859"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "rapt_AdditionalMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "AdditionalMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments",
        "label": "Additional milestone payment",
        "documentation": "Additional milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r855",
      "r856",
      "r857",
      "r859",
      "r927",
      "r979"
     ]
    },
    "rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional square feet area of laboratory and office facilities under lease.",
        "label": "Additional Square Feet Area Of Laboratory And Office Facilities Under Lease",
        "terseLabel": "Additional laboratory and office facilities under lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r155",
      "r156",
      "r157",
      "r158",
      "r169",
      "r205",
      "r206",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r241",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r444",
      "r445",
      "r459",
      "r460",
      "r461",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r490",
      "r491",
      "r492",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Proceeds from sale of pre-funded warrants in private placement, net of issuance costs",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r80"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r756",
      "r766",
      "r799"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r759",
      "r769",
      "r802"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r794",
      "r803",
      "r807",
      "r815"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r331"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed Securities",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r701",
      "r874",
      "r879",
      "r880"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r94",
      "r124",
      "r148",
      "r183",
      "r187",
      "r198",
      "r199",
      "r221",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r392",
      "r396",
      "r446",
      "r532",
      "r602",
      "r670",
      "r671",
      "r700",
      "r723",
      "r887",
      "r888",
      "r936"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r129",
      "r148",
      "r221",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r392",
      "r396",
      "r446",
      "r700",
      "r887",
      "r888",
      "r936"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market.",
        "label": "At The Market [Member]",
        "terseLabel": "At The Market",
        "verboseLabel": "ATM Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r752"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r752"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r752"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r234",
      "r531"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r529"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r528"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r234",
      "r423",
      "r524",
      "r691",
      "r695",
      "r866",
      "r928",
      "r929",
      "r930"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership limitation percentage of shares outstanding maximum.",
        "label": "Beneficial Ownership Limitation Percentage of Shares Outstanding Maximum",
        "terseLabel": "Beneficial ownership limitation, maximum percentage of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership limitation percentage of shares outstanding minimum.",
        "label": "Beneficial Ownership Limitation Percentage of Shares Outstanding Minimum",
        "terseLabel": "Beneficial ownership limitation, minimum percentage of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r120",
      "r661"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r65",
      "r145"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r65"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "label": "Cash Equivalents, at Carrying Value",
        "negatedLabel": "Less: Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r946"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r116",
      "r154",
      "r205",
      "r222",
      "r223",
      "r224",
      "r230",
      "r231",
      "r237",
      "r241",
      "r365",
      "r373",
      "r374",
      "r382",
      "r383",
      "r385",
      "r399",
      "r400",
      "r411",
      "r412",
      "r444",
      "r445",
      "r460",
      "r476",
      "r477",
      "r490",
      "r491",
      "r553",
      "r554"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r116",
      "r205",
      "r222",
      "r223",
      "r224",
      "r230",
      "r231",
      "r232",
      "r237",
      "r241",
      "r365",
      "r373",
      "r374",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r398",
      "r399",
      "r400",
      "r401",
      "r411",
      "r412",
      "r413",
      "r416",
      "r444",
      "r445",
      "r460",
      "r476",
      "r477",
      "r490",
      "r491",
      "r553",
      "r554",
      "r840"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r168",
      "r227"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "verboseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r185",
      "r261",
      "r262",
      "r263",
      "r265",
      "r268",
      "r273",
      "r275",
      "r568",
      "r569",
      "r570",
      "r571",
      "r678",
      "r839",
      "r851"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per warrant share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "rapt_ClassOfWarrantOrRightPurchasePricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ClassOfWarrantOrRightPurchasePricePerWarrant",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, purchase price per warrant.",
        "label": "Class of Warrant or Right, Purchase Price Per Warrant",
        "terseLabel": "Purchase price per warrant"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ClosingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ClosingPricePerShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price per share.",
        "label": "Closing Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "rapt_CollaborationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "CollaborationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements.",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r110"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r249",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments",
        "verboseLabel": "Commitments (see note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r86",
      "r533",
      "r589"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r243",
      "r244",
      "r646",
      "r883",
      "r885"
     ]
    },
    "rapt_CommonStockCapitalSharesAvailableForFutureIssuanceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "CommonStockCapitalSharesAvailableForFutureIssuanceValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for future issuance of shares",
        "label": "Common Stock Capital Shares Available for Future Issuance Value",
        "documentation": "Common stock capital shares available for future issuance value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares reserved",
        "verboseLabel": "Additional common stock reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r855",
      "r856",
      "r859",
      "r927",
      "r978",
      "r979"
     ]
    },
    "rapt_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock number of votes per share.",
        "label": "Common Stock Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_CommonStockOptionsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "CommonStockOptionsIssuedAndOutstandingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options issued and outstanding.",
        "label": "Common Stock Options Issued And Outstanding [Member]",
        "terseLabel": "Stock Options Issued and Outstanding Under the 2019 Plan and 2015 Stock Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r590"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r52",
      "r590",
      "r608",
      "r979",
      "r980"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 132,006,828 and 34,398,312 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r535",
      "r700"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Number of votes for each share of common stock",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r133",
      "r135",
      "r140",
      "r525",
      "r546",
      "r547"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r101"
     ]
    },
    "rapt_ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payments upon achievement of specified commercial milestones",
        "label": "Contingent payments upon achievement of specified commercial milestone",
        "documentation": "Contingent payments upon achievement of specified commercial milestone."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent payments upon achievement of specified development and regulatory milestone",
        "documentation": "Contingent payments upon achievement of specified development and regulatory milestone.",
        "terseLabel": "Contingent payments upon achievement of specified development and regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payments upon completion of manufacturing technology transfer",
        "label": "Contingent payments upon completion of manufacturing technology transfer",
        "documentation": "Contingent payments upon completion of manufacturing technology transfer."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ConversionOfCommonStockForPre-FundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ConversionOfCommonStockForPre-FundedWarrants",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Common Stock for pre-funded warrants",
        "documentation": "Conversion of Common Stock for pre-funded warrants.",
        "terseLabel": "Exchange of common stock for pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ConversionOfCommonStockToPreFundedWarrantsInPrivatePlacement",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Common Stock To Pre Funded Warrants In Private Placement",
        "documentation": "Conversion of common stock to pre funded warrants in private placement.",
        "negatedLabel": "Conversion of common stock to pre-funded warrants in private placement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r682",
      "r691",
      "r701",
      "r712",
      "r975"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r826"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r826"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r828"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r828"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r830"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r828"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r823"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r825"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r825"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r826"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r829"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r827"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r824"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses or other impairment charges related to marketable securities",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r234",
      "r235",
      "r236"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r868"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r85",
      "r355"
     ]
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRentCreditNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r845",
      "r935"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current",
        "totalLabel": "Deferred Revenue, Current, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Research and development capitalized expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "rapt_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "negatedLabel": "Lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal and state research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves",
        "terseLabel": "Accrued liabilities and reserves"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "DeferredTaxLiabilitiesGrossDepreciationAndAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities gross depreciation and amortization.",
        "label": "Deferred Tax Liabilities Gross Depreciation And Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "rapt_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right-of-use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expenses",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r291",
      "r322",
      "r323",
      "r326",
      "r684"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared",
        "totalLabel": "Dividends, Common Stock, Total",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r80"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r752"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r752",
      "r795"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r171",
      "r173",
      "r175",
      "r176",
      "r177",
      "r182",
      "r380",
      "r389",
      "r420",
      "r421",
      "r526",
      "r548",
      "r664"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r173",
      "r175",
      "r176",
      "r177",
      "r182",
      "r380",
      "r389",
      "r420",
      "r421",
      "r526",
      "r548",
      "r664"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r179"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r178",
      "r180",
      "r181"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r340",
      "r368",
      "r688"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r688",
      "r854",
      "r921"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "terseLabel": "Global Intangible Low-taxed Income (GILTI)",
        "negatedLabel": "Global Intangible Low-taxed Income (GILTI)",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r921",
      "r923"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "negatedLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r854",
      "r921",
      "r923"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r854",
      "r921",
      "r922"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Tax",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r688",
      "r854",
      "r921"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "terseLabel": "Foreign losses not benefited",
        "negatedLabel": "Foreign losses not benefited",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r921",
      "r923"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r854",
      "r921",
      "r923"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Incremental stock-based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost, expected period to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized incremental stock-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 ESPP",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Share-based Payment Arrangement, Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r113",
      "r137",
      "r138",
      "r139",
      "r151",
      "r152",
      "r153",
      "r156",
      "r163",
      "r165",
      "r167",
      "r184",
      "r226",
      "r233",
      "r238",
      "r277",
      "r363",
      "r364",
      "r376",
      "r377",
      "r378",
      "r381",
      "r388",
      "r389",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r419",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r462",
      "r481",
      "r545",
      "r555",
      "r556",
      "r557",
      "r575",
      "r629"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r756",
      "r766",
      "r799"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated shares issuable under employee stock purchase plan.",
        "label": "Estimated Shares Issuable Under Employee Stock Purchase Plan [Member]",
        "terseLabel": "Estimated Shares Issuable Under the 2019 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ExchangeOfCommonStockForPre-FundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ExchangeOfCommonStockForPre-FundedWarrants",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Of Common Stock For Pre-Funded Warrants",
        "documentation": "Exchange of common stock for pre-funded warrants.",
        "negatedLabel": "Exchange of common stock for pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ExchangeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ExchangeWarrantsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Warrants [Member]",
        "documentation": "Exchange warrants.",
        "terseLabel": "Exchange Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r438",
      "r693"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r438",
      "r693"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r436",
      "r437",
      "r439",
      "r483",
      "r484",
      "r485",
      "r676",
      "r677",
      "r680",
      "r681",
      "r682",
      "r691",
      "r695"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r523",
      "r691",
      "r696"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r281",
      "r286",
      "r424",
      "r437",
      "r483",
      "r680",
      "r681",
      "r682",
      "r691"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r281",
      "r286",
      "r424",
      "r425",
      "r437",
      "r484",
      "r676",
      "r677",
      "r680",
      "r681",
      "r682",
      "r691"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r436",
      "r437",
      "r439",
      "r483",
      "r484",
      "r485",
      "r676",
      "r677",
      "r680",
      "r681",
      "r682",
      "r691",
      "r695"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Foreign",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "terseLabel": "Gain on foreign currency translation",
        "negatedLabel": "Loss on foreign currency translation",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r626"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r803"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r612"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "rapt_HanmiPharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "HanmiPharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hanmi Pharmaceutical Company Limited.",
        "label": "Hanmi Pharmaceutical Company Limited [Member]",
        "terseLabel": "Hanmi Pharmaceutical Co., LTD",
        "verboseLabel": "Hanmi Pharmaceutical Co., LTD"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "verboseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r752"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment losses on long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r71",
      "r692"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r73"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r339"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r88",
      "r93",
      "r527",
      "r542",
      "r666",
      "r670",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r339"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r89",
      "r141",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r173",
      "r175",
      "r176",
      "r380",
      "r389",
      "r421",
      "r526",
      "r947"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r141",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r173",
      "r175",
      "r176",
      "r177",
      "r389",
      "r421",
      "r526",
      "r947"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r242",
      "r429",
      "r433",
      "r438",
      "r550",
      "r552",
      "r613",
      "r658",
      "r694",
      "r949"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r429",
      "r433",
      "r438",
      "r550",
      "r552",
      "r613",
      "r658",
      "r694",
      "r949"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r340",
      "r341",
      "r349",
      "r360",
      "r688",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r340",
      "r341",
      "r349",
      "r360",
      "r688",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r335",
      "r340",
      "r345",
      "r346",
      "r347",
      "r352",
      "r359",
      "r369",
      "r370",
      "r371",
      "r372",
      "r573",
      "r688"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r337",
      "r338",
      "r352",
      "r353",
      "r358",
      "r362",
      "r567"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable, accrued expenses and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "rapt_IncreaseDecreaseInLicenseFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "IncreaseDecreaseInLicenseFeesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In License Fees Payable",
        "documentation": "Increase (decrease) in license fees payable.",
        "terseLabel": "License fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r850"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "rapt_IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in deferred tax assets related to capitalized research expenses",
        "label": "Increase In Deferred Tax Assets In Process Research And Development",
        "documentation": "Increase in deferred tax assets in process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_IncreasedAreaOfLeasedPremises": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "IncreasedAreaOfLeasedPremises",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increased area of leased premises.",
        "label": "Increased Area Of Leased Premises",
        "terseLabel": "Increased of leased premises"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r794",
      "r803",
      "r807",
      "r815"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Remaining Contractual Maturities of Marketable Securities",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_IssuanceOfWarrantsOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "IssuanceOfWarrantsOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants offering expenses.",
        "label": "Issuance Of Warrants Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease, Cost, Total",
        "label": "Lease, Cost",
        "terseLabel": "Rent expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r699"
     ]
    },
    "rapt_LeaseTerminationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "LeaseTerminationMonthAndYear",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination month and year.",
        "label": "Lease Termination Month And Year",
        "terseLabel": "Lease termination term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r474"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r475"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r475"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease existence of option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "rapt_LesseeOperatingLeaseExtendedLeaseTerm": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Lessee operating lease extended lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Non-Cancelable Lease Payments",
        "verboseLabel": "Summary of Maturities of Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "verboseLabel": "Total future undiscounted lease payments",
        "totalLabel": "Total future undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: Imputed interest",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee operating lease option to extend",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r50",
      "r148",
      "r221",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r393",
      "r396",
      "r397",
      "r446",
      "r588",
      "r665",
      "r723",
      "r887",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r87",
      "r538",
      "r700",
      "r852",
      "r882",
      "r931"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r119",
      "r148",
      "r221",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r393",
      "r396",
      "r397",
      "r446",
      "r700",
      "r887",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "License Agreement [Member]",
        "documentation": "License agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_LicenseFeesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "LicenseFeesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Fees Payable Current",
        "documentation": "License fees payable current.",
        "terseLabel": "License fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Contingency losses, accrued",
        "documentation": "Amount of cash outflow reducing loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "rapt_MarketableSecuritiesAtAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "MarketableSecuritiesAtAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities at amortized cost.",
        "label": "Marketable Securities at Amortized Cost",
        "totalLabel": "Marketable securities, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_MarketableSecuritiesAtUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "MarketableSecuritiesAtUnrealizedGains",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities at unrealized gains.",
        "label": "Marketable Securities at Unrealized Gains",
        "terseLabel": "Marketable securities, Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_MarketableSecuritiesAtUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "MarketableSecuritiesAtUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities at unrealized losses.",
        "label": "Marketable Securities at Unrealized Losses",
        "negatedLabel": "Marketable securities, Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities, Fair Value",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "rapt_MaximumAggregateOfferingPriceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "MaximumAggregateOfferingPriceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate offering price of common stock",
        "label": "Maximum Aggregate Offering Price Of Common Stock",
        "documentation": "Maximum aggregate offering price of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r287",
      "r332",
      "r427",
      "r488",
      "r549",
      "r551",
      "r565",
      "r580",
      "r581",
      "r634",
      "r636",
      "r638",
      "r639",
      "r641",
      "r656",
      "r657",
      "r675",
      "r678",
      "r683",
      "r695",
      "r696",
      "r697",
      "r698",
      "r710",
      "r889",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r287",
      "r332",
      "r427",
      "r488",
      "r549",
      "r551",
      "r565",
      "r580",
      "r581",
      "r634",
      "r636",
      "r638",
      "r639",
      "r641",
      "r656",
      "r657",
      "r675",
      "r678",
      "r683",
      "r695",
      "r696",
      "r697",
      "r710",
      "r889",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "rapt_NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "NOLUtilizationSuspendedWhenTaxableIncomeExceedsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N O L Utilization Suspended When Taxable Income Exceeds Amount",
        "documentation": "N O L Utilization Suspended When Taxable Income Exceeds Amount.",
        "terseLabel": "N O L Utilization Suspended When Taxable Income Exceeds Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash used in operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "negatedLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r67",
      "r90",
      "r117",
      "r132",
      "r134",
      "r139",
      "r148",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r167",
      "r174",
      "r221",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r380",
      "r389",
      "r421",
      "r446",
      "r544",
      "r610",
      "r627",
      "r628",
      "r721",
      "r887"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_NonCashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "NonCashOperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Operating Lease Expense",
        "documentation": "Non cash operating lease expense.",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r760",
      "r770",
      "r794",
      "r803"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Nonoperating Income (Expense), Total",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "rapt_NumberOfFinancialInstitution": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "NumberOfFinancialInstitution",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institution.",
        "label": "Number Of Financial Institution",
        "terseLabel": "Number of financial institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r666",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "rapt_OperatingLeaseExpirationYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "OperatingLeaseExpirationYear",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration year.",
        "label": "Operating Lease Expiration Year",
        "terseLabel": "Lease expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r470"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate, percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r699"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r699"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "rapt_OperatingLossCarryforwardsExpirationBeginningYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationBeginningYear",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration beginning year.",
        "label": "Operating Loss Carryforwards Expiration Beginning Year",
        "terseLabel": "Operating loss carryforwards expiration beginning year"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_OptionsAvailableForFutureGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "OptionsAvailableForFutureGrantMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options available for future grant.",
        "label": "Options Available For Future Grant [Member]",
        "terseLabel": "Options Available for Future Grants"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_OptionsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "OptionsIssuedAndOutstandingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued and outstanding.",
        "label": "Options Issued And Outstanding [Member]",
        "terseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Foreign currency translation gain (loss)",
        "verboseLabel": "Foreign currency translation loss",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r545"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "verboseLabel": "Unrealized gain (loss) on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r220"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r700"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r758",
      "r768",
      "r801"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r761",
      "r771",
      "r804"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r761",
      "r771",
      "r804"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Common stock and pre-funded warrants, issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "rapt_PercentageOfIncreaseInSharesReservedForIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "PercentageOfIncreaseInSharesReservedForIssuance",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in shares reserved for issuance.",
        "label": "Percentage Of Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of increase in shares reserved for issuance on common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "rapt_PreFundedWarrantsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "PreFundedWarrantsIssuedAndOutstandingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants issued and outstanding.",
        "label": "Pre-funded Warrants Issued and Outstanding [Member]",
        "terseLabel": "Pre-funded warrants issued and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants.",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_PreFundedWarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "PreFundedWarrantsToPurchaseCommonStock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants to purchase common stock.",
        "label": "Pre-funded Warrants to Purchase Common Stock",
        "terseLabel": "Pre-funded warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r261"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r590"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r261"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r590",
      "r608",
      "r979",
      "r980"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r534",
      "r700"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Net proceeds received after deducting underwriting discounts and commissions and other offering related costs",
        "terseLabel": "Proceeds from issuances of common stock in \"at-the-market\" offerings, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from sale of common stock and pre-funded warrants in a private placement, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds from issuance of pre-funded warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from stock option exercises",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under employee stock plans",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r132",
      "r134",
      "r142",
      "r148",
      "r155",
      "r163",
      "r166",
      "r167",
      "r221",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r380",
      "r389",
      "r391",
      "r394",
      "r395",
      "r421",
      "r446",
      "r527",
      "r543",
      "r574",
      "r610",
      "r627",
      "r628",
      "r689",
      "r690",
      "r722",
      "r849",
      "r887"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r102",
      "r105",
      "r106"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r121",
      "r541"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r474",
      "r530",
      "r541",
      "r700"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r102",
      "r105",
      "r539"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r280",
      "r287",
      "r317",
      "r318",
      "r319",
      "r332",
      "r427",
      "r486",
      "r487",
      "r488",
      "r549",
      "r551",
      "r565",
      "r580",
      "r581",
      "r634",
      "r636",
      "r638",
      "r639",
      "r641",
      "r656",
      "r657",
      "r675",
      "r678",
      "r683",
      "r695",
      "r696",
      "r697",
      "r698",
      "r710",
      "r715",
      "r884",
      "r889",
      "r929",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r280",
      "r287",
      "r317",
      "r318",
      "r319",
      "r332",
      "r427",
      "r486",
      "r487",
      "r488",
      "r549",
      "r551",
      "r565",
      "r580",
      "r581",
      "r634",
      "r636",
      "r638",
      "r639",
      "r641",
      "r656",
      "r657",
      "r675",
      "r678",
      "r683",
      "r695",
      "r696",
      "r697",
      "r698",
      "r710",
      "r715",
      "r884",
      "r889",
      "r929",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "rapt_RepricedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "RepricedStockOptionsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repriced Stock Options [Member]",
        "documentation": "Repriced stock options.",
        "terseLabel": "Repriced Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r658",
      "r670",
      "r944"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ResearchAndExperimentalExpensesRequiredToAmortizedTerm",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and experimental expenses required to amortized term.",
        "label": "Research And Experimental Expenses Required To Amortized Term",
        "terseLabel": "Research and experimental expenses required to amortized term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserved shares of common stock for future issuance.",
        "label": "Reserved Shares Of Common Stock For Future Issuance Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r762",
      "r772",
      "r805"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "rapt_RestrictedStockUnitsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "RestrictedStockUnitsIssuedAndOutstandingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units issued and outstanding.",
        "label": "Restricted Stock Units Issued And Outstanding [Member]",
        "terseLabel": "Restricted Stock Units Issued and Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit (\"RSU\")",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "RestrictedStockUnitsRSUsSubjectToFutureVestingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units (RSUs) subject to future vesting.",
        "label": "Restricted Stock Units R S Us Subject To Future Vesting [Member]",
        "terseLabel": "RSUs Subject to Future Vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of workforce reduction",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reduction existing headcount",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r80",
      "r537",
      "r559",
      "r564",
      "r572",
      "r591",
      "r700"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r151",
      "r152",
      "r153",
      "r156",
      "r163",
      "r165",
      "r167",
      "r226",
      "r233",
      "r238",
      "r363",
      "r364",
      "r376",
      "r377",
      "r378",
      "r381",
      "r388",
      "r389",
      "r402",
      "r405",
      "r406",
      "r409",
      "r419",
      "r460",
      "r462",
      "r555",
      "r557",
      "r575",
      "r979"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue recognized",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r183",
      "r188",
      "r189",
      "r197",
      "r199",
      "r201",
      "r202",
      "r204",
      "r278",
      "r279",
      "r489"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r659",
      "r662"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities not Included in Diluted per Share Calculations",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r688",
      "r921"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r474"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Plans",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used to Value Under Stock Option Plans",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r76",
      "r78",
      "r79",
      "r80",
      "r125",
      "r126",
      "r127",
      "r185",
      "r261",
      "r262",
      "r263",
      "r265",
      "r268",
      "r273",
      "r275",
      "r568",
      "r569",
      "r570",
      "r571",
      "r678",
      "r839",
      "r851"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r687"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r577",
      "r578",
      "r579",
      "r635",
      "r637",
      "r640",
      "r642",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r660",
      "r679",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r711",
      "r715",
      "r890",
      "r948",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r976",
      "r977"
     ]
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r669",
      "r674"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r668",
      "r673"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r202",
      "r667",
      "r668",
      "r672"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance Costs",
        "verboseLabel": "Restructuring charges",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "rapt_ShanghaiJemincarePharmaceuticalCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ShanghaiJemincarePharmaceuticalCoMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Jemincare Pharmaceutical Co., Ltd.",
        "label": "Shanghai Jemincare Pharmaceutical Co[Member]",
        "documentation": "Shanghai Jemincare Pharmaceutical Co."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Outstanding, RSUs forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Outstanding, RSUs granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "terseLabel": "Shares not vested and subject to repurchase",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Outstanding, RSUs vested and settled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs vested and settled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Fair value",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase in shares amount.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Amount",
        "terseLabel": "Increase in shares at the beginning of each calendar year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate on salary",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total shares reserved",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Outstanding, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Number of stock options, exercises intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares Outstanding, Stock options forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value",
        "terseLabel": "Stock options grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares Outstanding, Stock options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "terseLabel": "Number of shares underlying all Eligible Options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares Outstanding, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Share-based compensation, shares at weighted average exercise price",
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Plan Modification, Exercise Price, Minimum",
        "documentation": "Share based compensation arrangement by share based payment award, plan modification, exercise price, minimum.",
        "terseLabel": "Stock option repricing program, minimum exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental cost",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "verboseLabel": "Modification stock based compensation expense",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Share-based compensation, employee purchased shares",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options granted",
        "verboseLabel": "Common stock exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Recognized Through The End Of The Retention Period",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Recognized After The End Of The Retention Period",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r295",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees, Officers, Directors, Advisors, and Consultants",
        "verboseLabel": "Employee and Non-employees",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Options granted, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Remaining Contractual Term (Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Remaining Contractual Term (Years), Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Remaining Contractual Term (Years), Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Stock option vested aggregate fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock as percentage of fair market value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SharesAvailableForFutureGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SharesAvailableForFutureGrantsMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Future Grants",
        "label": "Shares Available For Future Grants [Member]",
        "documentation": "Shares available for future grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies line items.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies table.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r146"
     ]
    },
    "rapt_SouthSanFranciscoAndCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SouthSanFranciscoAndCaliforniaMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South san francisco and california.",
        "label": "South San Francisco And California [Member]",
        "terseLabel": "South San Francisco and California"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Square feet area of laboratory and office facilities under lease.",
        "label": "Square Feet Area Of Laboratory And Office Facilities Under Lease",
        "terseLabel": "Laboratory and office facilities under lease"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SquareFeetAreaOfOfficeFacilityUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SquareFeetAreaOfOfficeFacilityUnderLease",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Square Feet Area Of Office Facility Under Lease",
        "label": "Square Feet Area Of Office Facility Under Lease",
        "terseLabel": "Additional office facilities under lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r52",
      "r55",
      "r56",
      "r113",
      "r137",
      "r138",
      "r139",
      "r151",
      "r152",
      "r153",
      "r156",
      "r163",
      "r165",
      "r167",
      "r184",
      "r226",
      "r233",
      "r238",
      "r277",
      "r363",
      "r364",
      "r376",
      "r377",
      "r378",
      "r381",
      "r388",
      "r389",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r419",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r462",
      "r481",
      "r545",
      "r555",
      "r556",
      "r557",
      "r575",
      "r629"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r577",
      "r578",
      "r579",
      "r635",
      "r637",
      "r640",
      "r642",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r660",
      "r679",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r711",
      "r715",
      "r890",
      "r948",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r976",
      "r977"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r184",
      "r462",
      "r489",
      "r566",
      "r576",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r611",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r629",
      "r716"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r184",
      "r207",
      "r462",
      "r489",
      "r566",
      "r576",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r611",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r629",
      "r716"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r757",
      "r767",
      "r800"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPlans",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares employee stock plans.",
        "label": "Stock Issued During Period Shares Employee Stock Plans",
        "terseLabel": "Issuances of common stock under employee stock plans, shares"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Warrants In Private Placement",
        "documentation": "Stock issued during period shares issuance of common stock and warrants in private placement.",
        "terseLabel": "Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued during period",
        "terseLabel": "Issuance of common stock from net of issuance costs, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r52",
      "r80",
      "r568",
      "r629",
      "r643"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares Outstanding, Stock options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r52",
      "r80",
      "r301"
     ]
    },
    "rapt_StockIssuedDuringPeriodValueEmployeeStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value employee stock plans.",
        "label": "Stock Issued During Period Value Employee Stock Plans",
        "terseLabel": "Issuances of common stock under employee stock plans"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Issuance of Common Stock and Warrants in Private Placement",
        "documentation": "Stock issued during period value issuance of common stock and warrants in private placement.",
        "terseLabel": "Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued during period value",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from of net issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r52",
      "r80",
      "r575",
      "r629",
      "r643",
      "r722"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r51",
      "r52",
      "r80"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r69",
      "r592",
      "r608",
      "r630",
      "r631",
      "r700",
      "r723",
      "r852",
      "r882",
      "r931",
      "r979"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r147",
      "r260",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r277",
      "r410",
      "r632",
      "r633",
      "r644"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r482"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Balance Sheet Classification Related To Operating Leases Table [Text Block]",
        "documentation": "Summary of balance sheet classification related to operating leases.",
        "terseLabel": "Summary of Supplemental Balance Sheet Information Related Operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update",
        "label": "Summary Of Balance Sheets Adjustments Related To Lease Accounting Standard Update Table [Text Block]",
        "documentation": "Summary of balance sheets adjustments related to lease accounting standard update."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "rapt_TaxableIncomeExceedsRAndDCreditUtilizationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TaxableIncomeExceedsRAndDCreditUtilizationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxable Income Exceeds R&amp;D Credit Utilization Amount",
        "terseLabel": "Taxable Income Exceeds R&amp;D Credit Utilization Amount",
        "label": "Taxable Income Exceeds R And D Credit Utilization Amount",
        "documentation": "Taxable income exceeds r and d credit utilization amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "rapt_TwoThousandFifteenStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandFifteenStockPlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock plan.",
        "label": "Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "2015 Stock Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandNineteenAndTwoThousandFifteenStockPlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen stock plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan and two thousand fifteen stock plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan And Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan and 2015 Stock Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Plan",
        "verboseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandNineteenStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandNineteenStockPlanMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock plan.",
        "label": "Two Thousand Nineteen Stock Plan [Member]",
        "terseLabel": "2019 Stock Plan"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandTwentyOnePublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandTwentyOnePublicOfferingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one public offering.",
        "label": "Two Thousand Twenty One Public Offering [Member]",
        "terseLabel": "2021 Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "rapt_TwoThousandTwentyTwoPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "TwoThousandTwentyTwoPublicOfferingMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two public offering.",
        "label": "Two Thousand Twenty Two Public Offering [Member]",
        "terseLabel": "2022 Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r155",
      "r156",
      "r157",
      "r158",
      "r169",
      "r205",
      "r206",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r241",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r444",
      "r445",
      "r459",
      "r460",
      "r461",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r490",
      "r491",
      "r492",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r680",
      "r945"
     ]
    },
    "rapt_UncertainTaxPositionsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "UncertainTaxPositionsReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain tax positions reserves.",
        "label": "Uncertain Tax Positions Reserves",
        "terseLabel": "Uncertain tax positions reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r350",
      "r687"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest expense or penalties related to unrecognized tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r687"
     ]
    },
    "rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increases (Decreases) Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions on tax positions related to prior years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions on tax positions related to current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r687"
     ]
    },
    "rapt_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront License Fee",
        "documentation": "Upfront license fee.",
        "terseLabel": "Upfront license fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r98",
      "r100",
      "r103",
      "r104"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "rapt_VestingRecognitionDuringAndAfterTheRetentionPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "VestingRecognitionDuringAndAfterTheRetentionPeriodMember",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Recognition During And After The Retention Period [Member]",
        "documentation": "Vesting recognition during and after the retention period.",
        "terseLabel": "Recognized Through The Retention Period And After"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per share, diluted",
        "verboseLabel": "Weighted average number of shares used in computing net loss per share, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used to compute net loss per share, basic",
        "verboseLabel": "Weighted average number of shares used in computing net loss per share, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workers' Compensation Liability, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "rapt_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rapt.com/20241231",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.rapt.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-11"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0000950170-25-034185-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-034185-xbrl.zip
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M7LPNN),&(L. V;Z3.[BS.:A/E>C'*A[RD-*H_+4H14 $4(4;J?YEZ'6>O\B
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MOD#MTAT#GH"XA3 $O!'@'V1A9*G28Q -Y(&D7(*P80X&)S<RN78AGZ>@QR#
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MJH-#U2.NWS]OJB*:,K>MJ+MQ@&\-VX:YV>EY"DBXRR(E[<BS(N&OU?A@#NB
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M33ZV+5,5_QZN2.O?Z\YM0R<^_4HE<*M8**"MVD95:7?C5#1/)=O7-J4MQF_
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MBBI#CM$F$L.*SOA)BP&6Y3"73Y@2MLX8&X9Q76G.WRN40B6)[-(*R-GO9[X
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MD#(?M$9?..(Z!>3='B-?]9_CW2!XGD(.[1YQG3"0*6$;-;"D<&M!*,:IL=:
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M(9HHHKRF%'=,E(I-? ;6SWPR4LAP\$^S,%$DFC@ICB0KKJ,&WQ0E2"9)%"4
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M^;]+<CN=9^J='A",RU37L\)N5-N:2'C=+K\W?=N4*T:J,FFT5=*(5EILBDJ
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MU/>.22!G3_[ADDO 0QCY#0P>2V;OQKCX$< J>2<BV791?LWQ"""./4[CI"-
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M% UV!M8DJ^"WKN4#O['SK*1WR^R/II;ZJ-B,./JAP<8_'^:YVKNEP*,YN(\
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M-C^K7$S&L=-"K1ASHYI:Y(+";UJ[R1GE&3W%(/>0XB?Y^PFW_^8VFKJ.*YL
MS528"&BTK!W,8ZMKZ_-6]Y861Z5!H2:P/-"'3=&WL0L1O!:_,GY&&DY\B'UL
M&AZ4%Q=0<H )>Y5OYKSAAV/;FB0(CW'O8X)!CEEFSEMAF/!LPJP<ZD"2DK:0
MTK4\ILD42F8+[182#<HBX9(\Q];I[FX+;ZK^-2:-BSMLB%5,V$ \' NB%A%!
M!$:,&TS[AJ]ML.5O-C;T.L?W!B8(3\N*,-8U"2IH8DS9J85+12GU8YA^&E"-
MA(&0:!>AF*YP%BI/0A5<L.J@>5V%;<&$3U,;Z22+7,S =JXI\V3Q.V<0$.X_
MCU7FM^)=SV*'V&D:7=I7J!A\X$>Z;LMUFCBYUW98<8*J7_[[G2:_4F$_R#^L
MZF$#$QCJSLI6/J.)\VR*D.3MM6E]0%68'XI4LIC'\+K O#IC'E.]8NA:Q3.P
M"*+16%W*-5A+UR%XKJ68L&(B>7=V50Y2:O;'R?S\!=G1VYE>2/O@+4E)(P:I
M%!)C/8$T)1"FB08E58?2-Z@)B>Y'.Q-C[<BYP:GV46 %D!!P0$\A80@&9-FD
M$OH+;$2_07LKQ:YKB /QU&1!T&%@*Q9^KXS^<!R-H1O,T[ R$'R(9P,IG\GG
MW;>"WWE<KE=7@'.H"@++/>WW*26.JVU#W?D$#7N*)5V#NI<0TL 0H IWF@R$
M@Y1'E##K35@VKQX$JR*(_:I*#!\8;@Z5?>=!%C0+=;TBLYA<^#+UV[.I>X,/
MUW;?@$Y[U=TP%>=6,.A+<TD*::UE0*5KRA3ES=/L%X-@I?8CW*H&/3.G'K7$
M_]836ZSZ./PH+7;.NRO;-#!</']^J"OA/*6DFHQ@6HU'VL0D56[L(/@=?9!S
M^9]65%[X\@<G[&0?G[.KF:R;E>W9GIQ;8GO9N<3"";-3$3MC)?4BP'1TWPK^
M#51HI%(.)-J4&Q^C?7\A3:50]:E)DP/&*[_W:A;#Z%C<5V'6\+OPA[0H:@QI
M)T]^<J>?1<N1M!73^D [AH2(W<N[0EDL*0Y>T!'TJ=:'\Z$0?FM"]R:P;#I&
M_]K#1'B#5DK9)669M21L_)6)@J4L3"73)5!P/\J.^E(6^@M#G8;W*/9I#B^H
M0'1V46QPT:ULQ;1LT\D\'X_FL9W3'H E/4R><'DG*EDCR7B43+3*>R6K2&.T
M4C01@" VC4Z@P1ML?DS6N]4AS%H[>Y/V[5%-$S0L<Q'+,NO:K7US=+?-P&I\
M%W/=I;[L,+D8 [KFZFHFQS;1O=O9W.3(W]##_D^SR P(F)7"X.]";L7?T;Y1
MA>%N(!W5-5'-JEE<?M!.)<GCNCQHQ/8F+V/\#F8I[J6BE6&Y6!RR:2Q[\1-A
MT4A_<L(DU&'&QLNK&;O_W,*7?\)H;M-TUJ%'!8B%3JC,:LBDY$%/  0(625:
ME-JVP^"A5%44>)\ */5U6VR.CH(O!3WDVGE-2*K1&'+HBGAF'UC\4/C:3Y?5
MNSZ9W&,_@#ZI3GJO I>-N# Y*\)"VK=@(>8\H ==_.S)6PO4_![>H*717<%G
M=/5F?D<ZUYBB=5V##];YOF++):IRH>8+A]6I>S,_C<ID*O>E7SPS;Q<]3=5[
M<G$RQ53(ZX<,#@VX*T2\C425BS8KZ[]"O/YP*G3'O:S^:W6Y3'4+N)K\X+7S
MQ0]@T@Q:N6]!OV'$+R@AP7M3<7KG:Z7GF%=MHZ%'=*BDC W:HSY/=3Y5[:9G
MO+6ALT/&XS@;D<RZK(=$?:1ID.W+*0/TYHU4"*TER'A#";3;OK:(Q7IU"$D>
M5S+$8(AN=1U\=3'MK YW/@_(17!<*:%-I<N]LQE=_VX!POI;P?D6+O9Y;X1(
M"IZPN%D)V=UP!=:T3"AVCX+MPGX]TGEXZ?XP14U0AQUBO(WAIW/0P%06FS?V
M5)<W_F'!@O$^P?X$4/O-D9UCB%&*58*#J417LVU*N;U/N]CHE'6T!O$SJ#YK
M;^#VDY&Z ,.DU2^ NQ<!\V>&V8WC^JX_7DR1MEL:<:C?J7761-JN%*>.7D,&
M+&7)CV4UFX0>'.RNS690O.B<"@PC.;S<T2E\11 /WYJ[OIKJR*<\'CH0Q;'B
MUA<8+(C5^UJ<N#CA?$9J9^F78_=3^7IK#1)-W);RR=_=8&>\=MYXX<J&^V4]
MIK-&$#X^VT+X_OE4F@,P@T,TL2SZAU.*0:R7T1&G!+% /8M[N/:GEL'D<0(0
M1Y"(1U(ZPJ?$!*/_C2ZD,^-VMU,8:?8]KEN<N+4!Q+'<E?"X$3VNN,__]E7)
M?\;^K[C&M=#FH/_(]@3P;0W1H:2S'G[\";%K2+0=USG]_\4:8@49;=-^^00P
M11 ^#/]PJ'0JW,5/(>?QF?^D71H0_E_1@]36AND)0+2V6W@/,(G;F0ZTQCT5
M/E 8FDY@?(7@S8_U%/M&$,RNN]LZAX^^$ZEN)P"7U1/ BK4YZA2$O@]+2]N]
MNSYJ>7PVASKCHXK6?2$?:O<6[D(EQM"9YH^#N]K%)X,V3F-P9PUM8C\)-2FK
MW-F0[R1H3?%D-<C7%%W5?2-SZP;K/^<46,?=)?ONQ@>D%Q7R=JM(2&J(ID[4
MSZ8"&SZ)%!M:1JY.Y/B,E3)9H]3Z[D;^=6% ;=#2]UZD2$ZQI!)OMS+!D'[F
M-+S:X9X-M%"W4[0_/4-F#(*L(TCKX73 2IN@#1X/![&).[[:-76]/U9'EO/#
M5L2)QG?V<6I;9R]S&(A(SM /X?:T-SKQ=(,R BVY;W"MXS-HZE &O3L1N31C
M/+QTSP@*111U<X#\YQR/WQ.(3J:"Z.[<A4_ 3",%UU)B/7M//A/=@=911NOO
M/"QYMV#*C-?%QG3,W1JM$A^GJ\GFU&].9;U-3S:JVO4/+5>\**A]VW+4PB^+
MYW;'3[@.&7?9%ZB?A6%C=I;K"A>AQ13,G%;JM*[/*YG7C4KTXZU,Q^BH#;=&
M%:GZ87.^C$V'D2VQ1N2#UT?+S/._%P_,F#-"Y*/%Z[QL*U 29L;%K_1P<< $
M_/#CR#2?/E^+H%^+$L)_9KKI^P)=FAZY[G=Y:3;]+VS*YC^_[>SD6AEBR[+(
M$3DHL-!\KL#::5.A^\+L;J%ZH'U99Y)J?P==.-2+Y)JLPX:&*X3.HW7PVC*I
M,P]:,K6XV=3H&B!4BWEHI:_R8<MIX'LD*4^RO+)ZW)1^BW'TW4&6Z^HQ&TDX
MKEDB7ONNGCN)S>L(@@\'-+=.0)36<@4>O3$9WZ&J5D_N!OJ<20ZSPNN^6JA7
ML;N;V?[/ /1"Z_!'3QJQI]D%7?)CQF>?P(B$H!6UM(^ZU:]4DP:,9^LF\@PD
MBUEV<PF[ T72_JQ67^/*;\/>38B>;?]$DZ/L]PC=R71F[YCC!1VUF?\]LJ[4
M,B"DJMC/IOXMKGG4T7;\KZ2YH0?UC1\V\TV2G3%2H@$5=>>$HF]=1EEG&/,V
M=G*6A:I98KAVPXVQ^?5=9J96:17K2Q-"#E(!&54$U":=X9C;ZGD]64#AF^]4
M1<)WK;8;?F<+&1.ECI<B2G?OU"1R4JW=(F!]UV 3ZI9=NEDJHG]I2MF$?ZFA
MH2CY':F^ 3Y46HSU&X-)O[HU]FNPQS\=@&O-RA5WIB">$*A 9D2_\>C3_"-E
M%D.PW9 ]?63QGUN8WU8,IOX%=G9?H%QLG:E.5U9(.\:_A ;IJIUNB-XUY3 V
M53?Q&OMKO*ZB?]=PUTWSD[1&=JQ[G1W(<#%BEJ3MS3#;04O@ZS.1>?EDF:>'
M^UV!LT ?!O]PJP9$MN#>N/LDD*6H_27+#5VC6_*R^><#G)T]E \"Y-..7YZJ
M9Z6@ 9&MO3#*<B*X+C3I5-1*AA8N2%<<V6#',;LG '9G)V_+RG?/L/7Y3V5,
MZS.>Z IHO+ T[,9_'Z"V^NLG"TLGIG693F#X-;=?6.0<]XVD-\W_FF_+=9UO
ME+#8QD&!.C4PIJ2>)2<KVYR"K,?1'')Y*C_&DA!@XX0<"M3'ROH><VKEW"TF
M1%5/:V'TFPH!VYQ<UU&;W]IO#JSM[AI P?Z@V]_M[IJ<?P-84BOT_NGVVBK#
M'7^67?<RN<E5> XV94J12X P!'XWJ\0R;CK  NV:*)ZO3X6GLX#N)-R<+7'H
MTTIS.YK5RJ1T92IK[3Q/L'_/ *OLIO+"B^4=-E<R*_%2)1872]!/(<G%)<T;
M*0ES>[?SCO^:K#.]U"U=V*]U7))4;LYO5.8P[5+!XAAW]0,79^9;^,:!5(+O
MOBN/3!4F&+W1UKH!6FDZ3@D#5TVUY3;4'[GVA_K"OYT*W2B,$8GM7(<5;:K3
MRP1+@Q; )2:KTKZ,Y>KKL,#LNFI S<I-)$D/*N<[&J(G^$7S_8K5ZR4%3Z#2
M(#;/SD%"*.\3;31YZY]@Y'[R9FMH*2S&*.*@-8S2VS/YDK_]M6PAB)EV"1\N
M0FG;2-S&ESL,W6E&I\1NRC[?NMJEN-;O&'B'IYH'2,LG36VP4T-)RY%UH#"+
M36C^-=C, ]K],A\$!:L)AJ"]@0&P"M)4K*8I"L98[N%O+R39*VX(]X3,Q6NJ
M>9 TDCP'I_ AZZ:":8,0\,X:YM.EWJ%D_O8*'U#A;P2S8G8HD;OT=6N2[4(W
M__I>R&>:!IBJOVS+&!G97*\[-C>.WR@9D4&C;T5AT+]B+)V-SUVK;UQ)K<QN
M+00#0Z1+OXFO9\RN9[E&%>WA-,7T^V=3)]4UZI$XJ9"#AC_/5X)PTR%[1%)6
MMT[4?KOD2!H^7+MM+/O!\*E*ON+<_Y%F8EX[_M>X$HN]S"XZT&9"KF!*EMNA
M2K$):S.R@_),U1(:G!PUDIEA[R96#V3%:UI0)1RT1>NBIWHY9M?XM;H'\G#0
M2IB!0\NPHM999_4>@@['#,QRK;.VHT!7=EV4\BLD?8\G.,1N+_7+TP]J/Q @
M.<&UK#S.>@HQIO4J 1>W0 LM_4$[9]$\,92X*ST4*\QNGM";I%@?O7HY_XLV
MWWBQJ89MD_JS=G!);N77P\'<L MMZ=.'Q(TW5&93X4YD;R3]VOP?CP49D-.H
M(MBD&TEW$1[I/@&\;M7X.+# =N4$8#6!3>(?G+)IIV8PVDA#;.^7FQM#$:R^
M/(4&$\7B!,7"6',#S]W@%^;>;9"V<9[0[?[@T*3AFF:PP<.VI8GL^J'"W-05
M:$EO8$5X?T@)=N$]0Q3VQHJ2C"[/E3,.S6=?X9>+"Q(4,)MJE3CE#M9V(1P%
MFN.BR \NGE@ A;N@ \FA6O"#K_O<<[J&;F:NI!/ >CYY3>M<1_-RK!+NHH^0
MTO"=]@N]8-*Q0@<(0@))0R)-R Z)ZHO8F-@;JPR)"?-$+$ACZ*K]+&'Z2W-X
MILR=X@:'5)=.G10A":ILUI$)+'S)^=Q#ZB7\T&58A3VE+N]J&_^O2?5GRL"-
MJG<HW_";]>.02A$J_]Q*B2/Z[)$)90]=]+.KC_"RX.FPKQ5\8D&'@"/+Q;9J
M41]T-MNB/M(\B1W:@M&36T#^W/UH38AR:2FMD+27*A>4S^VTFC\-@53^6.,_
MGHK%LIBSSPA?G.E][MG4"(ILN2+5LN^7]25W=%1[+0E=*M>* ;G,I$G<%Y,V
MHIM*M[D26MH/H2\G9FKV1XYN] ?[(5VJ%]BXCXQ&7%9G\.OM[.=L)A7;[,C$
M&(:T;QR5>1/\U!'!0330_@>IG:VHW!Q6!PZ&5OZ<,0^6[@Q?>&@XXI[$=8U3
M2N2VM9Y%E(T-0.KU%P#@$L"N@W@5JN6WC!>NO1 3"7< 03^N$7DA=MW]T(4-
M!-EH"APD?(:N1WW&KT [ 1B<DNFLY22;U=_81EC)APV]V?9\4#!8*:-X('?"
M],%>*2VET+N=I7TB:"B&F] 0VR[DC> 0&7&BQ?.U>O'$MII#"ASI:K10T?T5
ML1- DF*% 4]S[J_,?6H=H2J._S?W9.  _-WM\7P9 KC)QX,[.RW!CZ BP3V;
M;1)*V!N5+V4AR*KK;[C8U3T=G7+F3+6K#:O'$<?MOAS&; A3/\W"[U<Z_G9E
MY;@_&J23X"(=T;>H"3PDC3 XX,8I7Z: -M]'7,3SCS%D::/,;9:OA8XRUU>9
MKILX/^6;^GK4-^?F#SE/,HXCQ3\I^E66P=69JBIZL4.D)OV&3*@O881H \)D
M3*6M%!1Y\=5G[-2O$I2@?HRPN(KY(=IM+WJJ:[3KGO\)X )N]V9>^Q_,&YWY
M@OQMHW ^Q'0OG?L$,!X1$O3_P\G_-^$$%#;&")T:$!8.OT& &U#"6TBF?M^4
M9#@</R/['U>G-V1ILL6PO'W!)VKX*R5"I3SU\GGA$M^DC4JKKK[? C>3S1';
M:H?,S8$9:CTOTA))M_OD35'Z%KX6Z< )8QEQY(0B4AZMGR>28<Q5P%P'T@VJ
ML$1='LP%VH@LJ =&IB46J#;PZ1OU6( 5QW3>#LW([3U#_$/0+EU(.>N==3B0
MPQ_6$%E5)]%B$CIPRWA<24Q&.4%1VC=1SD_L2.LG0JQS*X[T=D-*6VK2'1(G
MS.KG-5YW= *XO#K'E5OUG*ZY)CA84&)2["BE!T$YIL*WL#-\''=-CMZ7LC4;
M%=Y$F!$;[#H2B+$N9ZE77A>NFI(VC'?N0]W1Q<BY;(%<Y57IW\X?566KAM,U
M+K\+/ANY+7!P?SPEKBZ!76B&EKK4L1%D^+RXKCE>.E:V;LTH[W")MOP8VIAE
MV]I<U]#8;#(M?OU!L.+C,OO"!T<J3)Y8A1OUD&O.YGP17;HND_#-NL^[6CD^
M@:[[-EJ[MBJXNCHYK:DZAC@U*_)NJUH7S7R]LMX>GA(KWY?.0.L-)S/S97+;
ME";L620<S@FDONFPJ7\/\;$)%0CXYM;^:#PHB$I,T<N*@WY [VIQ3TI0+[UY
MCG8UK<W6PWJ[XN5]&Z[K9ZGW$I"OA):65 MFSU:*_8APW.4A;47ONEZC:XQK
M,E&6NT @TDR8]EA7N.BXXHS)@( +U2ZNPWZ>4I46RFEVF!054?A1>8CO'5?2
M=XOF\GP)"J[#E-]9QXJ60@9?^6-''4JDZY!F3/YR#Q;/\B"--S9B4^<.(?)<
M_.DO@#_#JO8&?]^QNN-?Y''+*7\,<ME[/T^D9IQ^9D'K#BU@OZ,!R+4?LVM^
M60L7W;U1Z_BM]O&PYQA3*F^56 .2[3X+#IG%6JO_KCE^OWHZJLPJ2\0JR>S5
M[&CZDP4I'^.KB\OE'U?U[[6\2=C?4N$2.]@TP&_:TTWEP&INR_<M/I*K'^<B
M0&8M*.8?*=ZDR#PQMV7+\D2IGDK+3Q.7QX.(@TA7/(3M=SC/!#3LG O-C;)F
MUHH<PL_)CD-1FA:5M&Q\S?>1MJ_QX.<.YJ2MZRVZ*RR]7A=WTC;N.=],LF<<
MGPK_N_#':Q3M&1*6RH-,^4=6-JHA#KSIUO:9FA*S.VO&. $84S6#[SG]5 R>
M2CU&*4F;I$H8N3N\?B?VE7Z+*H</@RS<V0]NKN.WB]S"T$V"2WS5P5W;RBUD
M-@WC5D=G?L:ST5_<F<$ASG4J%A6K%U<7'M<;9'R4EOITVO*_%I(E?\*Q8L.$
M;>LH/X/;.:CL]%L(0I[ ,+A5C;L)!"FV=[[_"E%"6.)JCZO*X_-[>JWC5</&
M/3R'D4A^''DUOL3*9VC&^G!"/=7,J"_R4UOZL_+;#;&F9FCE@_5/)#&NV^.+
MQ_T=K1H%W9O6WL<F[,=9L7C+]-O?++]+FH$X@-?QS6\=P(9FF1Q7FUYL$<R4
M5OIJ2RWC*PZ5U0"'8V*PPG@C\6>&EBJO7"PK^!^6 _7?93.7E3,%=-U^;+2@
MN/@O.K%]65N:ZV@P$50@]Q8JHWQDS@$F_LKN=P!'MJC(G@#DOA,; C9[5%B7
M<+(Z%<DB,[VG.0XW"KP4LTYWI_QQ;AX73S&I'T'O$J^L!KH,@'GV$I6OVAL$
M*CC5/>Z!/&DPS/?5]XH+U^VDT5Y3?A+ZRU)X:2KK+T 6ORWGD@(-MD6HYZMC
M/XWF(>K6G2T-[U83,GGD_.3+W,ZGY*TC/-AT'M6._#6&G54PQXTHG@"F]_J(
M-C44;*+*NV\4[>W#U="R&^;OB5TX/ZCW=)[&_38O'JHA-5]Y#/&4R&%O#RNQ
MHR44]9.)5V%9'<B]?/+N*-RZ&1>-96?RYL?%%%-=/MR94VB*-^< O204I?J&
MV'0W430G1YU^X_$)I:T>RA:?MHYZT"#Q/'1CR5X-L'USY$<OLBJ_Q70M.*A^
MVG>7CEWQ0E31E:@")+OXW@2E_"NT%#P/D8+>=7;O:)>9L-A XTA<N)$;RI@B
MHJM3[Z4?&V"'\ZGR_7N7MK^_^\IPD'9TIKVCU _=SWX<!NI$KBO/"4VT!A?]
M;@YCQ"#"*G]X<S<@T3V%'W]\"[B^"54.-F4;U[/QNV[GL["]%/1'8&MZ;F^_
M0YB7?NU4\FKG7VCH@L2^I1N/0&_7B?/PAU<U#\703;5SR29Z.!/G8,/F*<7+
MI*:&>L; D7X<(OCIO%&-+WG7?%I]K2M<B:J21#>H@.G^L3G-'%)]FS)!)7X#
M3;]%%I"[#!)BK\%1S#[P)!:.6'Y;QUI!@Y0V5*QP1V[C'M$D_2+4LW0?5X>Z
MS J3AB*7%=&&+.0B-MM;H**X0*!M=C(+K(W^G1XZ=RSC/DL7HYI\ 6YF++!?
M4U1NYQC=,7U@U$ 50I&%UY/$)U<7'"B8&+@1R!_ZLL&<]<=GJF!TWM KD;ZI
M=R80YF\\J=N+/BX VE\EL.B%'MNTWU,\:2Z@ZXZ]"'(3UIQ]13TEJ;)PBGY?
M-J' E[]X,*;0A59J^EHI[.\?#C/?PDJE?Y8=<:9F+>RR3_=OZ+!K@N=+QW><
M/2&<:XQK5+9TPF1^)6'&QV[N.F4H4I%%H,4QA1U$L*UUKP"ZP&RU@HTF*I4N
M%XUMS<T*S6WR>C@T21QGP;TT.\<>TPK=*E;L_OP^/ '$8J#"ETKIH@1<0A F
M"AC361O04!_25I4%*G::GG5<L^Q2;((D_5( 8OOU7G@9.V7Z*=V0\X"\F@5*
M'FPN%]9G&J^T\.2WA/B:&X1Q9:<=;'B5M#DC:W?Z75-T+LO0H6#*S-_C<!FM
M^MSY&:+P*F'O QIF-M7)X!O)>IQMV)#Q=;P N;I@T>[XWJ$NV^0]VEU2C$XI
M_GG6U2RK&W=%O)E"5X"E=*3.N=B;8V N:DJF_$;+8S<C'OA7>A>4R#XOK#>*
MS-J#1>K=^-)?KW:6OEL5WK^?YI,YV<Y'!4>_"?2@E))2\)SV=9)@,&0]7!A6
M +]?UA&LG8;R.<1&9Y!G=!0>MIMR,_"V8V@/4)*.M=&H?"OWZR,>7R3/&[C1
MO&HKHL2\$+9%VLN=QW'Z7J<%6J8YCFPJ2FJ:BF?XSX=.MYK<.?3\\$+SH<C$
M':@T6G?3O-HH$%+6"T69WY&0X:XJ(6^FF2H3QI"F,Z$JI8X.$/] &V" Q.1*
M449N*K!^K^W0Y?A.6%/!*H./JH]$8F*@;#PNHZ6@BB#<J-\=K("DH*?(-GL=
ML.YS%@_@N$1DIG7X445[0W,01H*F1AEECYKC:AKA'L/O-33G85]5K9;B?<CW
M2V=]>5X @6UC_63,:2FQ;VS)9+FM>5 R_A N:G&?_Z&0N7VEQS.B-#@(@L _
M\)[K6Y$ 6TZ'O+H YSO5[:PG@%032C]C4&>^@5'$,34'_7<&'>Q,:.\.3I7A
M'63^N=T41GH*NET \155@IBJTSF\$(SM@"N? -Y9/3H!8+P1.\Q;(/G.^-L?
MV6_39JA9';C:$P#>_!H=2(M0ZJ9X12[4YKLV4QAQH626-1:3F2.P&J1H+&@W
MM*2FH;$E<N[G)][UC?Z?@Y:7?T'I7T\=T P?1;!JB\(Y6VEJ).F4JW.T_B_M
M8K2"!1V.[)0KOMPA0KF%M"WR5*(2D06S]ZOO3LFXDHR"931T;,$]4,"16%AR
M9S'D^!FU- :NM.#*3$OIT):IJQ^GJY$'V&TH>RTE3I$P3%"2RR"(3?>2 2L@
MU*?HS%YJ4AQ/QGEXS-'9\!X&QW%B^U7?=K9A+$B.$Q0N0PUO(.=?I36/W&W&
M%K3F]7<BX0&O4C<;1N!J7#F648$L:W; V76IA!"+D+_4I=ELKR_MC>:(F8JG
M^D?XU%?NI"@LU;8$1A.(3+H5758YX/4"ILY"+"'0/S5IJS"_UM3G4^1^>WZ@
MA1[7H!^GA1[@O\*X_CU&L?L]$1[ F,!MAQ IIN9'PCCO_&-+E0DL.QGQ4YUX
MZ%F0 8G0V=V+8>27A">=NA-7]E\ 4F?^&&R8_#<JT1129 -I>C'<LI1,]FXN
M[VD<OZ\^ 3S\[^ME/$(PW?E,)X!.5Y*@E=$VP0+J%0@1!>6T!G92OKZY$3'2
M OC[JZC0)YSF?]NG*<7EWG%6*U\Q'$!KHR20$7$[KC'^1A_A:K0L"AY_J0?X
MLF4^VZA(2'BLU:K0819? 0OM"A'*>3JZ6<R]K^Y9P56D,CGZ9;O?#]D1.)9N
MT]2T()IM3#4V(FPXETPF.#I/%VWD$!))$J&W!V6*"&9F;"[?ZMJFJF;W#59G
MN:C"=!4$/N503*<NB\%G?@U!7=4AM3!N($8DCXMPE#Y8PJF#EGLV.EG4E(,8
M;"F=&(G[>A3P-C%""T0VI_F=4J[PCC'"1XXNGR=R E@81^"#Z:>Y]\GJR A!
M2J?RG "$"J>M&:X].DM"D_E_PJ^? &[]1L2ZL,9T97+H4J5KI1<TM_5?J3X_
M,[.]@J1S'-?@YI&91%X)K/:-')JZQ:L J$_0#'?JE!VV4;;3:-T-]B3+ MOX
M;K&^L;&O64/W>QF/<"7XZ"5<^<4#^.WCHMA;EQAW2F.;0QE'AY[5FS@P>^24
MEP)<Y+B(E[K?SD1[W>P^Z>J[]<7]WC34>ZIS/$/J77/S"Y\2I._CC 4QSXWO
M2'.;<ENJPL\4,;(FZ_8ZD<F$+RH[,4=*ZFV.!__;LF)CK(09]M+ Y3_&28;&
M%F;7ER*+>4[U-9[!-$$] 1@(26)IM50!:ZH7OM^<72Z&+DVB03:9?:\!W@J:
M.^I':S0^JQVKK 2O5_YJRI-VL+W/!TM55OA"V(IH_\ND")87"I;NG&.C_,P\
M]"RJWSL,NC=4\<4"C7SH4(R$W=E)2,A^):J?;-)[KXS])F9&T& /1S. NLM\
MI!D=&?;42,L:=+!?O19Q^2;9+3$BE,%%)<9K&E%XNH5NI;B,:U]E#%O][%Q]
M;$)Q[!*[G#1G^'"/Z+TM&SZXW2\J!/=[ZN-4PN*_28+%<%,5*I*7*HR#BB_I
MY]=&<AYPWE+5^]9Y/0.)4JTX#2%Y"PMM#D7*D$2F3<R77XIE3_QA<*C4FG"L
M3<53B?OD,#20JT)/ZD?\W25+_#!*B;<O0S74V \JA<O19H*K3&K? 7K/"5)D
M"]1AP$$*:)\A"[H\6!HBJ\17.K9N(2Z+J3 L&UU5K^QF^7*5Q<E,X:CZ2 <N
M74US)E4DR7\UVUZU&RI?M5-YA/8/1BC><XP3G;[AC6*]^H#5,/:LR)6B-->_
MZ*K'G]HOTK7'R-4C#-;PX9<6['.\02> U_RSE1?U :U13X)20N?/=@>\.+,N
M/7WKN#F<O^ML:2>"8'AF[%_A@Z/MOFJJ\HK[[FMV+Q%%RFDJU.MC:P@Z*#>3
MTMP.:)G65[]=]&['2:Q3#<)*\FY2A^6,*K;E/@\HM65)_::?R9]AG-&.T;UK
MS&V989RW4SZ>EIG_(NA3^ZT30/06S?^T4I3NI9YV+9)D.8:6P?^4@=2P#/-%
MNCO#BQ *1 S03.@I#;<QL2> _RDQ+4X ;$3* B/.?$/LM&FK+E=Z2(J'U0&"
M]P3P_M\<^]U<$-$!/ %XN$:'RU,0>*+0"DX +K/@*CS@ 9DGLJV>LL?ND;-5
MEY6O.O+WI%&)HV)+%=M@V9H']QQ_8*T:YHE.0S ^0\R\,X7PB$OT:C@S+/;J
M_8[S?#67M9+<C8NE)J1'"X%1P$:?GCSQ#*F=<FO\>#J7X1CFLFE?XB*3OG^2
M'I\QFY$$]X>IV$XR)?W%^QQ;=KXHO"=GJ>N9V"ZW>YRWW<O&4%)*TD\J;(J9
M8>76:_K6Y=8%4F^C[/MRBDIYN/;^'Y8JV[F^TFW&O1. 0AIAC 'I=/T5UJ0'
M-_CW[M._4[Q"I?+[:;UT_'_%H:X7$1VZ)X!?J73Y$T!M"DWF!( ZOUNEX[<5
M(\'P^3>MX801\\4XBN4&Y"$5L;Y<^),Q@.,+@DSOX<DE&0NG6$?LX>?4YL%1
ME4X 4>1F9PT]RFYZC2N;=AC_TOY1&%KIV\X1YJI8D06A&^)SH7MD_ON?1[@8
MBM(?^#('ZQ7'-Q:9$EQ62(MB_K2DVRZ*A9809+&AP>P;"YQBDQN?4>A/!;S:
MEL R3(B7Y-1<[Y_OF89BO>BL:[TRT646)?4>6:[0998DUJ^;9'2T*[+8_^V*
M3]\]Q @[WNT$P%GRX03@,ISR3;H-<^4X5_L.7(XV3<GJ)%X+OPIK,:/F1V#[
ME91#<A/6&['-D1?:1J%HK2%"75B@Z?OL,!/C-L--M*>P?!V$,S4T"133Y48-
MNDW^C%UY^N)'_&-T3-=C%',=R +%I0[UL2E99$Y?YBYFZC&33S!5_M"1\L4]
MH-5/3N;[Y_<YN+M?R%*D>XTW/)C?/W?AX-(-*'5EC\-/)DJ-H/6+/)C3RW45
M(M,24WT[+,R65(O\)RS>AP/R\F-\,Y%]@L:?OSZY?VFN7HV]@YTF:=!KSNMS
M> IW'$+8RM_:5YNRK7"3^4:@;#ZHP(;RS6;/+.UJ4*!/X(7*D0&H8F;FME\C
M[&GJ0R0O02'K!'">2"L.)]:!8UZ'"YF0[=MYUT[I<7&<[D6:!5F-MUJX?:1E
M&R+%1G=-99>,@/V=U+4L%9[?>^\^A55VP7^W#U>(;!,IC]&NG=HJM(R%-@[K
ML:4875K81_R2]L<I=5@356NQ2[[H\%$F.OL#KC9JH%GT>^H&*$5$V>Z*5B^#
M*? C#$0JHGJ'A*R03P!D[GSQM@JGOZDFBJEU"K[JLGE>30-_''],FXCTUM@9
M>07>^E0-0/!2S:][[(2GON)B\K\HGW-/K<0JHS/2N^&.L@3[FV2A*KNHW$=Z
M*B:R/>Z+4GP1$9&^QO7RY?BGA<8<B-FF"^SKQ$]^ZM'2493=ZA]T[E? *,.I
ME(GJ1KC?O05OZD5WXSSN(M^E:3.7,IO^&XOJ=84FLB75J@::>K?V]N)O8]87
M:(;_XT-J_UF3_I.UASX!I$V>RFY?Q(_CHX<G@-5W[9B1<OKB<07BU^ZIK,C?
MTPD?T3DL@E3X"G>= !JAN)V!!U+$\XBU#?9CG4?'_)_BI3D>_^LE_G_2SEQF
MO7SK9N+5T#=.NUM101K[<OYN?NLA:?QI6Y/-4K?/)9\ (CGPKCML]2< G"2#
M$]')1,(<7IQ!$--/ ,SKWA^O:#"NFK,AAI5G&/12VFF9ORP1C?LM #X!A%O1
MI:L__:.Z1;NO>5H0_IZ!'&WGDPSH-_/X3P ?P0W'!^:4JIYXP$+*/W3%D)5Z
MXOZB3F>A,'NK[!5$S4;@"<#IM%R10=C3)D;F=5B3D1YEA[KY))/_R"EPI/.4
MJ>-S8-Q6'R)*F!(! S%>__<3MO#?/G?P[O115-(<'\8PF$&GR?$#&]\Y>S.[
M6YBU\,-Y4-P9VN+3HL\K?:GL#8+2AW^G?6$(I!J\7<G\V%+[]J]'9[_;O^Y]
MA&3 $/,5Q.VT(9IXZ7%2/BMB-\1^:N>#:SKE1O:"#G<:N(RJ;/8)4P/7^"<$
M/GTLL_#HEC 3(S$@T3*0<A1_ VD; $I6>)8=!@1*[PS_W_HKO>M^4/2_N*+_
MEX_-[A[UTGQP)R9^[AR5':\3V\X\HNDXG\_I* !V?3 !ON[XZC+;+^<9PQ:O
MS^.5/^,JH=*23]IK<FT=?19>L(5T<V7X*OHK^I*HG*BI I><%=M"X+4*8[34
M.W^4&5H-I1NTS+V@:J3:)U."]-+GX(G_\O3SC_4KXNWL F\P)ER1W220-9[\
MHA')D62LFJ@58AD%5"H;3_2UJC"SR)'@NOU-\0/](]V*QG%D?0+HX Z7=J4'
M'&=#=O/C\VN$XY4,1:GYD4I66HOM"9Y_SJ<84">PG^Z.89Z3$;4P$-GE YC]
M_7EN]>_&OU8.\W=N'=T*G]:Y@'A^VJ?5YU\-O[Y6/I5)=<0OL)];3;W/GM#*
M7FGX(>O1E"+M5P!%,4%BSZ_6VW-T%P3]L[[)PE00L[)A9SRF-'M*XOJ3=6N"
MKH838%G%8W.3\8TG[6.[+ *-2($*C1F-],RYU4DR#ZPT C8GZ>YI8&NIA^#7
MH5BP1X9(T#GV]UHI!\>OPV5AI1U$#FTIG_V]P]Z.E'-A%1;CK9<U@90?*TBQ
MR-\-5!>?=NE4AF,**\W<LK9ULDY29AU3M\(MJ:FC*?S&2Y$ZQZS^8=)4Y0,L
M-+''JC2)9/SC?:_@NP5_+)B9+F-US2+,G=VE,J?BV79:>MCJ.+)T _28,4%2
MG]89W51L-$B0-(BA!_35(">V$1QW7T&-?OUT3U]4A4K],+]^^\GM_E75=2'N
M:\D\\85F=\LR-&7%U(DVG0L(/\;IU7?8!@U="B?@6!'/S"-<V?S"-7Q5"']H
MH>3=Y6B,?QD-8M5F8Q^TQ:KJ7SSK3-,7;9J$@[4K%('0XAP.GX1@CS 0(M#G
MZ(+K.V&*,8XFH859?SVOQA"G6S?$.!Z7:(M/RTPE0!V;;HV74I3?P5?@<+X2
M7]8_'Z!,R]N;=-<*O&:,]81(\J3DTN<Q]&+^3@6YH5OF$NE?\W.%ZFO,^/4;
M:FM>%SIL>E[3C&I_^;B>LF$5>/-;T@TNNX!8H@^^:1":3IGT[]&^M<0+SV>)
MS?D3E6D=I>I&LY)(NOV /0(3&Z44V[4@<8&Y$>?S?5*JL- X77SY$BTFO@D2
M@VW$W)HWOR1/UP\TC_EL0:+C$_)$VHP9?U$%NJS1*8.??TA.Y;&<R1A%J[]_
MA')+MW&ZP&N'<6E3TOU$-STM-/$P#_H]JH(3-3@I"+2ATIEW-[77<!B+J^[7
MB2X9OX6]MW1(LC71$'RJYJ5?U]IF./%$7C_YB_)@Q9XH=:L3$Y-WK^$-V36I
M3E"<^&#X.K$#.(<**W#TN=XK6@V\C-7(SBX(+B(:*'687IP8(2S-+F5467>Z
MZXC G].:JL)'0G ]8>Q=R)YJ@9]K_HXT!%X]O 7C9% Z/2-6-#FYYMO)QO4$
M:=/0'/_ ;_]OS2^;SPWS=6BZ,QTZK*T*_E"J[!!>2( JE%4A.2HZ5;FE4[>E
M"'[>:1XKN]#&4^O; ,Q(S;]E71<Y/3W#3D37&DAF'9R+58V1&*0_PI"OF&2.
M#MY5\U0YES<OY:E(I19O?/X,XU?->5"JFXVW1-FJ/M?G8$F"/3=5G_@,\S-.
MF&DX=L3?D$MTX7J6=\-?6VM>VO.#IWPR?XG=KO?3,BN4IJP<5W1)Q12*U46<
ML_I]O%*UJI(CFR/;@WL8VURUX0*U$X!K)O]<0GF4N@NFQ/=^8;*-,L]>0^BG
M3!UER4O3BVF2HHC6I/:UTL$BC!+*]6MXRY&Y'FDKSD5PF"$(RUON$!E<U7IP
MGZJ="PTLF?9%1BK+^_C?]Y&?,?" \17J/)NKG=:$7-7[:U9@+VO/\[@*[JA<
M6O+[!""@Z4;:HRQ]?NNX(G1[HB>W= [_RM_K'% 64SYM"BKQ:\?Q<*^*CE5^
MPMK5L_N+IEY'%,$,>G,28FM]GOU8;^!()POZ6I<MN,7A%^111V#)OBIQ<Q9'
MUESSV4!S-BGC0HL,^V\_&$$+D$+(-4J]R8T3@.S YP^37(\QP'9G37'I,[E6
MAVVY]L.=>NYW:0W\$,+V6'=G;>F6?N+"EC JR,91>DU&GR ]H+T]R1B$SK+-
M9G39V8[)[7_*NY0JR3-[(R7DC?EXX;CCXX?8<1FSW#+34C5<#7+ +^\RZ>VL
MO>)'EA:F\QUNK0GWC%>D4-\]<:_B Q-RPG[KZ9L9E:2F&<L>6X$=JI;_/%_D
M-5-<.O U[;L7F689$.%G/#G2+4YX&:*@'Y]L(%4DCI>TVW8/_B$*M>P(C/A[
M8>DO^_+%S_XV0=-*3,]E1"? &V@EB0CEMOJZQM *;UGF%'E56:';0MX3-=SZ
M\?+XU,)B;;N^1=BTD?[/_@_U19N%X5Y<?6.I3JBZ;#,CI<&F"0WC3?F,\6?S
M34X<B259=SP/QA(%+-.MBSG'GTVLWOY4]/D_(YXP@ZZ$!H:Y(X,)=0)PW]_@
M. &4ZQ_B]"O^?7F'+D-P,$BG/XXIL5; K_V?UHR:ZOZ/71C_TX9"A'F5.,SZ
M\NQ? SHXW!<;F/B^6=W->D_RE6CP4P#SQ[PFB=>I?V/2-,%'UG"-YE$E06&\
M^G+L<^CT^E*HC O;V>#/M2W8=\\<36905V2 N[>\'_8EWTQV5?M@O*$CV$T/
M[<QACX+2$M3[/_/&-SXWA>/DNA8^OW?R\[FC'G_8?C%/"LMKC;*L7+%(+%6U
MB%S5FT"9,5NFC+PXE1W+K:;.EGWR/SUETZ4MB^.[ASNG,#$=^A7@B:Z^)/7D
MNU&J@Y6%O'V%D<*B8N)IAX?Q](7JXTI-+Q*1Z2"XOEF[!=4=,,4-'$0'#7>_
M*I&^!W(LKM5[&6#\3:BH47GO#M$WF1P:>(>1]9'Q V@5C>"D 4VU1TW D\#,
M!%1)L?=^9=GD7A9Y<^[+R@J<C]$;)-H<E>CQ[(<S$WU!ZM"09O6^G]W@6N[3
M;;CI<R56/:!#B<U[J^+(7 \[9+2$0'1!W)>Q7#[+="\;,C>_TTZN^MA>[-&-
MX#=.H6^2@.DU?6I1_-#RT4B*_;KHJIWUK(9U872%;;*X[Z>R')]RE^F  ;,<
M)^B1?OP?N2B=:V/DX.A+<3P&S2/N8?J'G02-$L_XX^>"3Y%;YIF&\ZGD.8TW
M,D4UL0]!@6#U6U]1S6W*N&?? G,:8@,J+P:G/PUOR/2$ >V_7Y&8MBW8H$S,
MEUN6HYY*CF(N6%Y/))=;1>9X\(GUBQ*7U9*=$_O\?U0VW"W<A?LQUU%HR"M!
MJ^HV**.>HALK9L5JJM]4^U,#C(VZ6TK>Z7$F]K56GUOU=RGHDE'*?>P1>^Y\
MJB'@S.ZMTVBUKE+2T'CFE?JL\ZSC>8^_^=R'/BX+'X?0K/8RCJOA:I1XPMQ@
MS^1R5[@(KK$^QFPX:/23T?DI)K\INV"_%+;*>W[!]M4RLS_B']9A<PHS_OQY
M/G/G:\VZ+21GP=MCVI-9:(PCL>M;3X;BKT+>8BZI#-_QG$*S).:[*)<V!]T,
M_D#4[>[##^)&V51Q4.37[1NX:\BE'X=Y0TRO.WMDT0ZWFP8MTQ?Y@[Q'2_EL
M,+$8=7NX%J\9-J1N1=?*-;0R_D?'J@HK]:W_U]T;R09H;5P^XLT)H*&T2^XB
MK9?<O=FZT#UW-76DU=&]T'FUYK@!?Y<((J2O@-A6HI?4%ATU7GMGCLJ@,OMZ
M!A\^O.?&R!C6F2_DWXH%[VZ$#Y&0#C2(<8(N=_6:RU_\X2UB<PW%RJC+;7'/
M/<=$:F'/:F%^-UO3GG-\<#*ZN>U.;[A-G<*WCK&9H9TFJ\YQ6+:K9XW[SBO<
MT/,PN>#(=RG!JO/)FF4F-_;.C8I./PN4F9+D&,8LP\_7_SA%\U"55IQ&+A\I
M3'O\G9)..8!"-EBU/3+<RM2;DE@OZ$4$41M7N0H3"QR%696,?>5+U491=NRV
MV"O&-<>!G]I-:-)'5K^%.2 [1!;?0^UBTA;_7/8VX;D_>N\=YTN+NI'!PW*S
MH:OC3^+)"^;),*[2^-E%W6LCYI-/?IU5YS_6D!BL:?W74!9>LGNLQ\U#[)*J
MI+YU^9$ZU$.W3>I=%)!KI1.M8IMDKXM6$>/KD6_6^6L(AE E5<*WOV^=<3R3
MF.AL.%9.4K4MW/ =2;[%#DPOM^@BE9LEZ9E<^]='HJR=4(,6XPRPSK]+40/Y
M=*Y0AN6K_WU:6"TIA8$QX6>D2?\9/'L"2!WK'CJ2W$8<>]V]M,4X!<%O)8=W
M3P#3;>3\8[_ )Z>LO!MXD/-_,'C:3>C-<,4SOX2%=X<2M 5H]ZC"3C0NDK-*
M#XY'D<CJRR-TGC*)#A6,2BY$1]DD?$]]6NUDZL-B&NI3\DVI+@2[V,KO..<@
M-N/\@#9PZM'GTTK_DK:@3WU9??2",<W=G-=P]!"V8#L!Q3#!$#U,HH>X-P(6
MF=X8N#-FQODC]]R=\<)9T,<?=[SS>(;/Z\Z"-R&68T;'>_)GOOS:VS@!3"GQ
MI5./+X;LK*T1VLV5Y^D-&N0[:;$*ZC\J+4F'T,4L#RX)TT7K/_RU;TJS^]G7
MQU?=*3OCJ,>YP+1B8TJ%<:[Z\'+6RD\%<A6B@\[4<X,=_\.I00;N[WK)7(<<
MSUG1&U?Q2]77YI9=%,J]K:4XYML]["*KF7R>,+O)M3C?*F$.EWKNFD*SIW^O
M@K9U&,Q&9'/A%>#R&T4<R\JPB5L%+-!FNGQ-;VED8_>,:+73RLO,>H;C"<#7
ME: H<_;G5XK+]\]?6EA#GQT_?341F&4Q-+YMN)R'^SLL!9,'(W;.,5$'TD."
M$X-D%%QK&W(](P3USS?9+SUZ2ZUX=HY8MLQW(S F]L:U2"I+E((L3P]9VDW2
M/2P*"%UQ+B/?Q1;&XLO'QQ(P,5 W8;"1\77__0)5LWL@_+R01/Y%JIE=E^OT
M>"#0GK_&/I'-9S"URZU"U[JB,]<[=!P4JO9M%.6C9WI[4#ZRF(?^)_S;":#6
M$[4@%WLH$>,'S;_F9%HY2!A*A.L&?14V&Y79*4T])'?*V)+'";/F_IR9]2]?
MOAS3?'%0>:T6I-XP>@*@6+(S,0;#61HI%_])J0(A^+,[]@[9([0%8+9CAN-8
MQRV6'S_/)]A1/0O*>Q7Y95_OS03'^7D80:!&UY>(YMBFJT[O$2YU!YI:I K#
M2D53!?/1YQON]G\U5&,C"*H++K$5S!]9IB0D\D*93[/"%S(=O+<_B8/@$A#<
M[3PP#5-JPYMVL9_>PI1(V)8%U3.N9$6(F;*43]I0,$BX/T$:ETVS.G6R>E,&
M(PZ[HSBSV,2AM?@Y+Q1UBX_F,*]RZ=D'<7_\AY8OGC3XR^NJ.>Z#-UXHUO*Y
ME3\ICN[/\"%+6"8+14LI*2BMKU4^*K]?;B;+F2OLU:,C3'\X4)O'3_;C[UR:
M%GM4R\?:(EN,#Y+RS*CQY8WG)4#_Z)2/=G9F/-=[SE*8)@>.SKR2(:EO,[Z@
MWH?[D@D<?$T>(>N<A[60JC G !:1,9M<)5?6E:_[?^QU,6*+>:B"GSZX9_=6
MJ :"C0G/;-M-MS4M_OYX#:C-0GOM'UR)QQ!]I[+FN$?!=5MG9U=XPL.S*FE>
MC\<VK5\=[D5L]YV?&GMT*W7)_I,C[:615$M7"<Y1T^8T0[]099,H69US<C0K
MZCFCUN-J18$-*Q<J)&[W@?('$GO<&Z!C</:7M1?NF6'\O7@TF-.%:](/O?0G
M#_QP]=WM\8?U[6=.6T'2;E%-NA'8WE[A1&'^=@&:G0%E/QJN5@;7F7H.-0H"
M!X AO9/M$LK#LSY[]9A@/RO]M(>3A6$.>TS7EU31<P\_)"(D\X^OT03X,CUI
M<]?(B9[&9>1VK-6%)!@\_,K=/"GS(XU+;RI,6)!3A>(K3P/HGA(*/<9%G^M6
MECB+%FW1<C6DH9+2>#7;8/RTG= +90$M5&)GF&6TVS_)TG(]9M8OK D#"C<Z
MHY[[&45UC29*N07"+_)(]I.,W+U<I2H+^14KPK-/T5U'TRH ;EY&"\3_66O&
M1/K5)9E;XC*7B#;U(T'9*T5CLG6+8Z,+X6_/6+SR$6Q_)Y( FYU<$O-XQ*A<
M34)57A64,E56:Y_Q]'.TXKDHO#ZB+OCW_;U@?9Z2J>_<X+_NWCEB[1OY97=Z
MPYBXWY&.+J7BC<<4V33,J1=S"YR=0#)@DJFX2>@W$;N6D<VB^Y#RZ]O=$'>(
M<#H$H]G_S -6$RYRC*8S51%IA?/BKZ$0-VH)L4?X1BNTJF,>$Z>^!K/JK%<W
MIDM/+350CE:!RMEA*GLO8\1:?)$^+=4M/G)GBPJ768G%% @3HOS5%0[)/ _-
MYR^2(>R:IA=X@-N1JVZ_1R-7.Y/XKR%1S+"<1T4%2I>MLYHN,W1Z?WK3QN*J
M/W1K%GAL\?$:\'Z&14X*I"I)CG8_E;8NC<X3:1</*M:W>?%>M9=@N8PR%CHV
M"D_X.?V[8?_0=/'[RV#^Y!R_S3H?X$-0K"9-^UNHTD?V3+L("];!\E6N+Z+7
MV4!37Y"R6.H51'PSHH-X5J(S)2(3=R&<@W:NBS 074":I@<>HX13H&$NA*/.
MN2N32Q-T:>4LDI:4,$N"8VZ -)-?%39TABMU5/6C_;,%./N1/AU!^T#N/]8=
MZ@@H[>S'Q+KR: N ;&/PAWJ1VE>&Z:R:%I]^P-"M7CK)5VK+::E_@,-@HA6E
MF28[_,"]HN*'&K?NYM9O"=/&SHD;A6;Y>#4Y?^- 9))B\>WM;R8$!\6VHG*)
MJIJ#D$"+#-L57?D*&Q4IB\F*)"GK8LM:_\2F^7F4\Q\EXUR9YTU_'=KS.6K8
M*U^Y<EGU5IGJUH:):RSB<WYTE3@5@6_C_7V(^?*2FK(>R%T,E8NA>Q.P6[T)
M:"^[$; P.:/HZQ2_:PS<D;+2BD](4*.;\%&[Y'\>($W;4,(P!I[@7/6:TM(;
M+EC3-HY9AVM13P +>0EN_I5K*G,W)X!#YK0W%1T W*22Y"9DE^53.3 T^T.>
MD8=7X#^Z<2@]JZ5]3-_"GF5SEG*#9>J1EL#Z =![--=+13B@S]B,/E!'_K3A
MQ;EK.3OS;-2G)"Q+C]/V(ND_.E_<=5""SIE"3MDHF$?,_-ES&V;<6&&P4<^;
M5/HV8];'9(A1$DB=#5RL^GF=*W#0)UHG#&K#&'6^L"EL&9J>W!$T*VPUAI4D
MF,N&X49F_0_W\2> B[#\KCQ6*B)64ZW$=TZ,]NI5!9$F[=#6<'V.YK?O/"8Z
M@@W-5=;U9VT@/$OQ4>""O(UVKBI?@&MY#Y<M2_F7Y4@(.8!?Z15M-4\9.<*:
M9$N45HPK.=U5+I8R.2O7)8Z!S.KM4GQNMU7Y>;]=G3Q43H-@7&9\@;_X/1*!
M@P5>SY]7;F'M-YZ:ZFZ/?F^-'B4LK9LJM56GZD=(&"(-I.Q7+?2>//^/S98Q
M##AS\]D_+Q02<UXHS$@D[GT\[Z4G5;E:^2O2]@G+M<2H\XNQ7P<5$E. 4(2.
M:UU^+R2Y7IA7T_*PR([2GB(ZB9KG:6D<94M.S>J'%-*R\9Y!J81#+FR<'U:C
MT2'UE5>Z:Y')>>89(=Y3;99$VR)Y10GANR:;/3^&?ZN<@84^&/?(V^]&A2EG
MO6Q6ZEXJWHNL4_=H;[B0_6@#["_8I9[4A?"I5QZI0&C9'-[W>.4JX)4CT]6J
M@GSFX&=AB^6'&]C6^7-*-T/=F /067>T[G@*\<:JV15+F?-(6NV9*2[S5Y<A
M="T/U:FV[IU\.EPO&%X97D-*7_""Q[F1:&.%HN+[$ZCHTECH,O^/9BZ9:)29
M==D8](#$_W-\F9?QQP0*/O_Y@5+7U8&@P<S/_8K^_0'4@M2'$2I/_LCKLS3W
M\):?_7XV<7P^XLSYJ_KW;T2PZ[*_ !U$TZ*H)GO1M!9RF#)U.<9A\DY=B\.C
M=M%Q5J17C!Q6PSYMO5FO/B-.L07EXMD$:_V4<DZZ;XC_G,2IY%PW+X4_&M.^
MO/(6;IF(1W]#.?^<[IIJ:.A0/%AX/3[S[16KQIWBQC_+V/C9\ %^X_XKMYBE
MI^81 C7)&@NL"&:/#]IN#U;M@8TXC%V.Z *S?Z%'(MZBU))7!ZPVGL1GSJ,=
M#O3WMY$*,/A./=?QR#RF]=[K(06AVWW5'T[+JE#T+=&.8<P1IC+4!T6B[GI<
M)COS/RZ4VFE'&[_8&S1!IKNK'4/U..TV>DD=CX?D'7M&O_YM?3XU],SX @XR
M6%*ETFO',?.;9PB@,7GIR=\2;P7.I;BH[I1D$)QG(V?3PMZ=UHP-<VJ6;DK'
MG @E\65(9FVH3/X,]Y0!S].E24=N4*R<6",V63].YKN\\_N(KU/W9NJ86*IY
MZ<)4X2Z,$%R5:O &N@;"7?/EGI.I:YJ$HEF<\CI:Y2Z]V4 _3<6[C&54N>>-
M=64B0,G.3T4ZI<.TEK G *,LW])Q! =6^.I/^./)W66<L\C1WZ'320.+[6B4
M@R^2&?A(+ZD-^P';$&/I4/(>FS9K%(8J2R2D1TC$M5O2WOE4K+$4.\!*'XUB
M\K;WG:@ZD72N>=<S/YU@;TPC0)**Q^J";N<;+OUOE+U7.!Q<]#XZ^9(0/:+W
M)%J,WD643T09$T3O1!F,48,8#!*]#*)W(GH9HO?>@B!&[V9T@ADMHX3_]SO_
MBW,NSGF>\U_/LV_VS;Y9>[WK77NO=^F@)2\-ZO]"A8HU9=$?A5DKY$/5@R:Z
M"@V"SM,B3_WH3@A;\S<):IS=]C)^,DXR"^NSO!21)=$#-N7Z%6:YE37P<CBI
M4/)>N?>&:2K35'5,!=59S.Y,;XN"06^&)4^#Z<MQAF@1@SK6\7"@]P&Z=Q85
M.F"]$S+Z0A7IJ)?ZQ-B<1Y@I.M;8,)R70I:NQJF(G)MTS9H09!YC.2EQ3,]U
M7.HX6K(OO5>RBS8)<EC@^J41?JP-<F4_T)^JXO0EN7SW>%"?M"99;C.SLZG:
M:4[6._5SA>B4EX<'6UQ::?N<J:D:\YA/F=S'+R#'BP-'?-:/(VIL0V/ T:ZQ
MP^GV$M8JII..$-0])\L;H=C8_LH?5FX"'2Y9T?Q;G=^9(34:\ZITN[F#0:K5
MM<#3U[ID?O_CA9M\X7,^6TBXE"+H!OBW1.&9DR43H:@XJ)<"HTBRMSB;8H=0
MJ[08$LHHW6,6^C3LXRVY%KDU[7((R00W8\,/^F1=PG8ND$VRWBG'J=^8] A5
M:60[+V<57BK.XM-EDTNQ->?YH3WMLXWNWV\4S5A"C7V,B'*9;(&8[Q(;P*2K
M5(/7WIY"&LDB^J76=P#(F(R>".8WCW5..[L9<L1Q)I6%(GVC#DEOHDT"<O@^
MNE\^S;?]!"5G ?3V8.CS?X3U()2B1U/49P;\S;7GF(WZW>C@3];Z&*Z\;XLH
M.E/(#S K8K.W)_O^;$JV.MZEYL-;A5)7B/U@+,Q?_2OH32+(AW8=F#=[D+=H
MANF,P&WT65'?F* 6'?T,.XJ-+2YU1B1A*1UMX2 .K<8(K2=C 3Z/@K&@ITVA
MHZS4(*Z:K[&?;OW:&3:$'R,,\+=I%,N+53&%\WM^"^AM>K%%D ^V#'44GB(W
M:?$[\T#%^%!(Z'GBEF#B><8W"/ACM'(\KN\M?A7%$%O?Q6H!DW7.I9Y"7R+X
ML%G^_BXOY30K09XPQ<@;\7]6/QU*Q?\M@-)_^[EHE!/TX-$3=5.=O\+KT@P>
M$>'>XM#7DN+(O.@/=X"R+48Y%2,!'K,<.Y- ^@Z!41HM(<H<TG130J7P12 +
M4T0R;MY<4E8(]B@?C-=2P$4(;PRDS(V56Q,".U6B\^/'E]DT3&;Y><?K6"UI
M]AF=#$1F;&IT!JQQ,UNQ [^J6>7P=6612 >KQ)*SO^N*D:MDA"S,DAL=@:9?
MUB>JGJ6NE@W\-J4P9/S$NMF1R\AX*]HN'$L,+U)QK^6TA?T3Z/2WH%-VY4:N
MQHR-J7NV@6E*>\K6& U],\YT)/0L&/0\;MN,7R*78#8L 'T: E//K[/*R_L>
M'V]',,*S8(/ZTH^.GQ%\BQ'/%6DEQAAT:M*T.^JC!WT95YS*6-/6G.=,("[
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MUU6'][D^45\6%!/Z!A7H";%8-K<A/Z/PPSM 77V-3ZG3G%_.WXYI9N]DI\S
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M3;N$1TDN@LJ-AR\B.AO@&/4UHBZEK;^?VJW7URC@]J>8\3:JJ$I4_$5QOIV
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M0?T=N!:9_9X\NU$J.R$O=>!]=@%?J4QSITD/REK2%2(H,*=_IB4HSU)#"&+
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M9BLZ9*Y1V#!.KR+-<%R<?.UATC9\\7^>Y1\FMP>8KNET:Z6\Y>'))7N$"2T
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M@@'ZD+!>_"YM(,PB^G>S!B#Z.G/5</S\]2F\&LJKRK_!@6$J<!5Y!S]$:\4
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M?V"3K&FUFV.W59OB8/%72ZW=9W8?'<#IW,<&1;5S]C3GMFC@[\:6OG,1HWW
M<MEL7@;%VP[^LU&CY?B/MVNAL3\I[*/U1LK4S^\$1ZXW!\[B>QYBY,,3B(MP
M^=-O,4]Z\!/_X2EAG@S*N!2Z#(DT.%,+KPU[Y[7JJ+Q"Z!A9,AH.M UK_A0!
MR9X![4,X.UWAG4R)VGD!TG.%"B!ESWC[8*"]@,'/YH;F>[#6XATGQJ6@'/?.
MK.X_56HO89J1ZIOY=3R,9X*>$:,5=@?MFA%+UB9E[@Y5TS4Q6<B\H.]CXFWX
MC\M>VA3&#QADX"F:_#V7WHU=\4V2BR(B*80KZR/B[=8#?ZU'QOM[U##V:3[^
M]I,NA74I->ZI$=/L/MNIMU7G7(.]:$-FAN!):F9T[2T_>@"9E'#17BMN8=W\
M#%=\I6%SYL>8F]&H5GHXQOC9[U7*J;681Y?>E.#H!+EHP#<7S:2I^FF23-T$
MDY\O/.(K9XO38+1JL@NYY%W</[$]8[*.!?79P!4@D1K*4^9\8 O#S=L?X7]B
M&%_1IZ!.<:3&6?EZJBFS;Y9?\- T]A;Y#R_4YQYA*777U"6Z/4V-JQI@)@ZD
MMD="G%;?U*&O(N0L E""%-U]+8G8;<-%OE.;"+X+PG*73V'O>S_J5ZR9.7$8
MD&TZWC%58W ,6F9Q\-"A8:%!'7<#:]KAHK@T-K'VK36SW91>7I!LU3K3GM$W
MI&CN4V:1'UI0H:SR<2\N&>CK<??XW:?K,O7QVWY**^K<S?!F@NU@5E]XU_,M
M05K?%6>MLG]X^$F1T%XR1FG[<[J_8A8RV[H!2@5VH51Y_ CQM.%C>B$'O>^Q
MMY:X5(PMRB J)E#I26;BK36$B&ZXA$&W#Q7D3S-#=F1@H(J:UQ,CP",HKZR4
M>@-[V$.+&\ ,;#\9SJP\]/P/7A<=T#OX5/I)?+X0AJ$ETSOSI9SHJOGJ1$67
M:)^8%F:"J'QF-'[\Z!W#D)QL:L).]6_$$KBJ=O HW=*X%5@48*;RY[YV%E$P
MV_IC.K& I-=1&^]P X +J!P)L'6/L[!23S$.:;X5A:O0B>]%P1&#9UCPJN$G
MW3XP>-4A%CMN<L(5:XB5N:</?G"_'$+V#\^V-L[-]Z;/A\S)G_$6O>*[V2?I
M(U*:A#HA^F"I 0[702WI-V_R74O44FB[EZYWODQ%F%NNK/_# UH]4A#R]=P^
MZW=]=/L)G9[87NH;,N+/3O>SP!HE+Q+$:]1DY,>23QCG-\\^1CDHRM%3".08
MSJLPJS9"0!>F\@9%Y6WJ&@HGQ.'<O="6FOS;!HN32N]&2Q!,3H)3?"YNMEB!
MXW;"!;JSD> 5M/#MF'*?F;S+B#G\5K#BR/F&N+GZC^>MI;E2?]BJ.T'[5FB0
M-&-^:X5" NS(M-J;.AMVB#6B!I>!,#&NM:;X*T/=U7:?Y]02*D4WI:3Z[J$A
M3B0XGMV[S+A /W3+67_/PT1!XN-6?UEM)GB5MD<,6$P_*/6C0J".2H49;U"4
M8>QK0]F @YKO;P(;M)_2DT?69H]P&] /5]--EJFL&.Y>Q[L+]?^L;<6&&.T9
ME-$$,$-.$"Y%Q8?#>A92Y0:PSQFR&3QQU>BO.7F2@?HPGIG2PS\!!M3XK2?2
M\BDX\WE$W-TS]--,*-QJPS?.R%.AL-Q"$^K.F_=#@^]S0Q6$5C6-G91)M366
MDCU\R@RWCS&=0))\A@J^3(L-^I V)R=;.NHF3NR!%C%]?U3FUQ+Q;GU#Y)S_
MN_57$W#D76(P#]?PV1=+4EQN![0TXY[U?B4!SN>0$2!W2#>UE^+";Y]G"'K5
M3A7L0;4>^ILRZ[7MG^F3*O[UJX1@VD-1OJD2)2"*6.DC<"+HW8F$=X%(Z",-
MQGIZ*0Y#%3;ZNN !WOYWPE,5ORKARB_T\\3+Q&5>>F)UC]+2I!FK9R%5*\R4
M>;:5=G\IU2\8ZRDI7E4>_'4RRF4]VJS^OK-76UR<XM.=E'**P@ 'Y2U=*7'3
MNAU+E[SMCT//SWU2Z.VS-2L@I<L),PB3]_C/B1M8G9^Y Y\D6<-\62"GR:?\
MXW^M1.L,4B?9ZYX*J)VO@H25!T5V7 :,:GSU!^K''NO<I4OR5%BEWAM__S"Z
M&OJ;G]N=UCR^=.LMGA%,!0EB2[)+3J;G7#;Y>J;\9)1LK$=)5H<U*M OA31T
MJ&7I@%ROE<^H,=P&1N!F7A]ND!)OT[U<4C+;,*>9-$[%HF@^?97.<?;3,S5=
M/6&E75WK5,_5:/+T&C'0]61;MB#BK?@)T\M6,)$-BG'P;0CU$[CK5SP31M\_
M!&>A[[I))J;7LE7BQ$AB>U[.=6D4(>'BJA;YZ]],P83+&N\"K*4M'R]F/H#9
M?F9\J/J4P?9/W)!IT&5/CLCW-$K-R8;7+(\DF 7:IC,*L\)'\;CE>1?^X5E7
MK0[5XTJ^=Z5HEJSXAJDM.$LVBKQ3@-O+;*I0_3Y1,YVE_>8Y(2SG59LY[3$J
M1VSN']+;_S,N;6[1JU*+HMWLC%9+)&RA_$]-V9I;CX^T X7'F%*0%;56<U'U
M-L%%1<<:Y@ FI>B6HO9G(D4;$OP=IU]C'BB%:P26-B5F/XLO3E+N^=S^\ET
M7])=LC]E%FN7SQ]""3N+*288FZJZ8F?(._ ?+E0VH5D.OS)Q!=062KS;F(N2
MS3%?6QT[SCIE350:4?R<J (HI9K]BT5KQM-:QRK*$R57;:/78W&3'GJ)3+V(
M7 XMU\Z2L?'- KYYZ+H2\_?=D[F*N &K]3(I@[(5Y8[TV?/],F[PXH?LV)VN
M$'=WT)8VW3IBFK]YH36\2\T=XOFH27]U[1UL8XP(/1HNYC'$6IW<\77TB.;E
MF]K^?WC4@5:X0A#_N>GM&TQ>QXCXH'NU)2^&[/'[E#>Q;?,X KQ'/<_8ERAE
M7$I^SR[P!S3.IK5#2LX\L2382-P-<G-EHE^&.4G.JFQC'6?Z9YA.)5)\HAM
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MFD,0:   R7Q-4##HWB6L4/LYSO-"K>2Y)+>@'_L)#GSS=@!%$E_0I#TH2'I
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M, $PA"C!/&LH0WA=!BWI]^2H25K\\^5(MKUGY0<D#+%_RW?)J@R/OUEJ:(#
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M*(N2[$%]\#M#!?);QAZ<$?*,X$ 8UW(VDFG*65(S$8!RI>%?67R:"J_])E
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MZK1/D-C7IDPC?35W4;F:G^X%CU$<L8.VUEGZT&.;8UN8-CF#EB#Q.](7+#^
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M/ \IQY\F0#[)$;2LB2I.H2QZN&J8P[&U\6\!:Z'&#9VA[DGYE]/XT$'YA!X
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MVYG/-J;M[P"?WQ%\22H5C4.+'(M[_/JB![ ! "R_8L0#L $ P*\1>CGKZ*9
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M_S[BQ?S5(_# @-P8KL>?W-R@8IN?CG+E:&CK;FSN[825Y%W>EW2ULO^+R-Y
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MN\,WICE/EXS=891;JC%?;?K=.9&V]4)+!A^S]C?1'C6J*6RKLVFGRWK!N;\
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M^/0IZ$60>]JDQO_,VOS_0T=;AN+'J+NG" BI6+J;[T_"^5%A?B=#L2)6NDD
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M<(0W[UJ,:##*^D:,W)"U-?\]\S?!%YE>4@/S"BD>%DD1"J$T'Y!Q_KXSX,!
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M-^:_87,KJ<%:OI^8BI&?Y9>OO^_S 6I$'GS[C"%#"'&A8#E0^H]3=D2%U]2
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MSHR!'VO"MJ=+9[4.762+BXQ&()IKWF1']7Q->:KXJP?"?Q17-E[GL?8IKF6
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MT"RM@0T$1+,A23$8=,)FH)CT \U#F>.$9]]F2"3#U;1Z$G<10'N&^J^)-$U
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MM4F(+HP%W FC-D)P>T0M2D(4^NT@=,77D6[8\1GN;]Z\3*C)T2<TB.;-[='
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MB:(H->8&%%R+?3/X3@W'<(&*^OA)';<ES2,=1)_)DA#$=[?UA@0WN0> W*&
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M0,R$#:#VNQ G:!/%WPO.SS\]>=1KZ//]N>S,?[#S_\_8O3WVWU!+ P04
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MKX"75S?NZEYY>(+Q/=>/(3U$_KKMG8S9EUT#'6;!0C 9O#0T9NE/.K#]#"^
M_&$_CMR3(>TA)92.XW9A="!-1X4.U*<SE%1E1SG-D'Q ,^RHH@VN"QW6?^R)
MET#C67M/9GMXLC]'RM3=%>O?GIF^D_JDOS^P>_YE@MREW[I+"V+0.I_90UX
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M^KJ6Q5XJ##Y3@IW*@;6E#S:I')CID6R9*S#^S[V*8QV,C\J-!K<GG3H @Q_
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MHV:/JO1C 4W;:L)E'K8JK?UZNH2BB.$WVTEXFVRLX&DR=Z_WQ?4#7L?%J,!
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MAC0$+LR"@1<FUEJ28!D*2'EX0 #7SBP!J3JTIK(S7)*.7_@ ]66[KU('[E"
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M'[S/><R/-.#X.LF+Z<[^1?^^ IM_\Y-8W,T%RA?-@GDAY,UP\F?<?UZ2+GA
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MVT($M2/36E$9L!:Q[,9N2R"&<V]<<(!WX$73='<"0&$]]9?G/V[Q0QBJ80Z
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M"++_)R"H]U\4:"&D%TD\)V4B:4?.ZG($RMWZ+.GB;4YNM;:#3E]%@(M,B<Y
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MF!G54&?/;]CG#5=Z1-?@#+9QNPGWC!H4F-54(62&R@Q>Y2[@[A(E*($H29#
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M7R4=]TS0-PB\Q$G(!NPR2X-W>E;__FG][YD7.3/?8U!OYP1_HX KR?$+G'H
MY0%8;.,-L,J"USB1U:SR&:B,0INU\Q6^OICK;&(_81;%P/43\/.($>DAS^=L
MS]^>9#&J\*0YKQ7RF8YQC!<CQU^/OT\Y3$]SW%@_;&J-LE!*E,/*86Y,8T_P
M?AHU7H.C[3FOFMEBO>9(.>R8"*-:8>)?Z,]__.>\K \P46.DD8S" X>\/\W_
MQ1!"5+#CGI$D-.F2@]GVD.N\&4BC#FJ,&]7J;[B?>(\ZD7?>I<1=L^)35?!!
M<FZ0@T%B3.W%BK,ZXX7N-W^=C#>+0&.]&\8)%G91M8IVQ95J80,N1,U=K!-+
MDY^C"N,"X9(ZEH4EOO85Y<[6];%"2'1.SI<'U\[%7_1T.JU^;D-<#9ZV(2<1
M<?W]Q75(XR7%5XWJ0P)S -]'D9Q'4Y@&76$,PX-+.T1\;-@:RC5]ZW'K)-R'
MZ:#5IZ;\/%]/SZ>KZ1R)&1Y_:72-'1%H7P3Z?UIH\PHF?*?S"T71O932UC*O
M/-DMQ[T .HK\0Q36,#%<%/8U3)[G!=#Z**IO'P158Y  Z2["\ NJ92QDFKP?
M?,/J2=@D'D'C/0'DW&,4K#T+H0MB[</M^W>LTMOE>ZKGL&DAR.<B0#$5G8/8
M1FQVF"KL+"!@D.S%2QW C9Q&<(?>+U[-.PQ$KG548FS!A,IAEE^,!^7A5T-)
MWI[1S9K8%<G J]U3X<SQ!KAQ#+RPXJ+9K'B'E<.@SE39OG&':+LCXDS-CQ43
M[N<#0UTJ#;%GT2?];#NQ;V9>ZVKL51#7+9ZH-GF3U!<_4'<EI+Y=FU%F5OO-
MKF@@@"'G[#1K.&J823\,5P5,&$,Y"$.,S]2X2(DE$:I?1#&479VUI2?IO>$T
MLAFF<.EKI!K=^ME$JSE'^I7*J9FE<PK;VS%__^'M3=.K4XM9F!ZDI>-:H'<#
MP2R@P'>RVW+A>URXC27!>:I;DKV;\8$]L5D6$;D0*<KU "D%X_+@%X/'W]:)
M5GZ(]:3D^U\7!DX1OKN!"0LD*>P42@:W4.4O#9#P<70YP3C"!'3GVH&NC-*R
M)[R?N8>Z<"&&:\H5*WH*:[N>HKM86O?TL1(\]RQJ8B0>H\I%6K&@*<@]FY,
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M@?% N24HSC59AL%X-E48+ ACFZ!>C&,U,4?!0)/4;CT@D"7V&UEK1<F34S"
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M<*_V>KCRBQC=19LSL,4VZ(,5AKF'K7NTL?E9U<55_SMF ^O39Q#-T"L+^8H
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MX'_R^K>3_]D^#NR]A8D>AOTXP.(YH 3[0_0 C^B!/3H, 8,=X/U?&\#^M^O
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ME2P%CSV8]YA0$X_3Z9G=5N<2UM<N_MB?I>L"-OY;][/1 _(:&_>KZ>@+6;J
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M:KR9(Z6K&L+VS(I,Z@^)04%T$_>1'RUC&^?NVK2]&6F.,/]&"-6YIOU#ZUE
M4&ZRP6_>_^(, WZ?!Q_D0+$[KM#0EA+4NL^5NLPZ3W(,=O/,#H!PKH#ICCO'
M;[<@!IZ!;NQ+X7@R%*RV]$!T>LQOO$88P&8>[3P.!5;B>&CF.N"+5D4C0*\?
M0_DT [EX6^<G,5HF5[4C@#U8\-I![B?NH?WQ7@OS(:Y2P!DFHF].87;_:VH=
M<;?W!;(H7A$R?HZ7&H[6X==9#02VY3*E/#]NZLC@IOU#W J]?-._-X=NRETH
M;8INW!'>Q*2&EQLK(&_=B#D-^?S(M0YO4DZEN= =X.[>!KY"ZK6)5]C\ZDT+
M TZ%'2<RE =6#3)R-%BJE5VS$D%6HAX)F-%8S-1DIH%/<87R.Z/I*(]L;DYH
M:=J'QF]UTZ9;*("R:BQ<3($F6=@^I$"HI&#9.\-$KA3'H0- )F]&.- Z548Y
M@<Q=K&=CP\M7!>M>PWB+\L78":G+2\I6E!EKS3/T6M(J0LCLD+DLA'0"[H'Y
M)'S<+OGL4T/.R3V8&,=F5@-,_#6S5JN3X9/5,I%G,R^';(K+1I%6_M%Z$=C:
MPIM@0;IK'7=((PT7+_<7PP@M\62RYJ_@QU6O/A_R5!WVPFMK=TB80 5^367.
M'G5.^HN3A86YH<ZT[K*<&QL29F4V.>'OF_Z3Z]UC$S7Q,RW6^<[TNZ7<IH@9
M5NQ^\/Z]?NG_O*X-"G(%;H.&+)7[G7H</5)7B1&(2G099:ZT%3= 1-\Q?5+C
MDFQ2>]UB_F2]009@XC<;!E@$1ZE&C,Q8R>OD7-)878-4J)EF_NRY*>J%24X$
MRQ_34\#&5?=X1%1#\<ZOQV,,FULZ22N 0]SMDZUZMK"'$Z*:M4&6)RQ/G+?^
MA4XC-DYV[<$R&N.H+/C]#;0HYE)HOJQD80W:VI@ZJOD,4UGFZWW\57)82WM[
MP8\_;K[3:]00ZGW.'3"!)W&, 737=$A2AVD0,Z6F9DUS\XL."J4MREI5VF9;
M@OZCI#.N\U\P;>XK-6V6[RM$$J>:B*=NY"?*1]'0=C^T03X]UK31H A;,]FL
M)]C,P.'TH#I*R%/0->&T6&7JVXFR([6Y?F9!-OH+]A5V;09!LDYC2S8(6I$@
M@Y0J?WSC'9MZ=#W+^"F)@10Q"DH!7R,.7QK0VQX_'0/$X.":Q?M*/N7ID;Q,
MO&:@I7[5I1J/ZXDXR_1FV?JDH;ZY^#;X?NC$LJ2ZUD3]/H=-!!@"G.VXK/8K
MK\<X:BQ?X[_'.0KL"-'6GF^X^+=<K=$FE!2.$*DD%X>Q?DF^\7/YK]T<<YUE
MM&PG'^3;HZC;V#)"./5=BG <PH#IELW1I[\3I;C2F.GD^X03WKZ]KT*C9^K$
MOL>V#273T^J029N.LL"AK'E#;%DUDWKP)62Z<X/C#.$'ME!\W'$TO&D/1IH5
MOE\@=U<9>@-41,,3Y^2N73LN9S6+Z>3KA!"LY$18P?RR$WCU^>)QJ2C2VL7[
M';_B7Q4FJ>Q\"+ =Z/,S/?2[2BVPDOE2/OA>]ZA?]2[U6!)?2J/ R,UHH$/0
M29_UIF8_ K>H<Y=%;5J&*[G]GJT=GU_^S.:N!H2?]@GP>C;[S\ZC--6ZH:R7
MI6G\,#$GV-?LCW#7/Z5/0[XT2>ZQ=C"8FJPO;>;ZW+N',@?E*9Q I=.E6D2N
M_=2\OIG3ZF\S/XC01JI/8_*3D%IGE5;]L!XW,;(7LYX7/"OZL?(\)7_BPX^5
M/]W=Q1Y]H-^K.G#R+]A Z"BN-?U;-KT#U4!QRKBR?!<;8E]T.\PE?3Y?V>2&
MO?YBM8VN1YJ=U_M<'PFW8H&<JI.["_8W"ESR.G^=N(6-B[F;B/_-)$WI;/D!
M*#I6$H\&B"NK *I[3L(L5FB3FM&IA",R2?%-)!GHD8*'<=DX>[S#.JBLJ\H_
M,_BZ"G=Z7=MN0M'[Y-C 6(;7+I_?;2B9P0NZ0!(=40R0'4M>Z6>P61%'<96U
M3EE<)<GE?<&[6SM*AO>=:O\FJ*>R98:M7-T1:V+>I,1B.NVZVM&?"[X5H7^=
M>D&1*L_+U+]6V)Q]:SYAI;!5'Z&OC)U/:$YH31_7'S3C#E'_F'$T,<4?@ZY'
MEP%/"0<5C"!3BQU12/U> N2\A7WY&PW4N8E)=?L27[YE>'N6#.R($GI_R;:F
M-2\2@XE38#-5/MSS3E]&3"20_C:U$BIT&]/7&#JR9#@]_C,4$_7<+]SG4-GS
M,)/LSQ?V8-.2L;_J _BYDS>N;)!2D @"+_YD<V<G5 WN9V>:AI:.\TA3G-,Z
M"TXG\N'.3#J-;\X(#GA:C:S5FMF^6'PY'6XRF$^96_)QSZ3U13W_Y#4;X&-M
M\*9I1,7Y*<<:BF-A#\[@[8&Y+(X<"YYLV.8VO4HF;2#%OQ>T/KB^X1"HX8<Y
M.ZO^LO/51\K(WUXJ>N&BZ#?EEC(.'TH->]3L?Q;DO"[[,1C6WC=MQS(.5JY:
M*/H6,% ;9C?6&/%N2#.H7T)"$6.OV^!Y*2.4(C&9)YIY<F(X([#43J>0H$SL
M.D<,1&44<&8UH+J=8]Q!H@@'%17S(N SE+S/PP]WB-=B//<==$*[PZKVLU]X
M[+;99+9#]7)K:\%@Z<\/\VNN;:\ZR7$?ZD[$(( >=/UO\%0U6WQ'A\-CKC49
MW1\AYP-:0"A&/$O!U[X1N%H-+ DA+TTXI<7(M3LS%*(\@"L/43>6D4G8'_K>
M]+:[A_D:ELGB!#E<4(^B&(!,)1R#$+19 W ]@'(?CZC%-5J,X)W9GJ.7O3<E
M@/SDM;753:QH<\*1QH!:4A@NXG+PHTA9$8?HM32$D %1 4,5W""GE!P:-S^%
M\W5LF, [ FM.X/7[=]EUPHNR?V4L3M>V,S4B+/V)%T:Q]'HYC54K5&MSFYCM
M5X=3F^\][6P,[=8K)!J_.H[9:2%.!FL3O[G@)QPSVUM/K2F__UPXKIYYL^67
MWUI^[MSLK>8O&1I[L/MHWDVO32A&)Q$-7V.!GLEX"29"W#:6>4XL>I*C!<QN
M_W*%B,PO_E<: Y^'S@J,Q<CMK DN3@9$U";'WHXR+Y;HR+XP\(V]);^;8=V7
MIKT'8^800X)BV'%W?4#;C%I4UQ!,GZL^R;&)0---R"G*$0<[Z\Q?*^>6;[?-
MR3#':H]ES?\TIB@&W]F#I7-U\2>@N I<M3_XJP>9K'CX(T?0_"&&'1'2PS4"
MAI*:ZOC\<0\TO)ODL!+A)A.5P6',Q<U7V&L5(\?'YQNS7=)^3#@H/]%6TL$R
M?_6@DA"2'=J=1I [B'B+%L=+_I+*"V/MP9)G3P/[>D;[UYU(GDO-_D1:059%
M>7-/:K#47X*-6O7'G)Y?>/JNU?CLC'-^4W9$LVQ#IG=4Y\-*;?M'\R,WOQ6V
M-RH4?+73KU#=,6C5K^P:359:5H]>._QS63I ??@C!:AF+'1C[Q/$47_@I: P
M!CI149#D,A:3"]31A@1#.T4^(ILW4[FC5>&9%:$>M\YBGR^)\]YMGTRM5?G)
M\CYY)<T =:%.'DK<.<\=FN/7)QZ!DEFM?:AX\I$FN&SO.L[0#TH$3;O,!8<Y
MOD=N3;36Z23%(,4P=R+RWLAZSWG[MR^Z?JF:"? 9O)#&4B'ZM[YJ;6]]L#2!
MNQYQ/3"--3T_ZU8PRYJ]XGV\A+_L:I97<&;>A8K,)R=M/&W4+4XUM,>&:[EB
M/=^SC^;(?6<??90^;JVA(?#.UT&-8K0Q[]@^0#QS\_I/3\?6V)OAJJ5_\1YU
M_O/_MDBLJZR>V GEOINK7VU-J".&HZ?EF,BW&BA%/XQDYY'74 5;0:7[-%2P
M0 ,7US$W0D?"L]^V-H1%AD]?R:_F#_ICSE>JK^#)/[M%R.M[L$^C6V_'\<Y/
MN?WDIJ&N.E(!]4'TKJD[>+T8:.^3-4R_SC%]MO3+\&Q!\(\:X?Q(4^^9.7\?
M?XN(DT\]O/_ST%/94?37YYQSOQ2O!R-N]STR&YFWW_I&>J,QDV?2?NS1#><H
MOS2/R)N_W'(JWDE)KI#U=WLPLP%+DU;+ZO^[XN:@)_9@WP)1,.(T@G!\#[8<
MA%.DAFJ 1-\]6&ZBV8$]6&@<E+P'J\EDW('M_OU_==RA3A:Z<HBT;Y(9!+AB
M:%I?;\NLWFA\OFH;EGY.<=*C323YJD!R3UZ QE\)TX5?4MPO3VWY@.D_VZ3Z
MZN!?I,['L^"TS!#+7!N)\O&. S4^RW?L6V5ROXYT^+-"G*)DO9&\7JN_KY_8
M@UWM 7HQP=+_6=^6UG2W!CNTB8GTKSFA6C$45]/>*\WA-D.[L^([4N8ZZ5KQ
M?<"MV'*U;QQ4<G]]LWNNW7]>D?G2F9_-96*BER,5 VG-53WHW0GQ.ZYM6W>X
M(50&=0YPW4%#*I0L8I"_;]?9DJ,@MD\'CJ/1D1+1\(,8V4/M^C4,!RH<1V+&
MII-2\.X4J-&F>02ORWIC2-^N*"DLM_Y[V:>D@D46G HO7;=K^2A32WTFRR7N
M2_J6.< FPI<K4(;L5L"\+9BCU27-B71*+]X9S*"*X]VK<:^6I!01XS$._G]"
M-FO==U22-B/T H9+B['-YTPOY7M]W'04=VMO][)Y&O3\RUOJISV8U8N^KL_5
MB[Q=N"'%>C$:S@?X[!C/\GGD]TG-^<.K(,/^L,#U4)<$</QFAO]%G^ZK1QM>
M=0Q6"(PD21@;6^_X61SIONVA9.R#4ABP=/.<[M 8+;Q!;:NRMBT0)K P 0O?
M*1QQ[-:'8226/"7%[%O5+5V2M?Y0<J:0+BG[([\<A_4 _@;(*=$*EQ<<QS@J
MS\-D^U+-_(W'FJZFG<QW:YY<BQZX.8N)"''T]77X7G-LIX&J@62DDWGUT5-K
M7'XV$,74+F;&P;OO3,8;#*419*#DH%+,]%"JT!ZL!\&/=P+1\83CF#LME-K%
M@G-+2VVMJ1W&Q.CI:SYXDZN9_YDF/"Q[,Y$;'!*+7"HF!+,)OMU3AAD$M:\<
MN*UX,F.EFBZLW?_J<M(9G,GC N-3@N?Z AN6W-6#5QE5-P/#7#-4DG(JG0HR
M<BIB56;R!M]<I/*XBK% \>[ !>\>.Q4/MS*U)DJ8QKN6L>97G@6X22>(C/LU
MP-01@_0NCL@Y/-(+K,49>D_&J+3]I(B;Q4XHZ@X?^UGA*D;CVXKJN";?E,WG
MAG(HI2(^-"QY/Y/$V8_7-QTW)(;=ZPLZL[WX\[W:7;P0_EP(WX??E6U%V0WS
MZ0T8^3GUIT4,RGWZ9;TC!L;-.IB\JUZ<:K&"C-+\B9LK-E(BB\V&0];C6^ZR
M)#/?#!^N&_<H'@Y]"P;1S&8 \@0%[780="2?/S%\:0[>X3)M4[A%% L;V7?A
M<,R6@T&$27_(--9V)L*B)<MYZSG?FN?V+: YGV[J6]@"DE,ZE&M\]%5;='%1
MW05UR92DR%-7'LU'V/:4*#FD%&BJ]QP]^X&4?^;5;[X(:^(Y',_&M7=X7MI"
MSLU9M2'<_04OCJ()VB?F3,<YF<#3X\#[8C]A/AG-4^<</:,RZJ,IZBYI6[>^
M$#7BI+@I1><V@KHC%>54V4XG6?ETF1*>,]F]]K6.B;0AG@0Z4T)]ZKHO*8_G
M3.8%EA_;+$;@49FJ[93WTBMTZAY,1)^:B! VBP5-_4;PJ-KO5#C^! LNL[2-
M?- D.">!:W<9X1A4?%[:3J0D=>@]JPXW/S8QW]3T)'I5L>ODF['K'>V^7E]+
MO(:IO!%_0[=WG''I7('<'3^.&'BUF*4 ?VNX!VM$]R&G,%O)P#6UFM!;<W+4
MJVM3A>YC,2G10N<U;W&/-S8Y.F$3R5(<W8,[V Y=UIH4_MQXQ<OQD]1D)VZJ
MNGZ2-/MTWU%G>NS\R4P/O7D]LR?6!XBX'Q\X^)4/ X_HY,5@XU[IQ]U.XM7V
M1:'N6=DTSXH42DK6<=/.VY;1E?:/ @;=%H2)81K/^W;^*&+SN\Y39',^4^3=
MU;[TB2<5/,A#V.0:&,ATOZB0':ZT?U'9%E:APAGDCO^[UXH 3+G\Z6 A2VJ?
M.MY#"YB%@#M;#]MV_^8:<0B[E>9RB_LCR!6R!N$L\HH[6+"^4J(,V%#9^RRB
MY<;W.Y+Y,65X%0CY+ "W<Q%[Z'N!2J)FV;X0%W1(&L-1Q? Z@$H/$CJYQCEJ
M<W> : =5,M%\G/] [T!T-T+<_$ 7BYR ;$3TK1*6WR+AS34G>HC"YF*XN_3M
M9]F1P,+;.U^'H3OL[E76/B4\ ")ZD7_@LED6$V;6U>&3R$!N^;.FYM>I@:]:
M6DLDNKR>)1E?=BD3\##TL&BZ<=I(7EC=XHB&V-MZFV-N7GDB:4I>8[Q>$Z?/
M'G0_X X3@,%@O#Z5TI-][A0G?79J8;1:3W6@FHWWE9<;E>]Z^O.%Y!MR5*L(
MO?Q&=EV#F<::_ZE 5*X/C.-B4#/KRM?\)K>26XJM0VJ5YR44 HC7?I37CGM7
M<*;W8%VV&VSFW#0/FYO,\(]B(-*XYPC[[L37"0O=@PEVZ("QME 2N2GV'L>9
ML8M&#YM)J*Q$! 8S,&M"'-2H#MXA+I(U)^W 7$N9/?P*@K.6?==2S)'<3Q^;
M([0'%7DL03Q! H1WK<*W;D-8!BE]#G##QJ-;X*OK( ^;U#WC&R?8C9;DN#-V
MH^QW*[,=7T,/01[?^//QM#V8 /<D&E>V=?<5X)G"0=<M<L7!LP_YXC?6^#[W
MQSZ=MBHG.CL>=3QYLRFRJ9Y/],(_SR[0[_$?O&YQ11@&;\I\"YN"73J1>>7V
M^5#EA\Z*?Z:=C,YXG:GP]G._S"/+-#L!__?W7S<*./K\L*OTO.[V]>]5EQK9
MIK^S,THK^Z9N7@[JYTXBKLY4J-O]8U=Q\'?(._M,#3>G2X^2A''JV6'V6F[1
M"P/)15<JDA\]>N-T:Q*,9[WB8)DZ2<36JV2P[&V TBX9[[@'$]HWQX-/H4(P
MBDU<O8OHPJ;.\KR!\E] A8PHW%P?591S AABHU/-#",9O@>;XNF7<&?G>@OX
MXCOT@/=(8<@$(18FFT6Z&Q:Q?7Q''\?';.W#'MJ?-7LS717Z4!*B286&EH;X
MF,B435(FN?YJ8AUAD-B8GZ4=#=]G-*+1[4,/3N.(;]&B'2&'JEE?_A 2'G*!
MWE5_1TB8V2*RS!3V_8('.M&3MZU%3F)^/,5-^];24OS?&'O/L*:6MFTX5J0+
M2$>B(M)!D2Z0;0$V1$!Z$[(1Z0+2)$(@6P1"9TN1+0+9@(#4B!!06H!0MK"1
MWI&01$2:K"B$)6EO[N?'=[S?<]_'\[P_YD=F'>N8F6NN.:_S7#-SY6)V,/)2
M=DAW$/Q,Q,6.7_B_J-4(MT D'QI ?/ZJ3%_A1SY?.74^Y82 A%3%KY0[GYM/
M9(G?.>GG]YMD;G]Q;E#P8BM4_+KYF=E+V.:,)-'DBV\,'_'E9JE]-S\#:ZYQ
MK)"!NH1C%'FMHLIT72J=@ZJ$*M;S^H:U0QT.:N%;NDWB56M2 ^\I\?A?9PO0
M]9?6C2;LZLGVT'_T^TWTR38O@$CZ<=I0?\ZBQ1V0G[)[@FL+M4[I2O;8RJDY
MTV,H!5K;$[8Z"C[;>0WH\,#VL*$T_4'8<939%/,F-<1]JR>!%V W 5KD PS7
MMVW[NR6G=\*85RE?5QE1>M )0N\GQ"!7$%H S5Y@#CD#<9QY<Y8M!RJXT-:?
MJL?$9_1Y:4]S0=<+B27JQ2V0MMN%VG3IA:%G/R4YOY:>7\LITSEMD.8E5?S+
MQL4C%>:G_TYWDC]W7:1=3;OBDK3C'Z>.IS]OJ_%8C(L; N=KY_^LFG+L:E62
M3B_VN?1^335O$!:B8CUHDZ5D57)F37+ *K?:5I"_ZJOW:_+:-9U-AIRF,/])
MRJN:P=/9(E;%CF=O;3G1"VI;BY3+TWOF_RN;Q?]2_O5].[&%:0WN VA*X78O
M-2<%W5R]H\&P8IK"^& /L +(YEY2<W7/Z%7J=)'D $$$M"#?AS63,I@AY"S_
MD:D6EM8-FD9;6N@#O.'ZPR?19T+T'5)'^&*KF:+-]+S9;EWF%6 WB:V0,(#
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MR&"[Z;W*5,,_MF3D$$NQIKU2F@B&K6W+HHA;6@_?T!K,<& O:(9<O.F*-*0
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M?_=9U.VVB=)-ZPO"J::\P%PF>?)5EZL$W5I/2V2C*->U:W%Q26/*O=[Z82O
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MJSF,LRANZ*J1?^'5QG!%?QA/&"?073OC.)!JQC"K9!*]6@A]^[&P;D.F 3>
M2XWXM.'>75CK;J:4P3Q)LXZN(BV1/&ZJ6I =GU&>!X@:BNI;GI4N..N:<E:_
M'PM>FMN>H_%3H-G&CRE:Z:;&4]$<B#18[4[3;*YV0];UZK4^,BK%Q6FLK556
MXM=30C57VQ(#I2^D;U(>3T#<%!^=R"F 22-5W59DY6K]NON>.V3WP=FB37+L
M)9',$36'EK 8^=NZ\)'[/YV_6U0+GT(.&VHJ'?^ZUKU2%9@X8(8.O+-&=WSX
M(EFE32.?.[\[DG4VUBAUIC\H2:ON)0D:ZU8&)IS/\"BELB4^5C1N^I@U9^VV
M[)Y"8L@\Z0FR03+LM)AP8[VA_G;QW=2*Z;U14[=S^C#?WS0;#M+$4;R ,#DF
M^_[[B4YQFGY_T=[LG(056VT&=2P>..AQ-WNFK[W94+MI] =-5-!OL?=!XX.H
M3[9V +[[_6,=NDQH=;C!TW]8]S@0C%/",&+/I5L!3?99%6;?WZ"R>3T9:J<^
MIZ+N@?E-\+:/::C@U2MG.H0^__"1/\-[:?!G7FSKX(>[HM81<S3;)ZQN?>G"
M+\MFA=0KFYBVX@C?U#+]E/PUS'J%<V'+6N7.UN*9*P;HH+IAW4H[\YRW&V7D
M'-DX 2%A:/YG Z:$%TTHV=!OI:_3M)5"TQ2O<::'1G>50&.[H2(R7GW%K_L$
M9^FDTE:);GY0NAQI#W_2Z+D 6E#G^FPS$ZX ,>D:4;=HY: QNB]^%9X!SU+G
M#S:Q+NN8*)\-4?_2DF9/'(@-6W3X4(Q8CN/9_HE#G9W6]=" ]JQ<[)S;[98'
M)?M_0Z:'G0I8X:-=JJA!=E!+"!EE&;>F.BWT\.$QKY9 !/MB@L;[6[F;9X]Z
M+!DLW6Y[WY8?[Z#$%&VC.SZWU0O+A(KZY>\_1\@@^=QLA\5>7 0J#'^*.SR'
MJ29_A;Q^Q8$D.B1\F,QZRW0',1>>_O$622 S?K>XF0(\DY;O"AX<#"<=H0+[
MU-2/8!:%)E[A[D1^-C9O67^-:*[[9C*_UL7QZ]Q G]R[6OF)>S[[!9[CY7/-
MR:O9^KTN9?MW,\YE"R6?N&'P>-TNNKS[_?[&QY3SBC:9FY3SF.*? '[:)/G-
MM\0&EY<_"/9@(1F=@I!B<^&YS[H1=!B8C45G=ZNA?@-?UB%E%N<&5L0(M)RL
M!I09&<NS8?3HI:JLM84MT/K4I^RGL_[#IB;/1_NA%=IFET.L^>D-0/0^(1&3
MH^E+>#]I? 50<YUK5.<:,V'R&Y7*\\3T\GQPZ16:.RE00B;^TRB5>:4IP[QE
MVOE^Z[3SQ8G)&7X=S.Z_MC9J6/F_]( =M#/"UZE0R)&?PKQ<D"/6$GRU#M5(
M(@2@">#A0+2C)\'=OL,W1%90:YR'"*8:DQ1^YGN:7:XKROFJY G+.-7L+$/'
MP?;0_$O4[<OSJE8C@B<!#L0>!:]V. .\>_ \&RJN^@WY^$M3 Y2>+J4J+K>V
M$UB+E^F-LPTT\)P=]-G48>-U",K[&;@C&VQA5A4>)X!<18Z9@\GHU6 3V9T$
M60+PJ(PG+=HVK3TG^S[>6LREJ[.38"L,!IMUZ+?/M"Z)OW1)G+@=<=O>MJ">
M0#TDL@G;Z+U&&?83&'D&]C;[)KKO$YCQQRD>MA@4<O_H]7-0\-;;(^=$C42/
M[-ASN=3Q!E:!0I&T V6W_QXP*O"W<";JZ'7D*S?Q7^7%CJ?X0E:?)CZ\WHN+
MT:3%/='>1/ZI'AJ7ADQOJ6W'?W]L7N[X4$K]N()6W52%N>W"*EG)P*XZYII!
M1R2\_Q]C%6KQ8*-\_1M#3>F)9-=W=T;O;0P[-<W71UL.+4TWN/..B2M_M\([
M%M\MIU1_@,XIPZ9O<B!W*[@*6"(]5OF6X_$_:FMY-V_\?L2@YR//;\HX*D]=
M6(?_/F5"ZY91NO*KRSAJ-9N/Y@.\)'(@@",_(D>4Z0PJTN+H56!\>0(1+<3F
M0?<:L4T3!JUIDF[@!!DK@HJ8\YO%ARTL4?73=WWU2I5;W]$(:9TN]<BIU94L
MC75BB4]/K">V/ZXC_I*X& =R;^9%9/G7@Z+G)?6?-HQ\9YLJ*I=C;>HBO8--
M*RNKRF2("471>TVZ,^E>?77BBTOPT^^SG V?OH:<;KEB8'S3DN4@)F>A.9E[
MI\;F81)6Y[QJ_J9-?J5]28!JM!*CS=3M5D$U9F \4#>=V"X(=P]AN#O=VQS4
MU%4\-9Q_OT"U)2AR4-#)TDJ;+=0(PZ/)CYF>T.9^]P7NHJY; M?9_&2EG6"E
MI!"F>8(VNJ\$C4&(5;#R+'+\4W2*J+UA-3D+2VSI--^825D[SRN=D+*4MVK%
MP#-6$9H,9WKGT1$99@CP4BR,>3I":ZD>])KK3P/P^*VP]&YU])(!TRKE5 &I
M7P5@HE2A^*>V8D$:55)SE#OZYH>$[M=1\9=(#EVS#7M=1H(^]HFS<W8S94VM
M&0Z$UK<_3 ?"XA*>:<Q,2Y0^(/BF/[Z?3?HG;]AQ90$71B8)+\P'R3A5)5>X
M;\2VM"<M5KT,JW*[[EUC71?&GGEYISG]1%MGH<./B^SQW"^&\C_B6*\^O&]V
M7-\N2[8Z_;)O_(/*:QL-\F;G\ZKSM;H!K<MO#+Y2SMYU%I\.VWJ3K>A4\$EG
MDQ"L#@^]<SCZ8+(BW]TIL'X2Z?ZVSB904<Y/PM474Y&ZUMPS70I=N,[8_3G,
M^KUE;(G'D964H#;$70E--*7M$3(4,\:!G#C/J@OE0'P[=A=]B-@S^QS(D\B$
M?FNJE@@.TY# OT$0XNKSB"6B&/-FW%).RM2 %O."RNK\_L7)5;V\@.T7L+?.
M+QBQ&VC L\0("BHKI1-\<R10O^:Q>9VH"\;\,0PE,)(2D]()#5Q]PG!FFGAD
MH,]XH.RG=36\UOMQ./[WY["W7^A,3S+_7#P?_>4:5\8\<G:.#2EI+*EV=Y\/
MI$N,+\S/+W@,!/O[!X;($,."@X./6ISHPG<J/[MY7/F9F8RJ>6TMA!GP[_*\
M>.V?&JW'#'4],<%1PTC'UV_>!;GZNM?7OZ^=I7O-UC<T6'[8OYID:%+Y,\R^
M^U)'IL+(*6/S"XWGIY)"=VQ>UFROX@"SD";&=;,SCA+_4VYNY&"MRTWP!UGC
M>K&ZJ3$81X'R&?35Q+OT%C54I^T%+/R9$A'5%38P:2%S4O7<B[_Y>.7'O*[2
MRK+SO%?#9-5T@E<1J6R)Z=W/UPL]^?NUEY%B7NIZ30$:>[L2\-<V?_W%_YNB
M_]$+PLTN(_<1V^_')'QS/B$678UW>2U1EWO\#:/Y'(IFME+'(CH/6V9RUXN+
MW+&2Q$>]_LRPO)%EN%Y/N#Q?(JBRUGF]@/QUND;VPU8:Y?;+M"9Q\?+WZY<*
MNQ[B4MFGQ<$PAB][&L&WXDJ>3+@,QI%Q.TZK6P;CKVXZ8:UR5M$#6P&2UVZZ
M;\*$NF7!EW<"IM7;2*<OEMJ2K!7TEPIH2COFN\ NE6?[&>/Z+U,WO?]B.G2R
ML*;GX5*.K5!A=&!&"(QH9#)884I<ZZUF1@-SO7KIEB_.I:B- /<S/\(3QGJ@
M._.-Y\D8@@30'?C<V[ZYQIBD5BJ;_E9.3T9(VW[@R_LQX=_>JCJOO4P)<1<I
MCG^%VW?%/=()1H^E \4=JI%?RISMXQ7XHBN=.)"YED-HR(29.*#T'[?,/G,@
M,K^;'F__FX=]R=W%"[VVH_8CC-HV* M]LG(4,_ 6B7"AC:7J<LDK4HF,)>Y"
MODK&^KVH [<HMOWQ"4M$+T%@H+NI 2Z4]9>[)V*YBXZGG'6^Z5,68)104PL7
M7%H<\@\_M*15LV]YX!B\@8A#YX*?0S3"ZK<TVE2/QFJ6CQ=-*4DKBJN(D+"A
M%0':V%._*6^:_^\)YYFFM!/8=&-Q*DSX7\FH#ULSHA]7!$O8L:KALRU=-RUF
M6^I*+,RG&Q1;"(5A2Y_E.)"%G+R7K/T?WR/B$#[LT1U6#IXUUT8WG9J/0RPS
M0FV#&=T^ZU=UH8UQRX2>@[OYRR:5M7%:P=L[3A-.C\\Z6=9VCV$7=!T*L'H+
M"9]*!8$3<UG&*@POI-\4W1LL7,URZ='3(-<)G]F$RG<:4CM@Z;%*6?A=B!?S
M,DV+N'O,#8D9*#SLA DR8UYQ7T)# N7/O:7QI(0^T'BP;Z K*/^- \$#.3M4
M!A3D0&[2<M*,>6C$&[2JK%68 !@V:'KN/="6S#X?W"8&^@\<9A8I8:+#> -C
M8YY^TT6G_D%"IDMW:NC A-6-':(KP59>IEK]]6HPD;?EZ_=.!8:,6Z 7#, ,
M(J#,(#"-%DF-P9AJ@+*4[B::&F+<^ 09!EJ>!_V! PJ,B#V*,FP"_)^TF$CV
MK? "\D^KF0ZTT.YQ\-$"OLMAP#UKI:XFJ(T?&?+7]_A(-B]V5<.!C,68RFP0
M9+K5P% M?A3?5/?1P"+Z2Q^RH1\!F,72=CB0 .E0E%W9F _K&<53WW-.L;!/
M7A5PH@QPHR_RAD4B_3QRY\K^<E.ZUG*%2J35%:O-<5<E^P+WW&C1$DL?PX<S
M9:<F$UEK01&.CS5ZI<C%)9_<P^W*6=_<#*TIW@*W+U2<)-M(11N!CX>=_*8J
M;>H]73]JS3Y /^#JB-+S- Q&HU,\GFPKAKI,0S_MYD?F$1$B7V;QGXYONE</
M[&;+:X#G4#HZUPA\GX+TVNG).*3/=@;YD]_(K9F+-)VV%;FY+\#(O/6C$BP1
MMR1)#P9Q]4J83D&:O,?N:3BU)))<'RO4M0I-ZSXQ.Y:-,ER5Q::[SV$^YE%)
M)T _EE\S&!,(RW#^^9>,TTK^A6!91EW&RX!+ "&92U!LA)-)?,90X* WEJ<?
M)N_)#2%0\LNO/[PV$D02X:T@@F$%$NG82?MO<S:3.SK@N>E.#^JU70&$A^OB
M4F\(.4Y6S$?./:?D6I'_MC2ESE80-)^R9[UA7PZ&GDZ H@)IA8/8$TQOJ$ "
M3R!;!S]MJ@3:]J^< AO*D*T]H!67VI)$A+,[KU&Z;GQ"N5 Z^'$BH/V7H5_"
MA*Q#JK\^+_(TA(O+>.T83->-I@=]4W%WK=>?<:P>.TX5T*'9!#HX!!48&L99
M;-<J\@E%A$9DNI=7W-]!>JO%61I\MZYVD!30;FMI\;;'J=NG%YOPW.5RE)2$
M?K9,.S!32F#<0-I:O1Q@RP"(3!1,<3"9^E[]&U.7=F'$H0M\7.NYJ=<M^FZJ
MQ9O:6Q'D+"_\=DZSY1.\OVBG'0RS:.ZDG1AM?*'O%LP(2A@NE''IRSD-S92)
M2I #IVJY! T4\PP[Q;QI?67_(BT $*#+7^G(Z^/EZ>L C2.Q)^"!-#>FF'&"
M)A3(-M*L8V=YV9&%0:4QXMA))!P.Q&/ZL:DNK4:WT4W&X5ZD13" ] DZ'SR@
M+Z\!')]+6>E3>ZQI'(Z. ) ?'5.N^)_^T6GT7.S*T)_,V]SQ.:-TP0H*]%2P
M^]@@*<.Y/2:)K0;^H$H!.'I8(C[^Z.X VY!55LUZ)<.X_=1U\IM'7U'C"TH&
M!LA:3]>YS'56_=_OX2>BX?-^K9(V4_T,#X/)*"^]^L>Y^?YR DH8NI-,9$R#
MN_@5_EL%*MZ4-2NK]DS%6LW\HL@LIQL9F3+VF4VBE1Z+E8I2KZ<JG*7BS-IV
M%-PMG7*:(@H[$D8XD-:Q/MRBT8$=H$5OS2+CLA8U\;3L.6?0XXR7RK/!)T A
M93>5+>6YY:Z4%HT3#O22IUE_OA-8=+*9*BA+E&G$O49>0I\)G&U?PY=TC18,
MC"V \D^_B]/0O81YHC5H05,SH[%(@]@TA,A>SM&[J%@": :L#QC!?F_!"3#5
M9]"!.?*CU-V,Q>=<A>=#/ Q+1SD>XC^TCN_)(B2#%DL(*5%(G."?13_L ANZ
M)^J([3AA3/1,D_P'U0TWK:!*Y=9\7X-*966;B1J[2"L;@/"VRMFQJUMA7FG[
M;&QV8K"3N?V7:MGAR4)U]QS"*2M-XYS%"-7]D,!-PJ)1S#'V#;VS&";[ID>W
M/C?T)8T,& M%[]PNY4'@+4>]-SB0[R)3A&T%;PZD\H_9W2P.Y',$S9:%P<-8
MJKG-A8PU&.-D P=2'2"HN*U8SM: L2Z4C?P6*_RW??+Q)]\S_]!&'E.25I([
M,LVPLSIU7%0?<ETM5_O(Y_L15Z<4GBVVWZ[O0",F$1&F*-")-KE.00SL+BJ1
M-;@+,"2FQP4&V8>FG+Y>MW6X@GD]2OVD0,%@HC^AX33QQJQRW05@H#CXK[M#
MP=6;125?&N)\P_U?>[D'BOZS&'6W!=N2TD9&9R<H@&ZT8/(MA""3-P1HHT '
M8:=0GD\I7D^HKM%A1U$JL\8F%6"'"VW]24N6Q(@#>+\H#WP^O-63IH>G8&@6
M"[J>EU8##EDO)DDO@:'M2IHD$2$)"\C)>,:>0X@I$5AE/H"<I(QB=1\V,=:$
M0*Q#IQ@E5B=Z XW-P>0TO(ECX(K@NUGFB1I+BC?Z4D?55IL1ZR?7RKDCMMU/
M-=?IRN@S()7ZL8860QW+8E]&*;'*E$I0GH"+!V#[I%,FJD',=B8D^E\':(#=
MP5U,$S*2ZEQ(%DZ.<:Y32FHQN38@$]\U^FFPK';+CP-QFM%5&VGT>@!WE/-6
M'IEW6<]R@><MQ4GR\9_>,+2Y2O^H.]7'L-*XX5BK/%A.CW-/+[BU^-#IX6R!
MKJZ^;5$^33.QV(='UKQ2:DBTS"G2/#SF:<3G,E9;M\(FH;FZ/V=1^!=6_KY+
MQNIZ/S;+2QRL6$5(H_R!PM]UQP206JNUBXA->:44AB,PP#3"977:E9,\]+*
M@0?;HY@TXUV!8"_MYF(/TEWV[X$NM*!#FV?U-X/C?(6:7VW$]NNY5]:\G5$O
MGWF@L7]J>_^:DCH]MJ#\;D,7J^*J+GXY\I=_!K5MOWRJ9HI=NPY8)(6A)+DK
M]0]P!,@QGX4%C$FR)TLO-M,$GV,8YALK*C0;@M"?QE?())$-4HL&*;O0>9PM
M2]JH0  [,VO]B\\[*($:G694_3E\EH)E!YZE-*6QNZ,SJCWE-%,UMP^W-AJ<
M<YC[]F![;RLKQJX-GRZ[$T2UF<HUN6:+=6JW#/O2-$7-[OL(3VEKSKX60+W>
M(!PXS*K-S:WXW?EEU:[;;^3]A1N.Y7F933:6@Z\"OUO)[9VUTLV_/.%T<U'?
MMG"A_=V0O).)BC'\L/A^;:.OLG=^B+(5:M-*MX)OVM?HX+()SV<56NW/)E0%
MZX$GAKGG'F(*VV]"S[D2]N[-OG)[A)AC:C-R)LR^FC[]:7=C#WJ=^1KW8>Q=
M]LA$PHT)LS,"RN6$<^A0KHZ2W'%@G&,Z3^*#$?,'1"\UUA]1V%1H,ZZ/),;T
MF&4;;+@+#^RF>QFQ7AG'5Z*,IZ)L%ZI7/Q9PS787.<D@)U0W!A9ALG1V9;9*
M^:=1%G[1=JN,N P-(0[$38AWNNY&DM/F/35[XJ3MK^WXJIK)S"K6O,IT?N"@
M0WB.,55VY5?[()TM)[0@GT.#_>+(PM3=J8>)![565SJ7SU5J_CKLW')_;FM?
MG+F*C&3S=UTJ8WBS%["\>)86/0 XZ,'.+R(6:SUCN9*,DM//T%JLHX1F,921
MQ^SF4.$-*!7@Q$$?,D$(.8HF7YG<C8(W\!&I?,@Z2X"54DWQ&#WQ(.1\[@&:
M2 #<M7)B_8G85"/)0>B"6 ];B%6_+XWV[L M$,C"&%.C960&>;T_1(W-IT89
M]>^%':F@K?<'CV$.S;A12Q>-*>) 4CIM)0=?Z^SR@RD?U3R%=Q*$VF=\IG<Z
M"_AGDGFG,FO5K>7$'QBEAT8_][7'JPL:W0&K$2+JIN?[,AUJI,;K5)\E/O5U
M]!J.+K-[;6QRV]KH(&C:2WB>%10-G:\THSP$"MS<BZN]\@.'0P/8J?_Y_NJ!
M[4(>FP\&4(>@S0=IIDKL.??UWK%Y#F0(RH<.R$E'OW49U+@ZA)9F:E0QM=K
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M4EWKNM9_'U8+ND]QU?;P2! 6M+O+%:,:08ZS$_5SI_L'^CZH*CSVB=Q1/_8
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M5BY;!AQ!T(:VIU:Q0FX(I@DXBVV>Z]_--CTZM0<5WCK\;'JEK? .()G:Z=0
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MC4X"!QAQR&/T)@"V<X6AM\34 $TJ F1<>M&)4%FT/U2:Z9!#MFF.\(:)=:N
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M#/RW_O /D1V#4,[6GR!0M:R3TY].CF9[[&3_=#+;(WP/ FDNP4]*_)R7Y^_
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M>[5ZLXA][UYX!&X974\.;K6W^?ZMJDZHSY"[(,;&G,0; F.=)WU!, )CKQ'
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MT8$AU^5Q7=J[H(#AH[@N+S]V9#+/M1)C/H+5[=U!\E1'([1=YB]FE2U\J&-
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M?5::AX_7WYH82D_6X_3_D, +!:Z?C07=H!LF(1B;TVIZ)=06D4NFOW;T60U
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M2PS(XS1R*V'2V(M4WAD@@^W.-.C!)<,:,RCP8VB$/8#B2##WT8YJU9D>X6F
M/^ 9ZW%>JH!31$SU$DP48\'TO#)_^/P<9"*8)5#UI\F@,#5+NZ 8@XPKVSB\
MPG_AL*&AR2GSQM-\!X^!<S>-7&.>VBX;TBOM*(X/^"R-$+QM4/#IRK6G(V;-
MI?D^R55I*<\ZU4_?KG$DVEB2_>R#'7]ZU@%M\S3@%.(QQHF!$V*E"ZL(S-8
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M#J!QX?KLE<B_FHN HG=(5-739<.()S*@S<//SA[Y<N.L/T^BC7-PMQ3BHW,
M+;ZH^E8DI03,HO;?6,1![I [U1K0^#L36U& TR"'CXSM,XC/\"U?:[^W(SR0
MFT_;\$/,^(2>MM/6;!1N")?[IX><_RJUWD8W6&)B(5<[0!M16>C0O4HEMK?D
MH=N;..2TTU;%@J\MVSN;PUKKM+5"*>YMY<Z0NGDQ-+6G6]A:S0C&F#\!.!E;
M^;=22OL+.+EE567!IV\I=V4'YH?5AUX15-21.&HI82#V\LHW[.%+)RHESYVZ
M<?B4V8W#CVZ<?7KM BFW%%!7Z$>)\6QV4TD+A3!Q_KE7"0->.N,9B1B'<$T%
M?_>.F<T3:!D$TQ,W;I&LY8'GU,2#:9FS1VX?ET1L=CWA"R%8AWKX*BQ.830K
M8_$%8%?_I:_R^QY(9L-(33Z?CHLQ##ZA;T"-)Z29145;>XPC<U/)NH0D7(35
MP8 T<.;-WYW"SC9%*]7V]KD!'R];C8=4O<2I['[3<K-4(8?9?""F5C/5S8(N
MI3JJGM%OR+506Y.-JM.W[""&-4Y.[H$0%_$9D$"=F82%\'4L*[]O#R3%0];.
M RE0=N>E$=;/FZQ4O6W:?!IYT2;!,7W3VGVD4,,0>4%6J%ZCD.G#7YXCCZ,:
MO#^TM4V%Y2N( H?X0J8LDA,0MX _B/$ CK!;%FXKG-ID:G:J,O R\$?=22$%
M<1-283*Y7\)/!>S\-?[US>MXPV('<R)5L^%Y"OBGD&,>NBE>ILOB36].D?.5
M[F0>23(;/CP;X=#2/BLS)GY3_&NN2VT L[XYOW?&$AN3CX"&0?R_X_^&(%#
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MZX4_-4L.B>?:EC"FS.,= Y;NY:8^UE#\ZVTR$,X_GK8'4A'F6LHO]LI<%7D
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MUV6ROSU7\0R%HZZF1W%PZ!ZF/6[#\1HPQGC^H,G!W:P]D#>$AJ!3U\<J ]E
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M;8G.6SZO\"N:=8OC#<AQC3#@UX UJ^VMFTW:0A=4VSQQ?=-79F ^I;J[V=.
MOSF03TLL088A9B2EGIA'M),--5UHM)EI=7=\CXG*?MFK\0<--A-#H;X6L.22
MH^30^A>-H;9'T;>&1&_0W3.,OX:WIL^[CNOB;(24?\J=)T#O]J'$(RYIWJV[
M\*L!J7:OYNMRF;*EZ3WL<58!5E+VH_"@5=!HK5F8Y73U_2>=<BZ]I>HI!9PB
M<IPE.4?.4LU-C%"^4N\Z:-<Q&S269W2 Z[(:2PSGB3ES2%.AFP?0YF^[+[!$
MXCHMZ<;>&(&*GGVZ/[Y&MJ[XOH/MQL/+9_)3K"=D9#./8A%GR6\'#1$=L2U]
M87E.G=_6)T[O-[> B5;<X=)UG=0B;<NW[):\E8\'O[8]]#=Z0/+[-?^9NJ"?
ML =ZL'DJ9KA$@C4P]IPOCJXP)8T3.Y#2=O^BG]TU>/E7H$'7<E=-8UEX%&XN
MND RC_\[**Q/0N^? ;G<KBZ"+>#,E>=) =9<P]72YHTT[.K.9B_T\=A 9$P3
M%EUQCQM35N.*_NC^@M@1$2HKB[S,<$+4FHPH$^Z.!=ZTRGJ18^UJY'CD3(U9
ML.T9FTY?/^PUI9*V\5:",]R+^HFZ.EE4_NW:^UU[K*"U^\_1JF)<G:5KERR1
MU@$Q@BSD&0SFZO/$AA?-4QPI59,XC"'WQE@PUC06H5*!"*+AD[Y8!_MD$2=$
M+[6W_6/4="'WS=\]&D:F/%_^,4-ZFO@@J3F6J;:P*>8R4(N.&HB5T!4YB2C
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M2$WX7MC,$[X@-5H%%XP'JADESRH!&09MCK$YRIHJ0X^CNY=GQ?1$53,PDE6
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M=JPS4!I+MSWQO=OD%9DG7<NS&">42@')L)/?W:J*&6/"KO""YI4=/;S6.K4
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MK?M6 S-0 **:4MG&9L[%130J2"'"=B925!/*)\LI4P.X7[-@]Z&T![^K3[:
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MX @ZE*"(F7 $JGUJO9$Y$=) T'I7GIY'@'RW4?JIB3SE[3_EZ%@]:.'=$8\
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MWX$N"UJ-P<Z5H=ZENE5T"N1,0]WII\S14*KDM5M2OVI.;$H@DJF<JX1)#R]
MC@_%9++2GPA,PIAKI[#!XUIA"MI0E_J, 7>:4 F(U/RG5:\I?)U ABOZ71^E
MM 6H%UV4C]:9MWR3HY4UQ7=VFZ_<YS'IA&\NEK&1KR"/H^UTOM+1Q$R##DN;
M='*5P.8[K[ZY84SE^,Z9G$+=VS_$3."Q,;#U=G;/3J4(%*20K@#0.G&''XM
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MGPV .<2?)\=M7UI+$(& )_?PZZ.E&=#U;<*,JPB4O4^?NC MW,8+7FW7)_^
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M$OII$A:<5H@FIR^.C#Z"\>B.C$BJ>,W]<SL]SH\S[P&H74\,>+4L>V%1JB;
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MR"XHYGG>\ AW; A4*8%;AE7:E")[4=<@5K*T6*]1OTJ]S P;7G-#T 06'9_
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M$W%"L'"B6:WWDE"+D*0$CK&=$,I[8$/> ,7HG13F VGAL1,"9S^_JFB"*\W
M;:5FQ$R535[>N3)__=5C0D,JG9=1>D#'EG^)EOPY*,!N\O6E:LO^HL:(+(\6
M*]/BLK,N-B,-52>;!OGMSB^='"(R@UQ<[2S*,B#I0" _' -&<*B]"%FL.<U@
M;:^[F.3]8.G&*)VD979X&^9Z<]L^4#@T@689@+^::9/IQ-5-#TLBKGT>;;W
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MV7J(O4,J6,^N*3S+PZU/^M\\A]3*P1,65TJR+]DXA C5S@&W\C.^!"+O3&=
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ML&K%5^PA@"^#TF*TL9OG89,2/)W$KMX!];SU^UL72UN6W*_S<B*XI,U/G_A
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MJR(P#I\1FD!SOT"/9=*Z<7KQ'-B,VS55%OX'1G,@X(C$#99NPBUB:-0S9%5
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M)9S/N%ZN":9---E8 _\=DN>9U)3M=SL@WA4LP3AORZ"TV#7JYGGL)'@'=%3
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M6_=SL)*%*4#VO=T?/\WFR#!NWXGJ!(LTQYS@)>RAI9G1T;M17)&U XH)5Y_
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MLS8GAZK+51DWRVRSSE19O:@3)O@8Z:,(Q(=3O34/#RS&)W]-N<5?C5+S1&!
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MDXQD_5EBP"4,/=*4MO"4 :8<BJ2:U .A<+HO2[@_OGP\0-6>80GFT^$!B\
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M+^L+=LL%[<L&W6(HLT$5R/BUJY0IQO/AZ1S6@%H'QV414CC+/83 R,:86Q^
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M><;GG]WY?3PSQ-]L?<P2:M+H.Z)-F<F$UXQ9ZJP6%1L+V9VV,18"_?_YM8T
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MM]#(RC\08T@"#=[T?WK4I8$&*I3$=P(Q,T##Q)4F;?_W91TO/[K^_$:DH%?
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M9@S]B1WDZ5E33(DR_&%9?VK3.RL),U=+8P'3S)Y5GD<T[8SU9^>#R2^BOX[
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M+AYBU#O:KT^D.<^?L+VLG"5[VIJJMTYE@^1^+RXPTV? K'BY!]!$S'<M"N:
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MQST/Z0%SJ_0\Z"M>'SK/V()9,(<I:W[C*R1'G27"3\%D(@5D QB3<;ZB.T
MNL3C^$*=O\9_0WD2\K:4(1B-3E/*,8+7LBU( 0;<EX?_OW^G-@7+C_Q(@5I7
M,"M18>QEVIIZC1X,G")P2+,-AJ8QKKYKZ*YA9ZCCP1/:2N$%P5&./9^$=H3C
M*T1( ;.C%ZE?NH:<(>Q1KAU\VO=Q7X%F#,WBSWM,>[MV 4- $V,]L%^3?UY0
M!BP1888<D@C#K/N'2OQ&<F6!MKT3#$$<7Q;FZ/PO7.R(/62N"H/S]>G&+L$I
M/@9'P<%&=FTGX(;AJ=)D@57/),$F028P6>S-X.H0T#"Q2#2NKJT*$9O@PGNI
MQCT*-\&;\T"(L'M-_4*[2>=GTR-PW#U_CCBCXP05W%PAHIWV$8#:45N U;^*
M6OBB<);V@C]@2C[)AMD);G:4]R \OB16D:5+@B339II FUW[4.T3;>T(\@6.
MZ\_81%O%@2VUOG\$Z26>%8S-&03XS%Z&*'VEHC</LGY@!%?C3;@"\]LQ;628
MBAAX'[A/VV%RL_]FX4\I-N6G2BS 0M/=NYZV[OCGK@'<> I+1!!=!X^S?I(=
MM1>N&<B*Q+T/]Z=LG"'0HGXE(X'/79R-4 M# >9*XSS[%>3" GP>)AS'-6 N
M"8Q;D:3@@[3)I'$,3\D/@/(^6JS_AK;!:53SF,#R=A!%@#D*.]@&A*.EF@Z3
M,_3G'?\_?F=@U,\>,_Z6MAQ(/ 8?$QE_ ,%A$AG D''+7A@V=HD'!_<667"U
M0D;0E0"/EY)&B@4**AIN6S.5 MK,5L)6OL *=)EMML)8@&E)-8]W!HY*$ AG
M(P<7.3]3C5Q3892A!$FTYBZ!6J_W-';(%[*TYX; O?O-AJ7(19HLO2<0LVQ.
M\\+Q=(%(RCHV@PX>7TD1(N*+\.YPI-2>TM8M-T+/ZL*%B.6<%[!V+!9MQ0@L
M.KO:,4,5D-4\%TY!\0_V- Q8A^B_4W'UY 7XB%H #Y9,P_= ?[B:7WGS.JFK
MHZV,M=TW,%Q-6'KFWL-\(;^1Y;]$!\&_80<KDLM#=]]%:+*/\F;^7[;9..A5
M51[_UI/^J*4R=W9=+S:[@2Z[GI47Y)/M.6@W=\KSY]*=R="1$9D#FQ,\+VW8
MLZM-9JV:@X.V2;!\GS.DRZ@DA>P%SH-\U=J,>LRG8/,S8/5XM/TE,#G':PS-
M5FM$B7C5Z7:7CGHO@38X,>(^L*]U,,GC,3^(I8UUB'4B-4+[4_DGO/V]?5TQ
M,]3P&A23HC!CF!U"<&=^EVA.DZ5K.[4ZL1GA]Y/%'IP>U$J-'^NZW+-J'E2
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M$+9\UXS@[LUVRF&^ 4-7A8@#)#+ M6'CH/<E1X<QGK@UK:3?@DB*!&9U(UM
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MW5J[L86-SDS,G[>S[X-TCEHC<CM_BY'JE3&PD&4I@>6X4-E=32.R3[2)>T9
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MEP!C'7*N2UEHRWR/[,:SDF<ZC[3Z@ICY"5CW.*R8*2--*I]<.N T*O2136#
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MN%*K)=J?*K:21OW8Y#LHSCVB\1@>=A+X &@E$92>6G%0BH*MS3QX1QA/\;;
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M@'-86_%H#BD!N1%_%XQH(ZJ]&&Y&K^D+KH,8KF<WR0.\^,03S+/IK8%*$HC
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MHUZH;?.UW?"!;\SA8?.)@XV9;R=QLP7ZI@_87VZA!UUGF]BNB^E(#.&V7'G
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MEE%E"A8-=A ARBU*]0)+AZ0 ,1N\6E>Y-0DMIJ;_']+>,ZJ)-8K[Q8I*"8*
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MQ)>$%!;B7Y588:8?I'?;Q$64WK#8UO1!'1[1)V<>26Z3YT  2'<S.V,?[T<
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MJO2T':[G)9\7XB&NH:E6>]?..1_W(NL*;ZR+I4X;H^Z8?#5% ->IK6?)V78
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M54]HV TI[6-0O0%'F-A*GAB+V-DBR38"^^B0>'F^<;@3$<SMF99,PLC%! 1
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MCN"T>)GDT7/XY=MV'EV(AH#4=U13C2#LB59Q4&'?K C%'@5QWD!VFCY6!!,
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MRDR5ZA#AEHM61.6"VU]]C#1=#-+,B7[^T_==7*)1B"_6ZC]QG0@)27HB4Q>
M]LQ*M$[H;1S'_%?! 8,) ''$P,UO7Z=?>KBV 1+$P@&LGV#'9-!.2.M;=C?-
MZ5T"\KR9UI>BUE?[FV.##*<):RZ[AD$/R[=F\['1P >SII8Q?8&2BO5U?ZS)
MNYS%E44KY:PA%CQ3F^_ /WP'['!/3^6._YPUF.J;]O;X%;D;'(L?OUS]QO)P
MK;6M]8Y>EO*;\G$GSX</EME*XK^G"GA3""EX&#$(*M%Z.K9_)R,#&R!GV#W!
M$VE@"3^GS^_Q2<)]"G_,*N9VN&]W0HY@=#/,\'(VE!ROFK#[/J-:=;N>84ZC
M&EI;YWSKS$\*$SJA=;!NZ"GT)IV8@ B /)[&=GD*S/L7M\J"<72$&.=RXL<
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MJV9\5+M/QE=0E\.,'2+48+NQT[YL\^%66;08^S8(\R,&>Y_$6.D3F6%TR*E
M]JSI\*U1T[-?D>_)TA($XB4Z0YD0%A9%*Y;<==Z9WK!*HZ=T0XV-F+%)0 \E
M#.>EPFW$AC 1-$+[T%0I(P+$NH+FQ."=1*8J*OK1(V*MU]&$Z=E-RJU1N['$
M-V4MA=\&ZT=^&^7(G*TVTI!9T;YQA-)XQPMU:<E)2:,(;^SZ&E[U&QYP)&%
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M(@F6LM5E/^;!F#/]%[+UNYWP?J\67GA*2]FYI);;G5*C=MY2Z\B3CY?."NJ
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M(Q\C!_WOR&H*0XITAL;>[9D7!TQ??C/ZFMXR9$W_K15A$K28FR9KGXK44"'
MM3MN5_Z"B(Y5P/4T=3F:[0(US?;:2S2*_8P]BY!%#H@%#AX]D72"/;7^DP.U
M/!"&:+0H8A_DPCF*Y<A^O\G&I/&TP.DF!E6#S$>F)@;8*J,7&$=$O NY8[RZ
M<U+1I3-'1*9X'[1NGPAM8;PKIPOZ/)AB@JD^<GW%N!3S9B#S;_=H>3"U6-/M
M7SFO4DM*Y\^BY_BK0?=ON!-LGS;''4^S7^85?O,3YY\##)@Z"29F'#F6:*MT
M*E*.::,TKK<7$A_?5=.R:Z7]3[.5[WR_4$F'F?=LSPGWOPIW;HC._G$MNE[M
MBA',;JM((NG7RZ]';+=K(8%+IS#DCS,MF.[ *Z/8 :QL;J'.0^M;2P7^J@Z1
MNAV.68U['YT+67MS8G_NU?)! ('U!2QB\HB-H]+M$U&&/$$.DJ0/W,8#&0./
MS'KI3\>C?NF&2R)4^]JX =%'V(RL*$,_6Q)QS#W$")E^9*+FSAM%WBY'C$G8
MR-[U^J;O=PRB#X"9]N_*$W[G5%3,\;RZV6CJ(R>6929?$6:D77NT7B?)1./X
M@:/0,E&M"G6+T4?3/7/J(Q_5] 5UGE;$W!N9XQ=Z^'J%Z,<4)[]X%6^\%JRC
M%7AKH-G+FYK?<]Y-<,'J9/V_ PV'** '&DD<@[[<U#)1#NY?E/S!(C0**UG,
MS9!^V(U[C+RL^%X;3R E8F=#9:E<[HBEAED [K.7E=+.E*_YRP):6+,>-5TF
MS:56\G2_>$'M=Z,']Q^4FGJ79+? C <9C@ZQ>:W3D5@! U4UB\M+3AEY#K7Q
M%NIN;L26U+>L+WCIZ+L(/TKX8[X:&[WAOVO&\^W*O)[)W*'^+[/H,/(LT]C&
MIBW?(6.-.52>"==+T_E!"7E"]S@7ZAKQN7-VF)O&Z[M(53Q+S)CBW@9P[)E^
M<@LZ"75JB/F+'"1&EV:2<_2,Q8Z%/*32D>4"I"N(Q.OD48)7;Z<U[/N,ZF,D
M7'DTQ*@;BZ5J5(7$>P[T&H?&>#$^>:J[P*KG<XM/)-K"0D+41:> RO^*'VVV
MY=MV7H!IN> ,JTM+E[\LDRG:@2]B/IF.!OTO5>(YG'6 A!@F;7V(X["QCG1B
MVB>C1-@;Y RBP8/O#(0B"YS4XG5%-_<TPMA]>T-[H7LDNN1&8\/FRUVY.;I2
MFQ.\K:OL\@:C&4OH[S9@2B?K^M%%6N2&,U#@A$?'?*9XAK6D6ARBDV']'*]+
MD/IOVQU&@-6N_;X7,]79E]YJGN@2WY]Z3\+\% K#+#^-\.J/^8UE)/&N8A$9
M8^93T>'"(>V>IE\,)B<A9T<:(>_QP=^'#YO8H+%SB:&/PLYTMPX0)9(+Y:4K
ME<YK4M5KE)\] 8'NYMF##KU7_5?-NNH+5D8YR&&\V;/?CC?;[5B$\604F=Y:
MM!./*/ :%2S+675P72+'RAF;3NEBG+ZWTTC2>YW_M #3[)*KKP$O3FP/6/(G
M^)3Y@DX&"<JYS?Y8R:[OX9NT8NS'D<HL FA%0?RMG]P,0D&HA Q8:.O.79M_
M%#.T@?_YR_5N*6/^QS[HWQT%H;TG57LE1(TZ^<!]D"5PI ZI,O*S-(#_7W%1
M-?]H%WNB=(^3'B2EWV[P76GXE-JES_37*<I/;]^:7V-"I0$_6O$13 91AK#B
MJ\J>K]KYM$+?3(\3K< RVDIJ?&!N_1^Y<V5"26WC]QK7O^2IWOV._^(2*)3_
M:<*ZH?OS=O^9?$>8>2.L3SE.8]I4S\'!#=X:&V'QPNG!<D''*U9)X?@_/UM\
M&L<^S7682K69Q'/CV9!V]N""?0\CU5=9/X@*.0K %L@":T%VI8T-HO4O$2C*
M39)^K,XI'=.FCK;\]X45:>\5)B_67@%+(BWW,"@MI"L W_T;,4@UBDE@R$+4
MD!;LH_@*A)SS)/PKFX<^@CK&NS:*/%#R1*.B]G#)H6PBQ'#L!SZ4"CE?IEMB
M$WX*&!R8\"^C6=/+J\<=LV&]#XK;=:NJ9GRJ<:&^DP^L2)T:>OC96@N'6[%+
M6=Z.9,0V SX>AK&/FS/5VE9=KV33:!#!\D5,-C&<J:7#;"#+D#3*Y;\QA'2S
M_6Y._<7V?1[*%!,&W#Z,M\H+2/^-H?HJ=8X$3?Y,^V'QMBESN,4L+CI&NZI1
MT3+!+\6/?8L@9U5/SJ] C3$.$Q6CF7(K)Y2)?&- &ET'XRNR!SZ@^)701*)+
M-9 P>3A7?]!V?/Z";4/A3N'M4(@T>RNM,4IC*/;ZF%XH66A-'$BD8-RX]V=G
M@Q]^<<7$"-2M1-[(5BYD-Y&[FPVDUG.X[;%2FYYJI:>Y^('*O-$J0UF?4W'>
M6O'DF%O),[$PXZXVZHKG!8>'O2&PP7KX=]_WX3)6&DKYH38:8&.>/P!E;<FC
M1@Z\!G5(I*6"24XXD)7F6N!]>+A2HD.HGRS2H)/=F+OW]%[;-G:]TOFY"-U*
M[W7"S*7Z&Y1!S;T:B"A 9FTPUA<-DF:LG0&OW9M(0Z"9A=ZP>:_YGDU(;C"Q
M@==FZUJ&1W"[;[ZO]]PK_L1+*KQ>]3$9%%YWOJINR CNM>-0X(^SLGX0N[EE
ML/UZ[DJK[M;N^_X'4QOF5S5B7''RIO'E^L%H(9Y+Y*XSL ]:M$]_-<9BSY>R
M\WO!@BA)H?C6M^,BW=SV6@2%Y5H?'W8"'63*;9).^M'E[*^$D?I]V%O*'>M,
MR(><Y9W?Z^ ]8K?3R&_(Z1AF;([)V<5N2T\VC]&RD\:SY4+%9Y#:'%&\?J72
MP]1>+<7>MB<^R.LCNK6YJ2WQ>*CGFQ'?>+BQ1]EMTQ9&\)[%JSH]K!1V\"BK
M8C!J;\J>F==LM].5%YM4$N;PT,,ZZV[Q<K'MT,!H^Z62G4HMA6*EXI97A95*
M)>2O87BVP6+L._L<649_^/14+^H$T([E60 N[!UF>RY/>C%<=G!!_N&8-V"+
MG?W&%^14/V=%5@ )E%O-Q$_5/AI43_.^TE;6X!FCPJR=8X_J. _W08]Y+KN:
M_%ZH?,L^2,IO!:(,3' &O8#G-9!\9G 8NBF<?YD_*MM0=N8 '1.1,K#[KU>E
M)XW@R\U8>@/A5*S;TY7?9<V:%RRV-?UJ)I(;$/X4TMF.D7"]N9,W)[6).O6X
M-!-C?6S0D<5OG5]B8HN1GJ22KY69MM9R6M>X=*'_$F;-Y,=[U4YTZ-F(:]!*
M50I>?AEM655'_WEW*U1Y\UM1NL$'%EX[R>UR)JQ5[Q1]*;$V+,[2+K2-4 \S
MKLJ[]RN(J;65#1%'D!?LUYOAS"&P(]L@F1PH?^F[%R>Y=1FKTE2)J.PQ,#J6
MN-&R5F_?U)BKD$Z@[EQ>D5;9:S6NQQLX7PTL:K,UWDNU_+4/@CY_U?2B@Z&7
M%\X*W;!JFRT/W!JS%;FMX'+0X2:.ZVAUOG'%<^?AZBD'<ZNK_V_[6;[^;,K"
M5TIY8DR9>A,0P1QG;Q"RD0%XY-\<3=BC6K]]$ S13%4Y7!^2];MP;O%=F'F#
M8%O;D,@+ 5EL-]&F[V&T9(/&%,X:?]RU7E!RSL W*\1:M]Y(V[%J=<S6HA*K
M9C7VP+9GP$X?_J+P_FE9@*@"(8D)><G_FZ-R^DR MZGZLX93%Y_BA+WOOTWO
MF:#0) 6=*]*<<4<\=9FR+P;$;;[X98%?EZ^W<]9H3D@KH)X]QI<(/SV[PI5U
M^5A'TCSP>MQLJ&WZ[=:6XK&_.:*8("4;":4'@2)CZG\5E@0K?@.G0H5YA]F9
MO9[ACR&R""=+=E!22_YE]V_%RJ_;6ZT:[UZ:G;-;'_7V]9VSOHEQFVKV]O4F
MR<9]^>?X9G!CYZ\V6$;OR#M6I"9*\7#*+7>D/#+P7*-4 NZ877%E:JF5(W9]
M8?;L^^/;/6_[W[?$&:*/LZN=2OR_\P@I#X2[3(?D88$>D\=4!]G/V_[AZ%6F
M44W"_,W$[*4SN#\792>Z6V&[GDW95M_MU BY*&U4C]\;,@TJO^HG05)%ZN93
M%70G-EIV32T]$OL5]$?*EADV;]K'UBOCX8>IG@'/M@_<7(72W\()Q^>O?>RJ
M'_UK[SE*<(8GAN$^R.T51HD-W^/F :[P2*JT,!OREJ3T3W3'3RN]#8J'.='J
M**Y;L.'&($C<K=O!T\;X8Y"E0&H9_+EURA]8P;>REVAW?#3EO77C[D]<:)ES
M.V/"YNP$6^<EU6JIO:TLPAQBFPL'1CQS6.!+8W-99R#08^6+L"^&WA?CYD_J
M%=<7WVZ^=_U^79M_ZH<092=Y2VFC<4ZDM<NBH_6RKJ_\"&L$;W(IJLLX^X^!
MWL&;[:.$?VQV+_KCS(7U7;?-$:H>DW-:S,]COW([]9XT172V2;HXJ_];]U*]
M[E])9V$0: %T!73_V!]%&=^]L3H9CIANM9"9'6P8+)2+#?BP$^,V#;87=*Z=
MF1Y+,H3UYGU)\@]QWEI?J5<.=EK&*$%.?[<IU&BF18/_10OJA4LA+3BD"J;[
MIHD-Q__=()M!HV>&&-5EQ_;4!]+17#,Z=I7N<;0Y_.SF^E^MW='.6O<])%/D
M4]>[V<8W.X&+\4$+:?Y=>^51V9'7 "OC$/KL,-/T,K78\UOG'#$0;MY?'?YC
M0FK;MC[SU]CS.WF&5I%;XVYWABXK2QYYYN\LJ6=E?J>^ILY&P.2/ZKS2[N)W
MX[6)MP!7J4@*=AU['BKAK4$Y6;-FG_K <*)(Q9WFZF%WU$5!.ZY;]*\RM:&1
M!XCTKY^]]:/5AW:M M\^-$S,[QM-=O]%Z/5+@HJAC@+J@\ROO?L@,1HS]SAL
MI[.Z$E9E&5\3(B2YW(J&X&JMM:-MNF;:=LV7J&^28!\BCHKWULK6I9F<9?LS
MR8]-X@X<5U RT5 !L^B7:6"DQ\AMQ9+&&_U\RO]N+1JV"FSM["H;^,]S9OA2
MTMC&AJ/KTR_/[S[9)#B\:BXSEC-DK=I+I[_@K#1$+?DV8+/M6BYJW:GZ,G_6
MQ%P]FM$:N??SBC.P**-=9RAJE5J9S_QV]Y?/&:CH-C$A6?.H5.F9IY3#?IJ)
M P?3E^*]B+D3<>4X42EX>X$C^7I@/.2CQ*^N1=IZ[BX4-=H<W,XX;7((SM+R
MIS2]/YK)DI/W\F9/I35HJ<!DO4Y-\@QJ89Y)DZ)C-_=!=SK+XH._%,>=RS!4
M*2S_!)% R@$!;-6>(C\Q_DF$V4VV7])Z0-ZRZ65;:0F]OO45">\0V>R?ZU.>
M*;@:NR>]^7XATFX&.F<N]"VG5:2?' O&JSY?=KGO_(;^/$6_VL<"-9IS%%'W
MO6>T='E\A8DUL)"PPUJ\^*<X6F6R.1_Y%B7)S%*)RV A=42_(,*4: Z_20;0
MBL)_8$%7.D5U[ZS<B32*4LS&V])$4K(J'%LJSS._F5?7C#F<?Y7!-/V^1!;A
M]Z&;Q9(@VO:<00I9($K^,LN$GE+10*GKBZB'8'"AG2UPJ5K"-_[IDEOY%".+
M]AJ+/FT]6P.KMBX3X@-+1>.F!E3?/JC9E<R>1R?];J<8RPT?L5G4LF=)=I>L
MTG^'%+MEZ\4)8^;/?3(QDZHIYF:CSQI+[QH[M#^^_<>LV1<Q;5+5JVZWLJ]A
M4:LFB[K1YQN,L :Y?8:C[O:A/UWL[/ +K_GS[:^70J?C0XA%W/SE7Z?9Q_[H
M35$5$A5FNM]NROL0D$FAI6X_&^FSN8*P+!X4M[I]2L/F$D)8; KK> E!J+UM
MVE4^4;,=A^[5280*\_]$&,V\\Q-$:@0PH<(]D::\HJ+1N7F?5=G2T?[VAVV$
MNA WZ>(R?)W/\3L>6ZU"7>GT*Q7)/G^EG,[/FD 'E#\NGD_GI%(ZRQ/\WXY"
M3$.+RI2 6MA>4R-M'R2@W^P?>60)_[54JBI_)5"C"]$HI77.YC1RY(._,@-Z
M]9.[Y>4/%6GXS)S;V3D:XJZE(< S5GW=SWI'@K"+>FNHVJYUH1H+YD1U>O%E
M27"<Z:IE=S'OA_K]=N&)07:<N9W\?ZL!'C'2XH\'MZ>7W&7^N7!%T_</DEMF
M[S_LO)=LX)Z^JB:5]8!G+JC+M&X3$O<3<KQ4X7H?DPE=Y[ ?^('[.$:+/;+1
M7[-8@"]*6-[Z=^C:#(PDTTKQL6+:=*NLKOJ<V^Z%E?)V.IN*EQ'3%46Q:04$
M"&"[>Q+U 7V8%Q"[N ]*00OI#AWKR[=\="0'%U$'I'KYB7F%6$2B8<Q0TUC7
M\0;B13@BK+&(J6L<+X5H#-.B9,)\3_YTD8SX>#G8H3XU)>B91?+#$Q2WBC.!
MYW3K;Z]\WS62A-5E2)ZGT)UOX729DHXP)9P&TRGQ"J3Q\K%G$TQ?^?IG 9]7
M?Y4=EG=2'L1E]@1>*;_#.<W35G$/\A++:F1_AKE01U]H.!<I)&$-U'5GD<>X
MP8!X-?\C6@C./P-[F!!R$=UK>^"Y);VMX'#3HI*@V(.;$XRU49BG'G9N$QM_
M-+=*^8LG/(&QZK;SAG)/6SO,U^.Y8V/3KAKRZ%2+6"9)>@(I)#F9RIFA/D&T
ML[*?3D9_HZ4CK\)CC_!D4TNEJO-7X/)++6Y"HOE:V>1B&2*A]/L/\U,V^A^6
M,JF+DU!)>^E,PAE7E6[9B?/.];ZGTU@K$R78\[Y1G%LIY_+W09CH"L$G2R_N
MC.%Z>%KVJH.7!.[*N*JJOM_^_=S5X]_^A1K_FMN7?D]'WZP43\:>\=;0LY$L
MG"1@6*]F?G^4Z+YGBH99XV\,_@=''>:I-0,8L3[ 1#ET'R0D*)9ZGW<^U[=H
MR^$%NO?0$9:?)?/K6'77(VUWR&C&5H16_OP-<E<>L_*7QCO-?=#"B_*FY-1<
M-Y96^[LML<9VA:KB#T9WBW/35-AP4F.VG$K%L<?8B?)>AX'J\]Q>W<C $NF
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M?-/3I_MC4_5*<?9<04]U3OCGK30%<'DON3F7:B\ZA\BD*FB]'86< %8'PB6
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M36R*&\*0Z[#A4(MA##).U)U#"0$BQJ@P#),>9T$!4P,/7-E9N29?@ (@?A2
MDPTMOKAJ'LN?K;J8V@'Z2K\YI;I;0-_VJ1PT)F* 3M"-JH\=_5RCUZ-:;:2T
M^5J1/&>O8U+CR"NK-=!XKO?< VW72/\:&N[MG;IGG&CUK;()IYYX2,QB[1TW
MP?R&G[V1^1I1;[0\1-Y]A6S"O#]?5^[:!"::M6G/YA3@,<B,:F7=QNNY!:SE
M,GUP<T:FJ<SYR&5QP5=:$?-";:\]R2M)%1H&7."I:G_M_7#,/S]9:9OK6WF
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MUX9H/[Y8H7H*LU7=!&U+98!R%+._27L!KF\ZP,:8J-)O'&*'3D?&=H>0*/*
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M1AJGSLXJ/FBJB5&I>/3<#_31:Y-**O@7ILTFX6P5\@"=CA)<USW@6B\7S'G
M&[8V1AC/NX6EWJ[;'K[0"73<_%:4WF%3VIW(LD5[N"* )D!N#;*)U*'4V]?:
MZ8U0!%5C@GHM=<9?W\KH]"5F C?<1^6,SB/N;%UO!P.*KAVZ8Z96F5 +K1/]
M8=7S+0F5;U#-2!7T0Y-M(%21\J9<GEDT0<G]1K%'E 2L.Z &H=B\B1@PBUB
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M+_T/^@$0'@04ICJ89H6G1"L^QF"QLT*&(NK;H^!2-WT8;?OQ^;,);:XGK^B
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M5>KQER!P#3P% I5RB"#2O=VS<*P,;:XQ[31I^%HW:7= QFSBC>USQZ\'>'@
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M3K8HRCVSH"+FI/<60/(J_U@VH91A)'*LBL)G OM+$:_I2[@E>/9Q8G4CNM.
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M(OW/%73;%>=TL&-ZJNYV?2=3);@5OSJ;>*VD?Y^7M>@N\^<%_0A*O?>'2/Z
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MI^J^-R6D-67/6*I])R\P:CHO\O4R85OY#9DTC_T]!;)RV3-S_C0S2HP$K [
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M_>"@WWINAO4=UE^).+#<DD"(#<@Q.^+LLF?6J4NJIY>XS0^78_4N>UD0WG.
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M_SW?=[OS!9=A;)"DG[YLX9R1SS>$O5Y]/J)<4Z7A#5?\A.6'6QO"22L5%(@
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MK==#0H?3@?( WY2?L61;S,S@AW9-9JEVA7:G>-8,.0CD3B^UQ<]KCW7(R!+
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M!(O*63M-P&M4X?N#QW T<:MUOHE:J%)>4Z*=)PE#6!V$%O^08;D>1Y$&QA$
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M:*,.&JZ:HKI*S+"C^N</4TFGFHQC]\JK\.ID,:V1*[\PSL+_DQ0J5A#&Z![
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MU4W?]7.[W'ZCVNLX,E,!_GLI5Y;:50'7 S4)V%/'+S=\,,81IL"I\BER]%T
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M7/]\*U![D1;#R!@LK>.XREQH(R:F\Z-*+-835O>5-O!LKNH!HH9[TD1%D35
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MV4K^ L*OFN_<>??HACIIY0Y6!*'Y%OZH\Q@76X#ND#9<J$=!73O-]"N7$=)
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MOV7YOP1'?[>E"J,'\5C8_S?0 @5C_P!02P,$%     @ Z4!F6OR38-$RF0,
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M-L.#!T"F\%?9<=O*'N?K-Q_8_3;)7^,F>8$,70HDZ?D.\?U($@I,2%SNAVX
M_XUM9ZB;=%2Q2N$[N#M@I.9@,&=&V9OM01[>V;\0$P9*_U^L 'N_^MJ^?+5O
MD+$[G[#!I@_\^!N[2*;U]-GL./-"%G*?N$R"<(]"T-I,4*(=!G:4BF'#@Z'N
M^ %+"F,X_'PY__-OT"(KQ.3R5W6FTBN<V3UTF,WJJC1/N \E@16#V2U+5>VE
MK"R7^T?-KPH,6'UDLX4*'CZ)1$)XDA+I*9_X BRPF 62<,%L93L.#^S!DLCN
M.2OD=1F]#SH^OU3*V)X?9FATK8L.4$>@9=>3.L?G^?$DKTN6R?=)IL#TRT W
M]+X]2#1^:4:#[S^96+KS+']!\8GKQZKZ"I4?35BA?F:EDA_9)6[7+LK:TT8T
MM^N^?M('\BXJC"TWQ&\[\/_S=N:_S8E4+AY=XI/NEV_B$PZZ4GD@2H/(!@,6
MW)48W!2BO=!V-0UC;>NA\LDQN]@#7RRI]D S7H*1C7RSO*\82$?)NBX2.LQ$
M/E70\6Y=3?("5N,*':$^!S[Y-1<L_7M=)*5,Q!TX]6%RTUNCW-2V'\;"07=2
M@ <.], T^)34I5Y(;3^0_+G(32/&#&.7NV<L21DXK =Y<5"C=?O+6DRI^\G/
MQL8#$L*IGJD[",T!D44H!04?7C )WCSW8D)E$!/F1*&G'!DZB@Z6+* %F:0F
MD'"D!#!EE:@2K.JTEDH>%/D4S>ZZ,F&,#WJ?@2N4G98?5=%HA<O5#?3V&J1,
M!=Y[U<:%/H,K57XZ^EP>U?QW):KCO*&Y?\)CT/*&]8AW=SWBK4^/4-@ZSPL8
MB7PWP%!W0%B@8A('@=9^Z &%#)9 ON*$+71)Q8"394<@S\44IIYFMG1!FL=V
M#*8P9X3'MD^"V(EX9/,0A/RP(CC-*;NWELG[8> X,._0CF$%N$,)#91'O CL
M'<:B"#S&H=+EUXR-=_ K2!2QE]=955R^2/N41JX3.!XG(8V!>+4(",407RAX
M+"GLK3=<Q8.FR ?=\R3Z=@E+086<%LK\L"X[!!1.":J*%9?8_@=MU%&OU]WJ
M>*)^8\47]> N'S.*- 0Z9"SVA'8)2$R/^ [5)'9CFR@PB6/*XIC:?*ATN($@
MXW"4&^/"5B#: X>!?/!\ 3:I=(@3"![& 0MI,%C_]0[1M]]@HRX;ACVH,[DV
MAV4=44CGN3@OE#,A/2J(<I4&G];#A(Q8@17DQ*ZK?8_9&S_"VK!MBE':O(G%
M;7177(*G7_Y:=D78#K=M240L;.+[/"3,=S@)0O E,(M'N_%@=^5F/;LR6KMA
M:;JD$!^X)T'$;$:<2 *G!!JL98?[)-:.LB,A0]L9[%':<SM8^7ST2WZFBLP8
MAFU*SSO%JT6$X=G(5\D#)W CXD@\:PDB0;@7VL1UE(ZECD.7#M9&OXMM]+%0
MJ'R5W)QQ=,7"A:UY? M7![%$^\F-04'Z$A/38.?PC-76MN.%?CQ82^KQ3LPV
M?TJU9MURYW['T['K/,$<'XA5>GB +(CO@O'#.'.)SVU7^4QA&N0SXXD;8M4O
M\"1D&/03^4)A<FP(]E2H(D(52%?;CFW7X5QYL3U4^GEZ&[>_@0XECGVW#6P>
M7=<&*L=U T[<$(C"9V@0>Y015P:N (VI7.T-*W8.A!Z""E^'7<>\6-E.'!"E
M0TSRIC%AT@</36 FMA/&.MCXY.]+O5B@\*LZ9>F^&<_R27!V.F')W]4TR00H
MM(^@U:9,J+I*!$OW\G6)P-O"OK\F(/)*M;; [_//Y6,>#9CMQH0[ 26^5@Z&
M 121G/M4LI!2M?$4VWM-'FOB@G5-/HP"I2*,@6@.1H:@P&$A(Y1&<<1<ZNI@
M")._ZIW<41"O59-&3(6QK8GMV[!2+@5+S%8AX3'6*D6^K^1PO1/Y>UTV-3P'
M>?%>G>\*@4=V27;ZL<@S^%.HZ?68WN(IL,DS"=9<^7DF80'1>[>C9\/@,F;4
M!<N'.9AA%MB2T% K8DONAZ$OJ*,':P,]^0GL9K:$VT'H"G!K8N/J^WY(8ELJ
MPL(@4K:6+DCAH6[)T[KZ2;9.5W\(:;>C^W\+GSC*][0;$1%X'&OY(K!2J"E,
MC*04-)3#33YX;N%P\_W/3'Q1\I$BX.L4J$ E/G6 /#P6$)]R2<"@LXD*?5NZ
M5"GE#-8Z:73</ Z.F<LH/9=WYQ>5 >FD((IV);A/25EAU>>9VK^8H3_S,KG?
MYT'@^AZ1C@?N;P3ZDCEXRA&$6K(X=J7VA[JI@TEI'$!J*O<E. C<)1%W)"((
M!&#M,$&"(-"2VTQ3.E@#]([AU+[Q\[$&"0_*^CFEE_/ <QRN! E]#U-4*;):
M'!$;HWFAIZGG#':+!EB%\ES=$@:[[=@A"<,8&-6. _ 48Y>$&M,/'.Z*S8>"
MAN^6/-4YX7=8G[<I,H?V'(;5=B[6TDB;,"8"(L-0NJ&,I1<,5MC=T:[8%:*>
MUBD\*S]4$X7P(;-"3;"U,]5(KPVGJ:UQMSR.<1$2<RP@0&27.!*:(+R( "4H
MJ3.X0Y"QD'@45&LA?:IY3+%B!L.$GJU)+'T'_A.+0!HHH^>:-_M8>5U74V?7
MM#$<_!G! B*DBZFSK@)SF<$^"16&?A *-QYLZNR++HK96-;VYH3>&GSZ^,X^
MO0$378M/+SSF>I$FTFAEA<GC$C&^E"\\F_HA#P=;CG,O8*:F-%D5\X>>C?(0
MU!'4C4G N"*^UB"C8N$2:NM <.Y+VQNL\ACMIN_$;AI =%+8,N:*,L(H8EE)
M\ LY=SCA81P&MB<=&0[VZ& 5X,8G-2L2T6:7-DRRMJJU%D#A)LI!60FO-,<7
M9FA 0K P'[+-'U X#I#$'0\H^H\^B'0<[3B*0G.":^(+- .5$"2DC ?4<2,1
M;OQX\IXKU21/W2V-\TJ>U8-6RA.Q ,U#)+5!&86<$> N10(OU+X=QW84#QP%
M8-#G<T\D.4$\A@Z2B5 >\:FFA,>1)-IG6DLN@0,&>SK_G1\:K/'H2(2AI[@7
M$FE\X9B[).:^2\(H=)B*;#>(!GMH<"?6[N@ >/L=)F7DQ@UXR0?O0KB1=GQ&
MO!BZ]X7M$D2B)[&C7 T2/&;18-/3[AH@E]( ;".J9B(/LSTV2RJ6OM3M9-P-
M/,(BB4G.,B9,,,0?BBB+A*V5-]@\BGOYZK\JL$(G>2H/I[,B/VMR>I^+OPZ[
MQ.V !40Q@<!_FA&J0*\JR2.IO5AJ?[#:]$7ZZ\_4*-/2UEI0$G'P:?TP0HQ
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M^+ )8%50V(Z(*1*)$.R)6/@>'^S9TI!1^P803]"1=%V?V43&0L'6!BB/PY"
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M\_"4P?48H11:%WX8NI[GQH$]V)2!S1<_](R"]DJ"QTD/&01A1%'@,DV4\@V
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M'T%W9R !%]+R$M_7=847*)F;D4KL(*\KD>-$0-BU_&)8I;Q-IFR#@+I<+<'
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M/[K.\"C1>+#X1 [DU!#S2)$C13XJ1>(/!3B@C4-931)8G1E,$@]X9GC8TT+
M0R<U1C)!5K??@(Q-EIH""L3J/["6U!\U2-<4 [.(#=_$<UE1X!&'B>2\':E\
MI/(GMEOP!"I-%9 T6"%@'@!IP</P1]6>ZW72&3Y/,IC'Z>7<*&D#FZ-?.I+U
M4Y+U53>R%S+I4:FHBP+#C/D8_1LI^*DI&#TS<T]E$P0_+90Y\FT.A"P&]#RK
M3*S%.&ZCI!WI]&GHM!?5Z!W5S(,+G[.DN0')!/:0EM&<*)I$>A"OO]=%4LHV
M7#%2ZTBMFZ76A5Y/D\X^2-EY67?@63,%5&GRTKIX&EK%2\;MUBI!.S]R[XP(
M_#P_M>_?[;+P'RWT'Y-12(]D_]C'-%43RFC.W8V3]T5=6J5(FA1)T44RNLOL
M@,[*/,M4.I+J2*J/2JI*:XPRG&&0K"%(8U:<%ODYB-'6Z.V'A4<"'0GT<>/"
MTYD"-ZU/J$;%JPN@,#R\:)Y(P$1NK(0,.FW=.(4Q90SSCE0[4NW&J;8I,)B7
M,)^RPARNU663@3HK<M'DBV)1RSROE"4E/E7UKB$<R74DU\?RTQJY:@@4]DME
M)=8^G.9GT(HQ3=OX Y#E2)4C56Y>B,[1O;MC7 S"CJ0WDM[FCP/.<A1TQO!L
MRRA!*1L5/BN2YB3 1*#RZ33' >?BB\$P&6ESI,V-BD63J6@*LHV#LU23O=46
MW!D;TN2W()TI.4]Y46AJFCR"#KL'&K(.&-YP76Y?J2Z]F81?+AJ)XWY[U?^P
MT+>6;U,8D4E>!#+)O0 L'D++PT*PP)KH*S@#J,TD@IVA4#.( /HZ)$6KI!?!
M]2T+AHW%;H4RAZ9UD2U:2C)C8AKQV)XLI9<6.V-):NI#J[S7TK9U=#O6A.FC
MK/GO;2W<C1@:C41/IE@PC5=(ZT8:=[7D"X ,UF2%=<5[;;IC6^&'<VU;[FK,
M;P;1F)^5-2U],YK&P4U#S8LFAS/A=:7:I*!).YH.O.XKE>&-_@(](6HSM/:,
MNVSSX-!CK5+XOE5DCX0R8%K>P6!-(NY!PGTU.S@\!.=MMQN=H? 1U(!UN&4U
M=Z/L(G_EY[#==8&T.LT+V+>O$(=5SD!) %LA"Y6=#8W'M\W?M^(6;B-0B9I5
M^&9;:VT(,F7GP,&J&67%OB#56#D'B=5P+1!:/9--(L_EK>@V.<(*8IYE#Y!!
M)(6HIZ7)] 'V0O6V-&@SXQ[YKP5EZ.4(Z=N1*%E:Y@O@H7DUOBE,_KWAZ25Q
MV)?%.<K,!CZGQI\DV()%FQK ZQ(,E'(A#IMH?U.(WPE$S!]8,HYA2UDO*HOO
M=4-"8(]_]Q _VO:VVM3R=KCP6'LL5LPS$IH";(&UHXV#V'4_1?P76!>82 ,,
M *+SL#?!!FNI7&BBWO+ 4TJPLKJR4C"Y#G]DJF"@$K,E4*,D*%H1"L0HKY[^
MN>(H&%79*)2;. #106Y0(.TKI@QPZ9V6JWJ 2KV=W+9:D-,YGFFG>M(6TT0:
M]FX2HU$/- UT^]WM]=8\,V].+V9#S= *0WSEUJ*RO:R+,W59;BU5+\ZA1O%%
M&,.,%1U842];9*O7>[>+^/:IRE2!8:D:A(]@;?U7+U)JFNWW4P*QP@+AQL/?
M4W3$#*0$3%?F1ODMEF*.>&H47O-B,[G&>C'+8GK ?V%CSI0T#1M":L@:+1V5
M8?/SUH!]<9-1?,];[61Q=3DS)-NTFAGY"6O 3D%@3+:LR[RV&F"BQKY235>]
MM5]J",,9K$#.ZK0V@U?F[?6&W8%ZM8^TPT(SZ2N$TD'T=%BYBR=;A7&S?+Y%
M&,=/(XPWC^_77$5E2B!7F"(C3I[Q,MJPBE2E ,L5Q0':/7/K%,G-V#/03(EF
M>G.@UX#*Y:)Q&9:2A/$-G:?0"#[:M+Z,#W-#(*?!FT,)9L3XERP_;ZR;LJ%[
MX#W@[(63TD*BM1!.R;23UQW"7D]^&\$O05"5>'K.S(G/DB;=ZH7=YQIKJX\9
MLD@!,4K)P'VT4A7CH$V$%!PD%'/-*I3=VL):KA/BR8V_Z]"H$\6A3UTO\B,W
M&&.C'Y;K2EHO%RA4UD#CO?Q1M&PTN/7&C*J-A2,5S,=D4L]Q#?IH.(;EOL9%
MC86X*'FQSKJ\U^T-' N,M#_2_H+V_Z6,GF)6#ZNC3>";X^6;["A4329GBK5X
M@$93I7E9HG7Z+]5FKG1EN$E6&[4"CDV-/L=IACFK&*=J7C%^5J/G4%TI$REK
M.:]);.VP8)F8&!V%)FA7[@B\"=,8F61DDL=B$D./8%QQU2M41+%ODK:T1M_1
MF%%U@LZ.-4MF9N>-<[02#@0M'R#J4Y8E_V[\>3#-)NS,!*=Z++94%]GJ%A.+
MP.#$2/LC[6_>OVG#)CT>*!3&69/&=;AG7:XA__,%2S5!D3;XVJ)G]OW[U,C^
M%'R#K&Q/+%84]XR<,'+"9CGA4)L@8XOZ5%I8>E8L()CQ<*%,"F/(E/#M/"O2
M'&V9&.$]&:6)5/?RV'OARR8.=IU=EIMHW7BNC D'SR0PDI%31D[9N+V$4.D&
MVAC/$C#*;^B\CW ,_-*>-9<B-X9^XQN;@OF^#WW=@NHT"'QC%$C-L$)#J7F$
MR_1N;"ETTQ-3,]?VN#B7;V/,+>_A2&[$[+PGXXX<-G+8QG71TH$3GOXUASSF
MY";MX+":"%9[GGA7..;V8&D.@57.@;5J$\3JCM:WFF 8IFF  U/JRSY\(IIL
MZO0JZ#DZ\4E9ML$"Q#!43.+"MLJNS_<&>II-%SK,Q-K@'1.&Z()J_9 :)J&8
M"PKR[/HA[XKH],BG(Y]NED]_5DUB4^ON&,XT)_=+A\5E>^*Q2#(SP2YSR4:9
MI]WYI@6VGLR+YG2_!V*'3E$#Q#N;I3>AS"QS>I_/.DXJKRB^#C2O9<VV]698
M> /)/.T*L[\PA;6H9^W'GJ>($0PC'<S1X:7U1XVV0&4$!/P]!O!&-GP4@Q3H
M3QDRS4HU+_<UR'@F,05I$O6AL2"-Y=BRR(*@._/P*F-UD>P*UK?J+%;CBX&W
MA=D:<[,4.7MQ^-K<S60B&DT'S1?+=NFV==B=A#91>!QD-Y(YWHFQ *ZSO$G9
M@$5-)'8W85F3-K)E.%:WYTXK&QES^;\M,V%8N?S^F,O_8G+Y1V6X+F5XEI1)
M$U/;F212JFP]ZO$YZL6^>0BJPNB+.4C&M?!C/SYR"UKG-2W4&+)7TQ[&0.1H
M]SU"F.1FW$U,)YW?I=!X5!A>[[RI/E$WY[/+ <,V!HE\4V==H4_'(GAJ-<\W
M[EJ$-6I*6TQV.ILUK-5&;PQ&TKFY5<+8$.:"%8LAINCB5M@K09\>3GE[ 62=
M=8G>68<_:D;67#_9149Y?\A?P=UMZC664J+&^.;(N(^0DM?FL3:0CU<C[LL(
MI8O,4J-MU,4,2S#J-B.CRT^=Y<AN M-;YR^T <1%<+#--RW+'#Y67;11YLC$
M\WAB7E?FB*]U])8 5$?F&)EC\\PQ)\5Y=/PK6::+4LB6@_AE'[>GC54@99N5
M!791,R#Q*>;_&0Z$_YA/(WV/]/T8B1;+AE53V[4U3P$%\L0",6%"Y5)IU:)6
M7[\$H\ 0PRU0P8VQ=RW]^WHNAHF9-96$M_33E(AWU\9L]1.=T EJI[,"D7#D
MJY&O-I_KW17_+_D1QL0YGV"A('@(>?'E*@@!^BW9:6>,J;,\/4-[Z//VT79C
M/N6%@CTW,-U;/;BW]MK@VCA#O4/D7O%UKU824\\SR0K9VFIB&>J@]TZ?F]M*
MS.2,B8:72P7<C,=*%BK*KL,"726AFN)!EJ0U%J-W15$=5-/MJ[+5<6X''VI\
MH_ZP&F6<*F9&UJOK3+(S+,[MGC-.GA%?\SN3S4HT!X!-*VUMO262LZ;B1!2(
MV&! S5K\<[PZL&NT7Z9LQ 7^-YFVV<93_((5/*D:LQ=$)M".+-^BY=O$_>>M
MOC4B-2GQ.*\/A[&P?GMU7(6:U55G24]8,=TR"?[-%=%-;EI>M/GZ.);VH+XI
M@,6XTF)_N]]ZIDU6@A@UP _+:Y.I4];BN/8JT=IQ8<E<#^NB:VZ4KZ-\W;Q=
MWJMD[ *?+21<(WQG=2$FL-U%N0H*;L'ZYL!]D3C7UMF,)#R2\$9)^%.+)-Q+
MU.Q AI&:FV06"=JSPTW).YJ?Y*E418.?8.ZVO8+ZCFJ@305K S,%$@Q\44XZ
MV_FJ;;[Z6'OD@I$+'B/ZB)@L,Y,JN2!O$Z)G2_6,QJS,3-%D*]$;46Z",,7"
MY5,7X"8NO6D,XAQLN[,&*J7"#I:L[GG'\]NH;R+^[QFEXKA@:,X67T9@BGL@
M*[7^16D :IOEVP+?J3AK3)>BQ9<POUH9PV$ \3>%+ V>1&.VS].2MJW=-+U'
M:W/PL [RYS88J**Y4V0>;<F[]"50-[,FA&*&5RS4PR!IU1HBB3YA@LN85?;L
MLLJ",:OLF3/=O<R&;YYT1[56(G'3BNHD&:H%\7'WT_&PU<;A-Z"2/1@BTNP<
M>C8GSDD71AOJ%AY6:M ["(;,MO7SM5CDG7?SB:S2C:_+AS,T$M7Y$.VBP8#R
MD :4)YE.Z^;0DC28GSS)9QATAR'558L5VD#UZ%S4+2IH5V +W6[U 42N)KGA
M=QD\F+;@/TE;VS #Q6DRT-+$G/J8HX\DTRE#O#BLZ3%7!G=C:^J+VM*'Y@S&
M'(@L1W&VK$\?CZGM;YDL/&O"4DW21*OF B'T"J9YEHNTS="I$I[+2^MUB]H\
MW>4M!/$/"+L'^]><!?$$#Z/P&NY)#4O>#NHTS>$':W_^^N'I?O?Z%G2.]VI*
M+*<O3+42H@YAIVFJ@%K$8BY#0F >I!_Q9 D#F?5."37EL(.N[?KFU-U8'\:[
MQ#S*# @+W$US,U4#):(6R976:_0M6^+XNX)N!/+?K^USN]US<YHS+' T8=GI
MA"76XHV/R\RXEV]O6;]6<DYX\R?[Y(=Q_D0F+<[FWQ-H]:+?Z"]%7L]NI;T8
M_N\I:&\(>]^M\?96"T(^+X,V55R+75_$F&^N\V]D$A[VIA(Z REEWC>'JIAY
MDN(K>Y,D8UO6WW+X\A\Y"M7?F&"U:>Z8)>>P)J^K_%2A%#7PS]<IZU@5!5XV
M>=G1@4%0Z] XVU$T9T&Y@1F<RV"V2(5,+['>N4E?[L&U6?FLA;^>-N#$&%6?
MXOQ )'+K]7_G*4N*;]Q"$(V&M%LA4-8SL/ 7^QIN1^OT6B+_L?#Y[S0BY-;,
M*","&F2AE9:2R%E93:9 'F)2Y*"[K7(&[[-,Y75IU6;QBH3-!<+>T>>%*.A>
M*8# P&_-:O1=VSR$C)5X\I^GE[.VG#W/9:NC+@V(,T/I ]+*N5+/W\$ -)&[
M!0TV](&4W=*;.8F?$TI#N0A>#7->J&=$ FZ9A+4%AJ:PL#K/\4:)KM@1(^$+
MFF/5 JI9YJ5J<A+:=J0"35]B7H*! U"S%@JDP9NNRQ;3&RBY;JYP@+:-BF_V
M0%H38&R#5(VG5.9+(>IIFX%R$QM<'9)AP%G*S*'6K"[*6JVNEEXL /S8L6&V
MM!UF5+"SS\]@"+;M,/H>KAU JS3/1), >-4RK9*S>JI$4F0FK:8%ZL.3(*"?
ME$SS5(DZ5=8>V0,JK1(-G M$_ 7A_AI@-) #_H+']S[Y<\N!X4D1<'E9+1FN
MI4KG-Q,GV23A24.?T^2T3=@!NFNL6:S#1TCS!OYICK=Q; F5IN6\UV^-9UR3
M\'Q#\AW&/B3^F.^0L1>K>HHWFUGOYO<#=.+5;:4J7L;;*>4&%[6!+I)(#.++
M+(=V2,;^ZT^N1]\:4,>,&/HQ^V2E=69H3H#DZK;L_='>KWOS<9AR\J[^H$^2
M!FPXGX)+T\)&-H5!JM=Q1T/YM^KYQ1)_[=#PF9J-,_ 6BKS3!N4D/S=7<RB#
MZ0:/Z:28HOML#F,;5D--CH#D#52A;/!ID!$-B(!2YL*(Y SUKBFU;Y $RA;+
M$WG*(*ZK;%GE@5)>'@PZOHT]=VFT$IX +TS2GAV[+*?F9*#,'3BMS&B_N.+Y
M]/V=O[%LFMSBZYP:;"TCI9I'KS@Y:'O/2=@\T6,E,)!A3;?68#PW?:\VG$VV
MJE+FMAYF\C>SYNH*W=P\M !,Z+-15\2#G5QI_7EH[D<ZJ!C<O.\5XG@12_%_
M59K-&=VDF!A-LK!$P,3HFQ;:0/+T(G1M#&O+6.U<(:,HD%0UZ^J"P'P'/I?Y
M%$8NM] 2%HKGI$U1P0O3.O5W%2T,;WTQ/D^3\0)KCC$S9>[N0?>E$PV[[Q8\
M^W..LJIY_UP5JNG/1"OGS1NQ9R[644VB^8$QL:&/=VBO[4I8K*3L\IF[7@[>
M[?;%SX'B18V1%0P+6;+!)&>8F)"@0]:E')M[B>9M'.W.PX,&X]Q$!MN<<0/Y
MG*E.]W<U5;OOFNEL=67!&-0QN<N(]"+2W$1K%[,V'MM[<!I[,:OY-4Y:*<F9
M^+) ]819F9B64.:9*_[(OQ?4,1>'"Y@9X\P8P.CV&KVJC?)>(9H%3$T7A\",
M/Q-$F8<92J95A1A0R#7/)"#Z\H]SAZP4-G]^!-+PR)A2IY>#/@"\2J /2%=U
M//I8Z:H8$0@&E*X:;+NQ%U+7=L"O<JGO/[]LU8U3VFX+HMO&J:I)D=>GDQLN
MJ,E7 UTLA1<')></^I$V<WC8SZDUM^P5S<59$\52T+B@NSBP5:>JEXKUMZS]
M&E,*V\(XLU#@%S3P;7, ..-\;;6E1L;)**TIUG[!OX[]Y\[/FN6S-NJXO3S*
M0K58!CC:%%'>VCO^%N.NLZFJ&L#DY3@L3G%^@QC8 60>;39A*Y-'+VO8[?EY
M)7!""P*"D.%U6B4SO%L%!E2N.&;8PJK6>9O],P=S?MJ=+RRP[6:+H -,!NNT
M>%V +6Y +&5>-O57I[#!6>,(]Z.N6=>%N=?3M'HEC(+17!/%!1/6_-VP"Q;B
MS6]46Q@W,)73I$VPYFHY9K+H=_L.>':C#!YE\!K%U/[%K('I7WUR .2Z=_1Y
M&=H$H5N[2VRO>6[E]J#"9V;P+7J$,Q> \^M-YX*PA8[H#B^+^3,(2-DRJTX*
M<%D-R_[-(7BJAA$S&&&&L_Y;?HX)&5N-C+HP]]O"RWXC=I=E!XZJ!:]NPG5-
MU.IJHUNWB=BY*.1)D\W2REES53DL/%<&F*:]Z1$40*GP@(V8RWX68A(]<!Q.
M-\!M:[<=9%^S;O7=K17R>&O3 GDIOZ=;PSL46(UYVL//TP['/.UG[MB/ALIH
MJ&S:4/E<)2;U"0:4,N"T'FY'>Y!23I)9V2 %SIK*+$SIS)&S53&U3G.,9P[)
M..FG<O0/UGNXBE^;+>KU)J@$!D"5YPB.G^"!H+G.%:R0)ET6K08,HZL;("9'
MQV/DYR<*_C KPVUK+]=#"_'J(1&RP:J0D,EBP].@IJ)YM3<R-'Z?WV0^P>.D
M0N&!<[DBPH();3CA>:2EO5.M!S!IIH\G'0W8$=X?!09N;FI>,2_\M%ND:Z#_
MQQ.7F$3R;/6J;36(02!<=M]M]4_-^CY@#WKA*X[@6 (^)X'6L49&=IRWINA@
M14G!/'5S16W!LSH[^*ZS_;L@R@UU([=M\K:)+,[,E>T@XO+F%CA$-3$9WEVL
M='YQ1\>NRSX[N,A+W+LZ;W?;^M<$47]ZWC8>OF."H E=S@,-51<(_9;( '["
M)):-!FL1+[KLCQ0#LZ2??]NR0"^6\)!P[5JH_:6DJEJ?35D#*IM;2E,,O9B4
MB6L5#RNK&9:;FR<^&8B[7CXX)D.SRF#4X5U0HK67S8:UR N+-]X:P/#F^3:;
M8&JH(BG+[HY2XSLT@Y<KFS:Y7&*B9)TV%*<N9DF3=^':OF.]1HI:0-UAC^W[
M2%=MB\8Q,1*A;"$&%YSSPS;H:01+7]5[<Q,E+LZ\"&/:Q290PS<H+5O6BJJ[
M]JFR,4%R;=:O;J[_,5^@S(!=2M,VS-MA&)J7\6Y*$R-$T#O8J]9FZ\R,=LG,
M+L]8(GM[QZS_],!0AZ5.4WREGL%"P[RZ7#^M5(^59^P2GL!U_<\P<K>#^6NP
MOO"G*JLFN^6R 9WO1@S_ F-C&GV17[*TNEP\\IKU,7!*8SCBSICM-B<X*&52
M1>3_S]Z[-K=M+>G"?P4U,YF1ZD"*)%\3U_M6*;(=>V([VK8S.7.^G ))4$1,
M MRX2.;^]:?[Z>YU 4'93NS9DHVJ73LR20 +Z]+7IY^FLX_=LJRN2/9T$_ML
M'Z 7H5TMR18#>?[-LC!O"=I"1O+/?.W;:&'B43\RR5DQ_83908KW5%.\_3+F
M6_(.HV'97]!_ K* K%+6D0DSQ*Z$UA8U5*R*CA\X";W.J[5O6QP]3&!Z@BTO
MLHL2<$.U^F*K,M"<43ZM*=Z[!TW);IV1Q4;Z:##G)N,8N+U4K1L.@=$'KCZ,
MM<K< )SQH]F&1U$7?7W@KO[@VRZR&9"<E^+P"^;!02:+^@9#6$;[=M>IJZ;D
M++#WD,NZH^2)#,)-T](YTZ1N(R!>-L'@TLA"-VSD%:W@B3,^<N1<:&4D%]_X
MG24^"INZ] F"96QFX2ZT+]N<(T=Z1.E09K54^,'+-/YL'9>47&G*>45&7,MN
MI56*X"WBV_(!F>6MM+_"V,ID8&!;;UYPGKED"_,?6LI82I-8/F#1(T!J+;>D
M"QRFV:Z&6:GH9K9BFWP?9F>FG,F2R@\>I^32P#?)^!!D>?"HZ0U1F@/1)@AJ
M8PM/W(PW1Q*8??0+#L^U(N? MSWMEID?-TSTWHV$W(&%"KG>.O/@=\Z::DT2
MJTDNBXPV0.-K\+CDAI[V=/KY3_]_O-FL2%'_1\I0\ODG;/>_Q%+SV4,IQQRE
MR+$-HY+F"3LD\/?A*D7;/2^GO-.9K))WA:T9GSW:-P-KG.]>,B@,SL] [8$L
M/E^B$8F#:P0,X5$\%*7)]%>C&ZSE]V 7KWHG-3W-9D6[8 6BY?"8.5UA9T.:
M,%1U_UB\L1LP$-[HV!?D67,@E]TB,*I<5JNBQ5_9A.LGP-".#A5T_O-_X!M.
M4+0+%E:N'3DY0?"G)DLYO?0YVKV>;L/X%';2DC]_(==HBR-VF/A %&77YM99
M&:2Y@L?AN;S,RBBRE LFQZ L--!YMTQ);[+MF9=&#!-&I-&C?4/S(;JV_S4+
MQ@,1MW*]'WD&U3S/:RW SOC=L_5BL\S>%XK#08S-7^(X@FO$V2U>SWYWZ1!%
MU9S^91*+3007\>+@5-4(8W&^POM.^0U8R,!?[0>71E#+K0*U/!A!+5\-J.5_
MWN[U>[E8721-/?W__H7^N/?@P8/C._?N_-^CPS_6%_]"@K(=_#S*"=^[>V_]
M_I&N]LG=A_0/VBVC22_4P]Q+EE6^]#: OY>QCF;KK60JLWG/UU;.^.RR*F8P
MR=4A#$Q99&.=2(\2KW8CI_+5;92Z/M7_TVG!R\"*097G(5<.Q8]5O<BU<FR3
M(EY)(T<:QHQ_3:' %^:&-L446C.Z!US4+.KA8$U+.%&334%PS'<CM8T&NZ@T
MG.<#GK"#S\KSV;7E%0+E\DMR "K!QVZ_'S=QXQB]8RDQSS[5##E3S,D2(42?
M.F:9@:>WF[76L*\Z7MJLKKFRH9EVN6IIZPD@.:(FM!::II@,F0K;10MB^F/W
M<,YBN9'4T_:#.&"R)BF^7M3T_^9F3)8=#W::U\P;$]F WE@-C<!)UY(#1QN=
M73@9^? /R;/(EW/+Z@6/YI'0&,F,@GVS/=243>.@"5C3\>8J7/D-C&G>$=BR
MOB??X#C&Y%@H:1[GD9^J/%@;WRV(OFQ:;4>TEFQC%E4.-X)QF=+\(AL:6]'.
M;P"D(X'.%@HQ7)"'KKKS^^$VT3ZR*U,#F(<R$1(1XB"4CMB R)Y$]$Z_,O!$
MZ%_T#9WS\NOSMYY!2MZZ*+E!5ZZ@]EHHH)INY4@A@M=E[B-Y4SGW4H2LC7[1
M13B990435]#O&XE)9ISO*:H9$F*T% N2,TQT(350AJ/AU*&$!#A6PWF@6<[9
M2G2;["T;@H(@=Z^+O.5Z;30UIE_2ZZ7)>;:D?_^CR+X,:]F]PZ.3>U\Q;UD:
M=;H>C*B::I.8-0V9O@[2CY&RY>^[UBMOKU88&S5+[BH*Y_A!LLDS9M'!(BZL
MD&,!*5EV*'V'UB,'VOJ)&>(B2\QHY@@Q[Q[PKC _)\)-S*S&N <5EVEX%Q:W
M(!1 &^P54L1\U-RIEATM=*9A2)Q;=$P+XR?K2EH6DN&M].F6G@,N9*C3V.0M
MSBM.%8EQ:R19+)<1T>]-V =CW#DJ'%=FF)XD4F%,-Q4Z20>1C%KXN7!0PXWL
MRHMNIWQ^\^(# CI61SWQG"&HW#AKF*82EH*,+=L*R;85C47W+YDHT\ZH!X<'
M]^3\ X/C=D]0#O0@Q-A0!054@S?,!<R339JJGN2.LZ-Y5\ :%)J\-N]/M;*
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M3B89A&RB\9YO.TU'B.X2\U:2AUER]V#.A:::IH"&=9?N:+?#\44R!%P(O^T
MZ8Y:$[$2-^Y^5][HO>#/1J R[OIQUP>[/MK&IG/0/M)R@LL<33$=TVJ,<P#7
MOO29S&EWTR$8]^RX9[_LGD7"0IL0<=*DK;.R$:^(@PS5#$6+V+Q-87$$H8=@
M/$0WSZ8LX36O@+B(H1RXB'\V;N!Q W]94T-)CBQ4]=]OGR2KKG7TXY("_/G8
MOG\Z!4V)O\!):D3( C!>U*HP_.4N5M,QHAXOS?FVG3:ZKW&_B2TK-3!D0S/7
MDM%F[@(XRMPD&MOR9K/GAM[S-Q4_4L[$?_[W3\?T]3["7;[!M7'PJ#=:YJ0
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MA: US<R!ZEDG>6CSUQ 9GY!LG?J?)WMG+U_OIUL!=_K4I7R' O';MQK[^7V
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M:6%9WV193=]) --)F?Y.\ <8&[<O$5*&>$3ME--DSAXF5F>@T_VTJYFZAC=
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MV_ SR<G(S$)#^&;V$+X@E>!!28-C!O?]VM7!SF #:\H6%>)_TES#1L&#X!<
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M*D84&0%2;TLS67=%P!IJ$_7WCO8D*@M"'CU,5)E=:):;M"CC I?Q6 :6@";
M4?IJ (16P@4H!+[97[5 A*,RV,@ (VI7X1E  (A)@2MDWTC;YPW*VN>5,I"[
M$NI;(7*^P5CXSRZ2E[R60QI$Q<>X\[_\_[_2+K;^>Q:U,S<S:)QI?>:X'BQ-
M:O#.!,08UM-A  T76$QSUV#)!UA)KISU>MJ!GQJU0[75TT0!V>"9@7LG?9H8
M0PU:;,2=V)0&3;N@:POA^S<\>M]Q-M&=AA-"XL$UK%ODY"\LA,(%I* KM><!
ML0B)8XV&5"\1AT/BJBADRMY+114[X$+>Z;$'!0G<J6L?8$.Y'1+FFS1J.'6#
M_FE!5T5O#WC(/8/?YOE,FO$UJ*[@2Y85JR=$T;?4DYT7UX8C];S=0#W@.?EP
MGU0IT1+K)QWD].Y1BD$["W2EK2L:I'3$X&?*?V4+I[[!F73M)+,BE[8:--OO
ML@O\B<9NW"MLQ@JYF"B%!)D&53U+WN7Y&C_SARZ;P2EJU!C37$+J;:B4^8_;
M U?V1Z_,9HA9&?&7@B/2"D2E/5'#RWP(D0U7$KKR04%.W7#3[<J7RQ7U[$!
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M9QQ]U:R\Y!IH#Z@XM J!"&;'CSA,?K;]G0Z^J>S27IML9C93<\$TL^6?YD&
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MLI8<IR84=4%A+,(I0TE=/,@F4AK-J(C6!I6^,:0'K$5<Z5AW\I'X,8Y]SKV
M0_)#14N#0$AR4OQ22N"VEKURZ([Y7$S0Q,=E:*N\068*B>R+*D[^($M46 ]J
MMBTD5[?(EW-R<^<WFZ5Z!%C=+H#5R0BP^OH 5F,5!(WSE1*K<G%* 'M%%PW@
M4<82B-MKFYXV3;="U%4 4O-N.4 <X.E5U2@8,&_X=[ZR-70"0YO'<>):6<
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MW1^YU<8Y\R@+*J^M?2\S>(*5)U1"J4/BN)E-$YJ>D#< :7*> T5#KM&T3;<
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MCLBC6XD\>C@BCT;DT5=A1H0<9G <)&VJUD/(MD6RCF0D>PA14UM(2.[NNI)
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MG(LP2"?54CR#[W>]2U4&'/..@SP0*A+'%*.+S&LR\%S[3^!ZO-'H)I)62TS
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ML#-39WUNG(MSLICB.S9%[XILW3_&<HBEN&[E?];R8(9SH'"V;10<I,VDQG/
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M_Y/IGO;<*AU-[+PM2.W 7ZWJ]PR%C3,<G>ZVNRR;ZI^ELHKV8\7X4YMX-(1
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M,K9#;2A!V&54I^;DD\:&5/CJD\0; 1''ST=^O_;M1*1:5*(W29B[B$Z1N!4
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M7G^R,WP_JZ^2WH 48>F?3:\0<-%/,Y>MHY9?2R*'CATT9NA??2LK1EN7C.+
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MA-H@8=@+4*Z$Z#40!,+2N /2H-;:%!NY8;\B(7$@^[;NP)V$VW!KK?<G>1F
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MWQ2AUBB5QGXFE^ZGCCP>A[KQW$Q2J[SWJ&M\0/HQ@X)#.&N#YD'XA,JF<0!
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MQ<9M,XE7>)E.X$+WHV.[%3%ZKS@-6QW^U+P/\2RQHVU43UA)A2M/N5,D;0B
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MG11$:"VB1R <H)A5]60_J3OY,-93F"CT)[2[7B0H)F[N] Q8-/QBBT6'/D[
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M=V&<BV.\;1Y!?E<!O-W>9O]<L'K+\%;>4'>>O*3\J>A&VW9BIOP*F=>4/O"
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M ^6%S]C^DR&V8>GZT77Z VTPRMX5=]G["8;8W#._E0FC(1C;7")8L$LW7/;
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MBI=/0K(@FY4L6]URI4K@O'3^5-2!NMQ#KOU#>,=YIEPE8VO"UW2<%>NIR->
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M4KB,4;QTC!BB1U/<B8^K+WQSB>.AX%P_U;V .T7]<Q[6<*L) I-,I3:E]Y/
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MIT/ZNVNJ"E]6)[+&E)5ZR=WM;X9V]_;A#NKOY 7]#OXIS54,M&)81-J9$G4
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M#,:@J>\HOC\-9#GK!3"AR*_O+0-IHH2&,2ET6 CQ;<,.,^1O9C"72B(Z8 /
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M6^3.OD#"8;R@[/I@&:N&F>CCC^1)%BK@@9!OA1!R?CBKMG>2+M4,56]!+HI
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MSLI8C&THL#R,63;1G2J>)5$@0Q.PI[ ^X(D3[^7_SI(@OBULP 76\Z-$8B9
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MHG3Z:!WL^C;EY)S\AE*0/1!S&&0IG^46['Y-09R4-=04JWAP$2@@=4+HG*%
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M3WW3W$:YC7+7\-$WS6V4VRAW#1]]T]Q&W8>A^B.=ABS+7]:I]7"0'\ GO?:
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M4;J*8$%L)"1L$4SY4A(-3L96D)H505Z%+T.?EBD$&PN$#AH,?2P2"]2W8))
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M);V,\"0PTYS2KE>+KWS:7:KJ.<^2"&B #M_P*R"=I.)"D!-,KN*CJV?/T2O
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M"-+@OGS^>MP9M+%_LFP"N-4G^35N77C3%1WU[ 7A2Z8O-+<9Y-RRC-IRJM:
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MJY+HLYPC*W'*,6@4(F&O,"5=) Z6J^U9@EOGY1'%'2(LKYM+:Y FRB,2649
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M,50VB\-^C%6V&A=GU30M$RU-M6CRL_6D;0M8M$<]3\Y'/KK9CRN?Y.I/2-*
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MXWQ)\06#8GB]F.4K?1]G]30L6]0.5MC3ONA]09Y'=ZH1SD;&:&#^0=LD0/_
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MAA'QENHHJ)(RWM');?-@M_NXCTA_C8Q0X.<.VB !]P<FO&&J&?BYH(B]4$3
MNX$);YAJ!G@'BM@+102\&YCPAJEFSS:NI]ZS:'U"7@B/N',)::$4BII[)C'F
M,;&;<3TUB3'C-,)&LQS72XULC KY:"1)3OGD,<3UNV20,)IED(TMK=$A9YL8
M2E_+:9PTMMA"/S 7J'U@PMMM:H=0!A01\ [P;NAJ!G@'BM@+102\&YCPAJEF
MSS9UHX@V4E..8G(>\>@U<BP01(0,-@7"<<*/F3ERE]1-VWS\4PDP7UV)+[LZ
M@MB,#(,=2L,V3V"!@0EOF&H&7B\H8B\4$?!N8,(;IIH!WH$B]D(1 >\&)KQA
MJMFSC?(I=9'Q()#"02-NHD2V;+PP!BL5971,A,=,'X$H?_?,$^:0#+)=X[=)
M%OHX7W2HQM.FJ3(&+.>-6#>.51-]MLMY'6&L"! _$#\$.J"(@'> =[NF9H!W
MH(B]4$3 NX$);YAJ!G@'BM@+102\&YCPAJEF@'>@B+U01,"[@0EOF&K6C\+=
M7>'NRFV\N[C_>B[I+9<*,96$)8X1\[2<MTW+(83)HAB%\<EQXE2Z62I,RE'%
M?$#<*XHX-@$992-27G*,M>?,F9NEPL/Y<9R52N L'L=)4W^*;R=^>A(OZQ<_
M3\=%$_YAZ\DOTZ8YG!Q=%"_V9W63G[I:8WP7YX?I@_UR]X)BDV]T_NT[E47!
MH*IXJ_[?7='^U@\0 :X:F/" JX"KOLE5S%#J*0W(F2 15\0@ZQ-'-)$@M;(F
MAO5YH@]H:^D/5P$=;8B.8#C)(+M=LB6U;2[]@'[P,.XF/)=M),XN'BGRJ9KI
MN [5N5KT1KR]]T$>*$O((#Z!,B\Y C-09\!5P-5A*2+@*N#J#JES;R0%N/J\
M%1%P%7 5U!F0=^?$NZNJ"O6,)ZMG&!]%<!@CSU5 G 6/K# $*:>3BMZ+%.1:
M[5UK&X512'%O$"?>(1TL1=ZJR BVWF!ULY[Q+LZ7!8Q2J^BZ8$ZH&6FY];VX
M@Z(YJ*P#FP&;]8G-(([8*8#MO3KW1E* J\];$2%*Z'N4H$)4CHB$##84<9'C
M!8<-1U(;BYW4,?_21=<31 D](['M-CP]?KS/CC!DIR;^DQW;B8^5G5>OHX\G
M+LXJ1D85Q92#$S)<)X3NT8(E8;HH8Y? #7F<&W(/:?;#$=G&QAU+(I.&(2]9
M0!PSAZP4V4&05(O@M1<QWG0+E+$J<&91!G>'.(T*66H<\E9&&YTDE*Y-\G\U
M/3F93MI)?^U(O^9P,6_F=E)NQ34OH6F?O>H>O'WWYGMN :,CC.5(4]TOU^"&
M!O;/.>B]1?=&4D N/?53_P0LTWN6D=*'&)1#0H;,&%H:I+7!B*H<C'(:J%&V
M"Y9I^>5X.LZWISGXUZ*>GW4U*7;K&VB 6(!8@%B 6(!8KF4U*>.!6((BE:SL
MY93(D920\C01&61RR=TDEJ 8LXE$1%GRB!/BD=4T(<*BM(D*%R5],F+1F(^8
MAK!EQ]AE4  )# 0,M!L,]"PJ>5Y@'&G*T9,F. =&V" 3<W3D.>8L)!9MJ<I=
MYSR#,6%,6*0X%64^CT!61(VT$"EQR8(D:[-V'L-Y=ROG2<)'@BL@/VC[ X8#
MA@.&ZV6,92.G2@>%F",6<6=RC*6C03AYP0UQ0;*UPYZQ2%9BRI"A@B N$D'.
M6(82PSPQJ0V6MQ\#M8D82V!@F-T*KWHC*2 6(!8@E@<2BZ.!26D28K@, +4*
M(\V21-%[I96@S/"UJA"+*D;,(E(JE:&AF8>,H2G3DK"1$4>2U4]7%=)F9# '
M=GER=CGO0\S_EA/JVE\W:3+WP_[+[_[6USU"#G=<+OW.%7QCP9=(].#\RMT$
MT'[RBWJ>O];?0R1',5;6^^E)OKJS_.IJ,IWG#Y]/JU1/[,37=IPOVL[C27Y]
MLW=#=J'^5/FQ;9IBBQ\C6EE064KI1_I[^X+5FO_=#KO[\@*QEVD<OZ!0SV)K
MYB^R-!8GDY>A;D[']NQ%>7;-//=$MK*RB%67;#&Z_UDT\SJ=G:^F?2.*D_#R
M=-K4[2?/XMC.ZT\QF_:7(LPBC@LK_W)'?B!#N/UWNMD$XVL@D._.ZF>YF<<7
MG<BK!=63<3W)5S:WL_D+NYA/7UY_(HMZ^?#RWK?]R#;E];ZPX\_VK'GYPX\7
M6G(K8I=[>D4M;MS>;N_BKD#6LUKKA6YN<M&/L]'/2X5UV2W:C%1^W7__H?KP
M\T'^]^"W#V]?'8VJM^]>W43BIQ!0ZV[F"VNW:&1*"+]?,L/OWC;'OZ?Q]'/3
M5T$>?=C_</#/VXH/O;G$@W<?CJK#-]6K_:.?JS>_'/[7T19N<T]E\]>WDVI^
M/%TT=A*:OSVA7'H&BF6YJ^.DK[%U.UFXI>/K7EA93'DYRK[5=+%ZR?*;LC^P
MA_]\_OI\I\?VM(DOFGAJ9]FPSX6RC'3:]_UP<]/2I[JI73W.L>"+\_??LAUI
M^752[6']YZLLOEKFDL9__,K;R)YXR+L>\!:ZIY_HFX:^I&_L7]/W']A]JS7=
M:5/;)C*=>@?SG)N0TY8 M@M!9:4LS_S'#_*'C0GME@5N4-DZ)N\["?F_HYU5
M!SEZ"T^ND7T0[L94M"_@>O6$@I+(W,QA".(;9R$ % ,4WT]HCQ^@L:-@?75_
M^R:U]L$S'?IP"P#2 =(!TCN#= J0ODE(?^"4$H!RP + @MW# @98T".WKK79
M>\[QZBP/FI_I,^1LUA0.3^/,SDLO2VDC^]0> PI WC,@[W$'YS ]!Y =&"L8
MZT 4;L=E=W^W:$OG.3_43[J:[/KF8<Z]<*-VYBSG 2/R9G8L]$5VP]E=U&,X
M[M2<;QVR\!1[D8Q5T@:&+#<2\4 M<BS_&2WCE/LD@U_;B_20\>CO9]-\.3L\
M&WWHIMWK*0E )#V5'1 )$,EJU"D)WBFAD$F4EY/U#++!*40I2]%3%WFD:Q/I
MHL1$486<H1IQ:06R7G 4M4@X6>9I&8_Z9$1"Y$B9K8^D&[IIW_?\C*=-O*^%
MG1!A?NU&[H>R8;/=+53VE\YB?LK7XUA-5J%G>;3\7K8258LFAJJ>5--;LODO
M($,(&<*M9[D@0]A3V8&Q@L*!L>Y..I\^93J?[HBSY?TLMN'4-%6A;GR^/=GO
MRG_GJ_HCKC:01K^8/;0_ I(USSU9\\1B@AQ-[W(TCE%B"4%!EZ-E!-7(>J60
M#CP8S;0/>FV"\D.2_1=@MG\RS;?^W[;\?IA>G\/:_B2\G\63>G'2O)U\BJL@
MLZ/A9'2DMW]J35],'JH!0#! ,$ P3T0PG$05.5/("F\0UR$BXR)&QC-)J,.:
MV+7#MA]2!-@JP8B18A((IO]5 @A<GR!P?1WSFWS=6F!E)Z&R5TRR'P /7L2@
M9 =>1$^\B-LYGFKKG6(Y="0Z(IZ80)JZA*@ES!"9A/>LBR#R*K!D/K_*]%V-
ML1Y1#)'BH*T.H'U0LANFDCT;:">>$1.)19B&D,,W3Y&UCB**C:-!1^$D[R)\
M>Q)H)Q"C=6AU4%,<7FC6GO^!G"V=6>7$@#AIEF%:_%)^C_U 5Z#P0<D.*+S7
M%&YU\D$1C[A2^0=V!CEE&,+1$FD\T52N'0S^D.CLZ-C.XD\%6EY=09:NV-N,
M#(,=/8.V.(#U0<ENF$KV;&"=\LBE9AHE1ACB7"9D*/.(6FZ5T/D!X;N(S#8+
MZVJ$#0%8WV94!@6S;4=E9>M:Z>O,II+OU*3RB]DL3OQ9-9_923.&NAE0.%#X
M#E*XEH$S&05*7!C$,_DB*XE#$BM/?*!$LMA%9/9FB2NO5K#RH:#*\D+^8>M)
M09^?8L&>#_;+(W?0IOI+#.C?<38M*J4IH2^!W(=LBP#X@Y+=,)5L!P%_6^V6
M1#LE3"82ZJ)'W-& C$P)):JC4RP$8V474>%&*.6;H:(4D/[K1X<EE/&V'3"^
MFTY0.V+A<K3".-HF0AD/? ?P'8;N.]S.[%$P*U0B*&">65IK@RQ.$AFE!4E"
M)RG6-E+<)UC,USA_D8'E5<:5B_GKOQ14.5B"2F>;\1CLE1BVS0&P#TIVPU2R
M9P/L3*LDI%5(IL@0]XPB&Z1"@F'*C</:K/=GW"=D>TI@AQ"MOZ6\;B;DT0U-
MR-N1R.S5L9U\S%=S?>Q=T\1YTVZ%&]?6U6,8@0=3M7HR&0JF:O54=F"LH'!@
MK+LS H\]99Z;[88W]7X63VT=SM/:2Q=J.C^.LY5/U8]0=>>@&F(SR(=L;[\*
MMD(0$Y&D-"'NB4=68H.L<](Q;JQ<GQCTD*ZHMQ,_*UF0UW'Y[]O)"FY>QQ1G
MLQA6Z9']23@LD+/?(D[71PS0$:70 #UHRP3X'Y3LAJEDSP;^C7+4"^&123S#
MO\V_V<@XTMP(DI*EP9(N.ICZ ?]: ?CW-V4.0=[3S#E?3C8_M6=EIOFHLM[/
M%O'6L&^Y-69^-8_>#WP&)V!0L@,GH"=.P+8:I0,F.9Y,&CD=LLO .$8N&)VC
M3.622HY[NC;8J)LH\QSOWB_AKDP[6N+=+Y>8UKF;,>+"@*.Q@?9I8!I@&F":
M(3#-[3S@$S5.8(TDS3]XCAB18=$@1K4FE%J%^8;"S6YYX)OPKZ U:]MQ)A03
MMQUG_E+[$DU6*<:+6+,?8 N,/BC9 :/WFM&#-4;@<MA(M 'Q%"32)(=JPDI&
M/-=22_SHC3+K=+Z"ES<975:,WA%Y,S'*L@+V'K+Q <(/2G;#5+)G@_#8*H\M
M]@A3G]':ZHB,CSD2"R%@3*)@[%$QVX81'H;D]"PV@QK@MF.SPQMS#*"\-TP"
M=]EBXNSBD3UQ.J^:Z;@.U;FB]$6ZO:?X!XIR!YV K9V-C).P6#%D.,^!I P<
M&>,($BJ[&")'A#B$S90(KV_3/<\'GW7?>ZJW/U3I&WJ^S)EBUAO0@,HAD!B0
M&)#8@$B,I!PH.Z60%)QF0O(6.1(M4M;*B!//S]K-U#>?C,045D!BSVAZX"9C
MZR$&S^_BO&JG 2[*L5[7)T]D:_@$8?30/)"^R*[W_@5X#YOU'H2)C 1E$4G!
M(<X\1Y9*CCBF05/&0U2==,EF""OCJ=[/II_J$,-/9[]E*+OB0NQ?X%CGG;%L
M1,W6_8>^&#P$N$ O0"] +T_6?&M#XL:A'%-&Q*UUR% :$.<18Y6LH9AU$9QN
MCUZ,&F&N@5YZ$7IN:#SB;H:>GY>B=--QN,>=>COY%)O'AYZ#TVP8G=;S\5\P
M.JVGL@-C!84#8]V=.8?D*=O?R&ZTO[U?S/QQZ7N;IBI?QQ]Q7KI+JR;ZQ0RR
M]Y!>@?0*I%<>TB>OJ96>2.2U9(@K[)!F+"+-B:><1\G%6GKE(=G[]_;L)%]'
M\V&Z[_^UJ&?QGQ<8=G0!81WMAM)T1 DD5"!?#X0"A *$\K2$PCESF)* 2-(1
M<>H3<M%A%(U-L1Q=SCWM(E__E(1")!EQJ  /(44/L>B3S-R?^AA#4Z79]"1'
MH_.5N4%L"JX$N!([YTI\I3!O/#&*)J0BRU$@QA$9P1GRB89@J,^!H^@D<ER!
MS9N,-4>V'8+USR7BG!VF39)^&:K!*9#^D*T1(']0LANFDCT;R->*2JLT15AG
MY.8R4F244$@JEVCR02C922_6MB"?2CE2V]_NNDO6"*7& 89W5TJ-I[.R4VA^
MUL[7C_]:U*<EZ](/W 5RA[W*L%?Y>:67"?'2$LU12LSF"#)Y9)B5*%'!6#*1
M$M_);J.U]/+[%1"^']O)/#LD!^=8>&??X^^$;CV:?+:;D(&=@)V G8"=-GPP
MG71&R!20\"('R)9FIK%8(*]2D,3XX.+:N:2=%#\?ST[?28:."-UZ7/QLR6L;
M-5*8H/&5"1JGJQV"E3NKZFZV,H'W 8GOGOL6S\5SN)W7HS%)2<F0E"$A+E(Y
M<%:;O +C.(TAF<>=%_"=3<@7.R8?L@GYF[PNRFBLK4>E8(4#$Q1 _7-3LF<#
M]0938FGTB%C,$=>\G>VKD(A6,4RX"%QM<-[$YJ">8#XBC '6][:X">,ENA@O
M\::>V(E_=$PV.(6&'>L]WW4-.]9[*CLP5E X,-9MCI> +3W;3F]?W]+3Y/BB
M='_YZ<G)M'SAU/_1=H"53T[YQL50?;:SF9W,FS)-VN8GZD]V'JO3<;Z 4G@:
M59,X+Y]1-\TB.V0Q?U@SA^PXI$P@9;)C*1/B'"-$!B2D$XAG'$$V48\H,RPY
M;#&GG>\$>KM"E</T?HD\[\^!IZMT"6<C+.!,W4&;(.#\H&0W3"5[-C@OJ.:F
M3'6(QB?$.==()R*04LH&ZC.($]GU]I^N<1X.UAU21AQ"OR</_<[#M68M_LMQ
M7K$8BE_:.9H?1[0<]= ^1E[FEZ<XRU_60.0''D&?, D\@HUY!%('C*ET2!)A
MLT>0*5YG1P 9AHE()(7$NMF-<ZM'\*I%IZ,"3EU-#AP9 6.>!FU[ /"#DMTP
ME>S9 'S,JR?,ED[7-N2C&+F$-;+82\:#8I)T,\UO,P /T5[/HCTH]/4SVEL+
M]DJ-;U;%D]/Q]"S&U8.G8SN!.&Y(- ^[:V%W[1.Y"CIJ%Z/C2 D7$1<Y(+2"
M.J2<%D[XX+Q?V_OZZ'F !9;*GM?.1L=SV.6Z2T;;%T$!=SQK-03N^#9W*.F\
MYCR'F=)CQ$FB2).(\PIBIHC@E0ZV\\&"77,'&7&^]>3A<V./;10<833"'48C
MI&ZVX0#] _T#_>\X_2?J-2U#_:1C!'$N/'(!V^P(Y-OEL(Z"K.VY[7"\PL6.
MP>[WW HZTF+K\Q6>FU, G *<LNMJ")SRG6951K3DU"./><L/%AGA!<(B6JU$
M#AR3WN <APUR"H290P@S80+?)L+,>N*S%)M8FE';D+-L2FQ_*;/I/V5SFD"G
MZ:!<@K[(KO>$_[SIG!K#6(P!:4XEXB)D.J>,(A<#HX):E6CH(D0L7%[^/[B$
MDU]C,Y_5?AY#>6)_$JX_<.65[^.LGF;R7V+4Z[C\-_\]7I1;=_#%']O)Q_BK
MG<>#E*+O;*\BI2,*C:O#-F7@BT');IA*]FSX0G(7.+,)8<D"XE1H9+40B#"&
M,_2S:%CJ(OP;)%_HD6!;3TKNDB%#%7+[X>&KKX6#E9U7+N;K*I_1GFG6FET_
M !E8'Q+'D#CND^=@,:6:$HPH2V4 L-)("\_*/. 4F'"!TK4]C<FXY TS2 1J
M$4^8(D,$1<E%'BPG(1C>J>=PX2.\KIO3:6/'_\CL<IK?D?\NEU9/%C$<9J"S
M965=I9ZY&G&EM^TX/+?<,Y 2D-*NJR&0TO=(B7 AHT2>Z9@)1N:H046-@J:"
M:4PLT>XF*6F<'V7.(,)]?H\S'!F5+-*<X,0H3Z&,ZQD\*3$],EP"*?4]XH6"
MZ)-&O#$_#K'N\-T*ND<+EH3IPHUC[QR+AQYS^*<M>QCWD.JS\3%<9 PK;Y#A
MV='@2>CB+^3HUTM!$DG>B;7Q?BRJ&#&+2*E$$<<QO]O0E+T-82,CCB2K=\#'
M(-*,%.O9UM ;.KR3;@:0%) 4D!20U.64 64U-9F:"%,YJ&6*(8TS]9"4%/64
M^L#63N*$[&Q?@&$G.>JV4'A;)[]U0W9T!\D.O(+^'A'5E;X]QR.B0'9@K*!P
M8*Q/<)Y;_M=F-Z[]M3\&=OG=W_JZ1\CACLNEW[F";RSX4FD>$DW=0P#M)[^H
MY_EK_3U$<A1C9;V?GN2K.RM-=)/I/'_X?'H^Y<..\T7;>7LN1[-W0W:A_E3Y
ML6V:8GD?(UI%"&4I^;/RHLL+5FO^=SM<\\L+Q%ZF<?R"0CV+;1CS(DMC<3)Y
M&7)$-;9G+\JS:_:Y)[(QED6<5Z+RG_^S:.9U.CM?3?M&%"?A90[,ZO:39W&<
MX[!/,8<N7XHPBS@NHI@O=V03,H3;?Z>;33"Y!@+Y[JQ^EIMY?!'BK!943\;U
M)%_9W,[F+^QB/GUY_8DLZN7#RWO?QCPVY?6^L.//]JQY^<./%UIR*SZ7>WI%
M+6[<WF[OXJY UD;7^CAU73O4NVMA_+K__D/UX>>#_._!;Q_>OCH:56_?O=H#
MZ2PWT1Y^.#BJ/AQ6;]Z^VW_WZNW^+]71A_T/!_\\>/?AZ*EDU#=KN4"WIU",
M-I'9$NCO\^GO^;+:-I%,GN'W"S;]_9Q-+Z_V]"9*WD,V%\G4=XN3.*O]*I>*
M3:14DX0B(QQQ0QRRW&"$"0O.,*?T^AZ9!XW=L?/%+!ZFJQG/V'A[FE\SGRWB
M'1E6/YQA'].*L7&3)'O5X>RCG=3_;H5S3R.4PY/* [W0UUEG9O5I6PR8IFI^
M'*N?%DWV,9KF5IE=G=7.]P1C?[YYI=L7XV;([SC;V6E<Y(BVR>0W\7O57U<G
M=Y7G+P[LFK4R7#WS:NG=KY[\6U4WE<UN>SUIP^*,1Q]C59^<+"9Y91_/D+--
MF?-73T^/[>PD+VS1QL_5*DBHTM0ORBORO0JEZ/&I/1ML5(7X*8ZGIR6(:#N7
MIB<9D0KDM1Y;#BSRT^6R\@+J+(.4+_(TFT7;U32N/Y77?*[GQU4]26-[<F+G
MT]E9^TD7U]9>1O[.LI6NV2O"J%9K^TO^B&A#%6:+CY7/;VIA=U3]^OZ#P7RT
M7/*Q'2<TKE.L\AV.[4G7)]/)U(^GD_RY=C*OW32<Y74T^=[G)W,0Y+*256F6
M@Z3C1;Y=JTOY.)ZZ199?=7 A_;<?#\[E.\I?]4?,GS/+/NNLZ'.3)3,K7S$>
MQZQK_O8UM*=8J)=-%JQO[\3::K(3G%'>U[.L*,LU97,I']R<Y(]&)]-Q](MQ
M_D#T*J\LQT:5/XXGTS^R(54YV(JG6:05O[CF5Z]^Y1=*D9=O/TXG=3._)H F
MCDN4EF_=6;XQQ[6KYZUJG=0?EX#?G@;72J59G&8+:)K\XOQM'Q?CY1W\4/DX
M'I>SQ//'S1<GT]EE&/E@N_H>8=S=K*I'7TN'-OYV4KW+9G+BLMY03+/BSB_U
M(\NQM<R5G96 O C_WW$\N=2);$NM,E27RI#O\M6[6^SNFHFME/&:+A;E\HO9
M+']'OO&GBUFS*/89ZG(28/GBI37?^.P,25E6/IMPV98WKO.%-M6)/<N6]ZE
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MV7 D2:I0*N-8RC3FDNZDW>4?MM;-.(LOJ(>W4J@\S((6N*=:X+$-[]E64$T
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M+K'9,AS!CU<O?KOFWN2(T#O>&1^E##_Z6^^\6'+GQ88]ACT^ISW^)%>%W;X
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M&?93!<!DI@W!P-XUQQ38.R-(\B1'-)4::T-U'*=/*1+N& "CA\CU0P LL/_
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M!$$0!(,2!!2XMI2%00;'$E%C8B3B+$6YS/*$9S1GQ;V2%JX1!*M%:3M+>QU
M,5H0 T$,!#$0Q, 0Q<!3.:BER@TGJ4%)$<>(XDPA;E*.E.8F3X6017(O!_6-
M!(TM=-M9@<4 RM\&*VA"@ER0.,/&M"!QGM;P(#)A6!&)E! *4<XI8JDR"*P1
M&>,\%YG92<!RFT@X6505K&V'SB?":! &CUF.![_;,QT2[UZ^^[K7W0L8'L,^
M+"Y,52KX6Y??_*?VKG*R$ WBV<\!4/\./R,U%G5M,>W,H 9%[.KA]; S>T&S
ML7^YD-6/EXB\*L;F!])E91PBP\/'BXO)*UW6L[&X?&F_W<"_HQ0PT.ZD#1K#
MGW]?U/.RN&RWY&Y$9J)?S:9UZ9Y<F3$L^9L!W/UAX6=ATJ'QCQOB:H)_ O);
M%Y/=E/WM^L23.%\Y;G^\[6&>=X'Y9D/E9%Q.8&5S4<U?BL5\^FKU"P"U_]B?
MO8O.BP+V^U*,OXO+^M6+WSHLV<:/W)GVT&+M>'=[BL^&2(<[M_"[/SLY'>N'
M <;GXT^GT>E?W\#/-U]/WYU\&47O/IP<!>@XZ'SX>/KF2W3Z,7K[[L/QAY-W
MQW]$7TZ/3]^\?_/A],MCP6AHU+(BJK9O^[I7>^VR+_T:]9+S+*:9$4CG*4$T
M-A1Q3$';C'.>4BKCE,3_B_NLJ9^U08]20OY\3>K&+66.NWQ'Z46[/I/C.IH6
MT6NCS(4T5422481C3._C)MKU$D?1_-R LMZZ<:*Q\^-$<-KVBY/I!2SRTJ6?
MYZ_J7D(5?"WFT7=3F:B<1+"1M6=$K0SSURBQJ.$;>0E7 R<Q]3RJQ!P^/Q>3
M,WB:F&A_X60ZC\1\7I5RX7.XYM-(54:7\V9I1]'I<F&@A,/-]A[[6'@&7%V;
M\=@M?GVQXN=KM<OH[3N29ER:;_  >'U91Q=3>,2X_(<97]I'3MR;W;/M3>4$
MKIS;"<EU]+V$14@3G9NQAM?-RW$$.I\=H7QI<<)>+MIH/9AB  XI-C=7ZF@;
MLMP"$Q[!W!0IS0CF&I&$2T2)-(@9*9&1G.J,Q;E*Y+JY24QN3$P,RO,"6Q["
M$>>X0%2FPI!$)H78&-6^UG)KK>7+\7@\_2XFROY]XO#%>B0W[="E]?GNP]L5
M\Q,!OE@3U&99UF9RU7;!UA.$&X,*E>9VRKQ&,DT*9"B312R5QMCLPKI^].U.
MIEOL["L,[R&PKKFCJ$I;@A8M..P.5_E%!!],@=ZJJ 2J*BLWP1S83F79CM.O
MC6,;)5#MQ;;4T4@X-CZDK6^(%,>XX!>RHA'>1_ OC>$&[PW&,A,\!K%/;90!
MJ)633"&3DHP669XF:J.74\**-,]IBC1F0"O&-M7.,$8IS:E)N<YCDJ[C_;LE
M%SVQ]G59E$;_?GD"#[98N!#C]V)NC^;R-1S=J3VL4WCC[^.I^L>+R-1*S*S*
M42U,4$%>_,6*DV)JJ0,NC3QJPQMK)Z2L%*K,A2CM<]S1-1 &0IBWV-](JW5-
M8'])Y9?2ZC;310TT4__ZLD<PK0.LV=9F#K(S^5<]/=8&L)>CL;B<+II+_$)8
M?!3_N;T<]C\6L]J\K,U,6-6G12+G)?:WO=A6*O"MK$M9C@'?7[;/N*(&P+\U
MBX]2RO[<]Q@TT/ N@]^NN9<>)2F_VZW)W6XCY AS\H"O_$D%!KM]G[&MN'NS
MJHQ[1L[8 $HP-FSY&U%A=!>/_8[;9.T*>COVA>P ?O!N^^U_O, O[@W+6Y46
M/E-H7VFQ/PCVWJ06;@@P?]#0>BB4>XI".:OD@>8'"A%<%UT:45EK:6SJPZB7
MVRDT[R3B]JS[ZQYEA!Q,MH?1MJ1($B039=UOC"!1F 3EFL6FT)0G.-^%^^WZ
M'LOO.X/QO\OY>3GY.#'_ ^SDK2BK79:O9\F(X/C)\T&>2:9':+S\R(+6I0@L
M9>W\'(!\=AX5Y3?_21"[PQ>[H65-:%ES/XF=8V,DYCD2)@'I*R5'LE IPK%4
M F-1Z&1CHOA#2NQCRY5 8)]Z=O06N)&5W?4]A7=1_C :_<M4TU[_LD$E<@ZF
M[TRPHO=7 )T>S.SPYR2W0Y%%*+*XEQ#/9*:$2%,0XIPCJ@J-F$IR5! 3YVG!
M,*'Z$;)>^AT_=EM[,1!3^S!++VY=CG! B:WW36G=R&Q)$A$S'%.4$#M=HJ ,
M\2PC*-$Y9I3QO% ;'K2[9+9\JJ8S0/O+3V,QF1]/M&WV.+.)+J_+6HVG]:*Z
M22;+-6DK[.[5&CL-">\:!>A1U,+.)3IU@+M/HLF#KSIZL%0L85):Y#1'*4D(
MHJDM^+:B*!:I8B2F+"8;&9<[1=A=)UQE3X.XNS[Q%20U+;#L0=1E;=,,FURJ
M94+6%;E(0]A,=*!U$SM. LN?)@DL/XKOF .6'*5WO?..M^$C]LAO?&Y;#$EN
M ^\.<= PV65ZVA 2H1XO^>S99TT&@@P$&0AR0*!\RB3/H*8$KOA,N&+(HG_Q
MEY X'\@YD/-S(F<2R#G4P3R_5)0_!*">F$^KRZ73_B 2>O:R6>J38]N@<W0.
M)O]&QSG'*DE1K!A#-)$&2<EB1/,$<Y%KF:ED/0::F4)HHB7*J4P1S9("[E$&
MX<P0S&.%<U/<. ;ZG]76ABMWRK7)1S%Y^J&,>YQ$$]AR8,N!+0^!+3-&##49
MBI/8("HD0Z+ $AF>%ZE1P+.+C>EG,4MX3A**L"H$HE(5".ZC**49*RCFFME4
MRB=ARX0__22"/6;+H=CP":P9(VIS#K:][7=63;\9UTHK",X@./=(ZSH8>2F5
M+K!.*<H8V"6T$#$2>0*V#!%9EDFL9+$QJT$I+"1.";)F#J)*@XQ5 N0ER\'R
M47%AR$8WR4>1EV2$!S!;/A#4,( 2N/%S09Z#X<8YT4E,<(&LIPC1&'@L,[%$
M6N; <A.-:;XYNSDE+$F$1B)-[#W B%D<)RC)959(:02-X\"-]Y&@0BSF\:T7
MVV9V89NDA$A,D)5!5@Y85L984<X290N@-:*:@-'"\Q3E6:9C8^(LVRR EHH(
M3/("!"I3B!J9(:%QBJ2ABL2<9C*3#R0K_Y+'61"&0Z28P&X'"Z?A(\_!L%M!
M)#7&1KD%RQ#-C49<%!*Q0BN:8\XSOC%VQ!@>*R4ERE0,]S E$->&(L$I6#6:
MIYP^E&GREQSG@=V&R,D^V1YO%W#1?%$95[]=@%$-OX?(R6 %8NC$&#HQWD^H
M<IIJADV!<B8I G,F!7E*.<KCI!!Y84R6;"21V<Y.*LD5,H:"W2-8C+B*4X1!
M$@N<Q(P(]5!"E2;)DPO59]Y",;#UP-;W$KT"6U\&U9DDP(: F2=%@L!L,H@)
MZV:2,8FQY*;0>)VMYSG)B[Q@2,4VGSBU[7EY:O_1+%,%UGF6/Q1;)YP&MCY$
M>RK$<N[=&3>:;6V*%<3O4,7O'A-Y<#/>6W1B:11+4@42T+:HQ5HBD?',37E5
M3' JLYU,DWF4#(@D&5'*GERT!HH:!E ".WXNR',P[%A2ZX>*%2+&5BP6&4$,
M#!5@QZG$O$@9S7<R;/ZQV#&(EL".]S JU._FZ]ZR([.FWU?5/;?_HOB:CL'#
MM7K^,'4=":46%XNQL$U_M8&GJ-)U;'=&D/!-^]T'0? .5? &-V1P0]X4V+_<
MIW'W/=2#0B@6IT6,%-8<46$*$/4B05RI7"2)SAEE.YDDMF1GKWO<#'X?&_L+
M: S'/:9VI3:Q*T4B'L4L1,)V7!;_:Y!%018%611DT=UD41+CA$N5(<92D$4Q
MDTB:@J,XR7&2D43D:D,6W<54'9@LXB.2/7VFXZ&(HA#&>WR#=OM4FU$T,2&*
MMR<:0YAV&:9=WB\LF&F#)5B6"3-@-&H;%@0K$C',#"],0KBF#QH6_&!V9CP.
M4& _P[&6000$$1!$P#,2 3(K")>:()XEMIC,I$AJF2%2%"1AF5),;W0JVFDH
M<G<B  \B+>39BX!;3#8>#D-_\/F2ASTB]?5UP=#(_)B920V/_FXJ$_UIFR?K
M%JMZ#*=7:@I).$&%(<#@,@I,41&)2(SS@N)8"KQ10'272;Q]L*TYN*[DB=D*
M3TQ_PA.W[T_%Q ZY3U&<Q128?JH1QT:C6.29$8G*N%'K^],FLSZ_'$F.&<!$
MI$BHE"+#TB(N!%$X%X^_O^0(;^'X5XB (5!*!/>/[4G MB) DO-V>O"E$54=
M&> ;.AK2@OMSTB([_,?1=W]LR!!6.8HJ4\\,G/<W,[X\6I%=VT13,VU^^R!N
MAHV21&BDI<:V:(2 1:PR)&-=&,V(Q.E&>M9=R/]8J>EB,J\_B4LK12V%*%4M
MC/ZC%&XL<&GJ,$3^^H-/CZ(&:-&;1LP<Z/AXDAM#DCA%A!'0Y'4&"$L-02;'
M$A>I+*02N\#:+^K<Z,78?"PVL?74XO%5B.K>74[@CN/Y31?\O\F+ U>M6NSN
ME*@P=WZ?[((P=_Z9#64_@"V&@:X#]Q\?-$S"F.LPYGIO1[(>!I0"B082'>"8
MU:"X[ V??(XP":.KPR3Z_>.I0?($ G\Z @^SZ9]::0K)]P^0B]4Z]2M3&U&I
M<Q=3U>:;&4]=4E3G[0]YF$/-PWQR%!QTCN7!Y$\*4^1*"X:2U*;0<Y<JQ#DB
M<4R8I@RKI+A/"CVL<?ZR81>?&VYQ/-&OE[RB#7OO+)$>DS =.:3(!]8<6/-^
ML^8XS@P1.$%93 FB5#'$M<I0$DN24I%+EL;W26U_=-:<C_  ^F/L,6L.XU>>
MSM11TPM+#*$]5A"=^Z9W'8[$-(9SD\1@Q\0@,9,T1C(!8T84'&,MD@SC>QDS
M;0KI?T\K6&5]TF,);1+IY<FBJG;7QR,;Y=:'&$3F\*@JL.3!PFGXR',P+)ES
M:NS(>902VPL0BP)QRB78-(;DF5 LR3<ZM]^E/O<Q63*) TL. 9N]M&)FU;0P
M=0T8*\8N:&.K,1;CN:V^J$WUK50A9A-$:1"E0Q2E,F=8TEP@(TQLN^YC,&P(
M1B8G+"F84HG<F!]VQ[:ZEE=\ZK&*M\;4NY6BR8CR($4'25"!&P\63L-'GH/A
MQG$L[!A[@I2B-G"N-6+ ;%'&),6:)LQD&^7*=VPLNPMN_!="0^@EA%[VRFCY
M.#\W59!_0Y5_H?U[:/]^/QD*\@X+@1G(0\D0Q7F">)$K1/,T+HB.,T8W^E3=
MQ:)QC&2SV\>M96A"MW5K&@S5/8?N?(&M![:^E^@5V'K'UHU)N4@RCK H.#!F
MDMCQD!K%A!8R%C3/U09;OXMIM#.VG@^M[>JS8^M/%O,)(R)O?(*GT[D-"JWU
MZPJ">C\$=>BD'CJIWTMJ*YVDAI,<)5EN>RG*! DI,R0S8I(B+0HI=V*,W5]@
M_VST5<K#)(T]UJ0#_P_\/_#_Q[?:F#2,<H,*6H %)K'EY2 $$H-YD<NX$%SN
M,*#U8/P_H:-D  EZSUX W&*.QD];F#>=E44/'6_<7?FWM?M[C[];X^4$WZKS
MLKM\T U\K^X4GR4DY:I( +09052!NL=ERE"<<,QPAE5A-DH,[])S^V1Z<5'.
M;4EA?3S1)^ZTSLQ$W:A!_'K?[9LL>K7O]C5G_5S[RF='40_H8=!+Z^,X-Q8N
ML)++R$GS.BHG\ZE#,2LI[)^N*?G$BI@Q?+ZH:F,[E<M%74Y,74??R_EY=/+Y
M8^U&8-@!(>-R8D4"[&VA :-]7FW[X;PJ06X=1?!F>) XJXQQ1V)3<;^5VKBG
M3*8@5-QK8$FP=L\():RQM#[.:";:2:>B,B.[P,K ??"K$A-EQJXY=[>'&X^/
M@%6*NK9R[\R@U1[>+U:Z^__+X<F/EXB\*L;F!])E99Q8M?VW%Q>35[JL9V-Q
M^=)^NR$-CU*0A_9$6F\?_/GW13TOB\OV:-R-R$STJ]FT+MV3*]B6'8?1;_C<
M"=4?-Y2<M^3E.VP9M6O,36*V<JQ>L+:'>=YY5)L-E1- 0%C9'##'=U)?_0)
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MN^0F+L2G0J-WD^@]2'H<)^FJ_'<*M9-Q3H)$=CZVF'O1 4!T<G7X@H))"N+
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M4\B8=(3QU1.LAT+0SU;&A,R20=FO40AK#-1;.6")\RS\Y@%^@7 #X>X+XAT
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MVZ;6W]9L<[FE423+:5T"!@)XC3W7T?+1WD-75M:;4LUMU&<.]C"L=@&@!>R
MI\\OG1M_MAC7SIO:^FBM![6*=+4X@PM+APQPPUDE+NK;)K#L8]C^CJ'>DW$Y
M<4&WTZITH;=^(-_BY)?%;#:^7 \%OX=3_D<(HR[#J!^FW]HP:L*N#:.J%N)S
M!W&U ?':0URL0MSZ%(NB')<-]W$G$/WRC\GTNQ/"[[^\[B(>]NU?00V!EWZQ
M11VU3](0$Z&!O2T<\P;H /OJKQ/V8YFOT9N+!-XS7OBBCWGY;7$!Q%Y-O!L+
M2%&6$[]ZM] 9P*&:CLM_+2Z$C'[Y?V_^Y_3SU]?'=Y3D:W6. !M3]0XQ.\IW
MF=N4TU=#TCA^'?EC7@U$?GJ-$GMP\%I@A7 $P&++AC%;1-$@*"Q;5O9'5:]J
M7R _7:T/6!/ /EOQLGK<WG3U".:0T?/U_K%:/OW_L_>FRVTD2;KH__L4:;I3
M9U1F#'3LBS2GS%0J58^.54FR$JO/G5]ML8KH!@$V$I#$?OKKD0F   'N()$
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M<1\P0+\TB%,FG-'"1;7FSU$AHB$:?$#J ^@,(9$-WH#BP#9:C /79O?XSX^
M:/G_"_QWQ9\KN;O'S=TM^G5=3M2=G@U&YS'.=Z9-Q_[$UB5?M[<*_IY;G?<8
M<!Z5'1^^<_RPC83 :=1!, 1H$A$GT6==KU!2E-M$-/=\;6AF\-8:$@@R#H-C
M:0@8%C@H9(*.7AA,.>O"/@=#C\"=[8*)<.\=]$6JBY(I2J;S[%B4S/5*1LI
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M&W#QO'7@=>C7H!'.7^5OUS;#]T1_V'#*O'D9_/F/:3WII_,YRS0GHC@,K\_
M)&JNW"1'@ ROW>A[YL_,<XL]]=]ON4?^(?)TT0:B"Q)%"%E9V&8+_6(Q3Q8-
MXF8OU!\.^D-XLHD=3U[9Z63T>O4+('7[<;OV39>X!FU?V<$W>UZ_?O&7!9=L
M[(^0UW2)+2XM[W97\8E:Q6Q[R=8[)3SFNSZ,7;^U:^< A1Z'&'^\^71<'?_W
M._CWW9_'[]]^/JK>?WC;*]1ITZT?C]]]KHX_5K^^__#FP]OW;WZK/A^_.7[W
M^[L/QY^?BD9=DY9E534WS&<]1.:%T ';$"5'EFGP#94%* M*HKQCQ7IFO!5K
M<WV)3D(I+E"@6B$>\S#(/ M8<,6C,$%AMF:7_]*OLZ\^';>U#MGV;-3I'VT"
M_VW.WS=>X<^@Y,,G>]Y8$L=PTY\'34U$!$O]+!N#X^EL,R]HY!C>3&[[%G\G
MMU1X>C<&Y*-+B.FU6V=00^)J>14>X@,\^G-O=@JN7D"Y?^O7W.I5SNGW_5WJ
M-1O;]>-98S9?GNIQ/_=I1\1[A,PPQ42LIGMM&)U-9H6ZO_[V_U4_]T=-V6>O
M.78^)07(N%)EW'R7/UWL+BM.ZA*9%]6X>>3,T69?<F3'(;M<K=.36RHM+T4[
MJZ;U1F$U<BK@:]RX#F9Y'=K]U4O;IR^V/BV6;&5']9*<U!<[!?_,GE\3#I[O
MBAKF /$L$K>XZ='JA9L]A>#[3F:["8:C*DW'36W:E]85GVTY. 6]U-8T-14F
MO>J_1]_BUSB^?+UO??#WYUHMN[!?@*[C]LG:_8OMZX+;/6F*X68/N#2SM;+?
M@,YUCAI\[8^F-5"D>9:6S(L'@#7+;LBD"0_E2ZPYQXMY0MD3WU ALR!*E?V?
M4]L4J ]R*,&#%Y1WX0-)_X\%AWE\7I%\X9B3VDW)FHO UYFQ+@YHJ[B;(N[Y
ML\1_3=NMF"_[/^Y!N44BA&FC.5+>2,1-"'D3D$/<.L)U"#ZIM7X0D1KGA<;(
MZZCS/G>%K+$$24Z9X9%0R5;KOS[%<98-<#8_IO<S2K\?KG4$W-@+\&RZ%&Y'
M=#4=]!/O="SSASFK7Q&Z69: F2@/;#VIW+3N-Z(<0!(7@?5<6IGZF1(M/\*?
M+_O 9!L%(<16S$$4@#MO!VV]JBUX7&+O+E&S>YL6[ 4>P:)T7]@E4]I&SY!/
MN>;;$(J<T0QA*ZS!(MJ4UD;GJABX:)*_Q//<GX\@K6E . ^RB$SZH%,'NG\>
M,26.#+MZ9$47..8J'&ABWYM5U_+^O&:#_EQM+536TC<GHS$\<9C?9H/:*RF3
M;EJC.;NZ;.3E'.G7?HB+C$)C#LWRK/V%I=G:;\,<Z9T 8P!FSQ3+V62Q[0 X
M83+N^\D%7ZRIH=G1N?L.4*:?"XWC; !C?93S;GT?Q_#;0E, ](6O_;HQAUO;
M+F=XL_'8JXZ76U8LW^"B^]!**BBW*FWW0X =/9Y_GU,PZSIL76<=5?74_2,W
M0EUTOP#"U<MVYL?9ZS6$[2W^G!N87\!J'C=&8'Z2*MNN#X7R%YL#5I$):W,C
M02,<1=S99N>^10&;F!33GN7@TR7X#<D&ZPRBR0#\*N&12U@@CC5V*DE/P]KD
M\HM@U'*@Y$U.M'UIZ/OS^5J\ZDTVP)L??VO7H]UD1E9P%]71OPK3<9XH4\=A
M1V0GC:;CQB*J%WARN>5PAS ORTO\?@;\FSVO'$', @X/]C@\QY, [@&5'[D,
M>:]&:KE/!&F#=YRFL&;?R^@R*^9V -X#IW&'+%=P">JD#EA3P_Q&GG,W\YR[
MS'/O,BV:@UN.VP.&@W_VA]_:/@%+6Y@:W&M,_8OM!GZ^D[B))H#\G[:-WFQ_
M7'W-6W&N*@!O3(S!><;O58O&;G)!-KD<OXX&@]&WIN%0[E,$9F!.R9]-W0!X
M>%[RT3[8S8^SNBDTEP+D</',M5HKN,LWO%QPMTZI.X9P]S$&?\\8[FV'-#_W
M<.Y'8/6-8<8-L<1K2+H>4GSW^=.GU<9A\PLOG(GN.Z6@50)78-)(%AE8110C
MHZQ$@GG/L&="NK4&\$EIIY5R"-/< #X0L*F:QG5>49FPLMJM.:7WMHH6FX+:
M/8L+-^OA7>PX/F*LXUL3K_ 9EOW218%3,\>B\2-<O C@CC9"]<+!:!EWP<]S
MSV=6BG5]E+=IG;&R.7+A.-\IOINCB\-@6S/RZ.I([]%<D^5*[/:17I)]"/-J
M&1+FV"-J3<XR8X><T!JQ8#RUEDBNUW:1W$7('C/,RU[\1#K>$& 1Z)WDT8\W
MU^Q="OPN;8-?JJ/VL?G^$F^^I/O ;T%0E1C3B CC@-\T1SIIC!A+Q% ?$Z5K
MD49+N.+P%3@HN7VNC J9R +"X.I2XEQD&J_PV[T1_3)SOCG-32^?%YZ/JY?L
MQXNTU6V,]1:1P:R>[4/))@EI^TX!5Y;LP1VS!]V78L(85A1S)"@'K>%";ORN
M&$@D#B2H9+!):YO%/"8.OD=>^]P7T$ED.7%(2(.Q%2DENMX7L)AFV\XF+&4#
MKL\GM!U,'I!6R$9;22MTT_G\<WVICC;$^)MH^]Q>OS#B%W;]9D8[FG7R]_">
M8._/=GO,>UF<V?/<37"^?Z?)+V3U 4<WVR>^Y[U.>X"!G"AE$C8H<!/!"@X4
MV20YDI( FCD6!%O?_?64[NGO]GO_='HZCQQ\GKK:C_M-DN,/.[FUE9TQ\2?2
M[8;J/RP<MCGK+D?^%D2[[%%>9'@6OF7&1/M((7>F4N(Q>:1P[L;F!$:6:& @
M3S11!"<>U@(:3V?[SIMZ7A-M!PF?G'0$P2Z,M@X'V5%#L8L-BF<-;>?XV*8Z
M&Z:;/E9JT>OH2,0))8>SO^4,LC@))'/.QAF!=5JKA7\ZGEMTDMB7#$_=_]ZN
MZ1XPWU*[DX:\N8RKC9O%85@ YJ6#KK0"VDV)L[C=#09 GKO6?07NF;))&X6$
M=QYQZD"!FQ01DR8Z8/AHV5K;@;N(QH,SH"M]5E;::<X":G=2X1T?%+F(E U&
MW]H069/5F_5K;9-[L[#O111V7C"\BJ\YAG'ER3/>GZRT VI.6VN07,^:47:)
M3&O=FILH2^Z0V:6G/%H"CSF5]\&F%T)%S0 #M.2@+4T>6Y B0]9Q1YC$SJUW
M=(B!24$H1YSXW/22@CF/ 4M \5(*<!%#7-LY=F^%V<8SYL"0@^;-QP\ODQ3Z
M2(B.MR"9;Y&?5&U..^=YOH(!_V6_VMV8W.O&.HVHI+G3$B/@. J#<,11J!12
M(&MZAX./((0TB(-J0AQ\&V0I S4$3,F\=,'BS7KG7E;9K#/3_YU1^4U+Y)D:
MNL2"VVG?]!/OF8YS7\;9[C.7"\Y*P0E*F@""<6Z1U9H#MPB/F=-2Q+4A0#1%
MQ4AT2(:D,T,RI"T FI5<$,"O'*#M/()I=215QUGH L#L.H3M9>LN02PUB:K<
M%AHC;A-&5@!"J> !QI(S*:V%-$@"LX4&AYAP>1:AX<@8Z5%D%@L%_Y-^<Q7A
MOF 9H3W6[?U'S;CBL_DFP\MAL7[=%&[W0SM8Z"*$ENO(SYH]<L.P4JXTCCYW
M[PBM^X?:ZKKER-N\-=.>L+5V>8<]X4@F+D'=&@$F(&8(&\T<-H)2M18UN8\=
M^&8P&/E<4;F9O]^U1+MUAZ^?2*_C"#CO9YX9: _X0"C!9%(:>4L!JI0!ST $
MCE(B4LD0)>#6-K3I]OF [0<?S'>Q[)^[?0E"+[?76HD)EN9:>]I<BY;F6OO>
M+N@9MX\JS;5*<ZV'-M=:;A-YA_9:?R?WZV=%#[>?U1;Z(=7+2[6D)AZ>)B8D
M4(]#0#%F#R9)\.,]N#'@D.L@H^"&KTU[ND_+M,_^)(;I8.YZKUFZS=O.7O9-
MMJWZD_/C7,-_5=>TYU[(]7EE'_6,8AO[VO3S-.I)MK@G)Y6+@]&W%>M['XSO
M5UUZNKNV<#L4'0':(?_OOR;-UII5$S@_:FOCKKHV^87RX0@<EM%T=DA[-X)Q
M#_\P/S[WOK)G=7Q5QS.;Q];."=,4'[;GO9@_ CS#P@;/6_M=?P#,_VI^C:4#
MX<BP(%US6TYZ2JD?EFWDV3NW1O)?KCF7](B^YYGW/ W\>2V>]I8]R>][ZCU/
MPSV#^1._9%G(/5S(__K+9+P) V;.<+8-G?7__#(>@1Y$,_V0FO^]SN5DK>_]
MJO7 \P>;M<9F^%AQR<'MOC3,'#Y>"\;TAU<XW7HG&N*^KL$DW(<@[?,^%YH
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MB(L=X_BEH97S?4E-G=.69E52TL.XX'O!]X+O!\4\NX7US4.&E(M*2Z&1]EX
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M2K2K2O3FF-,>@\#CL=>=0G6'K7\]C30YSI%,42'NP>DQ)E#DE-=,AD"$7IL
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M3I=%$DOFDY&Q9X3LJJ8FAQXW F:H0> :NQ<+IC/0#(?$0K^*-I,]^,K6BCR
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M3&("%V;X#C&1C&,F9 X?ZDP_)(),+%CUEO7TD!<HE[Y%%8T$?)0Z'F5*-;G
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MBPVU9^L]6R6_IS2VZQV)OA$_W3#_7*-2]6M9"*7G\U?MJ?QU' 5!S%_&7]N
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MRJ14V'/1;?UB]KP0U%#Z,;V#/[+!0Q?/C-&@ TGXTIZ. -AUS]32HCB>F<'
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MI%\TGL 6$[2+>P!,I8+]P8%N@\I+@DZFP3).N%!1YI=C)/VY>0;L.P+\4 L
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MUQ3, M"T 58**$9<HNR"OOB!>X+/AJ6"_%./L2):>LL8GJ+*NN.ZSZLJU"W
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M#$;./2*"LYS9._=/I$CU>22I;$ZL;GH-5<U9(F18G?I?7,S13%VJ)Q0E<93
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MD&'O3EX4 XF<<&-_=@+XPVGH?7;BWXF6R<9\S]+XR(R<!TZ24!"(T^3TF<P
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MZ4$<RW>!^ G_!Y'F_;^?O']_\H$V1OV7>KJ#Q:GV516#2,!Q#_O9B9_B;56
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MLW,(PQ?*;T0:;R5GMSM WY/.9"*3/0X\+S0FX8$K I QE10)#BFJ=$8KR7H
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M$\%WG9'''@-12%>_@;>D'AA@-)U/0]9FT&U02<.D=P1J E6.KZ3KXC>6Z@S
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M;74 $_-T,C')>9K@?V3@3GLF_[,B[XSP">;4$"6'@)XEO^!-%$JP#^%0&-D
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M@$IXE?QP3O[ML_-Q'<6TC^8=[YBA,Z8,/S-6J,!K@02W(Q>^ )*.R9$ W9P
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MF_4BH7W)MK_-94RL0))Q)_ZEG[A.\%=RQR$7.ZAQ&1KVXZY\1@\!0:A-I'5
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M,GWXE.QX6Y;Z NEG$'WY)2(?"DW#A%IDCK<^75J1@GFE#':!Q'!1/EY:_;U
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MGSD$*4WA8E]-BM)SA2M2HDRVQI^CA-IG_TT21],[,G$3);[RX*BS#V$#@IK
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M_Z^'Q?WG(HKYM_2)FV:B%G# O6QQA59D!2U^_'"V^/C#QS^10OC#C].ARBE
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MY WSKBRYN6--Y1</;J&0-.8^"=ZP1+@/O17J$?)$GZ#H,!9T'-S:SG L^5#
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M/XY,_= ['8?$A]F^/)K\F782R2. =/1ET"1H:\UJ<@7!'*4<6WSD.X,,DKR
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M'6U^\7M/NDK^8&V9W*%,AIY]'41>M!H2D!R"1#0PXWF'=F#&QV=#":0^)[:
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M6 N^B=9QLL5K9M14  /W9U_LRJ$ 81F%B(8TXTOJ?@U^SJ"5/:'5)HK#^/5
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M%6F(QMU[)OK"$L"'AW-B^D#^,GG F@U6,U_"PVWP&PH/3W&UU -Z):L@:O%
M-%A/3JRWZWT2D6"9<T##_T;"9C1I")6E[<OK3_C:M\UC>\E='?02D@FNY(5Z
MO\>'/%[AFL0!/=IR<6MH4LY43X!N+3BQE/'8UD&FNJT5OSHQV )4\ U%>Z1-
MCBPKZ001]PD;FQ'RN+JT$\24#6'\9;O99,9+.D$$V9_()R"DQC?DQDIND$81
ML@&.\7RU2O9>J/4VUA1W@AP!KX$;70-$7ZET4D!2W ER!!"5IUAAX6-F=+6$
M:-V($Z0W@BIJ"SI!0N6,,<7#K11V@A0&,"\%EM><L@;5G"!O_!P+-)']H-;"
MEGT?!Z/3]GE]*G@$I0S+G1@^\!B<8#QX;BW7 I$JCR]I02=(>$3 7%R,)(>1
M@PV7BS@Q[,LX#&E2]> -"7PUSK9L7-T1<FLAA[HP14UQ5\@I)W82G!04]"C+
M.T%0^;[8)I+:K*831/;!UNW:AGU;G30X+K>EP5&$)XG]6C/.M:GL *F%5,1'
M-T]W*;VZFI1W8M'V=,J].,@;4!WT(W;GGK56$G]2F%][XQ'T:MV)M5>XALNU
MXR([-1'^SU& -P^HQ RZY= F2&V0+JR_ 5.'67+1\HA3\)67>9*[<%-9)^9?
MG5(7W.18G@;\UR]!M@FB983^&Y^ 6BBZ?BW:/V%ZY<5V, -VY7[GQPT0,[)R
M3A P7O#"SR1R07&EMPW V')PQSU57,FHD$G44'9^I%PW'3:RMU7/;GA]516\
MT@].K -^86KV$G1(SI#G!+ CR<:;_^C(4,'E6!%SP),L-6MH'9JQ?T[C"PM)
M\5)*+(%UCOL$?5>.,ZG[HQA7=6*689!@5H:G.SQ'VL#J>D$G2.@LEG.('R*
M1=WR<]6:,79?Q\W(EL@5CBE!+0?GQ%3EGFTH>0L@.XJ,.7G<+.%#^A33T)W\
M=SAJ[N+LOU'VD*?7I$S RU( ^Y6^BDP[ B>8SG)8-P:VR<HY08#H/<21_I=K
M7:*E=C6=(%(;&T*S#^J414TU)\BK9"2_A20Y( @5!EE-<2?( 7A)S'+X!P3U
MFQ?J8-/4I9T@AC[I2 U7Y!<G!MDYLD#F&@+[ ZRK3RC9#INIM[$W^[<$063
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M.(N7J]Q128/"95#-^AYC_#Y\^/A"U-KJ/JO^;E]2:C,@E.%L0R^JF_U;UG>
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M:I?<UM%TMA1"F#F#L!RN7G@3I5F0[:78*KK"CLP+R_&@5@=+)=P8="6U'KW
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MCC52*J/1+@QY61?"@J2K1EW._L*1"7+S\%D7\^GFPWN"ZTH3#;20O<'N7]+
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MCDR7EK,)KXSO"BFZ0O1?81TPVV=S3@W3!APB\CY!.R_PKY@89O!<^/Y)KE0
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MJY82L[J3+A>R3B61H.7?['&[ )JYCA,-<K0FF+5=&T-#%>D$H"R*T[26 QM
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MRZ\19M8FV)'@-_*@SC(*>*]@8"$'Q'*?I1F^5,,%.HC@()21T;]1=ZBDQ_W
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MQ\]F+WK.Q=,VD!GN[%9^^YQSIVWV,.6<+&J <^C=TM$4G\ Y=>*8@X;G:YM
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MLLF.+0!)(WNDAW\"'R",C\1?76QKJ&_+X$QS:3\@ HD7HKVM@@-2F?"5P[7
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MW*"*:D0*8,[TRD@OH_\P:&5D^6/-Q^RL\FQ/>.M@!=C>8/.;=SO@B,KJ.,?
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MMP>;E,@N=(G1_<I+]N7O(?37VRU(N+5+J..,(;AJ#%6UWFK00:GR#?=;%%W
M(B"1DG]$>FW5\+9L&8Q+JN!'M6A^*PRPT&+&@$?W? LS3EA/8\"2B*2</S]$
M'T6Z]53^S%O(''%YI\I@Y)-NVT78#'XIS[(FB^Z$YMH1L5[UV 4MH7$3JWF1
MM7S*9(9) H@Z4+1=+ZLYX.*EN(@,[FR/..8!YH>TH&D". LUXQ:SC0O<P\A#
MASJ="_ 6,OG$D";=N(+'V3\UD(0C.?G*L]3[4@>Z&>0&(#:*62:Z"/BNY"!X
MA-X[#'F<=^1B5M 7?N_1]KYX&7XA3NNMS(LCO8XQD#^!8P+\HJ4[/HT&]V,
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M]_YS%W_\T3\%110=^L,Y> []Y:OLMA@989.64A(UJ!Y46L&%\>N8 O(F]I(
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MI@S21 D5<X[ 7HH<2H&O!1FKD:"PWBX%48XZJ]5R36EYT5'WZG2L31$;'?4
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M(/]OX%&QSAVO>&_GAU AWJ<OJIFF6E\^R1$1<Z[B/3]$?H+7#4K,D3\_)^
M&:4;^!,4[ZYXJKN46LAKY"\;D!QHNQ2;:%AHZ6X/IFB#/D"'7T@D<;%CKA@C
MNH95H+Z "'SS0LKAB<Y23F<E2<"(\, O2$+!@= LWLD=;PS5/8X.HAZSX8\U
MZZND%.+I_VX)=@?$7,9@2S;_,X"[?898^ ?ZUQVZ6%@JK'[$9/UG(; $EK$3
M8*RLXS8,+TBG>@:)SXX"D%[&6<^FH%F@;?#DJ-XV>Q*$_2T"QH6JT1Q'F;<9
M%0*6O3&4,6 :L!HC@WUH!^TV-4VPM75',,#J4CL=!6YX9@<:3PZ:8\X-N85L
M(XX[SB0XQ30CC..N(UD\\4T[CCN.9)&AP);D>/K<U&O&MDLYG@(GBY@!XY?C
MZ6ZRV! TMCF>X#9:SQ&VUCF>W*8(02T;GPZ4_,U*E B8$[4(>7;K@PS+I!9,
MV"GO4@R=6J"W4XH=LJ%J086=,NQXBZP6)-DIMHZWXCH2,W8.%WM$HCABAM@<
M$(=AH<'@0]LE -@;1-;8ZP=8)0GN"'TH>_H^Q9'/^'F#_I1Z/H9@L/.MTD]8
MD(^M !ZQS&UE'S*7VMG;M$??)[]7C^0JBGW*[>L<!=5%KRXV.QY*<*:2XTF!
M_Y^[^../ 8#%R: _G \$_>7K790A?DJ-,NO]K!B%__2B WS>>XCI^2#/L'D5
MAT][T>D1'B!Z"=@X%)TZ:_3>"Z8^ZIZ[O\ZZK2_>=WC(#\R-M7\WQA5P(/EZ
MV[C5G/((]+'7Q= T5100H7%&$//YMYEXUR/8>6'!H2A;HHVPCZGJBM9].R+Q
M'"?PD,?E'E##$ON#5$=>";^*BE]!5@SG'M'HWH/_ @<8^5X"NF\()XQ9<*JV
MV-HO, 1I%D>58DW;)&>T<OFG]/]GE9[_=HPC_ @7Z83K[1<ORK>(9>6XXM\&
M^/LH#N/=B7"R+4LTFKKH+%"N_#T$10;@>OMZ!#[<0IQ5^0'"F"1%(?;] G8X
MV3).3O5)B$,\]@,&H3^7^E0&+VU)U;<+AZZ 0(A9,L<Z&Q2F0\VG%\90IQT[
M&DXR452L?0^B:J>C:&()3S7\PCJCHPA@Z)%5O%5'E[,:2*'2*5RMKU6^0/;B
M.((;7N$47<AQ)#AO,%*SIXQ6UZ1U@]R%D:/C8DC[S-(14&DT+PFK&R0\HO*/
M:C]"DTTP^(G-&!00J71)L2PSBN-1O%,ET#DESAG0,BAQ"IN,;$: )8R(RN1M
MQIMI]L.S_MD<)6\)O76$1)LQ9IK2%-AS'<]4,(#>T89DQU,<K$$UU6KM>)J$
MW@>):3!W)#2/4LXMCEZSV/_5SD@\W/X*$2S>8.]4NB%UU+$6Q,:1'=V<R/[$
M@MSZ,\P5J ^]Z,D[#'2 : ]2[*7:?(LW^SA/O2C8?$-7];1&8F#^'D)_O44O
M+V)V;+>U\%QS=%(E&^.:DMD)BQR(#=>-*>F4PIUS78% RF,D//02"D1L4,>9
MHR*OYAOX(JZW#41QKZ[ 1-5.YVRS!T6/,#9V^X.,<T!>OZ+F$.,;E6#5=O3E
M:7 P[M[I8\W=N?P]!;_EF U_@*(4,(]G,T;;M'T^IV".=Q\$76&(SPFXS['
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M9HF'RXB) "8VU]G &$U/&3U*1BG[M]DV/D)DU_ T-@^!^Y#8C$HQ-X/ .RF
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M('I#8)46;S( CS K&I"KK'R>\5.7]DL@T^>< R<Q-V;$!]EHL.R>XR?PGC4
M:Z*"'!TU1(A)"^W5K$>*-J+ S[1#,5$ZB**SQKEXS.<$W9CV_>G[SVP-I!I#
M,16&1'K0V!YK89)2\*7J4\J/DI=KBG L<?!-&5EDVBP[[;]:HIOMS31G_!M)
M@5VSG^PRU@#,?FV% &5.GYD"RR=2G@"+B=8<Q\AW;@Q1"JZ]U)$U<\*=]TGI
M";?7=EGU? &X.332#*LDO=P+FR75:"1A@?YX-NVV#JQSG*UW@]>AC\N4S^C
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MC&B=Z-_G:+'2;<D?9,MS/FBDH8AC];$-"FZ]D58RLX;HA>6M!.*?O;"2O5X
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M#8_^G.@<*!F^4HZCO_49?[W'-%>E<%A@A2K+; U,,/%V]HBM07AH@KP=B:@
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MQ[,Q7)"EC:8UO!?\5L)TX8+!\>4PU</ +[MVA'TN7T?@MRT%=I\G2 X5LF'
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MYN*6 _99!1[BIGR/$E99,4QTC)FP/OQ..HY72OCKY+[\P+M,1[-IGPW%%Z@
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M7RQ.R&]SZ]);+[WN87SKAG_6NI2(R@1]%[O+RP>^_<7*?9/A[ @ C[G;&VB
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M !17/U=QZ4;*PJDB(L3Y B^EN0SMM_4%ZL&K?MM<O?X-4$L#!!0    ( .E
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M#% U*)V(;8.=JKC5NT(A>="Y']VB\;NBL;N1:'R#-RTAP.4S=JGT1$(R@D8
MI0EH3#2.K;1CU(L+Q;B:L5(Y4P)JSYT'%.&3LQQ_X;XI6<IC;#),YQC..!WD
M;@@HB,%:;F8DDO-+P'D7QK38EJ R.*4D5TESD$ L3%SF**:P.VJ2@&%HL3AC
MMJ2/>?\)&*@&H07DPDJ,;=$H;")<A@NT!<1>01H7^2!T@LL<8[>$#6>+9MBR
M;"U8MO^T6 8L%0IQ3)28X[:!%$-QO&P6K@N5HE/@E#CA]UB6"8Z)W%@ :0-Y
M)8R<,5R.)5826Z6<TZY"O%V:&C5-?$;6((E2H@!R32-T_736ZQ-SF[%4ZHFM
MB6A@A&@WF/TQ3HU!;]2RL< G6RMS0]LMI=:"4@<;2:F+:_@+<=*KGJU84T7I
MM-/K-!7XTT/SE'$#G@0(:C&40&!E@)88(L@R$B>Q'+T<>3KZC:N/I;8E]J/)
MC9:!#871,238;-DN@C\!9%- ^& :9UR-@/71M9R7$B4Z^[R.Y#J'N_#<C] Y
M3*XUAE9!*:4*G*39&'FC!:H&ZI!F#YTV735MBM.2#9;IC((4ID:/0=&*5L08
M F[WY1Q3/QIKCPZ[G:.7+PY>=?>/#HZZAX]$8;Z1%'X+%N\)HM>';5\F6H,B
MRIB7]OY=*+0; M*DFBD$B[HT. !"="RL=WHH!<J/0VG]W%TNNMQ0JT3>5='B
MG"V-RAW318&N$W6Q6HJ$.Z_HT(I$<"-H 2+$M#X(4#12:2G.])N6]4&I=Y':
M BKDT"53IP)OLHA+R<FSX[*\$O-X%7N$Z'<Q:,=O0R!!O(78'Y)'<;9;)G]K
M)@^? )/O[<)N$/K^SN_>O,:]8"P2HBNW6G'R^0CVTE#R2!SF)JGYA P7?"BD
M<#.*<%=-2[N+IYYG5=@8KHDN))\^M)A6"RI*4R"KK8_(XQBAXA7P:>@(% ;:
M$LF-5Z"@78-$,,4.!,;=113HS[<4W@@*QQM)X<&8R])[+,(WI"FFB6*,R+0K
MTKUYN'T/%QQ^KDX!/66Q([I/&Q+-H2[=[2K<)TC@5]) 673ZY=H.&];YN=^%
M()@"]>G1X%O6;0+KDHUDW=N YYN\H!IKE<_Y*ZO9]P!_27&MCN/2$/P7@LA5
MP^;:.KQ CS=Q,!OC2'^5:&8<>_>V/BDR&7W9DGBE>XQ ]15B*A[[)QU!L^=!
MKXS;JYB;O*!G/B0^// FJ5SWC$EQ";(J%R_)-_ZYE1Z-[C\JMQ^O*'6XD73^
MRJ*4?R"8U%M!8^Z.R#LNDG'NF8A-#XBS;^2L<]TX)JY.&WL5V_H&'#//A7,
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M,)12KE_ @4-S6)0/['CJP$1<3OC,^@#O>(]>\W[]T_&>?T'\_U!+ P04
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M<P/NH@6[T)872V[MSSNH7U:7PKHZ2,B ;C+JF(/9J5:4")M+/HE2">-YRWU
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M$%I )JS$B!:-PD;"#7"!-H?8*TCC(A^$3G"90^R6L-YDW@Q;EJT%RP[>%LN
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M#DS$Y8A/K(_%3O;I[>O3'T[V_7O;_P=02P,$%     @ Z4!F6A8*4>2N!0
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M+%HIVR=PX.)P,2FSL*.1 NE2/J?+W"SP.E7]0L39BT[5O$KQ-U!+ P04
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M-S$S-3-?,"YJ<&=02P$"% ,4    " #H0&9:O'OFVQ:1  !(GP  $0
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M,#(T,3(S,2YH=&U02P$"% ,4    " #I0&9:)I\OI.!  0 3N1( $0
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M   /              "  0R5"P!R87!T+65X,S)?,BYH=&U02P4&      T
,#0 G P  VIH+

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>rapt-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rapt="http://www.rapt.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rapt-20241231.xsd" xlink:type="simple"/>
    <context id="C_80a183b9-14ce-4b94-97fa-8410f324fd16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8234c17c-ee4d-4a80-9c05-28fda21083ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_835d629a-8341-447d-9b31-2b46252b4801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8a36a6b4-2ad5-4767-8ac9-f1a57de88015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8a7cc3d9-d3e4-4c52-8a5d-bca0e011b505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b9b3e34-2570-4302-8da4-f3602f968f0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f0468c1-4f1c-4002-aff0-929369045db5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:SharesAvailableForFutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f6dc9ac-cad7-4b38-9d58-a1763e1d61e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9001335a-7425-4825-a5e8-855ff463d619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_93fa0d2c-4808-4cba-b804-5817b70b6002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="C_94651108-608c-4b19-95e3-37570aa77a57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9721513b-6988-4fc5-9022-6cb8d96513e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9aa83cf2-b703-419f-8280-e04589a8890b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9abc0e8c-51a8-434c-a1d1-15cb685a695f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9bacd39c-e2ef-403d-878e-b81822f43a06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="C_9c01b00d-c8c0-44b6-a41b-56900a5fff28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9db51527-1de4-457c-b360-21ef8df86299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9f58d34c-283d-4d45-8629-2ad0f013648f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a14673d3-4c5c-4205-aba2-4b02e4aef4ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a1474cef-956f-46e7-9e3d-008021bbe380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_a1e1225b-2612-4af9-939a-2d52c9f5e2f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:ShanghaiJemincarePharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a395a028-b159-4fe1-a41e-dbb49da699ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a7ae680f-040b-4295-a0e6-b8be8d744edf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ad8a92e7-a170-450d-96fe-0db4664c91f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b0562cd3-883d-4446-80de-a657e0fd2fe1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3f24917-b3a5-49bd-8fb0-e640d29eee1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b4b55243-d136-47d3-a127-156fda882df4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4dd74b2-7b1d-41b5-80ac-555fdb0af990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b5311bec-6438-4c93-a187-0201963f9310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ba019106-668d-4085-9682-6ff1e01b2cec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ba2021a0-4327-4bd0-aac5-d66d26d8d350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ba3ba657-8b8c-4939-87cf-2c03c023d913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_bb74bca5-cd20-442e-a1a9-9ce66456c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_bc3a237f-db8c-4eb6-ad25-be4c30946b6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc91c928-5abe-4ffe-a8c2-90f5cbb4d036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c0d8be9a-a9d5-4da0-bb1b-b686503d1d6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="C_c1f11e91-1cbf-4c2e-aecc-69ab59127c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="C_c3c8c90f-d90e-46ba-865e-536f40880787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c5036115-0ce3-49f9-b87d-f4affdbd9129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c663eb36-dd20-48b2-8b42-6761ae70257c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc2ab253-a7db-4cd8-aca4-5879a7c0fe34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cc2b05a5-eacc-40fa-9ee3-edb7df38df49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d07dd25e-838e-46eb-b796-57384523a826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d10cbbed-ca3e-473c-ae9c-39f3c1a71274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d431e111-293a-40bd-89cf-4ae204a20ac1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d733af1e-23fc-411c-a82f-13e6af25be62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d9234fac-4296-4532-b5c8-44c5a7ab179e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dc38ef0e-2c99-4a0f-bab8-195d55c11e72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dcaa91d1-9b01-4910-b0d7-9d8ec5902432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_de601727-b928-46a5-ac54-e85f0fa3c27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_df1b1c57-47c3-4026-b445-8a31e755c7c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0707604-10e1-4c66-b961-1f5ccf14dc5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1066a6a-e09d-458e-acdd-6e64892bf012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e29bc580-c8e8-4a17-a9a1-642394e12639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e2cf0836-a57d-4015-a9af-0546d1d46c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e791417b-0181-463a-ab8a-f33a0e466058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e82bdaae-dee6-461f-b8f4-c790e6fb1c0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ec7bc9d3-76ec-4a11-8d01-81dfe77946de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed365124-41c8-4f2d-90b2-8eb22147ede5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ee90ccbb-6c06-48ca-9de4-a94e0bd95940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef44fb3b-2619-440a-8db8-260a42eaf37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0afabfb-107b-4ed2-bd84-3925d8b53326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f53811ad-a51a-40a4-8001-17b6fbbea400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f57a54f1-5233-4d73-9bd8-566ae74872e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f719cc4a-1b2f-4a9f-8aa9-a03779cd52bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f78b877b-0271-4d1a-947d-9c726f07a8bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_f7b273cd-4c72-409d-97ae-7c64008c43b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f7d224a0-d8ce-405f-8a66-7a5c7ceec004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f88ae597-74c9-41cb-8da2-ca7e310ac907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fa219022-bcdb-4c57-9659-88770a219b25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_fb99ca50-d416-41f6-891a-c4cf6cba220c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_006a226d-1684-4b7d-aef7-38226ec504b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_02b5724b-2262-4373-b315-c82a3fbab1fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_05fa6023-9251-45f1-b9a3-f304f3689065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_06cd052d-df60-42b2-bbee-bb15f02e89e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_08197314-2cfa-4bcf-ab84-5468f429d84d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_08bbabe7-2cfc-4fb4-869c-d82c58a794fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_093ed038-7ba6-4156-b45c-e468a7894554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0986cdf2-4ce0-4de3-bb22-9ebbf6a743b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="C_0e2a4e95-63a9-4653-b397-04670a792eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_108ceae3-8677-4c2a-bece-c31f8942d06e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_110c283e-33db-423a-9912-c4662332850f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_117752af-ee4a-40bc-b530-1ca28e52766e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_119abe86-5d9b-4ff1-b9ae-9decf2c2298c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_11ca0293-f87d-4136-bd9f-6c3103db98f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_12ad4aaf-5e7d-4fa1-9234-52fe93bfd5bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17084da0-52d8-4270-8220-a08b6ecfaf36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_18730f9a-a885-4097-a823-63b86ec6829b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_18f57745-d287-4eac-8622-5474e59d7035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_19638482-6283-456c-9cef-dc88ad0ab44d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_1b3ef3ae-d5cc-45c4-ae05-160ed7b1ac2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_1bcb0469-f3b0-4af9-b7bf-1fed7508ba3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_1f0242db-35be-4a94-996c-e3a0577776cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1f4d112b-20a6-4e9d-97f9-f7a1a462f430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_2152facb-460b-4ca8-8869-28dc2ee681ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2424ad23-6a69-42b1-a6e1-2f30f781a186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="C_255e918e-22cd-4e56-adc9-8e0aea00d489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:PreFundedWarrantsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_26ef2d05-ad13-40b9-b1cd-8c679a6ad1df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_28f891fe-292b-4351-a216-491a3a56cdf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29f339b8-0983-4068-aee7-ce961fb7cfc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2f4f1a74-621e-4e7e-aeb7-2562d72aa3c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2fe731eb-6df8-4233-8a24-a64517ed6900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3072375a-82e6-4b42-a83d-501afdf94d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:PreFundedWarrantsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_365cd7e2-07a9-4efd-af57-00bb25764e5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3706be79-6eca-451d-b612-a19d5eada7ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_388b46ad-84e8-4acc-b6cd-3a828d7b5577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_39770d05-317d-4e4d-a9cd-aadde8fbebc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="C_3a7401ae-87da-4602-a270-a264467fbebd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:ShanghaiJemincarePharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3ad90f5b-fa56-4503-84e3-c127661aabaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_3bb7c759-dbd3-4996-adf8-03437b940c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_46e9a44b-4010-48bc-aa78-5d77603ab178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="C_474bbfae-df71-4a9f-b05e-2f653dc760c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4dc15569-4eb9-4821-a23f-93603c6bda00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4eb091eb-a136-4c83-90f1-55a88abbc9c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_508274a6-0773-4df0-8e48-b81976e6b710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:SharesAvailableForFutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_52a5a19e-2682-4c27-890f-1cf4909b6bb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_54a69405-ede9-4232-ba03-df78ed069f51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5850ebc9-a864-4a07-a4fc-8f60c63fa87e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_60522021-60ee-4c57-928c-e5bf166e8dd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_60748a66-c7ad-493a-bbe4-e095553212e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_628c0f63-7e74-4ded-878d-c94d2ab2ac7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_63adb612-f691-4603-b16a-5c0d182d8352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6693188f-4e4f-4506-9db1-d13478fdd1b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_67fdbf90-7e52-44e3-b080-ab409b95b669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RepricedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6d1d2bf1-3fd1-4020-ae5b-151e6c3dfe1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e61294d-f16c-4cf1-97b3-5a12f717970c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6ebc3359-abcc-404b-a473-e2b68d08293c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6efad3db-74b5-461f-bbce-26e3290c27ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_70e17388-d873-445b-a20e-38ec5ac336ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7737f7f8-c088-4597-a957-a9d86cf2d767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7dfadab9-2f94-475c-bf05-4080b7f6c2de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7e94663b-2499-455a-afcd-6856ab82b16c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ed4539c-e1c4-44f1-882d-04dd7e36cd8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <unit id="U_Employees">
        <measure>rapt:Employees</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Vote">
        <measure>rapt:Vote</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Institution">
        <measure>rapt:Institution</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_de655c8d-69da-4a1b-a3af-7cf99da5ff3d">0001673772</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_7cfe9c1d-8752-4820-9e9b-980e63244ca3">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_e4a453de-31ed-4ee0-be8d-8dbbc0fd1745">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      id="F_119d5c31-574a-41b1-bb0c-c45232e3a0fb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      id="F_29c1e797-26fc-49db-8445-893357da5c44"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      id="F_f4cafdc4-5da6-43ff-95bd-69630443c804"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      id="F_60da1fb1-1699-4d6e-8077-8710d40b7a31"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_5478996a-804a-4f18-89f0-88f2679981b1">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_02b5724b-2262-4373-b315-c82a3fbab1fb"
      id="F_5b2c0381-34b5-4225-b14c-08e039f44849">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_768a7b42-ecbf-4a0f-8cfc-39dcf36d8695">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_0ba8831a-5c71-43b9-920b-b98befea66cc">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_43f99aa5-70bc-486c-84c9-29a6225bf706">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_d54cb0c5-5eb2-49fc-bdd3-dc2a6431af5b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_1dacc67f-cbaa-4484-9e98-bb22db3e7c88">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_ed00cc7e-af5c-4b51-805d-c55850a08922">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_e7dbf976-1410-4184-bd26-c6917dcbd83d">001-38997</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_ce943e60-e24e-4b8b-87ea-146b4d58affa">RAPT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_4f8faeb4-8f17-4fd1-b5f5-ed650a73bbcd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_de489393-eac0-45b8-813c-266adb1a2551">47-3313701</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_abfd0d5b-6ba0-4690-bf4c-54785a9dea5a">561 Eccles Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_5c3e896b-fb1a-4287-bbd4-6930845ac945">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_de407228-7d82-4e28-9dca-bfaca76c1870">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_9e1a83ca-3aca-4dea-b603-cba95e2aded4">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_abfc093b-ddf7-430c-a3e7-7344d21f2798">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_bed0990c-7cfa-4c42-b351-18f4785aa6ae">489-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_ebe7c0e1-798a-4e95-8225-7842bf709d07">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_d2726bdc-d200-474f-b4f3-8032969cdc9d">RAPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_8133232d-eea3-4726-9b79-a1956e437633">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_6f6831a3-ef19-4d61-8ed0-8bacfa93536a">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_da3a15f5-554f-4112-8cec-ca2931c0f74d">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_e586ead7-cf5e-41b8-9338-04ae18c251d5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_a220f39b-f5a0-4a1c-9625-43b2d58b6fc5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_196be88c-c5eb-437c-8809-3b67d6602247">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_1a98a1e7-04ab-48b4-9d1c-9ac20efb30cb">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_68b734b2-5e41-47fb-9dd2-8b1bdec486f4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_7ffdf790-0657-4746-bc8f-ac9c4fe6104e">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_f094f5a5-d9a5-43ca-9eb9-ffc62755df9b">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_0d6f8e5b-1205-4f9f-b96c-c6d975093c91">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_a1e1225b-2612-4af9-939a-2d52c9f5e2f3"
      decimals="-6"
      id="F_ebd894b0-5b8e-4d30-b3c4-b36c93d30be4"
      unitRef="U_USD">75000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_93fa0d2c-4808-4cba-b804-5817b70b6002"
      decimals="INF"
      id="F_4b2c105a-a921-4c8d-84f0-2b794f8fdebb"
      unitRef="U_shares">132006828</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_599cef7b-c543-4958-be6e-612b9720c07a">&lt;p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_6e355224-ab73-41aa-a26b-02ddb3887d9f">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, hardware, software and critical data, including intellectual property, clinical trial data, and other confidential information that is proprietary, strategic or competitive in nature (&#x201c;Information Systems and Data&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security function, led by our Director of Information Technology, helps identify, assess and manage the Company&#x2019;s cybersecurity threats and risks. Our Director of Information Technology helps to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example, monitoring provided by a third-party security operations center, deploying manual and third-party service provider automated tools in certain environments, subscribing to reports and services that identify cybersecurity threats (and analyzing such reports), conducting scans of certain environments, evaluating our industry&#x2019;s risk profile and threats reported to us, conducting internal audits and threat assessments for certain threats, conducting vulnerability assessments using third-party tools to identify vulnerabilities,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; engaging third parties to conduct threat assessments, using external intelligence feeds and monitoring the dark web.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment and system, we implement and maintain various technical, physical and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data including, for example: incident response plans and policies; vulnerability management policy; disaster recovery and business continuity plans; risk assessments; encryption of certain data; network security controls and data segregation for certain systems; access controls; physical security controls; asset management, tracking, and disposal; systems monitoring for certain systems; employee training; penetration testing of certain environments and cybersecurity insurance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our assessment and management of material risks from cybersecurity threats are taken into account as part of the Company&#x2019;s risk management processes. For example, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;our Director of Information Technology works with management to help mitigate cybersecurity threats that are more likely to lead to a material impact to our business.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers to assist us from time to time to identify, assess and manage material risks from cybersecurity threats, including for example professional services firms (including legal counsel), threat intelligence service providers, cybersecurity consultants and software providers, managed cybersecurity service providers, penetration testing firms, dark web monitoring services, forensic investigators and endpoint detection and response vendors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations, contract manufacturing organizations, distributors and supply chain resources. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, we may utilize various vendor management processes that may include reviews of security assessments or certifications and contractual measures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;If our information technology systems or those of the third parties whom we work with, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse consequences.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have a Corporate Information Security Steering Committee (&#x201c;CISSC&#x201d;), which includes several members of senior management, including the Chief Financial Officer (&#x201c;CFO&#x201d;) and General Counsel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CISSC oversees corporate information security initiatives and the Company&#x2019;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#x2019;s corporate security programs and investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#x2019;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company&#x2019;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from management concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_d292a549-b0e0-409a-b1fe-49ff251e3619">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_795c187e-2868-4d08-8c4a-365b0d42a496">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_5eaad186-f4c9-412a-9951-dac23de1df54">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_c075e99e-44ea-4441-bd3c-4346fca8808e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have a Corporate Information Security Steering Committee (&#x201c;CISSC&#x201d;), which includes several members of senior management, including the Chief Financial Officer (&#x201c;CFO&#x201d;) and General Counsel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CISSC oversees corporate information security initiatives and the Company&#x2019;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#x2019;s corporate security programs and investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#x2019;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company&#x2019;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from management concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_dff422ea-cf50-4686-b7b0-2a853fbec5b7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_16307ed2-8967-48ef-af5b-2506469d2888">&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have a Corporate Information Security Steering Committee (&#x201c;CISSC&#x201d;), which includes several members of senior management, including the Chief Financial Officer (&#x201c;CFO&#x201d;) and General Counsel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CISSC oversees corporate information security initiatives and the Company&#x2019;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#x2019;s corporate security programs and investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Hernandez is responsible for hiring appropriate personnel, helping to develop the Company&#x2019;s cybersecurity risk management strategy and communicating key priorities to relevant personnel. Mr. Hernandez is also responsible for helping prepare for cybersecurity incidents, approving cybersecurity processes and reviewing security assessments and other security-related reports. Mr. Young is responsible for approving cybersecurity-related budgets.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company&#x2019;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_9390dcbe-d67a-4bac-a1a8-03e5759257bd">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have a Corporate Information Security Steering Committee (&#x201c;CISSC&#x201d;), which includes several members of senior management, including the Chief Financial Officer (&#x201c;CFO&#x201d;) and General Counsel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CISSC oversees corporate information security initiatives and the Company&#x2019;s responses to cybersecurity incidents, and reports to the board of directors on certain of the Company&#x2019;s corporate security programs and investments.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_cfa5780d-8650-43f8-afc7-8e4fd7ab9d3b">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_8365e303-036e-4844-86b9-17eff60ee1f2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Director of Information Technology, Gio Hernandez, who has over 15 years of experience in information security. Mr. Hernandez reports to our CFO, Rodney Young, who has approximately 20 years of experience supervising the information technology function.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_07e4c2b6-f76a-4ac1-8a5c-dddf7b3e4d92">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of senior management depending on the circumstances, including our CFO and Chief Executive Officer. Senior management through the CISSC works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company&#x2019;s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_9485de9e-cc87-4890-94b6-4b528e49f639">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_a8b94fe3-a2a7-45f1-898c-998b3bdcd59f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from management concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorFirmId
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_8cc12c61-2d04-447b-a298-d2fad83e61c4">42</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_3f86c96e-0643-4e38-8b55-bbda2bf8f589">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of RAPT Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stockholders' equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_8897d51a-b699-4190-819e-8486a12b5b32">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_0d5e4488-64c4-4024-8c2c-319491e1d0a3">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_64b71b29-a35c-4987-9b4b-026d51d02a2e"
      unitRef="U_USD">169735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_e18cc0a2-fa79-4094-b137-e2e46a18dc24"
      unitRef="U_USD">47478000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_de82d0ef-ab56-45f9-9e05-ef07f048df82"
      unitRef="U_USD">61320000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_d5cc1794-4c28-44ec-8215-f9940374c607"
      unitRef="U_USD">111384000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_0f8ca948-f539-40de-9d18-d6830e0dec7f"
      unitRef="U_USD">4181000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_06d54b38-ed2b-4b85-b7dd-c040e50fff85"
      unitRef="U_USD">2920000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_d6937699-250d-4c8a-bbeb-87c96b4f0489"
      unitRef="U_USD">235236000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_4a38bdf1-b9a8-4099-9e28-3d0bdd6c27da"
      unitRef="U_USD">161782000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_6746c8e5-d82c-459a-8353-0124872fa5eb"
      unitRef="U_USD">1367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_a7afa0b3-0293-49d8-b11b-2e7a5e8c8fb6"
      unitRef="U_USD">2448000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_402e25d6-59b0-4dee-b6ee-28df42378ce8"
      unitRef="U_USD">3333000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_4077603e-dc50-4613-8fa7-7cc4005c0515"
      unitRef="U_USD">5228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_bb24991c-40e5-4a9f-8ed8-7add6121b96d"
      unitRef="U_USD">389000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_22f43ebb-9bee-41e1-b759-4693f978e9e4"
      unitRef="U_USD">3871000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_6d75e059-d66b-4878-aa70-34fa63a705b8"
      unitRef="U_USD">240325000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_64725e62-dfa0-47a7-8354-14e1936f23ad"
      unitRef="U_USD">173329000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_147b4cda-0d87-437a-9a01-750f2a72e91f"
      unitRef="U_USD">1275000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_05ad8d36-a943-40da-a1c3-05aca1658056"
      unitRef="U_USD">5176000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_8cacf1c2-6fa4-4ea6-90e1-3bb990d5f40d"
      unitRef="U_USD">9597000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_62708ea6-5bff-4247-8452-9aa2452bf8f2"
      unitRef="U_USD">14103000</us-gaap:AccruedLiabilitiesCurrent>
    <rapt:LicenseFeesPayableCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_060b9bca-22e3-4890-b9fc-64b69a99554a"
      unitRef="U_USD">35000000</rapt:LicenseFeesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_c1443eac-637b-4705-8dc5-0c823c1c4074"
      unitRef="U_USD">2422000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_4bab648c-2f91-4c3d-ac8e-2d311d2eff19"
      unitRef="U_USD">2448000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_1225de06-c312-4ca3-b85d-43eea89755d5"
      unitRef="U_USD">57000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_05a0fa9e-439f-41a8-830b-02b53cbca9ab"
      unitRef="U_USD">109000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_8649582b-1bc5-4783-9972-68a353bd345e"
      unitRef="U_USD">48351000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_a468320a-627c-4e9b-bce2-30dc66c53929"
      unitRef="U_USD">21836000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_ee449fd0-b708-4612-89e1-8983b2cbf416"
      unitRef="U_USD">2070000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_f27f2fb1-e132-447f-a879-4ccd5ef2df43"
      unitRef="U_USD">4458000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_ff2519c1-1181-4fd6-a21c-a635baaa81d4"
      unitRef="U_USD">50421000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_2d3caf73-88d3-403d-9a71-033fbc5bd434"
      unitRef="U_USD">26294000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_31ca3b57-3729-47bd-9908-83534a8679f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_eae186fa-4e50-4396-8680-dfb51982bf89"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_eaab2ad8-fa13-4116-9fd5-6483108563c4"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_bf72d60b-455f-4164-a490-eef7a33da449"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_e4447f30-b6a1-4f3a-b7c5-cd7173704253"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_804ef9d1-5686-4b53-82e9-ceeb226ca855"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_c62ff526-dfe5-47db-9163-c9479b60e54c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_a860e120-ad56-475f-939e-2cdc14178560"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_b1cedc61-0713-4a44-a60f-2ce55f0c7021"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_8c70174b-1344-46a9-817c-1e3a316e0f4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_fd0ac2e9-8da7-4ac3-991d-54a0f86ef8c7"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_b74f800d-1ab0-4303-887f-94b920db6af4"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_1792d97a-6418-4de7-b76f-1f4a306f8111"
      unitRef="U_shares">132006828</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_d819af5a-eb7a-46e9-a9c6-45d7a79ed003"
      unitRef="U_shares">132006828</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_78883bb3-5c25-46a2-bf75-f3584a57d1dc"
      unitRef="U_shares">34398312</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_bfe1bba4-3dfe-4c89-a9c3-176d61e2b98b"
      unitRef="U_shares">34398312</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_f9e94d3e-a0be-45ba-ab15-137fc7330cd2"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_6e224045-4d17-42aa-99b3-9d92a1faba95"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_070cc20a-6c85-4997-9416-2b742a09a777"
      unitRef="U_USD">804388000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_d7bde45f-01d7-40a8-9c71-58e8bb7246a5"
      unitRef="U_USD">631611000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_749af9fc-a9da-455b-8889-36455e07913e"
      unitRef="U_USD">50000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_f707fb1f-46e4-43be-ab9a-b3bb0dd90b1e"
      unitRef="U_USD">103000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_159d86f2-261e-49b4-98d1-9f46007d3c2d"
      unitRef="U_USD">-614547000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_37a4772c-3a85-4463-8ae5-5c3264b707b4"
      unitRef="U_USD">-484682000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_dab20569-cb30-4f44-b16d-1e0117ba46a2"
      unitRef="U_USD">189904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_b6b5d057-8462-45ea-96a3-27cb4d826404"
      unitRef="U_USD">147035000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_3bcc8644-3b27-47b1-9f19-1ec7131066e1"
      unitRef="U_USD">240325000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_7aa52a0f-0f19-4b5a-be49-7152a09967ac"
      unitRef="U_USD">173329000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_82a1a9b3-7aca-4fc5-8961-af85a6595055"
      unitRef="U_USD">107217000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_60558d9e-05c8-4956-8a8a-85beece514fb"
      unitRef="U_USD">101002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_fe6cd925-cf58-45a8-a95c-906b40a26d18"
      unitRef="U_USD">28884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_fb1cd388-a650-405b-9e4f-3f43c5c44197"
      unitRef="U_USD">26060000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_4e4a36c0-f498-4b86-a19a-488192161b6b"
      unitRef="U_USD">136101000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_c195cd14-46cf-41f4-a59d-b8526868daa8"
      unitRef="U_USD">127062000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_5cc3df17-e61a-4306-a60a-4233ebaec14d"
      unitRef="U_USD">-136101000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_286dc46e-2f28-4f9b-bc3b-41664fd1fdbb"
      unitRef="U_USD">-127062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_fad2bde6-3767-4ffa-aede-c5b390c652c6"
      unitRef="U_USD">6236000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_a2f8b954-8094-48b2-9bf3-506558c5168e"
      unitRef="U_USD">10264000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_e37f4237-1463-4e0e-993c-b43de3e86330"
      unitRef="U_USD">-129865000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_77a67614-a47f-4dc4-8e42-bf3c6aa56828"
      unitRef="U_USD">-116798000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_c9bfac4c-f2cb-4bab-a017-f80818505ae3"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_0b5c9dbe-ff08-46e5-a1a8-50386123ef41"
      unitRef="U_USD">-655000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_ecefb05b-5036-4396-9c0c-e7ea8f723952"
      unitRef="U_USD">-53000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_833651ba-b1d4-4c5d-92dd-2cb8b61e0eb7"
      unitRef="U_USD">784000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_50d3bb79-a3c2-40ae-b54e-6befcf4bc051"
      unitRef="U_USD">-129918000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_e5faebb1-a7ea-4bd1-b333-c7b3a23808ca"
      unitRef="U_USD">-116669000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="2"
      id="F_c37bd809-f96c-4db9-929c-1c2c6bd1e5a6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="2"
      id="F_415f983d-0134-4d72-9054-17cfabe5f23a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.19</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="2"
      id="F_485d61b7-f463-4787-8850-a02f33aa3833"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="2"
      id="F_698beb3e-9a11-4bfe-a4f4-ffc3034991a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_355fd057-e71c-4c84-be30-03ec79f7fbe6"
      unitRef="U_shares">40761143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_6120a431-d426-478b-8708-2fa6beac533a"
      unitRef="U_shares">40761143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="0"
      id="F_d8f5738e-9258-43eb-a2f6-ba29c7867f34"
      unitRef="U_shares">38338161</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="0"
      id="F_34105604-43f9-4eea-8794-7fcc9eda71f8"
      unitRef="U_shares">38338161</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_df1b1c57-47c3-4026-b445-8a31e755c7c5"
      decimals="INF"
      id="F_28b4cf0a-1ae0-4ff8-9c9c-956ddefa5034"
      unitRef="U_shares">34254314</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_df1b1c57-47c3-4026-b445-8a31e755c7c5"
      decimals="-3"
      id="F_c444e659-2896-4280-9f1c-1e81ca2cc9da"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5850ebc9-a864-4a07-a4fc-8f60c63fa87e"
      decimals="-3"
      id="F_ffeb7171-f05b-4f2b-9ce3-54e13e42e7ed"
      unitRef="U_USD">613073000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3706be79-6eca-451d-b612-a19d5eada7ce"
      decimals="-3"
      id="F_bc74ad00-9ee1-4d0c-b0e4-723172d5c298"
      unitRef="U_USD">-367884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ba2021a0-4327-4bd0-aac5-d66d26d8d350"
      decimals="-3"
      id="F_82c245d2-651e-48aa-99bc-7ccf9976e604"
      unitRef="U_USD">-26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_80a183b9-14ce-4b94-97fa-8410f324fd16"
      decimals="-3"
      id="F_ad88a1c0-6a35-4de9-ad25-47105cedb6f6"
      unitRef="U_USD">245166000</us-gaap:StockholdersEquity>
    <rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans
      contextRef="C_e1066a6a-e09d-458e-acdd-6e64892bf012"
      decimals="INF"
      id="F_006e76ed-45fa-475e-9876-17f1e44a2d48"
      unitRef="U_shares">143998</rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_06cd052d-df60-42b2-bbee-bb15f02e89e9"
      decimals="-3"
      id="F_beb3f4d9-7d8e-4428-b167-877d8c78cde3"
      unitRef="U_USD">1447000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_a99fec52-e3b5-4a3d-bab6-ea1937a2835e"
      unitRef="U_USD">1447000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_06cd052d-df60-42b2-bbee-bb15f02e89e9"
      decimals="-3"
      id="F_5b8eb995-92aa-4755-adcc-3bbd68efecb8"
      unitRef="U_USD">17091000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_b67228b0-225d-47b3-a1ba-6743d064aed5"
      unitRef="U_USD">17091000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_70e17388-d873-445b-a20e-38ec5ac336ff"
      decimals="-3"
      id="F_03bc2916-1804-4095-a83c-3ec526007913"
      unitRef="U_USD">-655000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_72d11c2c-0d85-4e71-9532-e912a824d5a1"
      unitRef="U_USD">-655000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_70e17388-d873-445b-a20e-38ec5ac336ff"
      decimals="-3"
      id="F_37c616f6-13b9-45a5-a516-98aeaf1a305f"
      unitRef="U_USD">784000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_f898de3f-ab36-45da-88b4-3f85df04fffb"
      unitRef="U_USD">784000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_b4b55243-d136-47d3-a127-156fda882df4"
      decimals="-3"
      id="F_6f289475-78b6-4ca0-9505-bf16abcc83a8"
      unitRef="U_USD">-116798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_56e9d299-cbda-4c13-b6ed-6aa2939600e6"
      unitRef="U_USD">-116798000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f0afabfb-107b-4ed2-bd84-3925d8b53326"
      decimals="INF"
      id="F_20d0fed4-f5f1-4acb-8303-e9901f18744a"
      unitRef="U_shares">34398312</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f0afabfb-107b-4ed2-bd84-3925d8b53326"
      decimals="-3"
      id="F_d44352b2-9202-40d8-b852-9ddb0d1e1a6a"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_12ad4aaf-5e7d-4fa1-9234-52fe93bfd5bf"
      decimals="-3"
      id="F_6114e7a3-08a7-4aad-8f94-a553d010e6e4"
      unitRef="U_USD">631611000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d07dd25e-838e-46eb-b796-57384523a826"
      decimals="-3"
      id="F_674125de-e6e3-41df-b92b-b1641f362357"
      unitRef="U_USD">-484682000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_006a226d-1684-4b7d-aef7-38226ec504b9"
      decimals="-3"
      id="F_72894586-758b-4f23-81d8-72bf78040733"
      unitRef="U_USD">103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_d7883894-ba25-4701-889e-d2d76e52e847"
      unitRef="U_USD">147035000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_08042118-b41f-42b7-bca8-2d6284afe924"
      unitRef="U_USD">6900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <rapt:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement
      contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352"
      decimals="INF"
      id="F_485b4328-f44b-4f36-8fed-d6b9a83a67b1"
      unitRef="U_shares">100000000</rapt:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInPrivatePlacement>
    <rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement
      contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352"
      decimals="-3"
      id="F_4817baf3-410e-44ca-994d-78f6d231ee6b"
      unitRef="U_USD">10000</rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement>
    <rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement
      contextRef="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71"
      decimals="-3"
      id="F_e7b96aed-5b4b-479f-bd69-488996dc6e0a"
      unitRef="U_USD">143040000</rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement>
    <rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_1d469980-9f6c-46d6-99dd-021dc5ac829e"
      unitRef="U_USD">143050000</rapt:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInPrivatePlacement>
    <rapt:ExchangeOfCommonStockForPre-FundedWarrants
      contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352"
      decimals="INF"
      id="F_09efd63e-c6e6-499a-b10f-465c938d1a56"
      unitRef="U_shares">2951425</rapt:ExchangeOfCommonStockForPre-FundedWarrants>
    <rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans
      contextRef="C_63adb612-f691-4603-b16a-5c0d182d8352"
      decimals="INF"
      id="F_6b30cb09-abac-4835-bd23-8a01c106dd4b"
      unitRef="U_shares">194625</rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71"
      decimals="-3"
      id="F_5835f398-908e-4564-a096-cc1e94282f22"
      unitRef="U_USD">845000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_fa755884-fe52-4d7a-a898-05409b8cab74"
      unitRef="U_USD">845000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_093ed038-7ba6-4156-b45c-e468a7894554"
      decimals="INF"
      id="F_5c410012-f8a3-436e-bda4-56730ee36aa8"
      unitRef="U_shares">365316</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_117752af-ee4a-40bc-b530-1ca28e52766e"
      decimals="-3"
      id="F_6b7246a6-3258-4787-94ec-053ce12258e7"
      unitRef="U_USD">8957000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_29f339b8-0983-4068-aee7-ce961fb7cfc0"
      decimals="-3"
      id="F_2cc3eacf-c55c-4bbf-8577-e84c36004ef3"
      unitRef="U_USD">8957000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_cc27f14a-3801-4c02-bbc0-81e2fd908a71"
      decimals="-3"
      id="F_71896824-efbc-4ec8-b3d1-156dafd140f0"
      unitRef="U_USD">19935000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_22be34d5-70d8-49e6-a4ec-99077e6eb35d"
      unitRef="U_USD">19935000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_f7b273cd-4c72-409d-97ae-7c64008c43b9"
      decimals="-3"
      id="F_02613f40-3c2c-4824-a0fa-ee59cfb41b7f"
      unitRef="U_USD">-53000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_3922c22d-b9d6-4719-acf4-2f1d687a9ed7"
      unitRef="U_USD">-53000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_f88ae597-74c9-41cb-8da2-ca7e310ac907"
      decimals="-3"
      id="F_9ce5db00-c47d-43dc-a591-7b8f7ecc5fd6"
      unitRef="U_USD">-129865000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_7de7b15f-9092-4500-b094-689a0b68e689"
      unitRef="U_USD">-129865000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221"
      decimals="INF"
      id="F_0a1e3693-c63d-403b-a652-46285dc8c5ee"
      unitRef="U_shares">132006828</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221"
      decimals="-3"
      id="F_66cded7b-56db-4869-8890-2709242d297a"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d733af1e-23fc-411c-a82f-13e6af25be62"
      decimals="-3"
      id="F_7234d1a1-e263-4716-b1ff-7c2f16d6fbfb"
      unitRef="U_USD">804388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9001335a-7425-4825-a5e8-855ff463d619"
      decimals="-3"
      id="F_c500e2f0-2810-4209-9ee7-c4043df3ea35"
      unitRef="U_USD">-614547000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_05fa6023-9251-45f1-b9a3-f304f3689065"
      decimals="-3"
      id="F_ae4278d7-3b1a-4b96-b8e9-0fc5491bd630"
      unitRef="U_USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_b2d3669f-3072-4a70-83f6-ecc78752394a"
      unitRef="U_USD">189904000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_b9a76ad3-a496-4d2a-b3d3-ea3424cf6dca"
      unitRef="U_USD">-129865000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_61dcb757-9f24-41c9-adb7-223fec2be4e2"
      unitRef="U_USD">-116798000</us-gaap:ProfitLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_6b321a11-d8fb-4528-ac77-8d4d9838cd85"
      unitRef="U_USD">2813000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_41e7e437-a5c9-48de-9be0-9c3612b081a9"
      unitRef="U_USD">5736000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_28acb738-a18e-4f35-82bf-2a13916f5cc3"
      unitRef="U_USD">1203000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_1c319e1a-02dd-48c2-aab2-209b2d8e5b64"
      unitRef="U_USD">1216000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_a8fcd71c-477c-40b9-b793-0ea169c1826b"
      unitRef="U_USD">19935000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_24e46838-f313-446f-923c-2a4a7584465c"
      unitRef="U_USD">17091000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_86d436e5-f459-427a-a61b-607c1cd2163e"
      unitRef="U_USD">-0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_18b7597a-2bec-4b2d-96ff-f28eb73dd9a6"
      unitRef="U_USD">655000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <rapt:NonCashOperatingLeaseExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_e53a57f1-d048-4889-a0f6-97851f58f659"
      unitRef="U_USD">2336000</rapt:NonCashOperatingLeaseExpense>
    <rapt:NonCashOperatingLeaseExpense
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_387f56a7-6fe3-4c32-ad67-530249b0896b"
      unitRef="U_USD">2335000</rapt:NonCashOperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_a0a5519e-622f-4c1c-a609-abb6b349a6a9"
      unitRef="U_USD">-2221000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_97b2c55c-9f4f-4a5c-ae34-84951ffa2da1"
      unitRef="U_USD">-871000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_d01bb6f8-b8d8-4340-bd98-ab7bf7fb4c24"
      unitRef="U_USD">-8459000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_cf29b508-6208-4e85-93e9-3288122a7041"
      unitRef="U_USD">7335000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <rapt:IncreaseDecreaseInLicenseFeesPayable
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_da9950c9-4ead-4fd6-81ac-5a631c486860"
      unitRef="U_USD">35000000</rapt:IncreaseDecreaseInLicenseFeesPayable>
    <rapt:IncreaseDecreaseInLicenseFeesPayable
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_0a7c0a0c-02c7-4a8e-9ce8-4ddd001e5331"
      unitRef="U_USD">0</rapt:IncreaseDecreaseInLicenseFeesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_60f5a073-944d-46d4-99b1-571e550350dd"
      unitRef="U_USD">-2855000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_1fa0cb77-6542-4eca-b1ea-7aa6e0f4a0ca"
      unitRef="U_USD">-2707000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_59e31d7a-1fdb-43c4-a264-402d8234de74"
      unitRef="U_USD">-83297000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_cfadf49b-a3ce-4aab-922d-44e007fa9203"
      unitRef="U_USD">-97048000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_082a6c16-c863-470b-833e-841c244e6453"
      unitRef="U_USD">82218000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_443b021d-1f8e-42cf-beb0-e9afea61b4c2"
      unitRef="U_USD">161497000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_c9c1972f-7e37-400e-9543-cf2dd92c4535"
      unitRef="U_USD">135042000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_8726a782-08ac-46e2-9757-67bf2fcd5763"
      unitRef="U_USD">266755000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_11c6a184-ff3a-4efc-93a6-f2533f9e21c4"
      unitRef="U_USD">122000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_96b956fd-5c5c-4a2c-8a05-c7fd619cdbe9"
      unitRef="U_USD">1125000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_e99f7663-66df-45fc-ae89-fa9b42edf960"
      unitRef="U_USD">52702000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_9021a2ec-1a04-4843-9447-5ea730145d47"
      unitRef="U_USD">104133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_1bb3116d-56b5-4cee-af2c-2393fb0a0425"
      unitRef="U_USD">143050000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_52849f8e-e9cf-4448-8f15-777ad2c4ea16"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_68d0026b-615a-4428-82c4-93015f1fdf34"
      unitRef="U_USD">8957000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_eadd13a9-facf-4420-bf08-a0c634d73612"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_8e8beeb4-75be-455a-a52b-7b85b5cdbcc9"
      unitRef="U_USD">845000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_76bc8449-f6c0-41f2-81e0-fae18fdc78da"
      unitRef="U_USD">1447000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_f2c82184-6b31-445c-bd0a-41160b08e517"
      unitRef="U_USD">152852000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_5318642c-c047-4eaa-95c5-05ea875727f8"
      unitRef="U_USD">1447000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_29933eed-8426-45da-9232-bed3252a7f2d"
      unitRef="U_USD">122257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_64bd43af-063d-4258-a855-133059d3e93f"
      unitRef="U_USD">8532000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_a0228210-23f4-4878-85c3-1a0fd35bd224"
      unitRef="U_USD">47478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_80a183b9-14ce-4b94-97fa-8410f324fd16"
      decimals="-3"
      id="F_a01456e6-c38e-4f6d-b7e8-d8253801a18b"
      unitRef="U_USD">38946000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_be3307c9-94e6-4f58-97f8-8c651f1fcb56"
      unitRef="U_USD">169735000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_87a82958-137e-4373-80f2-1ff72c22cd30"
      unitRef="U_USD">47478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_09e2281f-e314-491b-a490-013db93b783f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of the Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RAPT Therapeutics, Inc. (&#x201c;RAPT&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. The Company's lead drug candidate, RPT904, is a half-life extended monoclonal antibody designed to bind free human immunoglobulin E (&#x201c;IgE&#x201d;), a key driver of several allergic diseases. The Company&#x2019;s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (&#x201c;CCR4&#x201d;) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the Company ceased development of zelnecirnon, its small molecule CCR4 antagonist for inflammatory disease. The Company is currently pursuing different novel CCR4 antagonists, which it believes may have improved safety margins. The Company is located in South San Francisco, California.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Management Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2024, the Company incurred a net loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and used $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash in operations. At December 31, 2024, the Company had cash and cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and working capital of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July, 2024, the Company's board of directors approved a reduction of the Company's workforce to conserve cash resources. The workforce reduction impacted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; people, or approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's headcount. All employees affected by the workforce reduction were eligible to receive, among other things, severance payments and paid COBRA premiums for a specified time period post-termination. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. The Company completed the workforce reduction and all cash payments related to the restructuring during the year ended December 31, 2024. As of December 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued expenses associated with this workforce reduction.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#x2019;s current cash and cash equivalents and marketable securities will provide sufficient funds to enable the Company to meet its obligations for at least 12 months from the filing date of this Annual Report on Form 10-K. The Company&#x2019;s evaluation was based on the facts known as of the date of filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_31c65794-2187-49a1-9a31-b1a9591469a4"
      unitRef="U_USD">-129900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_d73df01c-57aa-499b-82c8-486e053477c6"
      unitRef="U_USD">-83300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-5"
      id="F_ba9145fd-fe86-4347-8953-745bd04f1bdc"
      unitRef="U_USD">231100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <rapt:WorkingCapital
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-5"
      id="F_1c533be0-11f3-492b-a922-a7c53de2ad18"
      unitRef="U_USD">186900000</rapt:WorkingCapital>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e"
      decimals="INF"
      id="F_91e7c505-5958-4bcb-ba9b-17c275fd1694"
      unitRef="U_Employees">47</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e"
      decimals="2"
      id="F_99472a91-32de-406f-ba40-1719c2dd8f90"
      unitRef="U_pure">0.40</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="C_246a1b3a-dae9-4f96-aeb9-f4af8f741a8e"
      decimals="-5"
      id="F_d270fcbb-6512-4d68-b7db-a7a0931d9623"
      unitRef="U_USD">900000</us-gaap:SeveranceCosts1>
    <rapt:AccruedExpensesRelatedToWorkforceReductionPlan
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_b73817d1-e7b9-46c5-8a6d-fa02e42b735f"
      unitRef="U_USD">0</rapt:AccruedExpensesRelatedToWorkforceReductionPlan>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_5f2902d8-e036-49bc-b532-b0fa75fd4ea3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the accounts of the Company. The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) until December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5478996a-804a-4f18-89f0-88f2679981b1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Brian Wong, M.D., Ph.D. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM assesses performance for the Company&#x2019;s operating segment and decides how to allocate resources based on the Company&#x2019;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of December 31, 2024 and 2023, all of the Company&#x2019;s property and equipment was maintained in the U.S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities primarily consist of commercial paper, corporate debt securities and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All of the Company's available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, the Company determines if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#x2019;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. If the impairment is a result of a credit-related loss, the Company recognizes an allowance for credit losses. If the impairment is not a result of a credit loss, the Company recognizes the loss in other comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5b2c0381-34b5-4225-b14c-08e039f44849;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record any impairment losses on long-lived assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. Amounts incurred in connection with license agreements, such as upfront license and milestone fees are also included in research and development expense. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines employee, non-employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company retrospectively &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ASU 2023-07 on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and will adopt it for its interim reporting starting with the quarter ending March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The adoption of ASU 2023-07 did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 requires disaggregated disclosures of certain categories of expenses in the notes to the financial statements that are included in expense line items on the face of the income statement in annual and interim periods. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on its financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this standard on the income tax disclosures within the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_cdc5a2cc-31f5-47d7-a600-fffdb37d344f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the accounts of the Company. The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) until December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_de2b2f26-2805-4b71-abc6-fb7fc096ed14">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_ee524c2f-de63-46d5-aa9f-7c45fe9dd2a2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <rapt:NumberOfFinancialInstitution
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_7b34932f-aca3-4e62-904c-7b91558c69dc"
      unitRef="U_Institution">2</rapt:NumberOfFinancialInstitution>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_0a789f07-6fa2-40f4-91c7-24c8a9dc8a6a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5478996a-804a-4f18-89f0-88f2679981b1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Brian Wong, M.D., Ph.D. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM assesses performance for the Company&#x2019;s operating segment and decides how to allocate resources based on the Company&#x2019;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of December 31, 2024 and 2023, all of the Company&#x2019;s property and equipment was maintained in the U.S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_490be401-b098-4c84-a148-82c7ca35e25c">The CODM assesses performance for the Company&#x2019;s operating segment and decides how to allocate resources based on the Company&#x2019;s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_93efbb92-380d-40f6-bc8b-090445669e41">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_c12093bb-d12c-428a-b310-b520a9cf6ad8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_701effce-51f6-46e0-bdbf-9f8fc6ab5a8c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities primarily consist of commercial paper, corporate debt securities and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All of the Company's available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, the Company determines if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#x2019;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. If the impairment is a result of a credit-related loss, the Company recognizes an allowance for credit losses. If the impairment is not a result of a credit loss, the Company recognizes the loss in other comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_35becc42-3808-4ecd-9e2e-f25fc644876e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5b2c0381-34b5-4225-b14c-08e039f44849;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_fb99ca50-d416-41f6-891a-c4cf6cba220c"
      id="F_a833d09d-1dc8-4e94-a251-57a7a71028fa">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_888efa48-92e2-4275-82a3-82859019fc93">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record any impairment losses on long-lived assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="INF"
      id="F_0b8a00c2-ec08-4d98-85f0-cc3585c9753e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_77026660-110a-4450-a49e-934c82e7a26e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_31616198-072d-41e9-b35c-5b00bb509b44">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_a7794f3f-669b-44e1-82e0-58ed60cadf50">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. Amounts incurred in connection with license agreements, such as upfront license and milestone fees are also included in research and development expense. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_546a9b82-28c0-443d-b2d8-a3cf1587d8fd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines employee, non-employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_f38db42c-eb13-445d-80f0-0153549b3b37">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_071a3128-3345-46d0-a33a-3fe3977b5fd5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_e7963dc3-1437-4dbc-8a6a-0b164ce49256">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_99ebdbc2-9c08-4058-8066-cdb1a8ef82eb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_a7ebf2f4-085c-4498-a887-4d0a2e5598e5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company retrospectively &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ASU 2023-07 on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and will adopt it for its interim reporting starting with the quarter ending March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The adoption of ASU 2023-07 did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 requires disaggregated disclosures of certain categories of expenses in the notes to the financial statements that are included in expense line items on the face of the income statement in annual and interim periods. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on its financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this standard on the income tax disclosures within the financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_a7ae680f-040b-4295-a0e6-b8be8d744edf"
      id="F_c596937a-5a74-49b4-b59e-b92653a4c29d">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_a7ae680f-040b-4295-a0e6-b8be8d744edf"
      id="F_c751aa81-0a17-4348-b7a6-ea1174a02438">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_a7ae680f-040b-4295-a0e6-b8be8d744edf"
      id="F_0aa67c15-f673-492f-87e0-06f9e4e968cc">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_996046ea-d753-40e4-924b-c079544b0530">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts payable and accrued expenses that approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair values of investments in corporate debt securities, commercial paper and U.S. government agency securities using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.582%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;230,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;230,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.582%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the unrealized losses on the Company&#x2019;s securities that were in an unrealized loss position were caused by interest rate changes and were not attributable to credit losses. The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record an allowance for credit losses or other impairment charges related to its marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.548%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.159%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:33.293%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_6b8b4898-b476-4544-beae-05abe128cbe1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.582%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;230,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;230,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.582%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.382%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7e94663b-2499-455a-afcd-6856ab82b16c"
      decimals="-3"
      id="F_a8549bd0-8117-4451-81b2-33655e0cf43a"
      unitRef="U_USD">152776000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7e94663b-2499-455a-afcd-6856ab82b16c"
      decimals="-3"
      id="F_8d3efc8e-c341-491e-b809-6ddb5c58b968"
      unitRef="U_USD">152776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb"
      decimals="-3"
      id="F_4d688794-7dce-4ec6-bed3-f6033a1fddb2"
      unitRef="U_USD">17772000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb"
      decimals="-3"
      id="F_2075ea1a-899f-4c52-b35a-6eca2d500dac"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb"
      decimals="-3"
      id="F_70c5cedf-d2f6-469a-996d-e231337da090"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6b8c37a7-da1a-490c-87ab-503aa7d46dfb"
      decimals="-3"
      id="F_0ad5871e-e655-468c-b660-92e37c3a6a18"
      unitRef="U_USD">17790000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9"
      decimals="-3"
      id="F_ffe4630b-495b-4377-8c1e-b9b2e3b34fe5"
      unitRef="U_USD">3820000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9"
      decimals="-3"
      id="F_1dd32f14-aaf0-46b7-9515-2282eec73c81"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b1e43f27-c53b-4f07-b192-40e7ddc96de9"
      decimals="-3"
      id="F_e224a728-22f4-45ca-a2e2-5f486ef15b70"
      unitRef="U_USD">3825000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8a36a6b4-2ad5-4767-8ac9-f1a57de88015"
      decimals="-3"
      id="F_d8037295-e1c4-4ce0-a079-4fdd68643f4d"
      unitRef="U_USD">16795000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8a36a6b4-2ad5-4767-8ac9-f1a57de88015"
      decimals="-3"
      id="F_2286c437-1676-4899-9ee7-6678e84d8b6e"
      unitRef="U_USD">16795000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0e2a4e95-63a9-4653-b397-04670a792eda"
      decimals="-3"
      id="F_d5afed3f-3d52-485a-98fc-542342dacf7f"
      unitRef="U_USD">39743000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0e2a4e95-63a9-4653-b397-04670a792eda"
      decimals="-3"
      id="F_ec63ba92-5687-46fb-a866-0b6c6353df48"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0e2a4e95-63a9-4653-b397-04670a792eda"
      decimals="-3"
      id="F_c208db33-01b7-49dc-a196-b726f805e78b"
      unitRef="U_USD">39770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_04c63f6a-cab3-444f-a4ca-1583726c8b29"
      unitRef="U_USD">230906000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_d60a9168-9126-4ec2-a3ae-aefa6e7c7f80"
      unitRef="U_USD">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_f4ee843c-10c9-4758-9662-0a366ff1faca"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_ef351a5d-9355-4787-8ea6-f68d5208c5f7"
      unitRef="U_USD">230956000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_f42e460f-1b25-4581-9f36-08e45ff189fe"
      unitRef="U_USD">169636000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_93e6ab76-e7f4-436d-8194-365454057df6"
      unitRef="U_USD">169636000</us-gaap:CashEquivalentsAtCarryingValue>
    <rapt:MarketableSecuritiesAtAmortizedCost
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_de04dd02-4d9f-4a79-b492-c0bcfe44de80"
      unitRef="U_USD">61270000</rapt:MarketableSecuritiesAtAmortizedCost>
    <rapt:MarketableSecuritiesAtUnrealizedGains
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_898acb52-0c10-4978-870c-2fb89d66615e"
      unitRef="U_USD">53000</rapt:MarketableSecuritiesAtUnrealizedGains>
    <rapt:MarketableSecuritiesAtUnrealizedLosses
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_2404e6af-d0de-4044-a054-f975567212c9"
      unitRef="U_USD">3000</rapt:MarketableSecuritiesAtUnrealizedLosses>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_62e2bb26-2896-42a2-9341-7859bdf6d22d"
      unitRef="U_USD">61320000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9abc0e8c-51a8-434c-a1d1-15cb685a695f"
      decimals="-3"
      id="F_c009c1ca-2ffa-4647-99ac-0da1c4c20a82"
      unitRef="U_USD">10869000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9abc0e8c-51a8-434c-a1d1-15cb685a695f"
      decimals="-3"
      id="F_7cc589bb-f78a-46ad-bb69-da2aaf7b234e"
      unitRef="U_USD">10869000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1"
      decimals="-3"
      id="F_3a9b2b16-a282-4dc9-a935-9aa29d2eac84"
      unitRef="U_USD">19531000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1"
      decimals="-3"
      id="F_b14750b7-a44d-47b5-935f-99f78fd22aae"
      unitRef="U_USD">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1"
      decimals="-3"
      id="F_47b0da59-9bea-4303-b723-83227ce49afa"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d431e111-293a-40bd-89cf-4ae204a20ac1"
      decimals="-3"
      id="F_47a4fdcd-3250-4cc6-85c7-e9de05585a08"
      unitRef="U_USD">19559000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8"
      decimals="-3"
      id="F_1226c244-9be9-4aa9-a7a6-e9e1bca664a2"
      unitRef="U_USD">5242000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8"
      decimals="-3"
      id="F_fd80bdbe-512c-4e27-8573-484e6716ebe7"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8"
      decimals="-3"
      id="F_b6de324c-d924-4783-b917-45bd2de4d005"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7ceac04c-89a5-470b-9d55-4330e9ab8cf8"
      decimals="-3"
      id="F_4bda3aea-287e-4a95-b418-19faecae21da"
      unitRef="U_USD">5245000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8"
      decimals="-3"
      id="F_1ca3dab3-4d80-49c8-a2ca-aeff696a0fe6"
      unitRef="U_USD">59828000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8"
      decimals="-3"
      id="F_b4a02ba9-f259-4ecd-8153-bc62cee215cc"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8"
      decimals="-3"
      id="F_2b188f35-6471-4955-873f-d6c2d3b8bed4"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_60748a66-c7ad-493a-bbe4-e095553212e8"
      decimals="-3"
      id="F_6a237852-186f-4f2c-82c6-67a94ee183c5"
      unitRef="U_USD">59827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011"
      decimals="-3"
      id="F_6c40d687-e875-448a-af61-e0e1374b1ed6"
      unitRef="U_USD">63206000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011"
      decimals="-3"
      id="F_4f5ba670-2377-456f-b685-dfaca11a97dc"
      unitRef="U_USD">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011"
      decimals="-3"
      id="F_064c13e8-9c9e-4b23-be3f-76c7f2a1ea79"
      unitRef="U_USD">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9c057a0a-17df-45f9-91b4-8f1e07cd6011"
      decimals="-3"
      id="F_5588ed2d-54a4-4b7b-8fae-5b4bf7403c00"
      unitRef="U_USD">63279000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_dd138a2d-7304-47ac-8113-638e023a65b6"
      unitRef="U_USD">158676000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_297ac28e-753b-428b-bcb9-f19e5df05dd4"
      unitRef="U_USD">142000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_cdf5e0a4-8be5-4968-92bd-9320c3fd8289"
      unitRef="U_USD">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_8636980c-ae72-45c6-a408-86f52f378edf"
      unitRef="U_USD">158779000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_3c304476-3e9c-478c-ad7f-0ab4a638fc3a"
      unitRef="U_USD">47395000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_c8a1c196-2cd7-4ca5-a7fb-40f7562f3325"
      unitRef="U_USD">47395000</us-gaap:CashEquivalentsAtCarryingValue>
    <rapt:MarketableSecuritiesAtAmortizedCost
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_8c6de256-69d8-4aa9-8f24-826da86a2e23"
      unitRef="U_USD">111281000</rapt:MarketableSecuritiesAtAmortizedCost>
    <rapt:MarketableSecuritiesAtUnrealizedGains
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_4dd9bbfe-e20b-4ee0-a065-7b67196478fa"
      unitRef="U_USD">142000</rapt:MarketableSecuritiesAtUnrealizedGains>
    <rapt:MarketableSecuritiesAtUnrealizedLosses
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_bc7e935e-1f00-426c-9e59-cd9e75aabf15"
      unitRef="U_USD">39000</rapt:MarketableSecuritiesAtUnrealizedLosses>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_3b182c3b-caac-4994-85ce-9bbb0277a6e5"
      unitRef="U_USD">111384000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_a546329d-319b-43be-8ebb-eb94d6807c1b"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_fffa39ee-fc57-493d-b51f-e48bf0bcd22e"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_e22b6a90-d740-422f-936c-e5364f6751cf">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.548%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.159%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:33.293%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_eda2e2b3-b1cb-4383-afe1-7d80efd49127"
      unitRef="U_USD">61320000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_72eeb297-ae12-4bb9-bfc5-20bca22afd10"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_6b6caa55-ae99-4cfd-8c17-f3e075f8234d"
      unitRef="U_USD">61320000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_11a08204-139c-4f48-9663-1d7284897fc7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expenses were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_ae54f747-5313-456c-9a55-0a5c8304803b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6efad3db-74b5-461f-bbce-26e3290c27ef"
      decimals="-3"
      id="F_d0792c15-0c88-41be-bb80-47129a7db6c1"
      unitRef="U_USD">7035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_08197314-2cfa-4bcf-ab84-5468f429d84d"
      decimals="-3"
      id="F_d883e4e6-010e-4ab8-af2b-e97f5ec792f3"
      unitRef="U_USD">7399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cc2ab253-a7db-4cd8-aca4-5879a7c0fe34"
      decimals="-3"
      id="F_bcdf2d54-68db-4fa0-a71e-b3a666b2cbf5"
      unitRef="U_USD">3295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f53811ad-a51a-40a4-8001-17b6fbbea400"
      decimals="-3"
      id="F_73d1032f-6efa-4053-8e0b-db72ab1d2473"
      unitRef="U_USD">3295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bc3a237f-db8c-4eb6-ad25-be4c30946b6b"
      decimals="-3"
      id="F_02c4981c-ae9d-4d3e-b975-766d0ee0664d"
      unitRef="U_USD">706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ee90ccbb-6c06-48ca-9de4-a94e0bd95940"
      decimals="-3"
      id="F_a3b4eebe-ba86-47ed-9afb-8fdc4729969e"
      unitRef="U_USD">727000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8234c17c-ee4d-4a80-9c05-28fda21083ac"
      decimals="-3"
      id="F_945d82ef-78b4-4985-8f49-701fa7fee611"
      unitRef="U_USD">411000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7737f7f8-c088-4597-a957-a9d86cf2d767"
      decimals="-3"
      id="F_b8b3f035-81f1-4eee-8a25-bb0302b9efd2"
      unitRef="U_USD">394000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_2bec815c-45f2-42db-a696-e536c8a94b67"
      unitRef="U_USD">11448000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_b4fa7f0c-3eb5-4f63-8737-e55b29f5847e"
      unitRef="U_USD">11815000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_fac805f0-c2d9-4aef-91a1-9cc7a11d7848"
      unitRef="U_USD">10081000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_10219bc6-8859-408b-bef9-01721631a7c8"
      unitRef="U_USD">9367000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_26de2ba1-18e2-4ddb-aee0-828e9fe139d4"
      unitRef="U_USD">1367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_b6f39bd3-9616-48e5-bdb6-3ff3186cc8d5"
      unitRef="U_USD">2448000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_15efb393-fe3a-4645-bc3b-3027f420ba21"
      unitRef="U_USD">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_c03aa555-0604-485d-92ed-0a76ea1c69ec"
      unitRef="U_USD">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_82ecb3ad-dbd2-4593-82c6-b0dfed83b25e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_37ee3105-3836-4d66-b4e3-e72b2f5bfbca">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <rapt:AccruedResearchAndDevelopmentExpenses
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_aef7cda8-15e2-4945-bc99-30038d482c1f"
      unitRef="U_USD">1239000</rapt:AccruedResearchAndDevelopmentExpenses>
    <rapt:AccruedResearchAndDevelopmentExpenses
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_006e3a21-6043-44c8-9dc6-10b354a7b850"
      unitRef="U_USD">7281000</rapt:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_0ee99e10-4903-4150-b199-af922da1622f"
      unitRef="U_USD">6723000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_994e7b6f-53d9-42af-949b-60e376ac8177"
      unitRef="U_USD">6303000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_b782b47a-eae0-4f62-af32-e7381f8cc1b2"
      unitRef="U_USD">1493000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_00a90cc3-cc42-49dd-8e7e-68b42d418e6a"
      unitRef="U_USD">341000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_dd92aa28-5db8-4271-9f7c-4750f3d06841"
      unitRef="U_USD">142000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_ee59a169-2af9-4b31-873d-034fb0a477c1"
      unitRef="U_USD">178000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_cd15e937-1677-4eb1-abb6-b63e1f5ffbb1"
      unitRef="U_USD">9597000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_e8be849e-f4fa-4b29-99b1-1e29f7b0fa9b"
      unitRef="U_USD">14103000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_61359cf1-b463-4cb6-9b58-01928262cfe0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; contingency losses were accrued at either &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2015, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,376&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of laboratory and office facilities in South San Francisco, California. In April 2018, the Company amended the lease agreement to include an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,378&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of laboratory and office space increasing the total leased premises to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,754&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet. The lease amendment extended the lease term to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and contained scheduled rent increases over the lease term and an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option for the Company to extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2022, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,232&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office facilities in South San Francisco, California, which expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The lease agreement contained an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and was included in net cash used in operating activities in the Company&#x2019;s statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the weighted-average remaining lease term and discount rate for the Company&#x2019;s operating leases was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes maturities of operating lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.856%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.703000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the supplemental balance sheet information related to operating leases at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.447%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For each of the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of lease expense included in operating expenses in the statement of operations in relation to operating leases. Variable lease expense was insignificant for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Rent expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively. The Company does not have any financing lease agreements as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_2a1ab948-caef-4af9-aeeb-603b101bdc8d"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="INF"
      id="F_f59c0346-3a22-4b0b-a3db-09d88bb387d6"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualPayments>
    <rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_0986cdf2-4ce0-4de3-bb22-9ebbf6a743b8"
      decimals="INF"
      id="F_8b401be7-fa56-4a2c-b506-a4c1337c1a14"
      unitRef="U_sqft">30376</rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_1b3ef3ae-d5cc-45c4-ae05-160ed7b1ac2f"
      decimals="INF"
      id="F_3dc0ead5-9e07-452d-98c0-abcd9022beeb"
      unitRef="U_sqft">6378</rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:IncreasedAreaOfLeasedPremises
      contextRef="C_1b3ef3ae-d5cc-45c4-ae05-160ed7b1ac2f"
      decimals="INF"
      id="F_858bed4c-4f0e-457c-81c7-9fc6358922b1"
      unitRef="U_sqft">36754</rapt:IncreasedAreaOfLeasedPremises>
    <rapt:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_19638482-6283-456c-9cef-dc88ad0ab44d"
      id="F_24dbbd3b-099b-4056-b7fd-4a890155b045">2026-11</rapt:LesseeOperatingLeaseExtendedLeaseTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_c1f11e91-1cbf-4c2e-aecc-69ab59127c69"
      id="F_03531d36-65e6-4309-9899-0c0ab3e5e0e2">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_a395a028-b159-4fe1-a41e-dbb49da699ec"
      id="F_e7105e57-ab53-44ed-a080-5d58af56fd3e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <rapt:SquareFeetAreaOfOfficeFacilityUnderLease
      contextRef="C_628c0f63-7e74-4ded-878d-c94d2ab2ac7a"
      decimals="INF"
      id="F_1f9de8b9-d26d-4483-8d26-8252d1a19497"
      unitRef="U_sqft">13232</rapt:SquareFeetAreaOfOfficeFacilityUnderLease>
    <rapt:OperatingLeaseExpirationYear
      contextRef="C_1bcb0469-f3b0-4af9-b7bf-1fed7508ba3b"
      id="F_b14b198e-6bc9-4da0-a871-3ad04981261b">2025-07</rapt:OperatingLeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_1bcb0469-f3b0-4af9-b7bf-1fed7508ba3b"
      id="F_e1a538a9-4506-4724-b403-e5f21e5f03d1">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_3ad90f5b-fa56-4503-84e3-c127661aabaa"
      id="F_c459b030-0fd7-4443-a200-9719cfcbba22">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_64a3e5ae-e51c-494a-b231-99c9deabf882"
      unitRef="U_USD">2900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      id="F_33d555a8-1524-407a-b933-4f7ba01a4b2f">P1Y8M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="4"
      id="F_fb31610e-8c76-4e90-a17b-1cc8b287a1de"
      unitRef="U_pure">0.0821</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_7f647d86-3cd3-4b9c-92dc-ea6cca5e896f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes maturities of operating lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.856%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.703000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_0b0e33c2-fa75-481f-b942-1add3d8810a0"
      unitRef="U_USD">2662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_a270d4df-7e50-403a-8c94-524b6466632c"
      unitRef="U_USD">2137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_540a7712-d8cb-4bbb-8597-1ee3cdc9ff8d"
      unitRef="U_USD">4799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_7529d34e-a3c7-463f-aea2-cf9642b0a439"
      unitRef="U_USD">307000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_cb4bc442-b429-4c2b-bd6b-d271f6f65b04"
      unitRef="U_USD">4492000</us-gaap:OperatingLeaseLiability>
    <rapt:SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_43f92133-b8ee-42f5-8fd9-c9054d48f59f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the supplemental balance sheet information related to operating leases at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.447%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rapt:SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_3ac5d8c6-add5-46a9-b230-c75833eec521"
      unitRef="U_USD">3333000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_176b8757-5e9f-437c-8c7c-d52498f6eaba"
      unitRef="U_USD">5228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_ef2e6e66-69be-43ef-a444-29d5960bcc75"
      unitRef="U_USD">2422000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_62bad25a-1997-4ffd-906a-e7274de82abb"
      unitRef="U_USD">2448000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_c380d335-a878-424c-b768-2070f79af570"
      unitRef="U_USD">2070000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_76f04fcf-49cd-4aea-a337-740da92f91a9"
      unitRef="U_USD">4458000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_c70c6b7e-c880-4a84-ac74-dd381b5e303f"
      unitRef="U_USD">4492000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_ef99071a-f19d-4834-abc2-957d1b6533db"
      unitRef="U_USD">6906000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_89b8edd9-77f7-40c0-9a67-29b3f64b9eb4"
      unitRef="U_USD">2300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_92c8d4e1-3d2f-46c5-bfd3-47575868498e"
      unitRef="U_USD">2300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_e91ebbc2-3b83-4fe6-b1d8-9e5ccd159b18"
      unitRef="U_USD">3100000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_6967ca0c-ecbd-4bda-984b-975efbd3ccfb"
      unitRef="U_USD">2900000</us-gaap:LeaseCost>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_31a21338-6b11-4893-b4e2-43cbf8f1d06f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. License and Collaboration Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement with Shanghai Jemincare Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company entered into a license agreement (the &#x201c;Jemincare License Agreement&#x201d;) with Shanghai Jemincare Pharmaceutical Co., Ltd., a company incorporated in the People&#x2019;s Republic of China (&#x201c;Jemincare&#x201d;), and a subsidiary of Jiangxi Jemincare Group&lt;/span&gt;&lt;span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Co., Ltd. Under the Jemincare License Agreement and subject to certain rights, Jemincare granted the Company: (1) the exclusive and sublicensable rights to develop, manufacture, commercialize and otherwise exploit Jemincare&#x2019;s anti-IgE monoclonal antibody JYB1904/RPT904 (together with certain related molecules, the &#x201c;Licensed Molecules&#x201d;) throughout the world, except mainland China, Hong Kong, Macau and Taiwan (together, the &#x201c;Jemincare Territory&#x201d;) for any and all uses; (2) the non-exclusive and sublicensable rights to develop the Licensed Molecules in the Jemincare Territory solely for the purposes of exploiting the Licensed Molecules outside of the Jemincare Territory; and (3) the non-exclusive and sublicensable rights to manufacture the Licensed Molecules in the Jemincare Territory solely for the purposes of exercising the Company&#x2019;s rights in the foregoing (1) and (2).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As consideration for the rights granted, the Company paid Jemincare a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront license fee, and could pay up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;672.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments, as well as tiered royalty payments (at percentages ranging from high single-digit to low double-digit) on future net sales. Those additional milestone payments include $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million contingent upon the completion of manufacturing technology transfer, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million contingent upon the achievement of specified development and regulatory milestone events, and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;445.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million contingent upon the achievement of specified commercial milestone events. As of December 31, 2024, the Company accrued the upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as research and development expense. The Company paid the upfront license fee in January 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Jemincare License Agreement, royalty payments will be payable on a product-by-product and country-by-country basis during the period commencing on the first commercial sale and continuing until the later of: (a) the 10-year anniversary of the date of such first commercial sale; (b) the expiration of the relevant patent claims; and (c) the expiration of the relevant regulatory exclusivity (the &#x201c;Jemincare Royalty Term&#x201d;). Subject to a certain floor, the Company&#x2019;s royalty payments will be reduced by specified percentages for patent expiration, biosimilar entry, payments for third party intellectual property, compulsory sublicenses or drug pricing programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Clinical Trial Collaboration and Supply Agreement with Merck&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company conducted a clinical trial evaluating tivumecirnon in combination with pembrolizumab (KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;), Merck&#x2019;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck supplied pembrolizumab for use in the clinical trial. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2022 and February 2024, the Company and Merck amended the agreement to provide for additional supply of pembrolizumab.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rapt:UpfrontLicenseFee
      contextRef="C_3a7401ae-87da-4602-a270-a264467fbebd"
      decimals="-5"
      id="F_30e111bf-50d9-45d7-86c2-253013c6d905"
      unitRef="U_USD">35000000</rapt:UpfrontLicenseFee>
    <rapt:AdditionalMilestonePayment
      contextRef="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53"
      decimals="-5"
      id="F_96dced10-6d7d-4952-bac3-6469c8713d66"
      unitRef="U_USD">672500000</rapt:AdditionalMilestonePayment>
    <rapt:ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer
      contextRef="C_3a7401ae-87da-4602-a270-a264467fbebd"
      decimals="-5"
      id="F_7518ca16-a885-44dc-bb38-eed83bb38e8c"
      unitRef="U_USD">1500000</rapt:ContingentPaymentsUponCompletionOfManufacturingTechnologyTransfer>
    <rapt:ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone
      contextRef="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53"
      decimals="-5"
      id="F_c4c529cb-fb33-4251-a602-04e5e3dcbd11"
      unitRef="U_USD">226000000</rapt:ContingentPaymentsUponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestone>
    <rapt:ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone
      contextRef="C_a38e0185-ef66-4398-ad4b-5c1b1f168f53"
      decimals="-5"
      id="F_7bcd6d5e-0b20-49b4-9a5d-79ccd4398e79"
      unitRef="U_USD">445000000</rapt:ContingentPaymentsUponAchievementOfSpecifiedCommercialMilestone>
    <rapt:AccruedUpfrontLicenseFee
      contextRef="C_3a7401ae-87da-4602-a270-a264467fbebd"
      decimals="-5"
      id="F_e68b7258-1b6f-44be-b704-a317c07c4b88"
      unitRef="U_USD">35000000</rapt:AccruedUpfrontLicenseFee>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_2bc93469-a0d6-4a05-a1d2-215116cf42f1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holders of the Company&#x2019;s common stock have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote for each share of common stock held by them. Holders of shares of the Company&#x2019;s common stock are entitled to dividends when, as and if declared by the board of directors. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends had been declared as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options issued and outstanding under the 2019 Equity Incentive Plan and&lt;br/&gt;&#160;&#160;&#160;2015 Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units issued and outstanding under the 2019 Equity&lt;br/&gt;&#160;&#160;&#160;Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future grants under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,489,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,032,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,403,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved under the 2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;492,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,390,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,556,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company sold through a private placement to a select group of accredited investors &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,452,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8499&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting offering expenses (the &#x201c;Private Placement&#x201d;). Also in December 2024, the Company entered into an exchange agreement  with The Column Group II, LP and certain of its affiliated funds (collectively, the &#x201c;TCG Funds&#x201d;), pursuant to which the TCG Funds agreed to exchange an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,951,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock for pre-funded warrants (the &#x201c;Exchange Warrants&#x201d;) to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,951,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock (the &#x201c;Exchange&#x201d;). The material terms of the Exchange Warrants are identical to the pre-funded warrants issued in the Private Placement and the accounting impact of the exchange was deemed immaterial.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company filed with the SEC, and the SEC declared effective, a shelf registration statement on Form S-3 related to the sale and issuance of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company&#x2019;s securities, including up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of shares of common stock that may be offered and sold from time to time in one or more &#x201c;at-the-market&#x201d; offerings pursuant to a Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) and Leerink Partners LLC. The ATM Sales Agreement replaced the Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Sales Agreement, dated November 4, 2020, by and among the Company, Cantor and Stifel, Nicolaus &amp;amp; Company, Incorporated. During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365,316&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock in &#x201c;at-the-market offerings&#x201d; under the ATM Sales Agreement, for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting sales agent commissions and other offering related costs. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No shares were sold under the ATM Sales Agreement or the Prior ATM Sales Agreement during the year ended December 31, 2023. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of the date of filing of this Annual Report there were up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock available for future issuance under the ATM Sales Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2022, through a private placement financing, the Company issued pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. Each pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The purchase price per pre-funded warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (representing the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share closing price of the common stock on May 24, 2022, less the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant). The private placement financing of the pre-funded warrants resulted in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting offering expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All pre-funded warrants, including Exchange Warrants were classified as a component of permanent equity in the Company&#x2019;s balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <rapt:CommonStockNumberOfVotesPerShare
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_11ce9230-59c8-4d05-947c-fe55afb9838f"
      unitRef="U_Vote">1</rapt:CommonStockNumberOfVotesPerShare>
    <us-gaap:DividendsCommonStock
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="INF"
      id="F_150af929-cae4-4bdf-9c75-9282cc2ffed4"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_13f19f19-8f86-4e94-a68b-1b2dbf0b852a"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_93f2fedc-4317-45ff-8dc2-e548f788ead8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options issued and outstanding under the 2019 Equity Incentive Plan and&lt;br/&gt;&#160;&#160;&#160;2015 Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units issued and outstanding under the 2019 Equity&lt;br/&gt;&#160;&#160;&#160;Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future grants under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,489,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,032,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,403,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved under the 2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;492,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,390,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,556,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_11ca0293-f87d-4136-bd9f-6c3103db98f2"
      decimals="INF"
      id="F_c1713829-1f9c-4385-af22-0549afb68a85"
      unitRef="U_shares">5005320</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_60522021-60ee-4c57-928c-e5bf166e8dd2"
      decimals="INF"
      id="F_af3a5879-32bb-4197-8877-fe0a140dbcc3"
      unitRef="U_shares">4099947</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f719cc4a-1b2f-4a9f-8aa9-a03779cd52bb"
      decimals="INF"
      id="F_ddb1a0f7-de39-482b-9025-65dd9278fa2a"
      unitRef="U_shares">13500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_508274a6-0773-4df0-8e48-b81976e6b710"
      decimals="INF"
      id="F_81ee5c12-8ab6-4055-9622-872bad015c62"
      unitRef="U_shares">3489005</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8f0468c1-4f1c-4002-aff0-929369045db5"
      decimals="INF"
      id="F_83badb0e-269e-4dac-88f9-683f9f8af6f6"
      unitRef="U_shares">3032820</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3072375a-82e6-4b42-a83d-501afdf94d3e"
      decimals="INF"
      id="F_db81947d-0871-4e0b-8e49-bd3e06b5387b"
      unitRef="U_shares">83403425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_255e918e-22cd-4e56-adc9-8e0aea00d489"
      decimals="INF"
      id="F_a39fca40-301b-4cd0-bd69-4235b985be76"
      unitRef="U_shares">4000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_dcaa91d1-9b01-4910-b0d7-9d8ec5902432"
      decimals="INF"
      id="F_d42e8d53-201e-41ec-8e07-f724af184c49"
      unitRef="U_shares">492307</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b4dd74b2-7b1d-41b5-80ac-555fdb0af990"
      decimals="INF"
      id="F_66d16259-c643-4ebf-a889-0098489b6858"
      unitRef="U_shares">410522</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="INF"
      id="F_100f8c7c-e072-41d5-ac8c-9ce6dd07db61"
      unitRef="U_shares">92390057</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="INF"
      id="F_b6e1e37d-f347-4bc4-9d98-c0f73eb315ed"
      unitRef="U_shares">11556789</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_474bbfae-df71-4a9f-b05e-2f653dc760c7"
      decimals="INF"
      id="F_6b20844f-3f4f-44f4-85d3-3831e6a7cd63"
      unitRef="U_shares">100000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_79a7d43a-cffb-42e7-a29b-ca6eaeb61221"
      decimals="2"
      id="F_af6048c2-9f19-458b-83a9-b92435356f36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.85</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f7d224a0-d8ce-405f-8a66-7a5c7ceec004"
      decimals="INF"
      id="F_3bc975f3-44ca-42c4-b400-ade7306d869d"
      unitRef="U_shares">76452000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <rapt:ClassOfWarrantOrRightPurchasePricePerWarrant
      contextRef="C_f7d224a0-d8ce-405f-8a66-7a5c7ceec004"
      decimals="4"
      id="F_a2971a7c-09b3-49f5-96ef-1f420606a7ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8499</rapt:ClassOfWarrantOrRightPurchasePricePerWarrant>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_9db51527-1de4-457c-b360-21ef8df86299"
      decimals="-5"
      id="F_479dea34-722c-4cba-a3f7-e7f30e58f350"
      unitRef="U_USD">143000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <rapt:ConversionOfCommonStockForPre-FundedWarrants
      contextRef="C_9aa83cf2-b703-419f-8280-e04589a8890b"
      decimals="INF"
      id="F_31b86910-736f-4a16-be08-1152f66f2576"
      unitRef="U_shares">2951425</rapt:ConversionOfCommonStockForPre-FundedWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_835d629a-8341-447d-9b31-2b46252b4801"
      decimals="INF"
      id="F_62582d27-ce6e-4a80-b8c8-af4bdd719fda"
      unitRef="U_shares">2951425</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1f4d112b-20a6-4e9d-97f9-f7a1a462f430"
      decimals="-6"
      id="F_a1b5c52c-aba0-4f15-b038-433d06171416"
      unitRef="U_USD">450000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bb74bca5-cd20-442e-a1a9-9ce66456c288"
      decimals="-6"
      id="F_6b16c209-ab81-4c49-a36e-d7881daac948"
      unitRef="U_USD">150000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_54a69405-ede9-4232-ba03-df78ed069f51"
      decimals="INF"
      id="F_005d8ffc-3e47-4303-84a5-2376275a1bea"
      unitRef="U_shares">365316</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_54a69405-ede9-4232-ba03-df78ed069f51"
      decimals="-5"
      id="F_068c8ffb-c727-42ca-9f70-8ea9d7b487d4"
      unitRef="U_USD">9000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <rapt:CommonStockCapitalSharesAvailableForFutureIssuanceValue
      contextRef="C_9721513b-6988-4fc5-9022-6cb8d96513e9"
      decimals="-5"
      id="F_b60c1ef4-2a44-4583-957b-f191ab903c34"
      unitRef="U_USD">140600000</rapt:CommonStockCapitalSharesAvailableForFutureIssuanceValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96"
      decimals="INF"
      id="F_734d0932-91c2-4ac3-bcbe-5b3cd80b5c9c"
      unitRef="U_shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96"
      decimals="4"
      id="F_9e238d99-1ca2-454a-96a7-a6cd644e43e9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rapt:ClassOfWarrantOrRightPurchasePricePerWarrant
      contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96"
      decimals="4"
      id="F_7a3474f0-3825-41f8-964d-be78ebced1aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.4999</rapt:ClassOfWarrantOrRightPurchasePricePerWarrant>
    <rapt:ClosingPricePerShare
      contextRef="C_9bacd39c-e2ef-403d-878e-b81822f43a06"
      decimals="2"
      id="F_3025dc5f-08cd-429f-b084-0dbfc1db25fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.5</rapt:ClosingPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ba9fb899-953d-430f-8d41-8d8c5d41dd96"
      decimals="4"
      id="F_4e28533a-45d3-43c1-b63c-ed27764db3d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_fa219022-bcdb-4c57-9659-88770a219b25"
      decimals="-5"
      id="F_0fd49bd9-f8c1-48af-80a9-40398e5ff688"
      unitRef="U_USD">49800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_ad0ade64-a38d-47ae-bd76-b480ac39ca52">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#x201c;2015 Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2019, the Company&#x2019;s board of directors adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d; and collectively with the 2015 Plan, the &#x201c;Option Plans&#x201d;). Upon the effectiveness of the 2019 Plan, the 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. In addition, the number of shares reserved for issuance under the 2019 Plan automatically increases on January 1 of each year beginning January 1, 2020 by a number equal to (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#x2019;s board of directors. As of January 1, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,375,932&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were reserved for issuance pursuant to the automatic increase to the authorized shares under the 2019 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Option Plans provide for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant. As a private company, the estimated fair value of the Company&#x2019;s underlying common stock was determined by the board of directors. Following its initial public offering, the fair value of the Company&#x2019;s common stock is based on the closing price of its common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;). The Company reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240,336&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock pursuant to purchase rights to be granted to the Company&#x2019;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance automatically increases on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240,336&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240,336&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of each employee&#x2019;s compensation. The 2019 ESPP generally provides for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-month offering period, which includes four &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, employees purchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,551&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares at weighted average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,671&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity under the 2019 Plan is set forth below for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.777%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price Per&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,648,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;728,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,224,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#x2019;s common stock for options that were in-the-money as of December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The options granted in the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; had a weighted average per share grant-date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and a total grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options exercised in the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash received from stock option exercises were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively. The Company issues new shares of common stock upon exercise of options. In connection with these exercises, there was no tax benefit realized by the Company due to its current loss position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate fair value of options that vested in the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs vested and settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee stock option valuation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expected term represents the period that the Company&#x2019;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected dividend&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.432%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.432%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. This unrecognized stock-based compensation cost is expected to be recognized over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Repricing of stock options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 12, 2024, the Compensation Committee (the &#x201c;Committee&#x201d;) of the Board of Directors of the Company approved an option repricing, which was effective on November 13, 2024 (the &#x201c;Effective Date&#x201d;). The repricing generally applies to options to purchase shares of the Company&#x2019;s common stock that: (i) were granted under the Company&#x2019;s 2019 Plan; (ii) as of the Effective Date, are held by the Company&#x2019;s then-current employees and consultants (subject to the caveat below) (each, an &#x201c;Eligible Participant&#x201d;); and (iii) have an exercise price per share greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Eligible Options&#x201d;). The Eligible Options include options held by certain of the Company's executive officers. Options held by non-employee members of the Board were not eligible for the repricing program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of the Effective Date, the Eligible Options were immediately repriced such that the exercise price per share for such options was reduced to the closing price of the Company&#x2019;s common stock per share on the Effective Date, subject to certain retention requirements outlined below. The closing price of the Company&#x2019;s common stock per share on the Effective Date was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which became the reduced exercise price per share for the Eligible Options. If an employee exercises Eligible Options in advance of the end of the retention period as described below, the employee will be required to pay a premium exercise price equal to the original exercise price per share of the Eligible Options. There were no changes to the number of shares underlying the Eligible Options or to the vesting schedules or expiration dates of the Eligible Options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In order to exercise the Eligible Options at the reduced exercise price, holders of the Eligible Options are required to remain in service with the Company through the end of the relevant retention period. The retention period begins on the Effective Date and ends on the earliest of the following: (i) the date 12 months following the Effective Date; (ii) a Change in Control (as defined in the 2019 Plan) if the Eligible Options are not assumed or continued by the successor or acquiror entity (or its parent company) in such Change in Control or substituted for a similar award of the successor or acquiror entity (or its parent company); or (iii) the option holder&#x2019;s termination of Continuous Service (as defined in the 2019 Plan) (a) due to such individual&#x2019;s death or disability, (b) by the Company (or successor entity in a Change in Control) other than for Cause (as defined in the applicable 2019 Plan) or (c) due to such option holder&#x2019;s resignation on or following a Change in Control under certain circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of the Effective Date, the total number of shares underlying all Eligible Options was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares. The effect of the repricing resulted in total incremental stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of which will be recognized on a straight-line basis through the end of the retention period, while the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will be recognized on a straight-line basis over the original vesting period for those options that vest after the end of the retention period. The incremental stock-based compensation expense was calculated using the Monte Carlo option-pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, the Company recognized incremental stock-based compensation expense totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the option repricing, which is included in general and administrative and research and development expense on the statement of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <rapt:PercentageOfIncreaseInSharesReservedForIssuance
      contextRef="C_e29bc580-c8e8-4a17-a9a1-642394e12639"
      decimals="2"
      id="F_f1138984-7c96-49dd-ab8b-4ab148ddcf70"
      unitRef="U_pure">0.04</rapt:PercentageOfIncreaseInSharesReservedForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7ed4539c-e1c4-44f1-882d-04dd7e36cd8f"
      decimals="INF"
      id="F_6378aec3-cfe9-4912-b983-0a5a905eaffb"
      unitRef="U_shares">1375932</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_7dfadab9-2f94-475c-bf05-4080b7f6c2de"
      id="F_e35aa4ca-95b2-4ba5-b03a-d09ef738c335">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_6ebc3359-abcc-404b-a473-e2b68d08293c"
      id="F_4f5ab9c3-e46d-4fcf-95b2-5d6adcb42fd0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_f78b877b-0271-4d1a-947d-9c726f07a8bf"
      decimals="INF"
      id="F_e2bd4705-63e3-4b20-97a6-53cc30c356b3"
      unitRef="U_shares">240336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <rapt:PercentageOfIncreaseInSharesReservedForIssuance
      contextRef="C_f78b877b-0271-4d1a-947d-9c726f07a8bf"
      decimals="3"
      id="F_86df040c-2a9d-470b-b588-3d9c2aa1648a"
      unitRef="U_pure">0.010</rapt:PercentageOfIncreaseInSharesReservedForIssuance>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount
      contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380"
      decimals="INF"
      id="F_d527f338-159b-4784-8f80-33f192cef22b"
      unitRef="U_shares">240336</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_9c01b00d-c8c0-44b6-a41b-56900a5fff28"
      decimals="INF"
      id="F_13307204-524d-4bdc-b373-000d1d7f909f"
      unitRef="U_shares">240336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_f78b877b-0271-4d1a-947d-9c726f07a8bf"
      decimals="INF"
      id="F_41779f09-d49e-4dd2-af64-661a5fb3d538"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380"
      id="F_37ff4efc-7027-4b50-a189-dc181710f4d3">P24M</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380"
      id="F_c8eb1e0f-fb0b-47b9-a0f5-6e2b6b9508f2">P6M</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_a1474cef-956f-46e7-9e3d-008021bbe380"
      decimals="INF"
      id="F_c37af897-5cbc-42b2-a9fe-369eb9e3ea31"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_ed365124-41c8-4f2d-90b2-8eb22147ede5"
      decimals="INF"
      id="F_557e83fe-864b-49a9-9fe3-ab4b1360bb88"
      unitRef="U_shares">158551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_4dc15569-4eb9-4821-a23f-93603c6bda00"
      decimals="2"
      id="F_9533aab8-262d-4231-af59-0e0e57fdfd11"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_2fe731eb-6df8-4233-8a24-a64517ed6900"
      decimals="INF"
      id="F_bdba6541-f81b-444a-a884-a25c03b865e6"
      unitRef="U_shares">87671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_1f0242db-35be-4a94-996c-e3a0577776cc"
      decimals="2"
      id="F_51a29f27-f190-4af0-a5b9-7dcfd1fb9ff3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ed365124-41c8-4f2d-90b2-8eb22147ede5"
      decimals="-5"
      id="F_8bac3914-6f46-4895-ab03-0983b0952272"
      unitRef="U_USD">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2fe731eb-6df8-4233-8a24-a64517ed6900"
      decimals="-5"
      id="F_57536f78-ca2e-479e-85d4-ff1676de696c"
      unitRef="U_USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_11d2c0dd-ee24-4f60-acc8-0578d6e54944">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity under the 2019 Plan is set forth below for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.777%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price Per&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,648,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;728,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,224,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3"
      decimals="INF"
      id="F_c927a638-ea61-4c0b-a188-ca029d413c82"
      unitRef="U_shares">4099947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3"
      decimals="2"
      id="F_d9d7d57b-8237-493e-91be-1d5ebe4226a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_cc2b05a5-eacc-40fa-9ee3-edb7df38df49"
      id="F_7be78658-8cc5-461f-b7d6-a02736c77ade">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4ac0cc6e-95e2-46b5-a0b7-cf999fd8dab3"
      decimals="-3"
      id="F_99c9908a-c686-410c-9b7e-f89136378912"
      unitRef="U_USD">23206000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      decimals="INF"
      id="F_fd120809-ae00-432d-9e42-53f41198d753"
      unitRef="U_shares">1648459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      decimals="2"
      id="F_609d411f-7da7-45ef-972c-d262cc38332f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      decimals="INF"
      id="F_8d3c2d4e-f8ed-4003-b164-0bc6b1dfedf6"
      unitRef="U_shares">14374</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      decimals="2"
      id="F_63c904c6-1341-4a17-85b2-ed251b064cd3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      decimals="INF"
      id="F_469cc0f1-52ad-4908-b1bc-9c0edd572bf5"
      unitRef="U_shares">728712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      decimals="2"
      id="F_104f9f1c-71a5-4d06-9bab-ab1703718db4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="INF"
      id="F_65967378-1985-48bb-8547-0563f53ba1d3"
      unitRef="U_shares">5005320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="2"
      id="F_063e3559-18e3-4036-b9e1-e51c5a5f8977"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      id="F_4bc80b8f-4f19-423d-94d3-48684c364c0a">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="-3"
      id="F_73a27210-ed79-41e8-a6c2-4899f71f9f87"
      unitRef="U_USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="INF"
      id="F_b0fbe57f-39ea-493f-bc9a-b5340ac61646"
      unitRef="U_shares">5005320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="2"
      id="F_758db90d-e64c-4571-b9b5-5dd7cc2f083c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      id="F_5505efe7-3252-484e-b181-2b9ca8ae286f">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="-3"
      id="F_45d07062-b262-4e41-ac12-53e2607647ca"
      unitRef="U_USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="INF"
      id="F_f9119525-374c-4c04-9998-233afc79ac7e"
      unitRef="U_shares">3224884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0814b1c2-dfb8-4253-aa98-816f8e1679c3"
      decimals="2"
      id="F_002e99a4-9e6f-43a3-a30f-f38f90f35768"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_6693188f-4e4f-4506-9db1-d13478fdd1b5"
      id="F_2288ad8f-f4e9-4b66-a14e-49b54995d8de">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="2"
      id="F_bef16608-2e3b-4034-a27d-6317c119231d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="2"
      id="F_4b07e5ec-e88e-43d2-8bb2-9b355d116450"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-5"
      id="F_f50e0ebc-f4b7-4cfd-ab61-9473e3f798a3"
      unitRef="U_USD">28800000</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-5"
      id="F_ae5db281-862f-462d-9020-ce38d409d2e2"
      unitRef="U_USD">24600000</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_f45bdf85-bb0a-43eb-b495-570b98874f4b"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_3ccd4eb9-782a-48e3-8476-7f834de68baa"
      unitRef="U_USD">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_34ae9348-03d4-4aba-8ef9-40f673ef7379"
      unitRef="U_USD">67000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_ed3d3a3c-73c6-4f8e-b5b8-6aec84631325"
      unitRef="U_USD">500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_6a8ad40d-2a1e-498a-a4f8-ae5a22c64788"
      unitRef="U_USD">18800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_a8081abd-f891-45e3-9eb1-728fc9d8c5e9"
      unitRef="U_USD">15200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_c6de9e56-d9b4-4fca-a663-69cb846e825f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs vested and settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e0707604-10e1-4c66-b961-1f5ccf14dc5d"
      decimals="INF"
      id="F_846c310d-3838-4abc-8fbe-de2322474b1d"
      unitRef="U_shares">13500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e0707604-10e1-4c66-b961-1f5ccf14dc5d"
      decimals="2"
      id="F_7ba6be89-e15e-403d-bc56-7b8fcb77625e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_a14673d3-4c5c-4205-aba2-4b02e4aef4ca"
      decimals="INF"
      id="F_7f578bc1-a657-421d-b74e-8fe4574a682a"
      unitRef="U_shares">13500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a14673d3-4c5c-4205-aba2-4b02e4aef4ca"
      decimals="2"
      id="F_83b77fd3-927a-4631-90c8-44a1c06355fb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_d9234fac-4296-4532-b5c8-44c5a7ab179e"
      decimals="INF"
      id="F_5e22b404-3fc6-4499-870d-184917f4a873"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_d9234fac-4296-4532-b5c8-44c5a7ab179e"
      decimals="0"
      id="F_02624d99-da65-4c45-857a-a142e1aefde7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_f17c8b21-45be-4d70-b54f-28d254eced01"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_108ceae3-8677-4c2a-bece-c31f8942d06e"
      id="F_3f9172f7-0ff7-439e-b65d-6855862fe585">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.432%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_08bbabe7-2cfc-4fb4-869c-d82c58a794fb"
      decimals="2"
      id="F_a8da5117-47ad-4b86-9099-c644ec3cd6b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_ba3ba657-8b8c-4939-87cf-2c03c023d913"
      decimals="2"
      id="F_b9ae292c-f867-4cbc-a437-e7e4f7d1373d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_e791417b-0181-463a-ab8a-f33a0e466058"
      decimals="2"
      id="F_3423bcb5-4729-4572-8b6f-e87f9adf3253"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_f57a54f1-5233-4d73-9bd8-566ae74872e1"
      decimals="2"
      id="F_a3c6322f-a5a0-427a-b9be-8467f0ed0d0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b0562cd3-883d-4446-80de-a657e0fd2fe1"
      id="F_0c83dd77-3812-4502-b779-46fba7d6c5d9">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8a7cc3d9-d3e4-4c52-8a5d-bca0e011b505"
      id="F_ee734c35-42e4-49bb-8400-e03240b101de">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4eb091eb-a136-4c83-90f1-55a88abbc9c3"
      id="F_2cb9d16c-197f-45d1-8b87-dfcfe53dc6ae">P5Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bc91c928-5abe-4ffe-a8c2-90f5cbb4d036"
      id="F_f1df6b6a-79ec-4bbc-b314-ab4a65f64d65">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb"
      decimals="3"
      id="F_bff32ad8-e299-47eb-a31c-bdc9e12ccfc2"
      unitRef="U_pure">0.996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb"
      decimals="3"
      id="F_57844a15-5dc8-4513-ad13-d7cf91be23c6"
      unitRef="U_pure">1.107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b"
      decimals="3"
      id="F_ad7c262c-f60a-451d-83ac-b004e2f2dca1"
      unitRef="U_pure">0.949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b"
      decimals="3"
      id="F_ee48802f-25ed-475c-98dd-13dc17f41986"
      unitRef="U_pure">0.978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb"
      decimals="4"
      id="F_7127f1e7-b42c-443d-9be4-e3374e0dcf08"
      unitRef="U_pure">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_cfd0ffc9-7b9a-4678-a1f9-7e2a90695bfb"
      decimals="4"
      id="F_f3a01cd7-ee8e-4c79-af67-193a3f06d59f"
      unitRef="U_pure">0.0464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b"
      decimals="4"
      id="F_09e55b3c-f0d1-400e-923a-cc91b583b28d"
      unitRef="U_pure">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_18730f9a-a885-4097-a823-63b86ec6829b"
      decimals="4"
      id="F_ae604d38-863c-47c2-8793-badd14644c3f"
      unitRef="U_pure">0.0471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_7e04bc99-d3b6-4c47-a06a-7b345bc2c271">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.432%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_d10cbbed-ca3e-473c-ae9c-39f3c1a71274"
      decimals="2"
      id="F_29dd6c76-3e59-4d8c-8e18-b311e562da63"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_ba019106-668d-4085-9682-6ff1e01b2cec"
      decimals="2"
      id="F_a4c55d6b-4526-4e39-b206-6546c3bcf72c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_28f891fe-292b-4351-a216-491a3a56cdf0"
      decimals="2"
      id="F_9d364ea0-f3cf-4214-9634-e79b911a4343"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_ef44fb3b-2619-440a-8db8-260a42eaf37c"
      decimals="2"
      id="F_b77e9f89-958d-459a-95ec-68994afc4637"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_dc38ef0e-2c99-4a0f-bab8-195d55c11e72"
      id="F_df744a95-a5a5-4772-b4f1-39d1b7acdc16">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9f58d34c-283d-4d45-8629-2ad0f013648f"
      id="F_1a8739f4-93de-45eb-b8e7-3651e8541114">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_119abe86-5d9b-4ff1-b9ae-9decf2c2298c"
      id="F_f206ecee-c54e-477b-870c-179461ba6e1a">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_26ef2d05-ad13-40b9-b1cd-8c679a6ad1df"
      id="F_ec444a36-c514-4f4c-8097-f4572e360118">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96"
      decimals="3"
      id="F_e7491996-5834-46ab-bf2b-7e06bb14a23f"
      unitRef="U_pure">0.956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96"
      decimals="3"
      id="F_88b50de2-0929-4aac-a571-884fdd550c6a"
      unitRef="U_pure">1.653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed"
      decimals="3"
      id="F_ff282e7e-827c-4292-985e-52fc523d5dd1"
      unitRef="U_pure">0.643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed"
      decimals="3"
      id="F_a8efe7dc-6ac3-43fe-815c-ad9c3b0c945f"
      unitRef="U_pure">0.932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96"
      decimals="4"
      id="F_e44987d4-9640-49f1-84c9-29931139e0fe"
      unitRef="U_pure">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3bb7c759-dbd3-4996-adf8-03437b940c96"
      decimals="4"
      id="F_9a744d97-6e06-4768-b585-1ae7168f4d8b"
      unitRef="U_pure">0.0553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed"
      decimals="4"
      id="F_904315e3-352d-4d8e-890d-eab375490192"
      unitRef="U_pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_6694cbc9-ae3a-49ec-9225-4b06177f81ed"
      decimals="4"
      id="F_5bf21f16-418e-434a-bed0-e511292a14ec"
      unitRef="U_pure">0.0551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_935d2f8c-6537-4e57-b2d9-f29370041247">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c663eb36-dd20-48b2-8b42-6761ae70257c"
      decimals="-3"
      id="F_90651cf6-4e75-4d69-b140-45e2251fdf08"
      unitRef="U_USD">9203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e82bdaae-dee6-461f-b8f4-c790e6fb1c0d"
      decimals="-3"
      id="F_8dbbd1db-016a-4053-93df-a819b02e55f2"
      unitRef="U_USD">7941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b3f24917-b3a5-49bd-8fb0-e640d29eee1f"
      decimals="-3"
      id="F_c2e2fb44-6fe7-4c36-99d2-b7c836dd1583"
      unitRef="U_USD">10732000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c3c8c90f-d90e-46ba-865e-536f40880787"
      decimals="-3"
      id="F_dc91b15f-61c6-41f5-8204-6f760e893661"
      unitRef="U_USD">9150000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_74a93fdc-f153-4e68-b148-e7f09e7bfdb8"
      unitRef="U_USD">19935000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_342232f4-619e-48c3-b7b2-69641a5bb5fa"
      unitRef="U_USD">17091000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-5"
      id="F_d885d744-cec3-4f33-ae79-78ddb9793134"
      unitRef="U_USD">32700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_04fb040c-f497-4859-bf83-0e3f649359c2">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum
      contextRef="C_46e9a44b-4010-48bc-aa78-5d77603ab178"
      decimals="2"
      id="F_34cbb760-2a9b-49ac-ba4b-fc0f6e7d84fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationExercisePriceMinimum>
    <us-gaap:SharePrice
      contextRef="C_46e9a44b-4010-48bc-aa78-5d77603ab178"
      decimals="2"
      id="F_d9eb7d84-12b4-4139-8e45-d4d603b48c74"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.57</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_46e9a44b-4010-48bc-aa78-5d77603ab178"
      decimals="-5"
      id="F_df4bc638-ba58-446e-828f-784d2670f2ff"
      unitRef="U_shares">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_39770d05-317d-4e4d-a9cd-aadde8fbebc7"
      decimals="-5"
      id="F_cb0c2f01-e673-4148-a79d-48f7464f5f2a"
      unitRef="U_USD">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_c0d8be9a-a9d5-4da0-bb1b-b686503d1d6f"
      decimals="-5"
      id="F_e5c8b955-c4e4-4918-902f-0b084fc11aa2"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_67fdbf90-7e52-44e3-b080-ab409b95b669"
      decimals="-5"
      id="F_7d51f061-a7bd-42cc-bc3d-5cbc2aab55a0"
      unitRef="U_USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_52a5a19e-2682-4c27-890f-1cf4909b6bb8"
      decimals="-5"
      id="F_b62a7142-b3d5-43b5-bc67-a561b1b705a0"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_16230db6-61d4-4f9d-835e-76c5cd3070e9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign losses not benefited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development capitalized expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with the 2017 Tax Act, research and experimentation (R&amp;amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;amp;E expenses are required to be amortized over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for domestic expenses and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for foreign expenses. As a result of this provision of the 2017 Tax Act, deferred tax assets related to capitalized research expenses increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively. The increase in the valuation allowance is mainly related to the capitalization of research and development expenses under Internal Revenue Code ("IRC") Section 174, capitalization of the Jemincare upfront fee as an intangible under IRC Section 197 and an increase in net operating loss carryforwards incurred during the respective taxable years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;317.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and are available to offset future taxable income. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Moreover, as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded federal and state reserves of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#x2019;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#x2019;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the 2017 Tax Act as modified by the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) the carryforward period of net operating losses generated from 2018 forward is indefinite but the ability to deduct such federal net operating losses is limited to 80% of taxable income; however, the carryforward period for net operating losses generated prior to 2018 remains 20 years. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. In February 2022, California Senate Bill 113 &#x201c;SB 113&#x201d; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. In June 2024, California Senate Bill 167 (&#x201c;SB 167&#x201d;) was signed into law, which suspends the NOL utilization for companies whose California taxable income exceeds $1 million and limits R&amp;amp;D credit utilization to $5 million. Given the Company&#x2019;s loss position, SB113 and SB167  did not impact the Company's tax provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#x2019;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest expense or penalties related to unrecognized tax benefits through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns with varying statutes of limitations in the United States and various states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Inflation Reduction Act of 2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was signed into law in August 2022 and contained several tax provisions to curb inflation by reducing the deficit, lowering prescription drug prices, investing into domestic energy production while promoting clean energy, and introduced the topic of corporate alternative minimum tax on applicable corporations. There is no impact to the Company&#x2019;s current tax provision from this legislation.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_dc6693b9-a020-460c-9fce-0f50ce8b4972">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_e25241d4-f0fc-46d4-a1d9-0176ee68c5c6"
      unitRef="U_USD">-129865000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_39d7afae-6655-4111-a0f4-1b29d842a900"
      unitRef="U_USD">-116798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_1ecf6cca-0af7-4d6e-8fa4-31eaca96f4bf"
      unitRef="U_USD">-129865000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_3454eeed-a0a8-46ae-b990-184e9bce123a"
      unitRef="U_USD">-116798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_c359e5e5-d30f-4f0d-852f-442b64f2fdd8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign losses not benefited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_d21be9bc-e702-47dc-b342-8a785ecaf196"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="INF"
      id="F_f1e6864e-ce4d-4aa7-99c3-2205766e1800"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="3"
      id="F_03a60a35-fae4-4c7a-896c-de9ba01a45e8"
      unitRef="U_pure">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="3"
      id="F_e8db00f7-8f89-46ae-8ead-f194b313020c"
      unitRef="U_pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="3"
      id="F_9c23811f-1b71-4f14-99b6-587d9acaf3cf"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="3"
      id="F_960e0f43-8823-4cfd-be30-813898284a8e"
      unitRef="U_pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="3"
      id="F_c6a49d80-5c6b-4cf3-b667-c5da09853ec8"
      unitRef="U_pure">-0.215</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="3"
      id="F_88b12aa8-b1ed-42d1-afd0-bcaf2cc1eb34"
      unitRef="U_pure">-0.224</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="3"
      id="F_36eb4154-5315-4919-b9a8-eba032d19386"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_f187fb3e-f246-4154-99a4-2a9d4b32d88a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development capitalized expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_db3f7279-349c-42fa-836e-758467d4d7ae"
      unitRef="U_USD">67565000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_08552d8f-dd8a-48a5-b0ea-9c70ab55c623"
      unitRef="U_USD">58248000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_30ba3916-48d1-4c2a-886a-a95cbb3b026e"
      unitRef="U_USD">15086000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_4655853d-4a4a-4b01-9047-81729cbf0bce"
      unitRef="U_USD">12601000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_d5934732-6c6d-4700-b39c-6abdf4ffc26e"
      unitRef="U_USD">1355000</rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves>
    <rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_f9bb0517-47b8-4f8c-b951-029c2bc16fab"
      unitRef="U_USD">1234000</rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_11571c16-f39c-431c-9e59-0426c645e98e"
      unitRef="U_USD">8588000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_25297a0a-f468-414f-93ce-7ae6438dfbcb"
      unitRef="U_USD">6238000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_b3a356c0-1765-4f4a-8730-89662db1d48f"
      unitRef="U_USD">8036000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_1635a6bc-f24f-4e1d-984c-9a9cc869e281"
      unitRef="U_USD">689000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <rapt:DeferredTaxAssetsLeaseLiability
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_c348a573-90d8-451c-9722-24015e878189"
      unitRef="U_USD">944000</rapt:DeferredTaxAssetsLeaseLiability>
    <rapt:DeferredTaxAssetsLeaseLiability
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_ed410974-b493-491d-af7a-081c5fd2e027"
      unitRef="U_USD">1450000</rapt:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_fa7afcb2-cb80-4b6b-8554-ae3199369b7f"
      unitRef="U_USD">33708000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_bdcd669e-3fab-449a-ba07-201e377c87c9"
      unitRef="U_USD">27290000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_cabe3397-2cc5-4d31-a59f-62b8f5c941bf"
      unitRef="U_USD">135282000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_e5212f9a-f0fb-4fe1-864a-ef006d0238cb"
      unitRef="U_USD">107750000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_be6c9739-323c-4de9-a370-3f3ff565abdf"
      unitRef="U_USD">134582000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_b50c8a55-689c-46c3-9250-ca8b4dfad0c3"
      unitRef="U_USD">106652000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <rapt:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_b59ad03b-aa52-418e-8b85-dba7b65f2dd4"
      unitRef="U_USD">700000</rapt:DeferredTaxLiabilitiesRightOfUseAsset>
    <rapt:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_9db638fb-d84d-464b-b08e-792c0c3474c7"
      unitRef="U_USD">1098000</rapt:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_f1657c25-fb34-4151-9895-3e4c52cd7027"
      unitRef="U_USD">700000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_e9fb4e34-b311-42ea-88c2-62c3be134cf5"
      unitRef="U_USD">1098000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_90bdf402-aea1-447d-974f-c2236521643f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_8970b9de-cd3f-4abe-ae0f-52a648e6211c"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm
      contextRef="C_94651108-608c-4b19-95e3-37570aa77a57"
      id="F_8e857ef3-0473-4ff5-a8b4-c12b30dd6af1">P5Y</rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm>
    <rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm
      contextRef="C_2f4f1a74-621e-4e7e-aeb7-2562d72aa3c0"
      id="F_724a646a-5738-4fb6-9c79-af1ce7630fef">P15Y</rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm>
    <rapt:IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_78859145-acee-4cd1-a18c-28d989d78532"
      unitRef="U_USD">6400000</rapt:IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment>
    <rapt:IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_f53ad444-57ad-454c-8e2b-8aa8bf7b748d"
      unitRef="U_USD">15500000</rapt:IncreaseInDeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-5"
      id="F_b8fdc3c0-5775-4836-8959-f47ab63b7555"
      unitRef="U_USD">27900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-5"
      id="F_400aff0b-f28f-4a3f-a75e-f751fd5ddffa"
      unitRef="U_USD">26200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ad8a92e7-a170-450d-96fe-0db4664c91f0"
      decimals="-5"
      id="F_e89c9c60-5743-4e78-8dce-fe04f9943749"
      unitRef="U_USD">317600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2424ad23-6a69-42b1-a6e1-2f30f781a186"
      decimals="-5"
      id="F_28b29194-bc97-4ee9-a010-4c5f448655bc"
      unitRef="U_USD">273300000</us-gaap:OperatingLossCarryforwards>
    <rapt:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_94651108-608c-4b19-95e3-37570aa77a57"
      id="F_99271060-f504-49a3-93cd-9d1fb8deaf48">2035</rapt:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_17084da0-52d8-4270-8220-a08b6ecfaf36"
      decimals="-5"
      id="F_e9c0dce9-3c8d-48c1-ab98-14e0babef325"
      unitRef="U_USD">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e2cf0836-a57d-4015-a9af-0546d1d46c80"
      decimals="-5"
      id="F_837d4e5a-5e7b-47df-8ddc-31a027878bda"
      unitRef="U_USD">12100000</us-gaap:OperatingLossCarryforwards>
    <rapt:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_365cd7e2-07a9-4efd-af57-00bb25764e5c"
      id="F_1d3aebf6-4614-41fc-bc68-0b5ebf0c094b">2035</rapt:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b5311bec-6438-4c93-a187-0201963f9310"
      decimals="-5"
      id="F_44f275b3-c09d-4d44-ae2b-ff3fea48a762"
      unitRef="U_USD">12400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c5036115-0ce3-49f9-b87d-f4affdbd9129"
      decimals="-5"
      id="F_7e8c61da-ad76-492f-a4a9-a82b02b75517"
      unitRef="U_USD">10200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2152facb-460b-4ca8-8869-28dc2ee681ef"
      decimals="-5"
      id="F_92c9ee59-3284-4848-b22a-2ef2833d8d5c"
      unitRef="U_USD">9900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_8b9b3e34-2570-4302-8da4-f3602f968f0f"
      decimals="-5"
      id="F_c07ee483-adf4-41ea-926e-385c1e9d080c"
      unitRef="U_USD">8400000</us-gaap:TaxCreditCarryforwardAmount>
    <rapt:UncertainTaxPositionsReserves
      contextRef="C_ad8a92e7-a170-450d-96fe-0db4664c91f0"
      decimals="-5"
      id="F_a7fdcd80-6bd6-4698-af4d-9988e1832901"
      unitRef="U_USD">3100000</rapt:UncertainTaxPositionsReserves>
    <rapt:UncertainTaxPositionsReserves
      contextRef="C_17084da0-52d8-4270-8220-a08b6ecfaf36"
      decimals="-5"
      id="F_c9fe84be-9d9f-4ed6-b3bc-74343f025384"
      unitRef="U_USD">2500000</rapt:UncertainTaxPositionsReserves>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_c428045a-9aea-480a-b3cc-d64c7efb4277">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_04cd5454-7ee0-4cd8-a86d-e2ddd77f62e4"
      unitRef="U_USD">4674000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_80a183b9-14ce-4b94-97fa-8410f324fd16"
      decimals="-3"
      id="F_8f98c294-3707-4721-a7dc-d265ab09c9d1"
      unitRef="U_USD">3663000</us-gaap:UnrecognizedTaxBenefits>
    <rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_ddfc0f40-e854-49ab-9b03-798f4fd33aca"
      unitRef="U_USD">-3000</rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_113bf786-e1b1-4d1f-99d5-7b4aa5e67de6"
      unitRef="U_USD">905000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_7a0daebc-652c-4e69-ac6f-ee6df252949a"
      unitRef="U_USD">1014000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3e7ee03e-77f2-40e9-992f-4b5ae31b1fa8"
      decimals="-3"
      id="F_20d4df33-8cba-43a6-bcb6-4f81eb190c44"
      unitRef="U_USD">5579000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f9bfc939-5d2a-4f02-9152-fbe4da41dd94"
      decimals="-3"
      id="F_fb3e3ed8-3cd3-4a7c-b1a9-f962a8560988"
      unitRef="U_USD">4674000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="INF"
      id="F_b38f3e23-d2f3-4bd3-aed7-c3b9ba4ba7a3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_77bab098-b7ad-4398-8064-2c591272ad16">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,761,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,338,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,403,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants to purchase the Company's shares of common stock, respectively, issued in private placement financings (see Note 8), were included in the basic and diluted net loss per share calculation.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.243%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.243%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options issued and outstanding under the 2019 Plan and 2015 Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated shares issuable under the 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,068,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,135,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_5bacb6eb-5c46-4720-a842-97e190b65e7f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,761,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,338,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="-3"
      id="F_4c0e3cbe-eaa2-4538-9f72-0f5507510503"
      unitRef="U_USD">-129865000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="-3"
      id="F_711c09ab-42d5-4189-bc61-af3fbe86b332"
      unitRef="U_USD">-116798000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_d50aa0ea-e332-405a-8d12-9bd25957f5d0"
      unitRef="U_shares">40761143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_63d0162d-a772-4c44-95d0-b7b6dd0e261f"
      unitRef="U_shares">40761143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="0"
      id="F_bf7ed9a7-c51e-4d73-bc89-1053750517f2"
      unitRef="U_shares">38338161</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="0"
      id="F_879b42ab-d7ce-4ecf-8fe4-ffc8162225bd"
      unitRef="U_shares">38338161</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="2"
      id="F_6702c7d7-6c03-4cd9-ace5-56f3a0ed0043"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="2"
      id="F_e98c9e23-4c8c-41e7-a5f4-91cd7d8ad067"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="2"
      id="F_b37dd211-7074-4062-b5e7-a4c787ba6332"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="2"
      id="F_e755885f-fcc9-49e1-8aaf-67a435f54a79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.05</us-gaap:EarningsPerShareDiluted>
    <rapt:PreFundedWarrantsToPurchaseCommonStock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_fe489c66-5345-446b-8230-edf21d00727c"
      unitRef="U_shares">83403425</rapt:PreFundedWarrantsToPurchaseCommonStock>
    <rapt:PreFundedWarrantsToPurchaseCommonStock
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="0"
      id="F_0f0f521b-5c6b-499f-b331-263fd1cfe1f7"
      unitRef="U_shares">4000000</rapt:PreFundedWarrantsToPurchaseCommonStock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      id="F_665109a1-048d-495a-98ab-448b0f8c2421">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.243%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.243%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options issued and outstanding under the 2019 Plan and 2015 Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,005,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated shares issuable under the 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,068,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,135,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_110c283e-33db-423a-9912-c4662332850f"
      decimals="0"
      id="F_f974d932-2e0c-40f1-b517-6fae64d0ada1"
      unitRef="U_shares">5005320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6e61294d-f16c-4cf1-97b3-5a12f717970c"
      decimals="0"
      id="F_e4c22ceb-59e7-426c-9dd4-da41b557dd18"
      unitRef="U_shares">4099947</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6d1d2bf1-3fd1-4020-ae5b-151e6c3dfe1c"
      decimals="0"
      id="F_24fbe2c0-a2e3-4a42-8d3f-d9dfa55cd978"
      unitRef="U_shares">62896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ec7bc9d3-76ec-4a11-8d01-81dfe77946de"
      decimals="0"
      id="F_18fa2c2b-36d5-4e33-8509-36ea905c4103"
      unitRef="U_shares">21904</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_388b46ad-84e8-4acc-b6cd-3a828d7b5577"
      decimals="0"
      id="F_cc26a23a-4b27-4ed1-9b60-01ae78a1592e"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8f6dc9ac-cad7-4b38-9d58-a1763e1d61e9"
      decimals="0"
      id="F_f0163091-d835-46f4-b6b9-f1c456f7aa04"
      unitRef="U_shares">13500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_18f57745-d287-4eac-8622-5474e59d7035"
      decimals="0"
      id="F_917fbc1a-655a-40e9-817b-e390729002bb"
      unitRef="U_shares">5068216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_de601727-b928-46a5-ac54-e85f0fa3c27a"
      decimals="0"
      id="F_8e57e2f8-3fa9-4226-9318-ba3503632f57"
      unitRef="U_shares">4135351</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c"
      id="F_e1514ce2-ec52-4619-adc0-013bfb5a2da6">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c"
      id="F_15465f8c-0a02-4a54-9d0a-a1801e7aba64">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c"
      id="F_4e585dac-0234-4db3-a460-ddecff306cb5">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_a675ee7d-c8fb-4cc9-ad6a-99787a292f5c"
      id="F_5e67b40c-ca3c-4cc8-973f-1e069b9456ef">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
